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EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Foreword

supported researchers, presented findings on methamphetamine/stimulant abuse among youth and young
adults. A second panel was comprised of international
researchers who presented findings on drug abuse patterns and emerging trends in Australia, Europe, Mexico, Southern Africa, and Taiwan.

Foreword
This publication includes papers presented at the 58th
semiannual meeting of the Community Epidemiology
Work Group (CEWG) held in Denver, Colorado, on
June 14–17, 2005, under the sponsorship of the National Institutes of Health, National Institute on Drug
Abuse (NIDA).

Information reported at each CEWG meeting is disseminated to drug abuse prevention and treatment
agencies, public health officials, researchers, and policymakers. The information is intended to alert authorities at the local, State, regional, and national levels and
the general public to current drug abuse patterns and
trends and emerging drug problems so that appropriate
and timely action can be taken. Researchers also use
this information to develop research hypotheses that
might explain social, behavioral, and biological issues
related to drug abuse.

Representing 21 sentinel areas in the United States,
CEWG representatives presented reports, citing the
most recent data on drug abuse patterns, trends, and
emerging problems in their areas. To enhance nonurban representation, guest researchers from Maine and
Ohio presented information on drug abuse patterns and
trends in their areas. The meeting also included presentations by two panels. One, comprised of NIDA-

Moira P. O’Brien
Division of Epidemiology, Services and Prevention Research
National Institute on Drug Abuse
National Institutes of Health
Department of Health and Human Services
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Introduction
This publication includes papers based on information and findings on drug abuse that were presented
at the June 2005 Community Epidemiology Work
Group meeting in Denver, Colorado.
The papers of the CEWG representatives provided
the most recent indicator data on the abuse of cocaine/crack, heroin, methamphetamine, narcotic analgesics/other opiates, and marijuana in 21 CEWG
areas and in the guest States of Ohio and Maine. The
meeting also included two panel presentations. One
panel focused on methamphetamine/stimulant abuse
among youth and young adults, based on findings
from NIDA-supported community-based research
studies. The second focused on drug abuse patterns
and emerging trends in other countries, namely Australia, Europe, Mexico, Southern Africa, and Taiwan.
Timothy Condon, Ph.D., Deputy Director, NIDA,
welcomed participants and provided an update on

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

NIDA research activities. The update included information on NIDA’s collaboration with other Federal
agencies in building partnerships to test NIDA’s research findings at the community level.
Wilson Compton, M.D., M.P.E., NIDA, led the discussion for the Panel on Methamphetamine and Other
Stimulant Abuse among Youth and Young Adults.
The Panel on International Drug Abuse Emerging/Current Trends was led by Steve Gust, Ph.D.,
NIDA.
At the June meeting, updates were presented on the
Drug Abuse Warning Network by Judy Ball, Ph.D.,
and on the National Forensic Laboratory Information
System, by James Tolliver, Ph.D. A session by Edward Boyer, M.D., focused on Using the Internet as a
Tool for Identifying and Monitoring Drugs of Abuse.
Jamie Van Leeuwan, M.D., M.P.H., C.A.C. II, Director of Development and Public Affairs, Urban Peak,
addressed the problem of homeless and runaway
youth and hosted a field trip for participants to visit
Urban Peak.
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The CEWG Network: Goals,
Functions, and Data Sources
The CEWG is a unique epidemiologic network that
informs drug abuse prevention and treatment agencies, public health officials, policymakers, and the
general public about current and emerging drug abuse
patterns. The network is comprised of researchers
from 21 areas: Atlanta, Baltimore, Boston, Chicago, Denver, Detroit, Honolulu, Los Angeles, Miami/Ft. Lauderdale, Minneapolis/St. Paul, New
Orleans, New York City, Newark, Philadelphia,
Phoenix, St. Louis, San Diego, San Francisco, Seattle, Texas, and Washington, DC.
Interactive semiannual meetings are a major and distinguishing feature of the CEWG and provide a foundation for continuity in monitoring and surveillance
of current and emerging drug problems and related
health and social consequences. Through the meetings, the CEWG…
•

Identifies changing drug abuse patterns within
and across CEWG areas

•

Plans followup on problems identified, e.g.,
emerging drug problems

•

Disseminates information on drug abuse patterns
and trends in each CEWG area

Papers presented by CEWG representatives include
quantitative and qualitative drug abuse indicator data.
Representatives go beyond publicly accessible data
and provide a broader perspective obtained from both
public records and qualitative research. Information
is most often obtained from local substance abuse
treatment providers and administrators, personnel of
other health-related agencies, law enforcement officials, and drug abusers.

ing drug problem identified in prior CEWG
meetings
•

Federal personnel who provide updates on data
sets used by CEWG members

•

Researchers from other countries who provide
recent drug abuse data/findings

The primary data sources used by CEWG representatives and cited in this report include the following:
•

National Forensic Laboratory Information
System (NFLIS) data, maintained by the Drug
Enforcement Administration (DEA)

•

Treatment data from State and local sources and
the Treatment Episode Data Set (TEDS), maintained by the Office of Applied Studies (OAS),
Substance Abuse and Mental Health Services
Administration (SAMHSA)

•

Drug Abuse Warning Network (DAWN)
emergency department data, accessed through
DAWN Live!, a restricted-access online service
administered by OAS, SAMHSA

•

DAWN and local drug-related mortality data
from OAS, SAMHSA, and/or local medical examiners/coroners

•

Law enforcement data from various sources,
e.g., DEA’s Domestic Monitor Program, local
DEA offices, Threat Assessment data from the
Nation Drug Intelligence Center (NDIC), U.D.
Department of Justice, and price and purity data
from Narcotics Digest Weekly, and local police
and sheriff’s offices

Other data sources used by CEWG representatives,
when available, include poison control centers, helplines, and surveys.

Time at each meeting is devoted to presentations
by…
•

Guest researchers, including NIDA grantees,
who provide data/findings on a current or emerg-
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Drug Trends in Metropolitan
Atlanta
Brian J. Dew, Ph.D.,1 Claire E. Sterk,
Ph.D.,2 and Kirk W. Elifson, Ph.D.1
ABSTRACT
Drug abuse indicators showed that cocaine/crack
remained a primary drug of abuse in Atlanta during
2004, with the drug dominant among ED reports,
treatment admissions, and seized items analyzed by
NFLIS. Marijuana use was widespread as well, with
the drug accounting for 21.7 percent of public
treatment admissions. This proportion, however,
was consistent with previous years. Methamphetamine abuse appeared to be increasing, with treatment admissions continuing to rise faster than for
any other classification of drug. Treatment admissions for methamphetamine remained low, at 8.5
percent, however, compared to admissions for other
drugs. Heroin indicators continued to reflect low
levels of use of this drug in the metropolitan Atlanta
area.
INTRODUCTION
Area Description
The metropolitan Atlanta area is located in the
northwest corner of the State of Georgia and includes
20 of the State’s 159 counties. The metropolitan area
comprises more than 6,100 square miles, or 10.5 percent of Georgia’s total size. Currently, Georgia is the
10th most populous State in the Nation. From April
2000 to July 2002, the State’s population grew 4.6
percent, ranking fourth among all States.
With an estimated 4.4 million residents, the metropolitan Atlanta area includes nearly 52 percent of the
State’s population of nearly 8.4 million residents
(U.S. Bureau of the Census, 2003). The Atlanta metropolitan area ranks ninth among the Nation’s major
population centers. The city of Atlanta, with a population of approximately 369,000, represents 8.2 percent of the overall metropolitan population (American Community Survey, 2003). The city is divided
into two counties, Fulton County and DeKalb
County, which include 18.8 and 15.9 percent of the
metropolitan population, respectively.
1

Drs. Brian Dew and Kirk Elifson are affiliated with Georgia State
University, Atlanta, Georgia.
Dr. Claire Sterk is affiliated with Emory University, Atlanta,
Georgia.
2
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There are demographic differences between the city
of Atlanta and the larger metropolitan area, which
more closely reflects the State as a whole. AfricanAmericans are the largest ethnic group within the city
(60 percent), followed by Whites (37 percent), Hispanics (6 percent), and Asians (2 percent). When
examining the overall metropolitan Atlanta area,
those numbers reverse. Whites account for the majority (62.5 percent), followed by African-Americans
(29 percent), Hispanics (7.9 percent), and Asians (3.7
percent). Per capita family income in 2003 for the
city of Atlanta was higher at $32,635 than in the metropolitan area, at $26,145. The poverty rate inside the
city is 24 percent, compared with only 9.6 percent in
the metropolitan area. The housing vacancy rate outside the city (8.9 percent) is much lower than in the
city (17.5 percent).
In fiscal year (FY) 2004, the Georgia Bureau of Investigation (GBI)’s statewide drug enforcement efforts were led by 3 regional drug offices and 13 multijurisdictional task force programs. As a result of
these combined efforts, 2,979 drug offenders were
arrested. As of December 2004, there were 23 existing drug courts in Georgia (of these, 13 were for
adult felony drug offenses, 3 were for adult misdemeanor drug offenses, and 7 were for juvenile drug
offenses). One adult felony drug court was located in
Atlanta. In 2004, 34 percent of those on probation in
Georgia, 19 percent of prisoners, and 37 percent of
parolees had been convicted of a drug-related offense.
Additional factors that influence substance use in the
State:
•

Georgia is both a final destination point for drug
shipments and a smuggling corridor for drugs
transported along the east coast. Extensive interstate highway, rail, and bus transportation networks, as well as international, regional, and private air and marine ports of entry, serve the
State.

•

The State is strategically located on the I-95 corridor between New York City and Miami, the
key wholesale-level drug distribution centers on
the east coast and major drug importation hubs.
In addition, Interstate Highway 20 runs directly
into Georgia from drug entry points along the
southwest border and gulf coast.

•

The city of Atlanta has become an important
strategic point for drug trafficking organizations,
as it is the largest city in the South. It is considered a convenient nexus for all east/west and
north/south travel. The city’s major international

7
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airport also serves as a distribution venue for illicit substances.
•

The entire State, Atlanta in particular, has experienced phenomenal growth over the last several years, with a corresponding increase in drug
crime and violence. With Georgia bordering
North Carolina, South Carolina, Tennessee, Alabama, and Florida, Atlanta is the base for several
major dealers who maintain trafficking cells in
these States, especially Mexican-based traffickers who hide within legitimate Hispanic enclaves.

primary drugs of abuse among clients admitted
to Atlanta’s public drug treatment programs between January and December 2004. Data for
non-metropolitan Atlanta counties of Georgia
were also reported.
•

Drug price, purity, and trafficking data are
from the Drug Enforcement Administration
(DEA), the National Drug Intelligence Center
(NDIC), and the Office of National Drug Control
Policy (ONDCP). Information for 2004 on the
price, purity, and source of heroin was provided
by the DEA’s Domestic Monitoring Program
(DMP). Additional information came from Narcotics Digest Weekly published by the NDIC.
Other data are from the Atlanta High Intensity
Drug Trafficking Area (HIDTA) Task Force, a
coordination unit for drug-related Federal, State,
and local law enforcement agencies.

•

Forensic drug analysis data are from the National Forensic Laboratory Information System
(NFLIS) and represent evidence in suspected
drug cases throughout metropolitan Atlanta that
were tested by the GBI Forensic Laboratory from
January through December 2004.

•

Ethnographic information was collected from
local drug use researchers and is used for several
purposes: (1) to corroborate the epidemiologic
drug indicators, (2) to signal potential drug
trends, and (3) to place the epidemiologic data in
a social context.

•

Acquired immunodeficiency syndrome (AIDS)
data are from the Department of Human Resources and represent AIDS cases in Georgia and
a 20-county Atlanta metropolitan from January
1981 through August 2004. Additional information was provided by the Centers for Disease Control and Prevention (CDC).

Data Sources
Principal data sources for this report include the following:
•

•

8

Emergency department (ED) data were derived for calendar year 2004 from the Drug
Abuse Warning Network (DAWN) Live! restricted-access online query system administered
by the Office of Applied Studies (OAS), Substance Abuse and Mental Health Services Administration (SAMHSA). Eligible hospitals in
the Atlanta area totaled 39; hospitals in the
DAWN sample numbered 30, with the number
of emergency departments in the sample totaling
33. (Some hospitals have more than one emergency department.) During this 12-month period,
between 16 and 18 EDs reported data each
month. The completeness of data reported by
participating EDs varied by month (see exhibit
1). Exhibits in this paper primarily reflect cases
that were received by DAWN as of April 14,
2005; an update on June 4, 2005, was also accessed for selected data (as shown in exhibit 3).
All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change. Data derived from DAWN Live!
represent drug reports in drug-related ED visits.
Drug reports exceed the number of ED visits,
since a patient may report use of multiple drugs
(up to six drugs and alcohol). The DAWN Live!
data are unweighted, and, thus, are not estimates
for the reporting area. These data cannot be
compared to DAWN data from 2002 and before,
nor can preliminary data be used for comparison
with future data. Only weighted DAWN data released by SAMHSA can be used for trend analysis. A full description of the DAWN system can
be found at <http://dawninfo.samhsa.gov>.
Drug abuse treatment program data are from
the Georgia Department of Human Resources for

DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
With 5,758 reports in 2004, cocaine continues to be
the most frequently reported ED drug in the metropolitan Atlanta area according to unweighted DAWN
Live! data (exhibit 2). Cocaine ED reports were
higher among men than women (exhibit 3), with a
ratio of 2.4:1. There were 991 cocaine ED reports by
White patients, 3,714 by African-Americans, 65 by
Hispanics, and 988 by persons of unknown
race/ethnicity. ED cocaine reports among patients
between the ages of 35 and 54 totaled 3,838 (67 percent of all ED reports).
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In 2004, cocaine continued to be the primary drug of
choice for individuals seeking assistance at publicly
funded treatment centers in metropolitan Atlanta.
However, the number of primary admissions in metropolitan Atlanta for cocaine (n=3,162) in this period
reflects a continuing downward trend (exhibit 4). In
2000 and 2001, more than one-half of all treatment
admissions in metropolitan Atlanta were cocainerelated. In 2003, this percentage decreased to 42.8
percent, and in 2004, cocaine-related admissions declined to 39.5 percent. The ratio of men to women in
treatment for cocaine was 1.27:1, a proportion that
was considerably lower than the 1.65:1 found in
2003. A smaller percentage of African-Americans
entered treatment for cocaine-related issues in 2004
than in previous years. Approximately 7 out of every
10 cocaine-related admissions were AfricanAmerican in 2004 (exhibit 5). In 2002–2003, African-Americans accounted for 75 percent of treatment
admissions. Whites accounted for a larger proportion
of statewide cocaine treatment admissions outside
metropolitan Atlanta. Whites represented 45 percent
of the treatment population outside the Atlanta area,
and African-Americans represented 55 percent. In
2004, those older than 35 accounted for the largest
number of both metropolitan and non-metropolitan
cocaine admissions (80 percent). In Atlanta, there
was a 31-percent increase in admissions among those
age 18–25 and an 18-percent increase in admissions
among those age 26–34 from 2003 to 2004. In metropolitan Atlanta, smoking continued to be the most
preferred route of administration (77 percent), followed by inhalation (13 percent), oral (3 percent),
and injection (2 percent).

ever, crack has become more difficult for undercover
officers to purchase, and it seems to have decreased
somewhat in popularity. Powder cocaine availability
at the retail level in Georgia is limited, except in large
cities such as Atlanta. NFLIS reported that cocaine
accounted for more than 44 percent of confiscated
substances in suspected drug cases that were tested in
forensic laboratories in 2004 (exhibit 6). In 2003,
cocaine had accounted for nearly 40 percent of all
confiscated substances in suspected drug cases.

According to the DEA and Atlanta HIDTA, cocaine
remains readily available in Atlanta. Atlanta is a
growing distribution hub for surrounding States and
Europe. Atlanta also serves as part of a smuggling
corridor along the east coast. Powder cocaine and
crack dominate the Georgia drug scene. The primary
sources for cocaine are Texas and California. HIDTA
intelligence analysts implicate Mexico-based drug
trafficking organizations, whose members blend
within enclaves of Hispanic workers. According to
HIDTA and NDIC, cocaine prices remain relatively
stable in Atlanta. Powdered cocaine typically sells for
$75–$100 per gram. Crack rocks sell for as little as
$3. In 2003, members of the Atlanta HIDTA Task
Force seized 186.69 kilograms of powdered cocaine
and 7.56 kilograms of crack cocaine. Both quantities
were similar to what was seized in 2002.

In 2004, treatment admissions for individuals who
reported heroin as their primary drug of choice accounted for 2.5 percent of all treatment admissions in
the State; these admissions were mostly concentrated
in metropolitan regions. Nearly 6 percent of metropolitan Atlanta admissions in 2004 were for heroin
(exhibit 4), compared with 1.3 percent in nonmetropolitan areas. Admission rates for men were
double those for women in metropolitan regions, with
a non-metropolitan male-to-female ratio of 1.3:1.
African-Americans outnumbered Whites (230 to 206)
in metropolitan Atlanta treatment admissions (exhibit
5). Outside of metropolitan Atlanta, Whites represented an overwhelmingly high percentage (87 percent) of heroin-related treatment admissions, followed by African-Americans (9 percent) and Hispanics (2.2 percent). A significant majority of heroin
treatment admissions in both metropolitan (81 percent) and non-metropolitan (79 percent) Atlanta were
age 35 and older, as in previous reporting periods.
While treatment admissions for heroin are relatively
low for persons younger than 35, it is important to

The Georgia Threat Assessment (DEA 2003) reports
that other than marijuana, crack is the most available
drug in the city. Officials estimate that 75 percent of
all drug-related arrests involve crack cocaine. How-
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Heroin
Heroin indicators for Atlanta are mixed. However,
ethnographic data obtained through corroboration
with local street outreach workers suggests that heroin use is increasing.
According to unweighted data accessed from DAWN
Live!, the number of ED reports of heroin in 2004
(n=483) was less than reports for cocaine, marijuana,
methamphetamine, and benzodiazepines (exhibit 2).
A sizeable majority of these patients were males (exhibit 3), with a 3.4:1 male-to-female ratio. AfricanAmerican heroin ED patients exceeded White patients (1.6:1). The ED heroin reports that involved
Hispanics represented approximately 1 percent (n=5).
More than one-half of all patients were age 35–54
(n=274). Twelve percent of reports occurred among
18–24-year-olds. Although injection remains by far
the most frequent route of heroin administration (74.4
percent), approximately 10 percent of those with a
documented route of administration reported inhaling, sniffing, or snorting their heroin.

9
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note that 8 percent of heroin treatment admissions
were for individuals younger than 17.
Treatment data suggest that oral and inhalation administration rates may be on the rise in both metropolitan and non-metropolitan regions and that injection use of heroin may be declining. More than 35
percent of all individuals admitted for heroin treatment report smoking, oral, or inhalation as their primary method of administration. Nevertheless, anecdotal reports from non-profit street outreach workers
suggest that rates of heroin injection, particularly in
metropolitan Atlanta, may be on the rise and are
likely underreported. Most heroin users admitted to
treatment did not report having a secondary drug of
choice, although metropolitan users were overall
more likely than non-metropolitan users to report a
secondary drug of choice. Among heroin users in
metropolitan Atlanta, 32 percent reported cocaine as
a secondary drug of choice, compared with 14.6 percent for non-metropolitan users. The Georgia Department of Public Health estimates the rate of heroin
addicts in Atlanta to be 159 per 100,000 population
(n=approximately 7,000).
The NDIC’s Georgia Threat Assessment (April 2003)
reports that heroin is readily available in metropolitan
Atlanta and that the city is a high traffic area for heroin distribution. The majority of heroin available in
Atlanta is South American, followed by heroin from
southwest Asia. The DEA (February, 2005) reported
that local purity ranged from 31 to 57 percent in
2003. According to the ONDCP, in the first half of
2003 heroin sold for $10–$20 per bag, $462 per
gram, $6,160 per ounce, and $112,000 per kilogram
in Atlanta. Law enforcement groups, including
HIDTA and the DEA, report local heroin is supplied
via sources in Chicago, New York, and the southwest
border, and that there has been increased Hispanic
involvement in trafficking. Reports from outlying
metropolitan Atlanta counties suggest an increase in
heroin traffic in their jurisdictions. Approximately 1
percent (n=194) of NFLIS seized drug items tested
positive for heroin in 2004 (exhibit 6).
Law enforcement groups, including HIDTA and the
DEA, report that Mexican criminal groups are primarily responsible for the trafficking of South
American heroin in Georgia. These groups use commercial and private vehicles to bring the drugs into
the State. Heroin also enters the State through Colombian and Nigerian groups that transport the drug
via airline couriers. Additionally, NDIC and the DEA
mention that Dominican criminal groups drive heroin
into Georgia from New York and Philadelphia. Some
of that heroin is sold in Atlanta and some is shipped
elsewhere.
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Other Opiates/Narcotics
Most indicators suggest that narcotic pain relievers
are growing in popularity in metropolitan Atlanta.
Unweighted DAWN Live! data show 212 ED oxycodone/combinations reports and 268 hydrocodone/combinations reports in 2004 (exhibit 7). A
greater percentage of oxycodone/combinations ED
reports involved men and Whites than other groups
(exhibit 3). African-Americans represented 16 percent of all opiate/opioid ED reports (exhibit 3).
Treatment data for other opiates or narcotics were
only available for secondary and tertiary drug abuse
categories. Continuing a stable trend, other opiates
accounted for about 2–3 percent of secondary drugs
abused statewide and about 1 percent of tertiary
drugs abused in 2004. The use of opiates as a secondary abuse category was cited more often in nonmetropolitan areas (2.6 percent) than in metropolitan
Atlanta (1 percent).
According to NFLIS data, oxycodone and hydrocodone each accounted for about 1–2 percent of lab
identifications of drugs seized by law enforcement
from January through December 2004 (exhibit 6).
OxyContin, the most widely recognized oxycodone
product, is a growing drug threat in Georgia, according to the DEA. Twenty-milligram tablets sold in the
illegal market for $20 in 2004. Hydrocodone (Vicodin) and hydromorphone (Dilaudid) are also
abused in Atlanta. These drugs are obtained by “doctor-shopping” or by purchasing from dealers. Some
dealers steal prescription pads or rob pharmacies.
Several such incidents were reported in Georgia in
2004.
Marijuana
Ethnographic sources consistently confirm that marijuana is the most commonly abused drug in Atlanta.
Most epidemiological indicators show an upward
trend in marijuana use, particularly among individuals younger than 17.
According to unweighted data accessed from DAWN
Live!, there were 2,001 marijuana ED reports in 2004
(exhibit 2). There were more than twice as many
marijuana reports for men as for women. The number
of ED reports involving African-Americans was
higher than that of Whites (1.4:1). Sixty-two percent
of all ED reports for marijuana were distributed
evenly among individuals age 18–35, with 35–44
year-olds representing the largest percentage by age
group (27 percent of all ED reports). Eight percent of
reports were among 12–17-year-olds, and no reports
occurred among those younger than 12 (exhibit 3).
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Nearly 22 percent of public treatment admissions in
2004 in metropolitan Atlanta were for those who
considered marijuana their primary drug of choice
(exhibit 4). Male admissions were just slightly less
than double those of females in metropolitan Atlanta
(1.9:1), with the gap narrowing in non-metropolitan
regions (1.6:1). In 2004, the proportion of AfricanAmericans who identified marijuana as their primary
drug of choice increased in metropolitan Atlanta (56
percent vs. 46 percent in 2003) (exhibit 5) and decreased in non-metropolitan Atlanta (24 percent vs.
39 percent in 2003). Similar to 2003, the vast majority of users (81 percent) in 2004 were at least 35
years old. In metropolitan Atlanta, treatment admissions of individuals 17 and younger (n=112) were
more frequent than admissions age 18–25 (109). This
trend was consistent in non-metropolitan public
treatment facilities where individuals 17 and younger
(n=401) were more likely to enter treatment than individuals 18–25 (391). Alcohol was the most popular
secondary drug of choice for marijuana users, followed by cocaine and methamphetamine for both
metropolitan and non-metropolitan Atlanta admissions.
Marijuana, which is readily available in Atlanta and
the rest of Georgia, retails for about $10–$20 per
gram and $100–$350 per ounce, according to the
DEA. Atlanta serves as a regional distribution center
for marijuana. Most of the marijuana in Georgia
comes from Mexico, although locally grown marijuana is also on the market. Colombian and Jamaican
marijuana are purportedly present but less available.
Mexican drug cartels are the primary transporters and
wholesale distributors of Mexican-grown marijuana.
Local gangs (African-American and Hispanic) and
local independent dealers (African-American and
White) are the primary resale distributors.
Marijuana seizures increased 150 percent between
2002 and 2003, with HIDTA Task Force officers
confiscating 1,741.17 kilograms of bulk marijuana
and 210 cannabis plants. The NFLIS report for 2004
indicates that 14.4 percent of all drug-related items
confiscated test positive for marijuana (exhibit 6).
This proportion indicates a decrease from 2003, when
23 percent of all drug-related items tested positive for
marijuana. According to The Georgia Governor's
Task Force on Drug Suppression, 58 percent of
Georgia’s 159 counties have been reported as significant locations for marijuana cultivation.
Ethnographic data continue to support treatment and
law enforcement data that indicate the widespread
availability and use of marijuana in Atlanta. Hydroponic cultivation of marijuana has become more
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popular due in part to the DEA’s eradication program.
Stimulants
Methamphetamine is the most abused stimulant in
Atlanta, and its use is increasing. Law enforcement
efforts to stop the spread of this drug have involved
seizures and closures of clandestine labs. Methamphetamine is an increasing threat in the suburban
areas because of the drug’s price and ease of availability, and it is replacing some traditional drugs as a
less expensive, more potent alternative. Moreover,
frequent media reports; recent strengthening of criminal penalties for the manufacture, transfer, and
possession of methamphetamine; and the statewide
illegalization of transporting materials used in its
production have fueled the growing concerns over the
dangers the drug poses. Methamphetamine is not
only a party drug, but it is also used for weight loss or
as a way to keep up with demanding work schedules.
There were 567 ED reports of methamphetamine in
the Atlanta metropolitan area from January through
December 2004 according to unweighted data accessed from DAWN Live! (exhibit 2). During this
same period, the ratio of men to women among
methamphetamine ED reports was nearly 2:1. Although race/ethnicity was not documented for 19
percent of these patients, Whites represented nearly
70 percent of the methamphetamine ED reports (exhibit 3). ED reports among patients between the ages
of 25 and 44 totaled 346 (61 percent of all methamphetamine ED reports).
There were 367 ED amphetamine reports in the Atlanta metropolitan area in 2004 (exhibit 2). The gap
between male and female ED reports for amphetamine was narrow (exhibit 3), with a male-to-female
ratio of 1.3:1. More than three out of four amphetamine-related ED patients were White, while AfricanAmericans represented 8 percent of these patients.
The proportion of treatment admissions in metropolitan and non-metropolitan areas for methamphetamine
continues to rise faster than for any other classification of drug. In 2004, 8.5 percent (n=680) of public
treatment admissions reported methamphetamine as
the primary drug of choice, compared with 5.1 percent (543) in 2003 and 3.1 percent (377) in 2002 (exhibit 4). The proportion of admissions for methamphetamine in non-metropolitan Atlanta was more
than 14 percent, the highest percentage ever reported.
The number of women in metropolitan Atlanta who
reported to treatment for methamphetamine-related
causes increased in 2004 and represented more than
53 percent of all admissions. In treatment centers
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outside of metropolitan Atlanta, the percentage of
women entering treatment (56 percent) remained
nearly identical to 2003. Most users were White; in
fact, Whites accounted for 96 percent of treatment
admissions in metropolitan Atlanta during 2004 (exhibit 5). Nevertheless, the proportions of AfricanAmerican and Hispanic users are growing. Regardless of demographic area, more than 78 percent of
statewide treatment admissions were individuals
older than 35. Metropolitan Atlanta treatment admissions were most likely to smoke methamphetamine
(47 percent), followed by snort (23 percent), and inject (13 percent). Non-metropolitan Atlanta treatment
admissions preferred to smoke (56 percent), inject
(15 percent), and orally consume methamphetamine
(14 percent).
According to the DEA and HIDTA, methamphetamine popularity continues to rise, in part because of
its low price and ready availability. In 2004,
methamphetamine typically sold for $110 per gram,
$1,316 per ounce, and $8,250 per pound.
Law enforcement officials report that methamphetamine has emerged as the primary drug threat in suburban communities in neighboring Fulton and
DeKalb Counties. The Atlanta HIDTA task force
found that more than 68 percent of participating law
enforcement agencies identified methamphetamine as
posing the greatest threat to their areas. Methamphetamine accounted for more than 30 percent of
NFLIS tests of seized drugs in 2004, compared with
23 percent in 2003. In 2004, the proportion of positive methamphetamine tests among seized drugs
ranked second behind only cocaine (exhibit 6). In
2003, the proportion of methamphetamine-related
items had ranked third behind cocaine and marijuana.
The HIDTA task force seized more methamphetamine in 2004 than in previous years. These seizures
in 2004 included 14.6 kilograms of methamphetamine and 11.4 kilograms of crystal methamphetamine
or “ice.” HIDTA investigators also report an increase
among African-Americans using methamphetamine
in Atlanta. Ethnographic data from Atlanta-area drug
research studies among individuals age 18–25 support this trend.
Depressants
The use of depressants, especially benzodiazepines,
is on the rise in Atlanta. The most commonly abused
benzodiazepine is alprazolam (Xanax). Only a few
people admitted for drug treatment chose benzodiazepines as their secondary or tertiary drug of choice,
but ME reports for these drugs continued to increase.
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The number of unweighted ED reports in metropolitan Atlanta consists of the following: 96 barbiturates,
814 benzodiazepines, and 268 miscellaneous other
depressants.
The treatment data from publicly funded programs
included depressants such as barbiturates and benzodiazepines only as secondary and tertiary drug
choices for 2004. In metropolitan Atlanta, nearly 1
percent of primary heroin and methamphetamine
users chose benzodiazepines as a secondary drug
choice. These percentages are consistent with the
figures from the previous 3 years.
The DEA considers benzodiazepines and other prescription depressants to be a minor threat in Georgia.
The pills are widely available on the street, but their
abuse does not seem to have reached the levels of
oxycodone and hydrocodone abuse. According to the
NDIC and DEA Georgia Threat Assessment (April
2003), local dealers tend to work independently and
typically sell to “acquaintances and established customers.” These primarily White dealers and abusers
steal prescription pads, rob pharmacies, and attempt
to convince doctors to prescribe the desired pills.
Hallucinogens
The epidemiological indicators and law enforcement
data do not indicate much hallucinogen use in Atlanta. Despite these data, there was an increase in
ethnographic reports of phencyclidine (PCP) in the
past 12 months.
In 2004, there were 24 total ED reports for lysergic
acid diethylamide (LSD) according to the unweighted
DAWN Live! data. Most of the 2004 ED reports involved men rather than women, with a ratio of 5:1.
Whites and African-Americans represented equal
numbers (n=9) of ED patients for LSD. In 2004, the
majority of LSD patients were age 18–29 (67 percent). The total number of ED reports for PCP in
2004 was 47. PCP reports were highest among White
males between the ages of 35 and 44 and 18 and 24.
Treatment data for hallucinogens are only available
for secondary and tertiary drug abuse categories, and
these are listed as PCP and “other hallucinogens.” In
2004, hallucinogens were listed 14 times as a secondary or tertiary drug of choice in metropolitan Atlanta. “Other hallucinogens” were listed 30 times as a
secondary drug of abuse and 41 times as a tertiary
drug in non-metropolitan areas, also consistent with
previous years.
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In 2004, LSD accounted for only 0.04 percent of
drugs analyzed by NFLIS. The DEA reports an increase in the availability of LSD, especially among
White traffickers/users age 18–25. LSD is usually
encountered in school settings and is imported
through the U.S. Postal Service. No PCP items were
reported by NFLIS in FY 2004.

ports were also predominantly White (8 to 1 AfricanAmerican, with only 2 Hispanic reports in this time
period). Seventy-six percent of GHB reports occurred
among those age 25–44. There were no ED GHB
reports for those younger than 18, and there was only
one report for the 45 and older category. The reported
preferred route of administration was almost exclusively oral.

Club Drugs
While so-called club drugs—methylenedioxymethamphetamine (MDMA or ecstasy), gamma hydroxybutyrate (GHB), and ketamine—appear relatively
infrequently in epidemiological data, ethnographic
and sociologic research suggests continued frequency
in use, particularly among metropolitan Atlanta’s
young adult population.
According to unweighted data accessed from DAWN
Live!, there were 75 ED MDMA reports in 2004 (exhibit 2). MDMA reports by males exceeded those by
females by almost double (1.6:1 ratio) (exhibit 3).
There was an approximately even ratio (1:1.1) among
Whites and African-Americans; there were no ED
MDMA reports involving Hispanics. Young adults
(age 21–29) represent 56 percent of ED MDMA patients. The reported route of administration for
MDMA was almost exclusively oral. More than onehalf of ED MDMA cases were referred to other treatment or admitted for detoxification or psychiatric
treatment.
Atlanta serves as a distribution point for MDMA to
other U.S. cities. According to the NDIC, most of
the MDMA available in Georgia is produced in
northern Europe and flown into major U.S. cities,
including Atlanta. The NFLIS reported that in 2004,
MDMA accounted for 2.0 percent of substances
tested in suspected drug cases (exhibit 6); methylenedioxyamphetamine (MDA) accounted for another
0.4 percent. The April 2003 NDIC and DEA Georgia Threat Assessment indicated that most dealers are
White middle and upper class high school and college students between the ages of 18 and 25. The
drug retails at $20–$30 per tablet, according to a July
2003 report by the NDIC, although ethnographic data
indicate that many users buy ecstasy in bulk. Users
report that bulk ecstasy rates are $5–$10 per pill. An
emerging trend among young adults is “candy flipping,” or combining MDMA and LSD, according to a
local university report.
There were a total of 50 unweighted GHB ED reports
in 2004. GHB reports for males exceeded those for
females (exhibit 3), at a ratio of 4.6:1. GHB ED re-
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The NDIC reports that the primary distributors and
abusers of GHB are White young adults. The DEA
Atlanta Division reports that in 2003, liquid GHB
sold for $500 to $1,000 per gallon and $15 to $20 per
dose (one dose is usually the equivalent of a capful
from a small water bottle).
In 2004, there were five unweighted ED ketamine
reports among males and none among females.
INFECTIOUS DISEASES RELATED TO SUBSTANCE
ABUSE
At the end of 2003, Georgia ranked eighth in the Nation for cumulative AIDS cases. At the end of 2001,
the State was ninth. The number of overall AIDS
cases was significantly higher in 2003 (22 per
100,000 population) than in 2002 (17.2 per 100,000
population). Approximately 1,907 new AIDS cases
were reported in the State in 2003, for a cumulative
total of 14,023 persons living with AIDS. HIV surveillance nationwide indicates a consistent increase
in new infections.
In 2003, nearly 73 percent of all new AIDS diagnoses
were male, while African- Americans accounted for
74 percent of these total cases. In Georgia, nearly 73
percent of the new HIV/AIDS cases were older than
25, with the highest prevalence occurring among 35–
44 year-olds. The majority of new AIDS cases in
Georgia continue to come from Atlanta’s Fulton and
DeKalb Counties.
New cases of sexually transmitted diseases identified
in Georgia in 2003 included chlamydia (n=35,686),
gonorrhea (n=17,686), and syphilis (n=585). In 2003,
there were 484 statewide total cases of hepatitis B
and 64 statewide reports of hepatitis C; the majority
of cases originated in the Atlanta metropolitan area.
For inquiries concerning this report, please contact Brian J. Dew,
Ph.D., LPC, Assistant Professor, Georgia State University, Department of Counseling and Psychological Services, P.O. Box
3980, Atlanta, GA 30302-3980, Phone: (404)651-3409, Email:
<bdew@gsu.edu>.
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Exhibit 1. Data Completeness for Atlanta Metropolitan Area DAWN Live! Emergency Departments
(n=30),1 by Month: 2004
No. of EDs Reporting per Month:
Completeness of Data (%)

Total Eligible
Hospitals1

No. of Hospitals in DAWN
Sample

Total EDs in
DAWN Sam2
ple

90–100%

50–89%

<50%

39

30

33

16–18

0–2

0–1

No. of EDs Not
Reporting
14–16

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital
Association Annual Survey.
2
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005

Exhibit 2. Number of Drug Reports in Drug-Related ED Visits, by Drug Category (Unweighted): 20041
Cocaine

5,758

Marijuana

2,001

Stimulants

934

567 Methamphetamine

367 Amphetamines

Heroin

483

MDMA

75

0

500

1000

1500

2000

2500

3000

3500

4000

4500

5000

5500

6000

6500

7000

1

The unweighted data are from 16–18 EDs reporting to Atlanta hospitals reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted, and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA; updated 4/13–4/14/2005
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Exhibit 4. Percentages of Primary Treatment Admissions in Atlanta: FYs 2000–2004
Drug
Cocaine/Crack
Heroin
Marijuana
Methamphetamine
Other Drugs1
Total Admissions (N=)

FY 2000
58.3
6.6
16.0
1.5
17.6
(6,990)

FY 2001
58.5
6.7
15.5
1.6
26.1
(7,996)

FY 2002
43.1
7.6
18.7
3.1
21.3
(7,909)

FY 2003
42.8
6.3
20.0
5.1
25.8
(7,178)

FY 2004
39.5
5.6
21.7
8.5
24.6
7,996

1

Includes “alcohol-in-combination.”
SOURCE: Georgia Department of Human Resources

Exhibit 5. Metropolitan Atlanta Public Substance Abuse Treatment Admissions, Selected Drugs by Race:
2004
2,500
2,000
1,500
1,000
500
0

Alcohol-inCombination

Cocaine

Marijuana

Heroin

Methamphetamine

White

632

834

656

206

653

Black

1,300

2,265

978

230

14

19

44

63

10

7

20

32

52

4

5

Hispanic
Other

1

1

Other Category includes Asian, American Indian, multicultural, or other race.
SOURCE: Georgia Department of Human Resources

Exhibit 6. Number of Analyzed Items and Percentage of All Items Tested in Atlanta: 2004
Drug
Cocaine
Methamphetamine
Cannabis
Alprazolam
MDMA/MDA
Hydrocodone
Heroin
Oxycodone
Methadone
Diazepam
Other1
Total

Number
7,923
5,434
2,578
380
424
315
194
159
83
65
301
17,922

Percent
44.2
30.3
14.4
2.1
2.4
1.8
1.1
0.9
0.5
0.4
1.9
100.0

1

Includes carisoprodol, amphetamine, clonazepam, morphine, codeine, psilocin, non-controlled non-narcotic drug, methylphenidate,
ketamine, gamma hydroxybutyrate, hydromorphone, 1-(3-trifluoromethylphenyl)-piperazine, lorazepam, and lysergic acid diethylamide.
SOURCE: NFLIS, DEA
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Exhibit 7. Number of Prescription Drug Misuse Reports in Drug-Related ED Visits,
by Case Type (Unweighted1): 2004
Benzodiazepines

814

Hydrocodone
Oxycodone

268
212

1

The unweighted data are from 16–18 EDs reporting to Atlanta hospitals reporting to DAWN in 2004. All DAWN cases are reviewed
for quality control. Based on this review, cases may be corrected or deleted, and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA; updated 06/04/205
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Drug Use in the Baltimore
Metropolitan Area: Epidemiology and Trends, 2000–2004
Leigh A. Henderson, Ph.D., and Doren H.
Walker, M.S.1
ABSTRACT
Heroin indicators for the Baltimore metropolitan
area as a whole have generally indicated an increase over 2001 levels. In 2004, heroin was responsible for 52 percent of drug-related treatment admissions. Heroin use in the Baltimore metropolitan
area is complex. There are several groups of heroin
users differing by urbanicity, route of administration, age, and race. Baltimore has a core of older
African-American heroin users, both intranasal
users (37 percent of all 2004 heroin treatment admissions) and injectors (19 percent all 2004 heroin
treatment admissions). White users entering treatment for heroin were younger and were predominantly injectors (29 percent of all 2004 heroin
treatment admissions) rather than intranasal users
(10 percent of all heroin treatment admissions).
Cocaine indicators also began to increase in 2001.
In 2004, cocaine use was reported by 50 percent of
drug-related treatment admissions in the Baltimore
PMSA, with 14 percent reporting primary use and
36 percent reporting use secondary to use of alcohol
or another drug. Cocaine smoking was the most
prevalent route of administration among both primary and secondary users, followed by injection
and intranasal use. Cocaine use was associated with
heroin use, but the preferred route of administration of heroin differed with the preferred route of
administration of cocaine. More than one-third (37
percent) of cocaine smokers used intranasal heroin.
Almost all cocaine injectors (90 percent) injected
heroin. More than one-third (35 percent) of intranasal cocaine users used heroin intranasally. Indicators of marijuana use have tended to increase
since 2000. Like cocaine, marijuana was reported
more frequently as a secondary substance than as a
primary substance—34 percent of drug-related
treatment admissions used marijuana, 15 percent as
a primary substance and 19 percent as a secondary
substance. More often than not, marijuana use in
the indicator data sets was associated with the use of
alcohol or other drugs—in 2004, 61 percent of
marijuana treatment admissions reported use of
1

additional substances. Persons entering treatment
for primary marijuana use were young—44 percent
were less than age 18. A large proportion of 2004
marijuana treatment admissions (62 percent) represented referrals through the criminal justice system.
Indicators for opiates and narcotics other than heroin have increased over the past several years.
Stimulants other than cocaine are rarely mentioned
as the primary substance of abuse by treatment admissions.
INTRODUCTION
Area Description
The Baltimore primary metropolitan statistical area
(PMSA) was home to some 2.6 million persons in
2004. It comprises Baltimore City and the suburban
counties of Anne Arundel, Baltimore, Carroll, Harford, Howard, and Queen Anne’s. Baltimore City is
the largest independent city in the United States. The
city’s population declined from 735,000 in 1990 to
629,000 in 2003. The population of the surrounding
counties has grown from approximately 1.7 million
in 1990 to 2.0 million in 2004.
The city and the suburban counties represent distinctly different socioeconomic groups. In 2000, median household income in the city was $30,000, and
23 percent of the population lived in poverty. In the
suburban counties, however, median household income ranged from $51,000 to $74,000, and the poverty rate averaged 5 percent. In 2000, the median
value of a single-family home was $69,100 in the city
and averaged $152,000 in the suburban counties. The
2000 population composition of the city differed
markedly from that of the surrounding counties: 32
percent White and 64 percent African-American,
versus 80 percent White and 15 percent AfricanAmerican, respectively. Two percent of the population in the city and 3 percent of the population in the
suburban counties was Asian. Two percent of the
population in both the city and the suburban counties
was Hispanic.
The Baltimore area is a major node on the north-south
drug trafficking route. It has facilities for entry of
drugs into the country by road, rail, air, and sea. Baltimore is located on Interstate 95, which continues north
to Philadelphia, New York, and Boston, and south to
Washington, DC, Richmond, and Florida. Frequent
daily train service is available on this route. The area is
served by three major airports (Baltimore-Washington
International Airport in Baltimore County and Reagan
National and Dulles Airports in the vicinity of Washington, DC, approximately 50 miles from the Balti-

The authors are affiliated with Synectics for Management Decisions, Inc., Arlington, Virginia.
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more City center). Baltimore is also a significant active
seaport. The area has numerous colleges and universities and several military bases.

the case types Seeking detox, Overmedication,
and Other are included. In the Baltimore PMSA,
there were 21 hospitals with 24 EDs in the
DAWN sample, reporting for 182 of a possible
288 months, a response rate of 63 percent.

Data Sources
•

Population and demographic data, including
population estimates for 1990–2003 and income,
poverty, and housing cost estimates for 2000 for
Maryland counties, were derived from U.S. Bureau of the Census data (electronic access:
<http://factfinder.census.gov> last accessed June
13, 2004).

•

Treatment admissions data were provided by
the Maryland Alcohol and Drug Abuse Administration, Department of Health and Mental Hygiene, for 1992 through 2004. Data are presented
for the PMSA as a whole, as well as separately
for Baltimore City and the suburban counties.
Included are those programs receiving both public and private funding. All clients are reported,
regardless of individual source of funding. Significant omissions are the Baltimore City and
Fort Howard Veterans’ Administration Medical
Centers, which do not report to the State data
collection system. Treatment data in this report
exclude admissions for abuse of alcohol alone
(about 15 percent of all treatment admissions).
Admissions with primary abuse of alcohol and
secondary/tertiary abuse of drugs (about 12 percent of all admissions) are included.

•

Emergency department (ED) drug mentions
data were provided by the Drug Abuse Warning
Network (DAWN), Office of Applied Studies
(OAS), Substance Abuse and Mental Health
Services Administration (SAMHSA), for the
Baltimore PMSA for 2004. Data reflect cases
that have been received by DAWN as of: 4/1314/2005. All DAWN cases are reviewed for
quality control. Based on this review, cases may
be corrected or deleted. Data are unweighted,
noncomparable across areas, and subject to
change. DAWN data are reported for the following case types: Suicide attempt, Seeking detox,
Alcohol only (age<21), Adverse reaction, Overmedication, Malicious poisoning, Accidental ingestion, and Other. Data are reported for all case
types combined (except Seeking detox, which is
reported for all major substances combined) for
major substances of abuse (Cocaine, Heroin,
Marijuana, Amphetamines, Methamphetamine,
MDMA (Ecstasy), GHB, Ketamine, LSD, PCP,
Miscellaneous hallucinogens, Inhalants, and
Combinations NTA). For other substances, only
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•

Mortality data were provided by the Drug Abuse
Warning Network (DAWN), Office of Applied
Studies (OAS), Substance Abuse and Mental
Health Services Administration (SAMHSA), for
the Baltimore PMSA for 2003. Drug Abuse Warning Network, 2003. Area Profiles of Drug Mortality. DAWN Series D-27, DHHS Pub. No. (SMA)
05-4023. Rockville, MD, 2005.

•

Illicit drug prices were provided by the National Drug Intelligence Center, Narcotics Digest
Weekly 3(52), December 28, 2004, for July
2004–December 2004.

•

Data on drug seizures were provided by the
National Forensic Laboratory Information System (NFLIS), for January-December, 2004.

DRUG ABUSE PATTERNS AND TRENDS
Polydrug use in general is the norm in the Baltimore
PMSA. About three-quarters of drug-related treatment admissions in 2004 reported problems with at
least one substance other than their primary substance. In 2003, 87 percent of the 538 drug-related
deaths reported to the area’s medical examiners involved multiple substances. DAWN emergency department (ED) data for 2004 (see notes under Data
Sources above) reported 3,876 DAWN non-detox
cases, and 10,528 mentions of major substances of
abuse among these cases, an average of 2.7 substances per case.
Cocaine/Crack
Cocaine indicators (treatment admission rates, rates
of ED mentions, and cocaine-involved deaths) all
began to increase in 2001 (exhibit 1). Cocaine was
present in 226 (42 percent) of drug-related deaths in
2003. The cocaine treatment admission rate increased
from 162 per 100,000 population age 12 and over in
2000 to 225 per 100,000 in 2003 (exhibit 2). The rate
declined slightly, to 203 per 100,000, in 2004.
In 2004, cocaine was mentioned by 43 percent of the
DAWN non-detox ED cases (see notes under Data
Sources above), a proportion similar to the 43 percent
of ED cases involving heroin. The cocaine and heroin
cases were demographically similar—64 percent
male, 44 percent and 46 percent White, respectively,
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and twenty-one percent of each aged 45 or older. It is
likely that many of the ED cases reflect co-use of
cocaine and heroin (see Exhibit 4, below).
Smoked cocaine (crack) represented 79 percent of the
treatment admissions for primary cocaine use in the
Baltimore PMSA in 2004 (exhibit 2). The population
in treatment for cocaine smoking has aged (exhibit
3). About three-quarters (72 percent) were age 35 or
older in 2004, an increase from 59 percent in 2000.
The median age at admission to treatment was 39
years, compared with 36 in 2000. Almost one-half
(45 percent) of those in treatment for smoking cocaine were women, and about two-thirds (65 percent)
were African-American. The majority (62 percent) of
the cocaine smokers had been in treatment before,
and most (67 percent) were referred through sources
other than the criminal justice system. Daily use of
smoked cocaine was reported by 42 percent, and use
of other drugs in addition to smoked cocaine was
reported by more than two-thirds (69 percent). Alcohol was the most common secondary drug (used by
47 percent), followed by marijuana (23 percent) and
heroin used intranasally (14 percent). Only 3 percent
of crack smokers reported heroin injection.
Primary use of cocaine represented 14 percent of
drug-related treatment admissions in 2004, well behind the 52 percent of admissions represented by
primary use of heroin (exhibit 2). Despite the apparent dominance of heroin in the Baltimore PMSA,
testing of some 40,000 items in FY 2004 by the National Forensics Laboratory found that 43 percent
were cocaine and 26 percent were heroin. This apparent discrepancy may be explained by the use of cocaine as a secondary substance. Cocaine was reported
as a secondary substance by 36 percent of treatment
admissions in 2004 (exhibit 2), meaning that 50 percent of treatment admissions reported cocaine abuse
as a primary or secondary problem.
Exhibit 4 compares the characteristics of treatment
admissions for primary and secondary cocaine use
according to the route of administration of cocaine.
Cocaine smoking was the most prevalent among both
primary and secondary users, followed by injection
and intranasal use. Differences between primary and
secondary users were generally small, although secondary users were consistently less likely to be entering treatment for the first time than primary users.
User characteristics were more pronounced between
routes of administration. Cocaine smokers were more
likely to be female (50 percent of cocaine smokers,
compared to 39 percent of injectors and 32 percent of
intranasal users), African-American (67 percent, 51
percent, and 42 percent, respectively), age 35 and
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older (70 percent, 60 percent, and 54 percent, respectively). Cocaine smokers were less likely to be age 25
and younger (9 percent, compared with 18 percent of
injectors and 25 percent of intranasal users). Cocaine
smokers and injectors were more likely to be treated
in the City (67 percent and 69 percent, respectively,
compared to 44 percent of the intranasal users).
Cocaine use was associated with heroin use, but the
preferred route of administration of heroin differed
with the preferred route of administration of cocaine
(exhibit 4). More than one-third (37 percent) of cocaine smokers used intranasal heroin—50 percent as
their primary substance, and 14 percent as a secondary substance. Almost all cocaine injectors (90 percent) injected heroin—93 percent as their primary,
and 60 percent of as a secondary substance. More
than one-third (35 percent) of intranasal cocaine users
used heroin intranasally—41 percent as their primary
substance problem, and 10 percent as a secondary
problem.
Thirty-seven percent of the cocaine smokers reported
cocaine smoking as their primary problem (exhibit
4). Secondary cocaine smokers were somewhat more
likely to be female (53 percent of secondary smokers,
compared to 45 percent of primary smokers), and
more likely to be treated in Baltimore City (71 percent and 60 percent, respectively). Other primary
problems reported by secondary cocaine smokers
were alcohol (21 percent) and heroin injection (21
percent).
Only 7 percent of the cocaine injectors reported cocaine injection as their primary problem (exhibit 4).
Secondary cocaine injectors were somewhat older
(49 percent of secondary injectors, compared to 37
percent of primary injectors). They were less likely to
be experiencing a first treatment episode (26 percent
of secondary injectors, compared to 33 percent of
primary injectors). They were less likely to enter
treatment through a criminal justice referral (25 percent of secondary injectors, compared to 31 percent
of primary injectors). Secondary injectors were
somewhat more likely to be treated in Baltimore City
(70 percent and 64 percent, respectively).
About one-fifth (22) percent of the cocaine inhalers
reported cocaine inhalation as their primary problem
(exhibit 4). Secondary cocaine inhalers were less
likely to be experiencing a first treatment episode (41
percent of secondary inhalers, compared to 49 percent of primary inhalers). They were more likely to
enter treatment through a criminal justice referral (38
percent of secondary inhalers, compared to 19 percent of primary inhalers). Secondary inhalers were
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somewhat less likely to be treated in the suburban
counties (55 percent and 63 percent, respectively).

urban counties, however, the rate for heroin injection
was 86 percent higher than for inhalation.

Exhibit 5 compares the number of cocaine treatment
admissions (primary, secondary, or tertiary use) in
2004 by route of administration, age, and race. For all
three routes of administration, the younger users
tended to be White rather than African-American.

Exhibit 6 compares the number of treatment admissions in 2004 by route of administration, age, and
race. Baltimore has a core of older African-American
heroin users, both injectors and intranasal users.
White users entering treatment for heroin were
younger and were predominantly injectors.

Prices for powdered cocaine for the second half of
2004 were reported as $20,000–$32,000 per kilogram
at the wholesale level; $900–$1,200 per ounce at
midlevel; and $0–$200 per gram at the retail level.
Prices for crack cocaine were reported as $20,000–
$26,000 per kilogram at the wholesale level; $600–
$1,200 per ounce at midlevel; and $40–$200 per
gram at the retail level. For powdered cocaine, the
price range at the wholesale kilogram level was unchanged from the second half of 2003, while the
lower limit for a retail-level gram was less. For crack
cocaine, the lower limit for a wholesale kilogram was
unchanged from the second half of 2003, while the
lower limit for a retail-level gram was less.
Heroin
Heroin indicators for the Baltimore metropolitan area
as a whole generally indicated an increase over 2001
levels (exhibit 1). Opiates were present in 469 (87
percent) of drug-related deaths in 2003. The heroin
treatment admission rate increased from 652 per
100,000 population age 12 and over in 2001 to 893
per 100,000 in 2003 (exhibit 2). However, it declined
slightly to 770 per 100,000 in 2004.
In 2004, heroin was mentioned by 43 percent of the
DAWN non-detox ED cases (see notes under Data
Sources above), a proportion similar to the 43 percent
of ED cases involving cocaine. The heroin and cocaine cases were demographically similar—64 percent male, 44 percent and 46 percent White, respectively, and twenty-one percent of each aged 45 or
older. It is likely that many of the ED cases reflect
co-use of heroin and cocaine (see Exhibit 4, below).
Heroin use in the Baltimore metropolitan area is
complex. There are several groups of heroin users
differing by urbanicity, route of administration, age,
and race. In 2004, the heroin treatment admission rate
was about seven times higher in Baltimore City than
in the suburban counties (exhibit 2).
In Baltimore City, intranasal use was the preferred
route of administration among treatment admissions
(exhibit 2), and the admission rate for intranasal use
was 26 percent higher than for injection. In the sub-
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African-American heroin intranasal users made up 37
percent of the heroin-using treatment admissions in
the Baltimore PMSA in 2004, and most (89 percent)
were treated in Baltimore City. Among heroin intranasal users in the city (exhibit 7), most admissions
were African-American (88 percent) and were age 35
and older (74 percent). Almost half (47 percent) of
the intranasal heroin users were women. The median
age at admission was 39, and the median duration of
use before first entering treatment was 14 years. Seventy percent reported daily heroin use. About onethird (31 percent) entered treatment through the
criminal justice system, and about one-third (34 percent) were receiving treatment for the first time.
Two-thirds (68 percent) reported use of other drugs—
42 percent smoked cocaine, 24 percent used alcohol,
11 percent used marijuana, and 9 percent used cocaine intranasally.
White heroin injectors made up 29 percent of the
heroin-using treatment admissions in the Baltimore
PMSA in 2004, and more than half were (59 percent)
were treated in the suburban counties. Among heroin
injectors in the suburban counties (exhibit 8), most
admissions were White (86 percent). More than onethird (38 percent) of suburban injectors were age 25
and younger. Sixty percent of the suburban heroin
injectors were male. The median age at admission
was 28, and the median duration of use before first
entering treatment was 6 years. About two-thirds (68
percent) reported daily heroin use. About one in five
(23 percent) entered treatment through the criminal
justice system, and one-third (31 percent) were receiving treatment for the first time. More than twothirds (70 percent) reported use of other drugs—, 29
percent injected cocaine, 28 percent used marijuana,
21 percent used alcohol, 15 percent smoked cocaine,
and 8 percent used opiates other than heroin.
African-American heroin injectors made up 19 percent of the heroin-using treatment admissions in the
Baltimore PMSA in 2004. Most (88 percent) were
treated in Baltimore City. Among heroin injectors in
the city (exhibit 8), the majority of admissions (58
percent) were African-American, and were age 35
and older (66 percent), although the proportion of
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injection users age 25 and younger increased from 9
percent in 2000 to 14 percent in 2004. Some 43 percent of the city’s heroin injectors were women. The
median age at admission was 40, and the median duration of use before first entering treatment was 14
years. Most (79 percent) reported daily heroin use.
Less than one-quarter (20 percent) entered treatment
through the criminal justice system, and about onequarter (27 percent) were receiving treatment for the
first time. Most (76 percent) reported use of other
drugs—47 percent injected cocaine, 23 percent used
alcohol, 15 percent smoked cocaine, and 7 percent
used marijuana.
White heroin intranasal users made up 10 percent of
the heroin-using treatment admissions in the Baltimore PMSA in 2004. Almost two-thirds (63 percent)
were treated in the suburban counties. Among heroin
intranasal users in the suburban counties (exhibit 7),
more than half (59 percent) were White, and 49 percent were age 35 and older, although the proportion
of intranasal users age 25 and younger was 23 percent in 2004. Some 35 percent of the suburban intranasal users were women. The median age at admission was 34, and the median duration of use before
first entering treatment was 7 years. Most (63 percent) reported daily heroin use. About one-quarter
(27 percent) entered treatment through the criminal
justice system, and 43 percent were receiving treatment for the first time. A majority (66 percent) reported use of other drugs—21 percent each smoked
cocaine, used alcohol, and/or used marijuana, 17 percent used cocaine intranasally, and 11 percent used
opiates other than heroin.
In 2004, there were 4,531 DAWN heroin ED cases, a
number similar to the 4,511 cases involving cocaine.
Given the co-use of heroin and cocaine demonstrated
in Exhibit 4, it is likely that these cases represent use
of both these drugs by the individual seeking ED
care. The heroin and cocaine cases were demographically similar as well—64 percent male, 44 percent
and 46 percent White, respectively. Twenty-one percent of both heroin and cocaine cases were aged 45
or older, and 56 percent of heroin cases were 35 or
older, as were 61 percent of cocaine cases.
Of the 37,000 items from Baltimore tested by the
National Forensic Laboratory in 2004, 26 percent
were heroin.
Most of the heroin sold in Baltimore is from South
America. Its purity for 2003 was reported by the
DEA’s Domestic Monitor Program as 35 percent
(based on 24 samples), and the price as $0.31 per milligram pure. Both priority and price were lower than
the national average of 42 percent putity and $0.77 per
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milligram pure. One Southeast Asian sample was purchased (purity, 20 percent; price $0.31 per milligram
pure, and one Southwest Asian sample was purchased
(purity, 2.8%, price $1.55 per milligram pure).
Other Opiates and Narcotics
For opiates and narcotics other than heroin, indicators
have increased over the past several years (exhibit 1).
Treatment admission rates for opiates other than heroin more than doubled between 2000 and 2003, from
23 per 100,000 population age 12 and over to 55 per
100,000 in 2003 and 2004 (exhibit 2). In 2004, there
were 1,307 ED cases involving opiates/opioids
among a subset of the DAWN ED cases (see notes
under Data Sources above). Forty-one percent of
these cases specified oxycodone, 7 percent specified
hydrocodone, 32 percent specified other opiates, and
the opiate was unspecified in 21 percent of cases
Opiates other than heroin were reported by 4 percent
of admissions as the primary substance of abuse, and
were reported by an additional 4 percent as a secondary or tertiary substance (exhibit 2). Exhibit 9 combines all admissions reporting opiates other than heroin as primary, secondary, or tertiary substances.
Treatment admissions involving opiates other than
heroin were primarily White (88 percent). Just over
half (57 percent) were male. Almost half (44 percent)
were ages 35 or older, although the proportion age 25
and younger increased from 21 percent in 2000 to 34
percent in 2004. The median age at admission was
32, and the mediation duration of use of opiates other
than heroin before first entering treatment was 4
years. Daily use of opiates other than heroin was reported by 67 percent. Only a small proportion (13
percent) entered treatment through the criminal justice system, and 44 percent were entering treatment
for the first time.
Marijuana
Indicators of marijuana use have tended to increase
since 2000 (exhibit 1). The rates of marijuana ED
mentions increased significantly in 2002 over 2001.
The annual marijuana treatment admission rate increased from 200 per 100,000 population age 12 and
over in 2000 to 249 per 100,000 in 2003, then declined slightly to 222 in 2004 (exhibit 2). The proportion of marijuana treatment admissions in 2004 was
higher in the suburban counties (20 percent of county
admissions) than in Baltimore City (11 percent of
City admissions), but the admission rate for 2004 was
higher in the city (380 per 100,000 population age 12
and over, compared with 173 per 100,000 in the
counties).
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In 2004, marijuana was mentioned by 12 percent of
the DAWN non-detox ED cases (see notes under
Data Sources above). Two-thirds (65 percent) were
male and 65 percent were White. Twenty-three percent were less than 18 years of age, and another 30
percent were aged 18 to 24.
More often than not, marijuana use in the indicator
data sets was associated with the use of alcohol or
other drugs. Marijuana was more frequently reported
as a secondary substance than as a primary substance
by treatment admissions in the total PMSA in 2004,
at 15 percent and 19 percent, respectively (exhibit 2).
Among treatment admissions for primary marijuana
use in the total PMSA, 61 percent reported using additional substances (exhibit 10). More than one-half
(53 percent) reported alcohol use, 8 percent reported
cocaine use, 3 percent reported use of heroin, and 3
percent reported use of opiates other than heroin.
Some 7 percent of admissions used other secondary
substances, primarily hallucinogens, stimulants, PCP,
tranquilizers, and sedatives.
Persons entering treatment for marijuana use were
young: 44 percent were less than age 18, and the median age at admission to treatment was 18 (exhibit
10). Marijuana admissions were primarily male (82
percent) and increasingly likely to be AfricanAmerican (51 percent in 2004, compared with 46
percent in 2000). A large proportion of marijuana
treatment admissions (62 percent) represented referrals through the criminal justice system. Admissions
were likely to be experiencing their first treatment
episode (66 percent), and more than one-third (35
percent) reported daily marijuana use.
Of the 37,000 items from Baltimore tested by the
National Forensic Laboratory in 2004, 30 percent
were cannabis.
Prices for marijuana for the second half of 2004 were
reported as $2,390–$4,000 per pound for hydroponic
marijuana or $1,000–$1,600 per pound for commercial grade marijuana at the wholesale level. Midlevel
prices were $275 per ounce for hydroponic and $130
per ounce for commercial grade. At the retail level,
prices were $35–$60 per one-quarter ounce or $20–
$40 per bag. The price range for hydroponic marijuana was slightly more for the wholesale-level kilogram than in the second half of 2003. The lower limit
for commercial-grade marijuana at the wholesalelevel kilogram was more than in the second half of
2003, but the upper limit was unchanged. The price
range was unchanged for a retail-level one-quarter
ounce or bag.
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Stimulants
Stimulants other than cocaine were rarely mentioned
as the primary substance of abuse by treatment admissions (exhibit 2). Nevertheless, the numbers, although small, increased from 42 admissions in 2000
to 76 in 2004. The majority (68 percent) of the 2004
stimulant admissions were for methamphetamine,
and 24 percent were for amphetamine. The treatment
admission rate for stimulants increased from 2.0 per
100,000 population age 12 and over in 2000 to 3.5
per 100,000 in 2004.
In 2004, all stimulants combined were mentioned by
1 percent of the DAWN non-detox ED cases (see
notes under Data Sources above).
Other Drugs
Drugs other than alcohol, cocaine, heroin, opiates
(other than heroin), marijuana, and stimulants were
responsible for less than 2 percent of treatment admissions in 2004 (exhibit 2). In 2004, in a subset of
DAWN ED cases (see notes under Data Sources
above), there were 59 cases involving methylenedioxymethamphetamine (MDMA), 34 involving phencyclidine (PCP), 19 involving inhalants, 18 involving
lysergic acid diethylamide (LSD), 7 involving ketamine, and 4 involving gamma hydroxylbutyrate
(GHB).
Treatment admissions for benzodiazepines and other
tranquilizers increased slightly, from 4.0 per 100,000
population age 12 and over in 2003 to 4.8 per
100,000 in 2004. In 2004, there were 888 DAWN ED
cases involving benzodiazepines.
Treatment admissions for barbiturates and other sedatives decreased slightly, from 4.2 per 100,000 population age 12 and over in 2003 to 3.7 per 100,000 in
2004.
Treatment admissions for lysergic acid diethylamide
(LSD) increased from 2.4 per 100,000 population age
12 and over in 2003 to 3.1 per 100,000 in 2004.
Treatment admissions for PCP declined from 4.3 per
100,000 population age 12 and over in 2003 to 2.0
per 100,000 in 2004. Between 2003 and 2004, treatment admissions for inhalants were relatively stable,
at 0.7 per 100,000 population age 12 and over in
2003 and 0.6 per 100, 000 in 2004. Treatment admissions for over-the-counter drugs were unchanged at
0.5 per 100,000 population age 12 and over in 2003
and 2004.
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INFECTIOUS DISEASES RELATED TO DRUG ABUSE
The annual AIDS case report rate for 2003 for the
Baltimore PMSA (39 cases per 100,000) ranked fifth
behind New York City (59 per 100,000), Miami (46
per 100,000), San Francisco (45 per 100,000) and
Fort Lauderdale (40 per 100,000) (CDC 2003).
The Baltimore PMSA accounted for 64 percent and
63 percent, respectively, of Maryland’s incident and
prevalent human immunodeficiency virus (HIV)
cases, 59 percent of its incident AIDS case, and 60
percent of its prevalent AIDS cases (AIDS Administration 2004). Baltimore City by itself accounted for
51 percent of Maryland’s 2003 incident and prevalent
HIV cases, 46 percent of its incident AIDS cases, and
47 percent of its prevalent AIDS cases. The Baltimore metropolitan area had an AIDS incidence rate
of 33 per 100,000 population for 2003, and an HIV
incidence rate of 49 per 100,000. The AIDS prevalence rate in the Baltimore metropolitan area in 2003
was 298 per 100,000 population, and the HIV prevalence rate was 382 per 100,000.
In 2003, Baltimore City’s prevalent HIV/AIDS cases
were about 62 percent male and 81 percent AfricanAmerican (AIDS Administration 2004). Forty-four
percent were aged 40–49 years, and another 24 percent were aged 30–39 years. Fifty-six percent of the
prevalent HIV/AIDS cases in Baltimore City in
which the risk category was determined were injection drug users (IDUs), 15 percent were non-IDU
men who had sex with men, and 26 percent involved
heterosexual transmission. In the suburban counties,
prevalent HIV/AIDS cases were 66 percent male and
55 percent African-American. Forty-one percent
were aged 40–49, and another 29 percent were aged
30–39. For cases in which the risk category was determined, 36 percent of prevalent HIV/AIDS cases in
the suburban counties were IDUs, 29 percent were
non-IDU men who had sex with men, and 31 percent
involved heterosexual transmission. In Maryland as a
whole, IDUs represented 47 percent of prevalent
HIV/AIDS cases in 2003.
In 1999, Baltimore City ranked highest among the 20
cities most burdened by sexually transmitted diseases
(STDs) for gonorrhea (949 per 100,000 population),
fifth for chlamydia (819 per 100,000 population), and
third for syphilis (38 per 100,000 population) (CDC
2000). By 2003, STD rates for Baltimore City had
decreased for gonorrhea (to 617 per 100,000) and for
syphilis (to 23 per 100,000), but had increased for
chlamydia (to 1,001 per 100,000) (AIDS Administration 2004).
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Voluntary HIV testing is offered to Maryland prison
entrants. Among those tested in 2003, 5 percent were
positive for HIV (AIDS Administration 2004). A 2002
survey of entrants to Baltimore City detention facilities
and Maryland State prison entrants found that newly
incarcerated females had much higher HIV rates than
newly incarcerated males (13 percent and 4 percent,
respectively) (AIDS Administration 2004).
The survey of prison entrants also found that 25 percent had been infected by hepatitis B and 30 percent
had antibodies to hepatitis C (Solomon et al. 2004).
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Exhibit 1. Annual Rates of Drug-Related Treatment Admissions and ED Mentions per 100,000 Population,
and Numbers of Drug-Related Deaths in Baltimore: 1994–2004
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Exhibit 5.

Numbers of Primary, Secondary, and Tertiary Cocaine Treatment Admissions in Baltimore, by
Route of Administration, Age, and Race: 2004
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Exhibit 6.

Numbers of Primary Heroin Treatment Admissions in Baltimore, by Route of Administration,
Age, and Race: 2004
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Patterns and Trends in Drug
Abuse: Greater Boston

•

Contiguity with five neighboring States (Rhode
Island, Connecticut, New York, Vermont, and
New Hampshire) linked by a network of State and
interstate highways

Daniel P. Dooley1

•

Proximity to Interstate 95, which connects Boston
to all major cities on the east coast, particularly
New York

Heroin and cocaine indicators remain at very high
and stable, if not increasing, levels of abuse. Marijuana indicators show widespread use and stable
levels of abuse. Prescription drugs, most notably
narcotic analgesics including oxycodone (OxyContin) and benzodiazepines, show stable levels of misuse and abuse as well. With the exception of
substance abuse treatment admissions, indicators
show no signs of overall decreasing misuse and
abuse. The number of treatment admissions has
fallen considerably during the past three years, but
field sources say reductions in funding caused reductions in available services and, consequently,
fewer admissions. In 2003, there were 269 adult
HIV/AIDS cases diagnosed in Boston. The primary
transmission risk factors for these cases included 12
percent who were IDUs, 5 percent who had sex with
IDUs, and 35 percent with an unknown/undetermined risk factor.

•

A well-developed public transportation system
that provides easy access to communities in eastern Massachusetts

•

A large population of college students in both the
greater Boston area and western Massachusetts

•

Several seaport cities with major fishing industries
(now in decline) and harbor areas

•

Logan International Airport and several regional
airports within a 1-hour drive of Boston

•

State budget cutbacks on social services

•

A high number of homeless individuals seeking
shelter

INTRODUCTION

Data sources for this report include the following:

Area Description

•

ABSTRACT

This report presents data from a number of different
sources with varied Boston-area geographical parameters. A description of the relevant boundary parameters is included with each data source
description. For simplicity, these are all referred to as
“Boston” throughout the text.
According to the 2000 U.S. census, Massachusetts
ranks 13th in population (6,349,097 people). The
746,914 people in the metropolitan Boston area represent 12 percent of the total Massachusetts population. The 2000 census data show that there were
589,141 residents of the city of Boston. The racial
composition includes 50 percent White non-Hispanic,
23 percent Black non-Hispanic, 14 percent Hispanic/
Latino, and 8 percent Asian.
Several characteristics influence drug trends in Boston and throughout Massachusetts:

Data Sources

Emergency department (ED) drug mentions
data were provided by the Drug Abuse Warning
Network (DAWN), Office of Applied Studies
(OAS), Substance Abuse and Mental Health Services Administration (SAMHSA), for a Boston
metropolitan area consisting of five Massachusetts
counties: Essex, Middlesex, Norfolk, Plymouth,
and Suffolk. DAWN weighted estimates for 2002
are presented in this paper and are the most recent
final estimates. In 2003, OAS instituted a redesigned ED system. The data from the new system
cannot be compared with those for 2002 and before. In the Boston metropolitan area, 29 of the 41
eligible hospitals are in the new DAWN sample
(exhibit 1). The EDs in the new sample total 34.
(Some hospitals have more than one ED.) For this
report, data were accessed from the DAWN Live!
restricted-access online query system for 2004,
updated on May 13, 2005. The 2004 data are unweighted. They are not estimates for the Boston
area and cannot be used for comparison with future data. Only weighted data released by
SAMHSA can be used in trend analysis. The data

1

The author is affiliated with the Boston Public Health Commission, Boston, Massachusetts.
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reported here are incomplete. Between 18 and 23
EDs reported each month during the year. Since
all DAWN cases are reviewed for quality control,
and cases may be corrected or deleted based on
the review, the data are subject to change. Data
presented in this paper represent drug reports in
drug-related visits in 2004. Drug reports exceed
the number of visits, since a patient may report
use of multiple drugs (up to six drugs plus alcohol). A full description of the DAWN system can
be found at <http://dawninfo.samhsa.gov>.
•

•

•

•

Drug-related death data were provided by
DAWN, OAS, SAMHSA, for 2003 for a Boston
metropolitan area consisting of five Massachusetts
counties, including Essex, Middlesex, Norfolk,
Plymouth, and Suffolk, and two New Hampshire
counties, including Rockingham and Strafford.
State-funded substance abuse treatment admissions data for a Boston region comprising the
cities of Boston, Brookline, Chelsea, Revere, and
Winthrop (Community Health Network Area
[CHNA] 19), for fiscal year (FY) 1997 through
FY 2004 (July 1, 1996, through June 30, 2004)
and the first half of FY 2005 (July 1, 2004–
December 31, 2004) were provided by the Massachusetts Department of Public Health (DPH), Bureau of Substance Abuse Services.
Analysis of seized drug samples for a Boston
region comprising the cities of Boston, Brookline,
Chelsea, Revere, and Winthrop (CHNA 19) for
1997 through 2004 was provided by the Massachusetts Department of Public Health Drug
Analysis Laboratory in Amherst, Massachusetts.
The Boston area drug sample counts do not include samples analyzed at the Worcester County
or State Police laboratories.
Information on drug mentions in Helpline calls
for a Boston region comprising the cities of Boston, Brookline, Chelsea, Revere, and Winthrop
(CHNA 19) for FY 2000 through FY 2004 were
provided by the Massachusetts Substance Abuse
Information and Education Helpline.

forcement Administration (DEA), New England
Field Division Intelligence Group, June 2005.
•

Data on Massachusetts pharmacy OxyContin
thefts for 2001 through 2004 were provided by
the Massachusetts Pharmacy Board of Registration.

•

Adult acquired immunodeficiency syndrome
(AIDS) and human immunodeficiency virus
(HIV) data for 2003, and cumulative data
through May 1, 2005, were provided by the
Massachusetts Department of Public Health
AIDS Surveillance Program.

Cocaine/Crack
Cocaine and crack are among the most heavily
abused drugs in Boston. Recent cocaine/crack indicators are stable at high levels of use and abuse.
In 2003, cocaine was indicated in 216 of the 486 drug
misuse deaths in greater Boston (44.4 percent)—
more than any other drug. Seventy-two of those were
single-drug deaths.
The cocaine/crack ED mentions rate of 156 per
100,000 population in 2002 was similar to that of the
2 previous years. Exhibit 2 shows 5,611 cocaine ED
mentions in 2002.
The 2002 ED rates by gender show that the cocaine/crack rate for males was almost 1.8 times the
rate for females (200 vs. 113 per 100,000 population). The highest rate by an age group (358 per
100,000 population) occurred among those age 26–
34. Within that group, those age 26–29 experienced a
rate of 403 per 100,000 population. A 2-year rate
increase of 76 percent was reported among those age
18–25. Similarly, a 2-year rate increase of 70 percent
occurred among those age 45–54.
In the unweighted data accessed from DAWN Live!
for 2004, cocaine reports totaled 3,348.

•

Drug arrests data for the city of Boston for
1997–2004 were provided by the Boston Police
Department, Drug Control Unit and Office of Research and Evaluation. For arrest data only, Black
and White racial designations include those who
identify themselves as Hispanic.

In the first half of FY 2005, there were 674 treatment
admissions (8 percent of all admissions) with clients
reporting cocaine or crack as their primary drug (exhibit 3). Of these, 401 (60 percent) indicated crack as
the client’s primary drug. There were 2,230 mentions (25 percent of all admissions) of current (pastmonth) cocaine/crack use among those admitted to
State-funded treatment programs (exhibit 3).

•

Drug price, purity, and availability data for
New England were provided by the Drug En-

A comparison of the last full year of data (FY 2004)
to previous years shows the proportion reporting co-
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caine/crack as their primary drug decreased 10 percent from FY 2003, 16 percent from FY 2002, and 62
percent from FY 1997. The proportion of mentions of
current (past-month) cocaine/crack use decreased 6
percent from FY 2003 and 33 percent from FY 1997.
Exhibit 4 shows demographic characteristics of all
treatment admissions, and exhibit 5a shows them for
cocaine/crack treatment admissions in Boston. For
further demographic comparisons of annual treatment
admissions, see “Patterns and Trends in Drug Abuse:
Greater Boston” in Proceedings of the Community
Epidemiology Work Group, Volume II, January 2005.
There were 1,650 Class B (mainly cocaine and crack)
drug arrests in 2004 (exhibit 6). Class B arrests accounted for the largest proportion of drug arrests (43
percent) in the city of Boston in 2004, similar to
2003. However, the proportion of Class B arrests
decreased 9 percent from 1997 to 2004.
The proportion of White Class B arrests (31 percent)
decreased 20 percent from 1997 to 2004, while the
proportion of Black Class B arrests (68 percent) increased 13 percent. The proportion of Class B arrests
represented by those age 40 and older (27 percent)
increased 66 percent from 1997, while arrests for
those age 25–39 (44 percent) decreased 19 percent
and arrests for those younger than 20 decreased 27
percent during the same period.
In 2004, 2,632 seized samples of cocaine/crack were
analyzed. The proportion of cocaine/crack samples
among all drug samples analyzed (30 percent) did not
change from 2003, but it decreased 14 percent from
1997.
Cocaine/crack was self-identified as a substance of
abuse in 1,017 calls to the Helpline in FY 2004. The
proportion of Helpline calls with mentions of cocaine/crack (18 percent) decreased 9 percent from FY
2003 to FY 2004.
The DEA reports that cocaine costs $50–$90 per
gram and purity is increasing in Boston (exhibit 7). A
rock of crack costs $10–$20. Cocaine is considered
“readily available at all levels” throughout Massachusetts.
Heroin
Heroin sits solidly among the most abused drugs in
Boston. A few of the most recent indicators show
heroin abuse possibly stabilizing at very high levels
after years of continued growth. Heroin was mentioned often among drug abuse deaths. Heroin ED
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mentions were stable at high levels. The proportion
of heroin treatment admissions continued to rise, with
more than one-half of all clients in treatment reporting heroin as their primary drug.
In 2003, heroin/morphine was indicated in 109 of the
486 drug misuse deaths (22.4 percent). Fifty of those
were single-drug misuse deaths.
In 2002, there were 3,999 heroin ED mentions; heroin was a factor in 22.3 percent of all drug episodes
(exhibit 2). The heroin ED mentions rate of 111 per
100,000 population was similar to that of the 2 previous years.
The 2002 ED rates by gender show that the heroin rate
for males is more than two times the rate for females
(152 vs. 72 per 100,000 population). The highest rate
by an age group (311 per 100,000 population) occurred among those age 26–29. A 2-year rate increase
of 215 percent was seen among those age 18–19.
In the unweighted data accessed from DAWN Live!
for 2004, heroin reports totaled 3,341.
In the first half of FY 2005, 4,589 treatment admissions (51 percent of all admissions) indicated heroin
as the primary drug, and there were 4,338 mentions
(48 percent of all admissions) of current (past-month)
heroin use among those admitted to State-funded
treatment programs (exhibit 3).
A comparison of the last full year of data (FY 2004)
to previous years shows the proportion of admissions
reporting heroin as the primary drug in FY 2004 was
stable from FY 2003 but reflected increases of 11
percent from FY 2002 and 68 percent from FY 1997.
Similarly, the proportion of mentions of current
(past-month) heroin use in FY 2004 was stable from
FY 2003, but this reflected increases of 7 percent
from FY 2002 and 62 percent from FY 1997
Exhibit 5b shows demographic characteristics of heroin or other opiates primary treatment admissions in
Boston. For further demographic comparisons of
annual treatment admissions, see “Patterns and
Trends in Drug Abuse: Greater Boston” in Proceedings of the Community Epidemiology Work Group,
Volume II, January 2005.
There were 791 Class A (mainly heroin and other
opiates) drug arrests in 2004 (exhibit 6). The proportion of Class A drug arrests among all drug arrests in
the city of Boston in 2004 (21 percent) was a decrease of 8 percent from 1997. The proportion of
Class A male arrests in 2004 (82 percent) reflected a
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6-percent decrease from 2003 but is similar to 2002
and 1997. The proportion of Class A arrests among
those age 20–24 in 2004 (18 percent) reflected an 88percent increase from 1997.
In 2004, 1,139 seized samples of heroin (13 percent of
all drug samples) were analyzed. The proportion of
heroin samples among all drug samples analyzed decreased 17 percent from 2003 to 2004.
Heroin was self-identified as a substance of abuse in
2,230 calls to the Helpline in FY 2004 (40 percent of
all mentions). The proportion of heroin Helpline call
mentions in FY 2004 represented increases of 9 percent from FY 2003, 13 percent from FY 2002, and 21
percent from FY 2001.
The DEA reports that in Boston, street heroin costs
$6–$20 per bag, with an average purity between 40
and 60 percent (exhibit 5). Boston’s heroin is typically from South America and transported to the area
from the New York metropolitan area. Heroin is
considered “readily available throughout New England” and is available in all forms: bag, bundle, gram,
ounce, kilogram, and cylinder-shaped bullets/eggs.

sics/combinations category) among all 21 DAWN
sites. Boston’s rate of 34 was 3.8 times the national
rate of 9 and an increase of 118 percent from 2000.
Preliminary unweighted data from DAWN Live! show
2,968 ED reports of opiates/opioids in 2004; there
were 1,587 oxycodone reports and 355 reports for hydrocodone.
In the first half of FY 2005, there were 195 clients (2
percent of all admissions) admitted to treatment who
identified other opiates/synthetics as their primary drug,
and there were 466 mentions (5 percent of all admissions) of current other opiate use among those admitted
to State-funded treatment programs (exhibit 3).
Though the half-year treatment data suggest decreases in the proportion and number of opiate admissions, a comparison of the last full year of data
(FY 2004) to previous years shows the number of
clients reporting other opiates as their primary drug
(n=781) increased 243 percent from FY 2000 to FY
2004 and 830 percent from FY 1997 to FY 2004. The
number of mentions of current other opiate use in FY
2004 (n=1,529) represented increases of 65 percent
from FY 2000 and 166 percent from FY 1997.

Narcotic Analgesics
After years of growing narcotic analgesic abuse, a
couple of indicators suggest that this trend may be
starting to stabilize.
Narcotic analgesics were mentioned 223 times
among 486 drug misuse deaths in 2003. Forty-nine of
those mentions were single-drug deaths, representing
24 percent of the 206 total single-drug deaths.
Morphine was identified in 85 of the total 486 drug
misuse deaths. Of these, 15 were single-drug deaths.
Oxycodone was identified in 72 drug misuse deaths
(15 percent of the total). Of these, 13 were singledrug deaths. Methadone was identified in 35 drug
misuse deaths; 8 of these were single-drug deaths.
Fentanyl was mentioned in 13 drug misuse deaths, of
which six were single-drug deaths.
There were an estimated 3,479 narcotic analgesics/combinations ED mentions in 2002. This number
represents a 73-percent increase from 2000 and 153percent increase from 1995. The 2002 narcotic analgesics/combinations rate of 97 ED mentions per
100,000 population is twice the national rate of 46
and fourth highest among all 21 DAWN sites.

In 2004, 246 seized samples of oxycodone (3 percent
of all drug samples) were analyzed. The proportion of
oxycodone samples among all drug samples analyzed
was stable from 2003 to 2004.
In FY 2004, there were 1,025 calls to the Helpline
during which opiates were mentioned (18 percent of
all calls). Oxycodone (including OxyContin) was mentioned in 691 calls. Helpline calls with oxycodone
mentions in FY 2004 (12 percent of total) reflected
increases of 25 percent from FY 2003, 52 percent from
FY 2002, and 261 percent from FY 2001. Other narcotic analgesics, including methadone, codeine, morphine, Percocet, Vicodin, and Roxicet, were mentioned
among 401 calls (7 percent of total calls).
Statewide OxyContin thefts continued to decrease in
number. There were 33 statewide OxyContin thefts
from pharmacies reported during 2004, compared
with 62 in 2003, 93 in 2002, and the peak of 139
thefts in 2001. Changes in pharmacy supply procedures are believed to have played a major role in preventing thefts.
The DEA reports that OxyContin is “available” on
the street and typically costs about $1 per milligram
(exhibit 7).

In 2002, Boston had the highest oxycodone/combinations ED rate (a subset of the narcotic analge-
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Marijuana
The most recent marijuana indicators for greater Boston are stable at relatively high levels.
Marijuana was identified in 18 of the 486 drug misuse deaths in 2003.
In 2002, there were 4,273 marijuana ED mentions;
marijuana was a factor in 24 percent of all drug episodes (exhibit 2). The marijuana ED mentions rate of
119 per 100,000 population was similar to that of the
2 previous years.
The 2002 marijuana ED rates by gender show that the
rate for males was almost two times the rate for females (156 vs. 83 per 100,000 population). The highest rate by an age group (321 per 100,000 population)
occurred among those age 18–25. Within that group,
those age 18–19 experienced a rate of 630 per
100,000 population.
The unweighted data from DAWN Live! indicate
there were 1,801 ED reports for marijuana in 2004.

panics) Class D arrests (29 percent) decreased 10, 21,
and 32 percent, respectively, during the same periods.
There were 3,358 seized samples of marijuana, more
than any other drug, analyzed by the drug lab in
2004. The proportion of marijuana samples analyzed
in 2004 (38 percent of all drug samples) was similar
to 2003 and 2002.
Marijuana was mentioned in 253 calls to the Helpline
in FY 2004. The proportion of helpline calls with
marijuana mentions remained stable at 5 percent from
FY 2003 to FY 2004.
The DEA reports that marijuana is readily available
in Massachusetts and sells for $800–$1,500 per
pound for “commercial grade” and $1,000–$1,200
per pound for “sinsemilla grade.” A marijuana cigarette or “joint” typically costs $5. Commercial grade
is said to be “readily available,” and high potency
hydroponic marijuana termed “Hydro” is said to be
“available” throughout New England.
Benzodiazepines

In the first half of FY 2005, there were 296 treatment
admissions (3 percent of all admissions) with clients
reporting marijuana as their primary drug (exhibit 3),
and 839 mentions (9 percent of all admissions) of
current marijuana use among those admitted to Statefunded treatment programs (exhibit 3).

As a group, benzodiazepines are showing high levels
of abuse.

A comparison of the last full year of data to previous
years shows the proportion of treatment admissions
reporting marijuana as their primary drug in FY 2004
was similar to the proportions in FY 2003, FY 2002,
and FY 1997. The proportion of mentions of current
marijuana use decreased 10 percent from FY 2003 to
FY 2004 and 34 percent from FY 1997 to FY 2004.

There were an estimated 3,665 benzodiazepines ED
mentions in 2002. Boston’s 2002 rate of 102 benzodiazepines ED mentions per 100,000 population was
highest among all 21 DAWN sites and nearly 2½
times the national rate of 42.

Exhibit 5c shows demographic characteristics of
marijuana treatment admissions in Boston. For further demographic comparisons of annual treatment
admissions, see “Patterns and Trends in Drug Abuse:
Greater Boston” in Proceedings of the Community
Epidemiology Work Group, Volume II, January 2005.
There were 1,247 Class D (mainly marijuana) drug
arrests in 2004 (exhibit 6). The proportion of Class D
arrests among all drug arrests (33 percent) in the city
of Boston in 2004 remained stable from 2003 and
2002 but increased 14 percent from 2001.
The proportion of Black (including Hispanics) Class
D arrests (70 percent) in 2004 increased 6 percent
from 2003, 13 percent from 2002, and 25 percent
from 1997. The proportion of White (including His-

40

Benzodiazepines were mentioned in 88 of 486 drug
misuse deaths in 2003. Of these, 16 were single-drug
deaths.

In the unweighted DAWN Live! data for 2004, there
were 2,095 benzodiazepine reports. Clonazepam,
alprazolam, lorazepam, and diazepam were the most
often indicated benzodiazepines in preliminary ED
data for 2004.
In FY 2004, there were 98 treatment admissions (less
than 1 percent of all admissions) with clients reporting benzodiazepines as their primary drug, but 1,613
mentions (8 percent of all admissions) of current
(past-month) benzodiazepine use among those admitted to State-funded treatment programs. Of treatment
admissions reporting current benzodiazepine use, 85
percent were White, 56 percent were younger than
age 35, and 66 percent were male.
Arrest and drug lab data are currently unavailable for
benzodiazepines.
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In FY 2004, there were 175 calls to the Helpline during which benzodiazepines (including Ativan, Valium, Xanax, Klonopin, Rohypnol, Halcion, and
others) were self-identified as substances of abuse (3
percent of all calls). The number and proportion of
Helpline call mentions attributable to benzodiazepines remained fairly stable from 2000 to 2003.

Methamphetamine
There were only 13 estimated ED mentions of
methamphetamine in 2002 (exhibit 2). This number
is similar to each of the 2 previous years.
In the unweighted DAWN Live! data for 2004, there
were 39 methamphetamine ED reports.

Methylenedioxymethamphetamine (MDMA)
MDMA (ecstasy) indicators show stable and relatively low levels of abuse.
There were an estimated 116 MDMA ED mentions in
2002 (down slightly from 140 in 2001) (exhibit 2).
Of these, 59 percent were among males, and 79 percent were among those younger than 26.
The unweighted data from DAWN Live! for 2004
show 101 MDMA reports.
Drug lab submissions show the number of MDMA
samples has decreased steadily from a peak of 106 in
2000 to 24 (fewer than 1 percent of the 8,901 total
samples) in 2004.
In FY 2004, there were 24 calls to the Helpline during which MDMA was self-identified as a substance
of abuse (fewer than 1 percent of all mentions). The
number of MDMA Helpline calls has decreased 47
percent from a peak of 45 calls in FY 2002.
The DEA reports that one MDMA tablet costs between $20 and $25 retail (exhibit 7). Distributed at
clubs and on college campuses, MDMA has remained widely available “in spite of law enforcement
seizures.”
Other Drugs
Amphetamines
There were an estimated 541 amphetamine ED mentions in 2002. The 2002 rate of 15 mentions per
100,000 population was the highest amphetamines
ED mentions rate that Boston has experienced in 8
years of DAWN reporting.
Unweighted DAWN Live! data for 2004 show 184
amphetamine reports.
The number of amphetamine lab samples decreased
from 47 in 2003 to 14 in 2004. The number of
Helpline calls with stimulant mentions remained stable from 60 in FY 2003 to 49 in FY 2004.
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Though still relatively small in number, methamphetamine treatment admissions increased from 5 in
FY 2001 to 66 in FY 2003 and 53 in FY 2004.
In FY 2004, there were 14 methamphetamine mentions among calls to the Helpline.
The DEA reports that methamphetamine costs $250
per gram and is available “in limited (user-level)
quantities” in New England (exhibit 7). The purity
level is unknown.
Ketamine
There were an estimated 13 ketamine ED mentions in
2002. This number is similar to each of the 2 previous years.
Only three ketamine ED reports appear in the unweighted DAWN Live! data for 2004.
Ketamine lab samples have decreased in number
from 43 in 2002 to 11 in 2003 and 8 in 2004. The
DEA reports that a vial of ketamine costs $55 to
$100.
Barbiturates
There were an estimated 637 barbiturates ED mentions
in 2002. Boston’s ED rate of 18 barbiturates mentions
per 100,000 population was the highest barbiturates
rate among the 8 years of DAWN reporting and 4½
times the national rate of 4.
In the unweighted DAWN Live! data for 2004, there
were 115 barbiturate ED reports.
Lysergic Acid Diethylamide (LSD), Phencyclidine
(PCP), and Gamma Hydroxybutyrate (GHB)
There were few estimated LSD, PCP, or GHB ED
mentions in Boston during 2002 (19, 20, and 27, respectively) (exhibit 2). The DEA reports that LSD
costs $5 per dose. GHB costs $150 per ounce.
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INFECTIOUS DISEASES RELATED TO DRUG ABUSE
In 2003, there were 269 adult HIV and AIDS cases
diagnosed in Boston. The primary risk factor for
these cases included 12 percent who were injection
drug users (IDUs), 5 percent who had sex with IDUs,
and 35 percent with an unknown/undetermined
transmission status. As of May 1, 2005, cumulative
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adult AIDS cases numbered 6,054. By primary risk
factor, these included 26 percent who were IDUs, 7
percent who had sex with IDUs, and 13 percent for
whom the risk behavior was unknown/undetermined.
For inquiries concerning this report, please contact Daniel P.
Dooley, Boston Public Health Commission, 1010 Massachusetts
Avenue, Boston, MA 02118, Phone: (617) 534-2360, Fax: (617)
534-2422, E-mail: Ddooley@bphc.org.
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Exhibit 1. DAWN ED Sample and Reporting Information: January–December 2004

CEWG Area

No. of Hospitals in
DAWN
Sample
29

Total Eligible
Hospitals1

Boston

41

No. of EDs Reporting per Month:
Completeness of Data (%)

Total EDs in
DAWN
Sample2
34

90–100%

50–89%

<50%

No. of
EDs Not
Reporting

15–23

0–3

0–4

11–16

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
2
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 5/13/2005

Exhibit 2. Estimated Emergency Department Mentions for Selected Drugs as a Percentage of
1
Total Drug Episodes : 1995–2002
Drug
Alcohol-in-comb.
Cocaine/
Crack
Marijuana/
Hashish
Heroin/
Morphine
Oxycodone/
comb.
Hydrocodone/
comb.

1995
No.

1996

(%)

No.

1997

(%)

No.

1998

(%)

No.

1999

(%)

No.

2000

(%)

No.

2001

(%)

No.

2002

(%)

No.

(%)

6,297

(39) 5,351

(40) 4,890

(40) 5,130

(38) 4,438

(38) 4,975

(33) 5,818

(35) 5,916

(33)

5,267

(33) 4,106

(30) 3,332

(27) 4,526

(33) 3,560

(31) 4,099

(28) 4,933

(29) 5,611

(31)

2,401

(15) 2,127

(16) 1,768

(15) 2,907

(21) 1,960

(17) 2,945

(20) 3,423

(20) 4,273

(24)

2,956

(18) 2,729

(20) 2,500

(21) 2,738

(20) 2,861

(25) 3,867

(26) 4,358

(26) 3,999

(22)

276

(2)

241

(2)

231

(2)

247

(2)

294

(3)

598

(4)

948

(6) 1,239

(7)

85

(<1)

74

(<1)

93

(<1)

97

(<1)

106

(<1)

201

(1)

208

(1)

288

(2)

PCP

81

(<1)

18

(<1)

22

(<1)

21

(<1)

7

(<1)

11

(<1)

23

(<1)

20

(<1)

LSD

184

(1)

82

(<1)

37

(<1)

53

(<1)

44

(<1)

41

(<1)

33

(<1)

19

(<1)

2

….

2

—

6

(<1)

12

(<1)

14

(<1)

14

(<1)

13

(<1)

(<1)

16

(<1)

39

(<1)

87

(<1)

125

(<1)

140

(<1)

116

(<1)

Methamphetamine

7

(<1)

….

MDMA

7

(<1)

9

Total drug
Episodes
Total drug
Mentions

—

16,065

13,530

12,224

13,656

11,668

14,901

16,853

17,965

30,026

24,904

22,383

24,875

21,217

25,854

29,795

32,488

1
Percentage of episodes for which each drug was mentioned (mentions/total drug episodes) rounded to the nearest whole number,
except when <1 percent.
2
Estimate does not meet standard of precision.
SOURCE: Office of Applied Studies, SAMHSA, Drug Abuse Warning Network, 2002 (03/2003 update); prepared by the Boston Public
Health Commission, Research Office
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Exhibit 3. Percentages of Admissions to State-Funded Substance Abuse Treatment Programs by Primary
Drug and Drug Used in the Past Month in Greater Boston1: FY 1997–1H FY 20052
FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

1H FY
2005

Primary Drug
Alcohol
Heroin and/or Other
Opiates
Heroin
Other Opiates
Cocaine and/or Crack
Cocaine (powder)
Crack
Marijuana
Other3
Total (N)

46
29

45
35

45
36

45
37

44
42

40
46

36
50

35
52

34
53

29
0
19
9
10
4
1

35
0
14
7
7
4
1

36
1
13
7
6
5
1

36
1
12
5
6
5
1

40
2
9
4
5
4
1

43
3
9
4
5
4
1

47
3
8
3
5
4
1

48
4
7
3
4
4
1

51
2
8
3
4
3
1

25,470

23,008

24,653

24,478

25,334

25,586

24,440

20,041

8,948

Drug Used Past Month
Alcohol
Heroin and/or Other
Opiates
Heroin
Other Opiates
Cocaine and/or Crack
Cocaine (powder)
Crack
Marijuana
Total (N)

60
29

59
34

59
35

58
37

56
42

53
45

50
48

47
49

47
51

28
2
34
22
19
16

33
3
30
21
16
14

34
3
30
21
15
14

35
4
28
20
13
13

39
5
25
18
12
13

42
6
24
17
11
11

45
7
24
18
11
11

46
8
23
16
11
10

48
5
25
16
13
9

25,470

23,008

24,653

24,478

25,334

25,586

24,440

20,041

8,948

1

Excluding prisoners and out-of-State admissions.
Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year. 1H FY 2005 runs July 2004–
December 2004.
3
Includes barbiturates, other sedatives, tranquilizers, hallucinogens, amphetamines, “over-the-counter,” and other drugs.
SOURCE: Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public
Health Commission, Research Office
2

44

Proceedings of the Community Epidemiology Work Group, June 2005

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Greater Boston

Exhibit 4. Demographic Characteristics of Admissions to Greater Boston State-Funded Substance Abuse
Treatment Programs1, by Percent: FY 1997–FY 20042
Characteristic
Gender
Male
Female
Race
White
Black
Hispanic
Other
Age at Admission
(Average age)
18 and younger
19–29
30–39
40–49
50 and older
Marital Status
Married
Separated/divorced
Never married
Annual Income
None
$1–$1,000
$1,000–$9,999
$10,000 and higher
Homeless
Criminal Justice System
Involvement
Mental Health
No prior treatment
Prior treatment
(counseling or
hospitalization)
Needle Use in Past Year
Total (N)

FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

72
28

75
25

74
26

76
24

77
23

77
23

74
26

73
27

47
35
14
3

49
32
15
4

48
33
16
4

49
32
16
4

48
30
18
4

49
29
18
4

50
28
18
4

54
26
17
3

(35.1)
3
25
43
22
7

(35.6)
3
24
42
23
8

(36.5)
2
22
41
27
9

(36.7)
2
21
40
29
9

(36.5)
2
22
38
29
9

(36.5)
2
24
37
28
10

(36.7)
2
24
34
30
10

(36.9)
2
26
31
30
11

10
22
68

10
22
68

10
21
69

10
19
71

10
18
72

10
18
72

10
18
72

9
17
74

56
3
26
15
32

56
3
24
16
31

54
4
26
16
31

59
3
21
30

61
2
19
18
34

69
2
14
16
37

68
2
14
16
37

63
3
18
16
36

26

26

28

27

26

27

24

23

82

80

79

80

81

80

80

78

18

20

21

20

19

20

20

22

22

25

26

26

27

32

37

38

(25,470)

(23,008)

(24,653)

17

(24,478) (25,334)

(25,586) (24,440)

(20,041)

1

Excludes prisoners and out-of-State admissions.
Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year.
SOURCE: Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public
Health Commission, Research Office
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Exhibit 5a.

Demographic Characteristics of Clients1 in Greater Boston State-Funded Substance Abuse
Treatment Programs with a Primary Problem with Cocaine/Crack, by Percent: FY 1997–FY 20042

Characteristic
Gender
Male
Female
Race
White
Black
Latino
Other
Age at Admission
(Average age)
18 and younger
19–29
30–39
40–49
50 and older
Marital Status
Married
Separated/divorced
Never married

FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

60
40

61
39

59
41

59
41

62
38

63
37

56
44

57
43

25
63
10
2

24
64
10
3

23
63
11
3

23
65
10
3

26
60
12
3

25
61
11
3

27
58
11
4

27
58
12
3

(32.8)
1
31
53
13
2

(33.6)
1
28
53
16
2

(35.2)
1
19
56
21
4

(35.5)
<1
18
55
23
4

(36.0)
1
15
55
26
4

(36.7)
<1
15
51
29
5

(37.1)
1
15
49
31
5

(38.0)
1
13
45
35
7

9
17
75

10
19
71

11
19
71

10
16
74

11
17
72

12
19
69

12
19
70

10
21
69

Annual Income
$0–$999
$1,000–$9,999
$10,000 and higher
Homeless
Criminal Justice System
Involvement
Mental Health Problem

59
28
13
28

57
27
17
26

56
29
16
23

59
24
17
21

58
22
21
23

60
23
18
28

56
26
18
24

54
29
17
24

20
21

25
22

30
27

29
28

30
29

33
31

31
36

31
36

Needle Use in Past Year

5

6

6

5

7

7

9

8

(4,920)

(3,266)

(3,165)

(2,837)

(2,291)

(2,230)

(1,985)

(1,470)

Total (N)
1

Excludes prisoners and out-of-State admissions.
Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year.
SOURCE: Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public
Health Commission, Research Office
2
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Exhibit 5b. Demographic Characteristics of Clients1 in Greater Boston State-Funded Substance Abuse
Treatment Programs with a Primary Problem with Heroin or Other Opiates, by Percent:
FY 1997–FY 20042
Characteristic
Gender
Male
Female
Race
White
Black
Latino
Other
Age at Admission
(Average age)
18 and younger
19–29
30–39
40–49
50 and older
Marital Status
Married
Separated/divorced
Never married

FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

69
31

72
28

72
28

75
25

76
24

77
23

74
26

72
28

49
26
21
4

48
24
22
6

49
24
22
5

51
22
23
5

50
21
25
5

53
19
25
4

56
18
22
5

61
15
21
3

(34.5)
1
28
45
24
3

(34.6)
1
29
42
24
4

(35.2)
1
27
42
25
6

(35.3)
1
27
40
27
5

(35.1)
1
29
39
26
6

(34.6)
1
32
37
24
6

(35.2)
1
31
35
26
7

(35.1)
1
33
32
26
8

11
22
68

11
21
68

10
20
70

11
19
71

10
17
73

10
15
75

9
16
75

7
16
77

67
23
10
28

69
21
10
25

67
23
10
26

72
16
12
22

73
15
12
29

78
11
11
35

78
12
10
40

74
16
10
39

16

18

20

19

19

19

16

16

Annual Income
$0–$999
$1,000–$9,999
$10,000 and higher
Homeless
Criminal Justice System
Involvement
Mental Health Problem

17

17

18

16

16

16

16

18

Needle Use in Past Year

64

63

63

63

58

62

68

68

(7,372)

(8,145)

(8,932)

(9,151)

(10,613)

(11,850)

(12,210)

(10,402)

Total (N)
1

Excludes prisoners and out-of-State admissions.
Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year.
SOURCE: Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public
Health Commission, Research Office
2
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Exhibit 5c.

Demographic Characteristics of Clients1 in Greater Boston State-Funded Substance Abuse
Treatment Programs with a Primary Problem with Marijuana, by Percent: FY 1997–FY 20042

Characteristic
Gender
Male
Female
Race
White
Black
Latino
Other
Age at Admission
(Average age)
18 and younger
19–29
30–39
40–49
50 and older
Marital Status
Married
Separated/divorced
Never married
Annual Income
$0–$999
$1,000–$9,999
$10,000 and higher
Homeless
Criminal Justice System
Involvement
Mental Health Problem
Needle Use in Past Year
Total (N)

FY 1997

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

76
24

78
22

76
24

73
27

78
22

77
23

77
23

71
29

37
39
20
4

32
42
22
4

28
44
23
4

28
47
21
4

29
47
22
3

27
48
20
5

26
49
22
4

29
47
20
3

(24.0)
33
43
18
5
1

(24.2)
29
48
18
5
1

(25.1)
24
50
17
6
2

(25.4)
19
56
18
5
2

(24.3)
27
51
16
6
1

(24.8)
24
50
19
6
1

(25.2)
22
52
18
7
2

(26.3)
17
52
21
7
2

6
5
89

6
6
89

4
6
90

5
7
88

5
6
90

6
7
88

6
6
89

6
6
88

58
28
15
8

50
31
19
8

59
27
14
9

55
27
18
10

57
22
21
11

60
21
19
12

64
21
16
9

53
28
19
11

38

47

53

48

48

50

43

44

25

31

23

27

25

29

31

35

1

2

2

2

2

2

2

2

(1,119)

(928)

(1,125)

(1,109)

(1,100)

(1,054)

(1,046)

(857)

1

Excludes prisoners and out-of-State admissions.
Fiscal years (FYs) run July 1–June 30, with the year named for the January–June portion of the year.
SOURCE: Massachusetts Department of Public Health, Bureau of Substance Abuse Services; prepared by the Boston Public
Health Commission, Research Office
2
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Exhibit 6. Boston Police Department Arrests, by Substance,1 Number, and Percent: 1997–2004
1997

1998

1999

2000

2001

2002

2003

2004

Number
(%)

Number
(%)

Number
(%)

Number
(%)

Number
(%)

Number
(%)

Number
(%)

Number
(%)

A
(Mostly
Heroin)

1,392
(22.7)

1,061
(22.5)

984
(24.0)

1,022
(27.1)

905
(26.4)

947
(22.5)

939
(22.5)

791
(20.8)

B
(Mostly
Cocaine)

2,918
(47.5)

2,225
(47.1)

1,847
(45.1)

1,532
(40.6)

1,428
(41.7)

1,762
(41.9)

1,736
(41.6)

1,650
(43.3)

D
(Mostly
Marijuana)

1,617
(26.3)

1,211
(25.6)

1,133
(27.7)

1,093
(29.0)

982
(28.7)

1,375
(32.7)

1,366
(32.7)

1,247
(32.8)

Other

216
(3.5)

226
(4.8)

133
(3.3)

123
(3.3)

111
(3.2)

125
(3.0)

133
(3.2)

119
(3.1)

Total Drug
Arrests

6,143

4,723

4,097

3,770

3,426

4,209

4,174

3,807

Total Arrests

27,843

25,481

23,592

22,216

20,470

21,025

20,686

19,577

Drug Percentage of
Total Arrests

(23.7)

(18.5)

(17.4)

(17.0)

(16.7)

(20.0)

(20.2)

(19.4)

Drug Class

1

Includes all arrests made by the Boston Police Department (i.e., arrests for possession, distribution, manufacturing, trafficking,
possession of hypodermic needles, conspiracy to violate false substance acts, and forging prescriptions).
SOURCE: Boston Police Department, Office of Planning and Research; prepared by the Boston Public Health Commission, Research Office

Exhibit 7. Drug Street Price, Purity, and Availability in Boston: November 2003–December 2004
Drug
Heroin
Cocaine (powder)
Crack

Price
$53–$100 per gram
$60–$100 per bundle
$6–$20 per bag
$50–$90 per gram retail

Methamphetamine

$10–$20 per rock
$5 per joint
$200–$250 per ounce
$250 per gram

MDMA (Ecstasy)

$20–$25 per tablet

OxyContin

$1 per milligram

LSD

$5 per dose

Ketamine

$50–$100 per vial
$5 per capful, $150 per
ounce

Marijuana

GHB

Purity

Availability

High (bag-40%-60%)

Readily

Increasing

Steady, available

Commercial Grade

Readily

Unknown

Limited quantities
High (clubs & colleges)

SOURCES: New England Field Division, Drug Enforcement Administration (DEA) as of June 2005; prepared by the Boston Public
Health Commission, Research Office
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Patterns and Trends of Drug
Abuse in Chicago
Dita Broz, M.P.H., Matthew Magee, Wayne
Wiebel, Ph.D., and Lawrence Ouellet, Ph.D.1
ABSTRACT
Most indicators suggest that heroin and cocaine
continue to pose a serious problem for Chicago and
Illinois. According to preliminary unweighted data
from DAWN Live!, cocaine and heroin were the top
two illicit drugs most reported in emergency departments in 2003 and 2004. Heroin-related treatment episodes increased between FYs 2000 and
2004, indicating continued high levels of use. The
purity of street-level heroin decreased between 2001
and 2003 from about 24 percent to 16 percent,
though ethnographic reports suggest a recent increase. Many cocaine indicators remain the highest
for all substances except alcohol. Cocaine-related
treatment episodes increased between FYs 2002 and
2003 by 20 percent, but they decreased slightly in
FY 2004. Marijuana remains the most widely available and used illicit drug. Methamphetamine indicators continued to show low but increasing levels
of use in some areas of Chicago, especially on the
north side, where young gay men and clubgoers
congregate. Methamphetamine use is significantly
higher in downstate Illinois. MDMA (ecstasy) ED
mentions decreased 60 percent between 2000 and
2002, but increases in use have been reported
among young African-Americans. LSD and PCP
indicators suggest a downward trend in use. The
proportion of new AIDS cases attributed to injection
drug use peaked at 33 percent in 1996 then steadily
decreased to 24 percent in 2002. Prospective studies
of young heroin users in Chicago conducted by the
authors of this report suggest low HIV and HCV
seroprevalence, but substantial levels of risk practices that place them at high risk for acquiring these
infections.
INTRODUCTION
Area Description
Due to its geographic location and multifaceted
transportation infrastructure, Chicago is a major
transportation hub and distribution center for illegal
drugs throughout the Midwest. Located in northeastern Illinois, the city of Chicago stretches for 25 miles
1

The authors are affiliated with the University of Illinois at Chicago, School of Public Health, Chicago, Illinois.
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along the southern tip of Lake Michigan's shore. The
2000 U.S. census estimated the population of Chicago at 2.9 million and Cook County (which includes
Chicago) at 5.4 million. In June 2003, the U.S. Office
of Management and Budget (OMB) revised definitions for the Nation’s Metropolitan Statistical Areas
(MSA). The Chicago-Naperville-Joliet, Illinois, MSA
includes Cook, DeKalb, DuPage, Grundy, Kane,
Kendall, McHenry, and Will Counties, and its population size was estimated at slightly more than 9 million (ranking third in the Nation).
According to the U.S. Census Bureau, the city population increased about 4 percent between 1990 and
2000, but it is estimated to have decreased about 1
percent in 2003. The number of Hispanics living in
Chicago increased 38 percent between 1990 and
2000, while the number of Whites and AfricanAmericans declined by 14 and 2 percent, respectively.
Based on the 2000 census, the Chicago population is
36 percent African-American, 31 percent White, 26
percent Hispanic, and 4 percent AsianAmerican/Pacific Islander. In 2000, the median age
of Chicagoans was 31.5, with 26 percent of the population younger than 18 and 10 percent age 65 or
older. The unemployment rate is 6.2 percent, and the
percentage of families living below the poverty level
with children younger than 18 is 11.4 percent.
Data Sources
This report is based on the most recent data available
from the various sources detailed below:
•

Drug-related mortality data were derived from
the Drug Abuse Warning Network (DAWN), Office of Applied Studies (OAS), Substance Abuse
and Mental Health Services Administration
(SAMHSA), mortality system for 1998–2003. The
DAWN system recently restructured its data collection methods; mortality estimates produced as
of 2003 are not comparable to previous years. In
2003, 122 jurisdictions in 35 metropolitan areas
and 6 States reported mortality data to DAWN. Of
the 14 targeted counties in the Chicago metropolitan area, only 5 (DuPage, Kane, Kendall, Lake,
McHenry) reported mortality data to DAWN in
2003, covering about 26 percent of the population.
A full description of the DAWN system can be
found on the DAWN Web site: http://dawn
info.samhsa.gov. Data on pediatric toxicity and
on deaths related to accidental drug poisonings
have not been available from the Illinois Department of Public Health (IDPH) Adverse Pregnancy
Outcome Reporting System (APORS) and from
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also described in the June 2004 Chicago CEWG
report.

the Chicago Department of Public Health, respectively, since 2002.
•

•

•

Emergency department (ED) data were provided by DAWN, OAS, SAMHSA, for 1994
through 2002. The 2000 ED data were unavailable
for methamphetamine. Also presented in this paper are preliminary unweighted data from the
DAWN Live! restricted-access online query system administered by OAS, beginning in 2003.
The 2003–2004 data represent a redesign of
DAWN, and the data are not comparable to those
from 2002 and before. The redesigned system
has 74 of the 88 eligible hospitals in the Chicago
sample, with 76 EDs in the sample. (Some hospitals have more than one ED.) Data completeness
differs considerably for the 2 years (see exhibit
1) due, in part, to limitations associated with implementing a new system in 2003. During 2004,
between 24 and 32 EDs reported data each
month. The completeness of data reported by
participating EDs varied by month. The 2003–
2004 data are incomplete (not all EDs reported
each month) and unweighted; these data cannot
be used as estimates, nor can they be used for
comparison with future data. Only weighted data
released by SAMHSA can be used for trend
analysis. All DAWN cases are reviewed for
quality control; based on the review, cases may
be corrected or deleted. Therefore, data presented in this report are subject to change. The
2003–2004 data were accessed from the DAWN
Live! update between April 14, 2005, and June 9,
2005, and represent drug reports. Drug reports
exceed the number of visits, since a patient may
report use of multiple drugs (up to six drugs plus
alcohol). For the purpose of this report, drugrelated reports include all DAWN case types,
and drug misuse reports include only the following three DAWN case types: “seeking detox,”
“overmedication,” and “other.” The latter is used
in the “Other Opiates” and “Depressants” sections of this report. A full description of the
DAWN system can be found on the DAWN Web
site: http://dawninfo.samhsa.gov.
Treatment data for the State of Illinois for fiscal years (FYs) 2000–2004 (July 1–June 30)
were provided by the Illinois Division of Alcoholism and Substance Abuse (DASA). National
and State-specific treatment admissions data for
1992–2002 were provided by the Treatment Episode Data Set (TEDS) maintained by SAMHSA.
Arrestee drug testing data were provided by the
Arrestee Drug Abuse Monitoring (ADAM) program, National Institute of Justice (NIJ), and are

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

•

Incidence data on drug-related calls were provided by the Illinois Poison Center (IPC) in Chicago for Cook County for 2001 through 2003.
The IPC answered more than 93,000 calls in
2003 on household products, herbal products,
medication overdoses, adverse reactions to
medications, alcohol or drug misuse, occupational accidents, chemical spills, and other poisonings.

•

Price and purity data were provided by the Drug
Enforcement Administration (DEA), Domestic
Monitor Program (DMP), for heroin for 1991–
2003. Price and purity data on drug samples analyzed through April 2005 were provided by the Illinois State Police (ISP), Division of Forensic Science. National and Illinois data on drug availability, demand, production, cultivation, and distribution were available from the National Drug Threat
Assessment February 2005 and the Illinois Drug
Threat Assessment May 2002 reports, National
Drug Intelligence Center, U.S. Department of Justice. The Office of National Drug Control Policy
(ONDCP) report on Profile of Drug Indicators,
Chicago, Illinois, published in April 2004, as well
as the National Drug Intelligence Center 2003 Illicit Drug Prices: July 2003–December 2003 report, were reviewed. Data from the National Forensic Laboratory Information System (NFLIS)
for FY 2003 and FY 2004 were used to report differences between different drugs in the relative
amounts submitted for testing in Illinois and Chicago. Ethnographic data on drug availability,
prices, and purity are from observations and interviews conducted by the Community Outreach
Intervention Projects (COIP), School of Public
Health, University of Illinois at Chicago (UIC).

•

Criminal justice data were available from the
Illinois Criminal Justice Information Authority
(ICJIA), which collects, maintains, and updates a
variety of criminal justice data to support its research and evaluation efforts. ICJIA regularly
publishes criminal justice research, evaluation
reports, and statistical profiles. ICJIA’s drug arrest data for 1990–2002 and the special report on
methamphetamine trends in Illinois were reviewed.

•

Survey data on student and household populations were derived from several sources. Student drug use data were provided by the national
Monitoring the Future (MTF) Study, the Youth
Risk Behavior Surveillance System (YRBSS)

51

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Chicago

survey, and the Illinois Youth Survey and are described in the June 2004 Chicago CEWG report.
National data on substance use and abuse were
provided by SAMHSA’s 2002 National Survey
on Drug Use and Health.
•

•

Most recent drug use estimates were derived
from two currently ongoing studies of young
heroin users in metropolitan Chicago conducted
by COIP at the UIC School of Public Health.
The Family Process and Risk Reduction Study
(Family Process), funded by the National Institute on Drug Abuse (NIDA), assesses a human
immunodeficiency virus (HIV) prevention intervention that targets young injection drug users
(IDUs) and their parents. Participants are age
18–25 and have injected in the last 6 months
(n=636 as of June 2005). All data from the Family Process Study are preliminary. Current noninjecting heroin users (NIHUs) age 16–30 were
recruited for the NIDA-funded NIHU Study to
evaluate the rate of transition to injecting and
drug and sexual practices associated with HIV,
hepatitis B (HBV), and hepatitis C (HCV) infections (n=649 as of June 2005).
Acquired immunodeficiency syndrome (AIDS)
and HIV data were derived from both agency
sources and UIC studies. IDPH and CDPH surveys provided statistics on AIDS and HIV
through October 2004 and December 2003, respectively. The CDPH Office of HIV/AIDS Surveillance provided data through 2003 (2003 data
are preliminary). CDC’s “HIV/AIDS Surveillance Report,” December 2001, provided additional data on HIV and AIDS. The agency data
are complemented by UIC’s studies of IDUs
conducted by COIP at UIC’s School of Public
Health. One is the NIDA-funded “AIDS Intervention Study,” based on a panel of IDUs participating from 1988 to 1996. The second is the
CDC-funded HIV Incidence Study (CIDUS I and
II). The CIDUS data are from analyses of a
1994–1996 study of 794 IDUs, age 18–50, in
Chicago (Ouellet et al. 2000) and a 1997–1999
study of 700 IDUs, age 18–30, in Chicago and
its suburbs (Thorpe et al. 2000; Bailey et al.
2001). Most sources have not been updated since
the Chicago CEWG December 2002 report.

Several of the sources traditionally used for this report have not been updated by their authors or were
unavailable at the time this report was generated.
Because some information has not changed—and to
avoid redundancy—this report occasionally refers
readers to a previous Chicago CEWG report for more
information in a particular area. For a discussion of
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the limitations of survey data, the reader is referred to
the December 2000 Chicago CEWG report.
DRUG ABUSE PATTERNS AND TRENDS
This report of drug abuse patterns and trends is organized by major pharmacologic categories. Readers
are reminded, however, that multidrug consumption
is the normative pattern among a broad range of substance abusers in Chicago. Various indicators suggest
that drug combinations play a substantial role in drug
use prevalence. Preliminary unweighted DAWN data
show that 26 percent of all ED drug reports in Chicago in 2004 were alcohol-in-combination mentions.
During FY 2004, heroin was the most often mentioned reason for seeking treatment in Chicago.
Among these treatment episodes, the most common
secondary substances reported were cocaine (37 percent) and alcohol (13 percent).
According to DAWN ED data, Chicago was reporting the highest ED drug mentions among the 21
DAWN sites between 2000 and 2002. Both DAWN
mortality cases and CDPH death certificates suggest
that total drug-related deaths remained stable at high
numbers between 2000 and 2002. According to
APORS, 718 children in Chicago were exposed to
some drug at birth in 2002, which corresponds to an
annual rate of 150 exposures per 10,000 live births.
In 2003, DAWN reported a rate of 57 drug misuserelated deaths per 1,000,000 and 14 drug-related suicide deaths per 1,000,000 in the Chicago MSA.
Drug-related deaths were more common among
males and those age 35–54.
Cocaine/Crack
The majority of quantitative and qualitative cocaine
indicators suggest that use remains stable at high levels and that cocaine continues to be a serious drug
problem for Chicago and Illinois.
In 2002, both the DAWN ME drug-induced or drugrelated death data and CDPH death certificate data
showed that cocaine remains a factor in more deaths
in the Chicago area than any other illicit drug. However, multiple drug use was involved in 65 percent of
these cases. According to the new 2003 DAWN ME
report, 77 percent (67 deaths) of all drug-related
deaths recorded that year were related to cocaine.
Five of the 67 cocaine-related deaths were ruled as
suicide. Multidrug use was involved in the majority
(64 percent) of cocaine-related deaths.
In 2002, ED mentions for cocaine remained at high
levels, and they represented a 52-percent increase
over 10,702 mentions in 1995. Chicago continued to
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have the most cocaine ED mentions among DAWN
sites in 2002 (16,227 mentions) and the highest rate
of mentions (275 per 100,000 population) (exhibit 2).
Preliminary unweighted data accessed from DAWN
Live! for 2003 and 2004 show that slightly more than
one-third of total ED reports were cocaine related (33
and 34 percent, respectively). ED cocaine reports
totaled 5,981 in 2004 (exhibit 3). In 2004, the majority of the cocaine reports involved males (65 percent), African-Americans (56 percent), and those
between 35 and 54 years of age (64 percent).
According to the Illinois Poison Center, approximately 120 cocaine-related calls were received annually in Chicago for 2001–2003. During this period,
cocaine generated more calls than any other “street
drug” (approximately 25 percent of all “street
drugs”).
The FY 2004 Illinois drug treatment report indicates
that cocaine abuse remains one of the top three reasons for entering treatment (excluding primary alcohol-only abuse) (exhibit 4). A total of 31,430 persons
were treated for cocaine-related problems in Illinois
during FY 2004, of which 48 percent occurred in
Chicago. Cocaine was the most commonly mentioned
secondary drug among persons treated for primary
heroin-related problems. In FY 2004, AfricanAmericans remained the largest group among total
persons treated (60 percent) for cocaine abuse. Males
accounted for more services rendered (57 percent)
than females. Smoking continued to be the most
common route of cocaine administration (85 percent)
in FY 2004.
According to the 2003 ADAM report, 51 percent of
adult male arrestees (exhibit 5) and 33 percent of
adult female arrestees tested cocaine positive.
Cocaine use appears common among heroin users in
Chicago. In an ongoing study of non-injecting heroin
users (NIHU Study), 70 percent of participants reported ever using powder cocaine, and 34 percent
used it in the past 6 months. Crack cocaine use was
reported by 67 percent of the study participants, and
52 percent reported using crack in the past 6 months.
Among injecting drug users (Family Process study),
84 percent reported ever using powder cocaine, and
64 percent of them used it in the past 12 months.
Somewhat fewer participants had ever used crack
cocaine (75 percent), but 83 percent of lifetime users
reported using it in the past 12 months.
According to IDPH’s Adverse Pregnancy Outcome
Reporting System, cocaine exposure among children
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at birth in Chicago decreased between 1999 and 2002
by 29 percent, from 95.2 to 73.8 per 10,000 live
births. Nonetheless, cocaine continued to be the most
often cited drug exposure among children in Chicago.
In 2002, the highest proportion of such births occurred among African-American mothers (approximately 78 percent) and to mothers between 25 and 34
years of age.
State (ISP) and Federal (NFLIS) labs reported that
cocaine was the drug most often received for testing
after cannabis. Cocaine purity for samples weighing 2–
25 grams tested by the ISP was 81 percent in 2003 and
77 percent in 2004, but analyses were conducted on
only a few samples, and reasonable comparison with
earlier data is not possible.
Cocaine prices have not changed since the June 2003
report. Ounce prices for powder cocaine were reported
by street sources to be between $400 and $800, depending on the drug’s quality and the buyer’s relationship to the seller. Gram prices for powder and rock
cocaine ranged from $50 to $150, with most reports
around $75. Ounces of crack cocaine (“rock”) sold for
about the same price as ounces of powder cocaine,
with reports ranging from $900 to $1,600. The NDIC
reported the wholesale price of a kilogram of cocaine
in Chicago was $18,000–$20,000 for powdered cocaine and $22,000–$24,000 for crack. The June 2003
report contains more detailed information about drug
prices in Chicago.
According to the 2003 YRBSS study, the proportion of
lifetime cocaine/crack use among Chicago-area 9th
through 12th grade students remained level at about 5
percent between 1995 and 2003. Male students reported cocaine/crack use nearly twice as often as their
female counterparts during this period. The 2002 Illinois Youth Survey of Chicago-area 8th through 12th
grade students reported a similar level of use (about 5
percent) between 1998 and 2002. The June 2004 Chicago CEWG report provides a more complete discussion of the 2002 Illinois Youth Survey.
Heroin
Similar to cocaine, heroin abuse indicators in this
reporting period continue to suggest high levels of
use in the Chicago area.
Of the 711 total drug-induced or drug-related deaths
reported by the DAWN ME for Cook County in
2002, 48 percent (339) had a mention of heroin/morphine. After reporting 1 death per year in
2000 and 2001 caused by accidental heroin exposure,
CDPH reported 18 deaths in 2002. The new DAWN
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ME system recorded 27 heroin-related deaths in 2003
in the Chicago MSA, and 5 of those were single-drug
deaths.
The rate of heroin ED mentions in Chicago increased
significantly from 83 per 100,000 population in 1995
to 220 in 2002 (exhibit 2), an increase of 167 percent.
This rate was the highest in the contiguous United
States.
Preliminary unweighted DAWN Live! ED data for
2003 and 2004 indicate that heroin is the second most
frequently reported drug, following only cocaine (exhibit 3). In the DAWN Live! 2004 data, the majority
of heroin ED reports involved males (63 percent),
African-Americans (52 percent), and those between
ages 35 and 54 (58 percent).
The number of persons treated for heroin use in Statesupported programs in FY 2004 was 30,531, a 12percent decrease from 2003. (exhibit 4). Nonetheless,
28 percent of treatment services rendered during 2004
in Illinois were for heroin. Seventy-one percent of the
total heroin treatment episodes reported in FY 2004
occurred in Chicago alone, supporting other indicators
of high levels of heroin use in the city. The majority
(73 percent) of persons treated for heroin in 2004 reported intranasal “snorting” as the primary route of
administration. In Chicago, 81 percent reported snorting as their primary route of administration (14 percent
injected), compared with 52 percent of patients reporting snorting (41 percent injected) in the rest of the Illinois. Demographic differences between patients from
Chicago and the rest of the State may account for some
of this difference. Patients entering treatment in Chicago were more likely to be African-American (81
percent), while patients from the rest of Illinois were
more likely to be White (58 percent). Preliminary
analysis of data collected for the currently ongoing
study of young non-injecting heroin users in Chicago
(NIHU), conducted by COIP at UIC, found that at
followup, White study participants and those younger
than 23 were significantly more likely to initiate injection. African-Americans in the study appeared resistant
to injection initiation despite a longer duration of use.
A recent report (Kane-Willis and Schmitz-Bechteler
2004) examined age and race trends among persons
treated for heroin use in Illinois and found that Whites
were far more likely to be age 18–24 (41 percent) than
were African-Americans (2 percent) and Hispanics (20
percent).
According to the 2003 ADAM report, 25 percent of
adult male arrestees tested opiate positive (exhibit 5).
The proportion of adult female arrestees testing opiate positive decreased significantly between 2000 and
2003, from 40 to 22 percent, respectively. The June
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2004 Chicago CEWG report provides a more complete discussion of the ADAM data.
According to the 2003 DMP report, availability of
heroin in Chicago, especially South American and
Southeast Asian heroin, continued (exhibit 6). Heroin
from other geographic source areas, including Southwest Asia and Mexico, was also available. The consistent availability of heroin from all four of these source
areas makes Chicago unique among other U.S. cities.
The purity of street-level heroin peaked in 1997 at
about 31 percent and has since declined. In 2003,
South American heroin exhibits purchased by DMP in
Chicago averaged 16.6 percent pure, a 19-percent decrease from 2002. However, the average price per milligram pure remained consistent, with a low in 2003 of
$0.45 for South American heroin. Recent ethnographic
reports suggest a new source of heroin on the south
side of Chicago that is said to offer a higher purity
level. On the street, this heroin has been referred to as
“tornado” for its strength or “retro-dope,” as it reminds
older users of higher-purity heroin from years past.
According to ISP, the amount of heroin analyzed in
Cook County decreased slightly from 21 kilograms in
2003 to 18 kilograms in 2004.
Participants in a study of young non-injecting heroin
users reported high availability of heroin on the
streets of Chicago. Sixty-three percent reported “a
lot” (the highest rating) of heroin on the street in the
past 30 days. Use of brand name heroin was reported
by 29 percent of participants. Most (80 percent) paid
$10 per bag in the 30 days prior to interview. Regarding heroin quality in the past 30 days, only 10 percent
gave the highest quality rating (“very good”); 31 percent thought the quality was “good,” and 50 percent
perceived the heroin quality as “fair.”
Heroin prices have not changed since the June 2003
report. On the street, heroin is commonly sold in $10
and $20 units (bags), though bags for as little as $5 are
available. Prices for larger quantities varied greatly,
depending on the type and quality of heroin, the buyer,
and the area of the city where the heroin was sold. At
outdoor drug markets, purchases of multibag quantities—versus grams and fractions of ounces—were the
most common means of buying larger amounts of heroin. Data indicated that buyers on the West Side could
obtain 11–13 $10 bags for $100 (sometimes called a
“jab”). Recent ethnographic reports suggest that some
dealers offer regular customers a free piece of crack
cocaine along with their heroin purchase (typically on
Fridays) and distribute free samples when they have
“new product,” practices that indicate a potential increase in competition.
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Among Illinois high school students, increases in
heroin use have not yet been evidenced in periodic
representative surveys. The Illinois Youth Survey
indicates that heroin use among Chicago-area students is still relatively rare. In 2003, 3.7 percent of
students reported lifetime use of heroin, compared
with 2.5 percent in 2001 and 3.1 percent in 1999.
More information is available in the December 2004
Chicago CEWG report.
APORS data indicated that opioid toxicity was decreasing between 2000 and 2002 among infants
tested for controlled substances, from 22.4 per 10,000
live births to 16.1 per 10,000 live births, respectively.
In 2002, and similarly in 2000 and 2001, most infants
who tested positive to heroin exposure at birth were
born to African-American mothers (69 percent) and
to mothers age 25–34.
Other Opiates
In 2003, 50 deaths related to opiate/opioid (other than
heroin and methadone) misuse were recorded in the
DAWN ME system. Multidrug use was associated
with 86 percent of deaths, and 11 were ruled as suicide. Methadone misuse was responsible for 15
deaths during the same year.
According to unweighted data accessed from DAWN
Live!, 1,399 opiate/opioid misuse-related ED reports
were recorded in Chicago in 2004. Hydrocodone accounted for 22 percent of the overall opiate/opioid
reports. A substantial proportion (46 percent) of hydrocodone ED reports were classified as “overmedication.” Six percent of the opiate/opioid-related reports were specifically attributed to oxycodone misuse. Unlike hydrocodone mentions, the largest proportion of oxycodone mentions (36 percent) were
classified as “seeking detox.”
Between 2001 and 2003, the Illinois Poison Center
reported a 55-percent increase in calls involving recreational abuse of Coricidin HBP, which contains 30
milligrams of dextromethorphan HBr (DXM) per tablet. DXM is a synthetically produced substance that is
chemically related to codeine, though it is not an opiate. The majority of the cases involving DXM (approximately 90 percent) were among those age 13–19.
The occasional use of other opiates is common
among young non-injecting heroin users in Chicago.
Fifty-seven percent of NIHU Study participants reported ever trying codeine, Tylenol 3 and 4, Dilaudid,
Demerol, morphine, or methadone without a legal
prescription. Ethnographic reports suggest that codeine may be used by heroin users to moderate withdrawal symptoms or to help kick a drug habit.
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In Illinois, treatment services rendered related to the
use of other opioids, tranquilizers, or sedatives in FY
2004 accounted for 2 percent of total treatment episodes (excluding alcohol). The majority (80 percent)
of treatment for other opiates occurred outside Chicago and among Whites (75 percent); the majority
(62 percent) reported administering these drugs
orally. Readers are referred to the June 2004 and December 2004 Chicago CEWG reports for more details
regarding other opioids, tranquilizers, or sedatives
treatment data.
Marijuana
Marijuana continues to be the most widely available
and used illicit drug in Chicago and Illinois.
According to the 2003 DAWN ME report, 11 percent
of total deaths recorded mentioned marijuana. All of
these deaths were multidrug related.
The rate of marijuana ED mentions per 100,000
population was 89 for both 2000 and 2001 and decreased to 78 per 100,000 in 2002 (exhibit 2), a
change of nearly 12 percent from 2001.
Preliminary unweighted data accessed from DAWN
Live! show that ED reports of marijuana in 2003 and
2004 represented 10 percent and 13 percent of all
drug-related reports, respectively. In 2004, marijuana
ED reports totaled 2,222 (exhibit 3). Marijuana patients in 2004 most often were African-Americans
(49 percent), followed by Whites (26 percent); males
(66 percent); and younger than 30 (52 percent).
Marijuana users represented 20 percent of all treatment
episodes in Illinois in FY 2004 and 28 percent of episodes when those for primary alcohol abuse were excluded. The number of treatment episodes for marijuana increased from 20,705 in FY 2000, to 26,371 in
FY 2003, but fell to 30,650 in FY 2004 (exhibit 4).
Alcohol was the most commonly reported secondary
drug among persons receiving treatment for marijuana.
During FY 2004, treatment episodes for marijuana
were highest for males (76 percent) and for Whites (48
percent). Approximately 25 percent of Illinois treatment episodes of marijuana occur in Chicago.
According to 2003 ADAM data, 53 percent of adult
male arrestees tested positive for marijuana (exhibit
5), a level close to proportions in 2002 and 2001. The
proportion of adult female arrestees who tested positive for marijuana increased from 25 percent in 2000
to 39 percent in 2003.
Marijuana use was common among the young heroin
users participating in local studies. Sixty-seven per-
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cent of non-injecting heroin users and 73 percent of
young injectors smoked marijuana in the 6–12
months prior to their interview.
The 2003 YRBSS data and the 2002 Illinois Youth
Survey both reported a recent decrease in lifetime use
of marijuana among 8th through 12th grade students.
For more information about results from these youth
surveys, readers are referred to the December 2004
CEWG report.
According to DEA, the bulk of marijuana shipments
are transported by Mexico-based polydrug trafficking
organizations that conceal marijuana among legitimate goods in tractor-trailers coming into the Chicago areas from the southwest border. The primary
wholesalers of marijuana are the same Mexico-based
organizations that supply most of the cocaine,
methamphetamine, and Mexican heroin in the Midwest. Marijuana produced locally (indoor and outdoor) by independent dealers is also available. According to the DEA Domestic Cannabis Eradication/Suppression Program, 14,409 outdoor and 1,273
indoor cultivated plants were eradicated in 2000.
In general, currently available marijuana is of variable quality. The abundance and popularity of marijuana across the city has led to an increased array of
varieties and prices. Marijuana prices, which remained level since the June 2003 report, ranged from
$650 to $4,000 per pound, depending on the type and
quality. Ounces typically sold for about $80−$250.
On the street, marijuana was most often sold in bags
for $5–$20 or as blunts. The NDIC reported the following prices for marijuana in Chicago in 2003:
$900–$1,200 per pound, $50–$75 per ounce, and $3–
$5 per gram.
Both ISP and NFLIS laboratories analyzed more marijuana samples than samples for any other drug. Fortynine percent of drug samples analyzed by the NFLIS
for Chicago in 2004 were identified as cannabis.
Stimulants
Since the mid-1990s, many indicators of methamphetamine (“speed”) use in Illinois increased steadily.
The most significant increases occurred from 1998 to
2002 in rural areas of Illinois.
Methamphetamine ED mentions in Chicago slowly
increased during the 1990s but remained stable between 2001 and 2002, when they totaled 45 and 42,
respectively.
During 2004, unweighted DAWN Live! data showed
47 ED methamphetamine reports for Chicago (exhibit 3). Males (81 percent), persons age 25–45 (74
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percent), and Whites (51 percent) accounted for the
majority of the 2004 ED methamphetamine reports.
As reported in the January 2005 report, methamphetamine calls to the Illinois Poison Center in Chicago are infrequent. From 2001 to 2003, the Poison
Center received a total of 29 such calls.
Like methamphetamine, amphetamine ED mentions
increased steadily in Chicago since 1995. By 2002,
415 amphetamine ED mentions were reported, an increase of 188 percent from 1995. A rate of 7 mentions
per 100,000 persons was reported for 2002.
According to unweighted data accessed from DAWN
Live!, there were 81 amphetamine ED reports for
Chicago in 2004 (exhibit 3). Sixty-five percent of
reports were among males, 42 percent were White, and
48 percent were among persons younger than 25.
Since FY 2000, treatment for methamphetamine as a
proportion of all State treatment episodes (excluding
primary abuse of alcohol only) increased steadily from
1 percent to 4 percent in 2004. Treatment services rendered for amphetamine also increased during this period but remained stable between 2003 and 2004 (exhibit 4). In FY 2003, the number of methamphetamine
treatment episodes (3,582) greatly outnumbered those
for amphetamines (476). Methamphetamine treatment
episodes totaled 4,628 during FY 2004, while those for
amphetamine remained stable at 485. Only 1 percent of
treatment episodes for methamphetamine were from
Chicago. Exhibit 7 illustrates the substantial difference
between the number of methamphetamine treatment
episodes recorded in the city of Chicago and those in
the rest of the State for the period of FYs 2000 to 2004.
This trend in treatment supports other indicators that
suggest lower use of methamphetamine in Chicago
compared to the rural parts of the State. Most treatment
episodes for methamphetamine during 2004 involved
Whites (97 percent) and males (53 percent); a similar
trend was observed for amphetamine patients (89 and
54 percent, respectively).
According to 2002 ADAM data, only 0.3 percent of
male arrestees in Chicago tested positive for methamphetamine, but 1.0 percent tested positive during the
first quarter of 2003, suggesting an increase in use.
The 2003 YRBSS data indicated that 3.7 percent of
high school students in Chicago used methamphetamine one or more times during their life. Male students
were nearly six times more likely to have tried
methamphetamine than female students. For more information about methamphetamine use among students
in Chicago, readers are referred to the December 2004
Chicago CEWG report.
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Data from the ISP indicated that more methamphetamine continued to be seized than cocaine or heroin in nearly 50 percent of Illinois counties in 2004. In
2004, the amount of methamphetamine received by ISP
from Cook County was about 8 kilograms, while the
total methamphetamine received from all Illinois counties was about 24 kilograms, similar to the previous
year. According to the NFLIS 2004 report, 0.41 percent of the items analyzed in Chicago were methamphetamine, which is a considerable increase from 0.21
percent reported the year before.
According to ICJIA, the number of methamphetaminerelated arrests in Illinois increased significantly between 1997 (3 arrests) and 2003 (1,112 arrests). While
methamphetamine arrests increased across all regions
during this period, rural task force units experienced the
greatest increase in arrests (from 0 to 514 arrests), followed by mixed urban/rural units (from 3 to 373 arrests) and by mostly urban units (from 0 to 225 arrests).
Since 1994, the ICJIA has reported a dramatic increase
in the quantity of methamphetamine seized, from 3,433
grams in 1994 to 26,597 grams in 2003, with a peak of
28,002 in 2002. Similarly, clandestine methamphetamine labs seizures increased from 24 in 1997 to 971 in
2003. Seventy-seven percent of lab seizures in 2003
were in rural counties.
Within Chicago, a low but stable prevalence of
methamphetamine use has been reported in some areas
of the city for a number of years, especially on the
North Side, where young gay men, homeless youth,
and White clubgoers congregate. Of note, ethnographic
data suggest that methamphetamine availability increased substantially since June 2001 among at least
some networks of gay White men on the North Side,
who may use the drug to enhance sexual experiences.
There were also reports from persons who said they
began to use methamphetamine in order to lose weight
but became addicted to the drug.
In the NIHU Study, 19 percent of participants reported
ever trying amphetamine or methamphetamine, and
only 5 percent reported using it in the 6 months prior to
the interview. Among injectors in the Family Process
study, 20 percent of participants reported amphetamine
use, and 8 percent used it in the previous 12 months. It
is likely that participants’ use of the drug often took
place somewhere other than Chicago or Illinois.
Methylphenidate (Ritalin) remained readily available
in some South Side neighborhoods, where it could be
purchased for injection, either alone or in combination with heroin. Pills, often referred to as “beans”
in these areas, are sold for $1.50 to $5.00 each, depending on the quantity being purchased. The cost of
Ritalin on the West Side of Chicago was reported to
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be $10 per pill. Some study participants report that
Ritalin was readily available in their schools and that
students knew which students had been prescribed
Ritalin and often requested the drug from them.
Methamphetamine prices have not changed since June
2003, when it was reported that bags of methamphetamine sold for $20. Most drug users reported that
the drug remained difficult to obtain. However, police
and street reports suggest that some Mexico-based drug
dealers are attempting to introduce methamphetamine
for local consumption by offering free samples, which
may eventually change the low and stable trend of
methamphetamine use in Chicago. Furthermore, one
street-level report suggested a limited availability of
methamphetamine on the West Side. There was also
one report of methamphetamine being sold at a South
Side street drug market. According to the NDIC 2003
report, methamphetamine cost $1,000–$1,300 per
ounce and $80–$100 per gram.
Depressants
Three patterns of depressant-in-combination use have
been common in Chicago and throughout Illinois:
•

Depressants are taken with narcotics to potentiate the effect of opiates. Pharmaceutical depressants are frequently combined with heroin.

•

Depressants are taken with stimulants to moderate the undesirable side effects of chronic
stimulant abuse. Chronic cocaine and speed
abusers often take depressants along with stimulants, or when concluding “runs,” to help induce
sleep and to reduce the craving for more stimulants (especially in the case of cocaine).

•

Alcohol, also a central nervous system depressant, is taken with pharmaceutical depressants
(such as hypnotics or tranquilizers). The practice
of mixing alcohol with other depressants may
indicate illicit pharmaceutical depressant use.

In 2003, 17 benzodiazepine misuse-related deaths
were reported to the DAWN ME system from the
Chicago MSA. Fourteen of these deaths were ruled as
suicide.
Benzodiazepine ED mentions increased significantly
between 1995 (n=1,959) and 2002 (2,776), a 42percent change. Both ED mentions and ethnographic
reports indicate that alprazolam appears to be the
benzodiazepine most readily available on the street,
closely followed by clonazepam and lorazepam, with
variations in different areas of the city.
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Preliminary unweighted data accessed from DAWN
Live! showed that 907 ED reports were related to the
misuse of benzodiazepines in 2004. Nearly one-half
of these mentions were classified as overmedication.
Benzodiazepine-related calls to the Illinois Poison
Center in Chicago repeatedly represented nearly onehalf of all substance misuse calls between 2001 and
2003. On average, approximately 500 calls annually
were reported during this time period.
Treatment data suggest depressants are not the primary drugs of choice for most users. In FY 2004,
DASA reported 2,472 treatment episodes for other
opioids, tranquilizers, and sedatives/hypnotics. The
majority of treatment episodes for depressants occurred outside of Chicago (80 percent) and among
Whites (75 percent). Primary opioid, tranquilizer, and
sedative/hypnotics users represented only about 2
percent of all treatment episodes, excluding alcohol.
Lifetime use of tranquilizers or barbiturates without a
prescription (Valium, Elavil, Ativan, Xanax) was
reported by 31 percent of young non-injecting heroin
users in the NIHU study. Thirteen percent reported
use in the past 30 days. In the Family Process study,
43 percent of young injectors reported ever using
barbiturates, and 30 percent used them during the
previous 12 months.
The 2002 APORS data indicate that the rate of infants testing positive for barbiturates has been decreasing since 2000. In 2002, the rate of children exposed to barbiturates at birth was 0.4 per 10,000 live
births, compared with 0.8 per 10,000 in 2001 and 1.4
per 10,000 in 2000.
No updated prices for depressants were available. As
stated in past Chicago CEWG reports, alprazolam
typically sells for $2–$3 for 0.5-milligram tablets and
$5–$10 for 1-milligram tablets.
Hallucinogens
Recent declines in lysergic acid diethylamide (LSD)
ED mentions suggest a downward trend in LSD use
in Chicago. Between 1995 and 2002, LSD ED mentions declined by 92 percent. The rate of LSD ED
mentions per 100,000 population was less than 1 in
2002 for the first time in the prior 7 years.
As observed with LSD, phencyclidine (PCP) ED data
showed declines in Chicago. After a peak in 2000,
when 1,003 ED mentions were reported, PCP ED
mentions decreased to 874 in 2001 and to 459 in
2002. Similarly, ED rates declined between 2001 and
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2002 from 15 to 8 (per 100,000), a 48-percent
change.
According to unweighted data accessed from DAWN
Live!, there were 17 LSD and 158 PCP ED reports in
2004.
No deaths related to hallucinogens were reported to
the DAWN ME system in 2003.
Recent trends in hallucinogen treatment have varied,
but overall the number of episodes in publicly funded
treatment programs in Illinois has been relatively
high, compared with trends in the 1990s. In FY 2003,
472 treatment episodes were reported, while there
were 324 in FY 2004. The percentage of Illinois hallucinogen treatment episodes occurring in Chicago
has increased since 2000, and during 2004, the majority of episodes occurred in Chicago (57 percent).
According to the 2003 ADAM report, the percentage
of adult male arrestees testing positive for PCP decreased between 2002 and 2003, from 2.2 percent to
1.3 percent. PCP use appears to be more common
among adult female arrestees; 5.6 percent of female
arrestees tested positive for PCP in 2003.
In the study of young non-injecting heroin users, 36
percent of participants reported ever trying LSD,
mescaline, mushrooms, or other hallucinogens, but
only a few (6 percent) reported use in the 6 months
prior to their interview. Among young injectors, 74
percent of participants reported ever trying hallucinogens, and 32 percent reported use in the 12 months
prior to their interview. Whites were much more
likely than African-Americans to report recent use of
hallucinogens.
Recent reports from young heroin snorters indicate that
in this population, PCP use is more common than LSD
use. Fifty-one percent of study participants reported ever
trying PCP, and 15 percent used in the 6 months prior to
their interview.
According to the 2002 Illinois Youth Survey, 5 percent of students in grades 8 through 12 reported lifetime use of “any hallucinogen” (including LSD and
PCP). This is a considerable decrease in use from
2000 (7 percent) and 1998 (8.5 percent). Further discussion of the Illinois Youth Survey is provided in
the December 2003 CEWG report.
The amount of PCP samples received by the ISP laboratory for analysis decreased significantly between
2002 and 2004, from 4.2 kilograms to 0.59 kilograms.
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Ethnographic reports on PCP use are available in the
June 2003 Chicago CEWG report. On the West side,
2–3 PCP “sticks” about the size of toothpicks were
reportedly available for $5–$10, according to the
June 2003 CEWG report. Some “wicky sticks” are
said to also include embalming fluid, and these cost
more. Sherm sticks typically are cigarettes or small
cigars dipped in PCP, drained, and dried. The cigarettes—most often Mores®—are sold for about $20–
$30 each and are mainly available on the far South
Side. PCP was also said to be sold in sugar cubes for
$20 each. Liquid PCP (“water”) was said to sell for
$120 for a vial.
LSD hits typically cost $5–$10. LSD is available in
the city and suburbs.
According to some accounts by White youth, hallucinogenic mushrooms remain available. Reported
prices were $20–$40 per mushroom.
Club Drugs
In the Chicago area, methylenedioxymethamphetamine (MDMA or ecstasy) continues to be the most
prominently identified of the club drugs, and its use
appears to have increased among African-Americans.
Of all the CEWG sites, Chicago had the most MDMA
ED mentions in 2000 (215), but it ranked 10th in 2002
(87).
The preliminary unweighted data extracted from
DAWN Live! show 27 MDMA reports in 2003 and 63
in 2004. MDMA ED reports in 2004 were more common among male patients (77 percent) and those
younger than 30 (84 percent). ED reports by
race/ethnicity were fairly evenly distributed between
African-Americans (38 percent) and Whites (29 percent), but race/ethnicity in 23 percent of reports was
unknown.
Illinois DASA treatment data related to “club drugs”
has been increasing slightly since FY 2002, when 50
such episodes were reported. In FY 2003 and 2004,
79 and 81 episodes were reported, respectively. During FY 2004, 69 percent of “club drug” treatment
episodes were among males, and 56 percent were
among Whites. Twenty-nine percent of treatment
episodes occurred in Chicago during FY 2003; this
proportion rose to 37 percent in FY 2004.
In 2002, the Illinois Youth Survey for the first time
included separate questions regarding MDMA use.
Lifetime and past-year ecstasy use appears to be low
among 8th through 12th grade students (0.6 percent
and 0.4 percent, respectively).
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MDMA samples sent to ISP from Cook County had
been decreasing since 2000, when 6.7 kilograms were
analyzed in the State laboratory. The amount of
MDMA samples then increased from 0.8 kilograms
in 2003 to 3.1 kilograms in 2004. Similarly, the
NFLIS reported an increase in the proportion of all
items analyzed for Chicago that were MDMA, from
0.16 in FY 2003 to 0.35 percent in FY 2004.
Drugs sold as ecstasy remained available in most
mainstream dance clubs and at many house parties.
“Raves” featuring ecstasy use are said to be close to
nonexistent. Recent ethnographic reports suggest
that ecstasy may be purchased in some “open air”
street markets on the west side of Chicago. It continued to be sold in pill or capsule form, and the price
range remained unchanged from December 2002:
$20–$40 per pill. Individuals with connections to
suppliers or producers reported prices as low as $12–
$15 per pill. These prices parallel the 2003 NDIC
report: wholesale prices ranged between $10 and $12
per tablet and the retail price was $25–$35 per dosage
unit. Along with other club drugs, ecstasy may continue to be used predominantly by White youth, but
there have been increasing reports of ecstasy use
from African-Americans in their twenties and thirties
who have been involved in club scenes. Among participants in the NIHU Study, 36 percent reported
MDMA use.
Gamma hydroxybutyrate (GHB), a central nervous
system depressant with hallucinogenic effects, is used
infrequently in Chicago, mainly by young White
males. ED mentions for GHB decreased 43 percent,
from 139 in 2000 to 79 in 2002.
According to preliminary unweighted data accessed
from DAWN Live!, there were only 6 GHB ED reports in 2003 and 45 reports in 2004.
GHB is sold as a liquid (also referred to as “Liquid
G”), in amounts ranging from drops (from a dropper
at raves or parties) to capfuls. Prices for a capful have
been reported at $5–$25. Compared with other club
drugs, overdoses are more frequent with GHB, especially when used in combination with alcohol. GHB
is not tracked in most quantitative indicators, but its
use is perceived to be low compared with ecstasy.
Ketamine, an animal tranquilizer, is another depressant with hallucinogenic properties and is often referred to as “Special K.” Ketamine ED mentions totaled 10 in 2002, compared with 14 in 2001. The rate
of ketamine ED mentions per 100,000 population
(0.1) also remained unchanged. DASA reported only
five patients served for ketamine use in FY 2004 in
publicly funded treatment programs in Illinois. As
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reported in the June 2004 Chicago CEWG report,
street reports indicate that ketamine is usually sold in
$5–$30 bags of powder or in liquid form. The drug is
somewhat available at rave parties or in clubs frequented by younger adolescents.
INFECTIOUS DISEASES RELATED TO DRUG ABUSE
Most sources regarding trends in HIV/AIDS and
other infectious diseases have not been updated by
their authors or were not available during this reporting period. Readers are referred to the December
2004 Chicago CEWG report for a more detailed review of the available information for Chicago and the
State.
As reported previously, findings suggest that the rate
of new HIV infections has declined among IDUs in
Chicago since peaking in the late 1980s.
Through October 2004, 30,865 diagnosed AIDS
cases were reported to the State. More than onequarter of adult AIDS cases occurred among IDUs,
while an additional 6.5 percent involved male IDUs
who had sex with men. Within Illinois, 79 percent of
the cumulative AIDS cases reported originate in the
Chicago metropolitan area.
HIV cases may represent more recent trends in risk
behaviors. From January to October 2004, 2,193 HIV
cases and 1,095 AIDS cases were reported to the
State. Of newly reported HIV cases, 82 percent were
in Cook County. Overall, IDUs accounted for 17 percent of cases in Illinois, while 3.5 percent occurred
among male IDUs who had sex with other men.
The most recent report on HIV/AIDS cases in Chicago indicated that by the end of 2003, 7,590 HIV
cases and 21,420 AIDS cases were reported. An estimated 17,169 individuals are living with HIV and
AIDS in Chicago.
In 2002, the number of deaths from AIDS declined 5
percent in Illinois and 9 percent in Chicago compared
to 2001, a level approximately equal to the number of
deaths in 2000. Given the long latency between HIV
infection and AIDS diagnosis, these figures do not
reflect the full scope of the epidemic. Data from the
authors’ studies provide additional information on the
extent of HIV infection among IDUs. In studies of
IDUs cited in previous CEWG reports, HIV prevalence ranged from 18 to 25 percent at baseline, with
reported incidence rates of 1 to 2 percent per personyear. Recent studies of young IDUs indicate high
levels of HIV risk behaviors but very low levels of
HIV infection, particularly among those who reside
in the suburbs. It should be noted, however, that the
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studies are not directly comparable, because each had
unique sampling and recruitment strategies. Analysis
of the NIHU Study (n=571) of young noninjecting
heroin users found an HIV and HCV seroprevalence
of 4 and 2 percent, respectively. During the 12-month
followup period, no HIV seroconversions and eight
HCV seroconversions were observed.
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Exhibit 1. Range of Emergency Departments (EDs) Reporting to DAWN: Monthly in 2003 and 20043

Year

Total Eligible
Hospitals1

2003
2004

88
88

No. of Hospitals in
DAWN
Sample
74
74

Total EDs in
DAWN
Sample2

No. of EDs Reporting per Month:
Completeness of Data (%)
90–100%

50–89%

<50%

No. of
EDs Not
Reporting

9–15
19–31

0–4
0–6

0–4
0–7

60–66
44–52

76
76

1

Short-term, general, non-Federal hospital with 24-hour emergency departments based on the American Hospital Association Annual Survey.
2
Some hospitals have more than one emergency department.
3
January through December.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/14-6/9, 2005

Exhibit 2. Estimated Rates of ED Mentions Per 100,000 Population in Chicago for Selected Drugs:
1995–20021
Year

Cocaine

Heroin

Marijuana

1995
1996
1997
1998
1999
2000
2001
2002

188
220
247
232
225
246
277
275

83
109
148
158
162
206
203
220

51
61
76
85
77
89
89
78

Methamphetamine
1
0
0
1
0
…2
1
1

Amphetamines
3
3
4
3
3
6
7
7

1

Data collected between 1995 and 2002 are not comparable to estimates produced on or after 2003.
Dots (…) indicate that an estimate with a relative standard of error greater than 50 percent has been suppressed.
SOURCE: DAWN, OAS, SAMHSA
2

Exhibit 3. Numbers of Selected Illicit Drug Reports in Chicago EDs (Unweighted1): 2004
Cocaine

5,981

Heroin

4,163

2,222

Marijuana

Amphetamine

81

Methamphetamine

47

1

Unweighted data are from 24–32 Chicago EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control.
Based on this review, cases may be corrected or deleted and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/14/2005–6/9/2005
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Exhibit 4. Numbers of Patients Served in Publicly Funded Treatment Programs in Illinois1 and Chicago, by
Primary Drug of Abuse: FY 2000–FY 2004
FY 2000

Primary
Drug
Cocaine
Heroin
Marijuana
Meth2
Amp3

FY 2001

FY 2002

Chicago

Illinois

Chicago

Illinois

Chicago

15,327
14,952
5,905
33
50

15,957
4,822
14,800
698
217

15,734
16,790
6,512
31
48

14,430
6,232
17,748
1,373
246

13,426
15,136
6,649
29
45

FY 2003

Illinois
13,238
5,649
17,526
1,955
272

FY 2004

Chicago

Illinois

Chicago

Illinois

16,443
24,396
7,959
35
32

17,439
10,219
18,412
3,547
444

15,034
21,758
7,539
47
48

16,396
8,773
23,111
4,581
437

1

Illinois data exclude Chicago
Meth = Methamphetamine
Amp = Amphetamine
SOURCE: Illinois Department of Human Services, Division of Alcoholism and Substance Abuse

2
3

Exhibit 5. Percentages of ADAM Adult Male Arrestees Testing Positive in Chicago for Selected Drugs by
1
Year: 2000–2003
Percent
60

Marijuana
Cocaine

50

53

50

49

Opiates

45

48

51

41
40

37
27

30

26

25

22
20
10
0
2000

2001

2002

2003

1

Data for 2000 are for the first through third quarters; data for 2001 are for the fourth quarter only; and data for 2003 are for the first
three quarters.
SOURCE: ADAM, NIJ
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Exhibit 6. Heroin Price and Purity Trends in Chicago, by Geographic Origin of the Heroin: 2000–2003
Trend

SEA
16.9

2000
SWA2
20.2

SA
23.8

$1.16

$0.32

$0.48

1

Purity (%)
Price Per Milligram
Pure

3

SEA
20.7

2001
SWA
20.8

SA
19.5

$0.45

$0.41

$0.71

4

SEA
20.8

2002
SWA
19.8

SA
20.4

2003
SWA
SA
18.4
16.6

$0.71

$0.39

$0.43

$0.52

$0.45

1

Southeast Asia.
Southwest Asia.
3
South America.
4
SEA data are not available for 2003.
SOURCE: DMP, DEA
2

Exhibit 7. Number of Patients Served in Publicly Funded Treatment Programs in Illinois for Methamphetamine: FY 2000–FY 2004
Patients Served
5,000

4,581
Chicago

4,000

3,547

Illinois
3,000
1,955

2,000

1,373
698

1,000
33

31

29

35

47

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

0
SOURCE: Illinois Department of Human Services, Division of Alcoholism and Substance Abuse
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Patterns and Trends in Drug
Abuse: Denver and Colorado,
2004
Nancy E. Brace, R.N., M.A.1
ABSTRACT
Alcohol remained Colorado’s most frequently
abused substance, and tobacco is responsible for
4,200 deaths in Colorado annually. Excluding alcohol and tobacco, the use and trafficking of illegal
drugs continues to be an expanding problem for
Colorado, with much of the transporting, distribution, and selling of illegal substances supported by
organized crime entities. Cocaine consistently had
the highest drug incidence rate per 100,000 population for emergency department visits, drug-related
hospital discharges, and drug-related mortality rates
for 1996 through 2002. In 2003, opiate-related drug
misuse mortalities exceeded those that were cocaine-related. Cocaine accounted for the highest
number of drug-related calls to the Rocky Mountain
Poison and Drug Center for 2001–2003 for the
Denver area. In 2004, amphetamines, methamphetamine, and other stimulants combined exceeded
cocaine in the number of these calls statewide. In
2003 and 2004, methamphetamine surpassed cocaine in the number of treatment admissions. Drug
enforcement officials and treatment providers have
corroborated this increase in methamphetamine use
and trafficking in Colorado. Marijuana has accounted for the highest number of treatment admissions annually since 1997 and in the highest percentage of users entering treatment within 4 years
of initial use. Methamphetamine ranks second in
the latter category, surpassing both cocaine and
heroin. Most indicators for heroin are decreasing,
with the exception of mortality data. Experts in the
field report an increase in opiate prescription diversion, especially among adolescents. Initial use for
most of these illegal substances seems to be occurring at a younger age.
INTRODUCTION
Area Description
Denver, the capital of Colorado, is located slightly
northeast of the State's geographic center. Covering
only 154.6 square miles, Denver is bordered by sev1

The author is affiliated with the Alcohol and Drug Abuse Division, Colorado department of Human Services, Denver, Colorado.
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eral suburban counties: Arapahoe on the southeast,
Adams on the northeast, Jefferson on the west,
Broomfield on the northwest, and Douglas on the
south. These areas made up the Denver Population
and Metropolitan Statistical Area (PMSA) through
2004.
In 2005 the Federal Office of Management and
Budget (OMB) added four new counties (Elbert,
Park, Clear Creek, and Gilpin) and renamed the area
the Denver-Aurora MSA. The Denver-Aurora MSA
covers 8,390 square miles. These additions should be
noted in the future when comparing 2005 with previous years’ data.
Denver and the surrounding counties experienced
rapid population growth from the 1990s through
2003. According to the 2004 Colorado census forecast, the Denver-PMSA population was 2,348,764.
The city of Denver accounts for 12 percent of Colorado's total population. The Denver PMSA accounts
for 50 percent of the total State population. By the
end of 2006, the Denver-Aurora MSA population is
expected to increase by 4.0 percent to 2,415,156.
Colorado was the third fastest growing State in the
United States until 2004, when the growth rate declined. The population more than doubled from 1960
to 2000. Recently, however, the population that
moved from Colorado to the surrounding States exceeded new arrivals. Colorado now ranks among
those States with the lowest rates of net domestic
immigration and is 14th on the list of fastest growing
States. Statewide, the population is expected to increase from the 2004 census projection of 4,642,589
to 4,706,754 by the end of 2005, or by 1 percent.
The median age in the Denver area is 33.1. Males
accounted for 50.5 percent and females represent
49.5 percent of the population. Ethnic and racial
characteristics of the area are as follows: 65 percent
White, 11 percent Black or African-American, 3 percent Native American Indian, 3 percent Asian, and
0.1 percent Native Hawaiian and Other Pacific Islanders. Hispanics or Latinos of any race compose 32
percent of the area’s population.
The average household size is 2.27, and the average
family size is 3.14. For the population age 25 and
older, 79 percent are high school graduates or higher,
and 35 percent have bachelor’s degrees or higher.
The major industries in Colorado are communications, utilities, agriculture, and transportation. The
employment growth rate in the State exceeded the
Nation’s at the end of 2004, with the United States
and Colorado employment rates growing at 1.6 and
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2.1 percent, respectively. The per capita income for
Denver is $24,101. The median household income is
$55,883, and the median family income is $47,203.
Eleven percent of families and 14 percent of individuals in the area live below the poverty level. The
unemployment rate as of March 2005 was 5.7; nationally, it was 5.6.

•

Emergency department (ED) data were derived
for 2004 from the Drug Abuse Warning Network
(DAWN) Live! restricted-access online query system administered by the Office of Applied Studies
(OAS), Substance Abuse and Mental Health Services Administration (SAMHSA). Eligible hospitals in the Denver area totaled 14; hospitals in the
DAWN sample numbered 14, with the number of
EDs in the sample totaling 14. During this 12month period, between 5 and 8 EDs reported data
each month. The completeness of data reported by
participating EDs varied by month (see exhibits 1a
and 1b). Exhibits in this paper reflect cases that
were received by DAWN as of April 13–14, 2005.
All DAWN cases are reviewed for quality control.
Based on this review, cases may be corrected or
deleted. Therefore, the data presented in this paper
are subject to change. Data derived from DAWN
Live! represent drug reports in drug-related ED
visits. Drug reports exceed the number of ED visits, since a patient may report use of multiple
drugs (up to six drugs and alcohol). The DAWN
Live! data are unweighted and, thus, are not estimates for the reporting area. These data cannot be
compared to DAWN data from 2002 and before,
nor can preliminary data be used for comparison
with future data. Only weighted DAWN data released by SAMHSA can be used for trend analysis. Exhibit 1c shows the number of unweighted
DAWN ED cases by case type. A full description
of the DAWN system can be found at the DAWN
Web site: http://dawninfo.samhsa.gov.

•

Drug related mortality data for the Denver
metropolitan area for 2003 were provided by
SAMHSA’s Drug Abuse Warning Network,
2003: Area Profiles of Drug Related Mortalities.
The Colorado Department of Public Health and
Environment (CDPHE) provided statewide mortality data for 2003. Data for 2004 were unavailable at the time of document completion. Data
for the Denver metropolitan area for 1996–2002
are also reported.

•

Hospital discharge data statewide for 1997–
2003 were provided by the Colorado Hospital
Association through the CDPHE Health Statistics Section. Data included diagnoses (ICD-9CM codes) for inpatient clients at discharge from
all acute care hospitals and some rehabilitation
and psychiatric hospitals. These data did not include ED care.

•

Drug/Alcohol Coordinated Data System
(DACODS) reports are completed on clients at
admission and discharge from all Colorado alcohol and drug treatment agencies licensed by

Two major interstate highways, I-25 and I-70, bisect
Denver. I-25 runs north-south from Wyoming
through New Mexico, and I-70 runs east-west from
Maryland through Utah.
The Violent Crime Rate National Ranking for Colorado is 27 out of 50.
Several considerations may influence drug use in
Denver and Colorado:
•

Easy transit across multiple States is possible via
the interstate highways.

•

The area’s major international airport is nearly at
the midpoint of the continental United States.

•

The area is marked by population growth and
expanding economic opportunities.

•

Remote rural areas are ideal for the undetected
manufacture, cultivation, and transport of illicit
drugs.

•

A young citizenry is drawn to the recreational
lifestyle available in Colorado.

•

The large tourism industry draws millions of
people to the State each year.

•

Several major universities and small colleges are
in the area.

•

The Denver-Aurora MSA unemployment rate
was 5.0 percent as of November 2004, a decrease
of 1 percent from a year earlier.

Data Sources
Unless otherwise specified, the data in this report are
for calendar year (CY) 2004 and were collected and
analyzed in May 2005. Although these indicators
reflect trends throughout Colorado, they are dominated by the Denver metropolitan area.
•
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Qualitative and ethnographic data for this
report were available mainly from clinicians
from treatment programs across the State, local
researchers, and street outreach workers.
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ADAD, Colorado Department of Human Services. Annual figures are given for 1997 through
2004. DACODS data are collected and analyzed
by ADAD.
•

Data regarding methamphetamine use in men
who have sex with men (MSM) in Denver were
provided by Dr. Mark Thrun, Medical Director,
HIV Prevention, Denver Public Health.

•

Availability, price, and distribution data were
collected from local Drug Enforcement Administration (DEA) Denver Field Division (DFD) officials in their fourth quarter fiscal year (FY)
2004 report, the Office of National Drug Control
Policy (ONDCP), Drug Policy Information
Clearinghouse, “Denver, Colorado, Profile of
Drug Indicators, June 2004” and from the December 28, 2004 issue of Narcotics Digest
Weekly, Volume 3, Number 52.

•

Communicable disease data were obtained
from the CDPHE. Data are presented from 1997
through 2004.

•

Rocky Mountain Poison and Drug Center
(RMPDC) data are presented for the Denver
area for 2001–2003 and for Colorado for 2004.
The data represent the number of calls to the center regarding "street drugs."

•

Arrestee urinalysis results were provided by
the Arrestee Drug Abuse Monitoring (ADAM)
program, based on quarterly studies conducted
under the auspices of the National Institute of
Justice. ADAM data in Colorado were collected
and analyzed by the Division of Criminal Justice.
In 2000, NIJ changed its procedures from a convenience to a probability sample. Thus, no
ADAM data trend analysis is presented. Rather,
2001, 2002, and 2003 use percentages by drug
type were included as a historical reference.

•

•

•

Sentencing data on Federal drug convictions in
the State of Colorado for Federal fiscal year (FY)
2002 were compiled by the United States Sentencing Commission, Office of Policy Analysis.

Information System (NFLIS) for Denver for
2004; the Rocky Mountain High Intensity Drug
Trafficking Area (HIDTA) Taskforce; and from
information reported by the Denver Police Department Crime Laboratory.
•

Alcohol data were obtained from the “U.S. Apparent Consumption of Alcoholic Beverages
Based on State Sales” by the U.S. Department of
Health and Human Services, June 2004, the
Rocky Mountain Insurance Information Association (RMIIA), the Department of Transportation
Fatality Analysis Reporting System (FARS), and
Colorado State Patrol statistics.

•

Drug testing index data for 2004 were provided
by Quest Diagnostics. The positivity rate is the
number of positive test results compared to the
total number of drug tests performed by Quest
Diagnostics (7.2 million workplace drug tests nationally) in 2004. Quest Diagnostics performs
workplace testing for three major populations:
federally mandated, safety-sensitive workers
(such as pilots, bus and truck drivers, and workers in nuclear power plants); the general workforce, and the combined workforce. (Note: The
positivity rate may also reflect the availability
and type of employment opportunities for different geographic areas of Colorado.)

•

Tobacco statistics for 2004 were excerpted from
the “State of Tobacco Control 2004” by the
American Lung Association. Statistics for 2003
were provided by the CDPHE, “Health Watch
2003.”

•

Crime statistics for Colorado in 2003 were
taken from the Colorado Bureau of Investigation
crime reports.

•

Cost estimates for untreated substance abuse
in Colorado were taken from National Estimates
of Expenditures for Substance Abuse Treatment,
1997, SAMHSA, February 2001.

•

Population statistics were obtained from the
Colorado Demography Office, Census 2000 including estimates and projections, and factfinder.census.gov.

Information about offenders in the Colorado
correctional system for substance abuse-related
crimes was supplied by The Colorado Department of Corrections, Overview of Substance
Abuse Treatment Services, FY 2004.

DRUG ABUSE PATTERNS AND TRENDS

Statistics on seized and forensically analyzed
drug items were provided by the DEA, Office of
Diversion Control, National Forensic Laboratory

Cocaine indicators remained mixed, with some increasing and some decreasing during this period. Cocaine was the most common illegal drug noted in
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Denver-area emergency department reports and second only to alcohol among all drug reports. Denver
PMSA ED mentions for cocaine increased steadily
from 1996 (53 per 100,000) through 2002 (82 per
100,000).
Unweighted DAWN Live! data showed 1,569 ED
reports for cocaine in 2004 (exhibit 2).
Males represented 63 percent of all ED cocaine patients; 47 percent were age 30–44 (exhibits 3 and 4).
Overall, those age 21–64 accounted for 89 percent of
all cocaine patients.
Statewide hospital discharges showed that cocainerelated visits per 100,000 population rose steadily
from 1997 (56 per 100,000) through 2003 (80 per
100,000) (exhibit 5). Cocaine was second only to
alcohol in drug-related hospital discharges in 2003.
The number of cocaine-related calls to the Rocky
Mountain Poison and Drug Center for the Denver
area rose from 2001 (59) through 2003 (68); during
that period, cocaine was the most common drug of
concern (second only to alcohol) (exhibit 6a). In
2004, the number (316) of statewide calls about
stimulants and amphetamines exceeded those for
cocaine (120). There were 95 methamphetamine calls
statewide in 2004.
CDPHE cocaine-related mortality data for the Denver
PMSA showed an increase in such deaths from 1996
(68) to 2001 (126); they declined slightly in 2002 to
108 (exhibit 7). Throughout this entire time period,
cocaine-related deaths were higher than those for any
other drug (including alcohol) in the area.
Statewide, cocaine deaths climbed from 92 in 1997
(23.6 per million) to 146 in 1999 (36.1 per million).
While they declined to 116 in 2000 (27 per million),
they increased again to 134 in 2001 (30.4 per million)
and to 153 in 2002 (34.1 per million). CDPHE data
from 2003 places cocaine deaths at 180 (39.2 per
million), the highest number and rate in the time period indicated. In spite of this increase, cocaine
ranked behind alcohol (1,141) and the opiates (heroin, morphine, other opioids, and narcotics combined
for a total of 247). Reports from clinicians, researchers, and street outreach workers around the State corroborate the continuing cocaine problems reflected in
the indicator data. However, qualitative reports indicate a shift to methamphetamine among some stimulant users, especially the younger population. Clinicians report cocaine is rarely a primary drug for those
younger than 18, regardless of urban or rural setting.
Cocaine use is slightly higher among 18–25-year-
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olds, but it is a major drug of abuse for those age 26–
64, especially in urban areas.
Cocaine was the primary drug for 21 percent of all
treatment admissions (excluding alcohol) in 2004
(exhibit 8). The proportion of clients admitted to
treatment with cocaine as their primary drug decreased slightly from 1997 (24 percent of all drug
admissions) to 2004. Since 2001, primary cocaine
admissions have remained in the 19–21 percent
range. Since 1997, marijuana as a primary drug has
exceeded cocaine, and this trend continued in 2004.
In 2003 and 2004, methamphetamine exceeded cocaine as a primary drug of abuse.
The majority of cocaine admissions were clients who
had been using this drug for 4 or more years. The
proportion of admissions of “new” cocaine users
(those using less than 4 years) rose from 17 percent
in 1997 to 19 percent in 2003 and 18 percent in 2004
(exhibit 9a). It takes an average of 10.7 years after
first use for the majority of those users with cocaine
as their primary drug to seek treatment (exhibit 9b).
The percentages of clients who smoke cocaine declined steadily from 65 percent in 1997 to 58 percent
in 2001, but rebounded in 2003 and 2004 to 63 and
62 percent, respectively. The proportion of clients
who inhale cocaine has been steadily increasing,
from 19 percent in 1997, to 26 percent in 2001, to 30
percent in 2004.
Whites accounted for the largest percentage of cocaine admissions in 2003 and 2004 (45 percent for
both years), showing a small decline from 2000 (48
percent). Hispanic cocaine admissions increased
dramatically from 19 percent in 1997 to 29 percent in
2000 and 33 percent in 2004.
The proportion of African-American cocaine admissions dropped sharply from 33 percent in 1997 to 20
percent in 2001, with a mild increase in 2003 (24
percent), followed by a decline in 2004 (to 18 percent). However, crack cocaine is fairly well entrenched in the African-American urban communities. African-American admission percentages for all
other drugs remain in the single digits, with the exception of marijuana (13 percent).
In 1997, 56 percent of cocaine treatment admissions
were younger than 36; this decreased to 50 percent in
both 2003 and 2004. The majority (68.5 percent) of
2004 cocaine admissions were between the ages of
26 and 45. Two percent of cocaine admissions in
2004 were younger than 18, and only 12 percent were
older than 45.
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Cocaine admissions remain predominately male, with
their proportion growing slightly from 1997 (57 percent male) to 2004 (61 percent). Sixty-nine percent
were admitted to treatment for cocaine dependence,
compared with 26 percent for abuse. Thirty-eight
percent of cocaine users indicated they used alcohol
as a secondary drug, and 24 percent used marijuana.
Treatment providers indicated that marijuana is
commonly used with cocaine to lessen the effects of
withdrawal and to potentiate the effects of the cocaine.
In Federal FY 2002, 34 percent of those sentenced to
Federal correctional systems in Colorado had drugs
as their primary offense category, compared with 41
percent nationally. Of the 34 percent, powder and
crack cocaine were each involved. Thirty-one percent
were sentenced because of drug trafficking.
According to recent ADAM data for a sample of
Denver arrestees, 35.4 percent of males and 46.5 percent of females had cocaine-positive urine samples in
2001. These numbers were down slightly in 2002,
with 32.7 percent of males and 43.6 percent of females testing positive. However, in 2003, 38.3 percent of males and 52.5 percent of females tested positive for cocaine (exhibit 10).
According to the National Forensic Laboratory Information System, in Denver, cocaine accounted for
49 percent of all drugs seized by law enforcement
and submitted to a forensic laboratory for analysis in
2004.
When drug testing for employment in Colorado,
Quest Diagnostics ranked cocaine lowest on the
Quest Drug Test Index (0-2.54 percent), possibly
indicating that few individuals undergoing screening
for employment that requires testing in Colorado
used cocaine (exhibit 11).
According to the National Drug Intelligence Center
and the DEA, powder cocaine was readily available
throughout the State in 2004. Crack cocaine was
more available in urban population centers. In general, Caucasians prefer powder cocaine and AfricanAmericans prefer crack. Cocaine was the drug most
often associated with violent crime in Colorado in
2004.
The majority of cocaine is Mexican; it is imported
into Colorado by organized Mexican nationals or
family groups who have connections to gangs on the
west coast. In the last year, two significant drug organizations began to compete to control the wholesale supply. They transport the cocaine from the
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Mexican border or from western States, such as California and Arizona, to Denver, using automobiles
with hidden compartments, commercial and cargo
airlines, delivery services, and other mail carriers.
Denver serves as a major distribution center for cocaine for the entire country, especially the Midwest
and east coast States. Proceeds from cocaine sales are
transported to Mexico or the western States via the
same means.
In Colorado, street distribution is controlled by
gangs. There are more than 10,000 gang members in
the Denver area, with an average of 1,500 new members added each year. According to the Denver Drug
Enforcement Agency and treatment providers, gangs
also control the market for distribution of cocaine in
the southern, northern, and western slope areas of the
State. Gangs are ubiquitous throughout Colorado, but
they are less dominant in the eastern region, where
the population is much less dense. Cocaine prices
depend on the purity of the product.
In 2004, powder cocaine sold for $16,000–$20,000
per kilogram and $600–$700 per ounce in the Denver
metropolitan area (exhibit 12). These prices are
slightly lower than in previous years. Crack cocaine
prices have remained relatively stable at $700–$1,200
per ounce, while “rock” prices on the street are $20–
$60 in Denver. Prices are slightly higher outside of
the Denver metropolitan area. Purity ranges from 60
to 75 percent for crack and 16 to 90 percent for powder. Treatment providers stated that crack is fairly
rare on the western slope, and its use remains entrenched in the African-American communities in
southern Colorado.
Overall, Colorado has seen a decrease in the wholesale price of powder cocaine, because some users
switched to methamphetamine. Treatment providers
indicate this switch is due to the cheaper prices and a
longer lasting “high” of methamphetamine.
Heroin and Other Opiates
Heroin and other opiate use pose a considerable
threat to Colorado, although indicators for both were
mixed. The number of heroin-related ED mentions in
Denver was 22 per 100,000 in 1996, with a gradual
increase to 43 per 100,000 in 2002.
In 2004, unweighted DAWN Live! data revealed 609
heroin ED reports (exhibit 2). Males represented 74
percent of these patients; 40 percent were age 30–44,
and 99 percent were age 21–64 (exhibits 3 and 4).
Opiates other than heroin include hydrocodone, hydromorphone, codeine, and oxycodone. ED mentions
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related to narcotic analgesics for Denver rose steadily
from 18 in 1996 to 41 in 2001, with a drop to 34 in
2002.
In 2004, unweighted DAWN Live! data show 699 ED
reports for prescription drug misuse of opiates and
opioids; 43 percent were classified as overmedication
case types, 40 percent were “other,” and 17 percent
were seeking detoxification (exhibit 13). ED reports
for hydrocodone totaled 174, with 64 percent of case
types being overmedication. Oxycodone ED reports
totaled 191, with 48 percent of these classified as
overmedication.
CDPHE statewide hospital discharge data for 1997–
2003 combined all narcotic analgesics, including heroin (exhibit 5). These discharges have been steadily
increasing, with the rate almost doubling in 7 years,
from 37 per 100,000 in 1997 to 73 per 100,000 in
2003. Treatment providers indicated a rapid rise in
popularity in the abuse of prescription narcotics such
as OxyContin and hydrocodone, especially among
youth; these discharge data may reflect that.
CDPHE’s heroin/morphine-related mortality data for
the Denver PMSA showed that such deaths increased
from 34 in 1996 to 79 in 1999, declined to 66 in
2000, rose to 77 in 2001, and declined to 64 in 2002
(exhibit 7). CDPHE reported that opiate-related
deaths increased from 53 (3 per 100,000 population)
in 1997 to 79 (4 per 100,000) in 1999 for the Denver
PMSA. From this peak, deaths declined back to 3 per
100,000 in 2002.
CDPHE statewide data for 2003 show there were 247
opiate-related deaths.
DAWN mortality data for the Denver-Aurora Metropolitan Area for 2003 identified opiates/opioids as
having the highest frequency in the top five drugs
related to drug misuse deaths, with 113 multiple drug
and 25 single-drug deaths (exhibit 14).
Heroin and other narcotic analgesic-related calls to
the Rocky Mountain Poison and Drug Center for the
Denver area have remained fairly steady, with 19
calls in 2001 and 22 calls in 2003 (exhibit 6a). In
2004, there were 20 heroin/morphine calls statewide
(exhibit 6b).
According to recent ADAM data for a sample of
Denver arrestees, 5.2 percent of males and 2.4 percent of females tested positive for opiates in 2001.
However, in 2002, 5.3 percent of females and 4 percent of males tested positive for opiates. In 2003,
male arrestees again showed a slightly higher per-
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centage of opiate-positive urines (6.8 percent) than
female arrestees (6.1 percent) (exhibit 10).
The proportion of Colorado treatment admissions
(excluding alcohol) for clients with heroin as their
primary drug has steadily declined. In 1997, 16 percent of all drug treatment admissions identified heroin as their primary substance, while in 2004 only 9
percent did so (exhibit 8) Admissions for primary
“other opiates” abuse remained steady during this
period, representing 3 and 4 percent, respectively.
Admissions for “new” heroin and other opiate users
entering treatment within 4 years of initial use fluctuated since 1997 at 17.9 percent, to 21.6 percent in
2000 and 16.1 percent in 2004 (exhibit 9a). The majority of those in treatment for heroin are long-time
users. According to ADAD’s 2004 data, it takes these
clients an average of 14 years from first use before
they enter treatment (exhibit 9b).
Opiates (heroin and other opiates combined) ranked
low for all four generations of users, from 2 percent for
the Y generation, to 8 percent for the X generation, and
13 percent for the Baby Boomers (exhibit 15).
Nearly all (99.6 percent) heroin and other opiate users were older than 18 at the time of admission to
treatment. Sixty-one percent were male, and 88 percent lived in urban settings.
Treatment providers reported an increasingly young
population in their early teens using OxyContin and
any other drug they can obtain, usually stolen from
their parents. Providers also stated they are seeing
more polysubstance abuse in clients.
Sixty-nine percent of treatment admissions for heroin
and other opiates were White, 20 percent were Hispanic, and 7 percent were Black or AfricanAmerican. Forty-two percent had completed the 12th
grade, and 3 percent completed college. Wages were
the primary source of income for 46 percent. Twentyseven percent had no prior treatment, while 29 percent had three or more treatment episodes before this
admission.
Fifty-four percent of these clients self-referred into
treatment. Eighty-six percent were dependent upon
heroin or other opiates, while 12 percent received the
diagnostic impression of abuse. Twenty-nine percent
had no use of heroin or other opiates in the 30 days
prior to treatment admission, while 44 percent used
daily. Sixty-two percent injected, and 29 percent reported the oral route of administration.
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Twenty-eight percent of these clients were younger
than 18 when they first tried heroin or other opiates,
and 48 percent were 21 or older. Forty-three percent
had no secondary drug, while 23 percent used cocaine as their secondary drug. Fifty-one percent of
clients indicated they began to use their secondary
drug before the age of 18, and 28 percent began at or
after age 21.
Seven percent of those in Colorado who were sentenced to Federal facilities were heroin or other opiate users, and this percentage mirrors the national
percentage for Federal FY 2002. Heroin represented
only 5 percent of all items seized by law enforcement
in Denver and submitted to forensic laboratories for
analysis in 2004.
Mexican black tar and brown powdered heroin are
the most common types available in Denver, with
black tar being slightly more available in Colorado.
Most new users are young adults who smoke or snort
it. Mexican drug trafficking organizations transport
heroin into Colorado and serve as the primary wholesale distributors and frequently as retail sellers, controlling the street-level market for heroin. Gangrelated crimes are frequently associated with the sale
of heroin. It is widely available in both urban and
rural settings. While typical users are older White
males living in the lower downtown Denver area,
new suburban users are emerging.
Prices for illegal drugs vary widely depending on
source, geographic area, purity, and risk. One ounce
of Mexican heroin at 40 percent purity costs $2,000–
$3,000. One gram of heroin that is 8–64 percent pure
costs $100–$150. Costs in Denver are slightly lower
than in the rest of the State. Heroin can be obtained in
Denver for $440 per one-quarter ounce or $100–$150
per gram (exhibit 12).
Pharmaceutical diversions of OxyContin and other
narcotic analgesics are increasing, as they provide the
abuser with reliable strength and dosage levels. A $4
prescription dose of OxyContin sells on the street for
$40, or $1 per milligram, 10 times the legal prescription price. One pill sells for $6.50 in Denver (exhibit
12). More abusers are using the Internet to obtain
prescription medications. Drug enforcement officials
have found a severe, systemic failure in pharmacies
and physicians’ offices related to keeping proper records, reporting thefts, and maintaining controlled
substances in Colorado. In response, Colorado recently passed Prescription Drug Tracking legislation
to monitor the use of controlled substances.
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Marijuana
Marijuana indicators are mixed. Marijuana is second
to alcohol in the number of users in Colorado, yet ED
data fall far below those for cocaine or narcotic analgesics. ED mentions increased steadily from 1996
(19) through 2001 (50).
In 2004, unweighted DAWN Live! data showed 755
ED marijuana reports (exhibit 2). Males represented
61.6 percent of the patients, and smoking was the
primary route of administration. Marijuana ED patients involved the widest age groups (exhibit 14).
Marijuana-related hospital discharges increased
steadily from 53 per 100,000 in 1997 to 71 per
100,000 in 2003 (exhibit 5).
Marijuana-related calls to the Rocky Mountain Poison and Drug Center remained fairly static from 1996
through 2003 for the Denver area (exhibit 6a). In
2004, there were 68 calls related to marijuana for the
entire State (exhibit 6b).
CDPHE reported that marijuana-related deaths for
the Denver PMSA have been quite few in number,
from 1 in 1996 to a peak of 31 in 2001, with a decline
to 5 in 2002 (exhibit 7). The number of cases in 2003
and 2004 were too small to report. According to
DAWN mortality data, marijuana was not one of the
top five drugs involved in drug misuse deaths for
2003.
ADAM data indicated that 40 percent of the male
arrestee sample and 33 percent of the female arrestee
sample had positive marijuana urine screens in 2001.
These percentages remained stable in 2002 (with 40.3
percent of males and 32.6 percent of females testing
positive), but increased slightly in 2003 (42.3 percent
positives for males and 34.3 percent positives for
females) (exhibit 10).
Overall, marijuana is second only to alcohol as an
entry substance to illegal drug use and abuse.
Excluding alcohol, Colorado has more treatment admissions for marijuana than for any other drug (exhibit 8). The percentage of clients admitted to treatment with marijuana as their primary drug has been
fairly steady from 1997 (41 percent) to 2004 (38 percent).
More “new” marijuana users seek treatment within 4
years of first use than for any other drug (exhibit 9a).
This finding has been consistent since 1997 (42.4
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percent) through 2004 (30.5 percent). Marijuana users take an average of 8 years from time of first use
to first treatment, which is a shorter time frame than
for any other drug discussed here, except methamphetamine (also 8 years) (exhibit 9b).
Males accounted for 74 percent of treatment admissions in 2004, maintaining the historical male-tofemale ratio of approximately 3 to 1 since 1997.
Thirty-nine percent were younger than 18 at time of
admission to treatment. This figure has been fluctuating between 45 and 35 percent since 1997. Sixtyseven percent of treatment admissions with marijuana
as their primary drug were living in urban settings.
Race proportions for marijuana admissions remain
relatively stable. In 2004 53 percent were White, 30
percent were Hispanic, and 13 percent were AfricanAmerican. Whites represented 56 percent in 2003,
followed by Hispanics (27 percent) and AfricanAmericans (11 percent). Sixty-five percent used tobacco products daily. Fifty-six percent had no prior
treatment episodes, while 27 percent had one. Sixtyseven percent were unemployed, and 62 percent were
living in a dependent setting (the majority with their
parents). Only 8 percent self-referred to treatment,
while 21 percent were referred by Social Services and
52 percent were referred by non-DUI criminal justice.
Forty-six percent of marijuana treatment admissions
were considered abusers, while 41 percent were dependent on marijuana. Smoking was the route of administration for 95 percent of treatment admissions
with marijuana as primary drug. Ninety percent of all
clients stated they started to use marijuana before age
18. Thirty-two percent had no secondary drug, while
44 percent used alcohol and 12 percent used
methamphetamine as their secondary drug. Of those
with a secondary drug, 76 percent started using it
before the age of 18.
Among persons 18 or older, 28 percent of those who
first used marijuana before age 12 were assessed at
treatment admission as having a mental health problem in addition to a substance abuse problem, compared with 21 percent of those who first used marijuana at age 18 or older. In both 2003 and 2004, 79
percent of treatment clients aged 18 or older reported
first use before age 18, and 9 percent reported initiating use before the age of 12.
Quest Diagnostics reported that their employment
testing showed marijuana with a higher positivity rate
in Denver than any other drug in 2004 (exhibit 11).
Of those individuals sentenced to Federal facilities in
Colorado, 17 percent had use of marijuana as their
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primary offense, which was lower than the national
percentage at 29.
Cannabis represented 19 percent of all items seized in
Denver and submitted to NFLIS for analysis in 2004.
Both Mexican imported and locally grown marijuana
were readily available statewide.
The marijuana used in Colorado was primarily produced in and imported from Mexico. A small portion
was grown in Colorado or other western States, particularly California. It was distributed primarily by
Mexican drug trafficking organizations and criminal
groups at the wholesale level and by Hispanic and
African-American street gangs at the retail level.
Caucasian criminal groups and local independent
dealers were the primary distributors of the marijuana
and sinsemilla produced in Colorado.
BC Bud, a Canadian import with a high level of tetrahydrocannabinol (THC), was available only in limited quantities and relatively hard to obtain in Colorado until 2003. Since then, an increase in availability
of BC Bud has contributed to an increased THC level
in both the Denver and Boulder areas. BC Bud sells
for $700–$1,000 per ounce and $3,200–$4,500 per
pound. On the street, BC Bud costs $10 per joint.
Locally produced sinsemilla sold for $1,000–$3,000
per ounce and $50–$200 per gram in 2004 (exhibit
12). Domestic marijuana grown indoors was preferred
over Mexican grown marijuana and sold for $1,000–
$3,000 per pound and $200–$300 per ounce. This
price range remained static from 2003 to 2004. DEA
officials report “grow” operations are becoming increasingly sophisticated and technical. Outdoor marijuana is most likely a product of eastern Colorado.
Prices of marijuana are slightly cheaper in Colorado
than in surrounding States. Trafficking on the western
slope is dominated by Hispanics importing it into
Colorado from Mexico. Officials are noticing more
individual Mexican nationals independent of the large
drug organizations trafficking marijuana statewide.
Treatment providers almost uniformly indicated that
marijuana use is socially accepted in their areas and
that the perception of risk associated with marijuana
use is declining. Treatment providers felt this decline
is related to national media coverage of marijuana as
a medicinal drug, and to a high frequency of parental
use of marijuana.
Methamphetamine
Most indicators for methamphetamine increased over
the past few years, and this drug was and remains a
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rapidly expanding social problem for Colorado. Violent crime related to methamphetamine use has been
increasing, and the social consequences, particularly
as related to children residing in methamphetamine
cook houses, are major concerns.
DAWN ED data for methamphetamine was fairly
static, shifting between 5 and 8 mentions per 100,000
since 1996, with the exception of 1997, when there
were inexplicably 19 mentions per 100,000 population.
The unweighted DAWN Live! data show 475 ED
methamphetamine reports in the Denver PMSA in
2004 (exhibit 2). Sixty-three percent of all ED stimulant reports for 2004 were related to methamphetamine. Fifty-eight percent of the ED methamphetamine patients were male (exhibit 3). Seventy percent
of methamphetamine ED patients were age 21–44.
Methamphetamine was not broken out from other
stimulants for hospital discharge data, but overall
amphetamine-related hospital discharges have increased since 1999 from 16 per 100,000 to 40 per
100,000 in 2003 (exhibit 5).
There were 39 methamphetamine-related calls to the
Rocky Mountain Poison and Drug Center for the
Denver area in 2003 (exhibit 6a). In 2004, there were
95 such calls statewide (exhibit 6b).
CDPHE reported a small but steady increase in
methamphetamine-related mortality since 1996 (3
deaths). In 1999, there were 8 methamphetaminerelated deaths, compared with 10 in 2000, 19 in 2001,
and 17 in 2002 (exhibit 7). However, deaths related
to amphetamines increased only slightly from 5 in
1997 to 13 in 2002. Though amphetamine-related
deaths in Colorado are far fewer than those for opiates or cocaine, the number increased sharply from
only 20 between 1996 and 1999 to 37 between 2000
and 2003 (an 85-percent increase). In 2003, there
were 47 deaths related to amphetamines statewide.
Colorado treatment providers reported that methamphetamine is the most popular illegal drug, and it is
frequently used in combination with alcohol, marijuana, and cocaine. It was readily available, inexpensive, and at times free. Potency was reported to be
good. Providers noted an increasing problem with
methamphetamine use statewide, especially in
younger populations. They indicated this increase
was in part related to easy access, difficulty obtaining
other amphetamines, and relatively low prices. Consistent with this trend, providers noted use of other
amphetamines has dropped in popularity.
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According to ADAM data, only a small percentage of
positive methamphetamine urine screens were reported in 2001: 3.4 percent of the male arrestee sample and 4.3 percent of the female arrestee sample.
These figures increased slightly for males in 2002
(3.8 percent) and slightly more for females (6.6 percent). Again, only small changes were noted in 2003,
with 4.7 percent of males and 5.0 percent of females
testing positive for methamphetamine (exhibit 10).
In 2004, staff at the Public Health Sexually Transmitted Disease (STD) Clinic in Denver surveyed clientele (N=981) and noted an increased use of methamphetamine among men who have sex with men
(MSM) (exhibit 16a). They found that MSM
methamphetamine users are typically younger than
non-users (exhibit 16b) and more likely to have been
arrested in the 12 months preceding the survey, use
erectile dysfunction drugs, be homeless, have more
sexual partners in the last 12-month period, have
more unprotected sex, and use the Internet for connecting with casual partners. Methamphetamine users
seen in the STD clinic were twice as likely to have
gonorrhea or HIV than non-users. At the Denver
Health Infectious Disease/AIDS Clinic in 2004, 11
percent of randomly surveyed patients (n=202) reported use of methamphetamine in the 3 months preceding the survey.
Colorado treatment admissions for clients using
methamphetamine as their primary drug have risen
dramatically. Methamphetamine is now second only
to marijuana in the number of treatment admissions
(excluding alcohol). Exhibit 8 shows that in 1997
there were 1,081 admissions for methamphetamine.
This number has since tripled to 3,209 in 2004.
The proportion of treatment admissions for new users
(those using less than 4 years at time of treatment)
does not reflect this steady rise (exhibit 9a), with 34
percent in 1997, dropping to 22 percent in 2001, and
rising slightly to 24 percent in 2004. According to
2004 treatment data, methamphetamine users take an
average of 8 years from first use to first treatment
(exhibit 9b).
A comparison of 2004 treatment admissions involving new (using less than 4 years, n=562) versus more
longstanding users (using 4 or more years, n=2,647)
shows some notable differences between these two
groups. New users were more likely than longstanding users to be female (56 percent vs. 41 percent,
respectively) and non-White (22 percent vs. 15 percent, respectively). Also, as expected, new users had
a higher proportion of those age 25 and younger (56
percent) than longstanding users (31 percent). Ac-
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cordingly, new users were more likely than longstanding users to have never married (58 percent vs.
44 percent, respectively) and to be unemployed (67
percent vs. 61 percent, respectively).
Looking at “severity” data, new users were less likely
to inject methamphetamine (10 percent vs. 25 percent) and more likely to ingest the drug by smoking
(74 percent vs. 60 percent, respectively) than were
long-standing users. Fewer new users were diagnosed
as drug dependent (57 percent vs. 73 percent), but
they had a higher proportion of concurrent mental
health problems (33 percent) than longstanding users
(29 percent).
Methamphetamines were combined with all other
stimulants in the generational snapshot of treatment.
Both the X generation and the Baby Boomers used
stimulants (36 percent and 25 percent, respectively)
more than the Y generation or seniors (18 percent and
5 percent, respectively) (exhibit 15).
During 2004, 4 percent of treatment admissions with
methamphetamine as a primary drug were for clients
younger than 18. The majority of those in treatment
(69 percent) were between ages 18 and 35. During
2004, 56 percent of treatment admissions for
methamphetamines were male. Methamphetamine
use was found in both urban (60 percent) and rural
(40 percent) areas of Colorado. Treatment providers
stated they are seeing an increase in methamphetamine use in both rural and urban areas and an increase in the social and community problems related
to this use.
Whites dominated among methamphetamine admissions (83 percent) in Colorado. Few Hispanics (13
percent) and even fewer African-Americans (1 percent) used methamphetamine as their primary drug.
However, treatment providers indicated that Hispanics, who have traditionally been involved in the trafficking of methamphetamine, were beginning to use
it in greater numbers. Fifty-two percent of all
methamphetamine users were referred to treatment
by the non-DUI criminal justice system, and 18 percent were referred by Social Services.
Injecting had been the most common route of administration for methamphetamine. However, the
proportion of those injecting declined from 1997
(32.6 percent) to 2004 (21 percent), while smoking
increased in the last 7 years. In 1997, only 29.1 percent smoked methamphetamine; in 2003, 61 percent
of methamphetamine treatment admissions smoked
the drug. In 2004, 63 percent smoked it, while 21
percent injected it.

74

Forty-one percent of clients began to use methamphetamine before the age of 18. Most (72 percent)
used a secondary drug in addition to methamphetamine, usually marijuana (37 percent), alcohol (21
percent), or cocaine (10 percent). Seventy-nine percent of those using a secondary drug initiated use of
this secondary drug before the age of 18.
Treatment outcomes for methamphetamine users are
as good as or better than outcomes for users of other
drugs.
Federal sentencing data report that methamphetamine
was the primary substance for 34 percent of the drug
convictions in Federal FY 2002. This is almost double the percentage of offenders sentenced because of
cocaine (powder and crack) and marijuana and four
times greater than heroin.
The DEA describes widespread methamphetamine
availability, with a majority of the drug originating
from Mexico or from large-scale laboratories in California. However, methamphetamine lab seizures in
Colorado increased significantly from around 25 in
1997 to 464 in 2002. These laboratories, generally
capable of manufacturing an ounce or less per
“cook,” varied from being primitive to quite sophisticated. The ephedrine reduction method remains the
primary means of manufacturing methamphetamine
in the area. In spite of law enforcement pressure,
there has been an increase in the number of small,
local methamphetamine labs, with the occasional use
of trucks for mobile labs.
Most lab operators are able to get the precursor
chemicals from legitimate businesses (e.g., discount
stores, drug stores, chemical supply companies, etc.).
Treatment providers report that the current practice is
for separate individuals or groups to each acquire one
of the key ingredients and then deliver it to the
“cook,” thereby decreasing the risk involved when
one party obtains all the ingredients. In 2005, Colorado passed legislation limiting public access to
methamphetamine precursor drugs. Impact from this
legislation has yet to be determined.
During 2004, several major cocaine and methamphetamine trafficking organizations that had been
transporting drugs to Denver from Arizona and California were shut down. Methamphetamine from one
of these organizations had purity levels of 95 percent.
An organization on the western slope of Colorado
employed a number of drivers who transported anywhere from 2 to 10 pounds from Sinaloa, Mexico, or
California. Federal drug seizures in Colorado in 2004
included 28.8 kilograms of methamphetamine.
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Methamphetamine prices fluctuated from 2003 to
2004, with prices in some geographic areas of the
State increasing while others decreased. In general,
methamphetamine could be obtained for $700–
$1,500 per ounce, $4,500–$5,600 per one-half pound,
and $16,000 per pound in the Denver area (exhibit
12). In southern Colorado, prices are $600 per ounce
and $13,000 per pound. On the western slope, it sells
for $1,000–$1,200 per ounce. Purity varied from 0 to
100 percent, with most in the 50–95 percent range. In
Denver “ice,” a smokable form of methamphetamine
that looks like rock candy or rock salt, is nearly 100
percent pure and widely available. Street prices for
methamphetamine in Denver rose from $80–$125 per
gram in 2003 to $150 per gram in 2004.
Other Amphetamines and Stimulants
Indicators for other amphetamines and stimulants in
Colorado were mixed, but overall use of other amphetamines and stimulants (excluding cocaine and
methamphetamine) is approximately one-half that of
cocaine or methamphetamine.
There were 280 unweighted ED reports of amphetamines in 2004 in the Denver PMSA (exhibit 2). The
age group most represented among patients was 30–
44-year-olds (exhibit 4).
CDPHE hospital discharge data did not differentiate
between methamphetamine and other amphetamines.
The statewide number of amphetamine-related hospital discharges rose steadily from 1997 (959) to 2003
(1,814) (exhibit 5).
Denver-area amphetamine-related calls (which exclude
methamphetamine) to the Rocky Mountain Poison and
Drug Center were the smallest of any of the major
drug groups: 3 in 2001 and 6 in 2003 (exhibit 6a). In
2004, there were 316 such calls statewide (excluding
methamphetamine and cocaine) (exhibit 6b).
In 1997, there were 52 (0.7 percent of the treatment
admissions) admissions to treatment with some other
amphetamine or stimulant as primary drug (exhibit
8). In 2003, there were a total of 78 (0.7 percent of
the treatment population) admissions. Such admissions declined to 46 (or 0.4 percent) in 2004.
CDPHE mortality data for the Denver PMSA showed
an increase in amphetamine and other stimulantrelated deaths, from 2 in 1996 to 13 in 2002 (exhibit
7). In 2003, the number of statewide deaths for other
stimulants/amphetamines was 47, more than deaths
for methamphetamine but only one-fourth the amount
of the deaths related to cocaine.
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Quest Diagnostics noted that in 2004, 0.14–0.33 percent of employment drug tests in the Denver area
were positive for amphetamines (exhibit 11).
Barbiturates, Sedatives, and Tranquilizers
According to DAWN Live! data, there were 409 ED
prescription drug misuse reports related to benzodiazepines in the Denver area in 2004. Fifty-nine percent of these reports were related to overmedication,
9 percent to those seeking detox, and 32 percent were
related to “other” (exhibit 13).
CDPHE data on drug-related mortality data for the
Denver PMSA were not available for 2003 or 2004.
DAWN mortality data identified benzodiazepines as
one of the top five drugs involved in drug misuse
deaths for the Denver-Aurora Metropolitan Area for
2003, with 30 multidrug deaths (exhibit 14).
During 2004, there were 87 treatment admissions for
barbiturates, sedatives, or tranquilizers as a primary
drug. Fifty-one percent were female, and 90 percent
were older than 18. Seventy-three percent were urban, and 69 percent were White. When comparing
this group to all clients who reported other primary
drugs, this group used daily tobacco the least and had
the highest percentage of married clients; unemployment (the category “unemployment” includes those
out of the workforce, such as students, homemakers,
persons with disabilities, etc.); mental health problems; and visits to medical and psychiatric emergency rooms. They also had the highest percentage
of slight to moderate socialization issues or concerns.
Sixty-four percent administered their drug orally, 25
percent smoked it, 7 percent inhaled it, and 1 percent
injected it. Forty-eight percent were younger than 18
when they began to use this category of drugs, and 41
percent were age 21 or older. Sixty-eight percent
used a secondary drug, such as alcohol (34 percent),
opiates (13 percent), and marijuana (6 percent); 59
percent of those with a secondary drug were younger
than 18 when they first used it.
These drugs are frequently obtained as prescription
medications and fall into the diverted pharmaceutical
class as well. Local independent dealers and Internet
services are the principal distributors of diverted
pharmaceuticals.
Club Drugs
Club drugs are a group of synthetic drugs commonly
associated with all-night dance clubs called raves.
These drugs include methylenedioxymethampheta-

75

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Denver and Colorado

mine (MDMA, or ecstasy), gamma hydroxybutyrate
(GHB), flunitrazepam (Rohypnol or “roofies”), and
ketamine (Special K).
Information on use of these drugs in Colorado, while
still limited, is expanding. ADAD added club drugs
to the enhanced DACODS data set in July 2002.
Also, there are currently three sources of institutional
indicator data that include the club drugs (DAWN,
CDPHE mortality, and the Rocky Mountain Poison
and Drug Center). In addition, ADAD has worked
with OMNI Research and Training, a Denver-based
firm, to add club drug questions to the Colorado
Youth Survey.
Unweighted DAWN Live! ED data showed 64
MDMA-related reports in 2004, 5 reports for GHB,
and 2 reports for ketamine (exhibit 2).
The Rocky Mountain Poison and Drug Center recorded 30 calls related to club drugs in 2001, 55 in
2002, and 40 in 2003 for the Denver area (exhibit
6a). In 2004, there were 11 calls statewide concerning club drugs (exhibit 6b).
CDPHE club drug-related mortality data for the Denver PMSA showed two deaths in 2000, four in 2001,
and two in 2002 (exhibit 7). These data were unavailable for 2003 and 2004.
MDMA, or ecstasy, originally developed as an appetite suppressant, is chemically similar to the stimulant
amphetamine and the hallucinogen mescaline and
thus produces both stimulant and psychedelic effects.
MDMA is readily obtainable at raves, nightclubs,
strip clubs, or private parties. The traffickers are typically White and in their twenties or early thirties.
They obtain their MDMA from Nevada or California,
with source connections in Europe, and target young
adults and adolescents as users. Mexican trafficking
organizations were making inroads in the Colorado
MDMA market. The DEA reported one tablet or capsule costs $6–$25, with larger quantities selling for
$8–$16 per tablet (exhibit 12). These price ranges
have dropped slightly from 2003.
GHB is a central nervous system depressant that can
sedate the body, and at higher doses, can slow breathing and heart rate dangerously. It can be produced in
clear liquid, white powder, tablet, and capsule forms
and is often used in combination with alcohol—
making it even more dangerous.
The DEA reported that the majority of GHB customers were White and in their twenties or thirties. Past
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DEA reports placed the GHB price at $5–$10 per
dosage unit (i.e., one bottle cap full).
Rohypnol (roofies) is a benzodiazepine sedative approved as a treatment for insomnia in more than 60
countries, but not in the United States. Rohypnol is
tasteless, odorless, and dissolves easily in carbonated
beverages, and its effects are aggravated by alcohol
use. There does not appear to have been widespread
use of Rohypnol among either the general population
or those in the rave scene in Colorado. What use
there was occurred in the adolescent to mid-thirties
age range.
Ketamine, often called Special K on the street, is an
injectable anesthetic that has been approved for both
human and animal use in medical settings. However,
about 90 percent of the ketamine legally sold today is
intended for veterinary use. Produced in liquid form
or white powder, it can be injected, inhaled, or swallowed. Similar to phencyclidine (PCP) in its effects,
it can bring about dream-like states and hallucinations.
Club drugs were primarily used by young adults and
adolescents, and either these clients did not enter
treatment or their small numbers did not draw the
attention of indicator organizations. Certain club
drugs are also used as “date rape” drugs and their use
in this manner may be underreported.
In 2002, there were 12 treatment admissions for club
drugs statewide, or 0.1 percent of all treatment admissions. In 2003 and 2004, there were 37 (0.3 percent) and 48 (0.4 percent), respectively.
Alcohol
Alcohol continues to be the most abused substance in
the State. Colorado ranks 19 percent higher than the
national average and 5th in the Nation in per capita
consumption of beverage alcohol. Alcohol use disorders are medically based disorders related to abuse of
or dependence on alcohol.
Alcohol has consistently been the most frequently
mentioned drug in EDs the Denver PMSA. Prior to
2003, DAWN data for ED mentions for alcohol in the
Denver area peaked in 1999 and 2000, with rates of
107 per 100,000 population and 109 per 100,000,
respectively.
Unweighted DAWN Live! data show that alcohol was
involved in 38 percent of all drug-related visits in
2004. Five-hundred-fifteen (22 percent) adults sought
detoxification through the emergency department,
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and 45 percent had other alcohol-related issues (exhibit 17).
Alcohol-related emergency department visits for
those younger than 21 (n=755) represented 33 percent of all alcohol-related visits and 12 percent of all
drug-related emergency department visits. Of these
youth, 61 percent were male; 53 percent irrespective
of gender were age 12–17; and 46 percent were age
18–20 (exhibit 18).
Statewide alcohol-related hospital discharges rose
yearly from 418 per 100,000 in 1998 to 518 per
100,000 in 2003 (exhibit 5). Discharge data for 2004
were unavailable for this report.
According to DAWN 2003 mortality data, alcohol
ranked second in multidrug deaths in 2003 and was
third among the top five drugs related to drug misuse
deaths (exhibit 14) for the Denver-Aurora metropolitan area.
During 2004, 41 percent of all clients admitted to
treatment stated their primary drug of abuse was alcohol (exhibit 19). This figure has been steadily increasing since 2001. Six percent of these clients were
younger than 18. Of those age 18 or older, 72 percent
began to use alcohol before age 18. Anecdotal information from clinicians in the treatment field indicated
that alcohol was one of two major gateway drugs (the
other being marijuana) Colorado youth used to enter
the drug culture.
During 2004, ADAD reported 44,514 detoxification
discharges and 20,452 discharges from the Drinking
Driver DUI education and therapy program. Untreated alcoholism accounts for some of Colorado’s
greatest concerns, such as violent crimes, homelessness, domestic violence, vehicular crashes, overcrowded jails, poverty, and overcrowded emergency
and foster care systems. Each year Colorado spends
$4.4 billion in costs related to untreated substance
abuse, adding a substantial financial burden to taxes
and already stressed governmental resources.
Even though laws exist that prohibit selling alcoholic
beverages to minors, alcohol is the number one drug
for adolescents in Colorado. It is readily available
and inexpensive, and purveyors target younger age
groups. Recent marketing trends include marijuana
and alcohol-flavored lollypops and gum, “jello shots”
(a mixture of alcohol and fruit-flavored gelatin),
sweet soda-pop-flavored alcoholic beverages, and
inhaled alcohol.
Colorado’s Youth Risk Behavior Survey noted that
almost 50 percent of students in grades 9–12 during

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

2003 currently were using alcohol, and 80 percent
had had one or more drinks of alcohol in their lifetime.
Abuse of alcohol at an early age is frequently a precursor to use and abuse of illegal substances. During
2004, deaths related to binge drinking on college
campuses brought national notoriety to Colorado,
with five confirmed deaths of college-age individuals
from alcohol poisoning.
Moderate use of alcohol among adults is culturally
acceptable, and denial of abuse is particularly difficult to overcome. The average treatment client in
Colorado with alcohol as a primary drug uses or
abuses it for 16.5 years before seeking treatment. For
detoxification clients, that time period expands to 20
years.
In 2003, the Colorado State Patrol (CSP) investigated
approximately 30 percent of all vehicular crashes in
the State, including about 70 percent of all traffic
crashes involving fatalities. CSP reported that the
majority of fatal crashes involved inebriated drivers.
Some 2,161 vehicular crashes were directly caused
by individuals driving under the influence of alcohol,
and 116 crashes were caused by individuals driving
under the influence of drugs. Seven percent of all
crashes were DUI-related.
In 2004, CSP made 9,509 DUI arrests and investigated 87 fatal crashes and 2,117 non-fatal crashes.
DUI-caused crashes usually were more severe than
other types, because of higher speeds, and often the
occupants were not wearing seat belts.
In 2003, 56.7 percent of DUI-caused crashes resulted
in fatalities or injuries, compared with 29.6 percent
when DUI was not the cause of the crash. Onehundred-eight of these DUI-related crashes were fatality cases, 1,184 were injury cases, and 985 were
property damage cases. In 39 percent of alcoholrelated crashes, the blood alcohol content (BAC) was
greater than 0.01; it was greater than 0.08 in 35 percent. CSP reported 8,600 DUI citations for 2003.
In 2003, FARS data indicated that 39 percent (246)
of the 632 individuals killed in Colorado in vehicular
crashes involved alcohol.
In 2004, 665 individuals were killed in motor vehicle
crashes in Colorado.
In 2003, the CDPHE reported 1,141 alcohol-induced
deaths unrelated to motor vehicular accidents statewide.
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The number of alcohol-related calls statewide to the
Rocky Mountain Poison and Drug Center increased
markedly from 110 in 2001 to 150 in 2003 for the
Denver PMSA (exhibit 6a). In 2004, there were 764
alcohol calls statewide.
Drug use by “generation” was analyzed for 2004 using four age groups: Generation Y, Generation X,
Baby Boomers, and Seniors. Exhibit 15 shows that
sedatives and tranquilizers, including alcohol, are the
primary drug types for the X generation, Baby
Boomers, and Seniors.
Tobacco
Tobacco use is the leading cause of preventable death
and disability in the State and one of Colorado’s most
serious public health problems. Tobacco use is responsible for more than 4,200 deaths and the development of 130,000 tobacco-related illnesses in adults
annually. Smoking tobacco causes 30 percent of all
cancer deaths, 21 percent of coronary heart diseaserelated deaths, and 18 percent of stroke deaths. Reports show that 193,000 children in the State are exposed to secondhand smoke at home, resulting in
asthma and respiratory illnesses.
Annual health care costs directly related to smoking
exceed $1 billion (or $259 per capita) in the State.
Every Colorado household incurs more than $511 per
year in State and Federal taxes to pay for smokingrelated health care costs.
Approximately 630,000 (19 percent) of all Colorado
adults use tobacco products, compared with the 23
percent nationwide average. Sixty-eight percent of
clients who received substance abuse treatment
and/or detoxification services in State fiscal year
2004 used tobacco products daily.
The American Lung Association Tobacco Report
Card for Colorado indicated a failing (“F”) grade for
smoke-free air, youth access, and prevention and control spending. Colorado was mediocre (a “C”) on the
cigarette tax.
Laws enacted in Colorado prohibit the sale of tobacco products to adolescents (those younger than
18). In spite of that, the Youth Risk Behavior Survey
identified 27 percent of students in grades 9–12 as
current cigarette smokers. Adolescents who smoke
are more likely to smoke as adults and be at risk for
tobacco-related illnesses.
The sale of tobacco products is monitored by Colorado’s Department of Revenue Tobacco Enforcement
Division, and tobacco prevention efforts fall primar-
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ily under the purview of the Department of Public
Health and Environment.
In 2004, several cities in Colorado passed legislation
prohibiting the smoking of tobacco in certain public
areas, and advocacy groups are initiating a statewide
awareness campaign. Colorado also increased the
tobacco tax from $0.20 to $0.84, with monies going
to health care-related concerns.
INFECTIOUS DISEASES AMONG INJECTING DRUG
USERS
Of the 8,088 acquired immunodeficiency syndrome
(AIDS) cases reported in Colorado through December 31, 2004, 9.2 percent were classified as injection
drug users (IDUs), and 10.7 percent were classified
as homosexual or bisexual males and IDUs (exhibit
20).
CORRECTIONS: THE HIDDEN POPULATION
The Colorado Department of Corrections reports annually on new court commitments and parole populations. Unfortunately, data for substance abusers are
not broken out by primary drug. However, this population is large enough that to exclude it would mean
giving a skewed picture of Colorado’s substance
abuse problem. As of December 31, 2004, there were
20,144 adult offenders incarcerated, 7,383 on parole,
and 225 youthful offenders.
In State FY 2004, there were 5,240 new court commitments. Eighty-two percent of these individuals
were identified as substance abusers. Substance abusers were more likely to be female, Caucasian, single,
and younger. Substance abusers had significantly
more crimes on their current incarceration and averaged more than six times as many drug crimes as
non-abusers. Substance abusers were also more likely
to have prior Department of Corrections (DOC) incarcerations. When assessed for measure of criminal
risk, substance abusers scored substantially higher,
indicating that they have more serious criminal histories than non-abusers. Substance abusers were, however, less likely to be identified as sex offenders or to
have medical needs.
New court commitment female offenders were more
likely to have higher substance abuse treatment needs
overall than males.
Substance abusers accounted for 89 percent of the
parole returns during State FY 2004. When compared
with non-abusing parole returns, no significant differences were noted in demographic characteristics.
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Seventy-eight percent of the prison population
(N=16,191, an increase of 826 individuals from FY
2003) were identified as substance abusers. These
individuals were more likely to be Latino, single or
common-law married, and younger. In the prison
population, substance abusers were significantly different from non-abusers on several needs areas. Substance users demonstrated higher needs in the following areas: academic, vocation, psychological, seriously mentally ill, and mental retardation. Substance
abusers demonstrated lower needs than non-abusers
in the following areas: sex offender, self-destruction,
assault/anger management, and medical.
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Substance abusers represented 85 percent of all
prison releases. There were no differences between
abusers and non-abusers on gender, marital status, or
age. However, releases with substance abuse problems were more likely to be African-American than
were non-abusers.
For inquiries concerning this report, please contact Nancy E.
Brace, R.N., M.A., Evaluation and Information Director, Alcohol
and Drug Abuse Division, Colorado Department of Human Services, 4055 South Lowell Boulevard, Denver, CO 80236-3120,
Phone: 303-866-7502, Fax: 303-866-7481, E-mail: nancy.brace@
state.co.us.
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Exhibit 1a.

Denver DAWN ED Sample and Reporting Information: January–December 2004

Total Eligible
Hospitals1

No. of Hospitals in DAWN
Sample

Total EDs in
DAWN Sam2
ple

14

14

14

No. of EDs Reporting per Month: Completeness of Data (%)
90–100%

50–89%

<50%

No. of EDs
Not Reporting

5–8

0–1

0–1

6–9

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
Some hospitals have more than one emergency department. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore these data are subject to change.
SOURCE: DAWN Live! OAS, SAMHSA, updated 4/13–14/05.

2

Exhibit 1b. Data Completeness for Denver Metropolitan Area DAWN Live! Emergency Departments (n=14)
by Month, 2004
Data Completeness
Basically
1
complete
Partially
2
Complete
Incomplete3
No Data
Reported
Total EDs
4
in Sample

Jan.

Feb.

Mar.

Apr.

May

June

July

Aug.

Sep.

Oct.

Nov.

Dec.

5

5

5

5

5

5

5

7

7

8

7

7

0

0

0

0

0

0

1

0

0

0

1

1

1
8

0
9

0
9

0
9

0
9

0
9

0
8

0
7

0
7

0
6

0
6

0
6

14

14

14

14

14

14

14

14

14

14

14

14

1
Total eligible hospitals in area=14, Hospitals in DAWN sample=14. Tables reflect cases that have been received by DAWN as of
4/13–14/05. Unweighted data from Denver hospitals reporting to DAWN.
2
90%+ Complete; 350–89% Complete; 4Less than 50% Complete.
Some hospitals in the DAWN sample have more than one emergency department. All DAWN cases are reviewed for quality control.
Based on this review, cases may be corrected or deleted. Therefore these data are subject to change.
SOURCE: DAWN Live! OAS, SAMHSA, updated 4/13–14/05

Exhibit 1c.

1
Number of Unweighted DAWN ED Cases, by Case Type (Unweighted ): 2004

Case Type
Suicide attempt
Seeking detox
Alcohol only (age<21)
Adverse reaction
Overmedication
Malicious poisoning
Accidental ingestion
Other

Number
600
412
755
1,370
1,235
12
196
2,979

1

Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted. Therefore these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05
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Exhibit 2.

Number of Unweighted1 Drug Reports in Drug-Related ED Visits,2 by Drug Category: 2004
Drug Category and Selected Drugs3
Major Substances of Abuse
Alcohol
Alcohol-in-combination with other drugs
Alcohol only (age<21)
Cocaine
Heroin
Marijuana
Stimulants
Amphetamines
Methamphetamine
MDMA (ecstasy)
GHB
Ketamine
LSD
PCP
Miscellaneous hallucinogens
Inhalants
Combinations not tabulated above

Drug Reports
6,186
2,304
1,549
755
1,569
609
755
755
280
475
64
5
2
9
12
32
62
8

1

Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted. Therefore these data are subject to change.
2
Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same case). Therefore,
the number of drug reports will exceed the number of ED visits.
3
This classification of drugs is derived from the Multum Lexicon, Copyright 2003, Multum Infomation Services, Inc. The classification
has been modified to meet DAWN's unique requirements (2004). The Multum Licensing Agreement governing use of the Lexicon is
provided in most DAWN publications and can be found on the Internet at http://www.multum.com.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05

Exhibit 3.

Unweighted Gender Percentages by Drug Type for ED Patients (Unweighted1), by Drug Type:
2004

100
74.2

80
63.1

61.6

58.1

60
40

38.4

36.9

41.9

25.8

20
0
Cocaine

Heroin

Marijuana
Male

Methamphetamine

Female

1

Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted. Therefore these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05
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Exhibit 4.

Unweighted1 ED Patient Age Data, by Selected Drugs: 2004

Age
5 and younger
6–11
12–17
18–20
21–29
30–44
45–64
65 and older

Cocaine
4
1
61
94
399
736
268
6

Heroin
1
0
3
22
151
246
182
4

Marijuana
4
1
178
115
186
195
73
2

Amphetamines
2
1
26
33
84
108
26
0

Methamphetamine
0
0
52
49
159
172
43
0

1

Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted. Therefore these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05

Exhibit 5.

Drug-Related Hospital Discharges per 100,000 Population for Selected Drugs in Colorado:
1997–2003

Drug/Rate per
100,000 Population
Alcohol
Rate per 100,000
Amphetamines
Rate per 100,000
Cocaine
Rate per 100,000
Marijuana
Rate per 100,000
Narcotic Analgesics
Rate per 100,000
Population

1997
1

NA

959
24.0
2,245
56.1
2,118
53.0
1,458
36.5
3,995,923

1998

1999

2000

2001

2002

2003

17,154
418.0
815
20.0
2,492
60.7
2,227
54.3
1,566
38.2
4,102,491

18,577
440.6
682
16.2
2,517
59.7
2,204
52.3
1,639
39.0
4,215,984

18,744
432.3
942
21.7
2,732
63.0
2,455
56.6
2,053
47.3
4,335,540

20,644
464.3
1161
26.1
2,787
63.0
2,755
62.0
2,237
50.3
4,446,529

21,433
474.02
1463
32.3
3,305
73.1
3,016
66.7
2,605
57.6
4,521,484

23,750
518.0
1814
39.6
3,658
80.3
3,246
71.0
3,368
73.4
4,586,455

1

NA=Not available.
SOURCE: Colorado Department of Public Health and Environment, Colorado Hospital Association

Exhibit 6a.

Number of Drug-related Calls to the Rocky Mountain Poison and Drug Center for Denver,
Colorado: 2001–2003

Drug
Alcohol
Cocaine/crack
Heroin/morphine
Marijuana
Methamphetamine
Other Stimulants/ Amphetamines
Club Drugs
Inhalants

2001
110
59
19
34
20

2002
149
66
16
37
39

2003
150
68
22
36
39

3

3

6

30
4

55
16

40
10

SOURCE: Rocky Mountain Poison and Drug Center
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Exhibit 6b. Number of Drug-Related Calls to the Rocky Mountain Poison and Drug Center for Colorado:
2004
Drug
Alcohol
Cocaine/Crack
Heroin/Morphine
Marijuana
Methamphetamine
Other Stimulants Amphetamines
Club Drugs
Hallucinogens

2004
764
120
20
68
95
316
11
29

SOURCE: Rocky Mountain Poison and Drug Center

Exhibit 7.

Drug-Related Mortality Numbers for the Denver PMSA: 1996–2002

Drug
Alcohol
Cocaine/Crack
Heroin/Morphine
Marijuana
Methamphetamine
Other Stimulants
Amphetamines
Club Drugs
Inhalants

1996
47
68
34
1
3
2

1997
49
56
53
4
6
5

1998
61
66
51
3
3
3

1999
74
82
79
20
8
5

2000
75
80
66
20
10
9

2001
99
126
77
31
19
8

2002
86
108
64
5
17
13

---

-1

-2

---

2
1

4
--

2
1

SOURCE: Colorado Department of Public Health and Environment
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Exhibit 8. Numbers and Percentages of Treatment Admissions in Colorado (Excluding Alcohol) by Primary
Drug Type: 1997–2004
1997
Drug
Heroin
N
1,200
%
15.7
Non-Rx Methadone
N
4
%
0.1
Other Opiates
N
195
%
2.6
Methamphetamine
N
1,081
%
14.2
Other Amphetamines/Stimulants
N
52
%
0.7
Cocaine
N
1,797
%
23.6
Marijuana
N
3,152
%
41.3
Hallucinogens
N
40
%
0.5
PCP
N
0
%
0.0
Barbiturates
N
7
%
0.1
Sedatives
N
4
%
0.1
Tranquilizers
N
37
%
0.5
Inhalants
N
28
%
0.4
Club Drugs
N
NA
%
NA
Other
N
31
%
0.4
Total N
7,628

1998

1999

2000

2001

2002

2003

2004

1,418
14.4

1,585
16.3

1,577
16.3

1,482
14.7

1,415
13.1

1,640
14.0

1,093
8.9

15
0.2

15
0.2

16
0.2

9
0.1

17
0.2

15
0.1

20
0.2

230
2.3

274
2.8

304
3.1

386
3.8

394
3.6

519
4.4

514
4.2

1,436
14.6

1,214
12.5

1,314
13.6

1,659
16.5

2,070
19.2

2,744
23.3

3,209
26.1

61
0.6

89
0.9

107
1.1

91
0.9

104
1.0

78
0.7

46
0.4

2,309
23.5

2,099
21.6

1,916
19.8

1,888
18.8

2,193
20.3

2,330
19.8

2,572
20.9

4,126
42.0

4,061
41.8

4,135
42.8

4,248
42.3

4,343
40.2

4,159
35.4

4,610
37.5

56
0.6

68
0.7

72
0.7

71
0.7

38
0.4

23
0.2

21
0.2

0
0.0

4
0.0

5
0.1

2
0.0

5
0.0

8
0.1

5
0.0

11
0.1

15
0.2

5
0.1

6
0.1

20
0.2

14
0.1

12
0.1

17
0.2

16
0.2

21
0.2

13
0.1

89
0.8

63
0.5

29
0.2

40
0.4

40
0.4

38
0.4

44
0.4

49
0.5

52
0.4

46
0.4

50
0.5

28
0.3

26
0.3

31
0.3

21
0.2

20
0.2

20
0.2

NA
NA

NA
NA

NA
NA

NA
NA

12
0.1

37
0.3

48
0.4

51
0.5
9,820

218
2.2
9,726

123
1.3
9,659

119
1.2
10,049

37
0.3
10,807

54
0.5
11,756

54
0.4
12,299

SOURCE: Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of
Human Services
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Exhibit 9a.

New Users of Selected Drugs Among Colorado Treatment Admissions: 1997–2004

Drug2
Heroin
N
%
Methamphetamine
N
%
Cocaine
N
%
Marijuana
N
%
Total New Users (N)
% of Total Admissions
Total Admissions

1997

1998

1999

2000

2001

2002

2003

2004

214
17.9

314
22.3

342
21.7

340
21.6

283
19.1

267
18.9

255
15.5

176
16.1

362
33.6

472
33.0

308
25.5

311
23.7

367
22.1

475
23.0

676
24.6

777
24.2

310
17.3

423
18.4

390
18.6

374
19.5

348
18.4

394
18.0

438
18.8

460
17.9

1,326
42.4
2,212
30.8
7,190

1,584
39.1
2,793
30.4
9,188

1,434
35.9
2,474
27.9
8,880

1,552
37.7
2,577
28.9
8,915

1,505
35.7
2,503
27.1
9,241

1,403
32.3
2,539
25.3
10,016

1,464
35.2
2,833
26.1
10,871

1,408
30.5
2,821
24.6
11,484

1

New Users are those reporting using for less than 4 years at the time of treatment
Reported primary drug of use
SOURCE: Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of
Human Services

2

Exhibit 9b. Average Number of Years Between First Use of Drug and First Treatment1: 2004
Drug2
Marijuana
Methamphetamine
Other Opiates
Cocaine/Crack
Heroin
Alcohol

Years
7.9
8.1
10
10.7
14.3
16.5

1

Includes only for those reporting no prior treatment admissions.
Reported primary drug of use.
SOURCE: Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of
Human Services

2

Exhibit 10.

Percentages of Denver Adult Arrestees Testing Positive for Drugs: 2003
Drug Type
Cocaine
Opiates
Marijuana
Methamphetamine
Any Drug
Multiple Drugs

Males
38.3
6.8
42.3
4.7
66.4
23.3

Females
52.5
6.1
34.3
5.0
69.1
24.9

SOURCE: ADAM, NIJ, February 2005
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Exhibit 11.

Quest Diagnostics Drug Testing Index Positivity Rate for Colorado1 Combined Workforce and
the Combined U.S. Workforce: 2004

Positivity Rate

Range for
States

Amphetamines

0–2.63

0.14–0.33

North
Central
CO
0.14–0.33

0.6–1.01

South
Central
CO
0–0.14

0.33–0.6

0.14–0.33

10.2

Cocaine

0–2.54

0.25–0.51

0.25–0.51

0.25–0.51

0.51–0.81

0–0.25

0.81–1.28

14.7

0–8.4

2.1–2.7

2.1–2.7

2.7–3.7

2.1–2.7

2.1–2.7

2.1–2.7

54.8

0–7.53

0.09–0.24

0.09–0.24

0.24–0.49

0.24–0.49

0.24–0.49

0.24–0.49

6.2

Marijuana
Opiates

Denver
Area

North.
West CO

South
West CO

South
East CO

U.S.

N=7.2 million tests.
1
No statistical data available for North East Colorado.
SOURCE: Quest Diagnostics Drug Test Index

Exhibit 12.

Drug Price and Purity in Denver: 2004

Drug

Wholesale Price

Retail Price

Street Price

Powder Cocaine

$16,000–$20,000/kg

$600–$700/oz

$70–$125/gm

Purity at Retail
16–90%

Crack Cocaine
Heroin
Methamphetamine
Marijuana
Ecstasy
OxyContin

$14,000–$18,500/kg
$15,000–$60,000/kg
$4,500–$16,000/lb
$16,000/lb
---

$700–$1,200/oz
$2,000–$3000/oz
$700–$1,500/oz
$1,000–$3,000/oz
---

$20–$60/rock
$100–$150/gm
$80–$150/gm
$50–$200/gm
$6–$25/pill
$6.50/pill

60–75%
8–64%
0–100%
--Prescription

SOURCE: DEA, treatment providers, National Drug Intelligence Center, local law enforcement

Exhibit 13.

1
Number of Unweighted Prescription Drug Misuse Drug Reports in Denver, by Case Type: 2004

132

Benzodiazepines

35

Opiates/Opioids

282

Hydrocodone
Oxycodone

Muscle relaxants

242

2

30

33

111
47

52

72

116

301

699

174
92

89

409

191
Overmedication
Seeking detox
Other

1

Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted. Therefore these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05
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Exhibit 14.

Top Five Drugs Involved in Drug Misuse Deaths in the Denver-Aurora Metropolitan Area: 2003

150

100
113
74

50

83
25

25

Opiates

Cocaine

0

Alcohol

Single-drug deaths

30

28

Benzodiazepines

Antidepressants

Multi-drug deaths

SOURCE: DAWN 2003 Area Profiles of Drug-Related Mortality

Exhibit 15.

Numbers and Percentages of Generational Primary Drug Use: FY 2004

Age Ranges
Y Generation2
X Generation3
Baby Boom4
ers
Seniors5
Total

Sedatives
1
Tranquilizers
1,512
28%
3,805
40%
3,067
55%
234
81%
8,618
41%

Stimulants

Opiates

Marijuana

1,008
18%
3,397
36%
1,408
25%
14
5%
5,827
28%

107
2%
773
8%
719
13%
28
10%
1,627
8%

2,754
50%
1,480
16%
364
6%
12
4%
4,610
22%

Hallucinogens
12
<1%
9
<1%
5
<1%
0
26
<1%

Club
Drugs
20
<1%
23
<1%
4
<1%
1
<1%
48
<1%

Other
Drugs
38
1%
21
<1%
13
<1%
1
<1%
73
<1%

Total
5,451
26%
9,508
47%
5,580
27%
290
<1%
20,829
100%

1

Sedatives Tranquilizers include alcohol
Y Generation includes anyone born after 1981
3
X Generation includes anyone born between 1965 and 1981
4
Baby Boomers include anyone born between 1946 and 1964
5
Seniors include anyone born before 1946
SOURCE: Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of
Human Services
2

Exhibit 16a. Methamphetamine Use Among MSM in Denver Community Survey: 2004–2005

MSM, N=981
HIV negative MSM, n=763
HIV positive MSM, n=153

Number
108
69
32

Percent
11.0
9.0
20.9

SOURCE: Dr. Mark Thrun, Denver Public Health 2004–2005 NHBS MSM Survey
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Exhibit 16b. Sexual Risk and Methamphetamine Use: 2004–2005

Mean age
Mean number of male/female
partners last 12 months
Any unprotected sex last 12
months
Ever tested for HIV
Most recent HIV test result was
positive

Meth Users
N=108
33.1

Non-users
N=873
39.4

12.5 / 5.0

7.7 / 2.3

76 (70.4%)

380 (43.5%)

101 (93.5%)

815 (93.4%)

32 (31.7%)

121 (14.9%)

Odds Ratio

3.1
(2.0-4.8)
2.7
(1.7-4.2)

SOURCE: Dr. Mark Thrun, Denver Public Health 2004–2005 NHBS MSM Survey

Exhibit 17.

Number of Unweighted1 Alcohol-Related ED Reports, by Case Type: 2004

Case Type

Number of Cases

Seeking detox
Alcohol only, <21 years of age
Other Alcohol

515
755
1,034

Percent of Alcohol
Cases
22
33
45

Percent of all Drug-Related
Cases
8
12
17

1

Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted. Therefore these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05

Exhibit 18.

1
Gender and Age of Alcohol Only (Age <21) ED Patients (Unweighted ), by Number and Percent:
2004

Gender
Male
Female
Age
5 and younger
6–11
12–17
18–20

Number

Percent

461
293

61
39

0
4
402
349

0
0.5
53
46

1

Unweighted data are from 5–8 Denver EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted. Therefore these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05
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Exhibit 19.

Numbers and Percentages of Treatment Admissions in Colorado (Including Alcohol), by Primary
Drug Type: 1997–2004

1997
Drug
Alcohol
n
6,353
%
45.4
Heroin
N
1,200
%
8.6
Non-Rx Methadone
N
4
%
0.0
Other Opiates
N
195
%
1.4
Methamphetamine
N
1,081
%
7.7
Other Amphetamines/Stimulants
N
52
%
0.4
Cocaine
N
1,797
%
12.9
Marijuana
N
3,152
%
22.5
Hallucinogens
N
40
%
0.3
PCP
N
0
%
0.0
Barbiturates
N
7
%
0.1
Sedatives
N
4
%
0.0
Tranquilizers
N
37
%
0.3
Inhalants
N
28
%
0.2
Club Drugs
N
NA
%
NA
Other
N
31
%
0.2
Total N
13,981

1998

1999

2000

2001

2002

2003

2004

7,833
44.4

6,573
40.3

6,577
40.5

6,311
38.6

6,839
38.8

7,044
37.5

8,531
40.9

1,418
8.0

1,585
9.7

1,577
9.7

1,482
9.1

1,415
8.0

1,640
8.7

1,093
5.2

15
0.1

15
0.1

16
0.1

9
0.1

17
0.1

15
0.1

20
0.1

230
1.3

274
1.7

304
1.9

386
2.4

394
2.2

519
2.8

514
2.5

1,436
8.1

1,214
7.4

1,314
8.1

1,659
10.1

2,070
11.7

2,744
14.6

3,209
15.4

61
0.3

89
0.5

107
0.7

91
0.6

104
0.6

78
0.4

46
0.2

2,309
13.1

2,099
12.9

1,916
11.8

1,888
11.5

2,193
12.4

2,330
12.4

2,572
12.3

4,126
23.4

4,061
24.9

4,135
25.5

4,248
26.0

4,343
24.6

4,159
22.1

4,610
22.1

56
0.3

68
0.4

72
0.4

71
0.4

38
0.2

23
0.1

26
0.1

0
0.0

4
0.0

5
0.0

2
0.0

5
0.0

8
0.0

5
0.0

11
0.1

15
0.1

5
0.0

6
0.0

20
0.1

14
0.1

12
0.1

17
0.1

16
0.1

21
0.1

13
0.1

89
0.5

63
0.3

29
0.1

40
0.2

40
0.2

38
0.2

44
0.3

49
0.3

52
0.3

46
0.2

50
0.3

28
0.2

26
0.2

31
0.2

21
0.1

20
0.1

20
0.1

NA
NA

NA
NA

NA
NA

NA
NA

12
0.1

37
0.2

48
0.2

51
0.3
17,653

218
1.3
16,299

123
0.8
16,236

119
0.7
16,360

37
0.2
17,646

54
0.3
18,800

54
0.3
20,830

SOURCE: Drug/Alcohol Coordinated Data System (DACODS) from the Alcohol and Drug Abuse Division, Colorado Department of
Human Services
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Exhibit 20.

Colorado Cumulative AIDS Cases by Gender and Exposure Category Through December 31,
2004
Number of AIDS
Casesa

Gender
Male
Female
Total
Exposure Category
Men/sex/men (MSM)
Injecting drug user (IDU)
MSM and IDU
Heterosexual contact
Other
Risk not identified

Percent of AIDS
Cases

Number of Individuals Testing
Positive for HIV

Percent of Individuals Testing
Positive for HIV

7,452
636
8,088

92.1%
7.9%
100%

5,394
612
6,006

89.8%
10.2%
100%

5,446
747
866
482
182
365

67.3%
9.2%
10.7%
6.0%
2.2%
4.5%

3,807
525
555
397
64
658

63.4%
8.7%
9.2%
6.6%
1.1%
11.0%

1
In October 2004, Colorado omitted cases who moved to other States, thereby reducing their HIV/AIDS database by 758 cases.
Thus reports produced before October 2004 show higher numbers of AIDS cases than reports produced after October, 2004.
SOURCE: The Colorado Department of Public Health and Environment
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which connects to the Atlantic Ocean. Many
places along the 85 miles of heavily developed
waterway between Port Huron and Monroe
County are less than one-half mile from Canada.
Michigan has more than 1 million registered
boats. In fiscal year (FY) 2002, three major
bridge crossings from Canada (Windsor Tunnel,
Ambassador Bridge, and Port Huron) had 9.7
million cars, 2.6 million trucks, and 93,000 buses
cross into Michigan. Southeast Michigan is the
busiest port on the northern U.S. border with
Canada. Detroit and Port Huron also have nearly
10,000 trains entering from Canada each year.
The Foreign Mail Branch in Detroit processes
275,000 foreign parcels and about 900,000 letterclass pieces monthly.

Drug Abuse in Detroit/Wayne
County and Michigan
Cynthia L. Arfken1
ABSTRACT
Cocaine and heroin are the two major drugs of abuse
in the area. Cocaine treatment admissions continued
to stabilize; a high percentage of ED drug reports
and a high number of items reviewed by forensic
laboratories involved cocaine. Heroin treatment admissions, especially as the primary substance of
abuse, are high and climbing, but there are few heroin ED drug reports and few heroin items reviewed
by forensic laboratories. Indicators for methamphetamine point to less involvement than for other
major drugs of abuse.

•

Additional factors influence substance use in
Detroit:

•

The percentage of individuals living below poverty line (26.1 percent) is more than twice the national level (12.4 percent).

•

The percentage of working age individuals (age
21–64) with disability is substantially higher than
the national level (32.1 versus 19.2 percent).

•

There are chronic structural unemployment problems. At the State level, the unemployment rate
has been among the highest in the country since
2002. Within the State, Detroit has one of the
lowest rates of employed adults.

INTRODUCTION
Area Description
Detroit and surrounding Wayne County are located in
the southeast corner of Michigan’s Lower Peninsula.
In 2000, the Wayne County population totaled 2.1
million residents (of whom 46 percent live in Detroit)
and represented 21 percent of Michigan’s 9.9 million
population.
Currently, Michigan is the eighth most populous
State in the Nation. In 2000, Detroit ranked 10th in
population among cities with 951,000 people, but the
population has since dropped below 900,000. It has
the highest percentage of African-Americans (82
percent) of any major city in the country. The following factors contribute to probabilities of substance
abuse in the State:
•

Michigan has a major international airport, with a
new terminal that opened 2002; 10 other large airports that also have international flights; and 235
public and private small airports. Long-term projections for the Detroit Metropolitan Airport forecast a 31-percent increase in flights during the
next 10 years.

•

The State has an international border of 700
miles with Ontario, Canada; land crossings at
Detroit (bridge and a tunnel), Port Huron, and
Sault Ste. Marie; and water crossings through
three Great Lakes and the St. Lawrence Seaway,

1

The author is affiliated with Wayne State University, Detroit,
Michigan.
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Data Sources
Data for this report were drawn from the sources
shown below:
•

Emergency department (ED) data were derived for 2004 from the Drug Abuse Warning
Network (DAWN) Live! restricted-access
online query system administered by the Office
of Applied Studies (OAS), Substance Abuse
and Mental Health Services Administration
(SAMHSA). Eligible hospitals in the Detroit
area totaled 38; hospitals in the DAWN sample
numbered 23, with the number of EDs in the
sample totaling 24. (Some hospitals have more
than one emergency department.) During this
12-month period, between 17 and 19 EDs reported data each month. The completeness of
data reported by participating EDs varied by
month (see exhibit 1a). Exhibits in this paper
reflect cases that were received by DAWN as of
April 13–14, 2005. All DAWN cases are reviewed for quality control. Based on this re-
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•

view, cases may be corrected or deleted. Therefore, the data presented in this paper are subject
to change. Data derived from DAWN Live! represent drug reports in drug-related ED visits.
Drug reports exceed the number of ED visits,
since a patient may report use of multiple drugs
(up to six drugs and alcohol). The DAWN Live!
data are unweighted and, thus, are not estimates
for the reporting area. These data cannot be
compared to DAWN data from 2002 and before, nor can preliminary data be used for comparison with future data. Only weighted DAWN
data released by SAMHSA can be used for
trend analysis. A full description of the DAWN
system can be found at the DAWN Web site:
http://dawninfo.samhsa.gov.

DRUG ABUSE PATTERNS AND TRENDS

Treatment admissions data were provided by
the Bureau of Substance Abuse and Addiction
Services, Division of Substance Abuse and
Gambling Services, Michigan Department of
Community Health (MDCH), for the State and
Detroit/Wayne County, as reported by State and
federally funded programs. MDCH, following
revised Treatment Episode Data Set (TEDS)
Federal guidelines, is converting to an episodebased reporting system in which changes in levels of care that are part of the treatment plan
(moving from residential treatment to outpatient,
for example) are not reported as new separate
admissions but rather as transfers within an episode. This transition has not been fully implemented by all publicly funded programs. As this
change is fully implemented, it is expected that
total admissions will decline, and comparisons of
admissions trends before and after this change
are not recommended. In contrast to including
previously reported ED data in this report, discussions included regarding treatment data in
this report will be limited to instances where
treatment is the only indicator source for a particular drug or group of drugs.

According to unweighted DAWN Live! data, cocaine
was the most frequent major substance of abuse reported in DAWN ED data in the metropolitan Detroit
area in 2004. The number of metropolitan Detroit ED
cocaine reports was 3,287, or 33 percent of the total
reports (including alcohol reports). Patients reporting
cocaine were most likely to be male (61 percent),
African-American (75 percent), and age 35–44 (37
percent).

•

Mortality data on drug-related deaths were obtained from DAWN, OAS, SAMHSA for 2003.

•

Drug intelligence data were provided by the
Michigan State Police.

•

Data on drug seizures were provided by the
National Forensic Laboratory Information System (NFLIS) for January–December 2004.

•

Information on the number of prescriptions was
obtained from a special report by the Michigan
Board of Pharmacists, 2004.
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Cocaine/Crack
For FY 2004, 24.6 percent of Detroit/Wayne County
treatment admissions listed cocaine/crack as the primary drug of abuse (exhibit 2). An additional 20.7
percent of treatment admission listed cocaine/crack
as the secondary drug. Between 1994 and 2003,
statewide treatment admissions for cocaine crept
from 2.1 percent to 2.8 percent (exhibit 3). In contrast, treatment admissions for crack declined from
17.7 to 13.9 percent during the same period.
Cocaine constituted 42 percent of drug items reviewed by forensic laboratories in 2004 (exhibit 4).

Cocaine represented 53 percent of drugs involved in
drug misuse deaths in 2003.
Availability, prices, and purity for powder cocaine
and crack remained relatively stable during the most
recent reporting period. Ounce and kilogram prices
have been stable over the past decade. There are
some reports of decreases in prices at the kilogram
quantity level and above. The cost of crack rocks is
approximately $20 (exhibit 5). Ounce amounts of
cocaine and crack generally have sold for the same
price ($750–$1,500) since 2001 in Detroit.
Heroin
In FY 2004, 31.8 percent of Detroit/Wayne County
treatment admissions listed heroin as the primary
drug of abuse (exhibit 2). An additional 3.1 percent
of treatment admissions listed heroin as the secondary drug. Between 1994 and 2003, the proportion of
statewide treatment admissions for heroin almost
doubled, from 7.3 to 12.6 percent (exhibit 3).
Only 12 percent of drug items reviewed by forensic
laboratories were found to be heroin in 2004 (exhibit
4).
According to DAWN Live! unweighted data, 19 percent of ED reports for major substances of abuse in the
metropolitan Detroit area were for heroin. Patients re-
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porting heroin were most likely to be male (61 percent),
African-American (62 percent), and between the ages
of 45 and 54 (45 percent).
Heroin deaths steadily increased in Detroit/Wayne
County between 1992 and 2002. In 1996, there were
240 heroin-present deaths; by 2000, the annual number had nearly doubled. Deaths with heroin metabolites present in 1999 represented a 24-percent increase from 1998, while in 2000, heroin cases
increased again, by 23 percent over the 1999 total.
The 465 heroin-present deaths in 2001 were a slight
decrease from the 473 deaths in 2000. During 2002,
496 heroin-present deaths were identified, which
again exceeded the number of cocaine-involved
deaths. In 2003, the Wayne County ME identified
446 heroin deaths, a level slightly below the 2001
findings. Heroin and prescription opioids, however,
were the drugs most likely involved in drug misuse
deaths. In Wayne County, they accounted for 75 percent, while in nearby affluent Oakland County heroin
and prescription opiates accounted for 78 percent.
Heroin street prices remained stable and relatively
low in Detroit. Packets or “hits” available in Detroit
are typically sold in $10 units (exhibit 5).
Other Opiates/Narcotic Analgesics
Other opiates represented 2.8 percent of primary
treatment admissions in Detroit/Wayne County in FY
2004 (exhibit 2). The percentage of statewide treatment admissions listing other opiates as the primary
drug of abuse increased from 1.2 percent in 1994 to
4.0 percent in 2003 (exhibit 3).
According to the number of prescriptions filled in
2002 and 2003, oxycodone products were most
common; they represented 38 percent of all opioids
prescriptions in 2002 and 34 percent in 2003 (exhibit
6). Prescriptions for fentanyl products, however, increased by 95 percent between 2002 and 2003 to represent 25 percent of the opioid prescriptions being
filled in 2003.
Marijuana
Marijuana indicators remain mostly stable but at highly
elevated levels.
The proportion of primary marijuana treatment admissions has plateaued since 1997–1998. Marijuana accounted for 9.3 percent of all substance abuse admissions (including alcohol) in FY 2004 in Detroit/Wayne
County (exhibit 2). Statewide marijuana admissions
increased from 9.7 percent in 1994 to 15.9 percent in
2003 (exhibit 3).
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In 2004, marijuana accounted for 45 percent of items
analyzed by forensic laboratories in Detroit (exhibit 4).
Mexican marijuana continued to be the dominant form
available, but there have been reports of increases in
marijuana from Canada.
According to unweighted DAWN Live! data, metropolitan Detroit-area ED marijuana reports represented
15 percent of the total reports for major substances of
abuse in 2004 (n=1,525). Marijuana ED patients were
most likely to be male (65 percent), African-American
(72 percent), and between the ages of 35 and 44 (23
percent).
Prices for marijuana at the retail level are $20 per
gram for commercial grade (exhibit 5).
Stimulants
The latest treatment data show that admissions for
primary drugs of abuse for stimulants other than cocaine included 0.9 percent for amphetamines and two
admissions for other stimulants in Detroit/Wayne
County in FY 2004. Unweighted DAWN Live! ED
data for 2004 show 115 reports of stimulants (99 for
amphetamines and 16 for methamphetamine).
Michigan’s border with Canada has been the focus of
efforts to stop the flow of large amounts of pseudoephedrine and ephedrine into the United States.
These imports are the necessary ingredients for making methamphetamine and have been destined for the
western United States and Mexico. Indictments of
numerous individuals and seizures of millions of
pseudoephedrine dosage units have continued.
Club Drugs
The club drugs category includes methylenedioxymethamphetamine (MDMA or ecstasy), gamma hydroxybutyrate (GHB), flunitrazepam (Rohypnol), and
ketamine. Indicators seem to be stabilizing for ecstasy and ketamine and declining for GHB.
The drug known as ecstasy is typically MDMA or
methylenedioxyamphetamine (MDA). Both drugs
have been identified in past lab testings of ecstasy
samples, sometimes in combination. There have been
many anecdotal reports of widespread and increasing
use since about 1997, but these drugs rarely appear in
traditional indicators identifying abuse.
For inquiries concerning this report, please contact Cynthia L.
Arfken PhD, Wayne State University, 2761 E. Jefferson, Detroit,
Michigan 48207 E-mail: carfken@med.wayne.edu.

93

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Detroit/Wayne County and Michigan

Exhibit 1.

Detroit DAWN ED Sample and Reporting Information: January–December 2004

Total Eligible
Hospitals1

No. of Hospitals in DAWN
Sample

Total EDs in
DAWN Sam2
ple

38

23

24

No. of EDs Reporting per Month: Completeness of Data (%)
90–100%

50–89%

<50%

No. of EDs
Not Reporting

7–21

0–2

0–2

3–15

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005

2

Exhibit 2.

Treatment Admissions in Detroit/Wayne County, by Primary and Secondary Drugs of Abuse and
Percent: FY 2004

Drug
Alcohol
Heroin
Cocaine
Other Opiates
Marijuana
Other Drugs

Primary Drug of Abuse (%)
30.9
31.8
24.6
2.8
9.3
0.5

Secondary Drug of Abuse (%)
20.8
3.1
20.7
3.1
11.0
1.2

N=15,243
SOURCE: Michigan Department of Community Health, Division of Substance Abuse and Gambling Services, Bureau of Substance
Abuse and Addiction Services

Exhibit 3.

Treatment Admissions in Michigan, by Primary Drug of Abuse and Percent: 1994–2003

Percent
20
18

17.7
16.2

15.7

16
14

13.2

13.9

12
10

Cocaine (Smoked)
Cocaine (Other)
Marijuana
Heroin
Other Opiates

9.7

8
6

7.3

4

4.0
2.8

2.1
2
0

1.2
1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

SOURCE: Michigan Department of Community Health, Division of Substance Abuse and Gambling Services, Bureau of Substance
Abuse and Addiction Services
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Exhibit 4.

Numbers and Percentages of Seized Drug Items Analyzed in Detroit: 2004

Substance
Cannabis
Cocaine
Heroin
Codeine
Propoxyphene
MDMA
Methadone
Methamphetamine
Total Items Reported

Number of Items Seized
2,041
1,890
546
24
4
3
1
1
4,510

Percent of Items Seized
45.25
41.91
12.11
0.53
0.09
0.07
0.02
0.02
100.0

SOURCE: National Forensic Laboratory Information System

Exhibit 5.

Illegal Drug Prices in Detroit: December 2004

Drug
Cocaine (Powder)

Wholesale
$17,000–$26,000
per kilogram

Midlevel
$750–$1,500
per ounce

NR1

NR

$65,000–$80,000
per kilogram
$5.25
per dosage unit
$4,000–$4,500
per pound
$16,000
per pound

$3,300–$6,000
per ounce
$7.25
per dosage unit
$150
2
per ounce CG
$1,200
per ounce

Crack
Heroin
MDMA
Marijuana
Methamphetamine

Retail
$100
per gram
$20
per rock
$10
per dosage unit
$17–$25
per dosage unit
$20
per gram CG
$175
per gram

1

NR=Not reported.
CG=Commercial grade
SOURCE: Michigan State Police

2

Exhibit 6.

Number of Drug Prescriptions for Opioids in Michigan: 2003–2004

Drug
Fentanyl
MS Contin
Dilaudid
Demerol
Morphine
Oxycodone
Methadone
Percodan
Total

2002
112,158
48,410
14,367
7,314
107,302
246,091
47,846
58,301
641,789

2003
218,872
59,562
21,393
7,760
113,521
296,629
79,845
103,687
863,100

SOURCE: Michigan Board of Pharmacists
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Illicit Drug Use in Honolulu
and the State of Hawai'i
D. William Wood, M.P.H., Ph.D.1
ABSTRACT
Substance use in the State of Hawai'i in 2004 was
mixed in terms of its indicators, yet consequences of
substance use remained clear. Little change occurred for cocaine treatment admissions; decedents
with positive cocaine toxicology results were down,
while police cases related to cocaine were up. Both
treatment admissions and positive toxicology reports
on decedents were down for heroin, but police cases
increased in number. Marijuana data show decreased admissions to treatment, fewer positive toxicology reports for decedents, but more police cases.
For Hawai'i’s drug of choice, methamphetamine,
data from treatment providers and the Medical Examiner are consistently higher than in previous
reports for previous time periods, while police cases
are lower. While the ice labs in Hawai'i are not
large, more were closed and more ice was seized
than in any previous reporting period.
INTRODUCTION
This report presents current information on illicit
drug use in Hawai'i, based on the Honolulu Community Epidemiology Work Group (CEWG), described
later in this section.
Area Description
Hawai'i, the Aloha State, had a population of
1,211,537 as of April 1, 2000, and by July 1, 2004,
the population was estimated to be 1,262,840.
Kaua’i
County
61,929

State of Hawai’i

Maui County
138,347
City and
CityCounty
and County
of
of Honolulu
Honolulu
899,593

Maui County

Hawai’i County
162,971

1

The author is affiliated with the Department of Sociology, University of Hawai’i at Manoa, Honolulu, Hawai’i.
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The State’s population is differentially distributed
across the seven major islands of the Hawaiian chain,
shown in the figure above. In fact, there are 26 islands within the State’s boundaries, which extend
from South Point on the Big Island of Hawai'i (the
most southerly point in the United States) to Kure
atoll, near Midway Island. The chain spans a total of
1,200 miles from one end to the other.
Hawai'i is unique within the Nation in that there is no
one majority race or ethnicity.
Hawai’i has the fourth largest foreign-born population
in the Nation. Seventeen percent are foreign born, with
27.8 percent speaking a language other than English as
the primary language in the home. Using U.S. Census
categories, the ethnic distribution of the population is
24.3 percent White, 1.8 percent Black, 0.3 percent
American Indian and Alaska Native, 9.4 percent Native Hawaiian and Other Pacific Islanders, 41.6 percent Asian, and 1.3 percent “Others.” Single-race-only
described 79.6 percent of the population.
In Hawai'i, ethnicity data are collected using many
more categories than the U.S. Census (for a total of
28 categories). The distribution of population of the
larger groups is as follows:
Primary Ethnic Group
White
Japanese
Filipino
Native Hawaiian
Chinese
Korean
Black or African-American
Samoan
Vietnamese
Tongan
Micronesian/Other Pacific Islander
American Indian/Native Alaskan
Other Asian

Percent
24.3
16.7
14.1
6.6
4.7
1.9
1.8
1.3
0.6
0.3
0.8
0.3
0.7

The history of the State of Hawai'i is rooted in a lack
of intolerance, a collective identity, and a strong
sense of group problem solving. The population affected by drug use also has strong ties throughout all
levels of the society; it is common for family members to enforce the laws of society on their own extended family members. The State’s strong multicultural history leaves many frustrated and unable to act,
for fear of offending the family or bringing shame to
relatives.
The year 2004 was to be a pivotal year for substance
abuse prevention, treatment, interdiction, and research in the State of Hawai'i. More monies were
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appropriated for substance abuse prevention and
treatment by the State legislature than ever before.

•

Drug price data were provided for 2004 by the
HPD, Narcotics/Vice Division.

Data Sources

•

Uniform Crime Reports (UCR) data were accessed from the State’s Attorney General’s Web
site for 1975–2003.

Much of the data presented in this report are from the
Honolulu CEWG, which met on May 6, 2005. The
meeting was hosted by the Hawai'i High Intensity
Drug Trafficking Area (HIDTA) program office,
whose staff facilitated the attendance of the Drug
Enforcement Administration (DEA) representatives,
as well as persons knowledgeable about drug data
from Honolulu and neighbor islands. The State of
Hawai'i Narcotics Enforcement Division, although
invited, did not participate in the CEWG meeting.
The Honolulu Police Department submitted data and
was able to attend and participate in the CEWG meeting. This report is focused only on drug activities in
O'ahu for calendar year 2004, with the exception of
State treatment data, which were available for all of
the State only. Other specific data sources are listed
below:
•

•

•

Treatment admissions and demographic data
were provided by the Hawai’i State Department
of Health, Alcohol and Drug Abuse Division
(ADAD). Previous data from ADAD are updated
for this report whenever ADAD reviews its records. These data represent all State-supported
treatment facilities (90 percent of all facilities).
About 5–10 percent of these programs and two
large private treatment facilities do not provide
data. During this reporting period, approximately
45 percent of the treatment admissions were paid
for by ADAD; the remainder was covered by
State health insurance agencies or by private insurance. The rate of uninsurance for the State is
about 10 percent.
Drug-related death data were provided by the
Honolulu City and County Medical Examiner
(ME) Office. These data are based on toxicology
screens performed by the ME Office on bodies
brought to them for examination. The sorts of
circumstances that would lead to the body being
examined by the ME include unattended deaths,
deaths by suspicious cause, and clear drugrelated deaths. In short, while the ME data are
consistent, they are not comprehensive and account for only about one-third of all deaths on
O’ahu. To allow a direct comparison between
ME data and treatment data, the ME data were
multiplied by a factor of 10 on the exhibits.
Law enforcement case data for 2004 were received from the Honolulu Police Department
(HPD), Narcotics/Vice Division only.

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

Emergency department (ED) drug mentions data
have not been available in Hawai'i since 1994. Discussions with the Healthcare Association of Hawai'i
regarding inclusion in the Drug Abuse Warning Network (DAWN) program have resulted in a briefing of
all hospital CEOs and the sharing of DAWN information. Over the past 2 years, the healthcare industry
of the State has been hoping for a meeting with this
program. To date nothing is scheduled.
DRUG ABUSE PATTERNS AND TRENDS
Hawaiians and Whites remain the majority user groups
among the 17 identified ethnic groups (plus 2 other
categories: "other" and "unknown/blank") who access
ADAD facilities for substance abuse treatment. During
the first half of 2004, 46.6 percent and 22.5 percent of
the admissions were Hawaiians/Part Hawaiians or
Whites, respectively. All other groups represented
significantly lower proportions of admissions.
Methamphetamine remains the leading primary substance of abuse for those admitted to treatment, accounting for 45.0 percent of admissions. Marijuana
remained the third most frequently reported primary
substance for treatment admissions (21.1 percent)
behind alcohol (22.9 percent). It is important to point
out, however, that almost all polydrug treatment admissions list alcohol as a substance of abuse. The 25–
44 age group had the highest representation among
treatment admissions and accounted for 25.0 percent
of admissions; 35–44-year-olds accounted for 24.3
percent. While marijuana abuse accounts for the majority of treatment admissions among those younger
than 18 (the third most frequently admitted age
group), the abuse of ice or crystal methamphetamine
still looms as a major treatment category for this
group.
During this reporting period, drug prices have been
stable, except for some minor upward price adjustments for crystal methamphetamine in smaller
amounts (exhibit 1). The size of the drug supply appears to make for a relatively stable drug market,
with only a few market adjustments caused by seizures of specific drugs or oversupply of others.
Ice continues to dominate the Hawaiian drug market.
Prices have increased slightly during the reporting
period, and this is likely reflective of several seizures.
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It is now easier, however, to purchase larger quantities than in the past. The final police evidence of increased ice availability is that of clandestine labs—
almost exclusively reprocessing labs that continue to
be closed at a regular pace.
Marijuana has been a drug of choice in the islands for
decades. All police departments in the State participate in the joint State-Federal “Operation Green Harvest.” However, police are now reporting that “Competition from Mainland marijuana growers and continuing law enforcement efforts have drastically reduced the state's outdoor production from the 1980s.”
During the latest “Operation Green Harvest,” more
than 10,400 plants were seized on the Big Island; in
Maui County, more than 16,800 plants were seized,
with about 10,000 recovered within a couple miles of
the Moloka'i airport; on O'ahu, 1,500 plants were
seized; and on Kaua'i, 250 plants were seized. The
most recent 10-day statewide sweep recovered about
39,000 marijuana plants, an indication that marijuana
cultivation has dropped dramatically from the 1980s.
Federal officials have said that marijuana cultivation
was a major problem during that decade; 1.9 million
plants were recovered in 1987 alone, mostly from the
Big Island.
The Hawai'i DEA continues its efforts with the
Honolulu Police Department to deal with crystal
methamphetamine and, in particular, to break the
supply route from California for the chemicals necessary to operate Hawai'i’s ice labs. During this period,
the HPD seized and closed 24 clandestine methamphetamine laboratories. In 2000, 8 labs were closed,
compared with 7 in 2001, 15 in 2002, and 10 in 2003.
The police data used in this report are only for the
Honolulu Police Department. In previous reports,
attempts have been made to include whatever data
were available from Neighbor Island police departments. The frequency and consistency of reporting
made it impossible to continue the practice, and from
this point forward only HPD data will be reported.
Cocaine/Crack
Powder cocaine and crack treatment admissions were
relatively stable during the current period. There
were 363 primary cocaine treatment admissions in
2004, compared with 355 in 2003, 428 in 2002, and
433 in 2001 (exhibit 2). This shows that the number
of clients listing cocaine as the primary drug, after
being quite stable for several years, began a decline
in 1999 that has now stabilized with data for 2004.
Powder cocaine/crack now ranks fourth among primary drugs of treatment admissions, after methamphetamine, alcohol, and marijuana.
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The Honolulu ME reported 22 deaths with cocainepositive toxicology screens in 2004, compared with
26 in 2003 and 22–24 in 1999–2002 (exhibit 2). It
should be remembered that data on the chart have
been adjusted to allow for their presentation on the
same axes by multiplying all death data by a constant
of 10.
According to the HPD, cocaine prices have remained
relatively stable over the past several years. Onequarter gram of crack currently sells for $25–$30,
and the same amount of cocaine powder costs $25–
$35 (exhibit 1). Police cases for cocaine/crack increased slightly in 2004 to 239 (exhibit 3). Over the
past several years, the number of HPD cocaine cases
plummeted from more than 1,200 cases in 1996 to
202 in 2003.
Heroin and Other Opiates
China white heroin has been uncommon in Hawai’i
for many years, but it is occasionally available for a
premium price. The heroin market for Honolulu is
dominated by black tar heroin, and it is readily available in all areas of the State. HPD data show 1,251
grams of black tar and 1.699 grams of China white
powder were seized in 2004. This is lower than the
3,502 grams of black tar seized in 2003 but higher
than the 0.019 grams of powder seized in 2003. For
2002, 992 grams of black tar and 494 grams of powder were seized. In 2001, 530 grams of powder were
seized, along with 3,258 grams of black tar heroin.
According to the HPD, black tar heroin prices remained stable in Honolulu at $50–$75 per onequarter gram, $150–$200 per half “teen” (1/6 ounce),
and $2,500–$3,000 per ounce (exhibit 1).
Heroin treatment admissions continued the decline
begun in 1999 (exhibit 4). In 1998, record levels of
treatment admissions were recorded, with more than
500 individual admissions that year. In 2004, however, heroin ranked fifth among treatment admissions
at 2.1 percent (n=175).
The Honolulu ME reported that deaths in which opiates were detected have declined in 2004, however,
the residuals of heroin versus other opiates could not
be definitively separated for several cases. For now,
only 12 heroin deaths are confirmed for 2004 (exhibit
4). Decedents with a positive toxicological result for
other opiates were primarily comprised of those in
whom oxycodone or methadone were detected. The
exact medication (OxyContin® or another) used was
not specified. However, the 15 decedents with oxycodone in their toxicology screens represent a death
rate for the city and county of Honolulu of 17.2 per
1,000,000 persons. An additional concern was ex-
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pressed by the Medical Examiner’s office this year,
and that was with respect to methadone. Previously,
the ME had been asked to review its records and to
monitor the appearance of methadone among decedents. In 2004, there were 25 decedents with a positive toxicology screen for methadone, compared with
22 in 2003 and 28 in 2002.
The HPD reported 25 heroin cases in 2001, 44 in
2002, 30 in 2003, and 34 in 2004 (exhibit 5). In spite
of the very high number of cases reported in 1998,
the decade-long trend in heroin cases is a downward
one from the 54 cases reported in 1995.
According to the Domestic Monitor Program 2003
Report, “In response to reports of a black tar heroin
problem in Hawaii, a Geo-Probe was conducted in
Honolulu in July and August 2003. This probe
marked the first instance of DMP purchases made
outside of the continental United States. Black tar
heroin is popular in the islands because of the price—
approximately $100 to $200 per gram. This price is
substantially cheaper than that for white powder heroin, which is very rarely encountered, but which is
sold locally for approximately double the price of
black tar. The Geo-Probe resulted in the purchase of
five exhibits, three of which were qualified samples
determined to be MEX heroin averaging approximately 51.3 percent pure. The samples cost, on average, $0.95 per milligram pure. Honolulu’s average
price was comparable to San Francisco’s, but the
purity levels were more than four times as high as
San Francisco’s, and higher than other Pacific coast
DMP cities.”
Marijuana
Statewide, marijuana treatment admissions decreased
slightly in 2004, with only 1,461 reported for the year
(exhibit 6). There was an increase in 2003, following
the slight decline in admissions in 2002. Those admitted for treatment in 2004 continue to be younger
persons referred by the courts. In examining these
treatment data, it is important to remember that the
number of persons in treatment for marijuana use in
2004 was triple the number in treatment in 1992. It is
also important to note that while marijuana is listed
as the primary drug of use at admission, many users
of other drugs use marijuana as a secondary or tertiary drug of choice.
Between 1994 and 1999, the O'ahu ME reported 12–
21 deaths per year in which marijuana was found in
the specimens submitted for toxicology screening
(exhibit 6). Those numbers increased to 25 in 2000,
36 in 2001, 30 in 2002, 32 in 2003, and 31 in 2004.
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Again, in most instances, marijuana was used with
other drugs if there was a drug-related death.
The HPD continues to monitor, but to not specifically
report, case data for marijuana. As mentioned in previous CEWG reports, possession cases are steady at
about 650 per year, although distribution cases have
continued to increase. Law enforcement sources
speculate that much of the Big Island's marijuana is
brought to O'ahu for sale. Exhibit 7 shows Honolulu
police case data for marijuana.
As shown in exhibit 1, marijuana cost $5–$20 per
joint, $25 per gram, and $6,000–$9,000 per pound in
2004.
Methamphetamine
Hawai'i’s drug of choice among the 18–34-year-old
population group remains crystal methamphetamine.
The California-based Mexican sources use Hawai'i’s
cultural diversity to facilitate smuggling and distribution to and within the islands. Analysis of confiscated
methamphetamine reveals that the product is still a
high-quality d-methamphetamine hydrochloride in
the 90–100-percent purity range, which makes it
ideal for smoking (the route of admission of choice).
Methamphetamine treatment admissions remained
extremely high (accounting for 45 percent of admissions in 2004), continuing the increase in admissions
observed for the past 13 years (exhibit 8). In 2003,
there were 3,182 such admissions, up from 2,677 in
2002. The rate of increase in demand for treatment
space for methamphetamine abusers has been nearly
2,000 percent since 1991. This situation has so far
outstripped the treatment system's capacity, that people who might want treatment for alcohol or any
other drug would not likely receive it in a timely
manner. With court diversion programs in place, the
available treatment slots for non-judicial treatment
admissions are extremely tight.
Between 1994 and 2000, the O'ahu ME mentioned
crystal methamphetamine in 24–38 cases per year
(exhibit 8). In 2001, that number jumped to 54, and
methamphetamine-positive decedents increased to 62
in 2002. In 2003, the number of decedents with ice
detected in their toxicology reports was 56. For 2004,
there were 67 deaths with positive toxicology results
for methamphetamine, representing 76.5 deaths per
1,000,000 for the island of O'ahu.
Crystal methamphetamine prices remained stable in
2004. The drug is sold in the islands as "clear" (a
clear, white form) or "wash" (a brownish, less processed form). Prices for ice vary widely according to
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these two categories and availability, as illustrated by
prices on O'ahu: $50 (wash) or $75 (clear) per 0.25
gram; $200–$300 (wash) or $600–$900 (clear) per
gram; $450–$600 (wash) or $1,000–$2,000 (clear)
per one-quarter ounce; and $2,200–$3,000 (wash) per
ounce.
HPD methamphetamine case data peaked at 984 in
1995 (exhibit 9). The annual number of cases subsequently declined annually, and they totaled 616 in
2002 and 964 in 2003. In 2004, a total of 883 cases
were reported. Minimal data are available from the
neighbor islands, but they also show an increase in
cases.

Prices remain stable at $3–$20 per unit for barbiturates and $2–$3 per pill for secobarbital (Seconal or
"reds").
Hallucinogens
Hallucinogen treatment admissions total less than
five per year. No hallucinogen ME mentions have
been reported since the beginning of data collection.
Prices for lysergic acid diethylamide (LSD) were $4–
$6 per "hit" and $225–$275 per 100 dosage unit
sheets (a "page") in this reporting period.
A Final Point

NFLIS data for FY 2003 and FY 2004 show that
methamphetamine was the most often seized substance, with 62 percent of the FY 2003 and 57 percent of the FY 2004 samples testing positive for
methamphetamine.
Depressants
Barbiturates, sedatives, and sedatives/hypnotics are
combined into this category. Few data were provided
about these drugs in the islands.
ADAD maintains three categories under this heading:
benzodiazepines, other tranquilizers, and barbiturates.
Treatment admissions for these drugs are minimal in
terms of impact on the system. Annually, the numbers admitted to treatment for these drugs total less
than 10.

An examination of Exhibit 10 shows that over the
past 13 years, Honolulu Police Department drug
cases have varied considerably. Brief descriptions of
drug trends, as seen from the interdiction view, were
very complex in the early 1990s, with similar numbers of cases for cocaine, methamphetamine, and
marijuana. In addition it is important to note that the
accumulation of drug cases in 1993–1995 was quite
high (1,752 for marijuana, cocaine, and methamphetamine). With no marijuana cases reported by
HPD in 1996, the accumulated numbers for methamphetamine and cocaine was 1,720 cases, with cocaine
accounting for 70 percent of the cases.

The number of ME mentions for depressants has remained stable for several years at five or less.

By 2000, cocaine, methamphetamine, and marijuana
accounted for only 1,097 cases, with methamphetamine accounting for more cases than the other two
drugs combined. In 2004, there were 1,257 cases for
these three drugs, with methamphetamine representing 70 percent of the cases.

The HPD has not reported depressant case data since
1991. Neighbor island police reported fewer than 15
cases per year since 1996.

For inquiries concerning this report, please contact D. William
Wood, Ph.D., Department of Sociology, University of Hawai’i at
Manoa, 265 North Kalaheo Avenue, Honolulu, HI 96822, Phone:
250-384-3748, Fax: 808-965-3707, E-mail: dwwood@shaw.ca.
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Exhibit 1.

Drug Prices in Honolulu: 2004
Paper
(1/4 Gram)

½ Teen
(0.88 Grams)

Heroin (White)

$50

Heroin (Black
Tar)
Cocaine

Drug

Quarter
(1/4 Ounce)

“O”
(1 Ounce)

“LBs”
(1 Pound)

“Kilos”
(1 Kilogram)

$200–$300

$2,000–
$3,000

$5,000

$50,000

$100,000

$50–$75

$150–$200

$750

$2,500–
$3,000

N/A1

N/A

$25–$35

$100–$120

$1,100–
$1,500

$13,500–
$25,000

$26,500–
$52,000

Rock Cocaine

$100

Crack Cocaine

$25–$30

$100–$250

Crystal
Methamphetamine (Wash)

$50

$200–$300

LSD

8 Ball
(1/8 Ounce)

$500–$600
$250–$350
$200–$300

N/A

$450–$600

$1,000–
$1,500

$24,000

$2,200–
$3,000

$30,000

$50,000–
$70,000

$6,000–
$9,000

N/A

$225–$275
per 100 hits

$4–$6 per hit
$5–$20 per
joint

$25

$100–$200

$400–$800

Hashish

N/A

$10

$40–$60

$150–$300

Dilaudids

$40–$80
per capsule

Marijuana

MDMA

$25–$40
each

Phencyclidine
(PCP)

$10–$20

$100

$350–$550

$900–$1,200

$1,400–
$1,800

N/A

N/A

1

N/A= Not available.
SOURCE: Honolulu Police Department

Exhibit 2. Cocaine-Related Death1 and Treatment Data in Hawaii: 1991–2004
Cases
6
65

2
66

0
55

1
53

0
56

600

7
64

2
66

700

400

3
36

3
43

2
42

8
42

500

1
29

300

320

300

2
16

230

210

200

5
35

380
290
230

240

260

240
220

230

220

150
100
0
1991

1992

1993

1994

1995

1996

1997
1998
1999
2000
2001
Year
O'ahu Deaths (x10)
Treatment Admissions

2002

2003

2004

1

To allow direct comparison between ME data and treatment data, the ME data have been multiplied by 10.
SOURCES: Honolulu Medical Examiner and Department of Health, Alcohol and Drug Abuse Division
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Exhibit 3. Cocaine-Related Police Cases in Honolulu: 1991–2004
Cases

87
4

90
1

1,000
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6
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9
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3
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6
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8

800

0
1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

SOURCE: Honolulu Police Department

Exhibit 4. Heroin and Opiate Deaths1 and Heroin Treatment Admissions in Hawaii: 1991–2004
Cases
700
600
500
400
300
200
100
0

1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004

O'ahu Heroin Deaths (x10)

140 120 220 400 210 130 140 190 190 140 160 140 180 120

Treatment Admissions

134 209 190 236 416 346 330 521 487 441 278 253 201 175

O'ahu Opiate Deaths (x10)

400 340 340 350 420 470 590 570 400 400

1

To allow direct comparison between O’ahu ME data and treatment data, the O’ahu ME data have been multiplied by 10.
SOURCES: Honolulu Medical Examiner and Department of Health, Alcohol and Drug Abuse Division
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Exhibit 5. Heroin-Related Police Case Data in Honolulu: 1991–2004
Cases
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SOURCE: Honolulu Police Department

Exhibit 6. Marijuana-Related Deaths1 and Treatment Admissions in Hawaii: 1991–2004
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Treatment Admissions

1

To allow direct comparison between O’ahu ME data and treatment data, the O’ahu ME data have been multiplied by 10.
SOURCES: Honolulu Medical Examiner and Department of Health, Alcohol and Drug Abuse Division
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Exhibit 7. Marijuana-Related Police Case Data in Honolulu: 1991–2004

Cases
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SOURCE: Honolulu Police Department

Exhibit 8. Methamphetamine-Related Deaths1 and Treatment Admissions in Hawaii: 1991–2004
Cases
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8
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Oahu Deaths (x10)

270
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340
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560

670

2003
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350
2000

2001
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Treatment Admissions

1

To allow direct comparison between O’ahu ME data and treatment data, the O’ahu ME data have been multiplied by 10.
SOURCES: Honolulu Medical Examiner and Department of Health, Alcohol and Drug Abuse Division

104

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Honolulu and Hawai'i

Exhibit 9. Methamphetamine-Related Police Case Data in Honolulu: 1991–2004
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SOURCE: Honolulu Police Department

Exhibit 10.

Honolulu Police Department Cases, by Drug and Year: 1991–2004
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A Semiannual Update of
Drug Abuse Patterns and
Trends in Los Angeles
County, California
Beth Finnerty, M.P.H.1
ABSTRACT
Two main themes dominate Los Angeles Countylevel substance abuse indicator data in the current
reporting period (through December 2004): (1) a
relatively stable or mixed pattern for many drugs
and (2) increasing patterns for methamphetamine.
Los Angeles is the only city that is a primary drug
market (i.e., distribution hub, transshipment area,
and final destination) for all five major drugs (i.e.,
heroin, cocaine/crack, marijuana, methamphetamine, and MDMA). With regards to treatment admissions, for the first time, a higher proportion of Los
Angeles County treatment admissions were for primary methamphetamine abuse (5,395 admissions;
23.4 percent of the total) than for primary heroin
abuse (5,341 admissions; 23.2 percent of the total).
The proportion of cocaine/crack admissions remained stable at 18 percent, and primary marijuana
admissions continued to creep to 14.4 percent of the
total. Once again, the Los Angeles HIDTA led all
California HIDTAs in terms of clandestine methamphetamine laboratory seizures, accounting for more
than one-half of the 449 seizures made in California
in 2004. Even though four States had more laboratory seizures than California, and despite the steady
decline in the number of methamphetamine laboratories throughout the State, California remains the
home of the domestic methamphetamine ‘superlab.’
Seventy-five percent of the 48 superlabs seized
throughout the United States were located in California; 64 percent of those were located in four
southern California counties: Los Angeles, San Bernardino, Orange, and Riverside. Drug prices and
purities were relatively stable in the second half of
2004, with small changes occurring at the midlevel
and retail level for certain drugs. Los Angeles
County-level California Poison Control System major
drug exposure calls in the first half of 2004 were
dominated
by
cocaine/crack,
methamphetamine/amphetamine, ecstasy, and heroin. Furthermore, among prescription and over-the-counter
medication-related exposure calls, benzodiazepines
were the most frequently mentioned category, fol1
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lowed by opiates/analgesics and Coricidin HBP. Adolescent substance use data gathered from the California Healthy Kids Survey for the 2003–2004 school
year illustrated that lifetime and past-month usage
percentages among Los Angeles County secondary
school students in grades 7, 9, and 11 were either the
same or lower than percentages reported in previous
school years. Aside from alcohol, students were most
likely to report lifetime marijuana use (20 percent),
followed by inhalants (13 percent), cocaine or
methamphetamine (each at 7 percent), and LSD/
other psychedelics or ecstasy (each at 6 percent). Indicator data for prescription drugs, PCP, LSD,
MDMA (ecstasy), and GHB remained limited, but
use and abuse are reported among some of the nontraditional indicators.
INTRODUCTION
Area Description
Los Angeles County has the largest population
(9,937,739, 2004 estimate) of any county in the Nation. If Los Angeles County were a State, it would
rank ninth in population behind California, New
York, Texas, Florida, Pennsylvania, Illinois, Ohio,
and Michigan. Approximately 29 percent of California’s residents live in Los Angeles County. The
population of Los Angeles County has increased 3.7
percent since the 2000 Census. Nearly 90 percent of
all Los Angeles County residents live within 88 incorporated cities; the remaining 10 percent reside in
unincorporated areas of the county. The five most
populated cities are, in descending order of population,
Los Angeles (3,694,820), Long Beach (461,522),
Glendale (194,973), Santa Clarita (151,088), and
Pomona (149,473).
Just over one-half of all Los Angeles County residents are female (50.6 percent) (exhibit 1). More than
one-quarter (28.0 percent) are younger than 18; 9.7
percent are older than 65. The racial and ethnic composition of Los Angeles County residents is quite
diverse. Of those residents who report being of one
race, just under one-half identify as White (48.7 percent), followed by Asians (11.9 percent), Blacks/African-Americans (9.8 percent), American Indians/Alaska
Natives (0.8 percent), and Native Hawaiians/Other
Pacific Islanders (0.3 percent). About one-quarter of
residents (23.5 percent) identify with another race (not
specified). Furthermore, 5 percent report two or more
races. Residents of Hispanic/Latino origin may be of
any race. Therefore, they are included in the appropriate racial categories above. Nearly 45 percent of Los
Angeles County residents are of Hispanic/Latino
origin; approximately 31 percent of Whites are not of
Hispanic/Latino origin.
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According to an April 2004 Policy Brief from United
American Indian Involvement and the UCLA Ralph
and Goldy Lewis Center for Regional Policy Studies,
3 percent of the Nation’s 3.7 million American Indians/Alaska Natives (AIs/ANs) reside in the Los Angeles area. The largest concentration of urbanized
AIs/ANs is located in the county. Furthermore, the
local AI/AN population grew 35 percent from the
1990 to the 2000 U.S. census, compared to the overall county growth of 7 percent.
Los Angeles County encompasses approximately
4,080 square miles and includes the islands of San
Clemente and Santa Catalina. The county is bordered
on the east by Orange and San Bernardino Counties,
on the north by Kern County, on the west by Ventura
County, and on the south by the Pacific Ocean. Los
Angeles County’s coastline is 81 miles long.

Pacific Ocean and Mexico. Los Angeles is a nationallevel transportation hub and distribution center, and it
is the only primary market for all five of the major
drugs of abuse listed above (NDIC 2005).
Data Sources
This report describes drug abuse trends in Los Angeles County from January 1998 to December 2004.
Information was collected from the following
sources:
•

Drug treatment data were derived from the
California Department of Alcohol and Drug Programs (ADP), California Alcohol and Drug Data
System (CADDS), and correspond to Los Angeles County alcohol and other drug treatment and
recovery program admissions for July 2001 to
December 2004. This is the first semiannual report for which user demographic data are presented by route of administration for the major
drugs of abuse (including cocaine/crack, heroin,
and methamphetamine). It should be noted that
admissions for heroin treatment are disproportionately represented because of reporting requirements for facilities that use narcotic replacement therapy to treat heroin users. Both private and publicly funded narcotic treatment
providers must report their admissions to the
State, while for other drug types, only publicly
funded providers must report.

•

DAWN emergency department (ED) data for
the Los Angeles division (i.e., Los Angeles
County only) of the Los Angeles metropolitan
area were accessed from the Office of Applied
Studies (OAS), Substance Abuse and Mental
Health Services Administration (SAMHSA)’s
restricted-access database—DAWN Live!—for
calendar year 2004 (based on updates from April
13–14, 2005, and June 10, 2005). Thirty-four of
the 79 eligible hospitals in the Los Angeles area
are in the DAWN sample. The sample includes
37 emergency departments (some hospitals have
more than 1 ED). The data are incomplete and
are based on 9 to 14 EDs reporting each month
over the 12-month period (exhibit 2). The data
are unweighted and, thus, are not estimates for
the Los Angeles area. The data cannot be compared to DAWN data for 2002 and before, nor
can the preliminary data be used for comparison
with future data. Only weighted DAWN data released by SAMHSA can be used for trend analysis. The preliminary unweighted data for calendar year 2004 represent drug reports in drugrelated visits; reports exceed the number of visits, since a patient may report use of multiple

Two of the busiest maritime ports in the world—
Long Beach and Los Angeles—are located in Los
Angeles County. The Port of Long Beach is the Nation’s busiest maritime cargo container facility, while
the Port of Los Angeles ranks second, according to a
report by the National Drug Intelligence Center
(NDIC) in 2001. Los Angeles County is also home to
the world’s third busiest airport—Los Angeles International Airport. The airport handles more than 1,000
cargo flights each day; 50 percent of this activity is
international in origin or destination (NDIC 2001).
Residents of Los Angeles County primarily rely on
automobiles for transportation, and the Los Angeles
area has one of the most intricate highway systems in
the world. Of these, Interstates 5, 10, and 15 connect
the area to the rest of the Nation. Interstate 5 runs
from the U.S.-Canada border to the U.S.-Mexico
border and links Los Angeles to other key west coast
cities, such as San Diego, Oakland, San Francisco,
Sacramento, Portland, and Seattle. Interstate 10
originates in Santa Monica, California, and runs
across the United States to I-95 in Jacksonville, Florida; Interstate 15 originates in the area and runs
northeast through Las Vegas, Nevada, to the U.S.Canada border in Montana. In addition, State highways 1 and 101 are extensively traveled roadways.
The National Drug Threat Assessment 2005 identified 12 primary drug market areas throughout the
United States that serve as major consumption and
distribution centers of cocaine, marijuana, methamphetamine, heroin, and methylenedioxymethamphetamine (MDMA or ecstasy). California is one of
the most active drug smuggling and production areas
in the United States and contains three market areas—Los Angeles, San Diego, and San Francisco.
This is caused, in part, by the State’s proximity to the
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drugs (up to six drugs and alcohol). The analysis
for this paper includes the “major substances of
abuse,” as well as prescription drug misuse. For
major substances of abuse, all case types are included (i.e., suicide attempt, seeking detoxification, alcohol only [<21], adverse reaction, overmedication, malicious poisoning, accidental ingestion, and other) (exhibit 3). For pharmaceuticals (nonmedical use), only overmedication, malicious poisoning, and other case types are included. As noted earlier, the data included in this
report are preliminary. All DAWN cases are reviewed for quality control. Based on this review,
cases may be corrected or deleted. Therefore,
preliminary data are subject to change. A full description of DAWN can be found at
<http://www.dawninfo.samhsa.gov>.
•

•

•
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Poison control center call data were accessed
from the California Poison Control System
(CPCS) for 2000 through June 2004. The CPCS
provides poison information and telephone management advice and consultation about toxic exposures; hazard surveillance to achieve hazard
elimination; and professional and public education on poison prevention, diagnosis, and treatment. The information obtained from the CPCS
includes calls in which there was a confirmed
exposure to an illicit substance (e.g., cocaine,
heroin, marijuana, ecstasy, etc.), a prescription
drug or substance with common household uses,
or a combination of both. The statistical analysis
contained in this report is preliminary and focuses mostly on illicit substances; more indepth
analyses of the prescription and household substance categories will be conducted for future
area reports.
Drug availability, price, purity, seizure, and
distribution data were derived from the Los Angeles Police Department (LAPD), the Los Angeles High Intensity Drug Trafficking Area
(HIDTA), the Los Angeles County Regional
Criminal Information Clearinghouse (LA
CLEAR), the National Drug Intelligence Center,
and the Drug Enforcement Administration (DEA).
Drug analysis results from local forensic laboratories were derived from the Drug Enforcement Administration, National Forensic Laboratory Information System (NFLIS). The statistics
correspond to items analyzed between January 1,
2004, and December 31, 2004. It is important to
note that data from the Los Angeles County
Sheriff’s Department laboratory are complete,
but data from the LAPD laboratory are not complete for some months.

•

Demographic and geographic data were provided by the United Way of Greater Los Angeles, Los Angeles County Online, United American Indian Involvement, the UCLA Ralph and
Goldy Lewis Center for Regional Policy Studies,
and the U.S. Census Bureau (State and County
QuickFacts).

•

Adolescent substance use statistics were accessed from the Los Angeles County-level California Healthy Kids Survey (CHKS) data for the
1997–1998, 1998–1999, 1999–2000, 2000–2001,
2001–2002, 2002–2003, and 2003–2004 school
years from WestEd. The CHKS is a modular
survey that assesses the overall health of secondary school students (in grades 7, 9, 11, and a
small sample of nontraditional school students).
In California, Local Education Agencies (LEAs)
and County Offices of Education (COEs) that
accept funds under the Federal Title IV Safe and
Drug Free Schools and Communities (SDFSC)
program or the State Tobacco Use Prevention
Education (TUPE) program must administer the
CHKS at least once every 2 years. Individual
school districts are given the opportunity to administer the survey in every school year, however, if the resources exist to do so. Section A
(Core Module) includes questions on lifetime
and past-30-day use of alcohol, drugs, and tobacco. Another module (Section C) is comprised
of additional questions related to alcohol and
drug use, violence, and safety.

•

Acquired immunodeficiency syndrome (AIDS)
and human immunodeficiency virus (HIV)
data (cumulative through December 2004) were
provided by the Los Angeles County Department
of Health Services, HIV Epidemiology Program,
Advanced HIV (AIDS) Quarterly Surveillance
Summary, January 2005.

DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
Approximately 18 percent of all Los Angeles County
treatment and recovery program admissions in July–
December 2004 reported a primary crack or powder
cocaine problem (exhibit 4). The total number of
primary cocaine/crack admissions decreased 20 percent from the first to the second half of 2004. But as a
percentage of the total, cocaine admissions have remained quite stable at 18–20 percent for several
CEWG reporting periods (exhibit 5). Alcohol was the
most commonly reported secondary drug problem
among primary cocaine admissions (37 percent) (exhibit 6), followed by marijuana (18 percent). Smok-
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ing is the reported route of administration for 86 percent of all cocaine admissions, followed by inhalation
(10 percent). When asked whether they had used any
drug intravenously in the year prior to admission,
approximately 4 percent of all primary cocaine admissions reported that they had used needles to administer one or more drugs intravenously at least
once during the specified time period (exhibit 6a).
Sixty-six percent of the primary cocaine admissions
reported in the second half of 2004 were male, similar to the gender breakdown seen in the first half of
the year. Black non-Hispanics continued to dominate
cocaine admissions (at 56 percent), followed by Hispanics (22 percent) and White non-Hispanics (16
percent). In terms of age at admission, nearly 40 percent were concentrated in the 36–45 year age group;
an additional 23 percent of all primary cocaine admissions were between the ages of 26 and 35.
Primary cocaine treatment admissions are more likely
than treatment admissions for any other substance
(alcohol, prescription medications, or illicit drugs) to
report being homeless at admission (28 percent). The
proportion of cocaine admissions referred to treatment through the criminal justice system in the second half of 2004 continued to decrease to 16 percent
of all admissions (down from 20 percent in the first
half of the year). More frequently mentioned referral
sources included self-referral (33 percent) or referral
through
Proposition
36
(a.k.a.,
SACPA)
court/probation (31 percent). Although slightly more
than one-third of primary cocaine admissions had
never been admitted to treatment for a primary cocaine problem, 44 percent had one or two prior
treatment episodes. Forty-three percent had earned a
high school diploma or GED. At the time of admission, approximately 15 percent were employed either
full- or part-time.

les division, 2,348 (26 percent) were cocaine/crack
(exhibit 7). Cocaine was the second most likely major
substance to be reported, following alcohol. Sixtyeight percent of the patients reporting cocaine use
were male; 44 percent were Black (followed by 28
percent Hispanic and 23 percent White); 33 percent
were age 35–44; and 54 percent reported smoking
crack. A total of 5,067 chief complaints were logged
for patients reporting cocaine. The top three specific
complaints were intoxication (973 complaints), psychiatric condition (943 complaints), and altered mental status (868 complaints). Cocaine-using patients
were most likely to be discharged home (44 percent)
or admitted to a psychiatric unit (25 percent).
California Poison Control System calls involving the
use of cocaine/crack by Los Angeles County residents increased from 69 in 2000 to a high of 97 in
2003. In the first 6 months of 2004 alone, 41 calls
involving cocaine/crack were received (exhibit 8a).
Between January 2003 and June 2004, 68 percent of
the cocaine-exposed callers were male, and 51 percent were between the ages of 26 and 44 (exhibit 9).
An additional 21 percent were between the ages of 18
and 25.

Cocaine injectors were more likely than cocaine inhalers or crack smokers to be White non-Hispanic
(70 percent), 36 or older (70 percent), homeless (53
percent), or to have been through four or more prior
treatment episodes (21 percent). Crack smokers were
more likely than cocaine inhalers or injectors to be
male (64 percent), Black non-Hispanic (63 percent),
or have a high school diploma/GED (43 percent).
Lastly, cocaine inhalers were more likely than their
counterparts to be Hispanic (56 percent) or employed
full- or part-time (40 percent).

According to CHKS data for the 2003–2004 school
year (exhibit 10), 7.4 percent of all Los Angeles
County secondary school students (including 7th, 9th,
and 11th graders, and a small sample of nontraditional students) who responded to the survey had ever
used cocaine (crack or powder), and 3.8 percent were
current cocaine users (defined as any use in the past
30 days). A breakdown of the data by grade level
illustrated that among responding ninth graders, 5.4
percent had ever used cocaine and 3.0 percent were
current cocaine users. A higher percentage of 11th
graders than 9th graders reported current cocaine/crack use in the past 30 days. Of the lifetime
cocaine users, 55 percent were male and 45 percent
were female. The gender distribution was slightly
wider for past-30-day use of cocaine (63 percent
male vs. 37 percent female). Frequent cocaine use is
defined as 20 or more days of use in the previous 30
days. Twenty-four percent of the current cocaine users reported frequent use. Among the frequent users,
74 percent were male. When asked about past-6month use of cocaine (any form), methamphetamine,
or other stimulants, 7.1 percent of 9th graders and 6.5
percent of 11th graders responded in the affirmative
(exhibit 11).

Preliminary unweighted data accessed from DAWN
Live! for calendar year 2004 indicate that of the 8,982
major substances of abuse reported in the Los Ange-

According to long-term trends calculated from CHKS
data spanning over the most recent 5 school years
(exhibit 12), the pattern of past-30-day cocaine

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

109

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Los Angeles County

(powder or crack) use among responding secondary
school students was similar to usage patterns for
some of the other licit and illicit drugs, such as lysergic acid diethylamide (LSD)/other psychedelics and
methamphetamine. Past-30-day cocaine/crack use
decreased consistently from the peak level seen in
1999–2000 (4.9 percent) to 3.8 percent in 2002–
2003. In 2003–2004, current cocaine use remained
stable at 3.8 percent of all respondents.
A total of 10,717 cocaine arrests were made within the
city of Los Angeles in calendar year 2004. This represented a 3-percent deficit from the number of cocaine
arrests made during the same time period in 2003. Cocaine arrests accounted for 30 percent of all narcotics
arrests made between January 1 and December 31,
2004.
Citywide cocaine (including crack and powder) seizures increased 31 percent, from 1,835 pounds seized
in the first half of 2003 to 2,404 pounds seized in
2004. The street value of the seized cocaine accounted
for 29 percent of the total street value of all drugs
seized in 2004.
Data from NFLIS for calendar year 2004 showed that
out of 54,916 analyzed items reported by participating
laboratories within Los Angeles County, 38.3 percent
(21,037) of all items analyzed were found to be cocaine/crack. Cocaine/crack was the most likely illicit
drug to be found among items tested in the county,
followed closely by methamphetamine and more distantly by cannabis.
Los Angeles remains one of the primary markets for
cocaine (in addition to Houston, Chicago, New York,
Atlanta, and Miami; NDIC 2004). Mexican and Colombian traffickers control the wholesale distribution
of cocaine and crack in Los Angeles; AfricanAmerican and Hispanic street gangs control distribution at the retail level. All substance use and abuse
indicators are higher for crack than for powder cocaine. Despite this, powder cocaine availability and
use is reported in the area. Current midlevel prices of
crack cocaine remained level (as compared to the
January 2005 report) at $500–$1,200 per ounce (exhibit 13), as did the retail price range ($10–$40 per
rock). The current wholesale price for 1 kilogram of
powder cocaine ranges from $14,000 to $17,000,
which is identical to the wholesale price cited in the
past few CEWG reports. The current midlevel and
retail prices of powder cocaine remained stable, as
well, at $500–$600 per ounce and $80 per gram. The
purity of powder cocaine is approximately 78 percent,
similar to the purity cited in the last few CEWG reports.
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Heroin
From July to December 2004, 5,341 Los Angeles
County treatment and recovery program admissions
were attributable to primary heroin abuse, compared
with 6,942 admissions reported in the county in the
first half of 2004 (exhibit 4). In 2003, it was thought
that heroin admissions were leveling off at roughly
25.4 percent of all admissions, after several half-year
decreases. In the first half of 2004, however, the proportion of primary heroin admissions among all Los
Angeles County treatment and recovery programs
decreased slightly to 24.5 percent of all admissions.
And in the second half of 2004, the percentage of
primary heroin admissions continued to fall to 23.2
percent of all admissions. For the first time ever,
methamphetamine surpassed heroin as the most frequently mentioned primary drug among treatment
admissions (by a very small margin).
Demographics of heroin admissions have remained
stable over recent reporting periods. In the second
half of 2004, primary heroin admissions were
predominantly male (72 percent), most likely to be
age 45–50 (22 percent), and somewhat more likely to
be Hispanic (42 percent) than White non-Hispanic
(39 percent) or Black non-Hispanic (11 percent)
(exhibit 6). Compared with other major types of illicit
drug admissions, primary heroin admissions in the
first half of 2004 had the largest proportion of users
age 36 and older (74 percent). Just over one-third (36
percent) of all primary heroin admissions initiated
their heroin use prior to age 18, which is quite low
compared to other primary substances, such as alcohol, marijuana, methamphetamine, and phencyclidine
(PCP). If primary heroin admissions abused another
drug secondarily to heroin, it was most likely to be
cocaine/crack (24 percent), followed by alcohol (11
percent).
Heroin administration patterns remained relatively
stable in the second half of 2004, with injectors accounting for 85 percent, smokers accounting for 8
percent, and inhalers (snorters) accounting for 5 percent (exhibit 6). When asked whether they had used
any drug intravenously in the year prior to admission,
88 percent of all primary heroin admissions reported
that they had used needles to administer one or more
drugs intravenously at least once during the specified
time period.
Sixteen percent of all primary heroin admissions
were homeless at time of admission, and only 4 percent were referred by the court or criminal justice
system. Primary heroin users were most likely to
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have self-referred for the current treatment episode
(77 percent of all heroin admissions, up from 72 percent in the first half of 2004). In a measure of current
legal status, the majority (77 percent) were not involved at all with the criminal justice system. This
corroborates with the very low proportion of criminal
justice referrals among primary heroin users. Seventeen percent indicated that they had never received
treatment for their heroin problem, whereas 51 percent reported three or more primary heroin treatment
episodes. Forty-five percent of all primary heroin
admissions graduated from high school (down from
49 percent), and, at the time of admission, 24 percent
were employed full- or part-time (an increase from
20 percent in the first half of 2004).

tional 11 percent of the callers were between the ages
of 18 and 25.

Heroin injectors were more likely than their inhaler
or smoker counterparts to be Black non-Hispanic (22
percent), homeless (16 percent), or to have been
through four or more prior treatment episodes (42
percent). Heroin smokers were more likely than heroin inhalers or injectors to be White non-Hispanic
(65 percent), employed full- or part-time (39 percent), or have a high school diploma/GED (53 percent). Lastly, heroin inhalers were more likely than
their counterparts to be male (76 percent), Hispanic
(61 percent), and 36 and older (89 percent).

A total of 934 heroin arrests were made within the
city of Los Angeles during calendar year 2004. This
represented a 24-percent increase from the number of
heroin arrests made in 2003. Heroin arrests accounted
for approximately 2.6 percent of all narcotics arrests
made from January 1 to December 31, 2004.

Preliminary unweighted data accessed from DAWN
Live! for calendar year 2004 indicate that of the 8,982
major substances of abuse reported in the Los Angeles division, 712 (8 percent) were heroin (exhibit 7).
Heroin was the fifth most likely major substance to
be reported, following alcohol, cocaine, stimulants
(amphetamines and methamphetamine), and marijuana. Seventy-three percent of the patients reporting
heroin use were male; 43 percent were Hispanic (followed by 35 percent White and 20 percent Black); 35
percent were age 45–54; and 82 percent reported injecting heroin. A total of 1,438 chief complaints were
logged for individuals reporting heroin. The top three
complaints were altered mental status (235 complaints), abscess/cellulitis/skin/tissue (231 complaints), and intoxication (213 complaints). Heroinusing patients were most likely to be discharged
home (45 percent) or admitted to a psychiatric unit
(17 percent).
Los Angeles County-based California Poison Control
System calls involving exposure to heroin fluctuated
between 15 and 20 from 2000 to 2003 (exhibit 8a). In
the first half of 2004 alone, 11 heroin exposure calls
were reported, which may indicate a shifting upward
trend. Between January 2003 and June 2004, 79 percent of the heroin-exposed callers were male, and 67
percent were between the ages of 26 and 54. An addi-
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According to CHKS data for the 2003–2004 school
year (exhibit 10), 3.3 percent of all Los Angeles
County secondary school students (including 7th, 9th,
and 11th graders, and a small sample of nontraditional students) who responded to the survey had ever
used heroin. A breakdown of the data by grade level
illustrated that lifetime heroin use was nearly identical among responding 9th graders (3.1 percent) and
11th graders (3.0 percent). When asked about past-6month use of other drugs, heroin, or sedatives, 6.3
percent of 9th graders and 5.2 percent of 11th graders
responded in the affirmative (exhibit 11).

Twenty pounds of black tar heroin were seized within
the city of Los Angeles in 2004, a slight decrease of 7
percent compared with the amount seized during the
same time in 2003. Seizures of other types of heroin
remained stable at approximately 16 pounds seized in
2004. The street value of all seized heroin accounted
for approximately 1 percent of the total street value of
all drugs seized in 2004.
According to NFLIS data based on 54,916 analyzed
items reported by participating laboratories within Los
Angeles County between January 1 and December 31,
2004, only 4.1 percent (2,236) of all items analyzed
were found to be heroin. This small proportion corresponds to the small proportion of heroin (black tar and
other forms) reported among Los Angeles City seizures.
As in the past, Los Angeles is the primary market for
Mexican black tar heroin, and to a lesser extent,
brown powder heroin distributed to other Western
States (NDIC 2004). In addition, Mexican black tar
heroin remains the predominant type of heroin used
by Los Angeles County users. Mexican criminal
groups control the transportation and wholesale, midlevel, and retail activity (NDIC 2004). According to
LA CLEAR, the wholesale price per kilogram of
Mexican black tar heroin is approximately $20,000
(the same price reported in the last few CEWG reports) (exhibit 13). The current mid-level and retail
prices are $500–$800 per “pedazo” (Mexican ounce)
and $90–$100 per gram, which are stable since the
last report. A regular ounce is 28.5 grams, whereas a
pedazo is 25.0 grams.
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Mexican brown powder heroin sells for a wholesale
price of $25,000 per kilogram, when available in the
area. Retail distribution of Southeast Asian heroin
remains limited, but it is associated with a wholesale
price range of $70,000–$80,000 per kilogram. The
lack of China white on the streets is related, in part,
to local users’ preference for black tar.
The LA HIDTA and NDIC continue to report that Colombian drug trafficking organizations may be establishing networks within the Los Angeles area to distribute South American heroin. The wholesale price
for a kilogram of Colombian heroin is $86,000–
$100,000. This type of heroin has a purity level of 94
percent. The LA HIDTA also reports that because the
Los Angeles metropolitan area has one of the largest
Middle Eastern populations in the United States,
Southwest Asian opium trafficking activities have increased in the area. Southwest Asian opium is associated with a cost of $650–$800 for an 18-gram stick.
Other Opiates/Narcotics
Other opiates/synthetics continue to constitute a marginal proportion of all Los Angeles County treatment
admissions. Recently, their representation as a primary drug of abuse increased slightly in the local
treatment data, rising from 1.5 percent of all admissions in 1999 to 2.1 percent (583 admissions) in the
first half of 2004. In the second half of 2004, however, the proportion of other opiates/synthetics
dipped down to 1.6 percent of all admissions (373
admissions). Despite the small overall numbers of
admissions, it will be important to carefully monitor
future treatment admissions data, given the increase
in prescription opiate abuse/misuse in other major
CEWG areas. Other opiates/synthetics admissions
were typically male (64 percent), White non-Hispanic
(76 percent), and age 36–50 (54 percent). None of the
primary other opiate/synthetic admissions were
younger than 18. Interestingly, 82 percent administered other opiates/synthetics orally, but an additional
15 percent reported smoking. Fifty-nine percent of
primary other opiate/synthetic admissions reported no
secondary or tertiary substance use. An additional 11
percent reported secondary alcohol use, and 4 percent
reported secondary cocaine/crack use. Reports of
primary non-prescription methadone admissions continued to be minimal among Los Angeles County
treatment admissions (23 admissions, 0.1 percent of
all admissions).
According to reports from many CEWG representatives, non-heroin opiate users across the Nation have
a definite preference of hydrocodone (i.e., Vicodin)
over oxycodone (i.e., OxyContin) or vice versa. In
Los Angeles, hydrocodone is much more likely to
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show up in the indicator data than oxycodone. This is
evidenced by the fact that among NFLIS exhibits, 25
percent of the analgesic samples were found to be
hydrocodone (vs. 6 percent oxycodone); among
DAWN opiate/opioid drug reports, 33 percent were
hydrocodone (vs. 2 percent oxycodone); and among
poison control calls for opiate/analgesic exposure, 60
percent were for hydrocodone (vs. 11 percent for
oxycodone).
In addition to encompassing major substances of
abuse, unweighted data accessed from DAWN Live!
cover pharmaceutical drug categories, such as psychotherapeutic agents (antidepressants, antipsychotics, anxiolytics, sedatives and hypnotics, and central
nervous system [CNS] stimulants), CNS agents (analgesics, anticonvulsants, antiparkinson agents, and
muscle relaxants), respiratory agents, cardiovascular
agents, and anti-infectives. The case types that are of
interest for pharmaceuticals include seeking detoxification, overmedication, and other. Of the 2,255
pharmaceuticals falling within these three case types
in calendar year 2004 in the Los Angeles division,
387 (17 percent) were opiates/opioids (exhibit 14),
and an additional 296 were other analgesics. For the
opiates/opioids, “other” was the most frequently
stated case type (56 percent of opiates/opioids), followed by overmedication (35 percent) and more distantly by seeking detoxification (9 percent). Among
other analgesics, 73 percent (215) of the drugs were
reported as overmedication cases.
Los Angeles County-based California Poison Control
System calls involving exposure to opiates/analgesics
increased from a low of 25 in 2000 to a high of 67 in
2003 (exhibit 8b). In the first half of 2004 alone, 31
opiate/analgesic exposure calls were reported, which
may indicate a stabilizing of the trend line. Between
January 2003 and June 2004, calls involving an exposure to hydrocodone were more likely than calls involving an exposure to oxycodone (58 calls vs. 11
calls, respectively).
Approximately 950 of the 54,916 items analyzed and
reported to NFLIS between January 1 and December
31, 2004, were identified as pharmaceuticals/prescription/non-controlled non-narcotic medications (as opposed to illicit substances). Of those, a large proportion
(401 items; 43 percent) were found to be narcotic/other
analgesics. The most frequently cited analgesics were
hydrocodone (224 items; 56 percent) and codeine (64
items; 16 percent). Other analgesics identified included
methadone (33 items), oxycodone (23 items), and propoxyphene (11 items). To put these numbers/percentages into perspective, analgesics accounted for 0.7
percent of all items analyzed by participating Los Angeles County laboratories.
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Efforts are underway throughout Los Angeles to quantify the extent of pharmaceutical diversion to the street.
One result of this effort is the availability of expanded
prices for diverted opiates/analgesics. According to LA
CLEAR, Vicodin, a member of the hydrocodone family of opiate pain relievers, retails for $1 per 10milligram tablet in Los Angeles County (down from
$5 per 5-milligram tablet reported in January 2005;
exhibit 13). OxyContin, the trade name for the powerful analgesic oxycodone hydrochloride, sells on the
streets for $50 to $80 per 80-milligram tablet. Percocet
sells for $1–$5 per 5-milligram tablet (down from $5–
$10); MS Contin sells for $20 per 60-milligram tablet;
codeine sells for $1–$2.50 per tablet (and $80–$200
for a pint of liquid codeine); Dilaudid (hydromorphone) sells for $20–$60 per 4-milligram tablet (down
from $100); fentanyl patches sell for $25–$100 each;
and methadone sells for $10 per tablet.
Marijuana
The number of primary marijuana treatment admissions has fluctuated over several semi-annual reporting
periods (exhibit 4), but the proportion of the total has
remained somewhat fixed between 11 and 13 percent.
In the second half of 2004, 3,318 primary marijuana
admissions were reported in Los Angeles County. As a
percentage of the total, marijuana accounted for 14.4
percent of all admissions (up 1 percentage point from
the proportion reported in January–June 2004). Like
many of the other major drugs of abuse, the user
demographics of primary marijuana admissions were
relatively stable in the second half of 2004. Three out
of four primary marijuana admissions were male, and
individuals younger than 18 constituted 48 percent of
these admissions (exhibit 6). Primary marijuana admissions were most likely to be Hispanic (49 percent),
followed by Black non-Hispanics (29 percent) and
White non-Hispanics (15 percent).
Alcohol was identified as a secondary drug problem
for 39 percent of the primary marijuana admissions in
the second half of 2004. An additional 16 percent reported methamphetamine, and 9 percent reported cocaine/crack as their secondary drug problem. Compared with other major illicit drug admissions, primary
marijuana admissions had the largest proportion of
males (75 percent) and users age 17 and younger (48
percent). When asked whether they had used any drug
intravenously in the year prior to admission, only 1
percent of all primary marijuana admissions answered
affirmatively.
Approximately 7 percent of the primary marijuana
treatment admissions in the second half of 2004 were
homeless at the time of admission, and 30 percent
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were referred to treatment by the court or criminal
justice system (most likely by the juvenile justice
system, given the large proportion of adolescents
represented among primary marijuana admissions).
Sixty-nine percent were entering treatment for the
first time. Twenty-five percent had graduated from
high school, and, at the time of admission, 14 percent
were employed full- or part-time. Such characteristics
reflect the fact that just under one-half of all primary
marijuana admissions were younger than 18 at the
time of admission.
Preliminary unweighted data accessed from DAWN
Live! for calendar year 2004 indicate that of the 8,982
major substances of abuse reported in the Los Angeles division, 1,067 (12 percent) were marijuana reports (exhibit 7). Marijuana was the fourth most
likely major substance to be reported, following alcohol, cocaine, and stimulants. Seventy-two percent
of the patients reporting marijuana use were male; 37
percent were Hispanic (followed by 30 percent Black
and 24 percent White); and 57 percent were age 12–
29. A total of 2,148 chief complaints were logged for
individuals reporting marijuana. The top three complaints were intoxication (544 complaints), psychiatric condition (334 complaints), and altered mental
status (316 complaints). Marijuana-using patients
were most likely to be discharged home (54 percent)
or admitted to a psychiatric unit (17 percent).
California Poison Control System calls involving
exposure to marijuana among Los Angeles County
residents were stable at 35–39 calls between 2000
and 2003 (exhibit 8a). In the first half of 2004, marijuana-related exposure calls plummeted to eight calls.
Between January 2003 and June 2004, 74 percent of
the marijuana-exposed callers were male, and 81 percent were age 25 or younger.
According to CHKS data for the 2003–2004 school
year (exhibit 10), 19.8 percent of all Los Angeles
County secondary school students (including 7th, 9th,
and 11th graders, and a small sample of nontraditional students) who responded to the survey had ever
used marijuana, and 10.3 percent were current marijuana users (defined as any use in the past 30 days).
A breakdown of the data by grade level illustrated
that among responding seventh graders, 7.3 percent
had ever used marijuana and 4.3 percent were current
marijuana users. A higher percentage of 9th graders
than 7th graders and a higher percentage of 11th
graders than 9th graders reported marijuana use in the
past 30 days. When asked about past-6-month use of
marijuana, 9.2 percent of 7th graders, 15.9 percent of
9th graders, and 22.7 percent of 11th graders responded in the affirmative (exhibit 11).
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According to long-term trends calculated from CHKS
data spanning over the 5 most recent school years
(exhibit 12), the pattern of past-30-day marijuana use
among responding secondary school students was
more likely than the use of many other drugs, but
slightly less likely than binge drinking. Past-30-day
marijuana use has decreased consistently from the
peak level of 13.2 percent seen in 1999–2000 to 10.3
percent in 2003–2004.
According to NFLIS data based on 54,916 analyzed
items reported by participating laboratories within Los
Angeles County between January and December 2004,
22 percent (12,327) of all items analyzed were found
to be cannabis. Cannabis was the third most frequently
identified substance in Los Angeles County.
A total of 6,139 marijuana arrests were made within
the city of Los Angeles in 2004; this represents a 14percent increase over the number of marijuana arrests
made during the same time period in 2003 (5,369).
Marijuana arrests accounted for approximately 17 percent of all narcotics arrests made between January 1
and December 31, 2004.
Marijuana continues to dominate drug seizures in the
city of Los Angeles. The amount of marijuana seized
increased nearly 115 percent, from 14,823 pounds in
2003 to 31,758 pounds in 2004. Between January and
December 2004, the amount of marijuana seized accounted for 92 percent of the total weight of drugs (in
pounds) seized. Cocaine was a very distant second,
accounting for an additional 7 percent of the total
weight. The street value of the seized marijuana accounted for approximately 59 percent of the total
street value of all drugs seized in calendar year 2004.
According to NDIC, California and Mexico appear to
supply most of the marijuana available throughout
the United States. In addition, cultivation of marijuana on U.S. public lands is widespread, especially
in California. This is evidenced by the fact that more
than two-thirds of all cannabis plants eradicated from
National Forest System lands were located in California (NDIC 2004). Caucasian, Mexican, and Jamaican trafficking groups are responsible for the wholesale distribution of marijuana to Los Angeles. Street
gangs and independent dealers distribute domestic
and Mexican-grown marijuana in both Los Angeles
and San Diego (NDIC 2004). The wholesale price of
Mexican-grade marijuana ranges from $300 to $400
per pound (exhibit 13). The midlevel and retail prices
of commercial grade marijuana are $60–$80 per
ounce and $10 per gram. All prices have been stable
since early 2003. The wholesale price of domestic
mid-grade marijuana ranges from $1,000 to $1,200
per pound. Midlevel and retail prices are $200–$250
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per ounce and $25 per gram. The wholesale price of
high-grade sinsemilla is $2,500–$6,000 per pound.
An ounce of sinsemilla sells for $300–$600, and oneeighth ounce sells for $60–$80.
Indications regarding the local availability of “BC
Bud,” a hybrid type of cannabis bud grown in Canadian British Columbia, continue to circulate. A pound
of BC Bud, which would cost approximately $1,500
in Vancouver, has a wholesale per pound value of
$6,000 in Los Angeles. Supposedly, a pound of BC
Bud can be swapped straight across for a pound of
cocaine. Demand for hashish, the compressed form of
tetrahydrocannabinol (THC)-rich resinous cannabis
material, remained limited throughout the Los Angeles HIDTA. When it is available, it has a wholesale
price of $8,000 per pound.
Stimulants
The proportion of primary methamphetamine admissions to Los Angeles County treatment and recovery
programs increased further from the first to second
half of 2004, surpassing heroin for the first time ever
(exhibit 4). The 5,395 primary methamphetamine
admissions reported in July–December 2004 accounted for 23.4 percent of all admissions. Methamphetamine is the one illicit drug that has continually increased among treatment admissions over
the past 4 years (exhibit 5). Compared with other
major illicit drug admissions, primary methamphetamine admissions had the largest proportion of females (40.1 percent), White Non-Hispanics (39.2
percent), Asian/Pacific Islanders (2.6 percent), 18–
25-year-olds (30.4 percent), and 26–35-year-olds
(33.7 percent) (exhibit 6).
For the past few years, the proportion of Hispanics
among primary methamphetamine admissions has
been growing, as the proportion of Whites has been
shrinking. In the first half of 2004, the proportion of
White non-Hispanics was 41.4 percent, whereas the
proportion of Hispanics was 41.9 percent among all
primary methamphetamine admissions. In the second
half of 2004, the racial/ethnic gap once again widened, with Hispanics accounting for 47 percent of all
primary methamphetamine admissions vs. 39 percent
for Whites.
At one time, females accounted for 49 percent of
both primary methamphetamine and other amphetamine admissions. This practically equal distribution
of males and females was unique to methamphetamine and other amphetamines. The shifting
gender distribution with methamphetamine treatment
admissions has been discussed in detail in recent reports. In the second half of 2003, the percentage of
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females among primary other amphetamine admissions plummeted to 36.8 percent. In early 2004, however, the proportion of females climbed back up a bit
to 40 percent of all admissions. But in the second half
of 2004, the proportion of females decreased once
again, this time to 32.1 percent of all amphetamine
admissions. It is important to monitor this drug category to see if the gender distribution will return to
equitable proportions.
In the second half of 2003, primary amphetamine
admissions were most likely to fall within the 31–35
age group (23.6 percent), which was the modal age
group in the second half of 2002. Between January
and June 2004, however, primary amphetamine admissions were most likely to fall within the 26–30
age group (20.6 percent). In the second half of 2004,
18–25-year-olds and 26–30-year-olds each accounted
for 17 percent of all primary amphetamine admissions. Primary amphetamine admissions were marginally more likely to be Hispanic (36.9 percent) than
White non-Hispanic (34.5 percent). Primary methamphetamine and other amphetamine admissions tended
to most frequently report secondary abuse of alcohol
or marijuana.
As shown in exhibit 6, smoking continued as the
most frequently mentioned way for primary methamphetamine admissions to administer the drug. In
1999, one-half of all primary methamphetamine
admissions smoked the drug. By the second half of
2004, 66.7 percent reported this mode of administration. Conversely, the proportions of injectors and
inhalers continued to decline, from 15.2 and 29.5
percent, respectively, in 1999, to 6.7 and 22.6 percent, respectively, in the second half of 2004.
Like primary methamphetamine admissions, the mode
of other amphetamine administration has shifted in
recent years, as well. Two-thirds of all other amphetamine admissions in the second half of 2004 smoked
amphetamines, followed by 22.6 percent who inhaled,
8.3 percent who ingested orally, and 1.2 percent who
injected. In 1999, a lower percentage smoked, and
higher percentages injected, inhaled, and used other
amphetamines orally.
Eleven percent of all primary methamphetamine admissions reported past-year intravenous use of one or
more drugs. Approximately one-fifth of the primary
methamphetamine treatment admissions were homeless (21.6 percent) and referred by the court or criminal justice system (18.1 percent). Forty-eight percent
were entering treatment for the first time. Forty-three
percent had graduated from high school, and, at the
time of admission, 19.2 percent were employed fullor part-time.
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Methamphetamine injectors were more likely than
their inhaler or smoker counterparts to be male (67
percent), White non-Hispanic (75 percent), 36 or
older (41 percent), homeless (41 percent), or to have
been through four or more prior treatment episodes
(12 percent). They were, by far, the most impaired of
all primary methamphetamine abusers. Methamphetamine smokers were more likely than methamphetamine inhalers or injectors to be referred by the
criminal justice system (19 percent). Lastly, methamphetamine inhalers were more likely than their counterparts to be Hispanic (56 percent) or employed (25
percent). No differences existed among the three
modes of administration with regards to the percentage of Black non-Hispanics or the percentage of admissions with a high school diploma/GED.
Preliminary unweighted data accessed from DAWN
Live! for calendar year 2004 indicate that of the 8,982
major substances reported in the Los Angeles division, 1,235 (14 percent) were stimulants (exhibit 7).
The stimulant category encompasses amphetamines
(326 reports, 26 percent of stimulant reports) and
methamphetamine (909 reports, 74 percent of stimulant reports). Stimulants were the third most likely
major substance to be reported, following alcohol and
cocaine. For the remainder of the DAWN discussion,
stimulant user demographics will be broken out for
methamphetamine and amphetamines.
Seventy-five percent of the patients reporting
methamphetamine use to the DAWN Live! system
were male, and 48 percent were Hispanic (followed
by 35 percent White and 6 percent Black). More than
one-half (55 percent) were age 25–44, and an additional 33 percent were 18–24. The three most frequently reported complaints were intoxication (412
complaints), psychiatric condition (392 complaints),
and altered mental status (350 complaints). Methamphetamine-using patients were most likely to be discharged home (47 percent) or admitted to a psychiatric unit (30 percent). Nearly 50 percent of the patients
reporting methamphetamine use indicated that they
smoked the drug, followed by 13 percent reporting
inhalation.
Sixty percent of the patients reporting amphetamine
use to DAWN were male, and 47 percent were Hispanic (followed by 34 percent White and 9 percent
Black). More than one-half (53 percent) were age 25–
44, and an additional 25 percent were 18–24.
California Poison Control System calls involving exposure to methamphetamine/amphetamine among Los
Angeles County residents have fluctuated over the
years, with 48 calls logged for 2000, a high of 63 calls
in 2001, and approximately 55 calls in 2002 and 2003
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(exhibit 8a). In the first half of 2004 alone, 33 methamphetamine/amphetamine-related exposure calls were
made to the system. If an equal number of calls are
made in the second half of 2004, the overall number
will exceed the peak level seen in 2001. Between
January 2003 and June 2004, slightly more callers
reporting exposure to methamphetamine or other amphetamines were male (53 percent) than female (44
percent), and 64 percent were between the ages of 18
and 34 (exhibit 9). In addition to calls relating to
methamphetamine and amphetamine exposure, a total
of 37 Ritalin/Adderall exposure calls were recorded
between January 2000 and June 2004.
According to CHKS data for the 2003–2004 school
year (exhibit 10), 7.3 percent of all Los Angeles
County secondary school students (including 7th, 9th,
and 11th graders, and a small sample of nontraditional students) who responded to the survey had ever
used methamphetamine, and 3.7 percent were current
methamphetamine users (defined as any use in the
past 30 days). A breakdown of the data by grade level
illustrated that among responding ninth graders, 5.4
percent had ever used methamphetamine and 2.9 percent were current users. A higher percentage of 11th
than 9th graders reported methamphetamine use in
the past 30 days. A nearly equal proportion of males
and females identified as lifetime methamphetamine
users (51 percent were male and 49 percent were female). The gender gap widened with past-30-day use
of methamphetamine (63 percent male vs. 37 percent
female). Frequent methamphetamine use is defined as
20 or more days of use in the previous 30 days.
Twenty-three percent of the current methamphetamine users reported frequent use. Among the frequent users, 68 percent were male and the remaining
32 percent were female. When asked about past-6month use of cocaine, methamphetamine, or other
stimulants, 7.1 percent of 9th graders and 6.5 percent
of 11th graders responded in the affirmative (exhibit
11).
According to long-term trends calculated from CHKS
data spanning over the most recent 5 school years (exhibit 12), the pattern of past-30-day methamphetamine
use among responding secondary school students was
similar to patterns seen for cocaine and LSD/other
psychedelics. From 1999–2000 to 2001–2002, past-30day methamphetamine use decreased consistently from
the peak level of 4.6 percent in 1999–2000 to 4.1 percent in 2001–2002. In 2002–2003, the percentage of
current methamphetamine users increased slightly to
4.3 percent, but it decreased to 3.7 percent (the lowest
level yet) in 2003–2004.
According to NFLIS data based on 54,916 analyzed
items reported by participating laboratories within Los
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Angeles County between January and December 2004,
32 percent (17,789) of all items analyzed were found
to be methamphetamine/amphetamine. Methamphetamine accounted for the second largest proportion of
samples positively identified by NFLIS. An additional
18 items were identified as amphetamine, and 15 items
were identified as pseudoephedrine (each accounting
for less than one-tenth of a percent).
Throughout calendar year 2004, 458 amphetamine
arrests were made within the city of Los Angeles,
exceeding the number of arrests made during the
same period in 2003 (274 arrests) by 67 percent. Despite this large increase in the overall number of amphetamine arrests, as a class, such arrests continued
to account for slightly less than 1 percent of the total.
Arrests for methamphetamine are included in the
category “other narcotics.” In early 2004, 17,825
arrests for other narcotics were made (many of which
could be attributable to methamphetamine, but there
is no way of knowing from the LAPD report), accounting for 49 percent of all arrests.
While methamphetamine is not reported separately in
citywide drug arrests, it is broken out in citywide
seizures. Citywide methamphetamine seizures actually decreased 33 percent, from 535 pounds seized in
2003 to 356 pounds seized in 2004. The street value
of the seized methamphetamine accounted for approximately 10 percent of the total street value of all
drugs seized in 2004.
Los Angeles is considered by NDIC to be one of the
largest methamphetamine markets in the United
States. Mexican criminal groups based in both Mexico and California control the wholesale and midlevel
distribution of methamphetamine and distribute the
drug via private vehicles and commercial trucks. Not
only does a large quantity of the drug stay in the
southern California region, but methamphetamine is
transported to other major cities and regions, including San Francisco and Phoenix, and the West Central,
Southwest, and Southeast areas of the United States.
Hispanic gangs, independent dealers, outlaw motorcycle gangs (OMGs), and Asian gangs control the
retail distribution of methamphetamine within and
beyond California.
The wholesale price per pound of methamphetamine
ranged from $5,000 to $7,000 (exhibit 13), which is
similar to the range reported in January 2005, but
higher than the wholesale price reported in 2002–
2003 ($3,700 to $5,000). The midlevel and retail
prices are $500–$800 per ounce (up from $450–$550
reported in January 2005), $50 per gram, $60–$75
per one-sixteenth ounce (“teener”), and $100–$120
per one-eighth ounce. According to one intelligence
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source, the purity of finished methamphetamine
available in the Los Angeles area remains at approximately 30–35 percent. Given the many different
production “recipes” and the multiple types of
methamphetamine entering into and staying in the
Los Angeles area (locally produced and Mexican
produced), however, it is very possible that there is a
wide range of purity (especially since such a high
percentage of users report smoking methamphetamine).
Crystal methamphetamine has a wholesale price of
$8,000–$11,000 per pound in Los Angeles. The midlevel price for an ounce of crystal methamphetamine is
$600–$900, which represents a slight widening of the
range reported in January 2005. A double case of
pseudoephedrine (17,000 60-milligram tablets per
case) sells for $3,250–$4,000.
In parts of the United States, the number of methamphetamine clandestine laboratory seizures has consistently increased. According to Rudy Lovio, Criminal
Intelligence Specialist in the LA CLEAR Research
and Analysis Unit, this increase is due to the proliferation of “Nazi” methamphetamine labs (small-scale
labs capable of producing gram to ounce quantities of
finished product) in the Midwest and rural South.
Since calendar year 1999, however, the number of
clandestine laboratory incidents has decreased consistently in both the LA HIDTA and in California overall. In 1999, 2,090 labs were seized in California
(1,187 of which occurred in the 4-county LA HIDTA
region). By 2004, only 449 labs were seized statewide (263 in the LA HIDTA). Possible explanations
for the decrease in seizures include precursor chemical restrictions, chemical control laws, increased
methamphetamine production in Mexico, and the
downsizing of clandestine laboratory enforcement
teams. Despite the decrease in the number of seizures, the wholesale and retail prices for methamphetamine have remained relatively stable over the
same time period, which is a barometer for methamphetamine availability in Los Angeles County.
According to EPIC’s National Clandestine Laboratory Seizure System, California had the fifth highest
number of laboratory-only seizures in 2004 (449),
following Missouri (906), Tennessee (798), Arkansas
(563), and Indiana (517). Within California, the Los
Angeles HIDTA once again led the State in the overall number of methamphetamine seizures (including
laboratories, dumpsites, and chemicals/glass/equipment) made in 2004, accounting for 59 percent of all
seizures made in California (236 of 449 total incidents). Of the 4 counties in the LA HIDTA, Los Angeles County had the third highest number of incidents during that time period (60), lagging behind
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San Bernardino County (115) and Riverside County
(70). Orange County rounded out the HIDTA with 18
incidents.
Even though four States exceed California in terms of
laboratory seizures, California leads the country in
the number of domestic “superlabs.” Thirty-six of 48
U.S. superlabs (75 percent) seized in 2004 were in
California. In the past, these large-scale labs were
capable of producing 10 or more pounds of finished
methamphetamine in a single production cycle, but
superlabs have stepped up the pace and are now capable of producing 20 or more pounds of finished
drug in a single production cycle (NDIC 2004). The
LA HIDTA reported the highest proportion of superlabs seized throughout California (23 out of 36 superlabs seized between January 1 and December 31,
2004, or 64 percent). Within the LA HIDTA, Los
Angeles County led with 13 superlab seizures, followed by Riverside County (5), San Bernardino
County (4), and Orange County (1). Furthermore,
totals reported in the LA HIDTA exceeded totals
reported by all States outside of California.
The cost to clean up labs located in the LA HIDTA in
2004 totaled $759,672. Thirty percent of this total
corresponds to the cost of cleaning up Los Angeles
County laboratories, second only to Riverside County
(38 percent of the cleanup costs). It is important to
note that these cleanup figures do not encompass
building and environment remediation, which each
cost taxpayers even more money.
A negative consequence of clandestine methamphetamine laboratory activity is the effect on children
living in or around the makeshift, often home- or
apartment-based, laboratories. Local, statewide, and
national efforts, known as Drug Endangered Children
Programs, have been launched to address the issue of
what happens to children who are found at a
methamphetamine laboratory when it is seized. Nationally, in 2004, 2,900 children were “affected” by
methamphetamine laboratories. Seven percent of the
affected children resided in California. Within California, 98 of the 200 affected children resided in the 4
LA HIDTA counties. The highest proportion was
reported in Riverside County (77 of the 98 children),
followed by San Bernardino County (26), Los Angeles County (9), and Orange County (8). It is important to note that these numbers are underreported, due
to differences in county- and State-level reporting
procedures.
Depressants
In the second half of 2004, treatment and recovery
program admissions associated with primary barbitu-
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rate, benzodiazepine, or other sedative/hypnotic abuse
continued to account for less than 1 percent of all
admissions in Los Angeles County.
Of the 2,255 pharmaceuticals reported among those
seeking detoxification, overmedication, and other
cases accessed from DAWN Live! for calendar year
2004 in the Los Angeles division, 249 (11 percent)
were antidepressants, 249 were antipsychotics (11
percent), 51 were barbiturates (2 percent), and 450
were benzodiazepines (20 percent) (exhibit 14). For
all of the above categories except for barbiturates,
overmedication was the most frequently stated reason
for visiting the emergency department. The proportion of overmedication cases ranged from a low of 51
percent (for antipsychotics) to a high of 73 percent
(antidepressants).
Los Angeles County-based California Poison Control
System calls involving exposure to benzodiazepines
fluctuated. From 2000 to 2001, benzodiazepinerelated exposure calls increased from 64 to 83 (exhibit 8b). In 2002, the number of calls decreased to
52, and such calls then increased to 70 in 2003. In the
first half of 2004 alone, 52 benzodiazepine exposure
calls were reported, which may indicate a further
increase from the number of calls seen in 2003. Between January 2003 and June 2004, 19 of the benzodiazepine-related exposure calls were for alprazolam,
29 were for clonazepam, and 20 were for diazepam.
In addition to calls for benzodiazepine exposures, a
total of 52 antidepressant exposure calls and 25 antipsychotic calls were reported between January 2000
and June 2004.
Approximately 944 of the 54,916 items analyzed and
reported to the NFLIS system in calendar year 2004
were identified as pharmaceuticals/prescription/noncontrolled non-narcotic medications (as opposed to
illicit substances). Of those, roughly 21 percent (195
items) were found to be benzodiazepines. The most
frequently cited benzodiazepines were diazepam (65
items; 33 percent) and clonazepam (58 items; 30 percent).
According to LA CLEAR, Valium retails for $1 per
5-milligram tablet (exhibit 13), which is one-half the
cost reported in the January 2004 report. Xanax retails for $1 per 4-milligram tablet.
Phencyclidine and Hallucinogens
Primary PCP treatment admissions accounted for 0.6
percent of all admissions in the second half of 2004
(exhibit 4). The proportion of PCP admissions among
all admissions has been stable for several years, but
the overall number of PCP admissions increased 89
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percent from 1999 to the first half of 2003. In the
second half of 2003, however, the number of PCP
admissions decreased slightly (16 percent) to 262
admissions, and they continued to decrease further
(12 percent) in the first half of 2004 to 230 admissions,
and in the second half of 2004 to 135 admissions (41
percent decrease from the first half of the year). Alcohol (20 percent), marijuana (22 percent), and cocaine/crack (15 percent) were the three most frequently
reported secondary drugs among primary PCP admissions. The majority (88 percent) of the primary PCP
admissions smoked the drug. Interestingly, 6 percent
reported taking PCP orally, and 4 percent reported
injecting PCP. This is the first time that such high percentages reported modes other than smoking. There
were no notable changes from the previous reporting
period in terms of user demographics. Other hallucinogens, such as LSD, peyote, and mescaline, continued to account for approximately 0.1 percent of the
total treatment admissions.
Preliminary unweighted data accessed from DAWN
Live! for calendar year 2004 indicate that of the 8,982
major substances of abuse reported in the Los Angeles County division, 164 (2 percent) were PCP (exhibit 7). Seventy-nine percent of the patients reporting PCP use were male and 46 percent were White
(followed by 29 percent Black and 22 percent Hispanic). Sixty-seven percent were age 30–54, and an
additional 11 percent were between 18 and 24. A
total of 398 chief complaints were logged for patients
reporting PCP. The top three complaints were
intoxication (95 complaints), altered mental status
(87 complaints), and psychiatric condition (65 complaints). Patients were more likely to smoke PCP (62
percent) than inject (10 percent). PCP-using patients
were most likely to be either be discharged home or
admitted to a psychiatric ward (each at 31 percent).
California Poison Control System calls involving
exposure to PCP among Los Angeles County residents fluctuated between 10 and 20 calls from 2000
to 2003 (exhibit 8a). In the first half of 2004, there
were five PCP-related exposure calls.
According to CHKS data for the 2003–2004 school
year, 5.8 percent of all Los Angeles County secondary school students (including 7th, 9th, and 11th
graders, and a small sample of nontraditional students) who responded to the survey had ever used
LSD or another psychedelic, and 2.9 percent had
used LSD/other psychedelics in the past 30 days (exhibit 10). A breakdown of the data by grade level
illustrated that among responding ninth graders, 4.4
percent had ever used LSD/other psychedelics, and
2.5 percent were current users. Among 11th graders,
5.9 percent had ever used LSD/other psychedelics,
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and 2.5 percent used a psychedelic at least once
within the past 30 days.
According to long-term trends calculated from CHKS
data spanning over the last 5 school years (exhibit
12), the pattern of past-30-day LSD/other psychedelics use among responding secondary school students
(in grades 7, 9, and 11) was similar to usage patterns
seen with other licit and illicit drugs. Current use of
LSD/other psychedelics has been trending downward
since the late 1990s, to a low of 2.8 percent in 2002–
2003. In 2003–2004, the percentage was slightly
higher at 2.9 percent of all respondents.
According to NFLIS data based on 54,916 analyzed
items reported by participating laboratories within Los
Angeles County between January and December 2004,
0.5 percent (n=280) of all items analyzed were found
to be PCP.
One hundred and forty-eight PCP arrests were made
within the city of Los Angeles in calendar year 2004,
which represented a 12-percent decline from 2003
(169 arrests). Like amphetamine arrests, PCP arrests
accounted for a very low proportion (less than 1 percent).
The street value of the PCP seized between January
and December 2004 represented approximately 3.2
percent of the total street value of all drugs seized
during that period. The total amount of PCP seized
throughout 2004 (26.5 pounds) was 15 percent lower
than the amount seized during the same period in
2003 (31 pounds).
The wholesale price for a gallon of PCP remains at the
high level reported in January 2005, ranging from
$15,000 to $20,000 (exhibit 13). The ounce price,
however, decreased recently, from $600 to $300–$350.
A sherm cigarette dipped in liquid PCP continues to
sell for $20–$30. A tight-knit group of Los Angelesbased African-American street gang members continues to produce, supply, and distribute PCP in the Los
Angeles area.
A sheet of approximately 100 doses of LSD has a
wholesale price range of $150–$200. Typically, a
single dose sells for $5–$10. At the retail level, psilocybin mushrooms cost about $20 per one-eighth
ounce.
Club Drugs
Comprehensive indicator data relating to the use and
abuse of club drugs is still lacking for Los Angeles
County. Therefore, it is difficult to accurately and comprehensively describe the use and abuse patterns of club
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drugs in Los Angeles County. Despite this lack of traditional indicator information, anecdotal evidence from a
variety of sources continues to circulate with regard to
the availability of club drugs in Los Angeles County,
particularly MDMA (ecstasy) and gamma hydroxybutyrate (GHB).
Collectively, club drugs played a limited role in preliminary unweighted data accessed from DAWN Live!
in 2004. Sixty-five of the 8,982 major substances of
abuse reported in the Los Angeles division were
MDMA (ecstasy), 5 were GHB, and 1 was ketamine
(exhibit 7). Rohypnol did not have a presence at all.
The demographics of patients reporting MDMA use
were interesting, when compared to the demographics
for many other drug users in Los Angeles. Fifty-four
percent of the patients reporting MDMA use were female, and 35 percent were Hispanic (followed by 26
percent White and 22 percent Black). More than onehalf of the MDMA users (55 percent) were between 12
and 24 years of age. Of the 148 complaints, the three
most frequently reported complaints were altered mental status (47 complaints), intoxication (40 complaints),
and psychiatric condition (35 complaints). Methamphetamine-using patients were most likely to be admitted to a psychiatric unit (43 percent) or discharged
home (26 percent).
California Poison Control System calls involving
exposure to ecstasy among Los Angeles County residents have decreased consistently over recent years,
from a high of 56 in 2000 to a low of 16 in 2003 (exhibit 8a). In the first half of 2004 alone, however, 12
calls relating to ecstasy exposure were reported. If an
equal number of calls are made in the second half of
2004, the overall number will exceed the 2003 level.
Between January 2003 and June 2004, more callers
reporting exposure to ecstasy were male (57 percent)
than female (43 percent), and 64 percent were between the ages of 13 and 25 (exhibit 9). In addition to
calls relating to ecstasy exposure, a total of 14 GHB
exposure calls, 4 ketamine calls, and 3 Rohypnol
calls were recorded between January 2003 and June
2004.
The California Poison Control System also kept track
of calls relating to Coricidin HBP and dextromethorphan (DXM) exposures. Between January 2003 and
June 2004, 50 Coricidin HBP calls and 17 DXM calls
were logged in the system (exhibit 8a). Fifty-two
percent of Coricidin HBP calls and 59 percent of
DXM calls were male. Furthermore, 84 percent of the
Coricidin HBP calls and 65 percent of the DXM calls
were made because of exposure to individuals
younger than 18. Those age 18–25 represented an
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additional 16 percent of the Coricidin HBP calls and
23 percent of the DXM calls (exhibit 9).
According to CHKS data for the 2003–2004 school
year (exhibit 10), 5.5 percent of all Los Angeles
County secondary school students (including 7th, 9th,
and 11th graders, and a small sample of nontraditional students) who responded to the survey had ever
used ecstasy. Current use of ecstasy was not assessed,
although a question regarding past-6-month use of
psychedelics, ecstasy, or other club drugs was included in the survey. Overall, 6.2 percent of all respondents reported use of these drugs (exhibit 11).
By grade, 6 percent of 9th graders and 5 percent of
11th graders answered in the affirmative.
According to NFLIS data based on 54,916 analyzed
items reported by participating laboratories within Los
Angeles County between January and December 2004,
less than 1 percent (277) of all items analyzed were
found to be MDMA, GHB, or ketamine. Of those three
club drugs, MDMA was most likely to be detected; it
represented 81 percent of the club drug samples analyzed by NFLIS. GHB represented an additional 10
percent of the samples, and ketamine accounted for 8
percent.
According to NDIC, the majority of MDMA available in Los Angeles is transported directly from
Western Europe. Los Angeles is a source of both
wholesale and midlevel amounts of MDMA, which
are destined for markets around the United States,
including Pacific, Southwest, and West Central States
(NDIC 2004). Israeli and Russian criminal groups
control the wholesale distribution, and independent
dealers (usually White males) are responsible for
retail marketing and distribution. Mail service and air
travel are the two most likely ways to transport the
product into Los Angeles. Within Los Angeles, Israeli and Russian traffickers control the distribution
at the wholesale level.
Wholesale and retail prices for club drugs remained
stable since the January 2005 report. In multiple
quantities, MDMA has a wholesale price of $12 per
pill or capsule (exhibit 13). At the retail level, ecstasy
usually sells for $20–$40 per pill. A standard dose of
ecstasy is 60–150 milligrams, which is equivalent to
one or two pills. In Los Angeles, ecstasy “boats” continue to be mentioned. A boat contains 1,000 MDMA
pills and sells for $8,000. Flunitrazepam (Rohypnol),
when available, has a retail value of $6–$10 for a 1milligram pill. On the street, ketamine sells for $100–
$200 per 10-milliliter vial. In addition, ketamine retails for $20 for two-tenths of a gram of powder. The
wholesale price for GHB is $275–$350 per gallon,
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and a liter sells for $80–$100. A 16-ounce bottle of
GHB, which once ranged from $65 to $100, now
sells for $120. Capfuls can still be purchased for $5–
$20 each. The vast majority of GHB users ingested
the drug as a liquid, either in straight shots or mixed
with a drink. When available, gamma butyrolactone
(GBL) sells for $600 per liter.
INFECTIOUS DISEASES RELATED TO DRUG ABUSE
A cumulative total of 49,116 adult/adolescent AIDS
cases were reported in Los Angeles County through
December 31, 2004. Of those cases, 1,384 were reported between July 1, 2004, and December 31,
2004. Currently, approximately 20,316 Los Angeles
County residents are living with advanced HIV disease. Los Angeles County cumulative cases represent
approximately 36 percent of the 135,975 cumulative
cases in California and approximately 5 percent of
the 929,985 cumulative cases nationwide. Of the cumulative cases reported in Los Angeles County, 47
percent were White, 30 percent were Hispanic, 20
percent were African-American, 44 percent were age
30–39, and 92 percent were male.
The proportion of newly diagnosed males solely exposed through injection drug use has ranged between
4 and 6 percent from 1998 to 2004 (exhibit 15). The
proportions for other exposure categories, such as the
combination of male-to-male sexual contact and injection drug use, heterosexual contact, blood transfusion, and hemophilia/coagulation disorder, have remained relatively stable since 1998. The proportion
of men exposed to AIDS through male-to-male sexual contact has decreased slowly but steadily, from
65 percent in 1998 to 61 percent in 2004. The proportion of male cases with an “other” or “undetermined”
exposure category accounted for 28 percent of all
male cases diagnosed in 2004. Since the 2004 data
are preliminary, it is possible that some of the cases
in the “other/undetermined” category will be transferred into the other exposure categories.
The modal exposure category for females diagnosed
with AIDS in 1998 was heterosexual contact (46 percent). This exposure category has been associated
with a lower proportion of female AIDS cases since
1999; in 2004, it was associated with 34 percent of all
newly diagnosed female AIDS cases. Female cases
attributable to injection drug use, which were stable at
17–19 percent of all female cases from 2000 to 2002,
decreased to 13 percent in 2003 and remained there in
2004. The proportion of female cases with an “other”
or “undetermined” exposure category continued to
increase, accounting for 49 percent of all female cases
diagnosed in 2004.
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In Los Angeles County in 2004, approximately 7
percent of all AIDS cases involved injection drug use
(alone) as the primary route of exposure. Among the
3,387 cumulative cases primarily attributable to injection drug use, 72 percent occurred among males.
African-Americans are the modal group of male injection drug users (IDUs) (accounting for 37 percent), followed by Hispanics (32 percent) and Whites
(30 percent). A similar pattern was seen with female
IDU AIDS cases. African-Americans continued to
constitute the greatest proportion (44 percent), followed by Whites (31 percent) and Hispanics (22 percent).
An additional 7 percent of the total cumulative cases
were attributable to a combination of male-to-male
sexual contact and injection drug use. Fifty-one percent of the male-to-male sexual contact and injection
drug use cases were White.
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Exhibit 1. Population Characteristics, Los Angeles County and the State of California, by Percent:
2000 U.S. Census
Population Characteristics
Population, 2003 estimate (N)
Population, percent change, April 1, 2000,
to July 1, 2003
Population, year 2000 (N)
Persons younger than 5
Persons younger than 18
Persons age 65 and older
Female
White
Black or African-American
American Indian or Alaska Native
Asian persons
Native Hawaiian or Other Pacific Islander
Persons reporting some other race
Persons reporting two or more races
White, not Hispanic/Latino origin
Persons of Hispanic/Latino origin

Los Angeles County
(9,871,506)
3.7

California
(35,484, 453)
4.8

(9,519,338)
7.7
28.0
9.7
50.6
48.7
9.8
0.8
11.9
0.3
23.5
4.9
31.1
44.6

(33,871,648)
7.3
27.3
10.6
50.2
59.5
6.7
1.0
10.9
0.3
16.8
4.7
46.7
32.4

SOURCE: U.S. Census Bureau, State and County QuickFacts

Exhibit 2. Data Completeness for Los Angeles County DAWN Live! Emergency Departments (n=37)1,
by Month: 2004
Data
Completeness
Basically
2
Complete
Partially
Complete3
Incomplete4
No Data
Reported
Total EDs in
Sample5

Number of EDs by Month
MayJunJulAug04
04
04
04

Jan04

Feb04

Mar04

Apr04

Sep04

Oct04

Nov04

Dec04

12

12

12

10

9

7

7

7

8

7

7

9

0

0

0

1

1

1

2

1

1

2

3

2

1

2

2

2

1

3

0

1

2

3

2

1

24

23

23

24

26

26

28

28

26

25

25

25

37

37

37

37

37

37

37

37

37

37

37

37

1

Total eligible hospitals in area=79; Hospitals in DAWN sample=34; Hospitals not in DAWN Sample = 45. Tables reflect cases that have
been received by DAWN as of either 4/13–14/2005 or of 6/10/05; the exact date will be indicated in future tables.
2
90% Complete; 350% to 89% Complete; 4Less than 50% Complete; 5Some hospitals in the DAWN sample have more than one
emergency department. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted.
Therefore, these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, update 4/13–14/05 and 6/10/05
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Exhibit 3. Number of ED Visits, by Case Type, in the Los Angeles County Division (Unweighted1) and Percent
of All ED Visits: January–December 2004
Number of ED Visits1 (%)
516 (6)
190 (2)
531 (6)
1,467 (17)
894 (11)
28 (<1)
119 (1)
4,739 (57)
8,484 (100)

Case Type
Suicide Attempt
Seeking Detoxification
Alcohol Only (age <21)
Adverse Reaction
Overmedication
Malicious Poisoning
Accidental Ingestion
Other
Total
1

The unweighted data are from 9 to 14 EDs reporting to Los Angeles area hospitals. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05

Exhibit 4. Number and Proportion of Semiannual Treatment Admissions in Los Angeles County, by Primary
Illicit Drug of Abuse: January 2002–December 2004

Primary Drug
Cocaine/Crack
Heroin
Marijuana
Methamphetamine
PCP
Total Admissions

01/02–06/02
Number
(%)
4,655
(19.6)
7,767
(32.8)
2,686
(11.3)
3,453
(14.6)
196
(0.8)
23,695

07/02–12/02
Number
(%)
4,354
(19.0)
7,096
(30.9)
2,816
(12.3)
3,692
(16.1)
219
(0.9)
22,934

01/03–06/03
Number
(%)
5,242
(19.3)
6,891
(25.4)
3,669
(13.5)
4,961
(18.3)
314
(1.2)
27,110

07/03–12/03
Number
(%)
4,815
(18.2)
6,704
(25.4)
3,452
(13.1)
5,095
(19.3)
262
(1.0)
26,393

01/04–06/04
Number
(%)
5,137
(18.1)
6,942
(24.5)
3,812
(13.4)
5,840
(20.6)
230
(0.8)
28,371

07/04–12/04
Number
(%)
4,124
(17.8)
5,341
(23.2)
3,318
(14.4)
5,395
(23.4)
135
(0.6)
23,059

SOURCE: California Alcohol and Drug Data System (CADDS)

Exhibit 5. Number and Proportion of Annual/Semiannual Treatment Admissions in Los Angeles County, by
Primary Illicit Drug of Abuse: 2001–2004
Primary Drug
Cocaine/Crack
Heroin
Marijuana
Methamphetamine
PCP
Total Admissions

2001
Number

8,703
17,560
4,286
5,418
405
46,127

2002
(%)

(18.9)
(38.1)
(9.3)
(11.7)
(0.9)

Number

9,009
14,863
5,502
7,145
415
46,629

2003
(%)

(19.3)
(31.9)
(11.8)
(15.3)
(0.9)

Number

10,057
13,595
7,121
10,056
576
53,503

2004
(%)

(18.8)
(25.4)
(13.3)
(18.8)
(1.1)

Number

9,261
12,283
7,130
11,235
365
51,430

(%)

(18.0)
(23.9)
(13.9)
(21.8)
(0.7)

SOURCE: California Alcohol and Drug Data System (CADDS)
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Exhibit 6. Characteristics of Treatment Admissions in Los Angeles County, by Primary Illicit Drug of Abuse
and Percent: July–December 2004
Characteristics
Gender
Male
Female
Race/Ethnicity
White, non-Hispanic
Black, non-Hispanic
Hispanic
American Indian
Asian/Pacific Islander
Other
Age
17 and younger
18–25
26–35
36 and older
Route of Administration
Oral
Smoking
Inhalation
Injection
Unknown/other
Secondary Drug
Positive for Intravenous
Drug Use in Past Year
Homeless
Employed Full- or PartTime
Graduated from High
School
Referred by
Court/Criminal Justice
System (Not Including
1
SACPA Referrals)
First Treatment Episode
Total Admissions (N)

Cocaine/Crack

Heroin

Marijuana

Methamphetamine

All
Admissions

65.7
34.3

71.5
28.5

75.2
24.8

59.9
40.1

67.2
32.8

15.6
56.4
21.5
0.6
1.4
4.5

38.7
11.4
42.2
0.8
1.0
5.9

14.7
29.1
48.5
0.8
1.6
5.3

39.2
3.2
47.3
0.9
2.6
6.8

30.7
22.7
38.4
0.8
1.8
5.6

1.3
9.3
22.8
66.6

0.2
7.7
18.4
73.7

48.1
23.4
15.6
12.9

8.2
30.4
33.7
27.7

12.2
16.4
22.2
49.2

2.5
96.8
0.6
0.1
0.1

3.1
66.7
22.6
6.7
0.7

21.5
48.8
7.7
21.6
0.4

2.2
86.0
10.4
1.1
0.3
Alcohol

1.4
8.3
4.5
85.3
0.5
Cocaine/
Crack

Alcohol

Marijuana

Alcohol

4.4

87.9

1.1

10.9

24.9

27.8

15.7

7.1

21.6

18.8

14.8

24.0

13.5

19.2

18.3

42.5

44.8

24.9

42.6

39.9

16.4

3.6

30.1

18.1

15.3

36.0
(4,124)

17.0
(5,341)

68.5
(3,318)

47.8
(5,395)

42.7
(23,059)

1

SACPA = Substance Abuse and Crime Prevention Act of 2000 (a.k.a., Proposition 36)
SOURCE: California Alcohol and Drug Data System (CADDS)
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Exhibit 7. Number of ED Reports, by Drug and Drug Category (Major Substances of Abuse), in the Los
Angeles County Division (Unweighted1): January–December 2004
Number of ED Reports1
3,307
531
2,348
712
1,067
1,235
326
909
65
5
1
5
164
3
44
26
8,982

Major Substance of Abuse
Alcohol
Alcohol only (age <21)
Cocaine
Heroin
Marijuana
Stimulants
Amphetamines
Methamphetamine
MDMA (Ecstasy)
GHB
Ketamine
LSD
PCP
Miscellaneous hallucinogens
Inhalants
Combinations NTA
Total
1

The unweighted data are from 9 to 14 EDs reporting to the Los Angeles area hospitals. All DAWN cases are reviewed for quality
control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05

Exhibit 8a.

Los Angeles County Poison Control Center Exposure Calls for Major Substances of Abuse:
January 2000–June 2004

Major Substance
Cocaine/Crack1
Heroin1
Marijuana1
Ecstasy (MDMA)1
Rohypnol/flunitrazepam1
GHB1
PCP1
LSD1
Mushrooms
Other hallucinogens
1
Other Illicit
2
Inhalants
Methamphetamine/
Amphetamine2
Ketamine2

2000
Number
69
20
35
56
7
57
10
18
2
2
2
1

2001
Number
66
15
35
50
4
35
17
2
1
0
1
0

2002
Number
77
20
39
33
4
25
13
6
0
2
2
3

2003
Number
97
17
39
16
1
10
16
1
2
2
0
2

1H2004
Number
41
11
8
12
2
4
5
1
0
1
0
2

Total
Number
350
83
156
167
18
131
61
28
5
7
5
8

48

63

51

54

33

249

3

2

3

1

3

12

1

Includes calls for all exposure reasons.
Includes calls for the following exposure reasons: intentional misuse, intentional abuse, intentional unknown, contamination/tampering, and other malicious.
SOURCE: California Poison Control System
2
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Exhibit 8b. Los Angeles County Poison Control Center Exposure Calls for Prescription and Over-theCounter Medications and Common Household Substances: January 2000–June 2004
Substance1
Antidepressants
Antipsychotics
Benzodiazepines
Alprazolam
Clonazepam
Diazepam
Other
Barbiturates
Opiates/Analgesics
Codeine
Hydrocodone
Methadone
Oxycodone
Narcotic analgesics
Other (non-narcotic)
Fentanyl
Dextromethorphan
Coricidin HBP
Miscellaneous
Anxiolytics
Muscle Relaxants
Ritalin/Adderall
Other Stimulants
Other
Unknown

2000
Number
10
4

2001
Number
8
5

2002
Number
12
5

2003
Number
15
4

1H2004
Number
7
7

Total
Number
52
25

10
14
16
24
0

14
23
17
29
1

8
10
8
26
0

12
15
16
27
2

7
14
4
27
1

51
76
61
133
4

2
5
3
1
5
9
1
8
4

6
10
4
4
6
14
1
10
13

2
32
5
7
6
10
2
10
26

4
39
3
9
8
4
0
12
28

1
19
1
2
3
5
1
5
22

15
105
16
23
28
42
5
45
93

1

4

2

8

1

16

7
5
2
13
2

6
10
4
20
2

8
11
2
23
3

13
9
1
16
4

8
2
0
12
2

42
37
9
84
13

1
Includes calls for the following exposure reasons: intentional misuse, intentional abuse, intentional unknown, contamination/tampering, and other malicious.
SOURCE: California Poison Control System
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Exhibit 9. Los Angeles County Poison Control Center Exposure Calls for Select Substances, by Gender,
Age, and Percent: January 2003–June 2004

Gender
Male
Female
Unknown
Age Group
Younger than 13
13–17
18–25
26–34
35–44
45–54
55 and older
Total Number of
Calls

Cocaine/
Crack

Meth/
Amphetamine

Ritalin/
Adderall

Ecstasy

Coricidin
HBP

Dextromethorphan

68
32
0

53
44
3

64
36
0

57
43
0

52
48
0

59
35
6

9
7
21
25
26
12
<1

14
10
39
25
7
4
1

18
36
28
18
0
0
0

7
14
50
18
11
0
0

6
78
16
0
0
0
0

12
53
23
6
6
0
0

138

87

11

28

50

17

SOURCE: California Poison Control System

Exhibit 10.

Reported Drug Use Among Los Angeles County Secondary School Students, by Percent: 2003–
2004 School Year

Usage Patterns Among
Survey Respondents
Cocaine (any form)
Lifetime
Past 30 days
Ecstasy
Lifetime
Past 30 days
Heroin
Lifetime
Past 30 days
Inhalants
Lifetime
Past 30 days
LSD/Other Psychedelics
Lifetime
Past 30 days
Marijuana
Lifetime
Past 30 days
Methamphetamine
Lifetime
Past 30 days

7th Grade1

9th Grade

11th Grade

All Respondents2

***
***

5.4
3.0

7.5
3.5

7.4
3.8

***
N/A3

4.3
N/A

5.7
N/A

5.5
N/A

***
***

3.1
N/A

3.0
N/A

3.3
N/A

12.5
5.5

13.7
5.3

12.6
4.1

13.4
5.3

***
***

4.4
2.5

5.9
2.5

5.8
2.9

7.3
4.3

20.4
10.9

32.8
15.1

19.8
10.3

***
***

5.4
2.9

7.2
3.4

7.3
3.7

1
The 7th grade data for several drugs (i.e., cocaine/crack, ecstasy, heroin, LSD/other psychedelics, and methamphetamine) were
based on responses from a very small subset of 7th graders. Therefore, these results have been suppressed (***).
2
All respondents include responding 7th graders (when applicable), 9th graders, 11th graders, and a small sample of nontraditional
students (enrolled in continuation or alternative schooling programs).
3
N/A=Not applicable.
SOURCE: California Healthy Kids Survey, Los Angeles County Sample, WestEd
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Exhibit 11.

Past-6-Month Substance Use Among Los Angeles County Secondary School Students, by
Percent: 2003–2004 School Year

Usage Patterns Among
Survey Respondents
Any Alcohol

7th Grade1

Inhalants

9th Grade

22.1

11th Grade

36.7

All Respondents2

52.5

34.7

10.4

9.2

6.2

9.2

9.2

15.9

22.7

15.4

***

7.1

6.5

7.5

***

6.2

5.0

6.2

***

6.3

5.2

6.2

9.9

9.4

12.4

11.4

Marijuana
Cocaine (any form), Methamphetamine, or Other
Stimulants
Psychedelics, Ecstasy, or
Other Club Drugs
Other Drugs, Heroin, or
Sedatives
Two or More Drugs at the
Same Time
1

The 7th grade data for several drug categories were based on responses from a very small subset of 7th graders. Therefore, these
results have been suppressed (***).
2
All respondents include responding 7th graders (when applicable), 9th graders, 11th graders, and a small sample of nontraditional
students (enrolled in continuation or alternative schooling programs).
SOURCE: California Healthy Kids Survey, Los Angeles County Sample, WestEd

Exhibit 12.

Long-Term Trends in the Percentage of Current Substance Users Among a Sample of Los
Angeles County Secondary School Students, by Percent: 1999–2004

Respondents1 Reporting Past 30-Day
Use of…
At Least One Drink of Alcohol
5+ Alcoholic Drinks/Occasion (a.k.a., Binge
Drinking)
Cocaine (any form)

School Year
1999–2000

2000–2001

2001–2002

2002–2003

2003–2004

29.2

28.4

25.4

24.8

24.6

14.4
4.9

13.4
4.3

12.4
3.9

12.4
3.8

12.3
3.8

Inhalants

5.7

5.1

5.0

5.3

5.3

LSD/Other Psychedelics

5.0

4.4

3.3

2.8

2.9

Marijuana

13.2

13.0

12.0

10.9

10.3

Methamphetamine

4.6

4.3

4.1

4.3

3.7

1

All respondents include responding 7th graders (when applicable), 9th graders, 11th graders, and a small sample of nontraditional
students (enrolled in continuation or alternative schooling programs).
SOURCE: California Healthy Kids Survey, Los Angeles County Sample, WestEd
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Exhibit 13. Illicit and Prescription Drug Prices in Los Angeles: July–December 2004
Type of Drug
Cocaine
Powder
Crack Cocaine
Heroin
Mexican Black Tar
Mexican Brown
Powder
Southeast Asian
Southwest Asian
Opium
South American
Marijuana
Mexico-produced
Domestic
Sinsemilla
BC Bud
Hashish
Methamphetamine

Price
Midlevel

Wholesale

Retail

$14,000–$17,000 per kilogram
N/R1

$500–$600 per ounce
$500–$1,200 per ounce

$80 per gram
$10–$40 per rock

$20,000 per kilogram
$25,000 per kilogram

$500–$800 per 25 grams
N/R

$90–$100 per gram
N/R

$70,000–$80,000 per kilogram
$30,000 per kilogram

N/R
N/R

$86,000–$100,000 per kilogram

N/R

N/R
$650–$800 per 18-gram
stick
N/R

$300–$400 per pound
$1,000–$1,200 per pound
$2,500–6,000 per pound
$6,000 per pound
$8,000 per pound
$5,000–$7,000 per pound

$60–$80 per ounce
$200–$250 per ounce
$300–$600 per ounce
N/R
N/R
$500–$800 per ounce

$10 per gram
$25 per gram
$60–$80 per 1/8 ounce
N/R
N/R
$50 per gram
$60–75 per 1/16 ounce
$100–$120 per 1/8 ounce

$8,000–$11,000 per pound
$3,250–$4,000 double case
(1 case=17,000 60-mg
tablets)

$600–$900 per ounce

$100–125 per gram

N/R

N/R

PCP

$15,000–$20,000 per gallon

$300–$350 per ounce

LSD

N/R

Psilocybin Mushrooms

$150–$200 per sheet (100
doses)
N/R

MDMA (ecstasy)

$8,000 per boat (1,000 tablets)

Crystal Methamphetamine
Pseudoephedrine

GHB
GBL
Ketamine
Rohypnol (flunitrazepam)
Steroids
Valium (diazepam)
Vicodin ES (hydrocodone)
OxyContin (oxycodone)
MS Contin
Percocet/Percodan
Dilaudid (hydromorphone)
Methadone
Codeine
Duragesic Patch (fentanyl)
Xanax (alprazolam)

$275–$350 per gallon
$80–$100 per liter
$120 per 16 ounce bottle
$600 per liter
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R

$20–$30 per sherm cigarette
$5–$10 per dose

N/R
$12 per tablet (multiple quantities)

$20 per 1/8 ounce

N/R

$5–$20 per capful

NR
$100–$200 per 10 milliliter vial
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R
N/R
$80–200 per liquid pint
N/R
N/R

N/R
$20 per two-tenths gram
$6–$10 per 1-mg pill
$10 per dose
$1 per 5-mg tablet
$1 per 10-mg tablet
$50–$80 per 80-mg tablet
$20 per 60-mg tablet
$1–$5 per 5-mg tablet
$20–$60 per 4-mg tablet
$10 per tablet
$1–$2.5 per tablet
$25–$100 per patch
$1 per 4-mg tablet

$20–$40 per tablet

1

N/R=Not reported.
SOURCE: National Drug Intelligence Center and LA County Regional Criminal Information Clearinghouse
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Exhibit 14.

Number of ED Reports, by Drug Category and Case Type (Selected Drugs) in the Los
Angeles County Division (Unweighted1): January–December 2004
Selected Drug Categories, by Case Type
Antidepressants
Seeking detoxification
Overmedication
Other
Antipsychotics
Seeking detoxification
Overmedication
Other
Benzodiazepines
Seeking detoxification
Overmedication
Other
Barbiturates
Seeking detoxification
Overmedication
Other
Opiates/Opioids
Seeking detoxification
Overmedication
Other
Muscle Relaxants
Seeking detoxification
Overmedication
Other
Total of Other Substances

Number of ED Reports1
249
2
181
66
249
0
204
45
450
25
251
174
51
2
6
43
387
35
134
218
81
3
72
6
2,255

1
The unweighted data are from 9 to 14 EDs reporting to Los Angeles area hospitals. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14/05
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Exhibit 15.

Annual Adult/Adolescent AIDS Cases by Gender, Year of Diagnosis, and Exposure Category:
1998–2004

Adult/Adolescent
Exposure Category1
Male-to-Male Sexual
Contact
Injection Drug Use
Male-to-Male Sexual
Contact/Injection Drug Use
Hemophilia or Coagulation
Disorder
Heterosexual Contact
Transfusion Recipient
Mother with/at Risk for HIV
Other/Undetermined
Male Subtotal
Injection Drug Use
Hemophilia or Coagulation
Disorder
Heterosexual Contact
Transfusion Recipient
Mother with/at Risk for HIV
Other/Undetermined
Female Subtotal
Total

1998
Number
(%)

1999
Number
(%)

1,117
(65)
102
(6)
115
(7)
<5
(-)
61
(4)
5
(<1)
<5
(-)
304
(18)
1,706

1,039
(66)
76
(5)
97
(6)
<5
(-)
57
(4)
<5
(-)
<5
(-)
300
(19)
1,573

47
(22)
<5
(-)
99
(46)
<5
(-)
<5
(-)
64
(30)
215
1,921

42
(20)
<5
(-)
101
(47)
<5
(-)
<5
(-)
67
(31)
214
1,787

2000
Number
(%)
Males
943
(64)
92
(6)
110
(7)
<5
(-)
53
(4)
<5
(-)
<5
(-)
273
(18)
1,481
Females
39
(17)
<5
(-)
103
(46)
<5
(-)
<5
(-)
82
(36)
226
1,707

2001
Number
(%)

2002
Number
(%)

20032
Number
(%)

20042
Number
(%)

914
(64)
92
(6)
100
(7)
5
(<1)
72
(5)
5
(<1)
<5
(-)
249
(17)
1,437

1,001
(65)
83
(5)
101
(7)
<5
(-)
60
(4)
6
(<1)
<5
(-)
291
(19)
1,543

871
(68)
56
(4)
81
(6)
<5
(-)
56
(4)
<5
(-)
<5
(-)
221
(17)
1,290

451
(61)
41
(6)
22
(3)
<5
(-)
18
(2)
<5
(-)
<5
(-)
206
(28)
738

42
(19)
<5
(-)
85
(37)
7
(3)
<5
(-)
92
(41)
227
1,664

43
(19)
<5
(-)
79
(36)
8
(4)
<5
(-)
90
(41)
221
1,764

22
(13)
<5
(-)
71
(41)
<5
(-)
<5
(-)
79
(46)
173
1,463

14
(13)
<5
(-)
35
(34)
<5
(-)
<5
(-)
51
(49)
104
842

1

Exposure categories are ordered hierarchically. Cases with multiple exposure categories are included in the category listed first.
Data are provisional due to reporting delay.
SOURCE: Los Angeles County Department of Health Services, HIV Epidemiology Program
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Drug Abuse in South Florida:
January–December 2004

tioned throughout this report. Exhibits for the report
follow the narrative text.

James N. Hall1 and Madeline Camejo,
Pharm.D.2

Located in the extreme southern portion of the Florida
peninsula, Miami-Dade County has a population of
nearly 2.6 million; 56 percent are Hispanic, 21 percent
are Black, 21 percent are White, and 2 percent are
Asian/Pacific Islander. Miami is Dade County’s largest
city, with 360,000 residents. More than 100,000 immigrants arrive in Florida each year; one-half establish
residency in Miami-Dade County.

Area Description

ABSTRACT
Cocaine continues to dominate the consequences of
drug abuse across South Florida as the epidemic
enters its fourth decade. Its steady flow into the region fuels consequences with widely available,
cheap cocaine. The majority of morbidity and mortality cocaine indicators are among those older than
35. Cocaine’s prevalence among selected populations is linked to poly-substance abuse patterns that
are reflected in rising consequences of intentional
medication abuse and the introduction of methamphetamine. Miami was ranked second to Jacksonville in the number of cocaine-related deaths in
2004. Broward and Palm Beach Counties led the
State in the number of heroin deaths in 2004. Overall, however, heroin deaths are down statewide, as
narcotic analgesic fatalities are steadily increasing.
Methadone-related deaths rose 40 percent between
2003 and 2004 statewide, as deaths caused by
methadone increased 51 percent. Problems linked to
the club drugs, GHB and MDMA, continue the decline observed since 2001. Five vectors of methamphetamine trafficking are spreading its abuse to
new populations. Benzodiazepine deaths are second
only to alcohol deaths in the State. Medication
abuse appears to be a significantly greater problem
in Broward County than in Miami-Dade.
INTRODUCTION
This report addresses drug abuse in Miami-Dade and
Broward Counties, Florida, during 2004. It includes
data on drug-related deaths, medical emergencies,
addiction treatment admissions, and law enforcement
intelligence. Information is presented by primary
substance of abuse, with topics including cocaine,
heroin, other opiates, marijuana, gamma hydroxybutyrate (GHB), methylendioxymethamphetamine
(MDMA or “ecstasy”), methamphetamine, and benzodiazepines. While the information is classified by a
single drug or category, the reader should note an
underlying problem of polysubstance abuse as men1

Mr. Hall is the director of the Center for the Study and Prevention
of Substance Abuse at Nova Southeastern University and is executive director of Up Front Drug Information Center in Miami, Florida.
2
Dr. Camejo is affiliated with the Memorial Regional Hospital,
Hollywood, Florida, and the United Way of Broward County Commission on Substance Abuse, Ft. Lauderdale, Florida.
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Broward County, situated due north of Miami-Dade, is
composed of Ft. Lauderdale plus 28 other municipalities and an unincorporated area. The county covers
1,197 square miles, including 25 miles of coastline.
According to the 2000 census, the population was
1,649,925. The population is roughly 63 percent White
non-Hispanic, 21 percent Black non-Hispanic, and 17
percent Hispanic.
Broward County is the second most populated county
in Florida and accounts for approximately 10 percent of
Florida’s population. Broward was the top growth
county in Florida in the 1990s and added 367,000 more
people during that decade. Palm Beach County (population 1,154,464) is located due north of Broward
County and is the third most populated county in the
State. Together, the 5.4 million people of these 3 counties constitute one-third of the State’s 16.3 million
population.
Starting in 2003, these three counties constitute the new
federally designated Metropolitan Statistical Area
(MSA) for South Florida, making it the sixth largest in
the Nation. Previously, the MSA included only MiamiDade County. This means that Broward County will
now be included in more national data sets tracking
health-related conditions and criminal justice information. One change is that more local hospitals will become a part of the national Drug Abuse Warning Network (DAWN) that monitors emergency department
(ED) reports of drug-related episodes.
Approximately 25 million tourists visit South Florida
annually. The region is a hub of international transportation and the gateway to commerce between the
Americas, accounting for sizable proportions of the
Nation’s trade: 40 percent with Central America, 37
percent with the Caribbean region, and 17 percent with
South America. South Florida’s airports and seaports
remain among the busiest in the Nation for both cargo
and international passenger traffic. These ports of entry
make this region a major gateway for illicit drugs.
Smuggling by cruise ship passengers is an important
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trend in South Florida drug trafficking and has apparently been growing because of airline security increases
after September 11, 2001.

by participating EDs varied by month (see exhibit 1). Exhibits in this paper for Miami-Dade
County reflect cases that were received by
DAWN as of April 13–14, 2005. Eligible hospitals in the Ft. Lauderdale Division only (that includes Broward and Palm Beach Counties) totaled 27; there were 22 hospitals in the DAWN
sample, and the number of emergency departments in the sample also totaled 22. During this
12-month period, 4 to 7 EDs reported data each
month. The completeness of data reported by
participating EDs varied by month (see exhibit
2). Exhibits in this paper for Broward and Palm
Beach Counties reflect cases that were received
by DAWN as of the dates described below. Data
from the two Broward County EDs for the first
half of 2004 were accessed by the CEWG representative directly on December 7, 2004, from the
two participating hospitals, since at least four EDs
in an area must report before the data are accessible through DAWN Live!. Data for the second
half of 2004 for the Ft. Lauderdale Division were
accessed from DAWN Live! on April 22, 2005,
for cocaine, heroin, marijuana, and MDMA (ecstasy). Data for the second half of 2004 for the Ft.
Lauderdale Division were accessed from DAWN
Live! for oxycodone, hydrocodone, and benzodiazepines on May 10, 2005. Data for the second
half of 2004 for the Ft. Lauderdale Division were
accessed from DAWN Live! for amphetamine,
methamphetamine, GHB, lysergic acid diethylamide (LSD), and phencyclidine (PCP) on June 10,
2005. All DAWN cases are reviewed for quality
control. Based on this review, cases may be corrected or deleted. Therefore, the data presented
in this paper are subject to change. Data derived
from DAWN Live! represent drug reports in
drug-related ED visits. Drug reports exceed the
number of ED visits, since a patient may report
use of multiple drugs (up to six drugs and alcohol). The DAWN Live! data are unweighted and,
thus, are not estimates for the reporting area.
These data cannot be compared to DAWN data
from 2002 and before, nor can preliminary data
be used for comparison with future data. Only
weighted DAWN data released by SAMHSA can
be used for trend analysis. A full description of
the DAWN system can be found at DAWN Web
site http://dawninfo.samhsa.gov/.

Several factors impact the potential for drug abuse
problems in South Florida, including the following:
•

Proximity to the Caribbean and Latin America
exposes South Florida to the entry and distribution of illicit foreign drugs destined for all regions of the United States. Haiti remains a link
with Colombian traffickers.

•

South Florida is a designated High Intensity Drug
Trafficking Area and one of the Nation’s leading
cocaine importation centers. It also became a
gateway for Colombian heroin in the 1990s. Millions of MDMA (“ecstasy,” or “XTC”) tablets
originate in the Benelux countries and often—
more recently—are flown to the Caribbean before
entering the United States in South Florida.

•

Extensive coastline and numerous private air and
sea vessels make it difficult to pinpoint drug importation routes into Florida and throughout the
Caribbean region.

•

Lack of a prescription monitoring system in
Florida now makes the State a source for diverted medications throughout the southeastern
United States.

Data Sources
This report describes current drug abuse trends in
South Florida, using the data sources summarized
below:
•

Drug-related mortality data were provided by
the Florida Department of Law Enforcement
(FDLE), Medical Examiners Commission’s 2004
Report of Drugs Identified in Deceased Persons
by the Florida Medical Examiners’ Commission.

•

Emergency department data were derived for
calendar year 2004 from the DAWN Live! restricted-access online query system administered
by the Office of Applied Studies (OAS), Substance Abuse and Mental Health Services Administration (SAMHSA). Eligible hospitals in
only the Miami-Dade County Division totaled
21; hospitals in the DAWN sample numbered 17,
with the number of emergency departments in
the sample also totaling 17. (Some hospitals have
more than one emergency department.) During
this 12-month period, 8 to 10 EDs reported data
each month. The completeness of data reported

•

Drug treatment data for 2004 were provided by
the Broward Addiction Recovery Centers
(BARC) of the Broward County Department of
Human Services.

•

Crime lab drug analyses data were derived
from the Drug Enforcement Administration’s
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(DEA) National Forensic Laboratory Information
System (NFLIS) 2004 Annual Report for MiamiDade County (January 2004 through December
2004) and by the Broward Sheriff’s Office
(BSO) Crime Lab for 2004 in Broward County.
•

Drug pricing data for South Florida were derived from the National Drug Intelligence Center
(NDIC), Narcotics Digest Weekly, December 28,
2004.

•

Heroin price and purity information is from
the U.S. DEA Domestic Monitoring Program
2003 Report.

•

Survey data on prevalence of drug use among
middle and high school students are from the
2004 Florida Youth Substance Abuse Survey.

Other information on drug use patterns was derived
from ethnographic research and callers to local drug
information hotlines.
DRUG ABUSE PATTERNS AND TRENDS
Beginning in 2003, SAMHSA’s national DAWN
Live! increased the number of hospitals reporting to
the national system and enhanced the surveillance of
drug-related hospital ED mentions to provide expanded and more rapid local reporting on such activity. In South Florida, DAWN is growing, with new
emergency departments for the system in Broward
and Palm Beach Counties to complete coverage for
the region’s newly expanded national MSA. The new
area is named the Miami/Ft. Lauderdale MSA.
DAWN will also expand to the Tampa/St. Petersburg
MSA in Florida, as well.
Cocaine/Crack
Now entering its fourth decade, South Florida’s cocaine epidemic is characterized by morbidity and
mortality rates that rank among the highest in the
Nation. The steady flow of cocaine into the region
fuels the epidemic with widely available cheap cocaine. Cocaine abuse indicators dominate consequences of drug abuse at high, yet stable rates. The
majority of cocaine deaths, medical emergencies, and
addiction treatment reports are among those older
than 35. Many of the indicators reflect cocaine use in
combination with other drugs, including opiates and
benzodiazepines.
Throughout Florida, the number of cocaine-related
deaths increased in 2004, continuing a rising trend
since 2000. There were 1,702 cocaine-related fatalities during 2004 across Florida (exhibit 3), a 5-
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percent increase from the 1,614 deaths in 2003. Cocaine-related deaths in 2004 were at their highest
peak statewide since the drug has been tracked in the
late 1980s. Among the 2004 cases, 75 percent involved the use of another drug, thus reflecting prevalent polydrug abuse patterns with cocaine. A large
proportion of cocaine ED episodes also involved at
least one other substance.
In Florida, a drug is considered to be the cause of
death if it can be detected in an amount considered to
be a lethal dose by the local medical examiner (ME).
Statewide, the number of lethal cocaine-induced death
cases increased 9 percent from 541 in 2003 to 591 in
2004.
There were 160 deaths related to cocaine abuse in
Miami-Dade County during 2004 (exhibit 4), representing a 15-percent decrease over the total from
2003. Cocaine was detected at a lethal level in 35
percent of the 2004 cases, up from 25 percent of the
2003 cases and 21 percent of the 2002 cocaine-related
deaths. Cocaine was found in combination with another drug in 62 percent of the 2004 cases. Three of
the 2004 cocaine-related fatalities were younger than
18; 16 percent were age 18–25, 17 percent were 26–
34, 40 percent were 35–50, and 26 percent were older
than 50. Cocaine-related deaths in Miami-Dade
County totaled 189 in 2003, 151 in 2002, 149 in
2001, 144 in 2000, 226 in 1999, and 273 in 1998.
There were 120 deaths related to cocaine abuse in
Broward County during 2004 (exhibit 5), representing a 13-percent decrease over the 138 cases from
2003. Cocaine was detected at a lethal level in 37
percent of the 2004 cases in Broward County, a proportion that is down from 45 percent of 2003 cases and
53 percent of the 2002 cases. Cocaine was found in
combination with another drug in 85 percent of the
2004 cases. None of the 2004 cocaine-related fatalities was younger than 18; 12.5 percent were age 18–
25, 12.5 percent were 26–34, 50 percent were 35–50,
and 25 percent were older than 50. Cocaine-related
deaths in Broward County totaled 138 in 2003, 121 in
2002, 94 in 2001, 80 in 2000, and a record high 139
in 1999.
The Jacksonville area had the highest number of cocaine-related deaths in the State during 2004, with 205
cases, followed by Miami with 160, West Palm Beach
with 151, St. Petersburg with 150, Orlando with 136,
and Broward County with 120. Jacksonville reported
the highest number of cocaine deaths with 74, followed by Palm Beach County with 68.
Unweighted data on ED cocaine reports in MiamiDade County were accessed from DAWN Live! for
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2004. Cocaine was the most commonly involved illicit drug in local emergency department visits, accounting for 59 percent of the 9,225 Miami-Dade
major substances of abuse reports (not including alcohol-in-combination with another drug, any alcohol
below the age of 21, and medications) in 2004 (exhibit 6).
Most (71 percent) of the 5,420 Miami-Dade cocaineinvolved ED patients were male. Non-Hispanic
Blacks accounted for 46 percent of the cocaine patients; 30 percent were non-Hispanic Whites; and 17
percent were Hispanics. Race/ethnicity was not
documented or unknown for 6 percent of the patients.
Cocaine-involved ED patients were age 35 or older in
61 percent of the reports, which continues a pattern
of older cocaine ED patients. The patients’ ages were
as follows: less than 1 percent (25) were age 12–17,
12 percent were 18–24, 26 percent were 25–34, 37
percent were age 35-44, and 24 percent were 45 or
older.
Broward County drug-related ED episodes are based
on a record review of two Broward County hospitals
participating in DAWN during the first 6 months of
2004 and from 4 to 6 hospitals through DAWN Live!
in the second half of the year. The network is expanding, and data from more hospitals will be included in
future reports. Cocaine was clearly the most commonly reported illicit drug in local emergency department visits, accounting for 58 percent of the
3,383 Broward major substances of abuse reports
(not including alcohol-in-combination with another
drug, any alcohol below the age of 21, and medications) in 2004 (exhibit 7).
Most (69 percent) of the 1,953 Broward cocaine ED
patients were male. Fifty-seven percent were nonHispanic Whites, 32 percent were non-Hispanic
Blacks, and 10 percent were Hispanic/other. Cocaineinvolved ED patients were age 35 or older in 48 percent of these cases. The patients’ ages were as follows: 1 percent were in their teens, 15 percent were
age 18–24, and 37 percent were 25–34.
Cocaine accounted for 2,924 (or 41 percent) of primary, secondary, and tertiary treatment drug mentions (excluding alcohol) among the 3,609 BARC
patients who cited as least 1 drug of abuse at time of
admission during 2004. Of the cocaine mentions, 51
percent were as the primary drug of abuse, 39 percent
were as secondary drug, and 9 percent were as the
tertiary drug problem. One-half of the cocaine treatment mentions were from White, non-Hispanic clients, 37 percent were from Black, non-Hispanic patients, and 13 were from Hispanics. BARC client data
are for clients age 18 and older. Those age 18–24

accounted for 7 percent of the cocaine treatment
mentions; 20 percent were age 25–34 years; and 73
percent were older than 34. If alcohol clients were
included, the number of total patients citing at least 1
substance of abuse rises to 6,114, of whom 37 percent cited alcohol as a primary, secondary, or tertiary
problem. The inclusion of alcohol lowers the proportion of cocaine mentions to 26 percent of all BARC
mentions including alcohol.
Powder cocaine and crack are still described as
“widely available” throughout Florida. Cocaine is
still the most commonly analyzed substance by the
Miami-Dade and Broward Sheriff’s Office crime
labs. It accounted for 10,972 cases (or 69 percent of
all items tested) in Miami-Dade for 2004 and for
5,458 cases or 68 percent of all items analyzed in
Broward County in 2004. The second most commonly analyzed substance was marijuana in both
counties.
According to the National Drug Intelligence Center,
in South Florida powder cocaine sells for $18,000–
$26,000 per kilogram wholesale, $700–$800 per
ounce, and $40–$110 per gram retail. Crack cocaine
sells for $700–$800 per ounce, $100 per gram, and
$10–$20 per “rock” in South Florida.
In 2004, current (past-30-day) cocaine use was reported in results of the Florida Youth Substance
Abuse Survey by 0.9 percent of Broward County
middle and high school students (down from 1.4 percent in 2000) (exhibit 8a). Current crack cocaine use
was reported by 0.6 percent of Broward students in
2004 (down from 0.9 percent in 2000). Among Miami-Dade County middle and high school students,
1.2 percent reported current cocaine use in 2004
(down from 1.5 percent in 2000). Current crack cocaine use was reported by 0.6 percent of Miami-Dade
students in 2004 (down from 0.8 percent in 2000).
Current cocaine use was reported by 1.6 percent of
Palm Beach County middle and high school students
in 2004 (up from 0.9 percent in 2000 and 2002). Current crack cocaine use was reported by 0.6 percent of
Palm Beach students in 2004 (up from 0.4 percent in
2000 and 0.3 in 2002). The proportion for the middle
and high school students in all of Florida reporting
current cocaine use was 1.5 percent in 2004, and 0.6
percent reported crack use.
Heroin
The wholesale and retail prices of heroin have declined locally recently, as the area has experienced a
diversification of opioid abuse to include oxycodone,
methadone, hydrocodone, heroin, and other opioids.
Frequently, benzodiazepines are involved as well.

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

135

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Miami-Ft. Lauderdale, Florida

Most deaths, ED visits, and addiction treatment admissions continue to be among older, White males.
South American heroin has been entering the area
over the past decade. Abuse of narcotic pain medication has fueled opioid consequences. Polydrug abuse
patterns have facilitated first-time use of opiate
drugs, including heroin.
Throughout Florida, there were 180 heroin-related
deaths in 2004, representing a 31-percent decline from
261 such deaths in 2003; heroin-related deaths totaled
326 in 2002 and 328 in 2001. Yet, heroin was found to
be the most lethal drug, with 83 percent (n=150) of
heroin-related deaths being caused by the drug in
2004, a 35-perent decline from 2003. Heroin deaths
continued a 4-year decline, but deaths from prescription narcotic opiates have increased over the same
period. Polysubstance abuse was noted in 83 percent
of the heroin-related deaths statewide (exhibit 3).
In 2004, Broward County (n=35) and Palm Beach
County (n=29) had the greatest number of heroinrelated deaths in the State. They were followed by
Orlando (22 cases), Miami-Dade County (18), Sarasota (15), and Tampa and St. Petersburg (each with
14 cases).
In Miami-Dade County, heroin was found at a lethal
dose level in all of the 18 deaths in which heroin was
detected. Other drugs were detected in 14 (78 percent) of the cases (exhibit 4). None of the heroinrelated fatalities was younger than 26; 33 percent
were age 26–34, 56 percent were 35–50, and 11 percent were older than 50.
The 18 heroin-related deaths in Miami-Dade during
2004 reflected a 44-percent decrease over the 32 in
2003. Heroin deaths peaked in Miami-Dade County in
2000 with 61 fatalities.
In Broward County, the 35 deaths in which heroin
was detected included 22 cases (63 percent) in which
the drug was found at a lethal dose level. Other drugs
were detected in 33 (94 percent) of the cases (exhibit
5). None of the heroin-related fatalities was younger
than 18; 11 percent were age 18–25, 20 percent were
26–34, 49 percent were 35–50, and 20 percent were
older than 50.
The 35 heroin-related deaths during 2004 in Broward
County reflected a 29-percent decrease over the 49 in
2003. There were 50 heroin-related deaths in 2002
and 41 in 2001. The relatively low number of 24 heroin-related deaths in 2000 was attributed to a sharp
rise in other opioid deaths linked to prescription narcotics. Heroin-related deaths rose from 9 in 1995 to
49 in 2003.
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Based on unweighted data accessed from DAWN
Live! from Miami-Dade County emergency departments during 2004, there were a total of 1,387 heroin
reports, representing 15 percent of major substances
of abuse reports (not including alcohol-incombination with another drug, any alcohol below
the age of 21, and medications) (exhibit 6). Males
accounted for 79 percent of these patients, and 47
percent were non-Hispanic Whites. Blacks represented 22 percent of the heroin ED patients, and Hispanics accounted for 21 percent of the patients. There
were two patients younger than 5 and three age 12–
17, while 12 percent were age 18–24, 37 percent
were 25–34, and 51 percent were older than 34.
Unweighted data for 2004 from the Broward emergency departments identified a total of 399 heroin
reports, representing 12 percent of major substances
of abuse reports (not including alcohol-incombination with another drug, any alcohol below
the age of 21, and medications) (exhibit 7). The heroin ED patients were predominantly older White
males seeking detoxification. Males accounted for 66
percent of the patients, and 77 percent were nonHispanic Whites. Hispanics accounted for 12 percent
of the heroin ED patients, and Blacks also represented 12 percent of the patients. There were no patients younger than 18, while 12 percent were age
18–24, 33 percent were age 25–34, and 54 percent
were older than 34. The most common reason for a
heroin patient to visit the ED was dependence and
withdrawal or seeking detoxification in 64 percent of
the cases.
Heroin accounted for 956 (or 13 percent) of primary,
secondary, and tertiary treatment drug mentions (excluding alcohol) among the 3,609 BARC patients
who cited as least 1 drug of abuse at time of admission during 2004. Of the heroin mentions, 80 percent
were as the primary drug of abuse, 12 percent were as
secondary drug, and 7 percent were as the tertiary
drug problem. Two-thirds (66 percent) of the heroin
treatment mentions were from White, non-Hispanic
clients, 23 percent were from Hispanics, and 11 percent were from Black, non-Hispanic patients. BARC
client data are for clients age 18 and older. Those age
18–24 accounted for 9 percent of the heroin treatment
mentions; 30 percent were age 25–34, and 61 percent
were older than 34.
Heroin accounted for 658 crime lab cases in MiamiDade for 2004 according to the NFLIS, representing
4 percent of all drugs tested. There were 153 heroin
cases worked by the Broward Sheriff’s Office Crime
Lab in 2004, a 40-percent decrease from the 254 heroin cases in 2003. The U.S. DEA Domestic Monitoring Program analyzed 40 street-level samples of her-
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oin in South Florida in 2003. All of the samples were
South American heroin, and they averaged 25.8 percent pure heroin. The average price per milligram
pure was $0.90. Compared with 2002 purities, the
average purity of samples declined modestly, while
the price per milligram pure rose by 50 percent
($0.29) and thus returned to levels recorded in 2001.
Nationally, there were 470 South American heroin
samples tested by the program in 2003. The average
purity was 41.8 percent heroin, and the average price
was $0.77 per milligram pure.

tracked, including heroin, totaled 279 in Broward
County and 140 in Miami-Dade in 2004.

Colombian heroin is widely available in South Florida as described by law enforcement officials and
epidemiologists/ethnographers. According to NDIC,
1 kilogram of heroin sells for $45,000–$65,000 in the
region and for $2,500 per ounce; retail prices are
roughly $100–$150 per gram. The top price for heroin has dropped 19 percent at the kilogram level and
25 percent at the gram level in the past 12 months.
The most common street unit of heroin is a bag of
heroin (roughly 20 percent purity) weighing about
one-tenth of a gram that sells for $10.

The number of oxycodone-related deaths increased 7
percent statewide between 2003 and 2004, when they
totaled 674. Oxycodone was the cause of death in 50
percent of the deaths related to it in 2004, causing a
14-percent increase in oxycodone-induced deaths
compared to 2003.

In 2004, current (past-30-day) heroin use was reported in results of the Florida Youth Substance
Abuse Survey by 0.3 percent of Broward County
middle and high school students, down from 0.5 percent in 2000 and equal to the proportion in 2002.
Among Miami-Dade County middle and high school
students, 0.6 percent reported current heroin use in
2004, up from 0.5 percent in 2000 and 0.3 percent in
2002. Current heroin use was also reported by 0.6
percent of Palm Beach County middle and high
school students, in 2004, up from 0.5 percent in 2000
and 0.3 percent in 2002. The proportion for the middle and high school students in all of Florida reporting current heroin use was 0.3 percent in 2004.

Methadone-related deaths statewide increased significantly in 2004, rising by 40 percent when compared to 2003, and deaths caused by methadone rose
51 percent over the same period. This continues a
steady increase of methadone-related deaths since
2001. Methadone was considered the cause of death
in 66 percent of the 849 deaths related to the drug in
2004.

The number of hydrocodone deaths increased 10 percent statewide between 2003 and 2004, when they
reached 572. Hydrocodone was the cause of death in
36 percent of the hydrocodone-related deaths during
2004, representing a 27-percent increase in hydrocodone-induced deaths compared to 2003.

Other Opiates

Additional opiate-related analgesic deaths statewide in
2004 included morphine (597), propoxyphene (347),
fentanyl (182), hydromorphone (98), meperidine (42),
and other opioids (194). When the ME mentions for all
opiate analgesics are added to those for heroin, these
opioid-related ME mentions in Florida during 2004
total 3,915 cases. This total is even greater than the
3,575 alcohol-related deaths during the same year.
Most of the statewide opioid cases were polydrug episodes, including 88 percent of the oxycodone ME
cases, 87 percent of the methadone ME cases, 87 percent of the hydrocodone ME cases, 83 percent of the
heroin deaths, 78 percent of propoxyphene deaths, and
74 percent of morphine ME cases (exhibit 3).

Following inhalants, the group of drugs mostly likely
to be cited across Florida at lethal levels as the cause
of death in cases where the drug was detected was
opiates. As mentioned above, in 2004 heroin was
considered the cause of death in 83 percent of the
cases where it was detected, followed by 66 percent
of the methadone deaths, 63 percent of fentanyl
cases, and 50 percent of oxycodone deaths. Deaths
from opiates other than heroin (including hydrocodone, oxycodone, and methadone) have been
tracked in Florida since 2000. Beginning in 2003,
morphine, propoxyphene, fentanyl, hydromorphone,
meperidine, and other opioids were included in the
Florida Medical Examiners Commission’s surveillance monitoring program. Deaths for all opiates

Miami-Dade County recorded 30 oxycodone-related
deaths during 2004, of which 11 (37 percent) were
oxycodone induced. Fourteen of these deaths (88 percent) involved oxycodone found in combination with
at least one other drug (exhibit 4). Miami-Dade
County recorded 19 hydrocodone-related deaths during 2004, and 5 (26 percent) were hydrocodone induced. Miami-Dade County recorded 17 methadonerelated deaths in 2004, with 7 (41 percent) considered
methadone induced. Miami-Dade recorded 41 morphine-related deaths during 2004, of which 8 (20 percent) were morphine induced. There were 15 propoxyphene-related deaths in Miami-Dade County in
2004, of which 4 (27 percent) were propoxyphene
induced.
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Broward County recorded 71 oxycodone-related
deaths during 2004, of which 48 (68 percent) were
oxycodone induced. All but two of these deaths involved oxycodone found in combination with at least
one other drug (exhibit 5). Broward County recorded
38 hydrocodone-related deaths in 2004, and 18 (47
percent) were hydrocodone induced. Broward County
recorded 73 methadone-related deaths during 2004,
with 45 (62 percent) considered methadone induced.
Broward County recorded 44 morphine-related deaths
during 2004, of which 12 (27 percent) were morphine
induced. Broward County recorded 18 propoxyphenerelated deaths in 2004, of which 4 (22 percent) were
propoxyphene induced.
Unweighted data accessed from DAWN Live! for
Miami-Dade County EDs for 2004 show 158 oxycodone ED reports. There were also 45 hydrocodone
ED reports and 215 ED reports for other narcotic
analgesics. Of the total 418 narcotic analgesic ED
reports, 40 percent of the patients were seeking detoxification, 17 percent were considered overmedication cases, and 44 percent were considered drug
abuse cases.
Unweighted data from the Broward County EDs for
2004 show 329 oxycodone ED reports. Males accounted for 58 percent of these patients. White, nonHispanics represented 74 percent of the patients; 14
percent were Black, non-Hispanics; and 12 percent
were Hispanic/other. There were no patients younger
than 18, while 24 percent of the oxycodone ED patients were age 18–24, 29 percent were 25–34, and 46
percent were older than 34. The most common reasons or chief complaints for the oxycodone ED patients to visit the ED were seeking detoxification (35
percent) and overdose (14 percent).
Unweighted data from the Broward County EDs for
2004 show 151 hydrocodone ED reports. Males accounted for 51 percent of these patients. White, nonHispanics represented 62 percent of the patients; 14
percent were Black, non-Hispanics; and 24 percent
were Hispanic/other. There were no patients younger
than 18, while 21 percent of the hydrocodone ED
patients were age 18–24, 35 percent were 25–34, and
44 percent were older than 34. The most common
reasons or chief complaints for the hydrocodone ED
patients to visit the ED were overdose (27 percent)
and seeking detoxification (24 percent), while 21
percent had adverse reactions.
Prescription opiates accounted for 714 (or 10 percent)
of primary, secondary, and tertiary treatment drug
mentions (excluding alcohol) among the 3,609
BARC patients who cited as least 1 drug of abuse at
time of admission during 2004. Of the prescription
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opiate mentions, 67 percent were as the primary drug
of abuse, 14 percent were as secondary drug, and 18
percent were as the tertiary drug problem.
The NFLIS reported 59 oxycodone crime lab cases,
26 hydrocodone cases, and 9 methadone cases in
2004 in Miami-Dade County. The Broward Sheriff’s
Office Crime Lab worked 250 oxycodone cases in
2004. There were also 173 hydrocodone cases, 15
hydromorphone cases, and 2 buprenorphine cases in
2004.
In 2004, current (past-30-day) use of oxycodone was
reported in results of the Florida Youth Substance
Abuse Survey by 0.4 percent of Miami-Dade County
middle and high school students, up from 0.2 percent
in 2002. Among Miami-Dade County middle and
high school students, 1.7 percent reported use of
other prescription pain medications in 2004 (exhibit
8a), up from 1.4 percent in 2002. Current (past-30day) use of oxycodone was reported in results of the
2004 Florida Youth Substance Abuse Survey by 0.3
percent of Broward County middle and high school
students, down from 0.6 percent in 2002. Among
Broward middle and high school students, 1.8 percent
reported use of other prescription pain medications in
2004, just above the 1.7 percent reported in 2002. In
Palm Beach County, current (past-30-day) use of
oxycodone was reported by 0.9 percent of middle and
high school students, up from 0.7 percent in 2002.
Among Palm Beach County middle and high school
students, 2.3 percent reported use of other prescription pain medications in 2004, down from 3.5 percent
in 2002. The proportion for the middle and high
school students in all of Florida reporting current
oxycodone use was 0.8 percent in 2004, and 3 percent reported current use of other prescription pain
medication.
Marijuana
Marijuana is abused by more Americans, particularly
youth, than any other illicit drug. Consequences of its
abuse and addiction continue, even as rates of its use
are declining among youth.
Cannabinoids were detected in 871 deaths statewide
in Florida during 2004, representing an increase of 21
percent from the 722 such cases during the year.
Unweighted data from DAWN Live! for 2004 show
that marijuana accounted for 2,098, or 23 percent, of
the 9,225 Miami-Dade major substances of abuse
reports (not including alcohol-in-combination with
another drug, any alcohol below the age of 21, and
medications) in 2004 (exhibit 6). Seventy-six percent
of the marijuana ED patients were male. Non-
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Hispanic Blacks accounted for 44 percent of these
patients; non-Hispanic Whites accounted for 29 percent; and Hispanic/others accounted for 21 percent.
Race/ethnicity was not documented or was unknown
for 6 percent of the patients. There were 79 patients
(4 percent) younger than 18, while 29 percent of the
patients were age 18–24, 30 percent were 25–34, and
36 percent were older than 34.
Unweighted ED data from Broward County show
that marijuana was involved in 25 percent, or 849, of
the 3,383 drug abuse ED reports (not including alcohol-in-combination with another drug, any alcohol
below the age of 21, and medications) in 2004 (exhibit 7). Sixty-eight percent of the marijuana ED patients were male. Non-Hispanic Whites accounted for
61 percent of these patients, non-Hispanic Blacks for
25 percent, and Hispanics/other for 13 percent. Marijuana is still the most commonly abused illicit drug
among young people visiting the emergency department. Two-thirds of marijuana ED reports were
among the 12–34 age group. There were 68 patients
(8 percent) younger than 18, while 27 percent of patients were age 18–24, 32 percent were 25–34, and 33
percent were older than 34.
Marijuana accounted for 1,949 (or 27 percent) of
primary, secondary, and tertiary treatment drug mentions (excluding alcohol) among the 3,609 BARC
patients who cited as least 1 drug of abuse at time of
admission during 2004. Of the marijuana mentions,
37 percent were as the primary drug of abuse, 34
percent were as secondary drug, and 29 percent were
as the tertiary drug problem. One-half (49 percent) of
the marijuana treatment mentions were from White,
non-Hispanic clients, 37 percent were from Black,
non-Hispanic patients, and 14 percent were from
Hispanics. BARC client data are for clients age 18
and older. Those age 18–24 accounted for 20 percent
of the marijuana treatment mentions; 32 percent were
age 25–34; and 48 percent were older than 34.
The NFLIS reported 3,250 marijuana crime lab cases
in Miami-Dade County in 2004, representing 20 percent of all exhibits analyzed. There were 979 marijuana cases worked by the BSO Crime Lab during
2004 (12 percent of all cases). Statewide, marijuana
was seized more frequently than any other illicit drug
in Florida. Marijuana is still described as widely
available throughout Florida, with local commercial,
sinsemilla, and hydroponic grades available. A pound
of commercial grade marijuana sells for $450–$1,000
per pound. Hydroponic grades sell for $2,500–$4,000
per pound. Commerical grade prices range from $100
to $150 per ounce, while hydroponic grade marijuana
sells for $350–$450 per ounce. Depending on its potency, marijuana may sell for $5–$18 per gram.

In 2004, current (past-30-day) marijuana use was
reported in results of the Florida Youth Substance
Abuse Survey by 10.2 percent of Broward County
middle and high school students (exhibit 8b), up
slightly from 10.0 percent in 2002 but down from
11.5 percent in 2000. Among Miami-Dade County
middle and high school students, 8.6 percent reported
current marijuana use in 2004, up from 6.5 percent in
2002. In 2000, 8.9 percent of Miami-Dade middle
and high school students reported current marijuana
use. Current marijuana use was also reported by 11.4
percent of Palm Beach County middle and high
school students in 2004, down from 13.5 percent in
2000 and 14.1 percent in 2002. The proportion for the
middle and high school students in all of Florida reporting current marijuana use was 11.5 percent in
2004.
Gamma Hydroxybutyrate
GHB, an anesthetic, has been a commonly abused
substance in South Florida for the past 8 years. There
are several compounds that are converted by the body
to GHB, including gamma butyrolactone (GBL) and
1,4 butanediol (1,4 BD). Most recently, GHB abuse
involves the abuse of 1,4 BD. Indicators of abuse of
these drugs continue to decline. Commonly used with
alcohol, they have been implicated in drug-facilitated
rapes and other crimes. They have a short duration of
action and are not easily detectable on routine hospital toxicology screens. GHB was declared a federally
controlled Schedule I drug in March 2000, and indicators of its abuse have declined since that time.
More recently, GHB and its related substances are
reported to be used by those seeking to come down
from stimulant effects of methamphetamine.
There were 11 GHB-related deaths statewide during
2004. The drug was considered the cause of death in
six (55 percent) of these cases. There were also 11
GHB-related deaths reported statewide during 2003,
of which 27 percent were considered to have been
caused by the drug. In all of Florida, GHB-related
deaths increased from 23 in 2000 to 28 in 2001 and
then declined to 19 in 2002 before declining to 11 in
2003 and again in 2004.
Unweighted data accessed from DAWN Live! for
Miami-Dade County show 21 GHB-related ED reports in 2004. There were six such DAWN Live! reports in Broward County during 2004.
From the previous tracking system for drug-related
hospital ED episodes in Broward County, there had
been a dramatic decrease in the number of GHB
emergency department cases treated in emergency
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departments from 2000 to 2003. The Broward General Medical Center (BGMC) Emergency Department
treated three people with GHB or GHB precursor
overdose in 1996. The number of these cases increased to 48 in 1999 and peaked at 77 in 2000.
There were 71 GHB cases in 2001 and 34 cases in
2002. In 2003, there were 30 GHB ED cases at
BGMC. This downward trend reflects the national
pattern with GHB since 2000, when the drug was
banned by Federal legislation.
The NFLIS reported 23 crime lab cases of 1,4 BD in
Miami-Dade County during 2004, along with 2 GHB
cases and 2 GBL cases. The Broward Sheriff’s Office
crime lab reported six cases of 1,4 BD, two cases of
GHB, and one case of GBL in 2004.

The NFLIS reported the Miami-Dade Crime Lab analyzed 250 MDMA exhibits and 42 MDA exhibits
during 2004, representing 2 percent of all substances
analyzed. In 2004, MDMA was the ninth most common case worked at the Broward Sheriff’s Office
Crime Lab, with 89 MDMA cases analyzed, and
there were also 22 MDA cases. In the last half of
2003, the Crime Lab analyzed 58 MDMA cases and
10 MDA cases. The number of MDMA cases peaked
in the first half of 2001, with 132 cases; such cases
declined to 42 in the second half of 2004.
In South Florida, ecstasy tablets sell for $5–$7 per
tablet wholesale (in bulk), $10–$20 retail for a single
pill, or up to $50 per pill at expensive nightclubs.
These prices have remained the same since 2002.

Methylenedioxymethamphetamine (MDMA, or
“Ecstasy”)
Measures of MDMA abuse suggest problems may
have peaked in 2001, declined thereafter, and then
stabilized between 2003 and 2004.
Ecstasy pills generally contain 75–125 milligrams of
MDMA, although pills are often adulterated and may
contain other drugs being sold as “ecstasy.” The major sources of the designer logo-emblazoned pills
seem to be clandestine labs in Western Europe, especially the Netherlands and Belgium (and more recently Spain). The pills enter South Florida from the
Caribbean and are brought in by cruise ship passengers because of post 9-11 airline security.
There were 41 MDMA-related deaths statewide in
Florida during 2004, with the drug being cited as the
cause of death in 8 of these cases. There were also 27
methylenedioxyamphetamine (MDA)-related deaths
statewide in Florida in 2004, with that drug being
cited as the cause of death in 5 of the cases. An additional six deaths were related to other unidentified
methylated amphetamines in 2004, with those substances being the cause of two of the deaths. In 2003,
there were 34 MDMA-related deaths, 20 MDArelated deaths, and 1 other death from an unidentified
methylated amphetamine in Florida.
Unweighted DAWN data show 106 MDMA ED reports from Miami-Dade County during 2004, representing only 1 percent of major substances of abuse
ED reports.
In the unweighted DAWN data for Broward County
during 2004, there were 24 MDMA-related ED reports. Males accounted for 58 percent of these patients; 79 percent were non-Hispanic Whites, 13 percent were Hispanics, and 8 percent were non-
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Hispanic Blacks. Thirteen percent were younger than
18, 38 percent were age 18–24, 46 percent were age
25–34, and one patient was older than 35.

In 2004, current (past-30-day) MDMA use was reported in results of the Florida Youth Substance
Abuse Survey by 0.6 percent of Broward County
middle and high school students (exhibit 8a), down
from 1.3 percent in 2002. Among Miami-Dade
County middle and high school students, 1.0 percent
reported current MDMA use in 2004, down from 1.4
percent in 2002. Current MDMA use was also reported by 1.3 percent of Palm Beach County middle
and high school students in 2004, down from 1.9
percent in 2002. The proportion of middle and high
school students in all of Florida reporting current
MDMA use was 1.1 percent in 2004.
Methamphetamine
Methamphetamine abuse continues to be a local
problem, as new supply sources have been identified.
“Crystal,” or smokable, methamphetamine has been
shipped by overnight delivery from California for several years. Law enforcement sources confirm increased trafficking from Atlanta and North Carolina of
high-grade Mexican-manufactured methamphetamine
in the last year. There have also been several seizures
of local methamphetamine labs. Mexican drug trafficking organizations are supplying powered methamphetamine directly to local Latino populations of Central and South American nationalities. Outlaw motorcycle gang activity involved with local lab production
and distribution has also been noted in the past year.
Signs of methamphetamine abuse spreading to new
populations indicate the local epidemic has progressed
from the incubation period of the past 3 years to an
expansion phase with growing numbers of users.
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Methamphetamine-related deaths totaled 93 during
2004 statewide in Florida, representing a 21-percent
increase from the 77 such deaths in the previous year.
Methamphetamine was considered the cause of death
in 19 of the 93 cases in 2004. There were also 95 amphetamine-related deaths in 2004 across Florida, a 28percent increase over 2003. Amphetamine was considered the cause of death in 7 of the 95 cases in 2004.
Unweighted data accessed from DAWN Live! show
38 methamphetamine-related ED reports during 2004
in Miami-Dade County. Among those patients, 92
percent were males, 55 percent were non-Hispanic
Whites, 26 percent were Hispanics, and 8 percent
were non-Hispanic Blacks. No methamphetamine ED
patients were younger than 18; 26 percent were age
18–24, 50 percent were age 25–34, and 24 percent
were older than 34.
Unweighted data accessed from DAWN Live! show
18 methamphetamine-related ED reports during 2004
in Broward County. Among those patients, 61 percent were males, 67 percent were non-Hispanic
Whites, 17 percent were Hispanics, and 11 percent
were non-Hispanic Blacks. One methamphetamine
ED patient was between 12 and 18 years of age; 28
percent were age 18–24, 44 percent were age 25–34,
and 22 percent were older than 34.
Methamphetamine and other amphetamines accounted
for 81 or (1 percent) of primary, secondary, and tertiary treatment drug mentions (excluding alcohol)
among the 3,609 BARC patients who cited as least 1
drug of abuse at time of admission during 2004. Of
these mentions, 46 percent were as the primary drug of
abuse, 22 percent were as secondary drug, and 32 percent were as the tertiary drug problem.
The NFLIS reported the Miami-Dade Crime Lab analyzed 153 methamphetamine exhibits during 2004,
representing 1 percent of all substances analyzed. In
2004, there were 96 Broward Sheriff’s Office Crime
Lab methamphetamine cases analyzed. In 2003, there
were 90 such cases. The number of these cases has
more than doubled since 2001.
Statewide, the number of clandestine methamphetamine labs or equipment seizures has risen from 30
cases in fiscal year (FY) 2000 (October 1999 to September 2000) to 332 in the FY ending September 30,
2004.
In South Florida, methamphetamine has some of the
highest prices in the Nation: $15,000–$20,000 per
pound and $900–$1,200 per ounce. Higher potency
“crystal” methamphetamine sells for $1,800–$2,000
per ounce and $50 per quarter gram.

In 2004, current (past-30-day) methamphetamine use
was reported in results of the Florida Youth Substance Abuse Survey by 0.6 percent of Broward
County middle and high school students (exhibit 8a),
down from 0.9 percent in 2000. Among Miami-Dade
County middle and high school students, 1.3 percent
reported current methamphetamine use in 2004, up
from 1.0 percent in 2000. Current methamphetamine
use was also reported by 0.7 percent of Palm Beach
County middle and high school students in 2004,
down from 1.1 percent in 2000. The proportion for
the middle and high school students in all of Florida
reporting current methamphetamine use was 0.9 percent in 2004.
Hallucinogens
Unweighted data accessed from DAWN Live! show
35 LSD ED reports in Miami-Dade County in 2004
and 6 in Broward County. There were 13 miscellaneous hallucinogen-related ED reports in Miami-Dade
and 2 in Broward in 2004. There were 10 PCP ED
reports in Miami-Dade during 2004 and 1 in Broward
County.
The NFLIS reported the Miami-Dade Crime Lab analyzed four LSD exhibits during 2004, and the Broward Sheriff’s Office crime lab analyzed three LSD
samples.
Benzodiazepines
Benzodiazepines in general and alprazolam (Xanax)
in particular are a substantial problem. Benzodiazepines were second only to alcohol in their involvement
in drug-related deaths throughout Florida for the past
several years. There were 2,011 benzodiazepinerelated deaths across Florida in 2004, representing a
12-percent increase over the 1,794 such deaths in the
previous year. Of the benzodiazepine-related deaths in
2004, a benzodiazepine was identified as the cause of
death in 460 cases (or 23 percent).
In Miami-Dade County, there were 64 alprazolamrelated deaths during 2004, of which 13 (20 percent)
were alprazolam induced. Seventy-eight percent of the
deaths involved at least one other drug (exhibit 4).
There were also 25 diazepam-related deaths in MiamiDade County, of which 2 (8 percent) were caused by
the drug; 64 percent of these deaths involved at least 1
other drug.
Broward County recorded 115 alprazolam-related
deaths during 2004, of which 38 (33 percent) were
induced by the drug. Only 10 (9 percent) of the deaths
involved alprazolam alone (exhibit 5). In the same
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year, Broward County recorded 101 diazepam-related
(Valium) deaths, of which 17 (17 percent) were diazepam induced. All but six of these cases involved
at least one other drug.
Unweighted data on ED benzodiazepine reports in
Miami-Dade County show 917 such reports for 2004.
Overmedication accounted for 33 percent of the reports, while seeking detoxification was the reason for
27 percent of the benzodiazepine reports.
Unweighted ED data from Broward County show
that there were 1,171 benzodiazepine ED cases in
2004, ranking third behind alcohol and cocaine in the
number of ED reports. Fifty-four of the benzodiazepine ED patients were male. Non-Hispanic Whites
accounted for 77 percent of these patients, nonHispanic Blacks for 10 percent, and Hispanics/other
for 14 percent. Nearly one-fifth of these patients were
younger than 25, including 4 percent of total users
younger than 18. Fifteen percent of patients were age
18–24, 21 percent were 25–34, and 61 percent were
older than 34.

Benzodiazepines accounted for 616 (or 9 percent) of
primary, secondary, and tertiary drug treatment mentions (excluding alcohol) among the 3,609 BARC
patients who cited as least 1 drug of abuse at the time
of admission during 2004. Of these mentions, 17 percent were as the primary drug, 46 percent were as
secondary drug, and 37 percent were as the tertiary
problem.
The NFLIS reported that the Miami-Dade Crime lab
analyzed 265 alprazolam exhibits in 2004, as well as
18 diazepam exhibits and 11 clonazepam cases. In
Broward, the BSO crime lab analyzed 553 alprazolam
cases, 67 unnamed benzodiazepine cases, and 29
clonazepam samples.
In 2004, current (past-30-day) depressant use (naming “Xanax” as an example) was reported in results
of the Florida Youth Substance Abuse Survey by 1.6
percent of Broward County middle and high school
students (exhibit 8a), down from 2.7 percent in 2002
but equal to the proportion in 2000. Among MiamiDade County middle and high school students, the
proportion doubled between 2000 and 2004, rising
from 0.6 to 1.2 percent. Current depressant use was
also reported by 2.9 percent of Palm Beach County
middle and high school students in 2004, down from
3.6 percent in 2002 but nearly double the 2000 proportion of 1.5 percent. The proportion for the middle
and high school students in all of Florida reporting
current depressant use was 2.8 percent in 2004.
For inquiries regarding this report, please contact James N. Hall,
Center for the Study and Prevention of Substance Abuse, Up Front
Drug Information Center, Nova Southeastern University, Suite
215, 12360 Southwest 132nd Court, Miami, FL 33186, Phone:
(786) 242-8222, E-mail: upfrontin@aol.com.
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Exhibit 1.

DAWN ED Miami-Dade County Sample and Reporting Information: January–December 2004

Total Eligible
Hospitals1

No. of Hospitals
Total EDs in
in DAWN Sample DAWN Sample2

21

17

No. of EDs Reporting per Month:
Completeness of Data (%)
90–100%

50–89%

<50%

5–9

1–3

0–1

17

No. of EDs Not
Reporting
7–9

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
2
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005

Exhibit 2.

DAWN ED Ft. Lauderdale Sample and Reporting Information: January–December 2004

Total Eligible
Hospitals1

No. of Hospitals
Total EDs in
in DAWN Sample DAWN Sample2

27

22

No. of EDs Reporting per Month:
Completeness of Data (%)
90–100%

50–89%

<50%

0–6

0–2

0–1

22

No. of EDs Not
Reporting3
15–20

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
2
Some hospitals have more than one emergency department.
3
Note that only 2 EDs participated in the first half of 2004.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/22, 2005

Exhibit 3.

Numbers of Drug-Related Deaths in Florida, by Single Drug or In Combination: 2004
2,000
1,500
1,000
500
0

In Combination
Single Drug

Cocaine

Alprazolam

Diazepam

Oxycodone

Methadone

HydroPropoxyMorphine
codone
phene

1,269

886

580

596

736

547

441

271

150

433

79

54

78

113

85

156

76

30

Heroin

SOURCE: Florida Department of Law Enforcement, Florida Medical Examiners Commission Report 2004
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Exhibit 4.

Numbers of Drug-Related Deaths in Miami-Dade County, by Single Drug or In Combination:
2004
200
150
100
50
0
Cocaine

Alprazolam

Diazepam

Oxycodone

Methadone

HydroPropoxyMorphine
Heroin
codone
phene

In Combination

99

50

16

26

14

17

31

11

14

Only Drug

61

14

9

4

3

2

10

4

4

SOURCE: Florida Department of Law Enforcement, Florida Medical Examiners Commission Report 2004

Exhibit 5.

Numbers of Drug-Related Deaths in Broward County, by Single Drug or In Combination: 2004
180
160
140
120
100
80
60
40
20
0
Cocaine

Alprazolam

Diazepam

Oxycodone

Methadone

Hydrocodone

Morphine

Propoxyphene

Heroin

In Combination

102

105

95

69

62

34

32

13

33

Only Drug

18

10

6

2

11

4

12

5

2

SOURCE: Florida Department of Law Enforcement, Florida Medical Examiners Commission Report 2004

Exhibit 6.

144

Numbers of Selected Drug Reports in Miami-Dade County DAWN ED Data (Unweighted1), by
Drug Category: 2004
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Alcohol

Alcohol only (age <21)

3,671

232

Cocaine

5,420

Heroin

1,387

Marijuana

2,098

1

The unweighted data are from 8–10 Miami-Dade EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control.
Based on this review, cases may be corrected or deleted, and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005

Exhibit 7.
Numbers of Selected Drug Reports in Broward County DAWN ED Data (Unweighted1), by Drug
Category: 2004
Alcohol

Alcohol Only (age < 21)

2,109

150

Cocaine

Heroin

Marijuana

1,953

399

849

1

The unweighted data are from 4–7 Ft. Lauderdale Division EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted, and, therefore, are subject to change.
SOURCE: Broward EDs, first half of 2004; DAWN Live!, OAS, SAMHSA, updated 4/22, 2005
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Exhibit 8a.

Percentages of Middle and High School Students Reporting Past-30-Day Substance Abuse:
2004

Percent
3.5

2.9

3.0

3.0

Broward

2.8

Miami-Dade
2.5

Palm Beach

2.3

All Florida
2.0

1.8
1.6

1.7

1.6

1.5
1.2

1.5
1.3

1.2
1.0

0.9

1.0

1.3
1.1
0.9

0.6

0.6

0.7

0.5

0.0
Depressants

Narcotic Pain Rx

Cocaine

Ecstasy

Methamphetamine

SOURCE: Florida Youth Substance Abuse Survey 2004

Exhibit 8b. Percentages of Middle and High School Students Reporting Past-30-Day Substance Abuse:
2004
40

Percent
Broward

35.1
35
30.3 30.9

32.3

Miami-Dade

30

Palm Beach
All Florida

25
20
15

13.3

14.6

15.6

16
11.4 11.5

10.2
8.6

10

11.4
7.8

8.1

9.6
4.6

5

3.7

4.4

4.2

0
Alcohol

Binge Alcohol

Marijuana

Cigarettes

Inhalants

SOURCE: Florida Youth Substance Abuse Survey 2004
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Drug Abuse Trends in
Minneapolis/St. Paul
Carol Falkowski1
ABSTRACT
The far-reaching consequences and public expense
related to the abuse and manufacture of methamphetamine remained apparent in the Twin Cities
and throughout the State in 2004, placing increased
demands on law enforcement, the corrections system, environmental health officials, child protection
workers, hospital emergency rooms, and treatment
centers. Ten percent of admissions to addiction
treatment programs were for methamphetamine in
2004—a record high. The number of overdose
deaths, methamphetamine labs, and children affected by methamphetamine labs declined slightly.
Cocaine abuse resulted in more hospital emergency
department reports than any other drug of abuse,
with 3,046 in 2004 (compared with 874 for methamphetamine and 779 for heroin), and accounted for
13.3 percent of treatment admissions. Opiate-related
accidental overdose deaths outnumbered those for
any other illicit drug, with 72 in 2004 (compared
with 49 for cocaine, 20 for methamphetamine, and
8 for MDMA, ‘ecstasy’). The accidental OxyContin
overdose death of a suburban high school student
brought heightened public attention to the nonmedical, recreational abuse of prescription painkillers by young people. Marijuana accounted for 19.9
percent of treatment admissions, and there were
2,556 emergency department reports of marijuana
in 2004. Nearly one-half of those receiving addiction treatment services were younger than 18, as
were 26 percent of the marijuana-involved patients
at hospital emergency departments.
INTRODUCTION
This report is produced twice annually for participation in the Community Epidemiology Work Group of
the National Institute on Drug Abuse, an epidemiological surveillance network comprised of researchers
from 21 U.S. areas who monitor emerging patterns
and trends in drug abuse. It is compiled using the
most recent data and information obtained from multiple sources. This report is also available online at
www.hazelden.org/research.

Area Description
The Minneapolis/St. Paul, “Twin Cities,” metropolitan area includes Minnesota’s largest city, Minneapolis (Hennepin County), the capital city of St. Paul
(Ramsey County), and the surrounding counties of
Anoka, Dakota, and Washington. Recent estimates of
the population of each county are as follows: Anoka,
313,197; Dakota, 375,462; Hennepin, 1,239,837;
Ramsey, 515,274; and Washington, 213,395. The
population of these counties totals 2,557,165, or
roughly one-half of the Minnesota State population.
In the five-county metropolitan area, 84 percent of the
population is White. African-Americans constitute the
largest minority group in Hennepin County, while
Asians are the largest minority group in Ramsey,
Anoka, Dakota, and Washington Counties. St. Paul
has the largest Hmong population of any U.S. city.
The Hmong were Laotian residents who were recruited by the CIA to fight in the “secret war” for the
United States during the Vietnam War. Later, after
their communist opponents won a long civil war,
many fled to Thailand and eventually resettled in the
United States and other countries.
The remainder of the State is less densely populated
and more rural in character than the “Twin Cities”
area. Minnesota shares an international border with
Canada, a southern border with Iowa, an eastern border with Wisconsin, and a western border with North
Dakota and South Dakota, two of the country’s most
sparsely populated States. Illicit drugs are sold and
distributed within Minnesota by Mexican drug trafficking organizations, street gangs, independent entrepreneurs, and other criminal groups. Drugs are
typically shipped or transported into the Minneapolis/St. Paul area for further distribution across the
State.
Data Sources
Data for this report were drawn from the following
sources:
• Mortality data on drug-related deaths are from
the Hennepin County Medical Examiner and the
Ramsey County Medical Examiner (through
March 2005). Hennepin County cases include
those in which drug toxicity was the immediate
cause of death and those in which the recent use
of a drug was listed as a significant condition
contributing to the death. Ramsey County cases
include those in which drug toxicity was the
immediate cause of death and those in which
drugs were present at the time of death.

1

The author is affiliated with Hazelden Foundation, Butler Center
for Research, Center City, Minnesota.
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• Hospital emergency department (ED) data
were derived from the Drug Abuse Warning
Network (DAWN) Live!, a restricted-access
online query system administered by the Office
of Applied Studies (OAS) of the Substance
Abuse and Mental Health Services Administration (SAMHSA). These unweighted data are
from participating hospital emergency departments in the Minneapolis and St. Paul Standard
Metropolitan Statistical Area from January 1,
2004, through December 31, 2004, as accessed
on April 14, 2005. The DAWN sample includes
26 of the 28 eligible hospitals in the area, with 26
emergency departments (exhibit 1). The data reported in this paper are incomplete. Over the approximately 12-month period, between 7 and 13
EDs reported data each month, with almost all
reporting basically complete data (90 percent or
greater). All DAWN cases are reviewed for quality control and based on the review, they may be
corrected or deleted. Therefore, the data reported
in this paper are subject to change. Data accessed
from DAWN Live! represent drug reports in
drug-related visits. Reports exceed the number of
visits, because a patient may report use of multiple drugs (up to six drugs plus alcohol). The unweighted data are not estimates for the Minneapolis/St. Paul area and cannot be compared with
data from 2002 and before, nor can these preliminary data be used for comparison with future
DAWN data. Only weighted DAWN data released by SAMHSA can be used for trend analysis. See a full description of DAWN online at
http://dawninfo.samhsa.gov.
• Addiction treatment data are from addiction
treatment programs (residential, outpatient, and
extended care) in the five-county metropolitan
area as reported on the Drug and Alcohol Abuse
Normative Evaluation System (DAANES) of
the Performance Measurement and Quality Improvement Division, Minnesota Department of
Human Services, from 1993 through 2004. Data
on methadone treatment programs are from the
Chemical Health Division, Minnesota Department of Human Services (as of May 23, 2005).
• Law enforcement data and information are
from various county, city, State, and Federal
agencies.
• Crime lab data for St. Paul are from the National
Forensic Laboratory Information System
(NFLIS). This system, which began in 1997, is
sponsored by the U.S. Drug Enforcement Administration and collects solid dosage drug
analyses conducted by State and local forensic
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laboratories across the country on drugs seized
by law enforcement. Minnesota data on
methamphetamine labs are from the El Paso Intelligence Center (EPIC), U.S. Drug Enforcement Administration.
• Human immunodeficiency virus (HIV) infection data for cases diagnosed in 2004 are from
the Minnesota Department of Health.
• Additional information is from interviews with
treatment program staff, poison control specialists, narcotics agents, and school-based drug and
alcohol specialists conducted in May 2005.
DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
Accidental overdose deaths involving cocaine decreased from 2003 to 2004 in Hennepin County
(from 44 to 39) and remained stable in Ramsey
County (10), as shown in exhibit 2.
Unweighted DAWN Live! data show cocaine reports
at Twin Cities emergency departments outnumbered
those for any other illegal drug in 2004 (see exhibit
3). Of the 3,046 cocaine-related ED reports in 2004,
65.2 percent of the patients were male and 34.8 percent were female. More than one-half of the patients
(62.3 percent) were older than 35, 27.0 percent were
age 25–34, 8.4 percent were age 18–24, and 2.2 percent were younger than 18. Of those with known
race/ethnicity, 41.7 percent were White, 55.0 percent
were African-American, and 3.2 percent were Hispanic.
Admissions to addiction treatment programs with
cocaine as the primary substance problem declined
very slightly in recent years (see exhibit 4). In 2004,
treatment admissions involving cocaine as the primary substance problem accounted for 13.3 percent
of all admissions, compared with 14.9 percent in
1998. Most cocaine admissions in 2004 were for
crack cocaine; 31.6 percent were female and 47.4
percent were African-American (exhibit 5). The average age of first crack use was 25.8. Most (86.9 percent) patients receiving treatment for cocaine were
age 25 or older; 62.1 percent were older than 35.
More than four out of five patients (81.5 percent) had
prior treatment episodes.
Cocaine accounted for 21.4 percent of the drug seizures reported to NFLIS in St. Paul in 2004 (exhibit 6).
Gangs continued to play a considerable role in the
street-level, retail distribution of crack cocaine. A
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recent sweep of drug dealers in Minneapolis in April
resulted in 31 warrants for felony sales of crack cocaine and 7 for misdemeanor marijuana sales. The
suspects came from 8 different gangs and all but one,
a juvenile female, had prior criminal records.
Cocaine generally sold for $100 per gram, $200 per
“eightball” (one-eighth ounce), $700–$800 per
ounce, and up to $22,000 per kilogram. The price of a
rock of crack was $10–$20.
Heroin/Opiates/Other Narcotics
Opiate-related deaths, mostly accidental heroin overdoses, outnumbered cocaine-related deaths in 2004.
In Hennepin and Ramsey Counties combined, there
were 72 opiate-related deaths in 2004, compared with
69 in 2003 and 77 in 2002 (exhibit 2). Eleven of the
47 accidental opiate-related deaths in Hennepin
County in 2004 involved methadone, as did 3 of the
25 deaths in Ramsey County.
According to unweighted DAWN Live! data, there
were 779 heroin ED reports in 2004 (exhibit 3). Of
these patients, two-thirds were male. More than onehalf of these heroin patients (54.7 percent) were older
than 35; 31.8 percent were age 25–34, 13.0 percent
were age 18–24, and 0.5 percent were younger than
18. Of those with known race/ethnicity, 61.8 percent
were White, 35.3 percent were African-American,
and 2.8 percent were Hispanic.
Prescription narcotic analgesics, used medically in
the treatment of pain, were increasingly used nonmedically as drugs of abuse for the heroin-like high
they produce. Of particular concern within this category were drugs containing oxycodone: Percodan,
Percocet (oxycodone combined with aspirin or acetaminophen), and the long-acting OxyContin.
The recent (May 2005) accidental death of a 17-yearold suburban boy from apparent overdose of OxyContin brought heightened public awareness of the
growing abuse of prescription painkillers and other
prescription drugs among Twin Cities-area high
school students. In 2004, there were 1,361 hospital
ED reports involving narcotic analgesics in the unweighted DAWN Live! data; 475 of these involved
oxycodone.
Of the patients receiving treatment for heroin in 2004
at programs that reported on the DAANES system,
78.7 percent were older than 25 (exhibit 5). Whites
accounted for 55.2 percent and African-Americans
represented 36.1 percent; 31.3 percent were women.
The most common route of administration was injection (64.2 percent), followed by sniffing (31.8 per-
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cent) and smoking, also known as “foiling” (4.0 percent). The average age of first heroin use was 22.5.
Most heroin admissions (88.4 percent) reported prior
treatment episodes.
Five methadone maintenance programs serve 1,636
patients in the metropolitan area. Because the private,
for-profit methadone programs do not report to
DAANES, exhibits 4 and 5 do not reflect the total
number of patients receiving treatment for heroin/opiate addiction in the Twin Cities. However,
effective July 1, 2005, all methadone maintenance
programs will report on DAANES.
The newest innovation in methadone service delivery
is the Mobile Medication Unit operated in Minneapolis by Hennepin Faculty Associates. This servicebased (versus program-based) delivery system increases treatment access while reducing the burden
and inconvenience often associated with methadone
treatment. It is a mobile methadone van that operates
in two locations. Since it began operations in October
2004, 66 patients who would otherwise have been
remanded to a waiting list received treatment. Similar
mobile units have been established in the Netherlands
(1979), Boston (1987), Baltimore (1993), Seattle
(1999), and Vermont (2004).
Heroin seized by law enforcement officers included
white, off-white, or tan powder, in addition to darkcolored Mexican “black tar” heroin. Four Nigerians
apprehended in April 2004 at the Minneapolis/St.
Paul International Airport were on a flight from Amsterdam carrying suitcases filled with 25 pounds of
heroin valued at $25 million. Retail and mid-level
heroin prices remained at $20–$40 per dosage unit or
“paper,” $300–$400 per gram, and $900–$2,000 per
ounce. Law enforcement seizures of oxycodone increased, as did pharmacy robberies involving OxyContin.
A very small segment of Minnesota’s Hmong immigrant population regularly smokes opium. Packages
concealing opium continued to be shipped from Asia
to residents of that Twin Cities community. One case
involved 30 pounds of seized opium, with a reported
street value of $1.3 million, which was delivered to a
suburban Woodbury couple in January. Luggage with
opium-soaked fabric was delivered to their house
after arriving in the country on a Korean Airlines
flight from Laos to Atlanta and being driven to Minnesota by car.
Marijuana
Marijuana remained the overwhelmingly popular
drug of abuse among adolescents and young adults.
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According to unweighted DAWN Live! data, there
were 2,556 marijuana reports at Twin Cities-area
hospital emergency departments in 2004 (exhibit 3).
Of these patients, two-thirds were male. Roughly
one-half were younger than 25, and one-half were
older than 25. Specifically, 26 percent were younger
than 18, 26 percent were age 18–24, 23 percent were
age 25–34, and 25 percent were age 35 and older. Of
those with known race/ethnicity, 65.7 percent were
White, 31.7 percent were African-American, and 2.6
percent were Hispanic.
Marijuana accounted for more admissions into addiction treatment programs than any other illicit drug in
the Twin Cities, with 3,856 admissions in 2004 (exhibit 4). One out of five (19.9 percent) patients entering addiction treatment programs reported marijuana
as the primary substance problem, compared with
only 8 percent in 1991. Most (76 percent) were
males; 65.8 percent were White, 22.0 percent were
African-American, 5.3 percent were Hispanic, 2.9
percent were American Indian, and 1.1 percent were
Asian (exhibit 5). For many, it was the first treatment
experience (45.2 percent). The average age of first
marijuana use was 13.9.
Marijuana was easily accessible, according to multiple sources, and sold for $5 per joint. Standard,
commercial-grade marijuana sold for $50 per quarter
ounce, $150–$175 per ounce, and $600–$900 per
pound. Higher potency “BC Bud” from British Columbia was increasingly available and sold for $100
per quarter ounce, up to $600 per ounce, and $3,200
per pound. One international marijuana smuggling
case involved the seizure of 827 pounds of BC Bud
near the U.S.-Canadian border in northern Minnesota
in April 2005. According to Border Patrol officials, it
was one of the largest cases of its kind to date. The
marijuana was valued at more than $4 million.
Marijuana joints that are dipped in formaldehyde,
which is often mixed with phencyclidine (PCP), are
known as “wets,” “wet sticks,” “water,” or “wet daddies.” Marijuana joints containing crack cocaine are
known as “primos.”
Methamphetamine/Other Stimulants
Aside from cocaine, methamphetamine, also known as
“meth,” “crystal,” “speed,” or “crank,” is the major
stimulant of abuse in the area. Prolonged abuse can
result in addiction, which is characterized by long periods (up to 2 weeks) of continual drug use, sleep and
food deprivation, weight loss, and extreme paranoid
delusions.
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In Ramsey County in 2004, there were 9 accidental
deaths related to methamphetamine abuse, compared
with 10 in 2003 and 3 in 2002 (exhibit 2). Excluding
methylenedioxymethamphetamine (MDMA)- related
deaths, there were 8 methamphetamine-related deaths
in Hennepin County in 2002, 14 in 2003, and 11 in
2004 (exhibit 1).
Hospital ED reports of methamphetamine totaled 874
in 2004 according to unweighted DAWN Live! data
(exhibit 3). Women accounted for 41.8 percent. Of
these methamphetamine patients, roughly one-half
were younger than 25, and one-half were older than
25. Specifically, 18.8 were younger than 18, 28.0
percent were 18–24, 32.4 percent were 25–34, and
20.7 percent were age 35 and older. Of those with
known race/ethnicity, almost all (93.4 percent) were
White; 4.6 percent were African-American and 1.9
percent were Hispanic.
Patients addicted to methamphetamine accounted for
10.0 percent of total treatment admissions in the
Twin Cities in 2004 (exhibit 4), compared with 2.9
percent in 1998 and less than 1 percent in 1991.
Women accounted for 38.4 percent of methamphetamine admissions, the highest percentage within any
drug category (exhibit 5). Almost all were White
(91.0 percent), and the average age of first use was
20.4. One-third (32.5 percent) were in treatment for
the first time.
Methamphetamine abuse took hold among a younger
population in 2004. All onsite, school-based drug
abuse counselors reported growing methamphetamine abuse by students who attend metropolitan-area
high schools. Smoking was the most common route
of first methamphetamine use. The use of light bulbs
as pipes for smoking methamphetamine was commonplace, especially among youth. The appetite suppressant effects, in particular, attracted young girls.
More than one-half (52.5 percent) of those receiving
treatment for methamphetamine were age 25 or
younger: 16.2 percent were younger than 18 and 36.3
percent were age 18–25 (exhibit 5). Among treatment
admissions, smoking was the most common route of
administration (63.6 percent), followed by sniffing
(18.2 percent) and injection (13.0 percent).
Methamphetamine dominated law enforcement efforts and criminal justice actions in the metropolitan
and non-metropolitan areas of the State. For example,
in Ramsey County, the number of methamphetamine
prosecutions rose from 20 cases in 1999 (2.7 percent
of drug cases) to 301 in 2004 (29 percent of drug
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cases). Statewide, methamphetamine was involved in
14 percent of all felony cases in 2004. According to
the Minnesota Department of Corrections, there were
139 methamphetamine offenders in Minnesota prisons in 2001, compared with 1,100 inmates in April
2005.

group was traveling across Iowa, Minnesota, North
Dakota, and South Dakota purchasing the two-box
limit. They had amassed 6,738 pills in less than 2
days. If convicted of acquiring the pills to manufacture methamphetamine, they could face up to 8 years
in prison.

Seizures of methamphetamine by law enforcement
continued upward trends and accounted 60.8 percent
of the samples reported to the National Forensic
Laboratory Information System (exhibit 6), which are
cases from the State crime lab. Seizures by metropolitan-area law enforcement agencies increased as
well in 2004.

The abuse of MDMA, a stimulant with mild hallucinogenic properties known as “ecstasy,” “X,” or “e,”
by young people continued and contributed to the death
of seven African-American males in their twenties in
Hennepin County in 2004. All were homicide victims
with “recent MDMA use” listed as an “other significant
condition.”

Methamphetamine prices were as low as $70 per
gram, $200 for a “teener,” (one-sixteenth ounce),
$240–$280 for an “eightball” (one-eighth ounce), and
$1,800 per ounce. Pound prices ranged from $6,000
to $14,000. “Glass,” or “ice,” the high-purity form
that is smoked, typically sold for twice as much.
Methamphetamine came in the form of crystals,
powder, or chunks that were white, off-white, tan,
orange, reddish, greenish, or light purple-colored.

Effects of MDMA include tactile sensitivity, hallucinations, and, at high doses, nausea, jaw clenching, hyperthermia, and muscle tension. According to unweighted
DAWN Live! data, there were 102 MDMA ED reports
in 2004.

The number of clandestine, makeshift methamphetamine labs dismantled with the assistance of the U.S.
Drug Enforcement Administration in the State decreased dramatically between 2003 and 2004 (from
182 to 96), but dismantled labs decreased only
slightly in the Twin Cities area (from 23 in 2003 and
21 in 2004) (exhibit 7). One rural county reported
more than $1 million in costs associated with
methamphetamine lab cleanup in 2004. The bulk of
methamphetamine consumed in the State is still imported from Mexico, however, not manufactured in
small labs.
The presence of minor children in locations where
methamphetamine was being made also declined
statewide and in the Twin Cities in 2004. Statewide,
there were 54 affected children in 2003 and 14 in
2004 (exhibit 8). However, child protection workers
all over the State reported larger caseloads attributable to drug abuse; they reported that most, up to 90
percent in some counties, involved methamphetamine-abusing or addicted caregivers.
Legislative efforts focused on restricting the sale of
over-the-counter cold preparations containing pseudoephedrine, a nasal decongestant used in the manufacture of methamphetamine. In April 2005, four
people were arrested in New Ulm, a small town less
than an hour south of the Twin Cities, after police
discovered nearly 7,000 pseudoephedrine pills in
their possession. Even though many stores voluntarily limit sales to two packages per customer, the
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Khat, a plant that is chewed or brewed in tea for its
stimulant effects in East Africa and the Middle East,
remained within the Somali refugee community in
the Twin Cities and Rochester, Minnesota. Its active
ingredients, cathinone and catheine, are controlled
substances in the United States.
Methylphenidate (Ritalin), a prescription drug used in
the treatment of attention deficit hyperactive disorder,
is also used nonmedically as a drug of abuse to increase alertness and suppress appetite by some adolescents and young adults. The pills are crushed and
snorted or ingested orally. Each pill is sold for $5 or
simply shared with fellow middle school or high
school students at no cost. Ritalin is sometimes
known as a “hyper pill” or “the study drug.”
Hallucinogens
Products that contain dextromethorphan, a cough
suppressant common in most over-the-counter cough
syrups, are ingested by adolescents in doses many
times in excess of the recommended amount for the
long-acting, hallucinogenic effects. Dextromethorphan (also known as “DXM”) is also the active ingredient in some over-the-counter cold preparations
in pill form, such as Coricidin HBP Cough and Cold
(known as “Triple Cs”). People intoxicated on dextromethorphan experience profound hallucinations and
altered time perception, slurred speech, sweating, uncoordinated movements, and high blood pressure.
Recent growth in the abuse of these products by
younger teenagers prompted many pharmacies, discount stores, and grocery stores to place these products behind the counter to prevent shoplifting. Being
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under the influence of these products is known as
“Robo-tripping” or “Skittle-ing.”
Lysergic acid diethylamide (LSD or “acid”) is a
strong, synthetically produced hallucinogen, typically
sold as saturated, tiny pieces of paper known as
“blotter acid,” for $5–$10 per dosage unit. There
were 20 hospital ED reports of LSD in 2004 according to unweighted DAWN Live! data.
PCP, a dissociative anesthetic, is most often used in
combination with marijuana, but it can also be injected or snorted. In 2004, there were 20 ED reports
for PCP according to unweighted DAWN Live! data.
In May 2004, a 28-year-old African-American male
died as the result of drug-induced excited delirium
involving PCP and MDMA.
Sedative/Hypnotics

admissions for alcohol in 2004, 28.3 percent were
women, 77.9 percent were White, and 71.0 percent
had prior treatment experience (exhibit 5). The average age of first intoxication was 15.8.
Roughly 80 percent of alcohol-related treatment admissions were age 26 and older, with 61.5 percent
being age 35 or older. Among patients reporting alcohol as the primary substance of abuse, only 3.1
percent were younger than 18.
Daily nicotine use remained widespread among patients in addiction treatment programs (exhibit 5).
Adolescents who smoke tobacco are many times
more likely to use alcohol and other drugs than adolescents who do not use tobacco.
INFECTIOUS DISEASES RELATED TO SUBSTANCE
ABUSE

Other Drugs

Most cases of HIV infection and acquired immunodeficiency syndrome (AIDS) in Minnesota are in the
Minneapolis/St. Paul area. Of the 307 cases of new
HIV infection in 2004, the exposure categories were
as follows: men who have sex with men (39 percent),
injection drug use (4 percent), men who have sex
with men and injection drug use (4 percent), heterosexual contact (11 percent), unspecified (19 percent),
and no interview (21 percent) (exhibit 9).

Alcohol remained the most widely used moodaltering substance. There were 760 ED reports involving underage drinking in 2004 according to unweighted DAWN Live! data (exhibit 3).

The level of hepatitis C virus (HCV), a blood-borne
liver disease, among injection drug abusers remained
high, with estimated rates as high as 90 percent
among patients in methadone treatment programs.

Overall, one-half of all admissions to Twin Cities
addiction treatment programs (49.1 percent) were
attributable to alcohol in 2004, compared with 57.2
percent in 1998 (exhibit 4). Of the 9,490 treatment

For inquiries concerning this report, please contact Carol
Falkowski, Director of Research Communications, Hazelden
Foundation, Butler Center for Research, 15245 Pleasant Valley
Road, Box 11, Center City, MN 55012-0011, Phone: 651-2134566, Fax: 651-213-4344, E-mail: cfalkowski@hazelden.org.

Gamma hydroxybutyrate (GHB), known as "G,”
“Gamma,” “Liquid E,” or “Liquid X,” is a concentrated liquid abused for its stupor-like, depressant
effects. It is also used as a predatory knockout, druginduced rape drug and sells for $10 by the capful.
There were 22 hospital ED reports of GHB in 2004
according to unweighted DAWN Live! data.
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Exhibit 1. Minneapolis/St. Paul DAWN ED Sample and Reporting Information: 2004

CEWG Area

Total Eligible
Hospitals1

No. of Hospitals in
DAWN
Sample

Total EDs in
DAWN
Sample2

28

26

26

Minneapolis/
St. Paul

No. of EDs Reporting per Month:
Completeness of Data (%)
90–100%

50–89%

<50%

No. of
EDs Not
Reporting

6–13

0–1

0–1

13–19

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
2
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005

Exhibit 2. Number of Drug-Related Deaths in Hennepin and Ramsey Counties: 2000–2004
County
Hennepin County
Cocaine
Opiates
Methamphetamine

2000

2001

2002

2003

2004

43
41
6

37
58
8

34
59
11

44
50
15

39
47
19

(includes 3
MDMA)

Ramsey County
Cocaine
Opiates
Methamphetamine

17
17
11

(includes 1
MDMA)

11
19
2

(includes 3
MDMA)

11
18
3

(includes 1
MDMA)

10
19
10

(includes 8
MDMA)

10
25
9

(includes 3
MDMA)
SOURCE: Hennepin County Medical Examiner and Ramsey County Medical Examiner, 2005
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Exhibit 3. Number of Drug Reports (Unweighted)1 in Drug-Related Emergency Department Visits in
Minneapolis/St. Paul, by Drug Category: 2004
3,500
3,046
3,000
2,556
2,500
2,000
1,361

1,500

874

1,000

779

760
475

500

184

102
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57
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20
LS
D
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P

B
G
H

ci
no
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nt
s
M

is
c.

H
al
lu

In
ha
la

M
D
M
A

U
H
nd
er
er
oi
n
ag
e
D
rin
ki
ng
O
xy
co
do
Am
ne
ph
et
am
in
es
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ne
M
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iju
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x
O
M
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ha
es
m
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et
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in
e

0

1

Unweighted data are from 7–13 Minneapolis/St. Paul EDs reporting to DAWN. All DAWN cases are reviewed for quality control.
Based on this review, cases may be corrected or deleted, and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/14/2005

Exhibit 4. Admissions to Twin Cities-Area Addiction Treatment Programs, by Primary Substance
Problem and Percent: 1998–2004
Percent of Total Admissions

54 .0
4 9.7

4 9.1

2004

50

2002

54 .5
5 5.6

60

57 .2
5 7.0

70

3 .5
3.6

3 .3

2002

2004

1 0.0

3 .2
3 .0

3.1
4 .8

2000

2.5
2 .7

2.9
2 .2

1998

10

5 .2
7 .6

13 .2
1 3.3

1 1 .8
12 .8

14 .9

1 4.6
13 .7

2002

1 9.9

2 1.4
2 2 .1

20

22 .4
2 1.5

20 .1
2 1.3

30

2000

40

Alcohol

Marijuana

Cocaine

Methamphetamine

2000

1998

2004

2002

2004

2002

2000

1998

2004

1998

2000

1998

0

Heroin

SOURCE: Drug and Alcohol Abuse Normative Evaluation System, Minnesota Department of Human Services, 2005
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Exhibit 5. Characteristics of Persons Admitted to Twin Cities Area Addiction Treatment Programs, by
Primary Substance of Abuse and Percent: 2004
Total Admissions
(N=19,340)
Gender
Male
Female
Race/Ethnicity
White
African-American
Hispanic
American Indian
Asian
Age Group
17 and younger
18–25
26–34
35 and older
Route of Administration
Smoking
Sniffing
Injecting
Oral
Secondary Drug
Tertiary Drug
First Treatment Episode
Average Age First
Use (in Years)
Daily Nicotine Use

Alcohol
(n=9,490)
49.1

Marijuana
(n=3,856)
19.9

Cocaine
(n=2,570)
13.3

Methamphetamine
(n=1,928)
10.0

Heroin
(n=640)
3.3

71.7
29.3

76.0
24.0

68.4
31.6

61.6
38.4

68.8
31.3

77.9
11.3
6.1
3.2
0.6

65.8
22.0
5.3
2.9
1.1

43.6
47.4
4.5
2.3
0.9

91.0
1.2
3.4
1.6
1.6

55.2
36.1
4.9
2.9
0.2

3.1
15.3
20.0
61.5

47.6
29.0
13.2
10.2

2.6
10.5
24.8
62.1

16.2
36.3
25.2
22.3

0.9
20.3
24.4
54.3

78.4
19.7
1.9

4.0
31.8
64.2
Cocaine
43.2
Cocaine
29.6

Marijuana
57.0
Cocaine
33.1

Alcohol
71.4
Alcohol
33.9

Alcohol
52.2
Marijuana
41.7

63.6
18.2
13.0
5.2
Marijuana
53.4
Alcohol
48.8

29.0

45.2

18.5

32.5

11.6

(15.8)

(13.9)

(25.8)

(20.4)

(22.5)

59.8

59.7

68.6

74.5

70.5

SOURCE: Drug and Alcohol Abuse Normative Evaluation System, Minnesota Department of Human Services, 2005

Exhibit 6. Number of Items Analyzed in St. Paul, Minnesota, and Percentage of Total Items: January–
December 2004
Substance
Methamphetamine
Cocaine
Cannabis
MDMA
Psilocyn
Acetaminophen
Oxycodone
Hydrocodone
Heroin
Amphetamine
All Other
Total Items Reported

Number of Items
2,256
794
208
62
56
55
38
34
32
30
146
3,711

Percent of Total Items
60.8
21.4
5.6
1.7
1.5
1.5
1.0
0.9
0.9
0.8
3.9
100.0

SOURCE: NFLIS, DEA
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Exhibit 7. Number of Methamphetamine Lab Seizures in Minnesota and Twin Cities: 2000–2004
Year
2000
2001
2002
2003
2004

Minnesota
(Number)
105
103
174
182
96

(Number)
23
30
40
23
21

Twin Cities1
(Percent of State Total)
21.9
29.1
22.9
12.6
21.8

1
Includes the counties of Anoka, Dakota, Hennepin, Ramsey, and Washington.
SOURCE: El Paso Intelligence Center (EPIC), National Clandestine Laboratory Seizure System, 2005

Exhibit 8. Number of Children Affected1 by Methamphetamine Labs in Minnesota and Twin Cities:
2000–2004
Year

Minnesota
(Number)

2000
2001
2002
2003
2004

17
20
48
54
14

(Number)
1
3
14
10
2

Twin Cities2
(Percent of State Total)
5.8
15.0
29.2
18.5
14.2

1

Children affected includes children exposed to chemicals, children present, children in protective custody, and children residing in a
methamphetamine lab.
2
Includes the counties of Anoka, Dakota, Hennepin, Ramsey, and Washington.
SOURCE: El Paso Intelligence Center (EPIC), National Clandestine Laboratory Seizure System, 2005
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Exhibit 9. Number of Cases and Rates per 100,000 Population of HIV Infection, by Mode of Exposure1 in
Minnesota: 2004
Exposure Category
4

MSM
IDU5
MSM/IDU
Heterosexual6 (Total)
with IDU
with Bisexual Male
with Hemophiliac/other
with HIV-positive, unknown risk
Perinatal7
Other
Unspecified8
No Interview 9
Total

Cases

Males
Percent

Rate

2

Cases

Females
Percent

Rate2

Cases

Total
Percent

Rate3

121
8
13
(9)
3
-0

56
4
6
4
----

X
X
X
X
X
X
X

-5
-(25)
1
3
0

-6
-28
----

X
X
X
X
X
X
X

121
13
13
(34)
4
3
0

39
4
4
11
----

X
X
X
X
X
X
X

6

--

X

21

--

X

27

--

X

0
0
31
35
217

0
0
14
16
100

X
X
X
X
8.9

0
1
27
31
90

1
1
30
34
100

X
X
X
X
3.6

1
1
58
66
307

0
0
19
21
100

X
X
X
X
6.2

1

HIV infection includes all new cases of HIV infection (both HIV [non-AIDS] and AIDS at first diagnosis) among Minnesota residents
in 2004.
U.S. Census 2000 data necessary to calculate race-specific rates (specifically a breakdown of the State population by "Race alone
or in Combination with one or more races" by gender) have not yet been released for Minnesota. When these data become available, this table will be updated. Numbers exclude Federal and private prisoners and refugees in the HIV-Positive Refugee Resettlement Program.
3
Rates calculated using U.S. Census 2000 data. Accurate population estimates for Black, African-born persons living in Minnesota
are unavailable – anecdotal (50,000) and 2000 U.S. Census data (35,188)) were used to create the range of rates reported for African-born persons. The population estimate for Black, African-American persons (167,784) was calculated by subtracting the U.S.
Census estimate for African-born persons (35,188) from the total Black population (202,972). Note that this assumes that all African-born persons are Black (as opposed to another race).
4
MSM = Men who have sex with men.
5
IDU = Injection drug user.
6
Heterosexual = For males: heterosexual contact with a female known to be HIV-positive, an injecting drug user, or a
hemophiliac/blood product or organ transplant recipient. For females: heterosexual contact with a male known to be HIV-positive,
bisexual, an injecting drug user, or a hemophiliac/blood product or organ transplant recipient.
7
Perinatal = Mother-to-child HIV transmission; birth may have occurred in a previous year.
8
Unspecified = Cases who did not acknowledge any of the risks listed above.
9
No Interview = Cases who refused to be, could not be, or have not yet been interviewed.
SOURCE: Minnesota Department of Health
2
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Drug Abuse in the Newark
Primary Metropolitan
Statistical Area
Allison S. Gertel-Rosenberg, M.S.1
ABSTRACT
In this report, drug abuse indicators in the Newark
primary metropolitan statistical area (Newark
PMSA) are presented using substance abuse treatment data, emergency department data, medical
examiner cases, and other information. Most primary treatment admissions (72.4 percent) in 2004
were for illicit drugs. Heroin accounted for 72.7
percent of all primary admissions for illicit drugs in
the Newark PMSA, compared with 11.3 percent of
admissions for primary crack/cocaine, and 11.8
percent of admissions for primary marijuana use.
Consistent with the treatment data, emergency department reports of heroin in the Newark PMSA
accounted for the largest proportion of drug reports.
Heroin purity remains high, at 61.3 percent in 2003.
Between January and December 2004, cocaine accounted for 45.5 percent of items analyzed by
NFLIS, followed by heroin (34.3 percent) and marijuana (9.0 percent).
INTRODUCTION
Area Description
The Newark primary metropolitan statistical area
(PMSA) consists of five counties (Essex, Morris,
Sussex, Union, and Warren). In 2003, there were an
estimated 2,069,188 residents in the PMSA, with 38
percent living in Essex County (which contains Newark City), 26 percent in Union County, 23 percent in
Morris County, and the rest residing in the remaining
counties. According to the 2000 Census, the population of the Newark PMSA is diverse with respect to
race: 66 percent are White, 22 percent are Black, and
4 percent are Asian. Hispanics accounted for 13 percent of the PMSA population in 2000. There is also a
wide variation in racial/ethnic breakdowns for each
county. In Essex County, 45 percent of the population is White and 41 percent are Black. Union County
is 65 percent White and 21 percent Black. By comparison, Morris County is 87 percent White and 3
percent Black; Sussex County is 96 percent White

1

The author is affiliated with the Division of Addiction Services,
New Jersey Department of Human Services, Trenton, New Jersey.
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and 1 percent Black; and Warren County is 95 percent White and 2 percent Black. Hispanics accounted
for 15 percent of the population in Essex, 8 percent in
Morris, 3 percent in Sussex, 20 percent in Union, and
4 percent in Warren. The counties are also very diverse by socioeconomic status. In the Newark PMSA
as a whole, 5.8 percent of families with children
younger than 18 live below the poverty level. For
counties within the PMSA, the poverty status for
families with children younger than 18 is 18 percent
in Essex, 3 percent in Morris, 4 percent in Sussex, 9
percent in Union, and 5 percent in Warren. These
social, demographic, and economic variations suggest
substantial differences in drug use behaviors of residents by county.
New Jersey is situated between major industrial markets in New York and Pennsylvania and has been
referred to as the “crossroads of the east.” It is a
gateway State, with major interstate highways, roadways, airports, seaports, and other infrastructures
capable of accommodating large amounts of passenger and cargo traffic from both the eastern and western parts of the United States. New Jersey can therefore be considered an ideal strategic, as well as vulnerable, corridor for the transportation of drug contraband and illicit currency.2
New Jersey has one of the highest concentrations of
pharmaceutical and biochemical manufacturing firms
in the country. According to the Drug Enforcement
Administration (DEA), the most prevalent sources of
diverted pharmaceutical drugs in New Jersey include
doctor shopping, prescription forgery, and organized
prescription rings. The forging of prescriptions is a
continuing problem among employees in the medical
field who use their positions to gain access to blank
prescription pads. The most commonly diverted
pharmaceuticals are the benzodiazepines and opiates,
especially the hydrocodone products, with Percocet,
Percodan, Xanax, Dilaudid, Valium, and Vicodin
representing the most common brand-name drugs
diverted. The DEA is also reporting an increase in the
diversion of OxyContin, both in Newark and South
Jersey, where it has become a particular problem
among teenagers and young adults.
Illicit Substances in the News
In January and February 2005, the New Jersey Poison
Information and Education System (NJPIES) reported eight cases of probable cyanide intoxication in
heroin users. The heroin users were hospitalized in
three different healthcare facilities in New Jersey.

2

DEA Briefs and Background State Fact Sheets. New Jersey
2004. http://www.usdoj.gov/dea/pubs/states/newjersey.html.
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deleted. Therefore, the data presented in this paper
are subject to change. Data derived from DAWN
Live! represent drug reports in drug-related ED
visits. Drug reports exceed the number of ED visits, since a patient may report use of multiple
drugs (up to six drugs and alcohol). The DAWN
Live! data are unweighted and, thus, are not estimates for the reporting area. These data cannot be
compared to DAWN data from 2002 and before,
nor can preliminary data be used for comparison
with future data. Only weighted DAWN data released by SAMHSA can be used for trend analysis. A full description of the DAWN system can
be found at http://dawn info.samhsa.gov.

The source of the heroin was reported as dealers in
Easton, Pennsylvania, Plainfield, New Jersey, and
Asbury Park, New Jersey.3
In March 2005, the New Jersey State Police and the
DEA combined forces to break up a nationwide crystal methamphetamine operation, arresting four individuals and seizing cash, narcotics, and weapons
from locations in New Jersey and California. The
investigation targeted the crystal methamphetamine
distribution activities of a member and past president
of the Bandanas Motorcycle Club, headquartered in
Monmouth County. As a result of the New Jersey
investigation, a total of 4.5 kilograms of methamphetamine was seized, with a street value of approximately $350,000.4

•

Drug seizure and law enforcement data were
provided by the National Drug Intelligence Center’s “New Jersey Drug Threat Assessment Update” released in April 2004. Updated data on
Federal drug-related sentences were gathered
from the United States Sentencing Commission,
Office of Policy Analysis, for fiscal year (FY)
2002.

•

Forensic analysis data on specific drugs were
provided by the Drug Enforcement Administration’s National Forensic Laboratory Information
System (NFLIS) for January through December
2004.

•

Mortality data were obtained from the
SAMHSA January 2004 report entitled “Mortality Data From the Drug Abuse Warning Network
2002.” The DAWN system compiled data for
counties in the Newark PMSA. The DAWN system covered 88 percent of the metropolitan statistical area (MSA) population in 2002. Additional mortality data were analyzed from the
New Jersey Department of Health and Senior
Services, Center for Health Statistics. The additional mortality data are for calendar year 2002.

•

Illicit drug price and purity data were obtained from the Current Intelligence Unit at the
National Drug Intelligence Center. The data for
July through December 2004 were reported in
the December 28, 2004, edition of Narcotics Digest Weekly. Additional information on heroin
purity was provided by the Domestic Monitor
Program (DMP) and represents the time period
of January through December 2003.

•

Human immunodeficiency virus (HIV) and
acquired immunodeficiency syndrome (AIDS)
data were obtained from the statewide AIDS
Registry maintained by the New Jersey Department of Health and Senior Services, Division of

Data Sources
This report uses data from various sources, as indicated below:
•

•

Drug treatment data were obtained from the
New Jersey Substance Abuse Monitoring System
(NJSAMS) and the Alcohol and Drug Abuse Data
System (ADADS), statewide, episode-based data
systems operated by the Division of Addiction
Services of the Department of Human Services.
The preliminary data for calendar year 2004 include profiles by primary drug of abuse in Newark
City, the Newark PMSA, and the State. The 2003
Treatment Episode Data Set (TEDS), Office of
Applied Studies (OAS), was used to depict demographic characteristics of statewide admissions
and was accessed May 27, 2005.
Emergency department (ED) drug reports data
were derived for calendar year 2004 from the
Drug Abuse Warning Network (DAWN) Live! restricted-access online query system administered
by the OAS, Substance Abuse and Mental Health
Services Administration (SAMHSA). Eligible
hospitals in the Newark metropolitan area totaled
47; hospitals in the DAWN sampled numbered
39, with the number of emergency departments in
the sample totaling 43. (Some hospitals may have
more than one emergency department.) During
this 12-month period, between 10 and 12 EDs reported data each month. The completeness of data
reported by participating EDs varied by month
(exhibit 1). Exhibits in this paper reflect cases that
were received by DAWN as of April 13–14, 2005.
All DAWN cases are reviewed for quality control.
Based on this review, cases may be corrected or

3

Perspectives: A journal on addiction research and public policy.
NCADD New Jersey, February 2005.
4
NJ State Police Press Release. March 21, 2005.
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AIDS Prevention and Control, HIV/AIDS Surveillance Program. Data on the State, Newark
PMSA, and Newark City compiled as of December 31, 2004, are used in this report.
SPECIAL CONSIDERATIONS: DAWN LIVE!
EMERGENCY DEPARTMENT REPORTS DATA
Preliminary analysis of ED visit data indicate 5,785
drug-related visits for major substances of abuse (including alcohol) in the Newark metropolitan area
between January and December 2004. Visits are
identified as belonging to one of eight categories.
These categories are related to ED visits associated
with substance abuse and drug misuse, both intentional and accidental. The case types are suicide attempt, seeking detoxification, alcohol only in patients
under 21, adverse reaction, overmedication, malicious poisoning, accidental ingestion, and other. The
“other” category is designed to capture all of the
drug-related ED visits that could not be classified in
any of the other categories—this category captures
most of the drug abuse cases.
In the Newark metropolitan area, the majority (44.7
percent) of DAWN visits are classified as “other,” a
category that includes most illicit drugs. This is to be
expected, given the protocol for assigning visits to
categories. “Overmedication” plus “other” plus
“seeking detoxification” accounted for 62.3 percent
of all visits. For a breakdown of all visits by type, see
exhibit 2.
DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
In preliminary data for January through December
2004, primary cocaine/crack treatment admissions
accounted for 7.2 percent of all admissions in Newark City (compared to 6.2 percent in 2003) and for
7.9 percent of admissions for illicit drugs (i.e., excluding alcohol, compared to 6.8 percent in 2003)
(exhibits 3 and 4).
In the Newark PMSA, the proportion of primary
crack/cocaine admissions (excluding alcohol) was
somewhat higher than in the city—11.3 percent in
2004, up slightly from 9.8 percent in 2003. The proportion of crack/cocaine admissions among all admissions was higher in the PMSA as well: 9.0 percent in 2004 and 7.8 percent in 2003.
The proportion of primary cocaine/crack admissions
(excluding alcohol) statewide increased slightly from
14.0 percent in 2003 to 15.1 percent in 2004. In 2004,
the proportion of statewide primary crack/cocaine
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admissions was much higher than reported in Newark
City (7 percentage points higher) and almost 4 percentage points higher than in the PMSA (exhibit 3).
TEDS data for the State for 2003 show crack admissions were somewhat more likely to be Black than
White (53 versus 43 percent) and male rather than
female (58 versus 42 percent). Admissions for primary abuse of powder cocaine, however, were substantially more likely to be White than Black (65
versus 30 percent) and male rather than female (70
versus 30 percent) (exhibit 5).
According to unweighted data accessed from DAWN
Live!, cocaine ranked second to heroin in the number
of ED reports for major substances of abuse in the
Newark PMSA in 2004 (exhibit 6). The data for 2004
collected from the DAWN Live! system on April 13–
14, 2005, indicate 1,505 cocaine ED reports for all
causes. Approximately 68 percent of the cocaine ED
patients were Black (exhibit 7), and 83 percent were
age 30 and older.
The most recently available mortality data from 2002
indicated 127 cocaine/crack-related deaths.
Between January and December 2004, cocaine/crack
accounted for 45.5 percent of the 2,858 items analyzed by NFLIS, the highest proportion for any drug
(exhibit 8).
According to the National Drug Intelligence Center
(NDIC) National Drug Threat Survey (NDTS) 2003,
80.1 percent of law enforcement agency respondents
in New Jersey reported that powder cocaine was
readily available (availability described as either high
or moderate), while 73.0 percent reported that crack
cocaine was readily available. Additionally, 29.2 percent of law enforcement officials throughout New
Jersey identified cocaine, either powder (12.1 percent) or crack (17.1 percent), as their greatest drug
threat.
More cocaine is seized in the State than any other
illicit drug except marijuana. According to Federalwide Drug Seizure System (FDSS) data, Federal law
enforcement officials seized 480 kilograms of cocaine in 2002. Data from the United States Sentencing Commission (USSC) indicate that the percentage
of drug-related Federal sentences in New Jersey that
were related to cocaine in FY 2001 (45.1 percent)
surpassed the percentage nationwide (42.5 percent)
for the first time in the previous 5 years. In FY 2002,
the percentage of drug-related Federal sentences attributable to cocaine rose to 56 percent (exhibit 9),
once again surpassing the national average (42.7 percent) (exhibit 9).
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Cocaine, particularly crack, is the drug most often
associated with violent crime in New Jersey. Federal,
State, and local law enforcement in New Jersey report that dealers frequently carry firearms and commit drive-by shootings, assaults, and murders. According to the NDTS, 49.5 percent of New Jersey law
enforcement agencies identified cocaine, either powder (15 percent) or crack (34.5 percent), as the drug
that most contributes to violent crime. The Essex
County Narcotics Task Force reported major increases in the number of cocaine-related homicides in
2003. As of June 5, 2003, there were 60 drug-related
homicides in Essex County; most were attributable to
powder or crack cocaine distribution.
Between July and December 2004, the retail price for
powder cocaine in Newark was $9–$100 per gram;
crack sold for $20–$100 per gram (exhibit 10).
Heroin
As a proportion of illicit drug treatment admissions,
primary heroin accounted for 81.8 percent in Newark
City in 2004, which was slightly lower than the 85.4
percent in 2003 (exhibits 3 and 4). In the Newark
PMSA, primary heroin admissions accounted for
72.7 percent of illicit drug admissions in 2004,
slightly lower than the 77.3 percent in 2003, and for
58.2 percent of all treatment admissions (including
alcohol).
Primary heroin admissions predominated across the
State in 2004, accounting for 59.2 percent of all admissions for drugs other than alcohol (exhibit 3). This
is down from 64.2 percent in 2003 (exhibit 4) and
represents the second annual decrease in the proportion of primary heroin admissions statewide since
1996.
TEDS data for 2003 indicate that, statewide, 56.4
percent of primary heroin admissions were White and
37.6 percent were Black (exhibit 5). Sixteen percent
were Hispanic. Primary heroin users were also predominately male (65.5 percent) (exhibit 5).
The unweighted data accessed from DAWN Live!
show that the number of ED reports for heroin in
2004 was higher than the number of reports for other
single illicit drugs, at 1,764 reports between January
and December 2004 (as of April 13–14, 2005). Of the
1,764 heroin ED reports, 55.2 percent were for male
patients, 62.5 percent were for patients who were
Black (exhibit 7), and 82.5 percent were for patients
age 30 and older.
Although heroin is the leading drug among treatment admissions and ED reports in Newark, it ac-
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counted for only 34.3 percent of the 2,858 items
analyzed by NFLIS between January and December
2004 (exhibit 8).
The most recently available mortality data from 2002
indicate 149 heroin death mentions. The number of
death mentions was down from 177 reported in 2001,
however, and 179 reported in 2000. The slight
downward trend in death mentions in 2002 is consistent with recent patterns in both treatment and ED
data.
According to the NDTS 2003, 73.4 percent of New
Jersey law enforcement agencies reported that heroin
was readily available, while 31.6 percent of agencies
identified heroin as the greatest drug threat.
According to FDSS data, Federal law enforcement
officials in New Jersey seized 91 kilograms of heroin
in 2000, 169 kilograms in 2001, and 188 kilograms in
2002. USCC data indicate that in FY 2001, heroinrelated Federal sentences accounted for a significantly higher percentage of all drug-related Federal
sentences in New Jersey (31.5 percent) than nationwide (7.2 percent). This trend continued in FY 2002,
when heroin-related Federal sentences accounted for
25.6 percent of New Jersey’s drug-related Federal
sentences, compared with 7.1 percent nationally (exhibit 9).
Heroin purity is still very high, but it decreased
somewhat in 2003 in the Newark PMSA. In 2001,
heroin was 70.5 percent pure, and in 2002, it was
71.4 percent pure. In 2003, however, heroin purity
dropped to 61.3 percent pure. The price per gram
between July and December 2004 was $25–$320
(exhibit 10). In 2003, despite the drop in heroin purity, the Newark PMSA had the highest heroin purity
coupled with the lowest price among the 21 DAWN
cities. According to the DMP, almost all of the heroin
sold in the Newark PMSA is South American.
Marijuana
Primary marijuana treatment admissions represented
7.1 percent of all treatment admissions in Newark
City in 2004, compared with 9.4 percent in the Newark PMSA and 12.0 percent in the State as a whole.
As a proportion of illicit drug treatment admissions,
marijuana accounted for 7.8 percent in Newark City
and 11.8 percent in the Newark PMSA (exhibit 3) in
2004, both approximately 1 percentage point higher
than in 2003 (exhibit 4).
Statewide primary marijuana admissions (excluding
alcohol) were more than twice the proportion of those
in Newark City (16.6 vs. 7.8 percent) and about 5
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percentage points higher than those in the Newark
PMSA (16.6 percent vs. 11.8 percent)(exhibit 3).
Statewide TEDS data for 2003 indicate that 81.7 percent of primary marijuana admissions were male,
51.3 percent were White, and 42.5 percent were
Black. About 17.2 percent of primary marijuana admissions statewide were Hispanic. Across the State,
30.9 percent of primary marijuana admissions were
younger than 18, and 72.2 percent were younger than
26 (exhibit 5).
According to unweighted data accessed from DAWN
Live!, the number of marijuana ED reports between
January and December 2004 was 505 (exhibit 6).
Individuals younger than 30 represented approximately 60 percent of the marijuana patients.
Among the 2,858 items analyzed by NFLIS between
January and December 2004, marijuana accounted
for 9.0 percent (258 items) (exhibit 8).
Marijuana is the most widely available and most frequently seized illicit drug in New Jersey. According
to the NDTS 2003, 96.9 percent of New Jersey law
enforcement agencies report that marijuana is readily
available, although only 30.6 percent of New Jersey
law enforcement agencies identified marijuana as
their greatest drug threat.
According to FDSS data, marijuana accounted for
57.0 percent (1,626 kilograms) of illicit drugs seized
by law enforcement officials in New Jersey in 2002.
Data from the DEA Domestic Cannabis Eradication/Suppression Program indicate that law enforcement officials eradicated 831 plants from outdoor
grows in New Jersey in 2001 and 957 in 2002. In
addition, law enforcement officials eradicated 182
plants from indoor grows in the State in 2001 and
1,345 in 2002. USSC data indicate that the percentage of drug-related Federal sentences related to marijuana in New Jersey in FY 2001 (8.4 percent) was
significantly lower than the percentage nationwide
(32.8 percent). The percentage of drug-related Federal sentences related to marijuana in New Jersey
decreased in FY 2002 to 4.9 percent, compared with
28.9 percent nationally (exhibit 9).
Between July and December 2004, locally produced
marijuana sold in Newark for $5–$30 per bag (exhibit 10).
Pharmaceuticals
The distribution and abuse of pharmaceuticals is
growing at an increasing rate in New Jersey. According to the NDTS 2003, 60.4 percent of New Jersey
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law enforcement agencies reported that pharmaceuticals were readily available. NDTS 2003 data further
indicate that New Jersey law enforcement agencies
reported OxyContin, Percocet, and Xanax as the most
commonly diverted or illicitly used pharmaceuticals
in the State. Diverted pharmaceuticals often are sold
behind closed doors and occasionally at open-air drug
markets, primarily in Essex (Newark and Irvington),
Camden, and Salem Counties. According to the DEA
Newark Division, diverted OxyContin sold for $15
per 20-milligram tablet and $30 per 40-milligram
tablet during the second quarter of FY 2003. Diverted
Percocet sold for $1 to $10 per tablet, and diverted
Xanax sold for $1 to $2 per tablet during that same
period.
Opiates Other Than Heroin
In 2004, primary treatment admissions for “other
opiates or synthetics” in Newark City totaled nine (or
0.2 percent of the admissions, excluding alcohol admissions). The number was higher in the PMSA—
137 (1.2 percent of the admissions, excluding alcohol). This is unchanged from 2003, when figures for
the city and PMSA, respectively, were 0.2 and 1.3
percent. In the State as a whole, primary admissions
for other opiates in 2004 totaled 1,142, or 2.9 percent
of all admissions, excluding alcohol. In 2003, the
number of primary admissions for other opiates totaled 1,112, representing more than double the admissions reported in 1997 (513). The biggest increase
in numbers of other opiate admissions occurred between 2000 (592) and 2002 (1,124). In 2003, admissions reporting other opiates as primary, secondary,
or tertiary drug of abuse numbered 2,303 and accounted for nearly 6 percent of all drug admissions
statewide. In the TEDS data for 2003, 91 percent of
the primary “other opiate” admissions were White
and 6 percent were Black (exhibit 5). Only 5 percent
of the primary “other opiate” admissions were Hispanic; about 62 percent were male.
In an analysis run April 13–14, 2005, the DAWN
Live! system recorded 469 opiates/opioids ED reports
related to seeking detoxification, overmedication, and
“other” between January and December 2004. Of
those reports in the ED, 10.4 percent were patients
seeking detoxification, 26.0 percent had overmedicated, and 63.5 percent were classified in the “other”
category (exhibit 11).
In 2002, there were 151 ME death mentions for narcotic analgesic/combinations, representing the largest
number of death mentions for any drug. Although the
number of mentions was down from 190 in 2001, the
number of mentions was more than twice that re-
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ported in 2000 (75) and more than 3 times the number in 1999 (44).

law enforcement officials in New Jersey seized 0.8
kilograms of methamphetamine in 2002.

Benzodiazepines

USSC data indicate that the percentage of drugrelated Federal sentences related to methamphetamine in New Jersey in FY 2001 (5.2 percent) was
lower than the percentage nationwide (14.2 percent).
Sentencing data from FY 2002 indicate that methamphetamine-related sentences in New Jersey represented 3.4 percent of all drug-related sentences (exhibit 9). This continues to be significantly lower than
the nationwide average of 15.5 percent in FY 2002.

In an analysis run April 13–14, 2005, the DAWN
Live! system recorded 383 benzodiazepine ED reports related to seeking detoxification, overmedication, and “other” between January and December
2004. Of those, 6.3 percent were patients seeking
detoxification, 39.4 percent had overmedicated, and
54.3 percent were classified in the “other” category
(exhibit 11). The proportion of ED benzodiazepine
reports to opiates/opioids reports is 0.8.
The 2002 DAWN mortality data show only 54 benzodiazepine mentions in the Newark PMSA. However, this represents an increase from 33 mentions in
2001 and 35 mentions in 2000. Benzodiazepines accounted for approximately 7.8 percent of all ME
death mentions in 2002, up from 4.2 percent in 2001.
Methamphetamine and Amphetamines
In 2004, only 31 primary amphetamine treatment admissions, including 5 primary methamphetamine admissions, were reported in the Newark PMSA. As a
primary drug of abuse, amphetamines were also rare in
the State. There were 149 primary amphetamine admissions in 2004, including 47 admissions for
methamphetamine. The number of total admissions for
primary amphetamine abuse demonstrated an increase
from the 112 admissions reported in 2003. According
to the 2003 TEDS data, amphetamine users are much
more likely to be male than female (68 percent versus
32 percent, respectively). Amphetamine users are also
significantly more likely to be White (81 percent) than
Black (10 percent) or Hispanic (11 percent). Approximately one-third of amphetamine users are age 25 or
younger (37 percent); one-third are between the ages
of 26 and 35 (34 percent); and one-third are older than
35 (29 percent).
Preliminary unweighted data accessed through
DAWN Live! for January through December 2004
show only four methamphetamine ED reports. ED
reports for amphetamines, however, were higher, at
42 (exhibit 6). Patients younger than 25 accounted for
approximately 50 percent of amphetamine reports.
Methamphetamine availability is limited in New Jersey. According to the NDTS 2003, 17.1 percent of
New Jersey law enforcement agencies reported that
methamphetamine was readily available, and 1.3 percent of agencies identified methamphetamine as their
greatest drug threat. According to FDSS data, Federal
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Methamphetamine prices at the wholesale and midlevel have fluctuated in New Jersey. These price
variations resulted primarily from increased costs
associated with obtaining methamphetamine (particularly crystal methamphetamine) from other regions of
the country and other countries and transporting the
drug to New Jersey.
Methamphetamine previously sold for $8,500 to
$20,000 per kilogram and $800 to $1,000 per ounce;
between July and December 2004, methamphetamine
sold for $15,000–$25,000 per kilogram and $800–
$1,500 per ounce (exhibit 10). On the retail level,
methamphetamine sold for between $20 and $180 per
gram.
Methylenedioxymethamphetamine (MDMA or
Ecstasy)
The number of unweighted MDMA ED reports in
2004 in the DAWN Live! system was 21.
Between July and December 2004, MDMA sold for
between $20 and $30 per tablet (exhibit 10).
Phencyclidine (PCP)
The unweighted number of PCP ED reports in 2004
accessed from the DAWN Live! system was 22 (exhibit 6).
Alcohol
In the Newark PMSA, alcohol-only treatment admissions as a proportion of all admissions decreased
from 12.3 percent in 2003 to 10.2 percent in 2004,
while alcohol-in-combination admissions increased
slightly from 8.0 percent to 9.8 percent during the
same time period.
Alcohol-in-combination with other drugs or alcohol
alone for those younger than 21 accounted for 1,273
ED reports in the DAWN system for the Newark
PMSA in 2004 (exhibit 6).
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INFECTIOUS DISEASES RELATED TO DRUG ABUSE
In 2003, New Jersey ranked fifth nationally in cumulative AIDS cases, third in cumulative pediatric AIDS
cases, and ninth in cases reported in 2003. As of December 31, 2004, there were 65,404 cumulative
HIV/AIDS cases reported in New Jersey, about 1,182
of which were reported in 2004. Of the cumulative
cases, 25,880 (39.6 percent of the State total) were in
the Newark PMSA, and 12,527 (19.2 percent of the
State total) were in Newark City. A total of 64,167
cumulative HIV/AIDS cases statewide, and 12,244 in
Newark City, were adults/adolescents age 13 or older.
Statewide, the proportion of HIV/AIDS cases involving injection drug use has declined substantially.
Thus, approximately 41 percent of cumulative
HIV/AIDS cases statewide historically involved injection drug use alone, compared with 14 percent of
the cases diagnosed between January and December
2004. In Newark City, 49 percent of cumulative cases
involved injection drug use alone (only cumulative
transmission mode data are available for Newark).
The proportion of cases linked to heterosexual transmission in New Jersey has increased dramatically.
Approximately 29 percent of cumulative cases and 46
percent of cases reported between January and December 2004 can be attributable to heterosexual
transmission. The majority of this difference can be
found in the “partners of unknown HIV risk” category. There has been a slight increase in the proportion of transmission cases among men having sex
with men (MSM). The cumulative proportion is 19
percent, while the proportion for this mode of transmission between January and December 2004 is 22
percent. Additionally, 15 percent of cases reported
between January and December 2004 are still recorded in the “other or unknown” transmission mode
category.
In Newark City, 10 percent of cumulative HIV/AIDS
cases involved MSM, 20 percent involved heterosexual contact, and 19 percent involved “other or unknown” transmission. A larger proportion of females
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(34 percent of cumulative cases in Newark and 53
percent in the State) were infected through heterosexual contact than males (11 percent and 19 percent
in Newark and the State, respectively).
There has been a steady increase in the number of
persons living with HIV/AIDS in Newark and in the
State as a whole. The total number statewide has increased from 25,343 in 1997 to 32,746 as of December 31, 2004.
Among people living with HIV/AIDS as of December 31, 2004, about 35 percent statewide and 41 percent in Newark City are female (exhibits 12 and 13).
Compared to the State as a whole, a substantially
higher proportion of people living with HIV/AIDS in
Newark are non-Hispanic Black (79 vs. 56 percent)
(exhibits 12 and 14). About 17 percent among those
living with HIV/AIDS in Newark and 21 percent
statewide are Hispanic, and about 3 percent in Newark and 22 percent statewide are non-Hispanic White.
With respect to transmission mode among people
living with HIV/AIDS, injection drug use alone accounted for 31 percent of cases statewide and 38 percent in Newark. Heterosexual contact accounted for
21 percent of cases statewide and 25 percent in Newark. Male-to-male sexual contact alone accounted for
19 percent statewide and 10 percent in Newark, while
such behavior and injection drug use combined were
involved in 3 percent of cases statewide and 3 percent
of cases in Newark. The continued increase in heroin
injection by the young (age 18–25) and the very high
levels of heroin abuse and heroin-related deaths continue to pose a serious risk for an increase in the
prevalence of infectious diseases. However, no data
are yet available to document any rise in the prevalence of HIV/AIDS in New Jersey.
For inquiries concerning this report, please contact Allison GertelRosenberg, M.S., Program Manager, Division of Addition Services, Office of Policy Management, New Jersey Department of
Human Services, 120 South Stockton Street, 3rd Floor, P.O. Box
362, Trenton, NJ 08625, Phone: 609-984-4050, Fax: 609-2921045, E-mail: Allison.gertel@dhs.state.nj.us.
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Exhibit 1. Newark DAWN ED Sample and Reporting Information: January–December 2004
Total Eligible
Hospitals1

No. of Hospitals
in DAWN Sample

Total EDs in
DAWN Sample2

47

39

43

No. of EDs Reporting per Month:
Completeness of Data (%)
90–100%

50–89%

<50%

7–10

0–2

0–3

No. of EDs Not
Reporting
31–33

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005

2

Exhibit 2: Distribution of DAWN ED Visits, by Visit Type (Unweighted1): 2004

Other
44.7%

Accidental ingestion
2.1%

Suicide attempt
3.2%

Malicious poisoning
0.3%

Overmedication
8.7%

Seeking detox
8.9%

Adverse reaction
27.7%

Alcohol only (<21)
4.3%

1

The unweighted data are from the 10–12 Newark EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.
SOURCE: Dawn Live!, OAS, SAMHSA, updated April 13–14, 2005

Exhibit 3. Percentages of Primary Treatment Admissions (Excluding Alcohol) for Selected Drugs in Newark
City, Newark PMSA, and New Jersey: January–December 2004
81.8
Heroin

72.7
59.2

7.9
Cocaine/Crack

City

11.3
15.1

PMSA
State

7.8
Marijuana

11.8
16.6
0

10

20

30

40

50

60

70

80

90

SOURCE: Alcohol and Drug Abuse Data System, New Jersey Substance Abuse Monitoring System, Division of Addiction Services,
NJ Department of Human Services
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Exhibit 4. Percentages of Primary Treatment Admissions (Excluding Alcohol) for Selected Drugs in Newark
City, Newark PMSA, and New Jersey: 2003
85.4
77.3

Heroin
64.2

6.8
9.8

Cocaine/Crack

City
14.0

PMSA
State

7.0
10.1

Marijuana

15.2
0

10

20

30

40

50

60

70

80

90

SOURCE: Alcohol and Drug Abuse Data System, New Jersey Substance Abuse Monitoring System, Division of Addiction Services,
NJ Department of Human Services

Exhibit 5. Characteristics of Primary Substance Abuse Treatment Admissions in the State, by Percent:
20031
Characteristic
Gender
Male
Female
Race/Ethnicity
White
Black
Hispanic
Age at Admission
17 and younger
18–25
26–35
36 and older

Alcohol
Only

Alcohol-inCombination

Crack

Cocaine

Marijuana

Heroin

Other
Opiates

73.7
26.1

74.7
25.2

58.0
41.9

69.4
30.4

81.7
18.2

65.5
34.4

61.9
37.9

81.8
13.1
11.2

67.4
28.1
10.1

42.6
53.2
8.8

64.8
29.5
17.6

51.3
42.5
17.2

56.4
37.6
16.0

91.4
6.0
5.2

1.1
9.0
17.5
72.4

5.1
20.4
25.8
48.7

0.7
11.1
33.2
55.0

2.4
19.3
32.6
45.7

30.9
41.3
19.1
8.7

0.4
19.0
31.5
49.1

1.7
17.4
30.5
50.4

1

Percentages may not add to 100 due to rounding or missing values.
SOURCE: TEDS, OAS, SAMHSA, accessed May 27, 2005
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Exhibit 6. Number of Drug Reports in Drug-Related ED Visits in the Newark PMSA, by Drug Category
(Unweighted1): 2004
Heroin

1,764

Cocaine

1,505

Alcohol

1,273
(250 are alcohol only f or patients younger than 21)

Marijuana
Amphetamines

505
42

Inhalants

27

PCP

22

MDMA

21

1

The unweighted data are from the 10–12 Newark EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.
SOURCE: Dawn Live!, OAS, SAMHSA, updated April 13–14, 2005

Exhibit 7. Race/Ethnicity of ED Reports for Selected Drugs (Unweighted1): 2004
Race/Ethnicity
White
Black
Hispanic
Race/Ethnicity NTA
Not Documented
TOTAL

Cocaine
N
251
1,024
128
3
99
1,505

Heroin
(%)
16.7
68.0
8.5
0.2
6.6
100

N
354
1,102
186
3
119
1,764

(%)
20.1
62.5
10.5
0.2
6.7
100

1

The unweighted data are from the 10–12 Newark EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.
SOURCE: Dawn Live!, OAS, SAMHSA, updated April 13–14, 2005

Exhibit 8. Number of Items Analyzed for Specific Drugs in Newark and Percentage of Total Items: 2004
Substance
Cocaine
Heroin
Marijuana

Count
1301
980
258

1

Percent (%)
45.52
34.29
9.03

1

N = 2,858
SOURCE: NFLIS, DEA
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Exhibit 9. Drug-Related Federal Sentences in New Jersey, by Drug and Percent: FY 2002

Marijuana
4.9%

Heroin
25.6%
Crack Cocaine
19.5%

Methamphetamine
3.4%
Other
10.2%
Pow der Cocaine
36.5%

N=266
SOURCE: United States Sentencing Commission, Office of Policy Analysis, 2002 Datafile

Exhibit 10.

Illicit Drug Prices for Newark City: July 2004–December 2004

Drug

Price in Dollars ($)
Wholesale

Midlevel

Powder Cocaine

$15,000–$34,000 per kilogram

$600–$1,800 per ounce

Crack Cocaine

$20,000–$35,000 per kilogram

$644–$2,000 per ounce

Heroin

$52,000–$120,000 per kilogram

Marijuana

$500–$1,700 per pound (boogie)
$3,500–$6,500 per pound (hydroponic)
$6,000–$7,000 per pound (purple
haze)

$1,600–$3,360 per ounce
$50–$600 per ounce
$100–$400 per ounce (hydroponic)
$400–$1,100 per 1/4 pound
$250–$1,750 per 1/4 pound
(hydroponic)
$400–$2,000 per 1/2 pound
$500–$2,500 per 1/2 pound
(hydroponic)

Methamphetamine

$8,000–$20,000 per pound
$15,000–$25,000 per kilogram

$800–$1,500 per ounce

MDMA

$7–$12 per tablet

NA

Retail
$9–$100 per gram
$20–$100 per gram
$150–$200 per 1/8 ounce
$25–$320/g

$2–$5 per joint
$5–$20 per blunt
$5–$30 per bag
$10–$30 per bag (hydroponic)
$20–$50 per gram
$20–$180 per gram
$9–$180 per gram (crystal meth)
$140–$300 per 1/8 ounce
$400–$1,200 per 1/2 ounce
$20–$30 per tablet

SOURCE: Narcotics Digest Weekly Dec. 28, 2004, National Drug Intelligence Center
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Exhibit 11. Prescription Drug Misuse – Number of Drug Reports in Drug-Related ED Visits, Selected Drugs,
by Case Type (Unweighted1): 2004

151

Benzodiazepines

Opiates/Opioids

24

122

208

49

383

298

Hydrocodone 2 16 7 27

469

Overmedication
Seeking Detox

38 14 38

Oxycodone

Muscle Relaxants

3

Other

90

14

0

100

200

300

400

500

600

1

The unweighted data are from the 10–12 Newark EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.
2
Hydrocodone: 4 seeking detox.
3
Muscle relaxants: 10 overmedication, 0 seeking detox, 4 other.
SOURCE: Dawn Live!, OAS, SAMHSA, updated April 13–14, 2005

Exhibit 12. Numbers and Percentages of Adult/Adolescent Cases Living with HIV/AIDS in New Jersey by
Exposure Category, Race/Ethnicity and Gender as of December 31, 2004
Males
Exposure Category
Men/sex/men (MSM)
Injection drug user (IDU)
IDU/MSM
Heterosexual Contact
Other/Unknown
TOTAL1
Race/Ethnicity
White
Black
Hispanic
Asian/Pacific Islander
Other/Unknown
TOTAL2

Females

Total

N

(%)

N

(%)

N

(%)

6,100
6,484
860
2,350
4,891
20,685

29
31
4
11
24
100

0
3,555
0
4,468
3,319
11,342

0
31
0
39
29
100

6,100
10,039
860
6,818
8,210
32,027

19
31
3
21
26
100

5,216
10,724
4,710
157
236
21,043

25
51
22
1
1
100

1,951
7,457
2,085
67
143
11,703

17
64
18
1
1
100

7,167
18,181
6,795
224
379
32,746

22
56
21
1
1
100

1

Does not include pediatric cases.
Includes pediatric cases.
SOURCE: NJ Department of Health and Senior Services, Division of AIDS Prevention and Control
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Exhibit 13. Adult/Adolescent Cases Living with HIV/AIDS in Newark City by Exposure Category and Gender
as of December 31, 2004
Exposure Category
Men/sex/men (MSM)
Injection drug user (IDU)
IDU/MSM
Heterosexual Contact
Other/Unknown
TOTAL

Males
N
565
1,292
159
506
822
3,344

Females
(%)
17
39
5
15
25
100

N
0
852
0
908
596
2,356

Total
(%)
0
36
0
39
25
100

N
565
2,144
159
1,414
1,418
5,700

(%)
10
38
3
25
25
100

SOURCE: NJ Department of Health and Senior Services, Division of AIDS Prevention and Control

Exhibit 14.

Race/Ethnicity of Cases Living with HIV/AIDS in Newark City: Through December 31, 2004

Race/Ethnicity
White, Non-Hispanic
Black, Non-Hispanic
Hispanic
Other
TOTAL

Adult/Adolescent
N
(%)
198
3
4,546
79
980
17
52
1
5,776
100

Pediatric
N
0
82
7
0
89

(%)
0
92
8
0
100

Total
N
198
4,628
987
52
5,865

(%)
3
79
17
1
100

SOURCE: NJ Department of Health and Senior Services, Division of AIDS Prevention and Control
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Drug Abuse Indicators in
New Orleans

Data Sources

Gail Thornton-Collins1

•

Forensic laboratory testing data were provided
by the Drug Enforcement Administration (DEA)
for 2004, as reported to the National Forensic
Laboratory Information System (NFLIS). Data
for 2003 are also included in this paper.

•

Drug treatment data were provided by the Louisiana State Office for Addictive Disorders and
by not-for-profit treatment facilities for Orleans
Parish for fiscal year (FY) 1995 through FY
2004, when 2,306 persons were treated in New
Orleans Parish. (Fiscal years run July through
June.) Data for FY 2004 in another eight of the
largest parishes in the State are also reported.

•

Emergency department (ED) data for calendar
year 2004 were accessed through the Drug
Abuse Warning Network (DAWN) Live! restricted-access online query system, which is
administered by the Office of Applied Studies
(OAS), Substance Abuse and Mental Health
Services Administration (SAMHSA). Nineteen
of the 21 eligible hospitals in the New Orleans
metropolitan area are in the DAWN sample, with
a total of 21 EDs in the sample. (Some hospitals
have more than one ED.) The data reported in
this paper were not complete. During the 12month period, between 8 and 11 EDs reported
data to DAWN each month (exhibit 2). Completeness of the data is summarized in exhibit 2.
The data in this paper were updated by OAS on
January 13–14, 2005; they are unweighted and
are not estimates for the New Orleans area. Since
all DAWN cases are reviewed for quality control, and may be corrected or deleted, the data
reported here are subject to change. The information derived from DAWN Live! represent drug
reports in drug-related visits; reports exceed the
number of ED visits because a patient may report
use of multiple drugs (up to six drugs and alcohol may be represented in DAWN). This paper
presents data on “Illicit Drugs of Abuse” (excluding “Alcohol Only” for patients younger
than 21), reports for prescription-type drugs, and
reports on visits involving alcohol. These data
cannot be compared with DAWN data from 2002
and before, nor can these preliminary data be
used for comparison with future data. Only
weighted ED data released by SAMHSA can be
used for trend analysis. A full description of the
DAWN system can be found at the DAWN Web
site: <http://dawninfo.samhssa.gov>.

Information for this report was collected from the
sources described below:

ABSTRACT
Although indicators continue to show a decline in
cocaine abuse, they remain high. In 2004, cocaine
accounted for 38 percent of drug items analyzed by
forensic laboratories, nearly 32 percent of treatment
admissions in Orleans Parish, and more than 49
percent of the (unweighted) ED illicit drug reports.
Marijuana abuse indicators are also high, accounting for nearly 53 percent of items analyzed by forensic labs, 32 percent of treatment admissions, and
25 percent of the (unweighted) illicit drug reports.
Heroin abuse indicators continue to be relatively
low. A growing problem is the abuse of narcotic
analgesics, especially hydrocodone. While not a
problem in Orleans Parish, methamphetamine accounts for around 4 to 6 percent of primary treatment admissions in four other large parishes, and
small clandestine methamphetamine labs are reportedly increasing in some rural areas.
INTRODUCTION
Area Description
Located in southern Louisiana, the city of New Orleans covers 366 square miles, of which 164 are water. Nearly one-half of the metropolitan area’s 1.3
million inhabitants live in Orleans Parish, the largest
of Louisiana’s 64 parishes. The total State population
is about 4.5 million people, based on 2003 census
projections (exhibit 1). As shown in exhibit 1, New
Orleans has a much higher percentage of AfricanAmericans than the State overall (67.2 vs. 32.1 percent) and a much lower percentage of Whites (28.1
vs. 64.0 percent). Nearly 21 percent of individuals in
New Orleans live below the poverty level, a proportion similar to the State overall.
Serviced by several deep-water ports, New Orleans is
located at the connection of two principal waterways:
the Gulf Intracoastal Waterway and the Mississippi
River. Barge lines, ocean carriers, and truck lines
serve the Port of New Orleans.

1

The author is affiliated with the New Orleans Health Department,
New Orleans, Louisiana.
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•

•

•

Drug arrest data were provided by the New
Orleans Police Department (NOPD) for 2003–
2004. Anecdotal information on arrests in 2004
was also provided by NOPD.
Drug price, purity, and seizure information
was extracted from Narcotics Digest Weekly,
Volume 3, Number 52, December 28, 2004, National Drug Intelligence Center (NDIC), and the
DEA for the last quarter of 2004. Data for heroin
purity were derived from the DEA’s Domestic
Monitor Program (DMP) for 2003.
Acquired immunodeficiency syndrome (AIDS)
and human immunodeficiency virus (HIV)
data were provided by the Louisiana HIV/AIDS
Surveillance System and represent cases reported
in the third quarter of 2004.

No recent drug-related mortality or survey data were
available for this reporting period. Trends in drugrelated mortality data (DAWN) and trends in data from
the Youth Risk Behavior Surveillance (YRBS) survey,
Centers for Disease Control and Prevention, can be
found in “Overview of Drug Abuse Indicators in New
Orleans,” Epidemiologic Trends in Drug Abuse, Proceedings Vol. II, published by NIDA, June 2004.
DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
Crack has been and continues to be the most serious
drug problem in New Orleans; it is associated with
high rates of violence and crime in the city. In 2004,
the DEA reported that crack and cocaine hydrochloride (HCl) were widely available in New Orleans in
quantities ranging from kilograms to grams.
Approximately 41.0 percent of all items analyzed by
NFLIS laboratories in New Orleans in 2004 were cocaine (exhibit 3), compared with 38.4 percent in 2003.
The proportion of primary cocaine/crack treatment
admissions in Orleans Parish has been declining since
1993. Cocaine/crack treatment admissions in the parish decreased from 40.4 percent of all admissions in
FY 1995 to 31.6 percent in FY 2004 (exhibit 4). A
possible reason for the decrease in the proportion of
cocaine admissions includes increases in court referrals of marijuana abusers to treatment.
A relatively high proportion (39.8 percent) of primary cocaine/crack treatment admissions in Orleans
Parish in 2004 was female. Most (80.3 percent) of the
male and female primary cocaine/crack admissions
were African-American. A relatively large percentage
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(41.4 percent) of the African-American female cocaine/crack admissions was age 35–44.
Across eight other Louisiana parishes in 2004, primary cocaine admissions were highest in East Baton
Rouge Parish (45.5 percent) and lowest in Calcasieu
Parish (15.8 percent) (exhibit 5).
Preliminary unweighted data accessed from DAWN
Live! show that cocaine ED reports totaled 1,607 in
2004, accounting for 49.5 percent of the illicit drug
reports (exhibit 6a), another indicator of the cocaine
problem in New Orleans. Patients involved in these
visits were most likely to be male (69.2 percent), 35
or older (56.0 percent), and African-American (59.1
percent) (exhibit 6b).
In 2004, there were fewer arrests for cocaine possession (n=2,249) than in 2003 (2,941) (exhibit 7), continuing the pattern from 2002.
In New Orleans, Mexican and Caribbean drug trafficking organizations (DTOs) are the primary distributors of cocaine HCl at the wholesale level. DTOs
usually do not sell cocaine in the crack form because
of the more severe Federal sentencing guidelines for
the distribution of cocaine in this form. Street dealers
generally assume responsibility for converting cocaine HCl to crack. The dominant street-level crack
dealers in New Orleans are African-Americans.
At the retail level, crack is commonly sold in the
form of rocks and cookies in small plastic bags, clear
plastic vials, and 35-millimeter film canisters. In the
last half of 2004, the DEA reported that purity levels
for crack ranged from 40 to 90 percent, while purity
levels for HCl were more variable in the 17–90 percent range.
Powder cocaine is commonly sold in quarter, onehalf, and 1 ounce quantities. Prices range from $800
to $1,200 per ounce at the midlevel and approximately $18,000 to $25,000 per kilogram at the
wholesale level (see exhibit 8). When cut/mixed with
adulterants, and less potent, powder cocaine can be
purchased at low prices at the street level. Crack has
been available at $5 to $25 per rock and can be purchased on the street for $900 to $1,200 per ounce.
Heroin
Heroin indicators remained relatively stable in New
Orleans from 2001 to 2004.
In 2004, 5.3 percent of all drug items (n=651) analyzed by forensic labs in New Orleans were heroin
(exhibit 3).
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After increasing from 12.2 percent of all treatment
admissions in 1999 to 14.8 percent in 2001, heroin
treatment admissions remained level, at about 11
percent, from 2002 to 2004 (exhibit 4). As in the
prior 3 years, most of the heroin admissions in 2004
were male (74.5 percent). Of the males, 80.5 percent
were African-American and 52.6 percent were in the
25–34 age category. More than one-half (53.8 percent) of the female heroin admissions were AfricanAmerican. St. Tammany (3.3 percent) was the only
other parish in which more than 1 percent of admissions were primary heroin abusers (exhibit 5).
The 2004 preliminary unweighted DAWN Live! data
show 490 ED reports involved heroin, accounting for
15.1 percent of illicit drug reports (exhibit 6a). More
than 76 percent of these patients were male (exhibit
6b). The patients were slightly more likely to be age
25–34 (37.1 percent), but 28.0 percent were younger
than 25. Most were African-American (59 percent) or
White (37 percent).
The DEA reported that the primary heroin traffickers
for the heroin that is marketed in New Orleans are
Colombian, Nigerian, and African-American. Much
of the heroin is transported into the area from Texas
in privately owned vehicles. Some of the heroin is
also brought into the ports near New Orleans via vessels.
Like crack cocaine, heroin distribution and abuse has
a major impact on the homicide and robbery rates in
New Orleans. In 2004, the NOPD reported that a
relatively high percentage of individuals arrested for
robbery in 2004 were African-Americans in the 25–
36 age category. The 2004 arrest data show that African-American males predominated in arrests involving heroin (exhibit 7). In 2004, there were 309 arrests
for heroin possession and 87 for heroin distribution.
Arrests for heroin distribution in 2004 were 50 percent lower than in 2003.
African-American trafficking organizations distribute
heroin in government-supported housing projects and
in other low-income neighborhoods. Heroin is most
commonly sold on the streets of New Orleans in
“bags” or “papers.” Mixtures containing 0.3–0.5
grams are wrapped in small foil packages which are
placed in plastic sandwich bags for multiple sales.
Bags or papers are sold for $20 to $25 each at the
retail level (exhibit 8), but it is possible to buy a bundle (25) of bags for about $300.
In 2003, most of the DMP heroin street buys in New
Orleans were of South American origin. The purity of
the heroin averaged 31.8 percent and sold for $1.62
per milligram pure.
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Other Opiates/Narcotics
Indicators for opiates other than heroin remained low.
Hydromorphone (Dilaudid) is being replaced by
OxyContin as the most popular opiate of abuse in the
New Orleans area, but hydrocodone (Vicodin), propoxyphene (Darvon), alprazolam (Xanax), oxycodone (Percodan), and hydromorphone are the most
widely diverted opiates.
Of the 12,290 items analyzed by NFLIS in 2004, 152
(1.2 percent) were “other opiates/narcotics” (exhibit
3); 91 (60 percent) of these other opiate items were
hydrocodone. The percentage of other opiates/narcotics in 2004 was the same as in 2003.
Among treatment admissions in Orleans Parish in FY
2004, 82 (3.6 percent) were for primary abuse of
“other opiates or synthetic opioids” or nonprescription methadone. All but seven were White:
57 percent were White females and 35 percent were
White males. Whites also dominated among these
other opiate admissions in other parishes. The proportions of these admissions in East Baton Rouge and
Ouachita Parishes (ranging from 4.7 to 5.0 percent)
were similar to that in Orleans Parish, while those in
the other parishes were higher, ranging from approximately 7 to 21 percent (exhibit 5). In St. Tammany Parish, 21 of the 216 other opiate admissions
were for nonprescribed methadone, the highest number in any of the 9 parishes represented in exhibit 5.
Across the other seven parishes (excluding Orleans
Parish), other opiates admissions were highest in St.
Tammany Parish (21.1 percent) and Lafayette Parish
(11.5 percent).
According to news reports, a large number of persons
abusing methadone were from pain management clinics. Because of the large number of deaths, many of
which involved methadone and other opiates, the State
of Louisiana asked for an investigation of pain clinics
in the New Orleans area. The legislative branch has
closed down many of these clinics and placed stricter
guidelines on others.
The unweighted DAWN ED data for 2004 show 1,221
reports of opiates/opioids. Of the opiate/opioid reports,
46.7 percent were hydrocodone reports and 8.7 percent
were oxycodone reports. Fifty-four percent of the hydrocodone-involved visits were for overmedication, as
were 46 percent of the oxycodone-involved visits.
In 2004, there were 1,087 arrests for possession of
Schedule II narcotic drugs and 366 for distribution of
Schedule II narcotics. Of the possession arrests, 55.6
percent were African-American males and 26.0 percent were White males (exhibit 9). More than 46 per-
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cent of these arrestees for possession were between the
ages of 21 and 33, nearly 41 percent were 36 or older,
and nearly 13 percent were younger than 21. Of the
366 arrests for distribution of Schedule II narcotics,
241 (65.8 percent) were African-American males.
Nearly 30 percent of those arrested for distribution of
Schedule II narcotics were younger than 21, with 34
percent being age 21–35, and 36 percent being 36 and
older.
Marijuana
Marijuana indicators were stable in 2004, but marijuana is still the most readily available illicit drug in
New Orleans and the State of Louisiana. The price of
marijuana decreased in recent years as the supply
from Mexico increased. Mexican DTOs dominate the
wholesale distribution of marijuana, which flows up
through the Southwest border and through such
Texas hub sites as Houston, Dallas, San Antonio,
Brownsville, and El Paso. African-American and
Mexican criminal groups transport large quantities of
the drug and make it available to local dealers. Local
independent dealers, street gangs, and other small
groups are the local distributors.
One-half of the items analyzed in NFLIS labs in 2004
contained cannabis (exhibit 3), down from 52.2 percent in 2003.
In FY 2004, primary marijuana admissions in Orleans Parish exceeded those for other substances for
the first time, accounting for nearly one-third (32.1
percent, n=740) of the 2,306 treatment admissions
(exhibit 4). Most (80.5 percent) were male. Marijuana treatment admissions increased sharply from
11.5 percent in 1993 to 16.5 percent in 1994 to 28.2
percent in 1995. However, from 1995 to 2004, the
percentage of marijuana treatment admissions remained relatively stable.
In the other eight parishes in FY 2004, primary marijuana admissions were proportionately highest in
Terrebonne (37.3 percent), Calcasieu (30.0 percent),
and Ouachita (26.6 percent) (exhibit 5).
There were 821 DAWN marijuana ED reports identified through DAWN Live! in 2004, accounting for
25.3 percent of unweighted illicit drug reports (exhibit 6a). Nearly two-thirds of the patients involved
in these visits were male, and 57 percent were White
(exhibit 6b). Nearly 41 percent were younger than 25.
In 2004, there were 5,967 arrests for marijuana possession and 1,048 arrests for marijuana distribution,
reflecting little change from 2003 (exhibit 7).
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According to NDIC, the price of marijuana was stable in 2004. Joints sold for as low as $2, and grams
could be purchased for $10 (exhibit 8). Marijuana
was sold by the ounce at the retail level for $125–
$160 and by the pound wholesale for $800–$1,000.
Methamphetamine/Amphetamines
Methamphetamine indicators remained at low levels
in New Orleans in 2003–2004. However, methamphetamine may be gaining popularity in some small
towns and communities in the State, according to the
DEA New Orleans Field Division (NOFD). Small
clandestine methamphetamine labs have reportedly
increased in some rural areas. Most methamphetamine seized in Louisiana came from Mexico and was
transported from California or Texas in private and
commercial vehicles.
Of the items analyzed by NFLIS labs in 2004, 58 (0.5
percent of all items analyzed) were methamphetamine or amphetamines (exhibit 3).
In FY 2004, only five primary methamphetamine
abusers entered treatment programs in Orleans Parish, representing only 0.2 percent of all admissions.
Primary methamphetamine admissions were higher in
eight other parishes, based on the assessment of the
Louisiana State Epidemiology Work Group. As
shown in exhibit 5, the parishes with the highest
numbers and percentages of primary methamphetamine admissions in 2004 included Rapides (6.7 percent), Bossier (6.2 percent), Calcasieu (4.2 percent),
and Ouachita (3.8 percent). Rapides is located near
the Texas border, through which most of the
methamphetamine in Louisiana was transported.
Of the preliminary unweighted DAWN emergency
department reports for illicit drugs in New Orleans in
2004, 112 involved amphetamines and 25 involved
methamphetamine (exhibit 6a).
Club Drugs
Use of club drugs continues to be reported in clubs
and bars around the city’s French Quarter. Drugs
such as methylenedioxymethamphetamine (MDMA
or ecstasy) and gamma hydroxybutyrate (GHB) are
most likely to be abused near metropolitan areas of
the State where there are large college populations.
Use of drugs such as ecstasy and flunitrazepam (Rohyphnol) and similar “date rape” drugs are on the rise
among youth in the city. Youth continue to be lured
to these drugs because of their “hipness” and the
myth that club drugs are safe. Ketamine abuse appears to have declined in the city, with little mention
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of the drug other than among teenagers experimenting with it.
Of the 12,290 items analyzed by NFLIS in 2004, 126 (1
percent) were MDMA (exhibit 3). Another five were
ketamine, and one was lysergic acid diethylamide
(LSD).
The unweighted DAWN Live! ED data for 2004 show
98 MDMA reports, representing 3.0 percent of illicit
drug reports (exhibit 6a). ED reports for other drugs
sometimes used in the “club scene” were few in number: 19 phencyclidine (PCP) reports, 13 GHB reports, 5
LSD reports, and 2 ketamine reports.
The retail cost of MDMA in the second half of 2004
was $15–$20 per tablet (exhibit 8).
Benzodiazepines
Benzodiazepines accounted for 0.7 percent of the
items analyzed by NFLIS in 2004 (exhibit 3). Of the
88 benzodiazepine-type items, 49 (56 percent) were
alprazolam, and 35 percent were diazepam. In 2003,
1.0 percent of all drug items analyzed were a benzodiazepine. Of these 120 items, 62 percent were alprazolam.
Preliminary unweighted data accessed from DAWN
Live! show that ED reports of benzodiazepines totaled 1,134 in 2004; 36 percent of the benzodiazepine-involved visits were for overmedication.

In Orleans Parish, primary alcohol admissions accounted for nearly 19 percent of all admissions in FY
2004 (exhibit 4). Primary alcohol admissions in eight
other parishes in 2004 ranged from a low of 25 percent in St. Tammany Parish to a high of 41 percent in
Bossier Parish (exhibit 5).
In the unweighted data accessed from DAWN Live!
for 2004, there were 1,217 reports involving alcoholin-combination with other drugs and another 133
“alcohol only” reports involving patients younger
than 21. Sixty-two percent of the alcohol-only reports
involved patients who were male; 74 percent involved patients who were White, and 19 percent represented Black patients. In this patient group, 69 percent were age 18–20, with the remainder being age
12–17.
INFECTIOUS DISEASES RELATED TO DRUG ABUSE
In the first quarter of 2005, there were 7,545 persons
living with HIV (n=3,702) or AIDS (3,843) in metropolitan New Orleans. Of the 4,866 for whom exposure risk was known, 16 percent (489 men and 275
women) were exposed through injection drug use.
Another 8 percent of the exposed cases were men
who have sex with men and inject drugs. In addition,
approximately 18 percent of the cases (650 women
and 240 men) were exposed through heterosexual
contact. Of the total 7,545 cases, 60 percent were
Black non-Hispanic and 35 percent were White nonHispanic. More than three-quarters (77.2 percent)
were older than 34.

Alcohol
Alcohol abuse is a serious problem in New Orleans,
as it is in many cities and towns in the United States.
Alcohol and drugs are often used together, also a
common pattern across the Nation.
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Exhibit 1. Population Demographics for the City of New Orleans vs. the State of Louisiana, by Percent:
2000 and 2003 (Estimates)
Population Demographic
Total Population (N)
Male
Female
Median Age (Years)
One Race
White
Black or African-American
Asian
Other
Two or More Races
Hispanic or Latino (of any race)
Average Household Size (n)
Median Household Income ($)
Individuals Living Below Poverty Level

2000
New Orleans
(484,674)
46.9
53.1
(33.1)
98.7
28.1
67.3
2.3
1.1
1.3
3.1
(2.48)
($27,133)
27.9

Louisiana
(4,468,976)
48.4
51.6
(34.0)
98.9
63.9
32.5
1.2
1.3
1.1
2.4
(2.62)
($32,566)
19.6

2003 (Estimates)
New Orleans
Louisiana
(451,316)
(4,361,271)
46.1
48.1
53.9
51.9
(34.3)
(34.7)
99.3
98.9
28.1
64.0
67.2
32.1
2.6
1.5
1.4
1.2
0.7
1.1
3.1
2.5
(2.49)
(2.61)
($35,677)
($34,141)
20.8
20.3

SOURCE: U.S. Census Bureau

Exhibit 2. New Orleans DAWN ED Sample and Reporting Information: 2004
Total Eligible
1
Hospitals

No. of Hospitals
in DAWN Sample

Total EDs in
DAWN Sample2

21

19

21

No. of EDs Reporting per Month:
Completeness of Data (%)
90–100%
50–89%
<50%
9–11
0–2
0–2

No. of EDs
Not Reporting
10–13

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005

2

1
Exhibit 3. Number of Analyzed Items and Percentage of All Items Tested in New Orleans, by Drug: 2004

Drug
Cannabis
Cocaine
Heroin
Other Opiates
Benzodiazepines
MDMA/MDA
Methamphetamine/Amphetamines

Number
6,174
5,013
651
152
88
126
58

Percent
50.2
40.8
5.3
1.2
0.7
1.0
0.5

1

A total of 12,290 items were reported.
SOURCE: NFLIS, DEA

176

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—New Orleans

Exhibit 4.

Percentages of Treatment Admissions in Orleans Parish, by Selected Drug: FY 1995–2004
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
Cocaine

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

40.4

41.1

36.2

38.1

35.5

34.4

32.5

34.5

34.0

31.6

3.5

3.6

6.2

8.4

12.2

11.2

14.8

11.8

10.6

11.1

Marijuana

28.2

31.3

30.9

30.2

33.0

29.2

30.5

29.8

28.9

32.1

Alcohol

25.5

22.3

24.9

21.4

17.8

20.5

18.6

19.3

21.2

18.7

Heroin

SOURCE: Louisiana State Office of Alcohol and Drug Abuse

Exhibit 5. Treatment Admissions for Selected Drugs in Eight Parishes Outside Orleans Parish, by Percent:
2004

Drug
Cocaine
Heroin
Other Opiates
Marijuana
Methamphetamine
Alcohol
Other Drugs
Total (N=)1

Bossier Calcasieu

East Baton
Rouge
45.5
0.8
5.0
13.2

Parish
LafayOuachita Rapides
ette
32.3
24.8
26.5
0.9
0.3
0.7
11.5
4.7
11.4
13.3
26.6
17.5

St. Tammany
28.4
3.3
21.1
17.3

Terrebonne
17.3
0.3
7.5
37.3

26.7
0.0
8.9
15.4

15.8
0.3
11.4
30.0

6.2

4.2

2.1

1.0

3.8

6.7

1.6

1.0

40.8
2.0
(292)

30.7
7.6
(983)

32.6
0.8
(3,432)

37.8
3.2
(885)

36.1
3.7
(914)

32.9
4.3
(1,295)

24.7
3.6
(1,026)

34.2
2.4
(986)

1
Excludes a few admissions for whom a primary drug was not reported.
SOURCE: Louisiana State Office of Alcohol and Drug Abuse
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Exhibit 6a. Number and Percent of Selected Illicit1 Drug Reports in DAWN ED (Unweighted2): 20042
Drug
Cocaine
Heroin
Marijuana
Amphetamines
Methamphetamine
MDMA
Other Illicit Drugs

Number
1,607
490
821
112
25
98
94

Percent
49.5
15.1
25.3
3.4
0.8
3.0
2.9

1

Excludes “Alcohol Only” reports for persons younger than 21.
Unweighted data are from 8–11 New Orleans EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control.
Based on this review, cases may be corrected or deleted and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 1/13–1/14, 2005

2

Exhibit 6b. Demographic Characteristics of Patients Reporting Abuse of Illicit Drugs in New Orleans DAWN
EDs, by Percent (Unweighted1): 2004
Characteristic
Gender
Male
Female
Age Group
Younger than 25
25–34
35 and older
Race/Ethnicity
White
Black
Hispanic
Other
Not documented

Cocaine

Heroin

Marijuana

69.2
30.7

76.3
23.32

66.4
33.6

16.6
27.4
56.0

28.0
37.1
34.9

40.6
28.0
31.4

36.8
59.1
1.0
0.1
3.0

36.9
59.0
1.2
0.2
2.7

57.4
35.8
2.1
0.1
4.6

1

Unweighted data are from 8–11 New Orleans EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted and, therefore, are subject to change.
2
Gender was not documented for 2 heroin-involved visits.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 1/13–1/14, 2005

Exhibit 7. Drug Arrests in Orleans Parish by Race/Ethnicity, Gender, and Offense: 2003–2004
Drug/ Offense
Cocaine
Possession
Distribution
Heroin
Possession
Distribution
Marijuana
Possession
Distribution
Other Drugs
Drug Paraphernalia

Males
White

Black

Other

Females
White

Black

Total

Other

2003

2004

2003

2004

2003

2004

2003

2004

2003

2004

2003

2004

2003

2004

2,134
1,086

1,662
1,106

306
38

140
11

14
6

7
6

385
120

367
156

101
11

72
7

1
1

1
0

2,941
1,262

2,249
1,286

230
155

220
76

66
5

42
3

0
0

0
0

24
16

22
6

38
0

25
2

0
0

0
0

358
176

309
87

4,389
832
197

4,468
860
198

1,034
80
51

925
67
58

18
1
1

9
10
1

447
119
24

412
94
239

182
23
25

152
16
17

0
2
0

1
1
0

6,070
1,057
298

5,967
1,048
513

1,404

1,435

631

524

18

12

402

541

195

188

2

2

2,652

2,702

SOURCE: New Orleans Police Department
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Exhibit 8. Illicit Drug Prices in New Orleans: July–December 2004
Drug

Wholesale
$18,000–$25,000 per kilogram
$9,000–$10,000 per pound
$20,000–$28,000 per kilogram
$8,000 per pound
$80,000–$100,000 per kilogram
$2,000 per kilogram
$800–$1,000 per pound

Powder Cocaine
Crack
Heroin
Marijuana

Price in Dollars
Midlevel
$800–$1,200 per ounce
$900–$1,200 per ounce
$4,000–$9,000 per ounce
$125–$160 per ounce

Methamphetamine

$20,000 per pound

$1,400–$1,600 per ounce

MDMA

$8–$12 per tablet

$12–$15 per tablet

Retail
$250 per ¼ ounce
$80–$150 per gram
$5–$25 per rock
$80–$125 per gram
$20–$25 per paper
$300–$600 per gram
$10 per gram
$2 per joint
$400–$500 per ¼ ounce
$100 per gram
$15–$20 per tablet

SOURCE: DEA and Narcotics Digest Weekly, NDIC

Exhibit 9. Arrests for Possession and Distribution of Schedule II Narcotics in New Orleans, by Age Group
and Race/Ethnicity: 2004
Possession
Age Group
<17
17–20
21–25
26–30
31–35
36–40
>41

Black
56
43
96
76
72
80
181

Males
White
0
24
50
53
60
31
65

Black
57
37
49
39
59

Males
White
1
5
16
4
37

Other
0
2
2
0
0
0
0

Black
2
7
19
16
16
21
36

Females
White
0
7
15
18
12
10
16

Other
0
0
0
0
0
0
0

Females
White
0
1
4
4
14

Other
0
0
0
0
0

Total
58
83
182
163
160
143
298

Distribution
Age Group
<17
17–20
21–25
26–35
≥36

Other
1
1
0
0
1

Black
2
4
5
5
20

Total
61
48
74
52
131

SOURCE: New Orleans Police Department
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Drug Use Trends in New York
City
Rozanne Marel, Ph.D., John Galea, M.A.,
Robinson B. Smith, M.A., and Gregory
Rainone, Ph.D.1
ABSTRACT
Drug use trends were again mixed for this reporting
period. Admissions to treatment with cocaine as a
primary drug rose again this reporting period. Although both cocaine powder and crack remain of
good quality, many crack locations are seeing a decline in buyers and sellers. Heroin indicators
remained stable. Heroin remains widely available,
although the purity levels have fallen recently. Marijuana indicators, which had been reaching new peaks,
seem to have stabilized. Marijuana continues to be
available in a wide variety of flavors and colors. Although the numbers remain small, there is concern
about methamphetamine. Many kinds of prescription
drugs continue to be available on the street, and they
seem to be growing in popularity, based on indicator
data and street observations. Of the 92,021 New Yorkers living with HIV or AIDS, men having sex with
men and injection drug use history remain the two
major transmission risk factors.
INTRODUCTION
Area Description
New York City, with 8 million people, is by far the
largest city in the United States. It is situated in the
southeastern corner of the State on the Atlantic coast
and encompasses an area of 320 square miles. It has
nearly 600 miles of waterfront and one of the world’s
largest harbors.
Historically, New York City has been home to a large
multiracial, multiethnic population. New York City is
the largest and most racially/ethnically diverse city in
the country. As has been true throughout its history,
immigration continues to shape the character of New
York City. It has contributed to a substantial shift in the
race/ethnic composition of New York. Findings from
the 2000 census show that the population diversity continues: 35 percent are White; 27 percent are Black; 27
percent are Hispanic of any race; and 10 percent are
Asian and Pacific Islander. The five largest Asian
groups in the city are Chinese, Asian Indian, Korean,
1
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Filipino, and Pakistani, and the five largest groups of
Hispanic origin are Dominican, Mexican, Puerto Rican,
Colombian, and Ecuadorian. Moreover, New York City
includes people who identify with races/ethnicities from
all over the world. It is estimated, for example, that in
Queens alone more than 120 languages are spoken.
Nearly 3 million New York City residents are foreign
born (2,871,032), which represents 36 percent of the
resident population, and about 1.2 million legal immigrants became New York City residents between 1990
and 2000. The Dominican Republic remains the city’s
largest source of immigrants.
The city remains the economic hub of the Northeast. Its
main industries include services and wholesale and retail trade. Of the more than 3.7 million people employed in the city, 22 percent commute from
surrounding areas. Overall, the unemployment rate in
New York City for April 2005 was 5.7 percent, compared with 4.9 percent in New York State and 5.2
percent in the Nation. According to the Bureau of Labor
Statistics, the New York City rate is dramatically lower
than it was in October 2003, when it was 8.3, but it is
higher than the unemployment rate for October 2000,
when the rate was 5.4. New York City is still experiencing the economic aftereffects of the September 11,
2001, attacks on the World Trade Center. Many jobs in
New York City were lost as a result of decreased business activity and the relocation of business firms.
Census 2000 data showed that the median household
income for New York City residents was $38,323, as
compared to $43,393 for State residents and $41,994
for U.S. residents as a whole. The percentages of persons living below the poverty level for New York City
and the State as a whole were 21.2 percent and 14.6
percent, respectively. The comparable figure for U.S.
residents as a whole in 2000 was 12.4 percent.
Data Sources
This report describes current drug abuse trends in New
York City from 1995 to 2004, using the data sources
summarized below:
•

Emergency department (ED) data were derived
for calendar year 2004 from the Drug Abuse Warning Network (DAWN) Live! restricted-access
online query system administered by the Office of
Applied Studies (OAS), Substance Abuse and Mental Health Services Administration (SAMHSA).
Eligible hospitals in the New York 5 Boroughs Division totaled 52; hospitals in the DAWN sample
numbered 39, with the number of emergency departments in the sample totaling 60. (Some
hospitals have more than one emergency department.) During this 12-month period, between 29
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and 37 EDs reported data each month. The completeness of data reported by participating EDs
varied by month (see exhibit 1). Exhibits in this
paper reflect cases that were received by DAWN
as of May 31, 2005–June 2, 2005. All DAWN
cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted.
Therefore, the data presented in this paper are subject to change. Data derived from DAWN Live!
represent drug reports in drug-related ED visits.
Drug reports exceed the number of ED visits, since
a patient may report use of multiple drugs (up to
six drugs and alcohol). The DAWN Live! data are
unweighted and, thus, are not estimates for the reporting area. These data cannot be compared to
DAWN data from 2002 and before, nor can preliminary data be used for comparison with future
data. Only weighted DAWN data released by
SAMHSA can be used for trend analysis. A full
description of the DAWN system can be found at
http://dawninfo.samhsa.gov/. ED drug mentions
data before 2003 were derived from the DAWN,
OAS, SAMHSA, for 1995 through 2002. The
weighted data are based on a representative sample
of hospitals in New York City and Westchester,
Rockland, and Putnam Counties.
•

•

•

Drug abuse-related death data are from the
DAWN mortality system. Data from 2003 covered
New York, New York, Newark, New Jersey, and
Edison, Pennsylvania. For 2003, the following nine
counties participated: Morris, New Jersey; Union,
New Jersey; Bronx, New York; Kings, New York;
New York, New York; Putnam, New York; Queens,
New York, Richmond, New York; and Suffolk, New
York. Data from 1995 covered New York City,
Long Island, and Putnam County and included heroin/morphine and unspecified types of opiates.
Between 1996 and 2002, DAWN covered only New
York City, and the category for heroin/morphine no
longer included other opiates. According to Mortality Data From the Drug Abuse Warning Network,
2001, incomplete data were received for the New
York metropolitan area, so data for New York are
not presented for 2001.
Treatment admissions data were provided by the
New York State Office of Alcoholism and Substance Abuse Services (OASAS) for 1995 through
2004 and included both State-funded and nonfunded
admissions. Demographic data are for 2004.
Drug-related arrest data were provided by the
New York City Police Department (NYPD) for
1994–2002.
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•

Forensic laboratory testing data for New York
City were provided by the Drug Enforcement Administration (DEA)’s National Forensic Laboratory
Information System (NFLIS) for January through
December 2004.

•

Drug price, purity, and trafficking data were provided by the DEA’s Domestic Monitor Program
(DMP) for heroin. These data are supplemented by
information from the OASAS Street Studies Unit
(SSU) reports.

•

Cocaine use during pregnancy data were provided
by the New York City Department of Health for
1995–2003.

•

Acquired immunodeficiency syndrome (AIDS)
and human immunodeficiency virus (HIV) data
were provided by the New York City Department of
Health and Mental Hygiene, HIV Epidemiology
Program, for 1984 through June 30, 2004.

DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
In general, many cocaine indicators, which had been
declining, are beginning to show increases, and the
drug still accounts for major problems in New York
City (exhibit 2).
For the five boroughs of New York City, there were
10,134 unweighted DAWN Live! reports for cocaine in
January–December 2004. Of these reports for cocaine,
39 percent of the patients were seeking detoxification.
While primary cocaine treatment admissions to Statefunded and nonfunded programs in New York City had
declined from 17,572 in 1998 to 14,059 in 2000, they
increased to 16,642 in 2004—the highest total in 6
years. It should be noted that even when the cocaine
treatment admissions were in decline, they did not show
the same type of dramatic long-term decline that was
seen in the other indicators. In 2004, cocaine admissions constituted 24 percent of all New York City’s
69,065 drug and alcohol treatment admissions (excluding alcohol-only).
Exhibit 3 shows demographic characteristics of cocaine
treatment admissions for 2004 by the two primary

modes of use: smoking crack (representing 62 percent
of cocaine admissions) and using cocaine intranasally
(representing 35 percent). Those who smoke crack are
more likely than intranasal users to be female (36 vs. 25
percent), Black (69 vs. 42 percent), readmissions to
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treatment (83 vs. 71 percent), and without income (34
vs. 25 percent), although for both groups, there were
fewer clients with no source of income than in the previous reporting period. Those using intranasally are
more likely to be Hispanic or White and to have some
criminal justice status. The two groups are similar in
secondary drugs of abuse, primarily alcohol and marijuana. It should be noted that all admissions for primary
cocaine abuse represent an aging population, and those
smoking crack tend to be older than those using cocaine
intranasally.
Another data source, the DEA’s National Forensic
Laboratory Information System, showed that of the
45,514 items reported for New York City in 2004,
22,264 (49 percent) were cocaine.
According to the Street Studies Unit, cocaine hydrochloride (HCl) buying and use continues at a stable
pace. Although cocaine has traditionally been sold from
indoor locations, field observers report that there has
been a steady increase in the number of street sellers
offering powder cocaine in various parts of New York
City, and they expect the trend to continue during the
summer. Cocaine prices can fluctuate, as sellers vary
the purity of the product and offer several differentsized packages. Cocaine is sold in $20, $25, $30, and
$60 packages. The most common price on the street is
the $20 packet, which contains approximately 0.25
ounces of cocaine powder.
A number of different methods are used in the packaging of cocaine in New York City, including vials, nailsized plastic bags, aluminum foil glassine bags, light
plastic wrap knotted at both ends, cellophane, folded
paper, magazine pages, and balloons. Of these, the traditional method of aluminum foil continues to the most
frequently used method, followed by plastic wrap and
cellophane. Although users prefer the malleability of
aluminum, they dislike the fact that the cocaine can
“cook-up” (melt) in the foil from simple body heat. The
use of brand names in association with the sale of cocaine is becoming increasingly rare, since brand names
may attract attention from law enforcement and may be
easily duplicated by competitors.
According to the DEA, the majority of the cocaine in
New York City is supplied by Colombians. Dominican
drug gangs continue to dominate the distribution of
cocaine in New York City. Many cocaine sellers appear
to be part of an extended organization composed of
family, relatives, and long-term friendships. At the
street level, most sellers are of the same ethnic identity
as the largest ethnic group in the community. There are
three basic methods used to sell cocaine HCl. The
techno-method or virtual connection method, in which
the buyer contacts the seller (via beeper, cell-phone, or
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Internet), places an order, and arranges a meeting and
location, seems to be enjoying great popularity. In the
second method, sellers work out of their own apartments. The third method is selling cocaine on the street.
These sellers deal solely with the “personal use” buyer
who may want to buy less than $50 of cocaine.
Cocaine selling is typically found in Black and Hispanic low-income communities, and the majority of the
cocaine HCl street buyers are Hispanic and Black.
Compared with heroin and crack, however, cocaine also
has a large number of White street buyers. Cocaine
users as a whole tend to have a higher social-economic
status (SES). This is probably the result of cocaine’s
popularity among young, white-collar professionals.
According to field observations, cocaine users appear to
be almost evenly split in terms of gender, but the majority of the individuals actually making the buys continue
to be males. Cocaine users appear to be younger on
average than either heroin or crack users. Observations
of large clusters of young buyers age 18–25 may suggest a new generation of cocaine HCl users.
According to street interviews, most cocaine HCl users
report that they “only” snort the drug. Some recent reports from the street, however, suggest that because of
“speedballing” cocaine and heroin, injecting may be
increasing. Most users report that they use cocaine
solely for recreational purposes, typically in group settings, at special events (such as parties or at clubs), and
only on weekends. Field workers have also reported
names of combinations involving cocaine and other
drugs. “Russian” refers to a combination of cocaine
HCl, crack, and Viagra; “Honey Devil” is a combination of cocaine, Viagra, and marijuana, or just Viagra
and marijuana.
Crack users report that crack cocaine continues to be
highly available; however, because of police pressure,
crack selling is less overt. Although there has been a
decline in “open-air” markets, the Street Studies Unit
expects that as the weather continues to get warmer,
there will be a gradual shift to outdoor selling.
Field researchers report that street-level crack in New
York City is being sold in $5, $10, and $20 packages.
The most common price/package combination is the
$10 packet. During the summer, the $5 amount becomes more popular.
There are three basic packaging methods associated
with crack in New York City. They are thumb-nail size
plastic bags, plastic vials, and glassine bags. Of these,
the thumbnail-size bag continues to be the most popular
packaging method. The field staff, however, reports an
increase in the appearance of thin, 1-inch plastic vials
with tops of various colors. Street contacts indicate that
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these containers serve to protect the product from body
heat and humidity, an issue of obvious importance during the summer. The downside, according to some
street contacts, is that the vials tend to be easier to find
and more difficult to get rid of when one is trying to
avoid arrest.
What currently serves as a brand name in the selling of
crack on the street is the color of the package or top—
(“blue bag” or “green tops,” etc.). The use of brand
names, in general, is becoming increasingly rare.
Street crack sellers are typically African-American or
Hispanic males, between 17 and 35 years old. Although
the sellers usually reflect the racial composition of the
community, there appear to be slightly more Hispanic
sellers than Black sellers. According to street contacts,
Dominican drug gangs are the midlevel suppliers of the
street sellers. The street-level sellers tend to be independent entrepreneurs with no direct connection with
the midlevel dealer.
Based on field observations of both high and medium
volume selling sites, there seems to be a trend away
from the large extended organizations controlling multiple sites. Most crack sellers are part of a two- or
three-person partnership that serves a specific location.
This street-level cooperative reduces overhead, extends
selling hours, enables larger and cheaper inventory
buys, provides mutual security for the sellers from ripoffs, and decreases challenges to the selling site by rival
sellers. The truly independent single seller may best be
described as a floater, who serves a small general area
but does not claim a specific location. The single seller
usually has a smaller client list and is more likely to
extend credit or other allowances to keep his clients.
Although midlevel dealers offer ready-made crack,
most street sellers would prefer to buy cocaine HCl and
cook their own crack. Preparing their own crack allows
them to control the purity or quality of their product,
thereby increasing profit margins.
Field researchers report that many of the heavy crack
selling locations around the city continue to be found in
or around public housing developments. While police
presence has pressured many “open-air” street locations
to move indoors, the SSU expects an increase in outside
selling locations during the summer. Operating in the
open is also becoming more difficult, because the police are installing more special surveillance cameras,
suspended from buildings and street lights, to monitor
heavy selling locations.
As a rule, street crack sellers do not sell other drugs.
Other drug sellers, however, may operate from the same
street corner. Crack sellers operating from indoor loca-
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tions, on the other hand, have the room, time, and opportunity to offer a secondary product line. The most
common secondary drug is marijuana, which many users smoke in conjunction with crack or use to reduce
the “crash-effect” after the prolonged use of crack.
The majority of the crack users are African-American
or Hispanic males with low socio-economic status.
Field researchers report that most observed buyers appear to be in their thirties. The SSU has not observed
young or new users; most buyers observed appear to be
veteran users.
Every crack user interviewed reported smoking crack,
typically using an old broken glass stem or tobacco
leaves. Field workers also report the use of the phrase
“Chasing the Dragon” again to refer to the use of crack
and heroin in a pipe together, with the crack first at the
bottom on a bed of ashes. Reportedly, this method helps
the drugs burn more slowly. There continues to be talk
on the street about some individuals injecting crack,
and there have been reports of users injecting crack
with alcohol.
The DEA reports that prices for cocaine powder for
July to December 2003 were $22,000–$26,000 per
kilogram and $800–$1,600 per ounce. The DEA reports
that crack sells for about $28,000–$30,000 per kilogram, $800–$1,600 per ounce, $27–$45 per gram, and
$7–$10 per rock.
DAWN figures for cocaine-involved deaths showed
520 cocaine-involved drug misuse deaths in 2003 (exhibit 2). For the cocaine drug-related deaths in 2003, 18
percent involved one drug.
The NYPD reports a decline in cocaine arrests since
1995 (n=40,846) (exhibit 2). The number of cocaine
arrests in 2002 was 13,574, a 67-percent decrease since
1995. Of the cocaine arrests in 2002, 79 percent involved crack.
Another important indirect indicator of cocaine involvement is the number of births in New York City to
women who admit using cocaine during pregnancy.
This not only indicates use among women, but it underscores a serious aspect of the cocaine problem. For
several years, the number of women using cocaine during pregnancy increased. In 1989, the number of births
to women who used cocaine peaked at 3,168. After
1989, the number steadily declined to 354 in 2003—an
89-percent decline over 14 years (exhibit 2). It should
be noted, however, that the change between 2002 and
2003, 2 percent, was the smallest decline in recent
years.
Heroin
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Heroin indicators remained stable during this reporting
period (exhibit 4). For the five boroughs of New York
City, there were 6,374 preliminary unweighted DAWN
Live! heroin ED reports for January through December
2004. Of these heroin reports, 52 percent of the patients
were seeking detoxification.
Primary heroin admissions to treatment programs in
New York City gradually increased between 1995 and
2004, from 18,287 to 23,687, an increase of almost 30
percent (exhibit 4). Primary heroin admissions in 2004
constituted 34 percent of New York City’s 69,065 drug
and alcohol treatment admissions (excluding alcoholonly).
Intranasal heroin use may have peaked in the second
half of 1998, with 62 percent of heroin admissions to all
New York City drug treatment programs reporting this
as their primary route of administration. Since then, the
proportions reporting intranasal use declined slightly, to
60 percent in 1999 through 2002, 59 percent in 2003,
and 60 percent in 2004. Meanwhile, heroin injection
increased among heroin admissions, from 32 percent in
the second half of 1998 to 37 percent in 2004.
Exhibit 5 highlights general demographic characteristics of heroin abusers admitted to all New York City
treatment programs in 2004 by mode of use. In general,
primary heroin admissions were overwhelmingly male
(75 percent), older than 35 (71 percent), more likely to
be Hispanic (53 percent) than Black (27 percent) or
White (18 percent), usually readmissions to treatment
(89 percent), and likely to report cocaine as a secondary
drug of abuse (40 percent). Compared with heroin injectors, intranasal users were more likely to be Black
(32 vs. 16 percent) and have some criminal justice
status (37 vs. 25 percent). In contrast, primary heroin
injectors were more likely than intranasal users to be
White (30 vs. 11 percent), to report cocaine as a secondary drug of abuse (46 vs. 36 percent), and to have
started use before reaching age 20 (56 vs. 41 percent).

methadone, and all other opiates/opioids, accounted for
more drug misuse deaths than any other category in
2003.
NFLIS data show that 12 percent of the 45,514 cases
for New York City in 2004 (5,313) were related to
heroin.
From 1992 to 2000, the DMP found average heroin
purities to be generally above 60.0 percent. Findings for
2003, however, show an average purity of 53.5 percent,
down from 61.4 percent in 2002. The associated price is
$0.48 per milligram pure, an increase from $0.36 per
milligram pure in 2002. According to the DEA, kilogram prices for January to June 2004 were $60,000–
$70,000 for South American heroin and $60,000–
$90,000 for Southwest Asian heroin.
According to the SSU field staff, heroin in New York
City continues to be highly available and accessible,
with no shortage of selling locations. The “count” or
amount sold in a $10 bag appears unchanged, and
comments from buyers appear to suggest that dealers do
not appear to be trying to stretch their supply. The majority of heroin copping locations are inside or off-thestreet operations. With the advent of warmer weather,
however, the SSU predicts a substantial increase in
heroin street dealing. Field staff members continue to
report seeing nodding behavior by heroin users.
While the quality of the heroin can vary by location and
seller, most street contacts indicate that the current
quality on the street is still fairly high, although the
quality has been higher in recent years. The source of
most of the heroin sold and used in New York City is
South America. According to the DEA, Colombians are
the principal importers and smugglers. Street sources
indicate that the high and middle level distribution of
heroin in New York City is done by Dominican drug
gangs. The majority of the low-level distributors and
street sellers continue to be Hispanics in some sections
of New York and Blacks in other sections.

In addition to heroin admissions to traditional treatment
programs, heroin admissions for detoxification or crisis
services in New York City have become sizable in
number. These special services are usually short term,
provided in a hospital or community-based setting, and
medically supervised. In 1995, 4,503 such admissions
were reported for heroin abuse; by 2004 that figure increased to 15,913, slightly less than in 2003 (16,067).

The most common price for heroin bought on the street
is $10 per packet. Each package contains approximately
0.10 grams of powder. Regular heroin users report that
they spend approximately $40 per day. Many of these
individuals pay for their habit through panhandling or
selling cigarettes or other articles on the street. Many of
the females often exchange sexual favors for money or
drugs.

DAWN medical examiner (ME) figures for heroininvolved deaths in the New York metropolitan area
show 104 drug misuse deaths in 2003 (exhibit 4). Of
these, 13 percent were single-drug deaths. The category
of opiates/opioids, which includes heroin (specified),

There are five basic packaging methods associated with
heroin in New York. These methods include the glassine bag, plastic wrap, and cellophane. The color of the
bag usually identifies a given dealer’s product without
identifying the dealer to the police.
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The heroin user is typically older (thirties to fifties).
While the majority of the heroin users are Black or Hispanic males, most street contacts report that heroin
sellers, regardless of where they operate, have frequent
White buyers. Although, at one time, heroin sellers did
not sell other drugs, the SSU reports that more heroin
dealers are selling crack in addition to heroin. There is an
increasing trend for heroin users to use both drugs in order to produce a speedball effect. Until very recently,
most heroin users would have described themselves as
snorters. There are reports, however, of greater use of
needles, particularly among users younger than 30.
There is less use of brand names in the marketing of
heroin on the street because these names or symbols
either attract too much police attention or they can be
easily duplicated by competitors.
Much like cocaine arrests, heroin arrests reached a high
of 28,083 in 1989, declined for a few years, and then
peaked in 1995 (n=38,131) (exhibit 4). Heroin arrests
decreased from 33,665 in 2000 to 27,863 in 2001, but
they increased again in 2002 to 34,098, an increase of
22 percent in the year.
Other Opiates/Narcotics
According to preliminary unweighted DAWN Live!
data for the five boroughs of New York City for January through December 2004, there were 3,732 ED
reports of opiates/opioids. Of these reports for opiates/opioids, 35 percent were for detoxification.
Street researchers are reporting more use and diversion
of OxyContin. Some users are using it by itself, while
others are injecting it with cocaine for a speedball effect. Reports indicate that to remove the special coating
on OxyContin in order to inject, some users are soaking
the tablet in hot water. Although street researchers have
not observed people hawking OxyContin, they have
encountered a number of street buyers asking for OxyContin and claiming that the tablets are selling for $10
per pill.
Among ME deaths for the New York metropolitan area
reported by DAWN, the category of opiates/opioids,
which includes all legal and illegal narcotic analgesics
and combinations, accounted for more drug misuse
deaths than any other category. For specific narcotictype drugs in DAWN ME reports, methadone accounted for 250 deaths in the New York metropolitan
area in 2003, while all other opiates, excluding heroin,
accounted for 532 deaths.
Marijuana
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In New York City, marijuana indicators, which had
recently increased steadily and dramatically, appear to
be stabilizing (exhibit 6). For the five boroughs of New
York City, there were 3,118 preliminary unweighted
DAWN Live! ED reports for marijuana for January
through December 2004.
Primary marijuana admissions to all treatment programs
had been increasing steadily over the past several years.
The number increased more than ninefold between
1991 and 2002, from 1,374 to 14,310, the highest annual number (exhibit 6). Although the number fell again
to 13,247 in 2004, that is still among the highest yearly
totals for primary marijuana admissions. In 1991, primary marijuana admissions represented less than 5
percent of all treatment admissions; by 2004, these admissions represented 17 percent of admissions
(excluding alcohol-only) to all New York City treatment programs.
Exhibit 7 shows demographic characteristics of primary
marijuana admissions to all New York City treatment
programs in 2004. The vast majority were male (79
percent), and 28 percent were younger than 21. More
than one-half (57 percent) were Black, about one-third
(32 percent) were Hispanic, and 8 percent were White.
Alcohol was the secondary drug of abuse for 38 percent
of the marijuana admissions, and almost two-thirds had
some criminal justice status (65 percent).
Marijuana continues to be the most widely abused illicit
drug in New York City. According to street contacts,
marijuana is readily available at levels similar to those
reported in the previous study period. Street contacts
also report that most of the marijuana currently available in New York City is of good to very good quality,
the same assessment as the last reporting period.
Field researchers report that street-level marijuana is
associated with three basic prices: $10, $20–$25 (halfounce), and $50–$60 (ounce) amounts. During the present study period, field researchers were unable to find
any location offering marijuana for $5 or in loose joints.
The most common street selling price continues to be
$10. Unlike most other drug users, marijuana users
commonly pool their money and share the drug. The
$50 amounts of marijuana are rarely sold on the street;
they are usually made through house connections. The
pricing pattern has not changed since the last reporting
period.
There are several packaging methods associated with
marijuana street sales in New York City: the thumbnailsize plastic bags, glassine bags, aluminum foil, and manila envelopes. The thumb-nail-size plastic bag is
currently the most popular packaging method. Since
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buyers prefer to examine the marijuana before buying,
the manila envelopes and aluminum foil have fallen out
of favor with sellers.

group. According to street observations, the majority of
marijuana buyers are Hispanics and African-Americans.

Marijuana sellers are on average the youngest group of
drug sellers. Most are adolescents and young adults
(16–30 years old). As is true for most drug sellers, the
marijuana sellers tend to reflect the ethnic make-up of
the community, and most sellers operate in the area
where they live. Most street-level sellers tend to be very
young, African-American or Hispanic males. In more
affluent communities, however, the seller is usually
White and operates out of his parents’ home. Most of
those selling marijuana are independent sellers, and
their customers tend to be from their circle of acquaintances. Most sellers initially start selling marijuana in
order to support their own habit. The general availability of marijuana, its low-price, and the perception of
minor legal consequences tend to attract sellers, who
with a small amount of money to invest can start their
own business. In cases in which marijuana sellers are
associated with large organizations, marijuana is typically a secondary product, and the organization’s
principal interest is another drug (i.e., heroin, crack, or
cocaine).

Marijuana users appear to be the youngest of any of the
buyers of the main drug categories. Many of the buyers
are currently in college or high school. Most users reported having tried marijuana for the first time in high
school or junior high school at the urging of a friend.
According to observations by field staff, the majority of
buyers are male, although there are a substantial number of lone female buyers. As a group, marijuana users
are somewhat higher than other drug users in terms of
socio-economic status.

As with other drugs, there are three basic selling methods associated with marijuana. The techno/virtual
method remains very popular. A buyer makes a connection with a seller through the use of a beeper, cellphone, or Internet. An order is made, and a meeting is
arranged or a delivery is scheduled. Another method is
the use of a private residence. Marijuana sellers typically work out of their own apartments, and for many
sellers, this constitutes a part-time avocation that helps
supplement their income and habit. Many of these individuals develop a client list and require an introduction
before they sell to a stranger. The third method, street
sales, is associated with the highest risk but is still quite
common in some communities.
Although the majority of marijuana selling is done from
indoor locations because of police pressure, marijuana
selling is also found in outside locations. Sellers, particularly during the summer, tend to gravitate toward
outside venues that attract crowds of young people (i.e.,
the park, beach, concerts). As a rule, street marijuana
sellers do not sell other drugs; however, on occasion,
phencyclidine (PCP) and methylenedioxymethamphetamine (MDMA or ecstasy) have been known to be
sold from the same location.
The use of marijuana cuts across all social demarcations
(age, race, ethnicity, social class). Nevertheless, this
drug seems to be most popular among adolescent and
young adult users. In general, from any given location,
the buyer and the seller tend to be from the same ethnic
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Most of the buyers interviewed on the street indicate
that they use marijuana for purely recreational purposes. The younger users indicate that most of their
friends smoke the drug, and the most frequently offered
reason for using marijuana is to “wind-down,” “loosenup,” or “chill” (relax). Almost all use some form of
alcohol in conjunction with smoking marijuana. Most
users indicated that they saw nothing wrong with marijuana use and felt that the legal penalties for using
marijuana were less severe than those associated with
other illicit drugs.
Traditionally, marijuana was smoked in a joint. This
method is no longer very popular, and many stores no
longer even stock rolling paper. Currently, the most
popular method involves the use of blunts: hollowedout cigars or marijuana wrapped in cigar leaves. Very
often, the leaves are dipped in brandy or some other
aromatic liquor. The tobacco industry has responded to
this by developing a large and varied selection of cigars
for the adolescent marijuana user, featuring such selections as grape or vanilla cigars. A popular type of
marijuana is called “Haze,” and it comes in a variety of
flavors, including strawberry and bubblegum. Another
street term is “Combo,” referring to a mixture of two or
three different flavors of “Haze” mixed with cocaine
and smoked in a blunt. Marijuana users seem to be
equally comfortable using the drug in a group setting or
in private. In private, the drug serves to reduce tension;
in social gatherings, it serves to lower social inhibitions.
DAWN ME mentions for marijuana-involved drug misuse deaths in the New York City metropolitan area
numbered 53 in 2003. None of these was a single-drug
death.
According to National Forensic Laboratory Information
System data, 25 percent of the cases for New York City
in 2004 (11,523) were related to cannabis.
According to the DEA, marijuana prices can range from
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$1,000 to $2,000 per pound wholesale and from $3,000
to $5,000 per pound for hydroponic marijuana.
In spite of decriminalizing possession of small amounts
of marijuana, the NYPD continues to make a large
number of marijuana-related arrests in New York City.
The number of arrests has stabilized, however (exhibit
6). Cannabis-involved arrests had reached a low of
4,762 in 1991, but they increased more than 12 times in
the next 9 years to 60,455 in 2000. Arrests for 2002
(47,250) were at the same level as in 2001, which was
the second largest yearly total. For arrests in 2002, approximately 98 percent were for misdemeanors, and 32
percent involved persons age 20 or younger. Moreover,
cannabis arrests accounted for 48 percent of all drug
arrests in New York City in 2002, a dramatic change
from earlier years and a continuation of the trend seen
in the last 5 years.

CMA has 22 meetings per week with an average of 30–
50 attendees per meeting. Many experts worry about
the implications methamphetamine has for the spread of
HIV and other sexually transmitted diseases (STDs).
Depressants
While some indicators of the nonmedical use of psychoactive prescription drugs (e.g., hospital
emergencies, deaths, and treatment admissions) have
not been increasing, the SSU continues to report a variety of drugs readily available on the street for $1 or
more per pill.
For the five boroughs of New York City, there were
1,751 benzodiazepine ED reports from January through
December 2004 according to preliminary unweighted
DAWN Live! data. Of these benzodiazepine reports, 25
percent were for patients seeking detoxification.

Stimulants
Although methamphetamine is popular in other parts of
the Nation, there were relatively few arrests, ED reports,
deaths, or treatment admissions related to the drug in
New York City. For example, in 2003, only seven stimulant deaths were reported in the New York metropolitan
area. In the five boroughs of New York City, there were
154 DAWN Live! ED reports for stimulants for January
through December 2004, according to preliminary unweighted data.
According to the SSU, numerous sources in the gay
community talk of the growing concern about the use of
methamphetamine among young gay males and the
relationship between the use of this drug and the spread
of HIV. A number of gay male users have reported experiencing crystal methamphetamine binges during
which they have engaged in unsafe sexual activity.
There are also indications that the use of methamphetamine has spread and is increasing among the “non
gay” club-going crowd and college students. Methamphetamine is also known as crystal, Tina, Christina,
crank, ice, speed, and chalk.
Since the use of methamphetamine continues to appeal
to a small segment of the general population, most sales
involve mutual acquaintances making the initial interactions. The closest thing to street sales is found at raves
or other public events.
Methamphetamine use appears to be especially on the
rise among young males in the gay community. The
recent growth in Crystal Meth Anonymous (CMA)
meetings in New York City is one indicator of this. In
1999, CMA had one meeting per week with six attendees. By 2002, CMA had 4 meetings per week with an
average of 20–30 attendees per meeting, and in 2005,
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According to the SSU, pill selling, the street diversion
of legitimately manufactured pharmaceuticals, seems to
be increasing. The three most frequently sold pills on
the street are Xanax, Elavil, and Catapres. The prices of
these three medications range from $1 to $5 per pill.
Although some pill buyers attributed their use of these
and other drugs to some physical or emotional medical
condition, most users indicated that their primary reason for buying these medications was to get “high.”
Very few respondents indicated that they used these
medications or others to reduce withdrawal symptoms.
Most street pill sellers appear to obtain their inventory
from their physician through Medicaid at no cost to themselves. Although there are exceptions, most pills are sold
individually and not in bottles. Most buyers seem to prefer or are only able to afford to buy 1 day’s supply. In
contrast to medication associated with pain, the diversion
of HIV medication has less to do with getting high and
more to do with making money. HIV medications are not
usually sold individually; rather they are sold in sealed
(unopened) bottles. In many cases, the price of a bottle
(or 30-day supply) of the medication may sell for as
much as $700. The buyers of the HIV medication do not
seem to be interested in buying the medication for their
own use or the use of a loved one. Instead, these medications appear to be bought in an effort to stockpile a
supply of the medication which is eventually either sold
back to a pharmacy for “re-sale” to another customer or
shipped out of the country to a less developed nation with
an AIDS problem.
There continue to be few (about 1 percent) treatment
admissions with a psychoactive prescription drug as a
primary drug of abuse.
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Among ME deaths reported by DAWN, benzodiazepine-involved drug misuse deaths numbered 201 in
2003—among the top five categories of drug misuse
deaths. Antidepressants were also in the top five categories of drug misuse deaths, accounting for 210 such
deaths in 2003. Moreover, antidepressants were the
number one category in suicide deaths in the New York
metropolitan area in 2003, with 29 such deaths.
Since these drugs are manufactured by legitimate pharmaceutical companies, purity is not an issue. Most of
these medications come in a variety of strengths, however, and not all strengths are found on the street.
Observations indicate that the following pills are sold
on the street: 1-milligram ($3) and 2-milligram ($5)
Xanax tablets; 1-milligram ($1) Elavil tablets; and 2milligram ($1) and 3-milligram ($2) Catapres tablets.

According to preliminary unweighted DAWN Live! ED
data for the five boroughs of New York City, there
were 157 reports for MDMA for January through December 2004.
Although the club drugs are, in fact, part of the New
York drug scene at some level, street research suggests
that their use is limited to a small segment of the New
York City drug-using population. Of these drugs, ecstasy seems to be the most popular and frequently used
club drug in the city. Lagging somewhat behind are
GHB and ketamine. LSD is a strong hallucinogen that
has not been a major problem in New York City since
the late 1960s and early 1970s. It is also known as acid,
boomer, and yellow sunshine. Most contacts indicated
that they never used LSD, nor did they know where it
could be obtained.

Hallucinogens
For the five boroughs of New York City, there were
294 preliminary unweighted DAWN Live! ED reports
for PCP for January through December 2004.
According to DAWN ME data for the New York metropolitan area for 2003, hallucinogens (including PCP,
lysergic acid diethylamide [LSD], and other hallucinogens) accounted for 12 drug misuse deaths.
Street sources continue to report that PCP is becoming
more readily available in the city. One method of use is
to pour liquid PCP on marijuana by placing the marijuana in a glass jar with a rubber cap. The PCP is
“injected” through the rubber top onto the marijuana.
Hydroponic marijuana is especially popular in this
method. Reports are that the caps on these PCP jars are
usually red or orange with a picture of a butterfly. Some
street sources say the butterfly symbolizes an angel, as
in angel dust, another name for PCP, while others say
the butterfly stands for “how high you can get.”
Club Drugs
Club drugs are a collection of various synthetic chemical compounds that are often abused by young people
in festive social settings, such as dance clubs, after-hour
clubs, “raves,” and other special events. Club drugs
include MDMA, methamphetamine, gamma hydroxybutyrate (GHB), and ketamine. Raves and other allnight parties are about endurance and sensory overstimulation, and, not surprisingly, many of the club
drugs have stimulant or hallucinogenic properties.
Since many of club drugs are synthetic and manufactured, purity is not a real issue, but the quality of these
products poses a serious concern. The chemical expertise of the producers, the ingredients used, and
laboratory conditions used to manufacture these substances are uncertain and potentially dangerous.

188

The price for a single pill of ecstasy ranges between $5
and $30. The prices tend to run at the high end if these
substances are purchased inside a club or rave. The
most common sales unit for ecstasy is the single white
pill or tablet. No additional packaging is required.
Club drug sellers are usually young (early twenties or
younger) White males, and many are attending college.
Many of the sellers are middle-class or higher. This
profile, however, is beginning to expand across racial,
ethnic, and social class boundaries. In a club setting, a
seller may also have marijuana, cocaine HCl, and other
club drugs for sale.
Club drug users tend to be White and young (ranging
between 15 and 30). According to street contacts, ecstasy is almost as popular among females as males.
Many of the users are older high school students, college students, or young working professionals. The
latter group tends to be of a mid-to-high socioeconomic status. The socio-economic status of the
younger users, who appear to be the fastest growing
group of users, seems to be more widely spread. According to some informants, the appeal for these drugs
is strongest among suburban White youth, who regularly venture into the city for entertainment, fun, and
excitement. There are, however, indications that club
drugs, particularly ecstasy, are making greater inroads
among New York residents, especially non-White users. There are reports that some Hispanic groups are
becoming involved in the distribution of ecstasy, which
may suggest that more Hispanics and other inner-city
residents are beginning to use this drug.
The route of administration varies with the drug. Club
drug use typically involves the ingestion of multiple
substances. Typically, a club drug user will also use
alcohol, marijuana, cocaine, or other club drugs.
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These club drugs continue to be used primarily for recreational purposes, with use largely limited to weekends
and special events. Except for clubs and other special
events, most connections are made through a network
of acquaintances that very often revolve around the
user’s high school or college.
The number of DAWN deaths involving the category of
club drugs (including MDMA, ketamine, GHB, and
Rohypnol) totaled 10 in 2003 for the New York metropolitan area.
INFECTIOUS DISEASES RELATED TO DRUG ABUSE
The AIDS epidemic, with its impact on injection drug
users (IDUs), has played a crucial role in shaping the
New York City drug scene over the last two decades.
HIV first entered New York City in the mid- to late1970s. AIDS reporting was mandated in 1983, but reporting of HIV infection began in June 2000.
According to the New York City Department of Health,
as of June 30, 2004, 92,021 New Yorkers were diagnosed
with HIV or AIDS; 32,688 were living with HIV (nonAIDS), and 59,333 were living with AIDS. The true
number of persons living with HIV/AIDS (PLWHA) is
actually higher, since the New York City Department of
Health and Mental Hygiene estimates that 25 percent of
persons living with HIV have never been tested and do
not know that they are infected. AIDS incidence in New
York City peaked in 1993, with 12,649 cases. Mortality
dropped sharply beginning in 1996, but New York City
residents continue to die of HIV. Between January 1,
2004, and June 30, 2004, 1,051 people with HIV or
AIDS died of all causes. In 2002, HIV/AIDS was the
leading cause of death among New Yorkers age 35–44
and the third leading cause among those age 25–34. In
2003, the age-adjusted HIV-mortality rate in adults with
AIDS declined by 12 percent.
Of the 92,021 PLWHA in New York City as of June
30, 2004, 64 percent were diagnosed with AIDS, and
36 percent were diagnosed with non-AIDS HIV. Sev-
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enty percent were male, and 30 percent were female. In
terms of race/ethnicity, 44 percent were Black, 32 percent were Hispanic, and 21 percent were White. For
transmission risk factors, 27 percent (25,066) were men
who have sex with men, 24 percent (21,881) had an
injection drug use history, 18 percent reported a heterosexual transmission factor, 3 percent had a perinatal
transmission risk factor, 1 percent had another risk factor, and 28 percent had an unknown risk factor or were
under investigation. Men and women showed different
patterns of HIV transmission in 2003. Among women
with known risk, heterosexual sex was the predominant
risk for HIV, accounting for 75 percent of new HIV
(non-AIDS) diagnoses. Among men with known risk,
sex with men accounted for 71 percent of new HIV
(non-AIDS) diagnoses.
In 2003, 4,205 New Yorkers were diagnosed with HIV;
1,050 (25 percent) first learned they were HIV-positive
at the time they learned they had already progressed to
AIDS. Also in 2003, 5,056 AIDS cases were diagnosed.
New AIDS diagnoses increased by 13 percent from the
previous year, with the largest increases occurring
among Hispanic women (26 percent) and White men
(29 percent). The majority (81 percent) of new HIV
(non-AIDS) diagnoses and 80 percent of new AIDS
diagnoses were among Blacks and Hispanics in 2003.
Black women accounted for 61 percent of AIDS cases
of women. Among Black men, the prevalence of
HIV/AIDS was 2.8, significantly higher than the citywide average of 1.1 percent. HIV/AIDS is concentrated
in the poorest neighborhoods of New York City.
The New York City Department of Health and Mental
Hygiene, Bureau of Communicable Diseases, also has a
surveillance of hepatitis C data. As of December 2004,
there were 15,129 newly reported individuals with a
diagnosis date (or specimen collection date) in 2003.
For 2002, that figure was 13,940.
For inquiries concerning this report, please contact Rozanne Marel,
Ph.D., Chief of Epidemiology, New York State Office of Alcoholism
and Substance Abuse Services, 501 7th Avenue, 9th Floor, New York,
New York 10018, Phone: (646) 728-4605, Fax: (646) 728-4685, or Email: RozanneMarel@oasas.state.ny.us.
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Exhibit 1: New York City DAWN ED Sample and Reporting Information: January–December 2004
Total
Eligible
1
Hospitals

No. of
hospitals in
DAWN
Sample

Total EDs
in DAWN
2
Sample

52

39

60

No. of EDs Reporting per
Month: Completeness of Data
(%)
90–100%
50–89%
<50%
20–31
2–11
1–5

No. of EDs
Not
Reporting
23–31

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual
Survey.
2
Some hospitals have more than one emergency department
SOURCE: DAWN Live!, OAS, SAMHSA, updated 5/31/2005–6/2/2005

Exhibit 2.

Semiannual Cocaine Trends for Selected Indicator Data in New York City: 1995–2004

Semiannual/
Annual
Periods

Year

1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total

1995

1996

1997

1998

1999

2000

2001

2002

2003

1H
2H
Total

2004

Deaths Involv1
ing Cocaine

908

659

501

438

394

492
–

421

Cocaine ED
Mentions/
2
Reports
9,915
9,808
19,715
11,070
10,522
21,592
10,233
9,969
20,202
9,989
9,560
19,549
7,386
7,413
14,799
6,883
7,367
14,250
7,449
6,450
13,898
6,679
7,282
13,961

520

Treatment
Admissions:
Cocaine as
Primary Drug
3
of Abuse
8,371
7,836
16,207
8,561
8,817
17,378
9,048
8,401
17,449
8,999
8,573
17,572
8,346
7,567
15,913
7,337
6,722
14,059
7,343
7,032
14,375
7,736
7,872
15,608
8,203
7,911
16,114
8,395
8,247
16,642

Cocaine
4
Arrests

Births to
Women
Using
5
Cocaine

40,846

1,059

38,813

1,005

35,431

864

35,577

742

31,781

626

31,919

490

23,498

438

13,574

363

354

10,134

1

SOURCES: DAWN, OAS, SAMHSA, including New York City, Long Island, and Putnam County through 1995; starting with 1996
the
data include New York City only. In 2003, data are for the 5 boroughs of New York City plus Suffolk and Putnam
Counties in New York, and Union and Morris Counties in New Jersey.
2
DAWN, OAS, SAMHSA, updated 5/31/2005-6/02/2005. The 2004 number of reports are unweighted data and are
from 60 EDs in the 5 boroughs of New York City reporting to DAWN in 2004. During this 12-month period, however,
between 29 and 37 EDs reported data each month. All DAWN cases are reviewed for quality control. Based on this
review, cases may be corrected or deleted, and, therefore, are subject to change. Prior to 2003, DAWN, OAS,
SAMHSA, weighted data, based on a representative sample of hospitals for New York City and Westchester, Rockland, and Putnam Counties
3
New York State Office of Alcoholism and Substance Abuse Services (OASAS)-funded and nonfunded treatment admissions
4
New York City Police Department
5
New York City Department of Health
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Exhibit 3. Characteristics of Primary Cocaine Admissions1 to State-Funded2 and Nonfunded3 Treatment
Programs in New York City, by Route of Administration and Percent: 2004
Demographic
Characteristic
Gender
Male
Female
Age at Admission
25 and younger
26–35
36 and older
(Average age)
Race
Black
Hispanic
White
No Source of Income4
Some Criminal Justice Status
Readmissions
Age of First Use
14 and younger
15–19
20–29
30 and older
Secondary Drug of Abuse
Alcohol
Marijuana
Heroin

Percent Total
(N=16,642)

Percent Smoking
Crack
(n=10,262)

Percent Using
Cocaine Intranasally
(n=5,754)

68
32

64
36

75
25

6
23
71
(39.2 years)

4
21
75
(39.9 years)

11
27
62
(38.0 years)

30
41
79

69
18
11
34
38
83

42
36
19
25
48
71

6
29
43
22

5
25
46
24

8
36
39
18

43
23
6

45
21
6

39
26
5

59
25
14

1

Figures on this table may differ somewhat from figures cited on other tables, because computer runs may have been executed at
different times and files are being updated continuously.
2
State-funded programs receive some or all funding through the New York State Office of Alcoholism and Substance Abuse Services (OASAS).
3
Nonfunded programs receive funding through sources other than OASAS.
4
Defined as not earning income, not receiving support from family or significant others, and not receiving any public assistance.
SOURCE: New York State Office of Alcoholism and Substance Abuse Services
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Exhibit 4. Semiannual Heroin Trends for Selected Indicator Data in New York City: 1995–2004

Year

Semiannual/
Annual
Period
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

Deaths
Involving Her1
oin

751

192

272

230

174

194
–

224

Heroin/
Morphine
ED Mentions/
2
Reports
5,288
5,440
10,706
5,654
5,478
11,132
4,900
4,581
9,481
4,613
4,605
9,218
4,153
5,150
9,302
5,378
5,630
11,009
5,428
5,216
10,644
4,954
5,443
10,397

104

6,374

Treatment Admissions: Heroin as
Primary Drug of
3
Abuse
9,286
9,001
18,287
9,161
9,617
18,778
10,276
10,431
20,707
10,793
10,203
20,996
10,690
10,189
20,879
10,944
10,672
21,616
11,324
11,455
22,779
11,357
11,157
22,514
11,540
12,023
23,563
12,029
11,658
23,687

Heroin
4
Arrests

Average
Purity of
Street Heroin
5
(%)

38,131

(69.4)

37,901

(56.3)

35,325

(62.5)

37,483

(63.6)

32,949

(61.8)

33,665

(62.9)

27,863

(56.0)

34,098

(61.4)

(53.5)

1

SOURCES: DAWN, OAS, SAMHSA, including New York City, Long Island, and Putnam County through 1995. (Between 1996
and
2002, the data include New York City only. Prior to 1996, the data include heroin/morphine deaths as well as opiates
not
specified by type. Between 1996 and 2002, the data include only heroin/morphine deaths.) In 2003, data are for the 5
boroughs of New York City plus Suffolk and Putnam Counties in New York, and Union and Morris Counties in New
Jersey.
2
DAWN, OAS, SAMHSA, updated 5/31/2005-6/02/2005. The 2004 number of reports are unweighted data and are
from 60 EDs in the 5 boroughs of New York City reporting to DAWN in 2004. During this 12-month period, however,
between 29 and 37 EDs reported data each month. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted, and, therefore, are subject to change. Prior to 2003, DAWN, OAS, SAMHSA,
weighted data, based on a representative sample of hospitals for New York City and Westchester, Rockland, and Putnam Counties.
3
New York State Office of Alcoholism and Substance Abuse Services (OASAS)-funded and nonfunded treatment admis-sions
4
New York City Police Department
5
U.S. Drug Enforcement Administration
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Exhibit 5.

Characteristics of Primary Heroin Admissions1 to State-Funded2 and Nonfunded3 Treatment
Programs in New York City, by Route of Administration and Percent: 2004

Demographic
Characteristic
Gender
Male
Female
Age at Admission
25 and younger
26–35
36 and older
(Average age)
Race
Black
Hispanic
White
No Source of Income4
Some Criminal Justice Status
Readmissions
Age of First Use
14 and younger
15–19
20–29
30 and older
Secondary Drug of Abuse
Alcohol
Marijuana
Cocaine

Percent Total
(N=23,687)

Percent Using Heroin
Intranasally
(n=14,146)

Percent Injecting
Heroin
(n=8,775)

75
25

75
25

75
25

7
22
71
(40.2 years)

5
20
75
(40.8 years)

10
25
65
(39.3 years)

27
53
18
27
33
89

32
55
11
28
37
88

16
52
30
25
25
92

12
34
35
19

10
31
36
23

16
40
32
12

13
8
40

13
9
36

12
6
46

1

Figures on this table may differ somewhat from figures cited on other tables, because computer runs may have been executed at
different times and files are being updated continuously.
2
State-funded programs receive some or all funding through the New York State Office of Alcoholism and Substance Abuse Services (OASAS).
3
Nonfunded programs receive funding through sources other than OASAS.
4
Defined as not earning income, not receiving support from family or significant others, and not receiving any public assistance.
SOURCE: New York State Office of Alcoholism and Substance Abuse Services
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Exhibit 6. Semiannual Marijuana Trends for Selected Indicator Data in New York City: 1995–2004

Semiannual/
Annual Period

Year

1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total
1H
2H
Total

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

SOURCES:

194

Marijuana
ED
Mentions/
1
Reports
1,516
1,460
2,974
1,723
1,848
3,571
1,939
1,900
3,839
1,986
1,696
3,682
1,799
1,692
3,491
1,856
1,688
3,544
1,904
1,598
3,502
1,827
2,097
3,924

3,118

Treatment Admissions: Mari2
juana as Primary Drug of Abuse
2,171
2,159
4,330
2,845
3,185
6,030
3,794
3,657
7,451
4,554
4,473
9,027
5,119
5,100
10,219
5,664
5,487
11,151
6,677
6,593
13,270
7,512
6,798
14,310
6,844
6,627
13,471
6,832
6,415
13,247

Cannabis
3
Arrests

12,357

18,991

27,531

42,030

43,122

60,455

47,651

47,250

1

DAWN, OAS, SAMHSA, updated 5/31/2005-6/02/2005. The 2004 number of reports are unweighted data and are
from 60 EDs in the 5 boroughs of New York City reporting to DAWN in 2004. During this 12-month period, however,
between 29 and 37 EDs reported data each month. All DAWN cases are reviewed for quality control. Based on this
review, cases may be corrected or deleted, and, therefore, are subject to change. Prior to 2003, DAWN, OAS,
SAMHSA, weighted data, based on a representative sample of hospitals for New York City and Westchester, Rockland,
and Putnam Counties
2
New York State Office of Alcoholism and Substance Abuse Services (OASAS)-funded and nonfunded treatment
admissions
3
New York City Police Department
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Exhibit 7. Characteristics of Primary Marijuana Admissions1 to State-Funded2 and Nonfunded3 Treatment
Programs in New York City, by Percent: 2004
Demographic Characteristic
Gender
Male
Female
Age at Admission
20 and younger
21–25
26–35
36 and older
(Average Age)
Race
Black
Hispanic
White
No Source of Income4
Some Criminal Justice Status
Readmissions
Age of First Use
14 and younger
15–19
20–29
30 and older
Secondary Drug of Abuse
Alcohol
Cocaine

Percent of Total
(N=13,247)
79
21
28
26
28
18
(26.8 years)
57
32
8
22
65
56
49
41
8
2
38
13

1

Figures on this table may differ somewhat from figures cited on other tables, because computer runs may have been executed at
different times and files are being updated continuously.
2
State-funded programs receive some or all funding through the New York State Office of Alcoholism and Substance Abuse Services (OASAS).
3
Nonfunded programs receive funding through sources other than OASAS.
4
Defined as not earning income, not receiving support from family or significant others, and not receiving any public assistance.
SOURCE: New York State Office of Alcoholism and Substance Abuse Services
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Drug Use in Philadelphia,
Pennsylvania

year (FY) refers to a year starting July 1 and ending
the following June 30.
•

Treatment admissions data for programs in
Philadelphia County were provided by the Pennsylvania Department of Health, Client Information
System, for January 1, 1998, through December
31, 2004. Data for 2004 are preliminary and subject to revision because of the treatment reporting
schedule, which results in frequent delays between
a treatment admission and the reporting of that
event.

•

Mortality data were provided by the Philadelphia Medical Examiner’s (ME) Office. These
data cover mortality cases with toxicology reports indicating the detection of drugs among
decedents in Philadelphia. The time period is
1994 through 2004. (The cases include persons
who died from the adverse affects of one or multiple drugs, as well as persons who exhibited
some substance presence but died from other
causes. The Philadelphia ME also distinguishes
between persons who appeared to have a lethal
reaction to what might be considered a light or
moderate amount of drugs and persons whose
toxicology reports showed a high level of drugs
in their systems.) Mortality cases with positive
toxicology reports for alcohol are only reported
if the alcohol was to be found in combination
with one or more other drugs.

•

Arrestee urinalysis data for booked adults were
derived from reports from the First Judicial District of Pennsylvania, Adult Probation/Parole
Department (APPD), for the period June 15, 2004,
through December 15, 2004.

•

Drug price information was provided by the
National Drug Intelligence Center for the period
January 1, 2004, through June 30, 2004, and focus group participants in the spring of 2005.

•

Heroin purity data were provided by the Drug
Enforcement Administration (DEA), Domestic
Monitor Program (DMP), through the first half of
2004.
Information on the identification of drug samples seized and analyzed by local law enforcement as reported to the DEA’s National Forensic
Laboratory Information System (NFLIS) during
2004 were provided for this report.

Samuel J. Cutler and Marvin F. Levine,
M.S.W.1
ABSTRACT
Indicators in Philadelphia remain highest for cocaine, heroin, alcohol, and marijuana. There has
been an increase in the number of drugs used in
combination and an expansion in the number of different drugs being used. During 2002, 2003, and
2004, the average number of drugs detected in decedents increased from 2.68 to 3.18 to 3.75 per case. In
2004, 47 percent of decedents testing positive for heroin/morphine also tested positive for cocaine. In
2004, 73 percent of male cocaine treatment admissions and 84 percent of female cocaine treatment
admissions were crack smokers. There are indications that PCP use is declining. Negative consequences associated with the use of benzodiazepines
are increasing.
INTRODUCTION
Area Description
Philadelphia, the largest city in the State, is located in
the southeastern corner of Pennsylvania. The 2000
U.S. census count of 1,517,550 Philadelphia residents
represents 12.4 percent of the State’s population and a
7-percent increase from the 1990 census count. The
2000 Philadelphia population was 45.0 percent White,
43.2 percent African-American, 4.5 percent Asian, 0.3
percent American Indian and Alaska Native, 4.8 percent other race, and 2.2 percent two or more races.
Hispanics (of various races) accounted for an estimated
8.5 percent of the population, and persons age 18 and
older accounted for 74.7 percent. The unemployment
rate was 6.1 percent for persons age 16 and older, and
49.8 percent of the population was employed.
Data Sources
This report focuses primarily on the city/county of
Philadelphia and includes data from the sources
shown below. For the purposes of this report, fiscal

1

The authors are affiliated with the City of Philadelphia, Office of
Behavioral Health/Mental Retardation Services, Coordinating Office
for Drug and Alcohol Abuse Programs (CODAAP), Philadelphia,
Pennsylvania. John H. Gossard, Richard C. Jones, and Nelson E. Martin provided assistance in preparing this paper.
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•

•

Acquired immunodeficiency syndrome (AIDS)
data were provided by the Philadelphia Department of Public Health’s AIDS Activities Coor-
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dinating Office on AIDS cases reported from November 1, 1981, to December 31, 2004.
•

Population and demographic data describing
the city of Philadelphia emanated from the U.S.
Census Bureau.

In addition to these sources, this report draws on focus group and key informant discussions with former
drug users currently enrolled in treatment programs,
as well as outreach workers assigned to homeless
populations, substance abusers, persons with human
immunodeficiency virus (HIV) infection, and law
enforcement officials.
A note to those accustomed to reading past editions
of this report: Due to the levels of incomplete and
inaccurate data from the Drug Abuse Warning Network (DAWN) Live! hospital emergency department
data set, the Office of Applied Studies (OAS) of the
Substance Abuse and Mental Health Services Administration (SAMHSA) suspended reporting from
Philadelphia metropolitan statistical area emergency
departments, and no such data will appear in the
Philadelphia paper until problems have been rectified
to the satisfaction of SAMHSA and DAWN.
DRUG ABUSE PATTERNS AND TRENDS
The four major drugs of abuse in Philadelphia continue to be cocaine, heroin, marijuana, and alcohol.
These are frequently used in combination with each
other and with other supplemental drugs. In 2003 and
2004, 91.7 percent of people entering treatment identified one of these drugs as their primary drug of
abuse.
In 2004, the average number of drugs detected in decedents by the ME (3.75) was the highest on record.
The average over the previous 10-year period (1994 to
2003) was 2.43 drugs per case (exhibit 1). The number
of mortality cases with positive toxicology reports
(n=888) in 2004 exceeded the previous record high of
841 in 2003. Of the 888 deaths in 2004, adverse reaction to drugs accounted for 31.0 percent, overdose
represented 10.1 percent, violence accounted for 24.7
percent, and “other causes” constituted 34.2 percent
(exhibit 2).
In 2004, African-American male decedents (n=292)
and White male decedents (n=292) exceeded all other
race/ethnicity and gender totals. White females
(n=121) outnumbered African-American females
(n=109). The remaining 74 deaths were among Hispanics, Asians, and American Indians. Overall,
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Whites accounted for 46.5 percent of the deaths; African-Americans accounted for 45.2 percent of the
deaths; Hispanics represented 7.5 percent; and Asians
and American Indians accounted for 0.8 percent.
Urinalysis data of booked arrestees from Philadelphia’s APPD in the second half of 2004 showed that
39 percent (n=9,330) of the 23,913 tested arrestees in
the sample were positive for at least 1 drug.
The Pennsylvania Client Information System is limited
to the identification of a maximum of three substances
as drugs of abuse at treatment intake. The highest average number of drugs of abuse identified at admission
to treatment occurred in the first half of 1999 (2.06). In
2002, the average was 1.45 drugs of abuse, in 2003,
the average was 1.74 drugs of abuse, and in 2004, the
average was 1.73 drugs of abuse at admission to treatment.
Cocaine/Crack
Cocaine/crack remains the major drug of abuse in
Philadelphia. ME data show that the proportion of
cases with cocaine present was 46 percent in 2002,
39 percent in 2003, and 45 percent in 2004 (exhibit
1). Cocaine was detected in 3,357 decedents from
January 1994 through December 2004, a total higher
than that for any other drug appearing in the toxicology reports. In 2004, the average age of mortality
cases with positive toxicology reports for cocaine was
40. At least one other drug was detected in 83 percent
of cocaine-positive cases in 2001and 2002, 85 percent in 2003, and 87 percent in 2004.
The treatment data for 2003 show that cocaine, as a
primary drug, accounted for 25.8 percent of all
treatment admissions, the same as in 2001 (exhibit 3).
In 2003, cocaine was mentioned by an additional
15.9 percent of clients as a secondary drug and by 2.8
percent as a tertiary drug. In 2004, cocaine accounted
for 26.4 percent of all primary drug mentions and
was mentioned by an additional 14.7 percent of clients as a secondary drug and by 3.1 percent as a
tertiary drug. The proportion of cocaine treatment
admissions peaked in 1991, at 63 percent of all primary drugs mentioned at admission to treatment.
In 2003 and 2004, males accounted for 59 and 60
percent of primary cocaine drug treatment admissions, respectively (exhibit 4). During these time
periods, African-Americans accounted for 79 and 80
percent of primary cocaine treatment admissions,
respectively, followed by Whites (16 and 15 percent), Hispanics (4 and 4 percent), and Asians and
“others” (1 and 1 percent). Among primary cocaine
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treatment admissions in 2003, the average number of
drugs of abuse noted upon entering treatment was
1.85; in 2004, the average was 1.68.

zolam (Xanax), marijuana, or heroin. Powder cocaine,
oxycodone, cigarettes, and methamphetamine were
less frequently mentioned as drugs used with crack.

Since 2000, an average of 81.5 percent of the primary cocaine admissions reported smoking the drug,
15.5 percent reported intranasal use, 1.6 percent reported injecting, and 1.4 percent reported
administering the drug through other/unknown routes
(exhibit 4). Since the first half of 1990, at least 77 percent of cocaine treatment admissions have reported
smoking the drug. Of all male cocaine admissions in
2003 and 2004, 77 and 73 percent, respectively, reported smoking the drug; the comparable figures for
females were 86 and 84 percent.

Heroin/Morphine

Urinalysis data of booked arrestees from Philadelphia’s APPD in 2004 showed that 13.8 percent
(n=6,808) of the 49,200 tested arrestees in the sample
were positive for cocaine or cocaine metabolites. Cocaine was the second most frequently detected drug;
marijuana ranked first.
According to the 2004 NFLIS report, 42 percent of
samples analyzed were positive for cocaine.
The predominant form of crack sold in Philadelphia is
the “rock,” which costs $5. The $5 rock ranged in size
from 6 to 9 millimeters from 1996 until 2002. Since
then, the size of the $5 rock was reduced to 5–6 millimeters. Treys ($3 rocks) ranged in size from 3 to 5
millimeters since 1996. They were reduced to 3 to 4
millimeters from the latter half of 2002 through the
spring of 2005, when it was reported that treys are not
as commonly available as in the past. Shapes of crack
range from circular, to bumpy-circular, to pieces cut
into the shape of a parallelogram. Powder cocaine is
not as readily available in small ($5) quantities; as of
the spring of 2005, $10 bags became scarcer, with the
$20 bag becoming the standard retail unit on the street.
According to the National Drug Intelligence Center,
the retail/street-level price per ounce of crack ranged
from $3 to $20 per rock and from $28 to $125 per
gram of powdered cocaine in the first half of 2004.
Focus group participants from the spring of 2002
through the spring of 2005 estimated that about 55–
65 percent of powder cocaine buys are for intranasal
use, 20–25 percent is injected straight, and 15–20
percent is injected in a “speedball.”
In the spring of 2005, crack users continued to report
frequent use in combination with 40-ounce bottles of
malt liquor, beer, wine, or other drugs, including alpra-
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According to the DEA’s DMP, the average streetlevel purity of heroin in Philadelphia was 71 percent
in 2001, 66.3 percent in 2002, 59.6 percent in 2003,
and 53 percent in the first half of 2004 (based on
only 70 percent of the samples analyzed). The authors pose that declining purity at the retail/street
level might have a causal relationship for the aforementioned increase in the average number of drugs in
mortality cases since 2001. With lower heroin purity,
users may perceive a need for more drugs to achieve
the desired effect.
Heroin was detected in 3,036 decedents from 1994
through 2004, making it the second most commonly
detected drug in decedents (exhibit 1). For the 4-year
period 1999 through 2002, positive heroin toxicology
reports occurred in 47 percent of all deaths with the
presence of drugs. In 2003, heroin was detected in
only 25 percent of all decedents with drug-positive
toxicology reports; the proportion was 24 percent in
2004.
From 2000 through 2003, heroin alone was identified
in 14, 11, 10, and 7 percent, respectively, of the respective heroin toxicology reports. In 2004, heroin
alone was identified in only 3 percent of the heroinpositive toxicology reports. The combination of heroin and cocaine was detected in 20, 19, 17, 10, and
11 percent of all decedents, respectively, from 2000
through 2004. Cocaine was detected in 47 percent of
heroin toxicology reports in 2004.
In 2004, heroin treatment admissions ranked second
highest after ranking first in 2003 (exhibit 3). Heroin
admissions accounted for 22 percent of all admissions
in 2002, 27 percent in 2003, and 26 percent in 2004.
During 2003 and 2004, 65 percent of all treatment
admissions for heroin, illegal methadone, and other
opiates were male (exhibit 5). In 2004, 60 percent were
White, 26 percent were African-American, 12 percent
were Hispanic, and 2 percent were Asian/other. Individuals who identified heroin as the primary drug of
abuse in 2003 used an average of 1.63 drugs; in 2004,
the average was 1.67.
As depicted in exhibit 5, the preferred routes of administration for heroin, illegal methadone, and other
opiates have been relatively stable among treatment
admissions.
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Heroin treatment admissions data from the second
half of 1997 through 2004 revealed that there was a
slow, but steady decline in the proportion of heroin
injectors entering treatment. It was determined that
the injection percentages were influenced by an influx of relatively new users who entered treatment
for the first time prior to converting to injection from
intranasal use, which is characteristic of new users.
However, most heroin users make the conversion to
injecting before entering treatment for the first time.
Urinalysis data of booked arrestees from Philadelphia’s APPD in 2004 showed that 6.2 percent
(n=3,035) of the 49,200 tested arrestees in the sample
were positive for opiates. Opiates were the third most
frequently detected drugs behind marijuana and cocaine.
According to the 2004 NFLIS report, 9 percent of
samples analyzed were positive for heroin.
Key informants in the spring of 2005 continued to report that the $10 bag of heroin remained the standard
unit of purchase. The $10 bag usually yields one hit;
$5 and $20 bags reportedly remain available. According to the National Drug Intelligence Center, the
retail/street-level prices for heroin were $10–$20 per
bag, $180–$250 per bundle, and $65–$300 per gram
of heroin in the first half of 2004.
Focus group participants in 2004 reported that the average age of new users is 20. In the spring of 2005, the
average age of new users was reported as the late
teens. All groups since autumn 2000 reported that the
average heroin user injects the drug four or five times
per day.
Narcotic Analgesics
Oxycodone
The use of oxycodone products, including OxyContin, Percocet/Percodan, Roxicet, and Tylox, continues
to appear problematic in Philadelphia.
Oxycodone was detected in 421 decedents from 1994
through 2004 (the ninth most frequently detected
drug during that time period) (exhibit 1). Detections
of oxycodone have been rapidly increasing since
2000. In 2003, oxycodone was present in 9.6 percent
of all drug-positive deaths; in 2004, oxycodone was
present in 11.6 percent of drug-positive mortality
cases.
Focus group participants since spring 2002 reported
the use of oxycodone by all racial/ethnic groups, with
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an age range of mid-teens to 40, with the largest user
group being people in their twenties.
Hydrocodone
The presence of hydrocodone in mortality cases has
also increased. There were 40 positive toxicology
ME reports for hydrocodone in 2003, 51 reports in
2004, and a total of 239 cases in the 11-year period
from 1994 through 2004. Hydrocodone detections
now rank 14th among all deaths with positive toxicology reports.
Opioid Analgesics
Fentanyl
In the spring of 2004, the Pennsylvania State Attorney General’s Office issued information about the
diversion and nonmedical use of fentanyl citrate. In
particular, Actiq lozenges were cited as being sold on
the streets of Philadelphia for $20 each. Actiq contains fentanyl citrate and is indicated for patients who
continue to experience pain while being treated with
synthetic opiates. Actiq resembles a lollipop, as the
medication lozenge is at the end of a small stick and
it is used by rubbing against the inside soft tissue of
the mouth. Locally, users call it “Perca-pop” or
“Narco-pop.” From 1994 through 2004, the ME recorded 70 deaths with the presence of fentanyl. Of
these, 16 occurred in 2003 and 35 occurred in 2004.
Marijuana
Marijuana continued to be readily available and widely
used in Philadelphia in the second half of 2004. The
proportion of clients who cited marijuana as the primary drug of abuse upon entering treatment was 17
percent in 2003 and 2004 (exhibit 3). Among all admissions in 2003 and 2004, an additional 10 and 11
percent, respectively, mentioned marijuana as a secondary drug. During the same time periods,
marijuana was mentioned as a tertiary drug by 7 percent and 6 percent, respectively. In 2003, among
primary marijuana admissions, males accounted for
78 percent; African-Americans accounted for 63 percent, Whites accounted for 21 percent, Hispanics
accounted for 13 percent, and Asians and others accounted for 3 percent. In 2004, the comparable
figures were 77 percent male, 62 percent AfricanAmerican, 24 percent White, 11 percent Hispanic,
and 3 percent Asians and others. Among primary
marijuana treatment admissions in 2003, the average
number of drugs of abuse noted upon entering treatment was 1.63. The average in 2004 was 1.71.
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Urinalysis data of booked arrestees from Philadelphia’s APPD in 2004 showed that 17.9 percent
(n=8,786) of the 49,200 tested arrestees in the sample
were positive for marijuana or marijuana metabolites.
Marijuana was the most frequently detected drug by
APPD.
According to the 2004 NFLIS report, 32 percent of
samples analyzed were positive for cannabis/tetrahydrocannabinol (THC).
Key informants continue to report the widespread
and increasing use of blunts, especially utilizing flavored cigars. The combination of marijuana and
phencyclidine (PCP) continues to be frequently reported. Blunts laced with crack (called “Turbo”) are
still common, but less so than the marijuana/PCP
combination. Blunt users commonly ingest beer,
wine coolers, whiskey, alprazolam, or diazepam
along with the blunt. Less commonly, blunt smokers
use powder cocaine, vodka, barbiturates, clonazepam, oxycodone, cough syrup, and/or methamphetamine. These comments by users continue to
underscore the common practice of multiple drug
use, either simultaneously or sequentially.
According to the National Drug Intelligence Center,
the retail/street-level prices per bag of marijuana
ranged from $5 to $35 in the first half of 2004.
Phencyclidine (PCP)
PCP began to gain popularity as an additive to blunts
in 1994, and its use increased from 2000 to 2003.
Users describe its effects as making them hallucinate
and feel “invincible,” “crazy,” “numb,” or “violent.”
PCP was detected in 449 decedents from 1994 through
2004, making it the seventh most frequently detected
drug during that period. In 2004, deaths with the presence of PCP declined to the second lowest annual total
in the past 11 years (exhibit 1).
In 2003, PCP was mentioned as a primary, secondary,
or tertiary drug by 4.3 percent of all treatment admissions. The average number of drugs of abuse mentioned by primary PCP treatment admissions was 1.92.
In the first half of 2004, PCP was mentioned as a primary, secondary, or tertiary drug in 4.6 percent of all
admissions, and the average number of drugs of abuse
mentioned by primary PCP treatment admissions was
1.89.
Urinalysis data of booked arrestees from Philadelphia’s APPD in 2004 showed that 3.5 percent
(n=1,731) of the 49,200 tested arrestees in the sample
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were positive for PCP, making this drug the sixth
most frequently detected drug by APPD.
PCP remains readily available. It is more commonly
found on mint leaves for use in lacing blunts or for
rolling and smoking. Additionally, some users prefer
PCP in liquid form that is used by applying the drug
to cigarettes. This method is referred to as “sherms”
or “dip sticks.” Focus group participants in the spring
of 2005 reported the application of PCP oil to the
outside of blunts before smoking.
Benzodiazepines
Benzodiazepines, particularly alprazolam (Xanax)
and diazepam (Valium), continue to be used in combination with other drugs. Diazepam, having been
detected by the ME in 585 decedents from 1994
through 2004, ranks fourth among drugs present in
mortality cases in Philadelphia. While users new to
treatment report that diazepam has become less popular in recent years, alprazolam use has increased.
Alprazolam was the 11th most frequently detected
drug among decedents by the Philadelphia ME
(n=285) from 1994 through 2004, including 72 cases
in 2004 (exhibit 1).
Treatment admission reports for 2003 show benzodiazepines as primary drugs of abuse in 67 cases,
compared with 31 in 2004 (exhibit 3); however, these
drugs were reported as secondary or tertiary drugs of
abuse in 382 additional cases in 2003 and 311 additional cases in 2004. Fifty-seven percent of the
mentions of benzodiazepines as secondary or tertiary
drugs of abuse in 2004 occurred with heroin as the
primary drug. Those who reported using benzodiazepines as their primary drugs of abuse used an
average of two drugs in 2003 and 2004. Benzodiazepine abuse was reported by focus group
participants as common among users of heroin, oxycodone, cocaine, marijuana, and cough syrup. Since
spring 2000, all focus groups have reported that alprazolam has overtaken diazepam as the “most
popular pill” on the street.
Alprazolam represented 3 percent of the drugs analyzed by the Philadelphia Police Department and
reported to the NFLIS.
Deaths with the presence of oxazepam (Serax) have
been increasing. In 2003, there were 16 positive toxicology reports for oxazepam, and there were 38 in
2004. In the 11-year period 1994 through 2004, there
were 167 mortality cases testing positive for this drug,
making oxazepam the 20th most frequently detected
drug (exhibit 2).
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Deaths with the presence of olanzapine (Zyprexa)
have been increasing. There were 43 positive toxicology reports for olanzapine in 2003 and 34 in 2004.
In the 11-year period, 1994 through 2004, there were
153 mortality cases testing positive for this drug,
making olanzapine the 23rd most frequently detected
drug.
Urinalysis data of booked arrestees from Philadelphia’s APPD in 2004 showed that 5.7 percent
(n=2,794) of the 49,200 tested arrestees in the sample
were positive for benzodiazepines, making this class of
drugs the fourth most frequently detected drug by
APPD.
Other Prescription Drugs of Note

Methamphetamine/Amphetamines
Methamphetamine and amphetamines remain a relatively minor problem in Philadelphia. There were 98
deaths with the presence of methamphetamine (ranked
31st) from 1994 through 2004 and 90 deaths with the
presence of amphetamine (ranked 35th) during that
same period.
Annual treatment admissions for methamphetamine/
amphetamines as the primary drug of abuse from 1998
to 2003 totaled 31, 33, 27, 83, 67, and 33, respectively
(exhibit 3). There were 37 such admissions in 2004.
Methamphetamine/amphetamines are rarely identified
as a secondary or tertiary drug of choice among treatment admissions in Philadelphia.

Prescription drugs are most frequently detected
among decedents in combination with other drugs of
the same type and/or in combination with cocaine,
heroin, or alcohol. ME mentions for the most frequently detected prescription drugs among decedents
in 2004 (not already discussed) included methadone
(n=132), diphenhydramine (n=129), and codeine
(n=120). With 493 detections from 1994 through
2004, codeine ranks as the fifth most frequently detected drug. Methadone ranks sixth (n=479), and
diphenhydramine ranks eighth (n=447). Regarding
codeine and diphenhydramine, each of which is an
ingredient in numerous over-the-counter medications
that are abused in Philadelphia, negative consequences appear most markedly among decedents in
combination with other drugs.

Urinalysis data of booked arrestees from Philadelphia’s APPD in 2004 showed that 0.2 percent (n=97)
of the 49,200 tested arrestees in the sample were
positive for methamphetamine or amphetamines.
This was the lowest result in the APPD data.

Deaths with the presence of fluoxetine (Prozac) began
to increase in the late 1990s. With 176 positive toxicology reports for fluoxetine from 1994 through 2004,
fluoxetine ranks as the 18th most frequently detected
drug.

Club Drugs

Dextromethorphan is a common ingredient in numerous cough and cold medications. Key informants
indicated that its use is increasing among people age
30–40, particularly in combination with alprazolam
and diazepam. The Philadelphia ME detected dextromethorphan in 40 cases in 2003 and in an
additional 53 cases in 2004. There were 140 dextromethorphan-positive cases from 1994 through 2004,
ranking it as the 26th most frequently detected drug.
Quetiapine (Seroquel), an antipsychotic, has only
been on the market for 3–4 years. Twenty of the total
56 quetiapine detections by the ME occurred in 2003,
and an additional 23 detections were in 2004.
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According to the National Drug Intelligence Center,
the retail/street-level price of methamphetamine was
$100 per gram in the first half of 2004.
For the second consecutive half-year, key informants
indicated a growing popularity of methamphetamine
among men who have sex with men. Methamphetamine continues to be reported as difficult to obtain, not
usually sold outdoors, and requiring a connection, but
it is reported that use has increased since 2001.

There has been relatively little consequence data for
methylenedioxymethamphetamine (MDMA). MDMA
was present in 6 mortality cases in 1999 (the first year
this drug was detected by the ME) and in a total of 42
from 1999 through 2004, including none in the lattermost 6-month period.
MDMA is reportedly used in combination with marijuana and lysergic acid diethylamide (LSD), which,
along with its users generally ranging in age from teens
to early twenties, helps describe its use among clubgoers.
According to the National Drug Intelligence Center,
the retail/street-level price per MDMA tablet ranged
from $9 to $35 in the first half of 2004.
The Philadelphia ME first detected methylenedioxyamphetamine (MDA) in the second half of 1999. There
were 30 positive toxicology reports for MDA through
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2004, including 6 cases in the first half of 2004 and
zero in the second half.
Ketamine was first detected in decedents in Philadelphia in 1996; it was detected in four decedents in
2000, four in 2001, two in 2002, three in 2003, and
in only one in 2004. It is not reported to be widely
available, and it is difficult to obtain.
There is almost no familiarity of gamma hydroxybutyrate (GHB) reported by treatment clients. The
Philadelphia ME does not test for GHB.
INFECTIOUS DISEASES RELATED TO DRUG ABUSE
As of December 31, 2004, Philadelphia recorded
17,084 cumulative AIDS cases among adults (exhibit
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6). Among those cases, 6,019 involved injection drug
users (IDUs) (needle-sharers). Another 859 were in
the dual exposure category of IDUs who were also
men who had (unprotected) sex with other men
(MSM).
Cases reported with (unprotected) heterosexual contact as a risk factor continued to exceed the historical
average. Heterosexual contact was the identified exposure category in 19.6 percent of all AIDS cases
reported through December 31, 2004.
For inquiries concerning this report, please contact Samuel Cutler,
City of Philadelphia, Office of Behavioral Health/Mental Retardation
Services, Coordinating Office for Drug and Alcohol Abuse Programs
(CODAAP), 1101 Market Street, Suite 800, Philadelphia, Pennsylvania
19107-2908, Phone: (215) 685-5414, Fax: (215) 685-4977, E-mail:
<sam.cutler@phila.gov>.
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Exhibit 1. Annual Mortality Cases in Philadelphia with the Presence of the 20 Most Frequently Detected
Drugs by the Medical Examiner: 1994–2004
ME-Identified Drugs
1. Cocaine

Year
1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

368

336

277

304

218

238

321

300

270

326

399

TOTAL
3,357

2. Heroin/Morphine

262

318

290

336

249

236

332

316

275

208

214

3,036

3. Alcohol-in-Combination

253

254

182

214

157

179

197

185

153

290

219

2,283

4. Diazepam

69

44

35

58

39

67

46

56

28

66

88

585

5. Codeine

34

39

19

20

3

15

19

45

57

120

120

493

6. Methadone

23

12

26

24

10

36

36

46

55

79

132

479

7. Phencyclidine (PCP)

46

44

29

46

19

35

48

45

51

58

20

449

8. Diphenhydramine

19

13

5

4

9

25

33

53

42

116

129

447

9. Oxycodone

4

2

1

14

29

17

49

53

68

81

103

421

10. Propoxyphene

30

30

27

32

21

22

40

43

31

41

48

365

11. Alprazolam

24

8

17

18

19

8

16

31

27

45

72

285

12. Nortriptylene

14

11

15

18

24

29

20

32

32

50

35

277

13. Amitriptylene

11

14

13

16

21

23

20

24

35

48

35

263

14. Hydrocodone

6

1

9

8

15

13

27

38

31

40

51

239

15. Temazepam

10

4

21

30

20

18

18

23

11

30

41

226

16. Doxepin

23

8

16

6

16

29

19

18

19

21

28

219

17. Ibuprofen

2

1

0

2

1

7

8

18

10

53

85

189

18. Fluoxetine

4

7

9

10

24

14

23

27

13

28

28

176

18

17

15

4

10

10

18

26

5

18

27

171

5

3

9

26

19

11

12

17

11

16

38

167

1,346

1,245

1,121

1,282

1,039

1,232

1,637

1,857

1,589

2,672

3,334

18,354

Total Mortality Cases

617

632

565

592

484

533

675

660

593

841

888

7,080

Average Number of
Drugs Per Death

2.18

1.97

1.98

2.17

2.15

2.31

2.43

2.81

2.68

3.18

3.75

2.59

19. Phenobarbital
20. Oxazepam
Total Drugs Mentioned

SOURCE: Philadelphia Medical Examiner’s Office

Exhibit 2. Causes of Annual Mortality Cases in Philadelphia, as Determined by the Medical Examiner, by
Percent: 1998–2004
ME-Identified Cause

1998

1999

2000

2001

2002

2003

2004

Adverse Effect of Drugs

60.6

55.7

56.6

56.4

57.7

30.4

31.0

3.7

3.8

2.1

3.8

2.5

6.3

10.1

10.7

9.6

13.0

10.0

11.6

17.2

16.3

7.2

6.6

5.6

6.2

5.6

10.5

8.3

17.8

24.3

22.7

23.6

22.6

35.6

34.2

Overdose
Violence by Another Person
Violence to Oneself
Other Causes

1

1

Other Causes include deaths with the presence of drugs caused by accident, injury, drowning, fire, or a health or physical malady.
SOURCE: Philadelphia Medical Examiner’s Office
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Exhibit 3.

Treatment Admissions by Primary Drug of Abuse in Philadelphia: 1998–2004

Primary Drug

1998

1999

2000

2001

2002

2003

20041

Cocaine

1,942

2,232

2,497

2,996

3,649

2,225

1,961

Alcohol

1,477

1,943

1,826

2,366

3,425

1,896

1,640

872

2,272

2,041

4,279

2,679

2,352

1,939

48

46

73

92

187

174

162

791

862

910

1,428

2,025

1,448

1,276

32

49

43

74

188

142

116

9

9

7

12

12

7

9

Heroin
Other Opiates
Marijuana
PCP
Other Hallucinogens
Methamphetamine/
Amphetamines
Benzodiazepines

31

33

27

83

67

33

37

32

46

37

89

66

67

31

Other Tranquilizers

6

4

8

1

3

3

5

Barbiturates

13

8

3

8

23

13

17

Other Sedatives/Hypnotics

13

18

16

36

19

20

19

Inhalants

2

0

4

1

0

0

1

Over-the-Counter

7

24

5

2

2

4

8

Other (Not Listed)

17

1

60

154

111

253

215

5,292

7,547

7,557

11,621

12,456

8,637

7,436

Total
1

Data for this period are preliminary and subject to revision.
SOURCE: Pennsylvania Department of Health, Client Information System
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Exhibit 4.

Cocaine Treatment Admissions in Philadelphia by Route of Administration and Gender:
2000–2004

Route of Administration and Gender
Smoked
Male
Female
Intranasal
Male
Female
Injected
Male
Female
Other/Unknown
Male
Female
Total Male
Total Female
Total

2000

2001

2002

20041

2003

No.

(%)

No.

(%)

No.

(%)

No.

(%)

1,112
1,002

(44.5)
(40.1)

1,377
1,039

(46.0)
(34.7)

1,802
1,212

(49.4)
(33.2)

1,014
786

(45.6)
(35.3)

857
657

(43.7)
(33.5)

198
104

(7.9)
(4.2)

371
140

(12.4)
(4.7)

384
139

(10.5)
(3.8)

256
105

(11.5)
(4.7)

274
98

(14.0)
(5.0)

38
12

(1.5)
(0.5)

30
14

(1.0)
(0.5)

28
8

(0.8)
(0.2)

37
8

(1.7)
(0.4)

26
8

(1.3)
(0.4)

16
(0.6)
15
(0.6)
1,364
(54.6)
1,133
(45.4)
2,497

18
(0.6)
7
(0.2)
1,796
(59.9)
1,200
(40.1)
2,996

71
(1.9)
5
(0.1)
2,285
(62.6)
1,364
(37.4)
3,649

9
(0.4)
10
(0.4)
1,316
(59.1)
909
(40.9)
2,225

No.

(%)

19
(1.0)
22
(1.1)
1,176
(60.0)
785
(40.0)
1,961

1

Data for this period are preliminary and subject to revision.
SOURCE: Pennsylvania Department of Health, Client Information System

Exhibit 5.

Heroin, Illegal Methadone, and Other Opiate Treatment Admissions in Philadelphia by Route of
Administration and Gender: 2000–2004

Route of Administration
and Gender
Injected
Male
Female
Intranasal
Male
Female
Swallowed
Male
Female
Smoked
Male
Female
Other/Unknown
Male
Female
Total Male
Total Female
Total

2000
No.

2001

2002

2003

(%)

No.

(%)

No.

No.

870
408

(41.2)
(19.3)

1,917
805

(43.9)
(18.4)

1,219
541

(42.5)
(18.9)

978
522

(38.7)
(20.7)

411
266

(19.4)
(12.6)

733
577

(16.8)
(13.2)

564
260

(19.7)
(9.1)

479
247

(19.0)
(9.9)

45
42

(2.1)
(2.0)

99
55

(2.3)
(1.3)

114
66

(4.0)
(2.3)

113
64

(4.5)
(2.5)

37
11

(1.8)
(0.5)

63
40

(1.4)
(0.9)

44
17

(1.5)
(0.6)

35
15

(1.4)
(0.6)

(0.6)
13
(0.5)
11
1,376
(65.1)
738
(34.9)
2,114

(1.1)
49
(0.8)
33
2,861
(65.5)
1,510
(34.5)
4,371

(1.1)
32
(0.3)
9
1,973
(68.8)
893
(31.2)
2,866

No.

(%)

(1.9)
48
(1.0)
25
1,653
(65.4)
873
(34.6)
2,526

20041
No.
(%)
741
391
399
207

(35.3)
(18.6)
(19.0)
(9.9)

82
66

(3.9)
(3.1)

19
9

(0.9)
(0.4)

126
61

(6.0)
(2.9)

1,367
(65.1)
734
(34.9)
2,101

1

Data for this period are preliminary and subject to revision.
SOURCE: Pennsylvania Department of Health, Client Information System
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Exhibit 6. Cumulative AIDS Cases in Philadelphia by Exposure Category: November 1, 1981, through 2004
Exposure
Category

November 1, 1981, to December 31, 2004
Number

Percent

6,019

(35.2)

Injection Drug Use
Male-to-Male Sex and Injection Drug
Use
Male-to-Male Sex

859

(5.0)

6,341

(37.1)

Heterosexual Contact

3,352

(19.6)

92

(0.5)

421

(2.5)

17,084

(99.9)

Blood Products
No Identified Risk Factor
Total Adult Cases

SOURCE: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
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Drug Abuse Trends in
Phoenix and Arizona
Ilene L. Dode, Ph.D.1
ABSTRACT
During FY 2004, 36,375 adults and children in Arizona received treatment through the Arizona Department of Health Services behavioral health system for substance use, abuse, or dependence. Excluding alcohol admissions, 37.5 percent were for
methamphetamine abuse, 21.4 percent were for
marijuana abuse, 19.6 percent were for heroin
abuse, 16.1 percent were for cocaine abuse, and 5.4
percent were for abuse of all other illicit drugs. In
2004, there were 8,116 (unweighted) drug reports in
drug-related ED visits; of these, 2,165 were amphetamine and methamphetamine combined, which
was slightly less than drug reports for alcohol. In
the last quarter of 2004, NFLIS forensic lab analysis of 2,009 drug items revealed that 32.3 percent
contained methamphetamine, followed by 32.2 percent for cocaine, 26.8 percent for cannabis, and 6
percent for heroin. A report based on 2002–2003
Arrestee Drug Abuse Monitoring program data
from Maricopa and Pima Counties concluded that
community prevention efforts based on the assumption that social disorganization and methamphetamine use go hand in hand may be ineffective and
not the best use of scarce resources. Methamphetamine was the primary drug of adolescents entering
intensive treatment.

Nearly one in four (23 percent) of Arizona’s residents
live in a county that borders Mexico. While border
residents are similar to other Arizonans, there are
notable differences. Despite a high percentage of
working families, and the fact that border residents
are more likely to be in school, families along the
border are poorer than other Arizonans; the median
income ($35,421) is 13 percent lower than the State
average of $40,558. Non-Hispanic White children are
37 percent more likely to live in poverty.
Data Sources
This report is based on the most recent available data
obtained from sources shown below:
•

Drug-related death data are from the 2003 Drug
Abuse Warning Network (DAWN) medical/
coroner (ME/C) system, maintained by the Office
of Applied Studies (OAS), Substance Abuse and
Mental
Health
Services
Administration
(SAMHSA), updated in September 2004. The
DAWN system covered 94 percent of the Phoenix-Mesa-Scottsdale area population in 2003. The
redesigned DAWN ME/C system covers any
death, accidental or intentional, related to recent
drug use among decedents age 6–97. The deaths
may be caused/induced by the drug, deemed to
have contributed to the death, or simply implicated in the death. A DAWN case may involve
multiple drugs; thus, the number of cases across
drug categories exceeds the number of deaths.
Rates for the area were provided for (combined)
“drugs of misuse,” estimated at 114.8 per 100,000
population; rates for males (177.5) exceeded those
for females (52.4). Data on specific drugs, as presented in this paper, were reported only by unweighted numbers. The 2003 data are not comparable to data for 2002 and before because of
changes in the ME/C system.

•

Drug treatment data are from four sources.
Statewide admissions data were provided by the
Arizona Department of Health Services (ADHS),
Division of Behavioral Health Services (DBHS),
Bureau of Substance Abuse Treatment and Prevention Services, through fiscal year (FY) 2004.
Treatment admissions data for adults and juveniles in the Treatment and Assessment Screening
Center (TASC) programs in Phoenix were derived from the Maricopa County Juvenile Probation Program’s report, March 2004, and the
Adult Deferred Prosecution Program’s Cumulative Statistical Report, March 1989–March 2004.
Data on detoxification admissions to Community
Bridges in Phoenix cover the period from July
2004 to April 2005, and data on persons treated

INTRODUCTION
Area Description
The population of the State is 64 percent White, 25
percent Hispanic, 3 percent African-American, 5 percent Native American, 2 percent Asian American,
and 2 percent other groups. Since 1990, the Hispanic
population has increased by 88 percent statewide.
The population of Maricopa County (Phoenix) is
3,389,260 (60.7 percent of State population); 66 percent are White, followed by 25 percent Hispanic, 4
percent African-American, 2 percent Native American, 2 percent Asian American, and 2 percent other
groups.

1
The author is affiliated with Emergency Mobile Pediatric and
Adult Crisis Team (EMPACT) – Suicide Prevention Center, Phoenix, Arizona.
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heroin price and purity are from DEA’s Domestic Monitor Program for 2003. Price data on methylenedioxymethamphetamine (MDMA) are
from the National Drug Intelligence Center Collection Unit for the State overall from January
through June 2004.

for methadone and nonmedical use of nonprescription drugs at Phoenix’s Valle del Sol Opioid
Treatment Program cover FY 2004–2005.
•

•

•

Emergency department (ED) drug data for
2004 were accessed from the DAWN Live! restricted-access online system, maintained by
OAS, SAMHSA, on April 13–14, 2005. All 25
eligible hospitals in the Phoenix area are in the
DAWN sample, with the number of EDs in the
sample totaling 26. (Some hospitals have more
than one ED.) The data were incomplete (see exhibit 1). During this 12-month period, between
11 and 13 EDs reported data each month.
DAWN covers eight case types; case data for
Phoenix appear in exhibit 2. All DAWN cases
are reviewed for quality control. Based on this
review, cases may be corrected or deleted.
Therefore, the data presented in this paper are
subject to change. Data derived from DAWN
Live! represent drug reports in drug-related ED
visits. Drug reports exceed the number of ED
visits, since a patient may report use of multiple
drugs (up to six drugs and alcohol). The DAWN
Live! data are unweighted and, thus, are not estimates for the reporting area. These data cannot
be compared to DAWN data from 2002 and before, nor can preliminary data be used for comparison with future data. Only weighted DAWN
data released by SAMHSA can be used for trend
analysis. A full description of the DAWN system
can be found at DAWN Web site:
http://dawninfo.samhsa.gov.
Drug arrest data are from the Arizona Department of Public Safety (ADPS), “Crime in Arizona Annual Report 2003.” The data show
statewide trends for trafficking/manufacturing/sale arrests and arrests for possession of opiates/cocaine, synthetic narcotics, marijuana, and
other nonnarcotic drugs from 1993 through
2003.

Employee drug screening data on heroin were
provided by laboratories for 1998–2003 and reported by the DEA.

•

Student drug use data are from the Arizona
Youth Survey supported by the Arizona Criminal
Justice Commission. The survey covered students, statewide, in grades 8, 10, and 12 in 2004
and prior years. The survey is designed to assess
school safety, adolescent substance use, antisocial behavior, and risk and protective factors that
predict adolescent problem behaviors.

•

Data on drug-endangered children were obtained from the Arizona Office of the Attorney
General, “Multidisciplinary/Integrated Protocol,”
September 2003.

•

Human immunodeficiency virus (HIV) and
acquired immunodeficiency syndrome (AIDS)
data are from the Arizona Department of Health
Services (DHS), Division of Public Health Services, Bureau of Epidemiology and Disease Control, Office of HIV/STD Services “HIV/AIDS
Annual Report,” March 2004, and represent new
and total cases for the State overall from 1998–
2002.

•

Chronic hepatitis C data for the State overall
from 1998 through 2003 are from the Arizona
Department of Health Services (DHS), Division
of Public Health Services, Office of Infectious
Disease Services, Chronic Hepatitis Infection,
Surveillance Report, 2003.

DRUG ABUSE PATTERNS AND TRENDS
Forensic drug data are from the National Forensic Laboratory Information System (NFLIS),
Drug Enforcement Agency (DEA), for the last
quarter of 2004.

•

Drug seizure data are from the DEA for 2003
and 2004.

•

Data on drug prices are from the DEA, Phoenix
Office, in its “Trends in Traffic” First Quarter
FY 2005 report, and the U.S. Customs Service,
the ADPS, Phoenix Police Department, and the
Maricopa County Sheriff’s Department. Data on
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•

Cocaine/Crack
According to 2003 DAWN mortality data, there were
130 cocaine-related deaths in the Phoenix area in
2003, with 30 being single-drug deaths (exhibit 3).
The ADHS, DBHS, Bureau for Substance Abuse
Treatment and Prevention, reported that 9 percent of
all clients admitted to State treatment programs (including alcohol admissions) in FY 2004 were for
primary cocaine abuse (exhibit 4). This reflects a 44percent decline in cocaine admissions from 2003.
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For the past 7 reporting periods, cocaine treatment
admissions (4,703) to the TASC Adult Deferred
Prosecution Program remained unchanged, at 29 percent of cumulative treatment admissions (10,238)
(exhibit 5a). Six percent of juveniles tested positive
for cocaine during the first quarter of 2005 (exhibit
5b).
The number of unweighted cocaine drug reports in
DAWN Live! was 1,591 in 2004 (exhibit 6). Cocaine
represented 27.5 percent of major substances of
abuse drug reports (excluding alcohol).
Between 2002 and 2003, the ADPS reported a 6percent decline in arrests for trafficking/manufacture/sale of opiates and cocaine. Arrests decreased by
1 percent for possession of opiates/cocaine in 2003
(exhibit 7).
The DEA reported numerous seizures at the Arizona/Mexico border that involved mixed loads of
cocaine and methamphetamine. A comparison of FY
2003 and FY 2004 seizure statistics revealed a 47percent increase in the amount of cocaine seized. In
FY 2004, 3,459 kilograms of cocaine were seized,
compared with 2,159 kilograms in 2003.
Cocaine remains readily available in Phoenix, Tucson, and Nogales. An ounce of crack cocaine that
sold for $400–$480 in Phoenix in 2002 sold for
$540–$600 in 2004 (exhibit 8).
Demand for crack cocaine remains consistently high.
Crack is available in ounce and pound quantities. In
the Phoenix African-American community, halfounce quantities of crack are called “half birds,” and
ounce quantities are referred to as “full birds.”
Heroin
According to DAWN mortality data for 2003, 227
drug misuse deaths involved opiates/opioids; 37 were
single-drug deaths (exhibit 3). Of these illicit drug
deaths, 13 involved heroin, with heroin being the
only drug found in 4 cases.
The ADHS, DBHS, Bureau of Substance Abuse
Treatment and Prevention, identified heroin as the
primary substance of abuse for 11 percent of treatment admissions (including alcohol) in FY 2004 (exhibit 4).
Among the 10,653 clients treated at Community
Bridges detoxification services from July 1, 2004,
through April 30, 2005, 10 percent identified heroin
as their drug of choice (exhibit 9).
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At the Valle del Sol Opioid Treatment Program,
which served an average of 350 clients per month in
FY 2004/2005, individuals seeking methadone treatment reported heroin as the first drug of choice, and
prescription opiates/opioids and benzodiazepines as
the second and third drugs of choice, respectively.
The number of unweighted heroin ED reports in
Phoenix in 2004 was 755 (exhibit 6). Excluding alcohol, heroin represented 13 percent of DAWN Live!
major illicit drug reports.
The DEA reported increased availability of black tar
heroin in the Phoenix area. There were continued
reports of the presence of South American white heroin. Heroin abuse was reportedly increasing because
of higher purity levels, lower cost, and the increase in
noninjecting heroin users. Kilogram quantities of
black tar heroin are readily available with 1–2 days
notice when the purchase is 1 kilogram or larger.
In 2003, the retail purity of heroin, before cutting
agents were added, averaged 58 percent pure heroin.
A review of the DEA’s Domestic Monitoring Program for the recent 5-year period revealed that the
average retail purity fluctuated between 41.3 and 48.9
percent pure heroin. In Phoenix, the price of heroin in
2004 was $60–$110 per gram (exhibit 8).
Drug screening laboratories in Arizona reported a
steady increase in the number of employees testing
positive for heroin. In 1999, 8 percent of all drug
screenings were positive for heroin, compared with
17 percent in 2003.
Other Opiates
The unweighted number of ED drug reports for
“other drugs” in DAWN Live! in 2004 included 1,226
for opiates/opioids, 232 for hydrocodone, and 291 for
oxycodone (exhibit 6). Case types included overmedication, seeking detox, and other.
The most commonly abused pharmaceutical controlled substances in Phoenix in 2004 included Vicodin ($5 per tablet), Lortab ($5–$6 per 10-milligram
tablet), and other hydrocodone products: Percocet ($5
per tablet), OxyContin ($20–$80 per 80-milligram
tablet and $20–$25 per 40-milligram tablet), and
other oxycodone products (exhibit 8). Also commonly abused are methadone, hydromorphone, morphine, Demerol, codeine products, and anabolic steroids. Soma ($2–$5 per tablet) in combination with
other analgesic controlled substances, Ultram and
Nubain, continue to be highly abused prescriptiononly substances.
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The ADPS 2003 arrest data on trafficking/manufacture/sale of synthetic narcotics revealed a 21.3percent increase from 2001. Arrests for possession of
synthetic narcotics continued a steady upward trend,
increasing 38.3 percent from 2001 to 2003 (exhibit 7).

46 percent (exhibit 10), down from the nearly 51 percent in 2002. Past-30-day use also declined, from
approximately 25 percent in 2002 to 19 percent in
2004. Nevertheless, marijuana continued to be the
most frequently reported illicit drug among Arizona
students in grades 8, 10, and 12.

Marijuana
Stimulants
The seeding of marijuana fields in Mexico takes
place in March or April, and the drug is harvested
from June through August. Availability of marijuana
increased between July and September 2004. Southern Arizona law enforcement reported an increase in
the number of vehicles being driven by Hispanic
males between the ages of 15 and 17. The young
males are recruited from the border communities of
Douglas, Nogales, and Naco. It was speculated that
the vehicle driving was a “summer job” for some
young males.
Marijuana remains readily available in quantities up
to hundreds of kilograms packaged for delivery, despite large quantities of seizures by the U.S. Customs
Service and the U.S. Border Patrol at the Ports of
Entry and at remote sites along the international border. In 2004, the Phoenix Police Department seized
large quantities of “BC bud” also known as
“chronic.” In 2004, 1 pound bricks of BC bud sold
for $4,500 each, compared with $500 to $750 for a
pound of ordinary marijuana.
ADHS/DBHS Bureau for Substance Abuse and Prevention data revealed that 12 percent of treatment
admissions (including alcohol) in FY 2004 were for
marijuana (exhibit 4).
Marijuana was reported as the primary drug of choice
by 23.6 percent of clients in the TASC Adult Deferred Prosecution Program from March 1989
through March 2005 (exhibit 5a). Seventy-three percent (4,194) of juvenile admissions to the TASC Juvenile Probation Program were for marijuana treatment during the first quarter of FY 2005 (exhibit 5b).
The unweighted number of marijuana ED drug reports in DAWN Live! in 2004 was 1,122 (exhibit 6).
Excluding alcohol, marijuana represented 19.4 percent of major substances of abuse drug reports in
Phoenix.
The DPS data show an 8.4-percent increase in arrests
for trafficking/manufacture/sale of marijuana and a
13.9-percent increase in arrests for marijuana possession from 2002 to 2003 (exhibit 7).
In the 2004 Arizona Youth Survey, the percentage of
students reporting ever using marijuana was nearly
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In 2003, there were 104 deaths involving misuse of
stimulants (amphethamine and methamphetamine)
reported to DAWN; 23 were single-drug deaths (exhibit 3).
The ADHS/DBHS, Bureau for Substance Abuse
Treatment and Prevention, reported that 21 percent of
all clients admitted to State substance abuse treatment
programs during FY 2004 were for primary methamphetamine abuse (exhibit 4).
TASC Adult Deferred Prosecution Program data revealed that 26.9 percent (4,436) of the March 1989
through March 2005 treatment admissions (10,238)
were for methamphetamine abuse (exhibit 5a). Eighteen percent of the juveniles (1,034) in first quarter of
2005 (who submitted urine samples) tested positive
for methamphetamine/amphetamine (exhibit 5b).
Slightly more than 11 percent of the admissions to
Community Bridges detoxification programs from
July 2004 through April 2005 were for methamphetamine abuse. Methamphamine (11 percent) was
the second drug of choice after alcohol (61 percent),
followed by heroin (10 percent), crack (6 percent),
and cocaine (3 percent) (exhibit 9).
The unweighted number of stimulant ED drug reports
in DAWN Live! in 2004 was 2,165 (exhibit 6). Excluding alcohol, stimulants (methamphetamine/amphetamines) represented 37.4 percent of major substances of abuse drug reports in Phoenix.
The NFLIS report for the last quarter of 2004 revealed that 32.3 percent of drug items tested by forensic labs in Phoenix contained methamphetamine.
Methamphetamine, cocaine, and cannabis together
accounted for 97.2 percent of all drug samples.
Methamphetamine is the number one drug threat in
the State of Arizona, according to the National Drug
Intelligence Center 2005 report. It has been a public
health crisis that crosses all socioeconomic levels and
all racial and ethnic groups. It is a statewide epidemic, not just a rural or just an urban problem.
Methamphetmine is the number one illegal drug contributing to violent crime in Arizona.
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Other Drugs
DAWN ME/C cases in 2003 included 54 deaths involving benzodiazepine misuse (exhibit 3).
The unweighted number of benzodiazepine drug reports in DAWN Live! totaled 963 in 2004 (exhibit 6).
The National Drug Intelligence Center Collection
Unit reported street-level prices for MDMA in Arizona from January through June 2004. The wholesale
price was $7–$12 per tablet per 1,000 tablets, and the
retail price was $20–$30 per tablet.
The DEA reported substantial seizures of gamma
hydroxybutyrate (GHB) and gamma butyrolactone
(GBL).
INFECTIOUS DISEASES RELATED TO DRUG ABUSE
HIV/AIDS
In 2002, there were 9,710 persons in Arizona known to
be living with HIV Disease (HIV or AIDS): 4,402 with
a diagnosis of AIDS, and 5,250 with a diagnosis of
HIV. In the State as a whole, the known HIV disease
prevalence rate was 184.1 per 100,000 persons. Based
on these prevalence estimates, at least 1 of every 543
persons in Arizona carries HIV. Maricopa County, the
State’s most populous urban county, had the second
highest prevalence rate of reported HIV Disease (207
per 100,000 population). With 60 percent of the State’s
population, it has 67.8 percent of known AIDS cases
and 66.7 percent of known HIV cases.

population in 2002 (exhibit 10). The rate for new
HIV diagnoses appeared to be increasing, from 1999
to 2002 from 7.0 to nearly 8.0 per 100,000 population, respectively.
The predominant reported mode of transmission of
HIV/AIDS in Phoenix continues to be contact among
men who have sex with men (MSM), which accounted for 57.5 percent of all reported new cases of
HIV in 2002 (exhibit 10). Injection drug use (with
and without male-to-male sex) accounted for 22.2
percent, and heterosexual exposure accounted for 9.6
percent of reported new cases of HIV/AIDS in Phoenix during 2002 (exhibit 10).
Chronic Hepatitis Infection
From 1998 through 2003, there were 40,427 cases of
chronic hepatitis C infection (HCV) reported in Arizona. Of the reported cases, 41.37 percent were confirmed by recombinant immunoblot assay (RIBA) or
polymerase chain reaction (PCR) test. Based on the
Center for Disease Control and Prevention (CDC)
estimates for the Nation, 92,000 individuals are living
with HCV in Arizona.
During 2003, there were 9,516 newly reported
chronic cases of HCV in Phoenix, of which 37 percent were confirmed. Most HCV-infected Arizonans
are between the ages of 31 and 50.
For inquiries concerning this report, please contact Ilene Dode,
EMPACT-Suicide Prevention Center, Inc., 1232 East Broadway,
#120, Tempe, AZ 85282, Phone: 480-784-1514, ext. 1116, Fax:
480-967-3528, E-mail <idode@aol.com>.

The rate for new AIDS diagnoses in Arizona has
shown a steady decline and was 5.31 per 100,000
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Exhibit 1. DAWN ED Sample and Reporting Information in Phoenix: 2004

Total Eligible
Hospitals1

No. of Hospitals in DAWN
Sample2

Total EDs in
DAWN
Sample

25

25

26

No. of EDs Reporting per Month: Completeness of Data (%)
90-100%
50-89%
<50%
9-13

1-2

0-1

No. of EDs Not
Reporting
13-15

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
One hospital has more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14, 2005
2

Exhibit 2. Drug-Related ED Visits in Phoenix, by Case Type (Unweighted1):2004
Suicide attempt
5.8%

Seeking detox
4.6%

Alcohol only (age <21)
3.7%

Other
41.8%
Adverse reaction
20.9%

Accidental ingestion
2.0%
Malicious poisoning
0.4%

Overmedication
20.9%

1

The unweighted data are from 11–13 EDs reporting to DAWN in 2004. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted, and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14, 2005
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Exhibit 3. Drug-Related Mortality Cases in Phoenix, by Case Type and Drug: 2003
Overmedication
4%

Suicide
21%

Could not be
determined
8%

All Other accidental
67%

300
264
250

200
160
150
120

127

100

50
6
0
Opiates/Opioids

Cocaine

Alcohol

Stimulants

Misc. Analgesics/
Combinations

Multi-drug deaths

227

130

110

104

6

Single Drug deaths

37

30

10

23

0

SOURCE: DAWN, OAS, SAMHSA, updated 9/24, 2004
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Exhibit 4.

Treatment Admissions in Arizona, by Primary Substance of Abuse and Percent: FY 2004

Methamphetamine
21%

Alcohol
44%

Marijuana
12%
All Other
3%

Heroin
11%

Cocaine
9%

SOURCE: Arizona Department of Health Services, Division of Behavioral Health Services, Bureau for Substance Abuse Treatment
and Prevention
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Exhibit 5a. Adult Deferred Prosecution Program Admissions in Phoenix, by Primary Drug:
March 1, 1989–March 31, 2005
Primary Drug Problem (may include more than one drug)
30%

28.5%

26.9%
23.6%

25%
20%
15%

11.4%

10%

5.0%

4.5%

Opiate (832)

Denies Drug Problem
(739)

5%
0%
Cocaine (4,703)

Meth (4,436)

Marijuana (3,886)

Polydrug (1,881)

Gender
80%
70%
60%
50%
40%
30%
20%
10%
0%

70.5%

29.5%

Male (7,213)

Female (3,025)

Ethnicity
70%

61.1%

60%
50%
40%

29.6%

30%
20%
6.1%

10%

2.1%

1.2%

Native American (215)

Other (118)

0%
Caucasian (6,2550)

Hispanic (3,029)

African American (621)

Employment
60%

53.2%

50%
40%

31.2%

30%
20%

11.7%

10%

3.8%

0%
Unemployed (3,197)

Part-Time (1,198)

Full-Time (5,449)

Disabled (394)

Marital Status
60%
50%

54.1%

40%
30%
20%

23.8%
14.7%
7.4%

10%
0%
Single (5,535)

Married (2,436)

Divorced (760)

Separated (1,507)

SOURCE: Adult Treatment and Assessment Screening Center (TASC) – Deferred Prosecution Program
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Exhibit 5b. Positive Tests Among Phoenix TASC Juvenile Clients, by Drug and Percent:
January–March 2005
PCP (n=2)
0.04%
Amphetamine (n=1,034)
18.11%

Cocaine (n=362)
6.34%

Opiates (n=109)
1.91%
Alcohol (n=8)
0.14%
THC (n=4,194)
73.46%

N=5,709
SOURCE: Treatment and Assessment Screening Center (TASC), Maricopa County Juvenile Probation
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Exhibit 6. Number of Drug Reports in Drug-Related ED Visits in Phoenix (Unweighted1): 2004
Selected Drugs
Major Substances of Abuse
Seeking Detox
Alcohol
Alcohol only (age <21)
Cocaine
Heroin
Marijuana
Stimulants
Amphetamines
Methamphetamine
MDMA (Ecstasy)
GHB
Ketamine
LSD
PCP
Miscellaneous Hallucinogens
Inhalants
Combinations NTA
Other Substances

Benzodiazepines

Opiates/Opioids

Opiates/Opioids, Unspecified

Hydrocodone

Oxycodone

Muscle Relaxants

Case Type
All
Seeking Detox
All
Alcohol-only
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
Seeking Detox
Overmedication
Other
All
Seeking Detox
Overmedication
Other
All
Seeking Detox
Overmedication
Other
All
Seeking Detox
Overmedication
Other
All
Seeking Detox
Overmedication
Other
All
Seeking Detox
Overmedication
Other
All
Seeking Detox
Overmedication
Other

Total
8,116
671
2,333
409
1,591
755
1,122
2,165
819
1,346
20
4
1
16
39
28
30
12
5,805
288
3,686
1,831
963
45
562
356
1,226
155
496
575
229
19
18
192
232
24
155
53
291
63
162
66
281
8
214
59

1

The unweighted data are from 11–13 EDs reporting to Phoenix hospitals reporting to DAWN in 2004. All DAWN cases are reviewed
for quality control. Based on this review, cases may be corrected or deleted, and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–14, 2005
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Exhibit 7. Arrests in Arizona for Trafficking/Manufacture/Sale and Possession of Drugs, by Drug Category:
1993–2003
Arrests
Trafficking/Manufacture/ Sale
Opiates/Cocaine
Syn. Narcotics
Marijuana
Other Drugs-Non Narcotics
Total
Possession
Opiates/Cocaine
Syn. Narcotics
Marijuana

1993
No.

1994
(%)

No.

1996
(%)

No.

1997
(%)

No.

1998
(%)

No.

1999
(%)

No.

(%)

1,048
507
1,376
866
3,797

27.6%
13.4%
36.2%
22.8%

1,030
629
1,456
1,675
4,790

21.5%
13.1%
30.4%
35.0%

1,606
596
1,343
1,320
4,865

33.0%
12.3%
27.6%
27.1%

564
641
1,404
1,778
4,387

12.9%
14.6%
32.0%
40.5%

1,776
760
1,084
1,716
5,336

33.3%
14.2%
20.3%
32.2%

1,788
578
1,150
1,540
5,056

35.4%
11.4%
22.7%
30.5%

1,917
1,225
7,326

16.1%
10.3%
61.7%

1,842
1,812
10,356

11.0%
10.8%
61.8%

2,752
1,803
12,939

13.5%
8.8%
63.2%

3,263
2,107
13,970

14.5%
9.4%
62.2%

4,088
2,223
13,576

17.3%
9.4%
57.6%

4,081
2,316
13,519

17.1%
9.7%
56.6%

Other Drugs-Non Narcotics
Total

1,403
11,871

11.8%

2,743
16,753

16.4%

2,965
20,459

14.5%

3,127
22,467

13.9%

3,678
23,565

15.6%

3,975
23,891

16.6%

Trafficking/Manufacture/ Sale
and Possession Grand Total

15,668

Arrests

21,543

2000
No.

25,324

2001
(%)

No.

26,854

2002
(%)

No.

28,901

2003
(%)

No.

(%)

28,947

% Change:
2002–2003

Trafficking/Manufacture/ Sale
Opiates/Cocaine
Syn. Narcotics
Marijuana
Other Drugs-Non Narcotics
Total
Possession
Opiates/Cocaine
Syn. Narcotics
Marijuana
Other Drugs-Non Narcotics
Total

1,635
542
1,283
1,587
5,047

32.4%
10.7%
25.4%
31.4%

1,602
573
1,310
1,588
5,073

31.6%
11.3%
25.8%
31.3%

1,489
607
1,132
1,840
5,068

29.4%
12.0%
22.3%
36.3%

1,405
695
1,227
2,193
5,520

25.5%
12.6%
22.2%
39.7%

-5.6%
14.5%
8.4%
19.2%

3,770
2,581
14,947
4,334
25,632

14.7%
10.1%
58.3%
16.9%

3,056
2,613
15,097
4,436
25,202

12.1%
10.4%
59.9%
17.6%

2,972
3,196
13,936
4,779
24,883

11.9%
12.8%
56.0%
19.2%

2,938
3,615
15,867
5,446
27,866

10.5%
13.0%
56.9%
19.5%

-1.1%
13.1%
13.9%
14.0%

Trafficking/Manufacture/ Sale
and Possession Grand Total

30,679

30,275

29,951

33,386

1

Data for 1995 are unavailable.
SOURCE: Arizona Department of Public Safety
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Exhibit 8. Drug Prices in Phoenix and Tucson: 2001 and 2004
Drug
Marijuana
Grams
Ounce
Pound
Methamphetamine
1/8 Ounce
1/2 Teener
1/4 Ounce
Ounce
Pound
Cocaine
Rock–1/3 gram crack
Eightball
Ounce
Ounce Crack
Kilogram
Heroin
A "20" "BB"
(80–100 milligrams)
A "paper" (.25 gram)
Gram
Ounce ("piece", 28 grams)
Kilogram

MDMA
OxyContin
Percocet
Vicodin ES
Valium
Lortab
Soma

2001

2004

Phoenix

Tucson

Phoenix

Tucson

$75–$150
$500–$750

$65–$105
$400–$600

$10–$25
$75–$150
$500–$750

$5–$10
$65–$105
$400–$600
$100–$120

N/A
$125
$300–$600
$3,500–$12,000
(higher for ice)

N/A
$275
$500–$900
$3,800–$6,000

$150 (ice)
$120–$150
$40
$250 (ice)
$500–$600
$5,000–8,600

$80–$135
$120–$300
$650–$1000
$6,500–$7,500

N/A
$100–$140
$500–$600
N/A
$15,000–$17,000

N/A
$80–$130
$500–$650
N/A
$15,000–$18,000

$20
$80–$100
$400–$600
$540–$600
$13,500–$16,000

$20
$80–$130
$500–$650
$550–$700
$14,000–$16,000

$20

$20–$25

$20

$20–$25

$20–30
$70–$100
$1,100–$1,500
$32,000–$40,000

$20–$25
$60–$110
$1,075–$1,300
N/A

$10–$15
$40–$47
$750–$950
$28,000–$35,000

$20–$25
$60–$110
$1,075–$1,300
$43,000

Dosage

Price

1 Tablet

$20–$30

80 mg Tablet
1 Tablet
1 Tablet
10 mg Tablet

$20–$80
$5
$5
$4

10 mg Tablet
1 Tablet

$5–$6
$2–$5

SOURCES: DEA Phoenix Division Offices, U.S. Customs, Arizona Department of Public Safety, Phoenix Police Department, Maricopa County Sheriff Department
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Exhibit 9. Drug of Choice and Characteristics of Detoxification Admissions in Community Bridges:
July 2004–April 2005
Drug of Choice
Alcohol
Atavan
Benzodiazepines - Other
Cocaine
Crack
Heroin
Klonopin
Marijuana
Methnadone
Methamphetamine
Not Reported
Opiates–Other
Other–Benzodiazepines
Other–Sedative
Other–Stimulant
Oxycontin
Valium
Xanax
Total

Number
6,559
4
7
298
649
1,073
10
16
55
1,195
423
213
11
14
26
59
13
28
10,653

Percent
61.57
0.04
0.07
2.80
6.09
10.07
0.09
0.15
0.52
11.22
3.97
2.00
0.10
0.13
0.24
0.55
0.12
0.26
100.00

Age Range
18–30
31–59
60–64
65–74
75–Up
Total

Number
1,761
8,393
255
201
43
10,653

Percent
16.53
78.79
2.39
1.89
0.40
100.00

Ethnic Background
Asian
Black
Hispanic
Native American
Not Reported
White
Total

Number
114
931
1,501
1,419
9
6,679
10,653

Percent
1.07
8.74
14.09
13.32
0.08
62.70
100.00

Gender
Female
Male
Total

Number
2,137
8,516
10,653

Percent
20.06
79.94
100.00

SOURCE: Community Bridges
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Exhibit 10.

HIV/AIDS Annual Report—Arizona Incidence: 1998–2002
NEW HIV

Characteristics
Cases

%
State
Total

NEW AIDS
Rate
Per
100,000

Cases

%
State
Total

TOTAL NEW HIV/AIDS
Rate
Per
100,000

Cases

%
State
Total

Rate
Per
100,000

Gender
Male
Female
Total

1,738

84.4%

13.48

1,204

87.7%

9.34

2,942

85.7%

321

15.6%

2.48

169

12.3%

1.31

490

14.3%

22.82
3.79

2,059

100.0%

7.97

1,373

100.0%

5.31

3,432

100.0%

13.28

14

0.7%

0.27

7

0.5%

0.14

21

0.6%

0.41

Age Group
12 and younger
13–19

45

2.2%

1.73

7

0.5%

0.27

52

1.5%

2

20–24

212

10.3%

11.67

41

3.0%

2.26

253

7.4%

13.93

25–29

338

16.4%

18.11

128

9.3%

6.86

466

13.6%

24.97

30–34

415

20.2%

22.06

255

18.6%

13.56

670

19.5%

35.62

34–39

420

20.4%

21.57

314

22.9%

16.13

734

21.4%

37.69

40–44

288

14.0%

15.26

264

19.2%

13.98

552

16.1%

29.24

45–49

170

8.3%

10.16

163

11.9%

9.75

333

9.7%

16.91

50–54

86

4.2%

5.81

104

7.6%

7.03

190

5.5%

12.84

55–59

37

1.8%

3.07

55

4.0%

4.57

92

2.7%

7.64

60 and older

34

1.7%

0.77

35

2.5%

0.8

69

2.0%

1.57

2,059

100%

7.97

1,373

100%

5.31

3,432

100%

13.28

11.64

Total
Race/Ethnicity
White non-Hispanic

1,204

58.5%

7.23

735

53.5%

4.41

1,939

56.5%

Black non-Hispanic

236

11.5%

28.64

150

10.9%

18.2

386

11.2%

46.84

Hispanic

514

25.0%

7.8

399

29.1%

6.06

913

26.6%

13.86

18

0.9%

3.39

11

0.8%

2.07

29

0.8%

5.46
12.69

1

A/PI/H non-Hispanic
2

AI/AN non-Hispanic

81

3.9%

6.5

77

5.6%

6.18

158

4.6%

Multiple race/other non-Hispanic

6

0.3%

N/A

1

0.1%

N/A

7

0.2%

N/A

Total

2,059

100.0%

7.97

1,373

100.0%

5.31

3,432

100.0%

13.28

Men having sex with men (MSM)

1,151

55.9%

N/A

827

60.2%

N/A

1,978

57.6%

N/A

291

14.1%

N/A

209

15.2%

N/A

500

14.6%

N/A
N/A

Mode of Transmission
Injection drug use (IDU)
MSM/IDU

172

8.4%

N/A

87

6.3%

N/A

259

7.5%

Heterosexual contact

275

13.4%

N/A

171

12.5%

N/A

446

13.0%

N/A

28

1.4%

N/A

29

2.1%

N/A

57

1.7%

N/A

3

O/H/TF/TPR

No reported risk/unknown risk
Total

142

6.9%

N/A

50

3.6%

N/A

192

5.6%

N/A

2,059

100.0%

7.97

1,373

100.0%

5.31

3,432

100%

13.28

1

Asian/Pacific Islander/Hawaiian.
American Indian/Alaskan Native.
3
Other/hemophilia/transfusion and blood products/transplant recipient.
SOURCE: Arizona Department of Health Services, Division of Public Health Services, Bureau of Epidemiology and Disease Control, Office of HIV/STD Services
2
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Patterns and Trends in Drug
Abuse in St. Louis
Heidi Israel, Ph.D., R.N., L.C.S.W.,1 and Jim
Topolski, Ph.D.2
ABSTRACT
Heroin and cocaine indicators remained mixed,
while methamphetamine has increased in St. Louis
indicators. St. Louis and St. Louis County law enforcement personnel continued to devote many resources to methamphetamine, and labs in rural areas continued to be a problem. Club drug use/abuse
continued to be sparse and decreasing. Marijuana
indicators have stabilized during this reporting period. Primary marijuana treatment admissions more
than doubled between 1997 and 2001 and remained
at this elevated level in 2003 and 2004. State budget
cuts may distort the actual degree of treatment need
in the future because of a reduction of available
treatment. In the St. Louis area, 5 percent of HIV
cases had a risk factor of injection drug use, and
another 5 percent were among men who have sex
with men and also inject drugs.
INTRODUCTION
Area Description
The St. Louis metropolitan statistical area (MSA)
includes approximately 2.6 million people living in
the city of St. Louis; St. Louis County; the surrounding rural Missouri counties of Franklin, Jefferson,
Lincoln, St. Charles, and Warren; in Illinois, East St.
Louis; and St. Clair County. St. Louis City’s population has continued to decrease to approximately
350,000, many of whom are indigent and minorities.
Violent crime increased in 2004, and it remains high
in drug-trafficking areas. St. Louis County, which
surrounds St. Louis City, has more than 1 million
residents, many of whom fled the inner city. The
county is a mix of established affluent neighborhoods
and middle and lower class housing areas on the
north and south sides of the city. The most rapidly
expanding population areas are in St. Charles and
Jefferson Counties in Missouri and St. Clair and
Madison Counties in southern Illinois, which have a
mixture of classes and both small towns and farming
areas. The populations in these rural counties total
1

Dr. Israel is affiliated with the Division of Infectious Diseases,
Saint Louis University School of Medicine, St. Louis, Missouri.
2
Dr. Topolski is affiliated with the Division of Evaluation, Policy,
and Ethics, Missouri Institute of Mental Health, St. Louis, Missouri.
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more than 800,000. The living conditions and cultural
differences have resulted in contrasting drug use patterns.
Much of the information included in this report is
specific to St. Louis City and County, with caveats
that apply to the total MSA. Anecdotal information
and some treatment data are provided for rural areas
and for the State. Limited data are also available for
other parts of Missouri and offer a contrast to the St.
Louis drug use picture.
Policy Issues
Methamphetamine production and use is a major
concern for both law enforcement and the legislature.
Small labs continue to place a hardship on law enforcement in terms of personnel and resources. The
legislature has taken bold moves to require precursor
drugs, such as pseudoephedrine, that are sold in local
retail stores to be locked up or placed behind pharmacy counters. While this policy may now slow
down local producers, it does not address the major
source of methamphetamine in the Midwest—
Mexico, a fact that gets lost in the local problem of
small “mom and pop” lab seizures.
Missouri has been in a budget crisis for years, resulting in cuts in services, particularly in health services
including drug treatment and mental health. Limited
treatment continues to be available for drug abusers.
The addiction model as understood through experience and research has shown that treatment services
are cost effective to both society and the individual,
yet the trend is to offer these services on a limited
outpatient basis. The result is that some of these indicators cannot fully reflect the degree of use or abuse
of the substances tracked.
Data Sources
The sources used in this report are indicated below:
•

Emergency department (ED) drug reports
data were derived for 2004 from the Drug Abuse
Warning Network (DAWN) Live! restrictedaccess online query system administered by the
Office of Applied Studies (OAS), Substance
Abuse and Mental Health Services Administration (SAMHSA). Eligible hospitals in the St.
Louis area totaled 37; hospitals in the DAWN
sample numbered 38, with the number of emergency departments in the sample totaling 38 (exhibit 1). (Some hospitals have more than one
emergency department.) During this 12-month
period, between 15 and 18 EDs reported data
each month. The completeness of data reported
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by participating EDs varied by month. Exhibits
in this paper reflect cases that were received by
DAWN as of June 3, 2005. All DAWN cases are
reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore, the data presented in this paper are subject
to change. Data derived from DAWN Live! represent drug reports in drug-related ED visits.
Drug reports exceed the number of ED visits,
since a patient may report use of multiple drugs
(up to six drugs and alcohol). The DAWN Live!
data are unweighted and, thus, are not estimates
for the reporting area. These data cannot be compared to DAWN data from 2002 and before, nor
can preliminary data be used for comparison
with future data. Only weighted DAWN data released by SAMHSA can be used for trend analysis. A full description of the DAWN system can
be found at the DAWN Web site:
http://dawninfo.samhsa.gov.

abuse in other cities and in the rural areas of Missouri,
cocaine has retained its dominance in the St. Louis
urban area. Possible reasons for this situation include
racial differences, with Caucasians using methamphetamine and African-Americans using cocaine, and
the strong influence of the distribution networks. The
distribution of cocaine and heroin is primarily conducted by African-Americans. Methamphetamine is
imported into St. Louis from Mexico or produced locally in the rural areas of the county and State.

•

Drug treatment data were derived from the
Treatment Episode Data Set (TEDS) database
through 2004. Private treatment programs in St.
Louis County provided anecdotal information.

•

Heroin price and purity information was provided by the Drug Enforcement Administration
(DEA), Domestic Monitor Program (DMP),
through 2004.

•

Drug-related mortality data were provided by
the St. Louis City Medical Examiner’s Office
through 2004.

•

Intelligence data were provided by the Missouri
Highway Patrol and the DEA.

Drug education and prevention activities have continued at the community level. The National Council
on Alcoholism and Drug Abuse (NCADA) and other
local education programs target prevention of drug
use in the area. Faith-based initiatives are being implemented. These groups are particularly active in the
surrounding counties of St. Louis. The poor city
economy continues to foster drug abuse and distribution. Marijuana continues to be a very popular drug
of abuse among younger adults. Gangs continue to be
involved in the drug trade and related violence, with
Latino, African-American, and Asian youth and
young adults involved in these groups. Interdiction
programs include Operation Jetway and Operation
Pipeline.

•

Data on drug seizures were provided by the
National Forensic Laboratory Information System (NFLIS) for 2004.

•

Human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS),
and sexually transmitted disease (STD) data
were derived from the HIV Vaccine Trials Unit
at Saint Louis University and the St. Louis Metropolitan Health Department and AIDS Program.

Linda Cottler, Ph.D., of Washington University, who
has multiple behavioral research grants, provided
additional data.
DRUG ABUSE PATTERNS AND TRENDS
Cocaine indicators are stable in St. Louis. While
methamphetamine has become a prominent drug of
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Two types of heroin have continued to be available in
the area, but the heroin is not as pure and is more expensive when compared with other cities. This Midwestern city is a destination market, with small entrepreneurial groups marketing the drug. Heroin is available in the suburbs and in some of the surrounding
rural areas on a limited basis, thus illustrating that this
drug is not confined to the lower socioeconomic strata
in the city.

While not reported separately, alcohol abuse and underage use of alcohol are community concerns. Many
traffic accidents and violence against persons include
alcohol use in the situation. In St. Louis, 15 percent
of treatment admissions are for alcohol alone, with
alcohol used in combination with drugs in another
12.5 percent of the treatment admissions. In the unweighted DAWN ED data, underage alcohol use
represents 6.5 percent of the reports in 2004.
With the severe cuts in services in this State over the
next year, the treatment admissions data, an important
indicator of longer term use of drugs, may not accurately reflect the severity of the drug abuse problem.
Cocaine/Crack
The St. Louis City/County Medical Examiner (ME)
reported that cocaine-related deaths trended downward from 128 in 1994 to 38 in 2004 (exhibit 2a).

223

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—St. Louis

Many of the recent deaths involved alcohol and other
drugs.
According to DAWN, the number of cocaine mentions increased significantly between 2000 (n=2,403)
and 2002 (3,536). The numbers of mentions among
those age 45–54 and 55 and older increased significantly. For 2004, the unweighted DAWN Live! data
indicate that ED reports for cocaine had the following
characteristics: more than one-half (51.8 percent) of
the patients were White, and 58.6 percent of the patients were older than 34. The top two reasons for the
ED visit were seeking detox or overmedication. The
dispositions for most of these patient visits included
referral to treatment, admission to the psychiatric
unit, or discharge to home; only three resulted in immediate death.
Among treatment admissions for illicit drug abuse in
2004, the proportion for primary cocaine abuse reflected a slight decrease compared with all of 2003
(exhibit 2a). Cocaine remained the most common
primary drug of abuse among all admissions (29.1
percent), followed by marijuana (25.0 percent) and
heroin (10.4 percent). The typical cocaine admission
was an African-American male age 35 or older who
smoked the drug.
Although the DEA’s emphasis has shifted from cocaine to methamphetamine and heroin, law enforcement sources, the DEA, and street informants continued to report high quality, wide availability, and low
prices for cocaine. Cocaine is used and most available in the urban areas. Powder cocaine grams sold
for $100–$125; purity averaged 70 percent (exhibit
2b). Crack prices remain at $20 per rock on the street
corner. All cocaine in St. Louis is initially in the
powder form and is converted to crack for distribution. Cocaine was readily available on the street corner in rocks or grams. The price of a gram of crack in
Kansas City was lower than in St. Louis (at $100–
$120). The “rock” price is the same in smaller cities
outside St. Louis when it is available, but the gram
price is higher.
NFLIS data indicated 2,389 (41.5 percent) of items
analyzed in 2004 were cocaine.
The continued use of cocaine has potentially severe
long-term consequences by contributing to the spread
of STDs through multiple partners. Crack cocaine is
considered to be a primary risk for HIV in many research trials.
Most cocaine users smoke crack cocaine, though
some use powder cocaine. Only injection drug users
(IDUs) who combine cocaine and heroin (“speed-
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ball”) use cocaine intravenously. Younger users tend
to smoke cocaine. Polydrug use is also evident in the
treatment data. The reported use of marijuana, heroin,
and alcohol in addition to cocaine suggests this trend
will likely continue.
Heroin
Heroin-related deaths reported by the St. Louis
City/County ME leveled off in recent years. In 2004,
there were 64 heroin-related deaths (exhibit 2a).
Statewide heroin deaths caused by overdose alone
were not much higher, because heroin purity is higher
in the St. Louis area than in other cities in Missouri.
While available primarily in the St. Louis and Kansas
City areas, heroin is found among small pockets of
IDUs who reside in small university towns throughout the State. More heroin deaths occurred in St.
Louis County than in the inner city in 2004 (32 versus 20); these deaths support other reports that heroin
use is increasing in the suburbs.
Heroin consistently appears in all indicators. Unweighted data accessed from DAWN Live! show that
heroin ED reports for 2004 had patient demographics
of 60.1 percent White and 28.8 percent age 18–24.
Heroin ED mentions had risen steadily from 1995 to
2002, when mentions totaled 1,167. The increase in
heroin mentions among many age groups over this
earlier 7-year period (1995–2002) indicates the wide
availability of this drug in this MSA.
While heroin treatment admissions increased dramatically as a proportion of all admissions between
1996 and 2000, they leveled off in 2001–2003. In
2004, this trend appeared to continue. There are limited slots for admissions to State-funded methadone
or modified medical detoxification in Missouri,
which may influence these data. While heroin availability increased throughout the region, the decrease
in admissions may in fact be a result of lack of adequate treatment resources; alternatively, the decrease
could be related to new users of heroin not yet seeking treatment. When queried, private treatment programs stated that 25 percent of their admission
screens were for heroin abuse, but admission depended on “ability to pay.” Some heroin abusers in
need of treatment utilize “private pay” methadone
programs. Rapid detoxification, using naltrexone, is
still a treatment option at private hospitals, but it is
expensive. About 35 percent of heroin admissions
were younger than 25 in 2004. Of all heroin admissions, intravenous use was the primary method of
administration in St. Louis County, but inhalation
was more popular among admissions in St. Louis
City. The increased availability of higher purity heroin has led to a wider acceptance of the drug in social
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circles. One of the reasons for its acceptance is that it
does not have to be injected to get the desired effects.
A steady supply of Mexican heroin remains available.
The DEA has made buys of heroin in the region in
addition to buys through the DMP. Mexican black tar
heroin showed a peak of 24.0 percent purity in 1998;
purity dropped to 15.1 percent in 2004. South American (Colombian) heroin, which is also white, is of
poorer quality, averaging around 10 percent. Most
heroin is purchased in aluminum foil or the number-5
gel capsule (one-tenth-gram packages of heroin in
plastic wrap and aluminum foil) for $10 (exhibit 2b).
Heroin costs were about $1.89 per milligram for
Mexican heroin in the 2003 DMP analysis. The city
is an end-user market and is dependent on transportation of the heroin from points of entry into the Midwest. The wholesale price remains at $250–$600 per
gram. On street corners, heroin sells for $250 per
gram or $10 per “button.” Most business is handled
by cellular phone, which has decreased the seller’s
need to have a regular location. Runners continue to
be used as “middlemen” between users and sellers to
deliver small quantities of drug. In St. Louis and
other smaller urban areas, small distribution networks
sell heroin.
NFLIS reported that 10 percent of the items analyzed
in 2004 were heroin.
Kansas City’s heroin supply differs from that of St.
Louis. Most heroin in Kansas City is black tar and is
typically of poorer quality. The supply is consistent,
and a $10 bag of heroin is available. Heroin has also
become available in the smaller, more rural cities of
Springfield and Joplin, each of which has a small IDU
population that uses heroin and methamphetamine.
Other Opiates/Narcotics
Other opiates continue to represent less than 1 percent
of all treatment admissions. Methadone remains available, which is probably a result of prescription abuse
as well as patient diversion.
The unweighted DAWN data for 2004 accessed from
DAWN Live! indicate 797 reports for other opiates; 40
percent were for overmedication and only 18 percent
were for patients seeking detoxification. Reasons for
the ED visit were not delineated for 40 percent of the
reports.
OxyContin (a long-lasting, time-release version of
oxycodone) abuse remained a concern for treatment
providers and law enforcement officials. Prescription
practices are closely monitored for abuse, and iso-
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lated deaths have been reported, but no consistent
reports are available on the magnitude of this potential problem. OxyContin costs $40 for an 80-milligram tablet on the street (exhibit 2b). The DAWN
data indicate 247 oxycodone reports in 2004, with 38
percent of these patients coming to the ED for overmedication.
The use of hydromorphone (Dilaudid) remained
common among a small population of White chronic
addicts. The drug costs $30–$75 per 4-milligram pill.
Marijuana
According to unweighted data accessed from DAWN
Live!, marijuana ED reports in 2004 (n=1,230) represented 20 percent of the total ED reports for major
substances of abuse. More than 45 percent of the patients who reported cocaine in 2004 were younger
than 25.
Marijuana treatment admissions more than doubled
from 1997 (1,573 admissions) to 2001 (3,210 admissions) and remained stable in 2003 and 2004, when
they represented 27.2 percent and 25.0 percent of all
admissions, respectively (exhibit 2a). Marijuana,
viewed by young adults as acceptable to use, is often
combined with alcohol. The 25-and-younger age
group accounted for 65.6 percent of primary marijuana treatment admissions in 2004. Some of the prevention organizations report a resurgence in marijuana popularity and a belief by users that it is not
harmful. Prevention programs are targeting this belief
through education.
Because of the heroin, cocaine, and methamphetamine abuse problems and the recent “club drug”
scare in St. Louis, law enforcement officials have
focused less attention on marijuana abuse. Limited
resources require establishing enforcement priorities.
Often, probation for marijuana offenders requires
participation in treatment for younger users who do
not identify themselves as drug dependent. In focus
groups with African-American adults from various
social groups, more than one-half identified regular
use of marijuana but did not identify this use as problematic. This ethnographic information supports the
idea of cultural acceptance of marijuana use. A college town made possession of small quantities of
marijuana a misdemeanor, further supporting these
beliefs.
Marijuana is available from Mexico or domestic indoor growing operations. Indoor production makes it
possible to produce marijuana throughout the year. In
addition to the Highway Patrol Pipeline program,
which monitors the transportation of all types of
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drugs on interstate highways, Operations Green Merchant and Cash Crop identify and eradicate crops.
Much of the marijuana grown in Missouri is shipped
out of the State. NFLIS reported that 40 percent of
the items analyzed in 2004 were marijuana.
Stimulants
Methamphetamine, along with alcohol, remained a
primary drug of abuse in both the outlying rural areas
and statewide. (Most of Missouri, outside of St. Louis
and Kansas City, is rural.) Methamphetamine continued to be identified as a huge problem in rural communities, with a focus on “mom and pop” box labs
and intergenerational use of the drug.
In 2004, unweighted DAWN Live! data show
methamphetamine ED reports totaled 286 (exhibit
2a). Ninety-two percent were White, with no predominant age group. ED methamphetamine mentions
in St. Louis increased in the late 1990s and totaled
150 in 2002.
Methamphetamine (“crystal” or “speed”) was found at
very low levels in city indicators in 1995, but reported
use has slowly increased over the last 8 years. In rural
areas, methamphetamine appeared regularly in the
treatment data, but methamphetamine has been identified as a problem in all parts of the State. The urban,
street-level distributors in St. Louis deal in cocaine, so
amphetamine use is not as widespread in the St. Louis
area; this could indicate differences in dealing networks
and access to locally produced drugs (“mom and pop”
local production). However, an increase in availability
and purity of Mexican methamphetamine and a growth
in Hispanic groups in the St. Louis metropolitan area
may change this trend. Methamphetamine use is reported in the gay male and club communities in the
city. An increase in treatment admissions may signal
this change. Traditionally, cocaine and methamphetamine use have been split along racial lines in
the State. The number of methamphetamine treatment
admissions in St. Louis was 544 in 2004. In rural
treatment programs, methamphetamine was the drug of
choice after alcohol.
The Midwest Field Division of the DEA decreased its
cleanup of clandestine methamphetamine labs after
training local enforcement groups; 2,788 labs were
reported for 2004. The intensity of these law enforcement efforts is based on the availability of funds
for local police departments to clean up box labs under Community Oriented Policing Service (COPS)
funding. Thefts of anhydrous ammonia continued to
be identified as an issue in rural areas.
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In the current methamphetamine scene, Hispanic traffickers, rather than the old network of motorcycle
gangs, are the predominant distributors. Shipments
from “super labs” in the Southwest are trucked in via
the interstate highway system. This network is in
contrast to the local “mom and pop” labs that produce
personal quantities for family and friends. These local labs tend to use the Nazi method of production,
with an output of 60 percent of the quantity of the
starting products, although the red phosphorus
method has been seen more frequently. Purity of the
drugs produced by these labs and the amount of finished
product
depends
on
the
experience/attentiveness of the “cooker” but tends to be
higher (greater than 80 percent). Most of the available methamphetamine is produced in Mexico and
trafficked through the Hispanic traffickers, with less
pure methamphetamine obtained through this source.
While much of the law enforcement resources and
personnel are directed at the local production, the
majority of methamphetamine that is available in the
area comes through these Hispanic organizations. As
the purity increases among the methamphetamine
obtained from these groups and precursor drugs are
less available, less local production may be seen.
Some crystallized methamphetamine has been noted
in the local market, usually indicating increased purity in the product.
The term “ice” has been applied to all methamphetamine with a crystalline appearance. Methamphetamine
sold for $700–$1,300 per ounce in St. Louis and for as
little as $100–$120 per gram in some areas. Methamphetamine was represented in only 1.5 percent of the
NFLIS analysis.
Use of methamphetamine and its derivatives has become more widespread among high school and college students, who do not consider these drugs as
dangerous as others. Because methamphetamine is so
inexpensive and appeals to a wide audience, it is
likely that its use will continue to spread.
Depressants
Benzodiazepine abuse by prescription continues. In
2004, unweighted DAWN Live! data showed 808
benzodiazepine ED reports, with slightly more than
one-half of the patients indicating overmedication. In
the ED data, the ratio of benzodiazepines to opiates/opioid drugs is 1.0, indicating a significant degree of usage of this class of drug.
The remaining few private treatment programs often
provide treatment for benzodiazepine, antidepressant,
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and alcohol abusers. Social setting detoxification has
become the treatment of choice for individuals who
abuse these substances. Since many of the private
treatment admissions are polysubstance abusers, particular drug problems are not clearly identified.

Of the total 6,672 persons living with HIV disease
identified through June 2004, 5 percent were IDUs
and 5 percent involved men who have sex with men
and are also IDUs (MSM/IDUs) (exhibit 3). The
number of infected African-Americans was increasing disproportionately among males and females.

Hallucinogens
HIV Research
Over the years, lysergic acid diethylamide (LSD) has
sporadically reappeared in local high schools and
rural areas. Blotters sell for $5–$7 per 35-microgram
dose (exhibit 2b). Unweighted DAWN Live! data for
2004 showed a small number of LSD ED reports: 9.
Phencyclidine (PCP) has been available in limited
quantities in the inner city and has generally been
used as a dip on marijuana joints. While PCP is not
seen in quantity, it remains in most indicator data,
including ED reports (29 in unweighted 2004 DAWN
Live! data), police exhibits, and as a secondary drug
in ME data. Most of the users of this drug in the inner
city are African-American.
Club Drugs
Unweighted DAWN Live! ED data show few reports
of methylenedioxymethamphetamine (MDMA)—
only 27 in 2004. Reports of other club drugs were
almost non-existent; one ketamine and three gamma
hydroxybutyrate (GHB) ED reports occurred in 2004.
MDMA is less available at dance parties and costs
$20–$30 per tablet. Most of the reports about MDMA
abuse are anecdotal or are part of a polydrug user’s
history. Public treatment programs reported no admissions for MDMA
INFECTIOUS DISEASES RELATED TO DRUG ABUSE

Saint Louis University has continued research on
HIV prevention vaccines. Most of the prevention
vaccine trials have been Phase I trials in low-risk
individuals, and MSM and high-risk women in the
United States and high-risk heterosexuals in the Caribbean are being recruited for a new expanded Phase
II trial. Another Phase II trial is slated to begin later
this year.
STDs and Hepatitis C
A resurgence of syphilis among MSM has led to increased surveillance and targeted prevention programs to this population. Rates of gonorrhea and
chlamydia remain stable and high in the urban STD
clinics. St. Louis ranks third in the country for gonorrhea, with cases remaining at approximately 1,000
per year, and second for chlamydia. HIV and syphilis/gonorrhea rates are high in neighborhoods known
to have high levels of drug abuse, underscoring the
concept of assortative mixing in cohorts. Inconsistent
reporting of hepatitis C has made estimation of the
problem and tracking of hepatitis C cases difficult
REFERENCES
Herlig, C. Strategic Intelligence, St. Louis Office of
the Drug Enforcement Administration. Personal
communication.

HIV
HIV seropositivity among IDUs remained low in St.
Louis. While the predominant number of cases occur
among men who have sex with men (MSM), the largest increase was found among young AfricanAmerican females, who were infected through heterosexual or bisexual contact, and young homosexual African-American males. As a result, increased specialized minority prevention efforts have been initiated.
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Exhibit 1.

St. Louis DAWN ED Sample and Reporting Information: 2004

Total Eligible
1
Hospitals

No. of Hospitals
in DAWN
Sample

Total EDs
in DAWN
2
Sample

37

36

38

No. of EDs Reporting per Month: Completeness of Data (%)
90–100%
50–89%
<50%
15–18
0–2
0–2

No. of EDs
Not Reporting
20–23

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
2
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005
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Exhibit 2a.

Indicators for Cocaine, Heroin, Marijuana, and Methamphetamine in St. Louis: 1996−2004

Indicator
Number of Deaths by Year
1996
1997
1998
1999
2000
2001
2002
2003
2004
DAWN ED Data—Weighted Data4
Number of Mentions (2002)
Number of Mentions (2001)
Rate per 100,000 Population (2002)
Gender of Mentions (%) (2002)
Male
Female
Age (%) (2002)
12–17
18–34
35 and older
Race (%) (2002)
White
African-American
Hispanic
Other/unknown
Route of Administration (%) (2000)
Smoking
Intranasal
Injection
Unknown/other
DAWN Live! ED Data—Unweighted Data4
Number of Reports (2004)
Gender of Reports (%) (2004)
Male
Female
Age (%) (2004)
12–17
18-24
25–34
35 and older
Race (%) (2004)
White
African-American
Hispanic
Other/unknown
Route of Administration (%) ( 2004)
Smoking
Intranasal
Injection
Unknown/other

Cocaine

Heroin

Marijuana

Methamphetamine

93
43
47
51
66
75
76
78
38

51
67
56
44
47
20
50
61
64

NA1
NA
NA
NA
NA
NA
NA
NA
NA

9
11
9
4
9
3
–
---

3,536
3,080
153

1,167
1,309
51

2,866
2,311
124

150
115
7

63.3
36.1

63.8
36.2

63.4
35.8

63.3
36.0

1.5
36.9
61.5

1.4
56.0
42.4

8.4
52.2
39.5

15.3
53.3
31.3

39.1
56.3
0.6
2.9

55.6
39.9
…2
3.1

54.9
40.7
0.4
2.7

91.0
3
--0.7
4.7

62.3
25.9
7.0
4.8

6.4
22.2
71.5
–

NA

18.8
15.6
46.9
18.8

1,702

601

1,230

286

63.3
36.7

69.2
30.8

63.3
36.7

56.6
43.4

<1
14.0
27.4
58.6

<1
30.3
30.9
38.8

--45.0
23.5
31.5

0
38.1
30.8
31.1

51.8
49.2
0.0
0.0
21.4
-2.4
9.0
67.8

60.1
34.4
2
…
5.5

68.6
27.8
<.1
<3
34.9

91.6
<1
<1
<1
7.9
8.6
7.5
73.6

0
9
35.2
52

62.3

1

NA=Not applicable.
Dots (…) indicate that an estimate with a relative standard error greater than 50 percent has been suppressed.
Dashes (---) indicate than an estimate has been suppressed because of incomplete data.
4
Unweighted data are from 15–18 St. Louis EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted and, therefore, are subject to change.
2
3
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Exhibit 2a.

Indicators for Cocaine, Heroin, Marijuana, and Methamphetamine in St. Louis: 1996−2004
(Cont’d)

Indicator

Cocaine

Heroin

Marijuana

Methamphetamine

Treatment Admissions Data
Percent of All Admissions (2003)

34.6

10.1

27.2

4.7

Percent of All Admissions (2004)
Gender (%) (2004)
Male
Female
Age (%) (2004)
12–17
18–25
26–34
35 and older
Race/Ethnicity (%) (2004)
White
African-American
Hispanic
Route of Administration (%) (2004)
Smoking
Intranasal
Injecting
Oral
other

29.1

10.4

25.0

4.6

54.9
45.1

62.5
37.5

74.0
26.0

54.2
45.8

0.6
8.0
24.0
67.4

0.8
34.9
25.6
38.6

25.5
40.1
20.3
14.1

26.1
73.3
1.1

40.1
59.0
0.9

41.1
57.9
1.0

98.9
0.2
0.0

90.5
5.1
1.7
1.6

1.7
46.7
50.4
1.0
4.9

96.7
0.3
0.1
1.6

48.9
15.1
32.5
4.0

4.4
32.6
36.5
26.5

SOURCES: DAWN, OAS, SAMHSA; DAWN Live!, OAS, SAMHSA, updated 6/03/2005; TEDS database

Exhibit 2b. Other Combined Indicators for Cocaine, Heroin, Marijuana, and Methamphetamine in St. Louis:
2002–2004
Indicator

Cocaine

Heroin

Marijuana

Methamphetamine
and Other Drugs

Multisubstance
Combinations

Older users combine with heroin,
alcohol

Older users combine with cocaine,
alcohol

Alcohol

Marijuana commonly
used in combination

Market Data (2004)

Powder $100–
$125/g, 70% pure;
Crack $20/rock,
50–90% pure;
eightball $300

$20/cap or foil;
$10 per number-5
gel capsule;
$3.17/mg pure—
depending if MBT,
SA, SWA, $250–
$600/g, 13.9–
23.2% pure

Sinsemilla $700–
$1,800/lb, 20% THC;
Imported
$2,000−$4,000/lb

Methamphetamine
$100–$120/g, Mexican
(20–30%) and local
(70–80% pure); hydromorphone $30–
$50/4-mg pill; LSD
blotters $5–$7/35 microgram, OxyContin
$40 mg

Qualitative Data

Readily available,
urban choice

Younger users, 1/3
younger than 25

Readily available,
younger users in
treatment

Rural/suburban users
of amphetamine

Other Data of Note

N/R1

Primarily Mexican
black tar; young
users smoke/snort

N/R

Methamphetamine lab
seizures plateaued;
producers are superlabs–controlled by
Hispanic groups; mom
and pop labs

1
N/R=Not reported.
SOURCES: DEA; client ethnographic information
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Exhibit 3. Persons Living with HIV Disease in St. Louis Metropolitan Area by Exposure Category, Gender,
Race/Ethnicity, and Age: Year-to-Date and Cumulative Totals Reported Through June 2004
HIV-Positive Test Results
Category

Jan 2004–June 2004
Number

Exposure Category
MSM
IDU
IDU/MSM
Hemophilia
Heterosexual
Blood transfusion
Perinatal
Unknown
Total
Gender and Race/Ethnicity
Male
White
African-American
Hispanic
Other
Unknown
Female
White
African-American
Hispanic
Other
Age
12 and younger
13−19
20−29
30−39
40−49
50 and older
Unknown
Total

Percent

Cumulative
Through June 2004
Number
Percent

61
6
3
0
12
0
0
41
123

50.0
5.0
2.0
0.0
10.0
0.0
0.0
33.0

4,583
301
319
58
920
34
41
416
6,672

70.0
5.0
5.0
1.0
14.0
0.2
1.0
6.0

40
62
1
1
0

33.0
51.0
0.0
0.0
0

2,914
2,582
79
19
208

45.0
40.0
1.0
0.0
3.0

4
14
2
0

3.0
12.0
0.0
0.0

170
671
15
13

2.0
10.0
0.0
0.0

0
5
39
30
41
8
0
123

0.0
4.0
32.0
24.0
33.0
7.0
0

53
160
1,644
2,799
1332
522
162
6,672

1.0
2.4
25.2
43.0
20.4
8.0
2.0

SOURCE: St. Louis Metropolitan AIDS Program
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Drug Abuse Patterns and
Trends in San Diego County,
California
Steffanie Strathdee, Ph.D.1
ABSTRACT
Methamphetamine abuse indicators continue to be
high in San Diego. Forty-five percent of the 2004
treatment admissions (excluding alcohol) in San
Diego County were for primary methamphetamine
abuse; approximately 27 percent of all items analyzed by forensic laboratories and nearly 27 percent
of the (unweighted) illicit drug reports accessed
through the DAWN Live! ED system involved
methamphetamine. Cocaine/crack indicators remained relatively low and stable in 2004. Marijuana
continued to be a serious problem, accounting for
50 percent of drug items analyzed by forensic labs
in 2004, nearly 18 percent of the county’s primary
illicit drug admissions, and more than 21 percent of
the (unweighted) illicit drug ED reports. Heroin
accounted for one-quarter of primary treatment
admissions (excluding alcohol) and for 16 percent
of ED reports for illicit drugs, but it represented less
than 2 percent of all drug items reported by forensic
laboratories.
INTRODUCTION
Area Description
According to the 2000 census, more than 2.8 million
persons resided in San Diego County (exhibit 1); 55
percent were White and 27 percent were Hispanic. In
2004, the county population was projected to increase
to slightly more than 3.0 million, with a decrease in
the White population (to 52 percent) and a slight increase (1 percent) in the Asian and Hispanic/Latino
populations. The median household income was
nearly $46,000 in 2000 and was projected at $50,543
in 2004.
Methamphetamine is a major drug problem in the
area. Several geographic and social factors foster the
manufacture, trafficking, and abuse of the drug in
San Diego County. The county is isolated from the
rest of California. There are 80 miles of border to the
south, 70 miles of ocean to the west, mountain ranges
to the east and northeast, and a military base to the

north. The three border crossings to Mexico include
the Tijuana crossing, which is the busiest in the
world. Mexico contributes 90 percent of all methamphetamine entering the United States and 98 percent
of all heroin west of the Mississippi river. The border
and the coastline represent a particular challenge in
attempts to control the import of illicit drugs. Isolated
rural areas provide an ideal setting for the establishment of small methamphetamine clandestine labs. In
addition, there was a 78-percent increase in opium
poppy cultivation in Mexico, from 2,700 hectares in
2002 to 4,800 in 2003, suggesting that heroin trafficking from Mexico will continue to be an important
problem for U.S.-Mexico border States.
Before 1989, there were many small methamphetamine labs in San Diego; these were operated by local
“cookers” and outlaw motorcycle clubs. Over the
years, the production and abuse of methamphetamine
“waxed and waned.” The Chemical Diversion and
Trafficking Act of 1988 and the Chemical Control
Diversion Act of 1993 helped curtail access to the
precursors used in making methamphetamine. A
DEA sting effort, Operation Triple Neck, resulted in
arrests and the closing of stores that supplied equipment and chemicals to methamphetamine cookers.
Most methamphetamine indicators declined for a
time, but new sources and distribution networks
emerged. Mexican nationals and MexicanAmericans, operating on both sides of the border,
began to produce large quantities of high-purity
methamphetamine. Already established networks that
distribute other illicit drugs are used to distribute
methamphetamine. The profits from these operations
have been large.
Data Sources
Data for this paper were provided by the sources
shown below:
•

Forensic laboratory data were provided by the
National Forensic Laboratory Information System (NFLIS), Drug Enforcement Administration
(DEA), for 2004, when 15,773 drug items were
analyzed by county laboratories. Percentages of
drug items analyzed in 2003 are also reported.

•

Treatment data for San Diego County were
provided by the California Alcohol and Drug
Data System (CADDS) on 14,105 admissions in
2004, of which 2,877 were primary alcohol admissions. The 2004 data from the State system
are not totally consistent with CADDS data accessed from San Diego County in prior years.

1
The author is affiliated with the University of California San
Diego, School of Medicine, San Diego, California, and The Johns
Hopkins University Bloomberg School of Public Health.
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•

•
•

•

•

Emergency department (ED) data for calendar
year 2004 were accessed through the Drug
Abuse Warning Network (DAWN) Live!, which
is a restricted-access online query system
administered by the Office of Applied Studies
(OAS), Substance Abuse and Mental Health
Services Administration (SAMHSA). Sixteen of
the 17 eligible hospitals in the San Diego
metropolitan area are in the DAWN sample, with
a total of 16 EDs in the sample. The data
reported in this paper were not complete. During
the 12-month period, between 6 and 10 EDs
reported data to DAWN each month (exhibit 2).
The data in this paper were updated by OAS on
January 13–14, 2005; they are unweighted and
are not estimates for the San Diego area. All
DAWN cases are reviewed for quality control.
Based on the review, cases may be corrected or
deleted; therefore, the data reported in this paper
are subject to change. The information derived
from DAWN Live! for San Diego in 2004
represents 6,214 cases, 2,999 reports of illicit
drugs (excluding alcohol), reports on nonmedical
use of selected prescription-type drugs, and
reports on alcohol-related visits. The number of
drug reports in drug-related visits exceeds the
number of ED visits, since a patient may report
use of multiple drugs (up to six drugs and
alcohol may be represented in DAWN). These
data cannot be compared with DAWN data from
2002 and before, nor can these preliminary data
be used for comparison with future data. Only
weighted ED data released by SAMHSA can be
used for trend analysis. A full description of the
DAWN system can be found on the DAWN Web
site: <http://dawninfo.samhsa.gov>.
Drug-related mortality data were provided by
the San Diego Medical Examiner for 2003.
Drug price information is from the National
Drug Intelligence Center (NDIC) for July
through December 2004.
Heroin price and purity data are from the Domestic Monitor Program (DMP), DEA, for 2003.
The data are based on 38 qualified samples.
Acquired immunodeficiency syndrome (AIDS)
data were taken from the San Diego County
Health and Human Services Agency (HHSA),
“Acquired Immunodeficiency Syndrome (AIDS)
Surveillance Report,” April 30, 2005. Data on the
human immunodeficiency virus (HIV) are from
the HHSA “Human Immunodeficiency Virus
(HIV) Surveillance Report,” 2004.
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DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
Cocaine indicators remained relatively stable over the
past decade, although this stimulant is still a problem
in San Diego and cocaine hydrochloride (HCl) and
crack remain readily available.
More than 14 percent of the drug items analyzed by
forensic labs in 2004 were cocaine items (exhibit 3),
up slightly from the 13 percent reported in 2003.
Treatment admissions for primary cocaine abuse,
excluding alcohol, accounted for 8.7 percent of admissions in 2004, according to State data; the county
CADDS data for prior years suggest a decline in cocaine admissions from 2001 to 2003 (exhibit 4).
Eighty percent of the cocaine admissions in 2004
smoked the drug, indicating most cocaine admissions
were for crack abuse (exhibit 5). Nearly 70 percent of
the primary cocaine admissions in 2004 were male.
Nearly 71.0 percent were age 35 or older, and 58.5
percent were Black non-Hispanic. More than 30 percent of the primary cocaine abusers reportedly used
only cocaine; alcohol and marijuana were the substances most likely to be used as a secondary drug
(32.1 and 22.0 percent, respectively).
Preliminary unweighted data accessed through
DAWN Live! show that cocaine was the most prominent drug in visits involving illicit drugs (excluding
alcohol). ED reports of cocaine totaled 558 in 2004
and accounted for 18.6 percent of the illicit drug reports (exhibit 6). Nearly two-thirds of the patients in
the cocaine-involved reports were male, 60 percent
were 35 or older, 48 percent were White, and 30 percent were Black (exhibit 7).
In 2003, there were 56 deaths involving cocaine, as
reported by the county medical examiner (exhibit 8).
In the last half of 2004, a gram of powder cocaine,
retail, sold for $60–$80, and one-quarter gram sold
for $25–$35 (exhibit 9). A “rock” of crack sold for
$10–$20.
Heroin
In 2004, 1.5 percent of the 15,773 drug items analyzed by forensic labs were heroin items (exhibit 3),
approximately the same percentage as in 2003 (1.7
percent).
Treatment admissions for primary heroin abuse (excluding alcohol) represented 25 percent of the illicit
drug admissions in 2004, based on the State CADDS
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data (exhibit 4). Of the 2,810 primary heroin admissions in 2004, the majority were male (70.6 percent),
age 35 or older (57.9 percent), and White (52.0 percent) (exhibit 5). Hispanics represented 38.4 percent
of these admissions. Eighty-seven percent injected
the drug. More than 61 percent reported using only
heroin. Cocaine/crack (12.9 percent) and methamphetamine (11.7 percent) were the most frequently
reported secondary drugs used by primary heroin
admissions.
Unweighted data accessed from the DAWN Live!
system for 2004 show 492 heroin reports, representing16.4 percent of illicit drug reports from participating San Diego emergency departments (exhibit 6).
Nearly 70.0 percent of patients involved in these visits were male, 70.5 percent were 35 or older, 54.5
percent were White, and 30.7 percent were Hispanic
(exhibit 7).
In 2003, the county medical examiner reported 62
heroin-involved deaths (exhibit 8).
In 2003, DMP reported that most heroin in San Diego
was black tar heroin, which was 44.9 percent pure
and sold for $0.25 per milligram pure. This heroin
was the cheapest of any recorded across the Nation.
Most of this heroin originates in Mexico.
NDIC reports that Mexican brown powder heroin
costs $60–$100 per gram, while Mexican black tar
heroin costs $50–$100 per gram (exhibit 9).

deaths, propoxyphene/combinations were involved in
19, and fentanyl/combinations were involved in 12.
Marijuana
Marijuana continues to be a serious problem in San
Diego. Fifty percent of the items analyzed by forensic
labs in 2004 were cannabis (exhibit 3), down slightly
from 2003 (52.7 percent).
Primary marijuana abuse accounted for nearly onefifth (17.6 percent) of treatment admissions (excluding alcohol) in 2004 (exhibit 4). Three-quarters were
male, 41 percent were White, and 34 percent were
Hispanic (exhibit 5). Seventy-two percent of the primary marijuana admissions were 25 or younger.
Slightly more than 26 percent reported using only
marijuana; 39.2 percent used alcohol as a secondary
drug, and 26.2 percent used methamphetamine.
Unweighted data accessed from DAWN Live! show
641 marijuana reports in 2004; these represented 21.4
percent of the illicit drug reports (exhibit 6). Male
patients accounted for nearly two-thirds of the visits
involving marijuana (exhibit 7). These patients were
most likely to be younger than 25 (46.8 percent) and
White (52.7 percent).
One death involving marijuana was reported by the
medical examiner in 2003 (exhibit 8).
In the last 6 months of 2004, an ounce of marijuana
cost $60–$100 retail (exhibit 9).

Other Opiates
Methamphetamine
Opiates other than heroin accounted for 2.2 percent
(n=344) of the drug items analyzed by forensic labs
in 2004 (exhibit 3). Of the other opiate items, 173
(50.3 percent) were hydrocodone items, 45 (13.1 percent) were oxycodone, 30 (8.7 percent) were codeine,
and 20 (5.8 percent) were methadone.
In 2004, there were 221 admissions for primary abuse
of opiates/synthetics other than heroin. These accounted for 2 percent of all illicit drug admissions.
The preliminary unweighted DAWN data for 2004
show 643 ED reports of opiates/opioids. Of the 643
reports, 208 (32.3 percent) were hydrocodone reports
and 94 (14.6 percent) were oxycodone reports.
In 2003, the county medical examiner reported a sizable number of deaths involving opiates/narcotic analgesics. The highest number involved morphine/combinations (67), followed by hydrocodone/combinations
(44) (exhibit 8). Codeine/combinations, methadone,
and oxycodone/combinations were involved in 22–24
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In 2004, methamphetamine accounted for 26.9 percent of all drug items reported by NFLIS; amphetamines accounted for less than 1.0 percent (exhibit 3).
In 2004, 45.2 percent of illicit drug admissions in the
county were for primary abuse of methamphetamine
(exhibit 4). Nearly 61 percent of these patients were
male, 56 percent were White, and 27 percent were
Hispanic (exhibit 5). Approximately 72 percent were
26 or older, with 38.5 percent being 35 or older.
Smoking was the most frequently reported route of
administration for methamphetamine, characterizing
68.6 percent of this admissions group. Slightly more
than 37 percent reportedly used only methamphetamine prior to treatment entry; marijuana (29 percent)
and alcohol (24 percent) were the most frequently
used secondary drugs.
Unweighted DAWN data show 797 ED reports of
methamphetamine in 2004, representing nearly 27
percent of illicit drug reports. There were also 388
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amphetamine reports; these represented nearly 13
percent of illicit drug reports (exhibit 6). Demographic data on methamphetamine-involved ED visits
show that approximately 69 percent were male, 45
percent were age 35 or older, 63 percent were White,
and 20 percent were Hispanic (exhibit 7).
In 2003, the county medical examiner reported 118
methamphetamine-involved deaths and 41 amphetamine-involved deaths (exhibit 8).
Price data from NDIC show that methamphetamine
cost $60 per gram in the last half of 2004 (exhibit 9).
San Diego County has had considerable experience
over many years in assessing and addressing problems associated with methamphetamine production
and abuse. The Methamphetamine Strike Force
(MSF), established in March 1996 as a collaborative
“assessment and action” effort involving more than
60 members and 10 data sources, continues to assess
the methamphetamine problem at the community
level, determine appropriate actions to take, and
evaluate results. The MSF has developed effective
plans and policies, controlled the availability of precursor chemicals, taken steps to protect endangered
children, made effective use of the media, and developed and used training at all levels. The two newest
initiatives include a focus on women and the border.
The MSF Web site is <www.no2meth.org>.
Club Drugs
There were few indicators of club drugs in recent data
sources. In 2004, 61 methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine
(MDA) items were reported by forensic labs. These
MDMA/MDA items accounted for 0.4 percent of all
drug items analyzed (exhibit 3). Twenty-seven phencyclidine (PCP) items were also reported by forensic
labs, representing 0.2 percent of the total items.
The retail price of MDMA per tablet was $15–$30 in
the last half of 2004 (exhibit 9).
Treatment admissions for primary PCP abuse totaled
39 in 2004, or nearly 0.3 percent of illicit drug admissions.
In the 2004 unweighted DAWN data, small percentages of the illicit drug reports involved MDMA (0.8
percent, n=23), PCP (0.8 percent, n=23), and gamma
hydroxybutyrate (GHB) (0.4 percent, n=11) (exhibit
6). There were also three reports each for ketamine
and lysergic acid diethylamide (LSD), drugs that are
sometimes included in the “club drug” category.
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Benzodiazepines
Benzodiazepine-type drugs accounted for 1.5 percent
(n=241) of the drug items analyzed by forensic labs
in 2004 (exhibit 3). Of the 241 items, 38.2 percent
were diazepam items, 30.3 percent were clonazepam,
25.7 percent were alprazolam, and 9.1 percent were
lorazepam.
Unweighted data accessed from DAWN Live! for
2004 show 545 benzodiazepine ED reports.
Alcohol
As in other areas of the Nation, alcohol abuse is a
serious problem in San Diego.
In 2004, primary alcohol abuse accounted for onefifth of all treatment admissions (n=2,877).
Across San Diego EDs participating in DAWN, the
preliminary unweighted data show 975 reports for
alcohol-in-combination with other drugs; another 184
visits involved “alcohol only” among patients
younger than 21. Of these alcohol-only involved visits, 48 percent were male, 58 percent were White, 38
percent were Black, and 14 percent were Hispanic.
(Race/ethnicity was not documented for 15 patients,
and 3 other patients were in an “other” category.)
Fifty-one percent of alcohol-only reports represented
patients age 18–20, with the remaining patients being
between the ages of 12 and 17.
INFECTIOUS DISEASES RELATED TO DRUG ABUSE
AIDS
From 1981, when the first AIDS cases in San Diego
County were diagnosed, through April 2004, there
were 12,273 adult/adolescent AIDS cases reported in
the county. The State has the second highest number
of AIDS cases in the Nation, and San Diego has the
third highest number of cases in the State. Since
1999, the number of annual AIDS cases reported in
San Diego has been in the mid-400 range. The 2004
report shows that, of the adult/adolescent AIDS
cases, 63 percent were White, 12 percent were African-American, and 22 percent were Hispanic (all
races). Eighty percent of male San Diego AIDS cases
have been attributed to male-to-male sex, 10 percent
to male-to-male sex and injection drug use, and 7
percent to injection drug use alone. For San Diego
females, heterosexual contact was the most common
mode of transmission (53 percent), followed by injection drug use.
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HIV
From July 1, 2002, to December 31, 2003, a total of
4,155 HIV cases were reported for San Diego
County. Of these, 89 percent were male, 62 percent
were White, 43 percent were age 30–39, and 72 percent were infected by male-to-male sex.
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Exhibit 1. Total Population and Population by Race/Ethnicity for San Diego County, by Percent:
2000, 2004
2000
(N=2,813,833)
55
5
9
4
27

Race/Ethnicity
White
Black or African-American
Asian
Other Race
Hispanic/Latino (of Any Race)
Median Household Income
Single Family Home Median Price

2004
(N=3,017,204)
52
5
10
4
28

$45,871

$50,543
$525,000

SOURCE: San Diego Association of Governments Census Publications

Exhibit 2. San Diego DAWN ED Sample and Reporting Information: 2004
Total Eligible
1
Hospitals

Number of Hospitals
in DAWN Sample

Total EDs in
DAWN Sample2

17

16

16

Number of EDs Reporting per
Month: Completeness of Data (%)
90–100%

50–89%

<50%

6–9

0–1

0–1

Number of EDs
Not Reporting
6–10

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005

2

Exhibit 3. Number and Percentage of Selected Items Analyzed by Forensic Laboratories in San Diego:
2004
Drug
Cocaine
Heroin
Other Opiates
Cannabis
Methamphetamine
Amphetamine
Benzodiazepines
MDMA/MDA
PCP

Number
2,259
239
344
7,888
4,248
15
241
61
27

Percent
14.3
1.5
2.2
50.0
26.9
0.1
1.5
0.4
0.2

N=15,773 items analyzed.
SOURCE: NFLIS, DEA

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

237

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—San Diego County, California

Exhibit 4. Percentages of Primary Treatment Admissions (Excluding Alcohol) for Selected Drugs in San
Diego County: 2001–2004
Drug
Cocaine
Heroin
Marijuana
Methamphetamine
Amphetamines

2001
12.1
12.3
25.9
46.7
0.6

2002
10.2
11.7
25.3
49.7
0.6

20041
8.7
25.0
17.6
45.2
0.4

2003
9.6
10.9
24.5
52.8
0.5

1

Data for 2004 are not totally compatible with data from prior years (see Data Sources).
SOURCES: San Diego County Alcohol and Drug Data System for the years 2001–2003 and the California Alcohol and Drug Data
System for 2004

Exhibit 5. Sociodemographic Characteristics and Drug Use Behaviors of San Diego County Treatment
Admissions for 4 Primary Drugs of Abuse, by Percent: 2004
Characteristic
Number
Gender
Male
Female
Age Group
25 and younger
26–34
35 and older
Race/Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic
Other
Route of Administration
Oral
Smoking
Inhalation
Injection
Other
Most Frequently Used Secondary Drugs
Cocaine/crack
Methamphetamine
Heroin
Marijuana
Alcohol
None

Cocaine/
Crack

Heroin

Marijuana

Methamphetamine

976

2,810

1,979

5,079

69.5
30.5

70.6
29.4

75.3
24.7

60.8
39.2

10.2
19.0
70.9

18.1
24.0
57.9

72.0
15.0
13.0

27.6
33.7
38.5

26.6
58.5
11.6
3.2

52.0
5.1
38.4
4.5

40.7
18.1
33.8
7.4

55.8
7.0
27.0
10.2

0.8
80.1
13.9
4.9
0.2

1.0
7.6
4.0
87.1
0.4

1.6
98.0
0.3
0.2
0.0

1.6
68.6
13.3
16.2
0.3

–
10.7
3.0
22.0
32.1
30.3

12.9
11.7
–
3.7
6.6
61.5

4.9
26.2
0.9
–
39.2
26.2

5.0
–
2.8
29.0
24.0
37.3

SOURCE: California Alcohol and Drug Data System
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Exhibit 6. Number and Percentage1 of ED Reports for Selected Illicit Drugs of Abuse (Unweighted2): 2004
Drug
Cocaine
Heroin
Marijuana
Methamphetamine
Amphetamines
MDMA
PCP
GHB

Number
558
492
641
797
388
23
23
11

Percent
18.6
16.4
21.4
26.6
12.9
0.8
0.8
0.4

1

Represents the percentage of all illicit drugs, excluding Alcohol Only cases for persons younger than 21.
The unweighted data are from 6–10 EDs reporting to San Diego hospitals in 2004. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 1/13–1/14, 2005

2

Exhibit 7. Demographic Characteristics of Patients Reporting Abuse of 4 Illicit Drugs in San Diego DAWN
1
EDs, by Percent (Unweighted ): 2004
Characteristic
Gender
Male
Female
Age Group
25 and younger
26–34
35 and older
Racer/Ethnicity
White
Black
Hispanic
Other
Not documented

Cocaine

Heroin

Marijuana

Methamphetamine

66.5
33.5

69.7
30.3

65.7
34.3

69.4
30.6

19.5
20.1
60.4

11.2
18.3
70.5

46.8
21.8
31.4

27.5
27.7
44.8

48.4
30.1
13.1
1.3
7.2

54.5
10.1
30.7
1.2
3.5

52.7
20.3
15.9
2.7
8.4

63.0
6.8
20.1
2.5
7.7

1

The unweighted data are from 6–10 EDs reporting to San Diego hospitals in 2004. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted and, therefore, are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 1/13–1/14, 2005

1
Exhibit 8. Number of Drug-Related Deaths in San Diego, by Drug: 2003

Drug
Alcohol
Illicit Drugs
Stimulants
– (Amphetamines)
– (Methamphetamine)
Heroin
Cocaine
Marijuana

Number
115
120
(41)
(118)
62
56
1

Drug
Benzodiazepines
Opiates/Narcotic Analgesics
Morphine/Combinations
Hydrocodone/Combinations
Codeine/Combinations
Methadone
Oxycodone/Combinations
Propoxyphene/Combinations
Fentanyl/Combinations

Number
121
67
44
24
23
22
19
12

1

More than one drug may be detected in a decedent.
SOURCE: San Diego Medical Examiner
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Exhibit 9. Retail Prices for Selected Drugs in San Diego: July–December 2004
Drug
Powder Cocaine
Crack
Heroin

Marijuana
Methamphetamine

MDMA

Price
$60–$80
$25–$35
$10–$20
$60–$100
$10–$15
$50–$100
$60–$100
$60
$20–$25
$150–$300
$15–$30

Unit and Type
Gram
One-quarter gram
Rock
Gram (Mexican brown powder)
One-tenth gram (Mexican brown powder)
Gram (Mexican black tar)
Ounce
Gram
One-quarter gram
One-quarter ounce
Tablet

SOURCE: National Drug Information Center
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Patterns and Trends of Drug
Use in the San Francisco Bay
Area
John A. Newmeyer, Ph.D.1
ABSTRACT
Cocaine use in the bay area remains low compared
with the rest of the United States. For the 2002–
2005 period, no consistent upward or downward
trend is evident. The cocaine user population is predominantly older than 30. Heroin indicators point
to a significant decline in use between 2000 and
2005; users remain predominantly White. The median age of heroin users remains high, perhaps as
high as 40. Local observers report that Internet trafficking in pharmaceutical opiates, such as Vicodin,
hydrocodone, and oxycodone, is ‘mushrooming.’
Indicators of marijuana use peaked in 2001 and
have declined significantly since then. Methamphetamine use is high compared with other metropolitan areas of the United States, though it may
now be leveling off after significant increases during 2001–2004. Among some vulnerable populations (youths, arrestees, gay men), ‘speed’ is far
more prevalent than heroin. Indicators of use of
‘club drugs’ reached peaks in 2001 and then declined in 2002; ED and medical examiner reports
remain few compared to those for cocaine, heroin,
or ‘speed.’ The prevalence of HIV among heterosexual drug injectors appears to have stabilized at a
low level (6 to 10 percent), but hepatitis C appears to
be close to full saturation of that population.
INTRODUCTION
Area Description
The San Francisco Bay area consists of the following
counties: San Francisco, San Mateo, Alameda, Contra Costa, and Marin. The population was 4,154,000
as of July 2004. The population is among the most
multicultural of any urban region of the United
States, with a particularly large, varied, and longestablished Asian-American representation (19 percent of the total). The Hispanic population represents
a wide cross-section of persons of Latin American
origin. Blacks account for some 11 percent of bay
area residents. San Francisco County has long been a

1
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San Francisco, California.

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

mecca for gays: gay men constitute more than 15
percent of the adult male population.
The bay area experienced its initial growth during the
California gold rush. In the succeeding century and a
half, it expanded greatly as a center for shipping,
manufacturing, finance, and tourism. In recent years,
Pacific Basin trade and high technology such as
software and biotechnology development have led to
further expansion and to a highly diversified economy.
From 1994 to 2001, there was a steep rise in the cost
of rental housing in the bay area, especially in San
Francisco, Marin, and San Mateo Counties. This
caused significant out-migration of lower income
people, which may be exerting downward pressure
on local drug-use prevalence. However, rental rates
declined significantly from 2001 to 2003, which may
have blunted these out-migration pressures. Unemployment rose from 2 to 6 percent during these 2
years, but it eased back to 5 percent in 2004 and early
2005.
Data Sources
The sources of data for the drug abuse indicators
within this report are described below:
•

Emergency department (ED) data were accessed from the Drug Abuse Warning Network
(DAWN) Live!, a restricted-access online query
system administered by the Office of Applied
Studies (OAS), Substance Abuse and Mental
Health Services Administration (SAMHSA). The
unweighted data are for three counties of the San
Francisco Bay area (San Francisco, Marin, and
San Mateo) for 2004. Seventeen of the 18 eligible hospitals in the area are in the DAWN sample. There are 19 emergency departments in the
sample (some hospitals have more than 1 ED).
The data for 2004 were incomplete. Over the 12month period, between 8 and 11 EDs reported
data each month, with most reporting data that
were basically complete (90 percent or greater)
(exhibit 1). Data are preliminary and are not estimates for the San Francisco area. The DAWN
Live! data were accessed on April 13–14, 2005.
Since all DAWN cases are reviewed for quality
control, and may be corrected or deleted, the data
reported here are subject to change. The information derived from DAWN Live! represents drug
reports in drug-related visits; reports exceed the
number of ED visits because a patient may report
use of multiple drugs (up to six drugs and alcohol may be presented in DAWN). This paper focuses on demographic characteristics of different
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drugs in drug-related visits. Race/ethnicity data
were absent in 11 to 18 percent of the total cases
within a drug category; percentages are shown
for those whose race/ethnicity is known. These
data cannot be compared with DAWN data from
2002 and before, nor can these preliminary data
be used for comparison with future data. Only
weighted ED data released by SAMHSA can be
used for trend analysis. A full description of the
DAWN system can be found at the DAWN Web
site http://dawninfo.samhsa.gov.
•

•

•

Treatment admissions data were available for
all five bay area counties for 1999 through 2004.
These data were compiled by the California Department of Alcohol and Drug Programs
(DADP). In addition, admissions data for San
Francisco County were provided by the San
Francisco Department of Public Health for fiscal
years (FYs) 2000 through 2004.
Medical examiner (ME) data on drug mentions in decedents in three counties (San Francisco, Marin, and San Mateo) were provided by
the DAWN mortality system for 2002, along
with comparable data for 1997–2001. The
DAWN system covered 100 percent of the metropolitan statistical area (MSA) jurisdiction and
100 percent of the MSA population in 2002.
Data were also available from the San Francisco
County Medical Examiner for that county for
FYs 2000 and 2003.
Reports of arrests for drug law violations and
counts of reported burglaries were provided by
the San Francisco Police Department (SFPD) for
2001 through the first 4 months of 2005.

•

Arrestee drug testing data are from the Arrestee Drug Abuse Monitoring (ADAM) program, National Institute of Justice, for San Jose
and Sacramento for 2003 for adult males and for
San Jose for adult females.

•

Price and purity data came from the Drug Enforcement Administration (DEA), Domestic
Monitor Program (DMP), and referenced heroin
“buys,” mostly made in San Francisco County.
Data for 2003 were compared with those for
1994–2002. Data on trafficking in heroin and
other drugs were available from the National
Drug Intelligence Center’s (NDIC) report, Narcotics Digest Weekly, December 28, 2004. Additional data on trafficking and production were
provided by the National Drug Threat Assessment 2005 publication of the NDIC.
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•

Ethnographic information was obtained through
interviews with treatment program staff and outreach workers in June 2005. Their observations
were compared with those they made in May
2004 and January 2005 and pertained mostly to
San Francisco County.

•

Acquired immunodeficiency syndrome (AIDS)
surveillance data were provided by the San Francisco Department of Public Health (SFDPH) and
covered the period through March 31, 2005. Beginning in 2005, the SFDPH provided counts only
of AIDS cases who were San Francisco residents;
this resulted in surveillance counts about oneeighth less than previous counts, which had included all persons, resident or non-resident, diagnosed in San Francisco.

•

A survey of younger gay men was conducted by
the San Francisco AIDS Office during 2004. Sixty
percent of this sample were younger than 35.

•

Hepatitis B (HBV) data for San Francisco
County were available for 1996 through 2004 and
were provided by the SFDPH.

•

Hepatitis C (HBC) virus prevalence estimates
were provided by the Urban Health Study for
2003.

DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
Local observers note an upsurge in crack use among
young (under 30) San Franciscans. Some of these
young people prefer to dissolve this cocaine for injection, instead of smoking it.
During 2004, there were almost twice as many unweighted DAWN Live! reports of cocaine as of heroin (2,456 vs. 1,278). The patient characteristics for
cocaine reports in 2004 were predominantly Black
(49 percent) and 65 percent male. There were twice
as many older than 45 (35 percent) as younger than
30 (17 percent). Smoking was the preferred route of
use for three-fifths of these patients.
In the five-county bay area, the overall number of
admissions for drug treatment, other than alcohol,
declined steadily between 1999 and 2004 (exhibit 2).
The proportion of cocaine/crack admissions among
these admissions rose from 24 percent to 26 percent
between 2001 and 2004, although the actual number
declined from 7,428 to 6,814. Among these admissions, more than 87 percent cited smoking—
presumably of crack—as the preferred route of use.
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During FYs 2000 to 2004, San Francisco County cocaine admissions fluctuated narrowly, with no particular trend, in the range of 2,250 to 2,600 (exhibit 3).
According to DAWN data, ME death mentions involving cocaine in three bay area counties fluctuated
within a narrow range, with no particular trend, between 1997 and 2000 (exhibit 4). In 2002, however,
total mentions were 39 percent below the 1997–2000
average. In San Francisco County, cocaine-related
deaths declined by 28 percent (95 to 68) between FY
2000 and FY 2003. In FY 2003, these decedents were
79 percent male, 49 percent White, and 33 percent
Black; they had a mean age of 40.
Cocaine-positive tests among arrestees in San Jose
and Sacramento, nearby metropolises which are
ADAM sites, may give some indication of cocaine
use prevalence in San Francisco. During 2003, 13
percent of adult male arrestees in San Jose and 22
percent of those in Sacramento tested positive for
cocaine. The two areas had, respectively, the fourth
and ninth lowest proportions of cocaine-positive arrestees among all 39 ADAM sites. For adult female
arrestees in San Jose, 10 percent tested positive—the
second lowest proportion among 25 ADAM sites.
A 2004 survey of young San Francisco gay men
showed 17 percent reported use of cocaine in the past
year, and 4 percent reported use of crack.
There were nearly 3,800 arrests on cocaine-related
charges in San Francisco in 2004. The rate of arrests
in the first 4 months of 2005 was about 12 percent
less than during a similar period of 2004.
According to the NDIC, local prices for powder cocaine in 2004 were $16,000–$21,000 per kilogram,
$530–$800 per ounce, and as low as $10 per quarter
gram. Crack prices were around $600 per ounce and
$20–$50 per “rock.” These prices were up slightly
from 2002.
In summary, cocaine use in the bay area remains low
compared with the rest of the United States. For the
2002–2005 period, no consistent upward or downward trend is evident from the indicators. The user
population is predominantly older than 30.
Heroin
Ethnographic observers note that young people seem
to represent a larger portion of heroin users, although
most users are well past age 35. Whites still predominate over all other ethnicities.
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ME death mentions involving heroin in 2002 were at
their lowest level in 6 years (exhibit 4). The count for
2002 was 43 percent below the average for 1997–
2000. Males accounted for 87 percent of the heroinrelated death mentions in 2000. The median age of
the decedents was 40. Heroin-related deaths in San
Francisco County declined by 37 percent (122 to 77)
between FY 2000 and FY 2003. In FY 2003, decedents were 79 percent male, 67 percent White, and 22
percent Black; they had a median age of 40.
According to preliminary unweighted DAWN Live!
data, reports of heroin during 2004 were two-thirds
male and 59 percent White. Thirty-nine percent were
older than 45 and only 18 percent were younger than
30. For some 93 percent, injection was the preferred
route of use.
The number of treatment admissions for primary heroin problems in the five-county bay area fell by more
than one-half between 1999 and 2004 (exhibit 1). As
a proportion of all primary drug admissions excluding alcohol, heroin constituted 64 percent in 1994, 55
percent in 1999, and only 34 percent in 2004. Injection remains by far the predominant route of use: 80
percent reported that route, compared with 14 percent
who reported inhalation as the preferred route. San
Francisco County heroin admissions fell by 9 percent
between FYs 2002 and 2004 (exhibit 3).
In the ADAM program in 2003, 3.1 percent of adult
male arrestees in San Jose and 6.9 percent of those in
Sacramento tested opiate positive; the median across
the 39 ADAM sites was 5.8 percent. Among female
arrestees in San Jose, 3.4 percent tested positive, well
below the 25-city median of 6.6 percent.
A 2004 survey of young San Francisco gay men
showed only 0.4 percent reported use of heroin in the
past year.
Arrests for heroin-related offenses totaled 6,136 in
2002, 16 percent higher than in 2001 and 3 percent
higher than in 2000. However, in 2003, such arrests
were about 30 percent below, and in 2004 about 55
percent below, the 2002 level. The rate of arrests in
the first 4 months of 2005 showed a significant further decline.
Because many heroin users support their habits
through property crimes, reported burglaries may be
a good indicator of use. The number of such reports
in San Francisco fell by 49 percent between 1993 and
1999 (11,164 to 5,704). After that low point, the
count rose to 6,706 in 2001, fell to 5,507 in 2003, and
rose again to nearly the 2001 level in 2004. The rate
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for the first 4 months of 2005 was higher by 10 percent than that for a similar period of 2004. These
changes may reflect the price of heroin more than the
prevalence of users; it is noteworthy that reported
burglaries and the local price of heroin are both
barely one-quarter of what they were 20 years ago.
The DEA’s DMP tested heroin street buys in the San
Francisco area during 2003. The 27 buys were all of
Mexican origin. The 2003 samples averaged 11 percent pure and $0.98 per pure milligram (exhibit 5).
Of the last 10 years, 2001, 2002, and 2003 were the 3
with the highest average price and lowest average
purity.
Prices of Mexican black tar heroin ranged from
$9,200 to $30,000 per kilogram and from $230 to
$850 per ounce in 2004. Gram prices ranged from
$50 to $75. In 2002, prices were $16,000–$30,000
per kilogram, $450–$850 per ounce, and around $60
per gram.
To summarize, most indicators point to a significant
decline in heroin use in the period from 2000 to 2005.
Users remain predominantly White. There are indications of more younger users, but the median age of
users remains high, perhaps as high as 40.

juana. The median across the 39 ADAM sites was 44
percent. Among female arrestees in San Jose, 29 percent tested positive, near the 25-site median of 32
percent.
Marijuana treatment admissions in San Francisco
County reached a peak in FY 2003, then dropped by
14 percent in FY 2004 (exhibit 3).
In 2004, sinsemilla marijuana sold for $3,000–$6,000
per pound, and domestic marijuana sold for $4,000–
$5,000 per pound. Domestic marijuana sold for about
$200 per ounce. A large, and increasing, quantity of
marijuana is sold legally from medical marijuana
outlets to certified purchasers. There appears to be
effective regulation of price and quality in that new
“market.”
In November 2004, Oakland voters passed Measure
Z by a margin of 65 percent to 35 percent. This may
portend an important development in American policy on marijuana, in that Measure Z explicitly instructs the city of Oakland to create systems for the
regulation and taxation of adult use of marijuana.
The overall indications are that marijuana use peaked
in 2001 and has declined significantly since then.

Other Opiates

Stimulants

Local observers state that Internet trafficking in
pharmaceutical opiates is “mushrooming.” Vicodin is
the most frequently cited in this regard; Tylenol-withcodeine is also prominent. Sources appear to be “all
over” the world—mostly outside of the United States.
ME death mentions in the overall “narcotic analgesics” category fluctuated within a narrow range in
1997–2000, but then they dropped in 2001 and 2002
to a level 29 percent below the 1997–2000 average
(exhibit 4). The combined count of hydrocodone and
oxycodone DAWN ED reports during 2004 was 14
percent that of heroin. The hydrocodone count was
nearly twice that of oxycodone.

Local observers report that the “speed” scene has
leveled off after the increases of recent years. White
users predominate, though there has been a recent
surge in use among Filipinos. Gay males remain a
very prominent portion of the user population, but not
so much as in the past.

Marijuana
Arrests for marijuana-related offenses in San Francisco County numbered 1,736 in 2000. The count of
arrests ranged between 1,300 and 1,450 in the next 3
years before returning to the 2000 level in 2004. The
count of arrests for 2005 will be about one-quarter
lower than that for 2004, if the trend from the January–April period is sustained.
Among adult male arrestees in the ADAM program
in 2003, 35 percent of those in San Jose and 49 percent of those in Sacramento tested positive for mari-
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In the three-county bay area, ME death mentions involving methamphetamine fell from 58 in 1999 to 32
in 2001 and 38 in 2002 (exhibit 4). Of the methamphetamine-related death mentions in 2000, males
accounted for 93 percent, and the median age was 40.
Amphetamine-related deaths in San Francisco
County increased by 87 percent (15 to 28) between
FY 2000 and FY 2003. In FY 2003, decedents were
83 percent male and 70 percent White; they had a
median age of 38.
Nearly as many preliminary unweighted methamphetamine reports as heroin reports (1,092 vs. 1,278)
were recorded in the DAWN Live! system during
2004. Four-fifths of the patients involved in methamphetamine ED reports in 2004 were male, two-thirds
were White, and fully 68 percent were older than 30.
The number of treatment admissions for primary
speed problems in the five-county bay area increased
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steadily between 1999 and 2004 (exhibit 2). The proportion of primary speed users among all nonalcohol
drug admissions rose from 13 percent in 1999 to 25
percent in 2004. It was noteworthy that fully 64 percent of speed users claimed smoking as the preferred
route; the proportions reporting injection or inhalation as preferred routes were each about one in six.
Amphetamine treatment admissions in San Francisco
County rose steadily from FY 2001 to FY 2004, with
the later year’s count 25 percent higher than the earlier year’s.

2003–2004 were mostly White (77 percent), male (63
percent), and older than 35 (69 percent). ME mentions dropped from a 1999–2001 average of 54 to 34
in 2002 (exhibit 4).

Two nearby metropolises that are ADAM sites may
give some indication of the methamphetamine situation in San Francisco. In Sacramento and San Jose,
respectively, 38 and 37 percent of male adult arrestees tested positive for methamphetamine in 2003.
These were the third and fourth highest proportions
of methamphetamine-positives among male adults in
all the 39 ADAM sites. Among the female arrestees,
45 percent tested positive, the fourth highest among
25 ADAM sites.

Club Drugs

A 2004 survey of young San Francisco gay men
showed 21 percent reported use of methamphetamine
in the past year.
According to the NDIC, in 2004 pounds of “crystal”
methamphetamine sold in the $10,000–$13,000
range, ounces in the $600–$1,500 range, and grams
in the $80–$100 range. In 1999, comparable price
ranges were $3,500 to $10,000 for pounds and $500
to $1,000 for ounces. The DEA San Francisco Field
Division reports that Mexican criminal groups control the local wholesale and midlevel distribution.
Several counties near the bay area (Alameda, San
Mateo, Santa Clara, Sacramento, San Joaquin, and
Stanislaus) have been sites of “superlabs,” capable of
producing 10 pounds or more of methamphetamine
per production cycle. The National Drug Threat Assessment surveys indicate that Mexican criminal
gangs control most wholesale and midlevel distribution, though Hawaiian, Filipino, and other Asian drug
trafficking organizations produce and distribute significant quantities of “ice.”
Methamphetamine use in the bay area is high compared with other metropolitan areas of the United
States. Among some vulnerable populations (youths,
arrestees, gay men) “speed” is far more prevalent than
heroin. There are indications of a leveling off after
significant increases during the 2001–2004 period.
Depressants

Hallucinogens
Lysergic acid diethylamide (LSD) ED reports among
the preliminary unweighted DAWN Live! data were
rare during 2004. Reports of phencyclidine (PCP)
were about five times more common.

The NDIC reports that in 2004, street prices of methylenedioxymethamphetamine (MDMA or “X”)
were in the range of $15–$40 per “tab.” The preliminary unweighted Dawn Live! ED reports of this drug
were predominantly (69 percent) among people
younger than 30. A 2004 survey of young San Francisco gay men showed 20 percent reported use of
MDMA in the past year. ED reports of gamma hydroxybutyrate (GHB) were on average older, with 64
percent older than 30. Ketamine reports were very
rare. The actual number of club drug ED mentions
remains small compared with mentions for cocaine or
methamphetamine. The same is the case for club drug
ME mentions (exhibit 4).
INFECTIOUS DISEASES RELATED TO DRUG ABUSE
AIDS
San Francisco County had a cumulative total of
26,117 AIDS cases among city residents through
March 31, 2005. Of these cases, 1,911 (7.3 percent)
were heterosexual injection drug users (IDUs). Another 3,572 AIDS cases (13.7 percent) were among
men who have sex with other men (MSM) and also
injected drugs. There were just 42 reported cases
among lesbian IDUs, barely one-hundredth the number among MSM/IDUs. A total of 321 AIDS cases
have been reported for transgender San Franciscans.
Among San Franciscans diagnosed in 2003 through
2005, heterosexual IDUs accounted for 15 percent,
up from 10 percent among those diagnosed in 1994–
1996, 14 percent of those diagnosed in 1997–1999,
and 14 percent of those diagnosed in 2000–2002.
However, the overall case numbers in 2003–2004
were far lower than those of the late 1980s and early
1990s. As a result, the percentage of heterosexual
IDUs among the cumulative AIDS caseload will
probably not increase significantly from the current
level of 7 percent.

According to preliminary unweighted data accessed
from DAWN Live!, ED reports of benzodiazepines in
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The demography of the cumulative heterosexual IDU
caseload with AIDS has changed very little in the
past 14 years. This caseload is 68 percent male, 51
percent Black, 35 percent White, 11 percent Hispanic, and 2 percent Asian/Pacific Islander. By contrast, the gay/bisexual IDU caseload is 71 percent
White, 16 percent Black, 10 percent Hispanic, and
1.5 percent Asian/Pacific Islander.
The heterosexual IDU demography is like that of
heroin users except for over-representation of Blacks,
while the gay male IDU demography is similar to that
for male speed users.
Data from the Urban Health Study (UHS), which
conducts semiannual surveys, indicate that in 2004,
seroprevalence of heterosexual IDUs in San Francisco remained within the same 6–10 percent range
that has prevailed for the past 16 years. By contrast,
HIV prevalence among MSM/IDUs had ranged
around 40 percent in the late 1980s, dropped to
around 25 percent in the late 1990s, and rose again to
the 30–35 percent range in 2004. Recent UHS data
show extensive self-reported past-month injection of
cocaine (21 percent) and amphetamines (30 percent)
as well as heroin (68 percent). A surprisingly low
proportion (c. 15 percent) of heterosexual HIVpositive IDUs reported being on drug treatment for
their condition.
Passage of SB1159, which enables California pharmacies to sell hypodermic equipment without prescriptions, has the potential for significant effects
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upon disease transmission. Many large pharmacies
have decided to opt into this activity.
Hepatitis B Virus
From 1997 through 2001, reported cases of HBV in
San Francisco County rarely deviated from a pace of
a bit more than one per week. The pace dropped in
2002 and 2003 to about one every 10 days, then
dropped further in 2004 to about one every 14 days.
Hepatitis C Virus
UHS data from 2003 disclosed that fully two-thirds
of all IDUs in the sample self-reported HCV seropositivity. UHS staff believe, on the basis of earlier
HCV antibody testing, that true prevalence is between 90 and 95 percent. This has enormous implications for the long-term health of San Francisco’s IDU
population—not only the current user population
estimated at 18,700, but also the possibly much larger
number with past (or future) injection drug use.
“Coinfection” is also a serious problem; a 2003 study
by the University of California at San Francisco
found that 73 percent of homeless and marginally
housed people with HIV were also infected with
hepatitis C.
For inquiries concerning this report, please contact John A.
Newmeyer, Ph.D., Haight-Ashbury Free Clinics, Inc., 612 Clayton
Street, 2nd Floor, San Francisco, CA 94117, Phone: (415) 9315420, Fax: (415) 864-6162, E-mail: jnewmeyer@aol.com.
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Exhibit 1.

San Francisco DAWN ED Sample and Reporting Information: January–December 2004

CEWG Area

Total Eligible
Hospitals1

San Francisco

18

No. of
Hospitals in
DAWN
Sample
17

No. of EDs Reporting per Month:
Completeness of Data (%)

Total EDs in
DAWN
Sample2
19

90–100%

50–89%

<50%

No. of
EDs Not
Reporting

7–10

0–1

0–3

8–11

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005

2

Exhibit 2.

Admissions to Drug Treatment Programs in the San Francisco Bay Area, by Primary Drug of
Abuse: 1999–2004

Drug
Cocaine
Heroin
Amphetamine
All Drugs

1999
8,727
19,763
4,595
36,069

2000
7,718
17,416
4,469
32,034

2001
7,428
14,673
5,073
30,920

2002
6,746
11,461
5,636
28,329

2003
7,114
9,898
6,438
27,626

2004
6,814
9,089
6,701
26,381

SOURCE: California Department of Alcohol and Drug Programs (DADP)

Exhibit 3.

Admissions to Drug Treatment Programs in San Francisco County, by Primary Drug of Abuse:
FYs 2000–2004

Drug
Cocaine
Heroin
Amphetamine
Marijuana
All Drugs

FY 2000
2,600
4,030
1,008
915
8,690

FY 2001
2,306
3,867
991
867
8,191

FY 2002
2,440
4,002
1,053
1,067
8,764

FY 2003
2,274
3,700
1,144
1,110
8,406

FY 2004
2,527
3,646
1,235
950
8,520

SOURCE: San Francisco Department of Public Health

Exhibit 4.

Medical Examiner Drug Mentions in Three Counties (Including San Francisco): 1997–2002

Drug
Cocaine
Heroin/Morphine
Methamphetamine
Narcotic Analgesics
Benzodiazepines
Club Drugs1

1997
127
159
49
156
71

1998
158
164
45
185
62

1999
158
192
58
198
50
6

2000
146
148
45
164
55
6

2001
106
117
32
124
56
5

2002
90
95
38
125
34
4

1

Includes MDMA, ketamine, GHB, GBL, and Rohypnol
SOURCE: DAWN, OAS, SAMHSA
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Exhibit 5.

Price and Purity of Heroin Samples, 1994-2003
Year
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003

Price Per Pure Milligram
$0.95
$0.83
$0.83
$0.63
$0.33
$0.47
$0.70
$1.40
$0.99
$0.98

Purity (Percent)
29
35
24
26
26
20
15
10
12
11

SOURCE: Drug Enforcement Agency, Domestic Monitor Program
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Recent Drug Abuse Trends in
the Seattle-King County Area
Caleb Banta-Green,1 T. Ron Jackson,2
Michael Hanrahan,3 Susan Kingston,3 David
H. Albert,4 Steve Freng,5 Ann Forbes,6
Richard Harruff,7 Richard Burt,8 and Hanne
Thiede8
ABSTRACT
The total number of drug-involved deaths increased
36 percent in 2004, due primarily to cocaine, prescription-type opiates, and prescription and over-thecounter depressants/anxiolytics/sedatives. Cocaineinvolved deaths are at their highest level in at least
10 years, with 92 cocaine-involved deaths in 2004.
Cocaine is the most common illegal drug among ED
reports. Treatment admissions for heroin are beginning to increase, along with the increased treatment
capacity. Heroin-involved deaths totaled 75 in 2004,
up a bit from 2003 but well below the peak of 144 in
1998. Deaths and treatment admissions involving
prescription-type opiates continue to rise steadily.
Methamphetamine mortality indicators have leveled
off in King County, while treatment admissions have
begun to increase again. Negative consequences related to prescription stimulants appear low, but the
number of prescriptions has increased substantially,
and anecdotal reports of youth and young adult misuse are common. Marijuana is widely used, particularly by youth. Prescription depressant-involved
deaths increased substantially. In 2004, 1 in 5 drugrelated deaths involved the combination of prescription-type opiates and depressants (and usually other
drugs as well). Hepatitis B and C infect the majority
of IDUs. HIV among IDUs is generally low, with the
exception of methamphetamine-injecting men who
have sex with men.
INTRODUCTION
Area Description
Located on Puget Sound in western Washington, King
County spans 2,130 square miles, of which the city of
Seattle occupies 84 square miles. The combined ports of
The authors affiliations are as follows:
1
Alcohol and Drug Abuse Institute, University of Washington
2
Evergreen Treatment Services
3
HIV/AIDS Program, Public Health – Seattle & King County
4
Division of Alcohol and Substance Abuse, Washington State Department of Social and Health Services
5
Northwest High Intensity Drug Trafficking Area
6
Washington State Alcohol and Drug Help Line
7
Medical Examiner’s Office, Public Health – Seattle & King County
8
HIV/AIDS Epidemiology, Public Health – Seattle & King County
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Seattle and nearby Tacoma make Puget Sound the
second largest combined loading center in the United
States. Seattle-Tacoma International Airport, located
in King County, is the largest airport in the Pacific
Northwest. The Interstate 5 corridor runs from Tijuana, Mexico, in the south, passes through King
County, and continues northward to Canada. Interstate 90’s western terminus is in Seattle; it runs east
over the Cascade Mountain range, through Spokane,
and across Idaho and Montana.
According to the 2000 census, the population of
King County is 1,737,034. King County’s population is the 12th largest in the United States. Of
Washington’s 5.9 million residents, 29 percent live
in King County. The city of Seattle’s population is
563,374; the suburban population of King County is
growing at a faster rate than Seattle itself.
The county’s population is 75.7 percent White, 10.8
percent Asian/Pacific Islander, 5.5 percent Hispanic,
5.4 percent African-American, 0.9 percent Native
American or Alaska Native, 0.5 percent Native Hawaiian and Other Pacific Islander, and 2.6 percent
“some other race.” Those reporting two or more
races constitute 4.1 percent of the population. Income statistics show that 8.0 percent of adults and
12.3 percent of children in the county live below the
Federal poverty level, lower than the State averages
of 10.2 percent and 15.2 percent, respectively.
Data Sources
Information for this report was obtained from the
sources described below:
•

Emergency department (ED) drug data were
obtained from the DAWN Live! restrictedaccess online query system administered by the
Drug Abuse Warning Network (DAWN), Office of Applied Studies (OAS), Substance
Abuse and Mental Health Services Administration (SAMHSA). Preliminary unweighted data
for 2004 are presented. Eligible hospitals in the
Seattle area total 22; hospitals in the DAWN
sample number 22, with the number of emergency departments in this sample totaling 23.
(Some hospitals have more than one ED.) During this 12-month period, between 10 and 13
EDs reported data each month. The completeness of data reported by participating EDs varied by month (see exhibit 1). Exhibits in this
paper reflect cases that were received by
DAWN as of April 13–14, 2005, unless otherwise noted. All DAWN cases are reviewed for
quality control. Based on this review, cases may
be corrected or deleted. Therefore, the data in
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this paper are subject to change. Data derived from
DAWN Live! represent drug reports in drug-related
ED visits. Drug reports exceed the number of ED
visits, since a patient may report use of multiple
drugs (up to six drugs plus alcohol). These data are
preliminary, meaning that they may change. Data
represent unweighted drug reports and are not estimates or rates for the reporting area. Data are utilized for descriptive purposes only. Data cannot be
compared to DAWN data from 2002 and before,
nor can preliminary data be used for comparison
with future data. Only weighted data released by
OAS may be used for trend analyses. Available
data are for King and neighboring Snohomish
Counties combined, Pierce County is part of the
statistical sample, but no EDs in Pierce were reporting during 2004. There are new case types in
DAWN, with the primary one presented here being
the “other” case type, which includes “all ED visits
related to recreational use, drug abuse, drug dependence, withdrawal, and any misuse” not classified in other categories such as over-medication
and seeking detox/treatment. For the sake of clarity
“other” will be referred to as “drug abuse/other” in
this report. Unless specifically stated, data presented are for the drug abuse/other case type. A full
description of the DAWN system can be found
online at http://dawninfo.samhsa.gov.
•

Treatment data were extracted from the Washington State Department of Social and Health
Services, Division of Alcohol and Substance
Abuse’s Treatment and Assessment Report Generation Tool (TARGET) via the Treatment Analyzer system. TARGET is the department’s statewide alcohol/drug treatment activity database system. Data were compiled for King County residents from January 1, 1999, through December
31, 2004. Data are included for all treatment admissions that had any public funding. Department
of Corrections (only a few cases) and private pay
clients (at methadone treatment programs) are
also included. Methadone waiting list data for
those seen at syringe exchanges are administered
and provided by Public Health—Seattle & King
County (PHSKC).

•

Drug-related mortality data were provided by the
King County Medical Examiner (ME). Data for
2004 are preliminary. The data include deaths directly caused by licit or illicit drug overdose and
exclude deaths caused by antidepressants in isolation and by poisons. Totals may differ slightly from
drug death reports published by the King County
ME’s office, which include fatal poisonings. Testing is not done for marijuana. Because more than
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one drug is often identified per individual drug
overdose death, the total number of drugs identified exceeds the number of actual deaths. A correction to the coding for alcohol-involved deaths
was made in August 2005. Data from 1997–2000
previously under-reported the number of deaths
in which alcohol was identified.
•

Toxicology and driving under the influence
(DUI) data were provided by the Washington
State Patrol’s Forensic Toxicology Laboratory
for methamphetamine-involved cases. Note that
the laboratory’s identification of a substance in
a death is not equivalent to the medical examiner’s ruling that a drug was causative in the
death. The toxicology lab is reporting on
chemical analysis for cases, whereas the ME’s
office utilizes these data along with their own
investigation to make a ruling as to the cause of
death. The number of positive toxicology cases
for a substance will invariably surpass the number of deaths ruled to be caused by a substance.

•

School drug use survey data are available from
the Seattle Public School’s Communities That
Care survey for 2002 and 2004. Response rates
were 50 percent in 2002 and 60 percent in 2004.
Trends cannot be determined from these data.

•

Prescription drug sales data are extracted from
the Drug Enforcement Administration’s Automation of Reports and Consolidated Orders
System (ARCOS) reports. The data provide retail drug distribution data by ZIP Code, covering primarily sales to hospitals and pharmacies.
ARCOS data presented here are for the 3-digit
ZIP Code areas of 980 and 981, which roughly
correspond with King County boundaries. The
population in these two ZIP Code areas is
1,969,348, compared with 1,737,034 for King
County in 2000. Available data report the
“grams of active ingredient” by year; this is
complicated to translate into the number of prescriptions or users, so data are reported in terms
of proportional change over time.

•

Methamphetamine production data are from
the Washington State Department of Ecology
(DOE), which is mandated to respond to and
document all “Methamphetamine Incidents,”
including operating labs, dump sites, and other
sites associated with the manufacture of
methamphetamine.

•

Forensic drug analysis data are from the National Forensic Laboratory Information System
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(NFLIS), which distributes data from the Washington State Patrol’s Toxicology Laboratory on
drug test results on local law enforcement seizures. These data include the top 25 drugs identified in fiscal year (FY) 2003 and FY 2004. Data
are presented for the Seattle-area lab in comparison to the rest of the State.
•

Data on infectious diseases related to drug use
and injection drug use, including the human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), and hepatitis, were
provided by three sources. One source is “HIV/
AIDS Epidemiology Report.” Data on HIV and
AIDS cases (including exposure related to injection
drug use) in Seattle-King County, other Washington counties, and Washington State (2001
through 2004) are provided by PHSKC, the Washington State Department of Health. HIV cases were
reported to PHSKC or the Washington State Department of Health between 2000 and 2004. The
third source of information, on 18–30-year-old injecting drug users’ preferred drugs over time, was
provided by the HIV epidemiology unit of PHSKC.
These data are based upon four studies conducted
from 1994 to 2003; they included the RAVEN
(1994–1997), RAVEN II (1998), Kiwi (1998–
2002) and DUIT (2002–2003) studies.

•

Syringe exchange data on the number of syringes exchanged and the number of encounters
with clients are provided by PHSKC’s HIV/AIDS
program.

•

Drug-related helpline data are from the Washington State Alcohol/Drug Help Line (ADHL), which
provides confidential 24-hour telephone-based
treatment referral and assistance for Washington
State. Data are presented for January 2001 to December 2004 for calls originating within King
County. Data presented are for drugs mentioned. A
caller may refer to multiple drugs; therefore, there
are more drug mentions than there are calls. The
data exclude information on alcohol and nicotine,
which account for more than one-half of the calls.
Data are presented primarily for illicit drugs only,
prescription drugs have not been coded consistently
over time, therefore limiting trend analyses. The
large number of unknown drugs in 2001 and 2002
may obscure some trends as well.

•

Key informant interview data are obtained from
discussions with treatment center staff, street outreach workers, and drug users.
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DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
The proportion of treatment admissions involving
cocaine (i.e., cocaine was mentioned as the primary,
secondary, or tertiary drug of abuse at the time of entry into treatment) increased for the first time in several years from 38.7 percent in 2003 to 40.1 percent in
2004 (exhibit 2a). Those entering treatment were older
in 2004 than those entering in 1999, with 22.6 percent
age 45–54 in 2004, compared with 10.4 percent in
1999 (exhibit 2b). Use is quite low among those
younger than 18: less than 3 percent in both years. The
largest group remained those age 30–44, representing
60 percent of admissions in 2004.
Unweighted cocaine ED drug reports for all case types
totaled 2,725 in 2004, more than those for heroin,
marijuana, and methamphetamine (exhibits 3a and
3b). For cocaine, drug abuse/other represented the
largest proportion of case types (89 percent), followed
by those seeking detox/treatment (10 percent). Almost
two-thirds were male, with almost as many Blacks as
Whites (note substantial missing data). They were an
older group, with 38 percent age 35–44 and 22 percent
age 45–54. Psychiatric conditions (24 percent) were
the predominant complaint, followed by altered mental status (16 percent). Route of administration data
were missing for 73 percent of reports, with 13 percent smoking, 10 percent injecting, and 2 percent inhaling/sniffing/snorting.
Cocaine was the most common drug mentioned by
adults calling the ADHL, representing 32 percent of
calls in 2004 (exhibit 4). For youth, 12 percent of calls
were for cocaine in 2004.
Cocaine was not commonly used by high school
seniors in the past 30 days (exhibit 5). Use levels
were 1.7 percent in 2002 and 2.5 percent in 2004
(not significantly different).
Cocaine was the most common substance identified
in the Seattle area according to NFLIS data on local
law enforcement drug seizure testing (exhibit 6).
Cocaine was the second most common drug detected in the laboratories for the rest of the State,
with about one-half of the level found in the Seattlearea lab. Minimal change occurred in the proportion
of cocaine-positive tests from FY 2003 to FY 2004.
Cocaine-involved deaths are at their highest level in
at least 10 years, with 92 cocaine-involved deaths in
2004 (exhibit 7a). The most common drugs com-
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bined with cocaine included heroin, representing 14
percent of all drug-involved deaths, prescription-type
opiates (10 percent), and depressants/sedatives/ anxiolytics (9 percent) (exhibit 7e). Twenty-one deaths involved only cocaine in 2004, accounting for 23 percent of all cocaine-involved deaths. The number and
proportion of cocaine-only deaths is second only to
2000, when 31 of 89 (35 percent) cocaine-involved
deaths were from cocaine only.
More than three-quarters of cocaine-involved decedents
were male, a higher proportion than for all drug deaths
(exhibit 7d). The average age for cocaine decedents
(41.2) was similar to the age for all drug decedents and
increased from 39.7 to 43.3 from 1997 to 2004. A disproportionate number of decedents were AfricanAmerican, 21 percent, higher than 11 percent for all
drugs and much higher than the county’s overall African-American population. Almost all deaths were ruled
accidental (94 percent).
The level of cocaine indicators is disproportionately high
for African-Americans relative to their representation in
King County. Though African- Americans represent
approximately 5 percent of the county’s population, they
represent 21 percent of cocaine-involved deaths, 47 percent of cocaine treatment admissions (exhibit 2c), and 42
percent of cocaine ED reports. Note that even though
African-Americans are overrepresented in the ED (26
percent of reports with race documented) and in treatment (22 percent of admits), their levels of cocaine use
are still disproportionately high.
The Seattle DEA field division reports that powder
cocaine availability is increasing. They also have noticed increasing availability of crack in smaller communities in Washington State.
Heroin
The proportion of treatment admissions involving any
use of heroin increased after several years of decline,
from 19.8 percent in 2003 to 21.6 percent in 2004 (exhibit 2a). Opiate treatment program capacity was substantially increased in the later part of 2004; there
were 673 admissions in the first half of 2004 and 997
in the second half. The caseload increased by approximately 200 from January to December of 2004 to
a total of 2,536 in public and private pay programs
governed by King County. Heroin users are older than
other drug users entering treatment on average and
they continued to get older during the timeframe from
1999 to 2004; the proportion of those age 45–54 increased from 27 to 34 percent (exhibit 2b). An increase was also seen among those age 55–64, from 3
to 6 percent of admissions involving heroin.
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Among those entering opiate substitution treatment,
the proportion reporting heroin as their primary drug
decreased from 95 to 87 percent from 1999 to 2004
(exhibit 8).
Heroin/opiate/morphine-involved deaths increased
in 2004 to 75; only 2 years had lower numbers since
1997 (exhibit 7a). (The category of heroin/opiate/
morphine is the best approximation of heroin deaths;
it excludes all deaths known to involve specific prescription-type opiates.) Heroin/opiate/morphine
combination deaths most commonly involved cocaine (14 percent of all drug- involved deaths), alcohol (8 percent), a depressant/anxiolytic/sedative
(8 percent), and prescription-type opiates (6 percent)
(exhibit 7e). In 2004, 17 percent of heroin/opiate/morphine-involved deaths had no other drug
present, slightly lower than the 20 percent average
for all years.
Heroin/opiate/morphine-involved decedents were
male 81 percent of the time, the highest proportion
for any substance (exhibit 7d). The average age of
40.6 was slightly lower than for all drugs, and that
average increased substantially from 38.0 to 43.8
from 1997 to 2004. Eighty-four percent of decedents
were White, and 10 percent were African-American.
The vast majority of deaths were ruled accidental: 92
percent. The average number of drugs involved was
2.4, similar to the average for all drugs (2.3). (Note
that heroin/opiate/morphine-involved deaths constituted almost one-half of all deaths, so the averages for
all deaths are heavily influenced by these data.)
The waiting list for methadone treatment programs
(which primarily use methadone) was at 487 at the
end of 2004 and 156 by June 2005 (exhibit 9). Recent increases in treatment capacity have resulted in
this decreased number on the waiting list.
The predominant form of heroin on the streets is
Mexican black tar. All DEA DMP buys of heroin
that have been positively identified were found to be
Mexican in origin. China white, a common form in
Vancouver, British Columbia, and on the east coast
of the United States, is uncommon in the local area
according to regional HIDTA and DEA information.
Historically, DMP data were reported for the Seattle
area, which included buys in Seattle and Tacoma,
and just the average purity was reported. Preliminary data for the Seattle area showed a spike in the
average purity of heroin for the Seattle area. The
Seattle DEA Field Division provided additional detailed data that included the city of purchase as well
the purity for each buy. This allowed the computation of medians in addition to averages. These de-
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tailed data revealed that the median heroin purity of
DMP buys in the city of Seattle was 14 percent in FY
2004, similar to the prior year, higher than in FY
2001–2002, and below the 17 percent seen in FY 2000
(exhibit 10). Most important are the four purchases in
FY 2004 that ranged from 37 to 46 percent pure; this
is a much larger range and higher purity than seen in
the prior 3 years. Followup discussions with local
DEA indicated that these buys were not different than
any others (i.e., high purity heroin was not being
sought). This large of a range is potentially dangerous,
because users may be getting much more potent heroin
than they are used to, which, particularly when used in
combination with other depressants, could prove
deadly. This is a very small number of samples, but it
does raise concerns about another potential cause of
heroin overdoses.
Unweighted data show heroin drug reports in the
DAWN Live! system were second only to cocaine
among illegal drug reports (exhibits 3a and 3b). Ninety
percent of heroin reports were of the drug/abuse other
case type, with almost all of the remaining reports for
seeking detox/treatment. Sixty percent were male, with
five times as many Whites as Blacks. However, 60
percent of reports did not have race/ethnicity documented. The group was relatively old, with one-third
age 35–44 and almost one-quarter age 45–54. By far
the most common chief complaint was abscess/cellulitis/skin/tissue at 39 percent, far higher than for any
other substance. Overdose was second, with 10 percent of documented complaints. Injection was noted in
almost all reports for which the route of administration
was documented.
Heroin mentions in calls to the Help Line represented 15
percent of adult calls and 4 percent of youth calls in
2004 (exhibit 4).
NFLIS results show similar levels of law enforcement
seizures for heroin in the Seattle area (5 percent) and
the rest of the State (5–7 percent) in FYs 2003 and
2004. Heroin was the fourth most common substance
detected in each of these regions (exhibit 6).
Price data for King County from the Northwest HIDTA
for 2003 for Mexican black tar heroin include $30–$150
per gram, $400–$900 per ounce, $8,000–$10,000 per
pound, and $16,000–$25,000 per kilogram.
Other Opiates/Prescription-Type opiates
For the purposes of this report, “other opiates/prescripttion-type opiates” include codeine, dihydrocodeine, fentanyl, hydrocodone (e.g., Vicodin), methadone (source, whether pain medication or opiate treatment program is rarely available), oxycodone (e.g., Per-
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cocet and OxyContin), propoxyphene (e.g., Darvon),
sufentanil, tramadol (e.g., Ultram), hydromorphone
(e.g., Dilaudid, Palladone), meperidine (e.g., Demerol) pharmaceutical morphine, acetylmethadol, and
the “narcotic analgesics/combinations” reported in the
DAWN ED data.
Treatment admissions to any treatment modality
increased from 81 to 264 for other opiates as the
primary drug from 1999 to 2004. A substantial increase was seen for the 18–29 age group, rising
from 16 to 40 percent of other opiate admissions
from 1999 to 2004. These numbers are an underestimate, as prescription-type opiate use is often noted
as secondary or tertiary to other substances.
Among those entering opiate substitution treatment,
the proportion reporting prescription-type opiates as
their primary drug increased from 3 percent in 1999
to 12 percent in 2004 (exhibit 8).
The number of deaths involving prescription-type
opiates continues to increase and has surpassed all
other drugs; prescription-type opiates were identified in 118 deaths in 2004, up from 84 in 2003 and
28 in 1997 (exhibit 7a). Thirteen deaths in 2004 (11
percent) involved just a prescription-type opiate, a
proportion similar to the prior 3 years, but about
one-half the level seen from 1998 to 2000.
Demographics for prescription-type opioid deaths
point to a relatively high proportion of females and a
group older than all drugs users on average (exhibit
7d). This group was also disproportionately White
and had a larger average number of total drugs present, 3.0, than among all drug decedents, 2.1.
Three specific prescription-type opiates make up the
majority of all cases, with methadone present in 57
percent of prescription-type opiate-involved deaths
in 2004 (exhibit 7b). Oxycodone was the next most
common, present in more than one-quarter of such
deaths in 2004. Hydrocodone was present in 14
deaths in 2004, with all of the remaining prescription-type opiates totaling 33 cases in 2004.
Demographics of oxycodone and methadone decedents are similar in terms of gender and the average
numbers of drugs present (exhibit 7d). Oxycodone
users were older on average, 44.7, compared with
41.4 for methadone, and the manner of death was
much more often suicide for oxycodone users (22
percent versus 1 percent for methadone cases).
The most common class of drugs found in combination with prescription-type opiates in deaths was
depressants (exhibit 7e). This combination was
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found in 20 percent of all deaths, the highest proportion of any drug combination deaths in 2004.
Fifteen percent of deaths involving a combination of
prescription-type opiates and depressants were determined to be suicides, slightly higher than 11 percent
for all drug-involved deaths and much lower than the
24 percent for all depressant-involved deaths. These
differences indicate that this combination is not just
part of the commonly seen multiple drug-involved
suicides, but appear to be also involved in accidental
deaths from those seeking to get high from this combination. These two classes of drugs are CNS depressants and their effects combine, or potentiate, to create
a dangerous physiological state. In 2004, 62 percent of
depressant-involved deaths also involved a prescription-type opiate, while 43 percent of all prescriptiontype opiate-involved deaths also involved a depressant
(exhibit 7c). This drug combination has been common
in the past as well.
Single-drug deaths were infrequent for prescriptiontype opiates (13 percent), compared with all druginvolved deaths (29 percent) (exhibit 7f). Thus, the
vast majority of prescription-type opiate-involved
deaths involved multiple substances. Illegal drugs
were present in two-thirds of all drug-involved deaths
(exhibit 7g), but in only a minority of prescriptiontype opiate-involved deaths (35 percent). It is likely
that most people using prescription-type opiates in
combination with illegal drugs were attempting to get
“high.” The proportion of accidental over-medications
versus those seeking a high is not known.
What constitutes a prescription-type opiate-related
death is unclear, however, particularly among opiatetolerant individuals. Issues of tolerance, potentiation
with other drugs, and overlapping therapeutic and lethal dose levels complicate assigning causation in prescription-type opiate-involved fatalities. The source
and form of prescription-type opiates involved in
deaths are sometimes undetermined.
According to unweighted data accessed from DAWN
Live!, ED drug reports for prescription-type opiates
totaled 1,956 in 2004, with the drug abuse/other case
type representing the largest proportion (41 percent),
followed by overmedication (25 percent) and adverse
reaction (21 percent) (exhibit 3a). Some misclassification of case type may remain, however it is believed
that the other/drug abuse case type is likely the most
accurate category, given that all other case types must
be ruled out prior to assigning this case type. To explain more about those who are intentionally misusing
prescription-type opiates, the drug abuse/other case
type is discussed further below.
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ED drug reports for the drug abuse/other case type
indicate that prescription-type opiate patients were
mostly age 35–54 (58 percent); about one-half were
male; most used orally, though some injected; and
withdrawal (23 percent) was the most common presenting complaint (exhibit 3c).
A comparison of drug abuse/other ED reports for
the two most common prescription-type opiates,
oxycodone (n=171, 21 percent) and methadone
(n=234, 29 percent) revealed a few differences. The
most notable difference was the age distribution,
with oxycodone patients being younger; 27 percent
were 18–29, compared with 16 percent for methadone patients. Methadone-involved patients tended
to be on the older end of the scale, with 44 percent
being age 45 and older, compared with 26 percent of
oxycodone patients. This is the inverse of the pattern
seen in deaths with regards to age. Route of ingestion information was missing for a substantial proportion reporting each drug. The most common
route was oral for both. Two people reported inhaled/snorted/sniffed for oxycodone (compared with
0 for methadone), and six people reported they injected methadone, compared with none for oxycodone.
In 2004, 198 calls about adults to the Help Line involved OxyContin, compared with 9 for youth (exhibit 4). There were 397 calls for “prescription pain
pills” for adults in 2004 and 6 for youth. As a point
of comparison, there were 589 calls about adult use
of heroin in 2004. Categorization of calls to the
Help Line for other opiates and prescription pain
pills has changed over time, and categories are not
mutually exclusive.
Three types of prescription-type opiates are among
the top 25 substances reported in the NFLIS data:
oxycodone, hydrocodone, and methadone (exhibit
6). For the Seattle area, these three substances totaled 2 percent in FY 2003 and 3 percent in FY
2004. For the rest of the State, about 3 percent of
seizures tested positive for these substances in both
years.
DEA data on sales of prescription-type opiates to
hospitals and pharmacies in the King County area
indicate that methadone sales have steadily increased each year, with a total increase of 359 percent from 1997 to 2003 (exhibit 11). Note that these
data for methadone only include prescriptions for
pain written by physicians; they do not include
methadone provided in opiate treatment programs.
Oxycodone prescriptions have continued to increase
in recent years. Prescriptions for hydromorphone
(80 percent), hydrocodone (93 percent), morphine
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(88 percent), and fentanyl (174 percent) have all increased as well. Codeine and meperidine prescriptions
have both steadily declined, decreasing 27 percent and
30 percent, respectively, between 1997 and 2003.
Several diverse factors may impact these prescribing
patterns: 1) increased advertising and promotion of
pharmaceuticals generally, 2) guidelines promoting
adequate use of opiates for management of pain released in 1996 by the Washington State Medical Quality Assurance Commission, and 3) recent efforts to
shift to methadone and morphine as less expensive
alternatives to other opiates by Washington State
agencies administering publicly financed health care
services.
Marijuana
Nearly one-half (47.8 percent) of those admitted to
treatment in 2004 reported current marijuana use (exhibit 2a). This represented a slight decline, but marijuana is still the most commonly reported illegal drug.
Those reporting marijuana as their primary drug are
much younger than other drug users overall: 45 percent of users were younger than 18 in 2004 (exhibit
2b). However, primary marijuana users are aging, as
those younger than 18 represented 63 percent of users
in 1999.
Unweighted DAWN Live! data show marijuana ED
reports totaled 1,160 in 2004, with 92 percent being
drug abuse/other case type, followed by 6 percent
seeking detox/treatment (exhibit 3a). More than twothirds were male, and patients were much younger
than for other illegal drugs. Eleven percent were age
12–17, and 42 percent were 18–29. Psychiatric condition was reported most commonly (27 percent), followed by altered mental status (20 percent).
Calls to the Help Line for marijuana constituted 51
percent of youth-related calls and 21 percent of adult
calls in 2004, similar to prior years (exhibit 4).
Marijuana was the most commonly identified illegal
drug used by high school seniors in Seattle’s school
survey. Use in the prior 30 days was reported by 27.0
percent in 2002 and 25.4 percent in 2004 (exhibit 5).
Cannabis was the third most commonly identified substance in NFLIS data for both the Seattle area and the
rest of Washington State in FYs 2003 and 2004 (exhibit 6). In the Seattle area, 17 percent and 15 percent
of seizures tested positive for cannabis in FYs 2003
and 2004, respectively. Similar levels were seen in the
rest of the State: almost 16 percent for both years.
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HIDTA data collected from King County law enforcement in 2003 show the following prices for
marijuana: $10–$40 per gram, $250–$500 per ounce,
and $2,200–$4,000 per pound. Price depends on the
quality and a variety of other factors, but “BC Bud”
from British Columbia, Canada, is widely available
and the most expensive of the marijuana varieties
available in King County.
Stimulants
Stimulants encompass a range of drugs, including
methamphetamine, which is available almost exclusively as an illicit drug. Amphetamines are primarily
prescription drugs, d amphetamine (e.g., Dexedrine)
for weight control, and dl amphetamine (e.g., Adderall) for attention deficit disorder/ attention deficit-hyperactivity disorder (ADD/ADHD). Another
prescription medication for ADD/ADHD is methylphenidate (e.g., Ritalin).
Prescriptions for stimulant medications are up substantially. DL amphetamine (e.g., Adderall) sales
increased 1,108 percent in the King County area
from 1997 to 2003 (exhibit 12). D amphetamine
(e.g., Dexedrine) sales increased 134 percent, and
methylphenidate sales increased 66 percent over this
same period. Note that Adderall was approved by
the U.S. Food and Drug Administration (FDA) in
1996 (i.e., fairly recently), while methylphenidate
was approved in 1956 and Dexedrine was approved
in 1948.
The proportion of ADHL calls related to methamphetamine represented 18 percent of both adult and
youth calls in 2004 (exhibit 4). Methamphetamine is
the only substance for which youth and adults call in
the same proportion. It is the second most common
substance for youth and third most common for
adult calls, similar to previous years.
The proportion of treatment admissions for King
County residents involving methamphetamine (exhibit 2a) increased in 2004 after several years of
stability. Approximately 14 percent of all people
entering treatment mentioned methamphetamine as
one of the drugs they used between 2001 and 2003;
this increased to 16 percent in 2004.
Treatment data indicate that primary methamphetamine users are much younger than heroin and cocaine
users and older than marijuana users overall (exhibit
2b). Only 5 percent of methamphetamine users were
older than 45 in 2004, compared with 25 percent of
cocaine, 40 percent of heroin, and 3 percent of mari-
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juana users. Methamphetamine users showed the smallest shift in age distribution from 1999 to 2004, with the
only group showing any change being those age 45–54;
their proportion increased from 3 to 5 percent.

abscess/cellulitis/skin/tissue (8 percent). Fifteen percent of methamphetamine-involved patients were
referred to detox/treatment, a larger proportion than
for the other common illegal drugs.

Deaths involving methamphetamine were level in
2003 and 2004 at a new high of 18 per year, up from 3
in 1997 (exhibit 7a). Since 1997, the average age of
decedents with methamphetamine involved was 37.9,
lower than the average for all drugs (exhibit 7d). However, the average age in 2004 was 42.8, higher than
any previous year.

Use of methamphetamine in the past 30 days was
relatively low among Seattle high school seniors: 1.1
percent in 2002 and 2.0 percent in 2004 (exhibit 5).

Deaths involving the category of prescription stimulants totaled 12 for the 8 years of detailed data (exhibit
7a). This is a small number, but it appears to have increased slightly; given the increase in prescriptions for
these substances, as well as national survey data showing increasing use and misuse, these cases were examined. The fact that these data are based on tiny numbers should be kept in mind.
Overall, prescription stimulant-involved deaths had the
lowest average age for all substances: 33.8, compared
with 41.6 for all drugs (exhibit 7d). Whites represented
92 percent of deaths—the highest of any drug. Cause
of death was accident 92 percent of the time, among
the highest for all drugs, and the average number of
drugs was much higher than for any other substance:
4.2 compared with 2.3 on average for all drugs. The
use patterns of the two prescription stimulants are
characterized below.
Amphetamine deaths totaled six from 1997 to 2004,
with a roughly even distribution over that time. The
average age of decedents was 31 (range=22–41). One
death involved only amphetamine. The average number of drugs involved was 3.3 All combination deaths
included an opiate plus at least one other drug.
Methylphenidate-involved deaths also totaled six from
1997 to 2004. However, three were in 2004 and one
was in 2003. Decedents were age 36.7 on average
(range=28–53), and the average number of drugs detected was 5.0. All but one death also involved an opiate of some kind.
According to unweighted data accessed from DAWN
Live!, 89 percent of methamphetamine ED reports in
2004 were because of drug abuse/other, and 10 percent
were seeking detox/treatment (exhibit 3a). Seventy
percent were male, and most patients were White.
Methamphetamine patients were younger than heroin
and cocaine patients, but older than marijuana patients
overall. Similar proportions, just under one- quarter, of
complaints were for psychiatric condition and altered
mental status. The next most common complaint was
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A category of amphetamine was added to the Help
Line data in 2003 (exhibit 4). There were 18 adult
calls and 0 youth calls about amphetamine in 2004,
though there may be underreporting because of an
overlapping category of “prescription drugs.”
Federal law enforcement sources report that less
methamphetamine is being manufactured in Washington, but that demand is being met by an increase
in supply from Mexico and Mexican groups in California.
Anecdotal information from both users and law enforcement indicates that “ice” (crystal methamphetamine) distribution has increased in Seattle and
that in some areas of Seattle, “ice” has supplanted
powder methamphetamine in terms of availability.
The DEA reports that crystal methamphetamine is
increasingly available and that prices are slowly
declining. Regarding purity, the DEA reports: “The
overall purity of exhibits collected in Washington
for the first six months of FY 2004 has averaged 50
percent, up from the average purity of 45 percent
seen during FY03 and surpassing the 30 percent
seen during FY01 and FY02. Of the DEA offices in
Washington, Seattle exhibits have currently yielded
the highest purity at nearly 66 percent.”
Methamphetamine incidents, a combination of active labs used for manufacturing and dump sites of
lab equipment or inactive labs, decreased for Washington State as a whole in 2004 (exhibit 13). The
peak in incidents for the State and the two most
populated counties was in 2001. In King County, the
number of incidents remained flat in 2003 and 2004,
while Pierce County to the south experienced increases, Snohomish County to the north had a slight
increase, and Kitsap County to the west experienced
a small decline. The rate of methamphetamine incidents per 100,000 population was 11 in King
County, 77 in Pierce County, 17 in Snohomish
County, 19 in Kitsap County, and 23 for Washington State in 2004.
It is important to note that these data do not indicate
the manufacturing methods or the quantities manufactured at the site of individual incidents. Reports
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from law enforcement indicate that “super” labs, those
capable of producing large amounts of methamphetamine quickly, represent a small minority of manufacturing labs in the State.
NFLIS data indicate that methamphetamine is found in
law enforcement seizures at a much lower level in the
Seattle area compared with the rest of the State (exhibit 6). In FY 2004, 29 percent of Seattle-area drug
tests and 52 percent of drug tests for the rest of Washington were positive for methamphetamine. These data
represent slight proportional increases from FY 2003.
Data from the Washington State Patrol’s Toxicology
laboratory show a more than fivefold increase, from
less than 100 to more than 500, in the number of drivers testing positive for methamphetamine in DUI cases
from 1997 to 2004. At the same time, the number of
deaths in which methamphetamine was identified
more than doubled to slightly more than 200 (note that
methamphetamine may or may not have been causative in the death).
Depressants
Barbiturates, benzodiazepines, and other sedative/
depressant drugs in this analysis include alprazolam
(Xanax), diazepam (Valium), lorazepam (Ativan),
clonazepam (Klonopin), temazepam (Restoril), triazolam (Halcion), oxazepam (Serax), butalbital
(Fioricet), chlordiazepoxide (Librium), diphenhydramine (Benadryl), hydroxyzine pamoate (Vistaril),
meprobamate (Equanil), phenobarbital, promethazine
(Phenergan), secobarbital (Seconal), and zolpidem
(Ambien).
Depressants are rarely mentioned as a primary drug at
intake to drug treatment. Less than 1 percent of admissions were for benzodiazepines, barbiturates, major
tranquilizers, and other sedatives. A slight increase
appears to have occurred, with 20 admissions for these
4 drug categories as the primary drug at treatment entry in 1999 and 51 in 2004. Key informants report that
these drugs are commonly used to enhance the effects
of other drugs and are rarely taken as the primary drug
recreationally.
Deaths involving depressants were at the highest level
since at least 1997 with 82 in 2004, up from 71 in 2003
(exhibit 7a). A steady increase has occurred since 1999.
As discussed in the other opiate section in detail, the
most common co-ingestent was a prescription-type opiate, representing 20 percent of deaths in 2004 (exhibit
7e). Other co-ingestents included cocaine (9 percent) and
alcohol and heroin/opiate/morphine (both 8 percent).
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The oldest group of decedents was those with depressants identified: 43.8 on average (exhibit 7d).
An increase from 41.9 to 45.9 years of age was seen
over the span of available data. A relatively large
proportion were female: 43 percent. The manner of
death was ruled accidental 63 percent of the time
and suicide 24 percent of the time. Suicides were
more than twice as common for depressants than for
any other drug. The average number of drugs identified was 3.5, more than the 2.3 seen on average.
The two most prevalent depressants in 2004 and for
the prior 7 years were diazepam and diphenhydramine (exhibit 7b). Diazepam-involved deaths
totaled 142 from 1997 to 2004, with 23 in 2004, a
bit below the peak of 27 in 2003 and at the higher
end of levels seen during this time. Diphenhydramine-involved deaths totaled 111 over this same
time frame, but showed a clear increase over the
years, with a peak of 29 in 2004.
Single-drug deaths were infrequent for depressants
(6 percent), compared with all drug-involved deaths
(29 percent) from 1997 to 2004 (exhibit 7f), meaning that the vast majority of depressant-involved
deaths involved multiple substances. Illegal drugs
were present in two-thirds of all drug-involved
deaths (exhibit 7g), but only in a minority of depressant-involved deaths (44 percent). It is likely that
most people using depressants in combination with
illegal drugs were attempting to get “high.” The
proportion of accidental over-medications versus
those seeking a high is not known.
Unweighted DAWN ED drug reports for depressants (barbiturates, benzodiazepines, and anxiolytics/ sedatives/hypnotics) totaled 1,218 for all case
types in 2004 (exhibit 3a). The most common case
type was overmedication (40 percent), followed by
drug abuse/other (28 percent), suicide attempt (16
percent), and adverse reaction (11 percent).
The most common substances in ED drug
abuse/other reports were benzodiazepines (350 of
420 reports, 83 percent), with type-not-specified the
most common, followed by alprazolam (n=83),
clonazepam (n=58), lorazepam (n=43), and diazepam (n=38). Miscellaneous anxiolytics totaled just
41 reports; diphenhydramine was the most common
(n=12). Barbiturates totaled 29 cases, the majority
with the type not specified.
NFLIS data showed that approximately 1 percent of
exhibits from the Seattle-area lab and the rest of the
State were benzodiazepines (i.e., diazepam, and
clonazepam), with no change between FY 2003 and
FY 2004 (exhibit 6).
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A benzodiazepine category was added to the Help
Line data in 2003; there were 81 adult calls and 1
youth call in 2004 (exhibit 4).
Hallucinogens, Club Drugs, and
Dextromethorphan
Hallucinogens include lysergic acid diethylamide
(LSD), mescaline, peyote, psilocybin (mushrooms),
phencyclidine (PCP), and inhalants. “Club drugs” is a
general term used for drugs that are popular at nightclubs and raves, including the hallucinogens, methylenedioxymethamphetamine (MDMA) (ecstasy), gamma
hydroxybutyrate (GHB), gamma butyrolactone (GBL),
ketamine, and nitrous oxide. Dextromethorphan, commonly found in over-the-counter cough medicines, can
have dissociative effects at high dosages.
Research chemicals are another important class of
drugs used locally, however few indicator data are
currently able to monitor these substances. Limitations
in tracking these substances include a lack of awareness of these substances by many providers, the continually fluctuating substances utilized locally, and the
multiple, often confusing, names of these substances
(e.g., foxy methoxy, 2CB, 2CT7). A community-based
survey conducted in the summer of 2003 found that 21
percent of subjects surveyed at rave venues in King
County had ever used research chemicals.
An important new development involving dextromethorphan occurred in April 2005 in Whatcom
County, Washington, north of Seattle. Two teenage
boys, ages 17 and 19, died after consuming dextromethorphan obtained in “wholesale quantities” from a
chemical company on the Internet, based in Indiana.
Three other deaths in the United States were also
linked to this company; as of this writing, the FDA has
shut down the Web page. These local boys mixed the
dextromethorphan in an energy drink, and high levels
of taurine and caffeine from the drink were detected
along with marijuana.
Treatment admissions in which hallucinogens are
mentioned as primary drug are infrequent, with just 44
in 2004, up from 16 in 1999.
Unweighted ED reports in DAWN Live! for all case
types totaled 85 for PCP, 91 for ecstasy, 17 for GHB,
23 for LSD, and 53 for psilocybin.
Help Line calls regarding PCP and LSD were infrequent, representing less than 1 percent of both youth
and adult calls in recent years (exhibit 4). Calls involving MDMA have declined in terms of number and
proportion since 2001 for both adults and youth,
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though the large number of calls for unknown substances limits trend analysis. In 2001, MDMA represented 2.5 percent of adult calls; this proportion
declined to 1.2 percent in 2004. A similar decline
was seen for youth calls, from 8.7 percent in 2001 to
4.4 percent of calls in 2004. Calls mentioning the
more general term “hallucinogens” have remained
small, but consistent, for adults (about 1 percent of
calls over time). For youth, hallucinogen-related
calls appear to have declined from 4 percent to 2
percent of calls from 2001 to 2004.
School survey data indicate that hallucinogens and
MDMA are the second most common illicit substances used in the past month following marijuana
(exhibit 5). Hallucinogens, broadly defined, were
reported by 2.5 percent of seniors and MDMA was
reported by 2.8 percent in 2004.
The combined category of dextromethorphan,
MDMA, GHB, and PCP was identified in 37 deaths
since 1997. This group was younger, 36.3, than for
all drugs on average and had the largest proportion
of females (43 percent).
There were two MDMA-involved deaths in 2004.
There have been between one and two MDMAinvolved deaths since 1999, with none in 1997 or
1998. GHB/GBL-involved deaths totaled three in
2002; none have been reported since, and none were
noted prior. There were 5 dextromethorphaninvolved deaths in 2004, a decrease from the 10 in
2003 (which was by far the highest level since at
least 1997). PCP deaths totaled two in 2004 and one
in 2002.
According to the NFLIS, MDMA was detected at
slightly higher levels in the Seattle-area lab than the
rest of the State (exhibit 6). The Seattle-area lab
reported 1.4 and 1.0 percent of evidence tested positive for MDMA in FY 2003 and FY 2004, while for
the rest of the State the levels were 0.5 percent in
each year. Psilocin, the active ingredient in psychedelic mushrooms, was seen at similar levels for each
region and in each year, between 0.5 and 0.7 percent. PCP was not among the top 25 drugs detected
in Washington, not including Seattle, while in Seattle it represented a bit less than 1 percent of evidence in each year.
Pill presses, necessary for tableting ecstasy, are still
occasionally seized locally according to Federal law
enforcement sources. Past customs seizure data indicated that much of the MDMA entering Washington was in powder form, suggesting that it was to be
used in creating ecstasy tablets.
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Federal law enforcement reports that “…crime related
to MDMA distribution has increased in areas such as
Seattle because of the introduction of polydrug traffickers distributing MDMA.” Additionally, the U.S.
Postal Inspection Service reported that Seattle had the
third highest amount of MDMA dosages seized in
2003.
Limited availability of LSD was reported by Federal
law enforcement sources. However, in February 2004,
DEA and the Seattle Police Department arrested an
individual who had chemicals, glassware, and instructions for making LSD.
INFECTIOUS DISEASES RELATED TO DRUG ABUSE AND
INJECTION DRUG USE TRENDS
Available data for people diagnosed with HIV infection between 1996 and 2004 are presented in exhibit
14. In King County, injection drug users (IDUs) and
men who have sex with men and also inject drugs
(MSM/IDUs) both represent 7 percent of recent HIV
cases. For Washington State as a whole, IDUs represent 10 percent and MSM/IDUs represent 6 percent.
Excepting male drug injectors who also have sex with
men, the rate of HIV infection among the 15,000–
18,000 IDUs who reside in King County has remained
low and stable over the past 14 years. Various serosurveys conducted in methadone treatment centers and
correctional facilities and through street and community-targeted sampling strategies over this period indicate that 4 percent or less of IDUs who are not MSM
in King County are infected with HIV. Data from a
CDC-funded HIV Incidence Study (HIVIS 1996–
2001) suggest that the rate of new infections among
non-MSM/non-IDUs in King County is less than 0.1
percent per year.
Syringes exchanged and numbers of encounters have
remained high in King County, with more than 2 million syringes exchanged and more than 60,000 encounters in 2004 (exhibit 15).

more than 4,000 IDUs by Public Health’s HIVAIDS Epidemiology Program between 1994 and
1998 reveal that 85 percent of King County IDUs
may be infected with hepatitis C (HCV), and 70
percent show markers of prior infection with hepatitis B (HBV). Local incidence studies indicate that
21 percent of non-infected IDUs acquire HCV each
year, and 10 percent of IDUs who have not had
hepatitis B acquire HBV.
Trends In Primary Injection Drug Use In SeattleArea Idus Age 18–30 Participating In 4 Studies,
1994–2003 (Authored by Richard Burt and Hanne
Thiede, Public Health-Seattle & King County)
Four different studies of Seattle-area IDUs were
conducted by Public Health – Seattle & King
County from 1994 to 2003. They are the RAVEN
(1994–1997), RAVEN II (1998), Kiwi (1998–2002),
and DUIT (2002–2003) studies. The four study
populations were each recruited by different strategies, and there are statistically significant differences among the study populations in age, race, sex,
and primary injection drug. The data show trends in
primary injection drug by year of study enrollment
among 18–30-year-old IDUs who had injected in the
6 months prior to enrollment (exhibit 16).
Heroin was the most common primary injection
drug in all study populations and in all years. There
was a clear increase in the proportion of participants
reporting amphetamine as their primary injection
drug, from 7 percent in 1994 to 32 percent in 2003.
The proportion reporting cocaine as their primary
drug declined from 19 percent in 1994 to 5 percent
in 2004. There does not appear to be a single consistent trend in heroin or speedball use.
For inquiries concerning this report, please contact Caleb BantaGreen, MPH, MSW, Alcohol and Drug Abuse Institute, University of Washington, 1107 NE 45th St, Suite 120; Seattle, WA
98105, Phone: (206) 685-3919, Fax: (206) 543-5473, E-mail:
<calebbg@ u.washington.edu>, Web: http://adai.washington.edu
or Ron Jackson, MSW, Evergreen Treatment Services, Phone
(206) 223-3644, E-mail: ronjack@u.washington.edu.

Hepatitis B and C are endemic among Seattle-area
injectors. Epidemiologic studies conducted among
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1

Exhibit 1.

King and Snohomish Counties DAWN ED Sample and Reporting Information:
January–December 2004

Total Eligible
2
Hospitals

No. of Hospitals in DAWN
Sample

Total EDs in
DAWN Sam3
ple

22

22

23

No. of EDs Reporting per Month: Completeness of Data (%)
90–100%

50–89%

<50%

No. of EDs
Not Reporting

8–12

0–2

0–4

10–13

1
Note that the 23 hospitals in the Seattle-area sample are in King, Snohomish, and Pierce Counties. As of June 2005, none of the
four counties in the sample from Pierce County are participating. Therefore, available data are presently just from Snohomish and
King Counties.
2
Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association Annual Survey.
3
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005

Exhibit 2a. Treatment Admissions for Primary, Secondary, or Tertiary Use of Selected Drugs Among
Residents of King County, Washington, by Percent: 1999–2004
Percent
90
80
70
60

Alcohol

50

Methamphetamine
Cocaine

40

Marijuana

30

Heroin

20
10
0
1999

Primary, Secondary, or
Tertiary Drug
Alcohol
Methamphetamine
Cocaine
Marijuana
Heroin
Total Admissions

2000

1999

2001

2000

2002

2001

2003

2004

2002

2003

2004

79.9

78.1

77.4

75.7

74.4

70.3

9.1
44.5
50.6
25.7
9,845

11.4
44.6
51.3
26.0
10,479

14.0
42.0
52.4
22.5
9,761

13.9
39.9
49.5
22.0
8,871

13.9
38.7
50.3
19.8
8,879

16.3
40.1
47.8
21.6
11,223

Data include all ages, all treatment modalities, Department of Corrections, and private pay clients at opiate substitution treatment
clinics.
SOURCE: Washington State Treatment and Assessment Report Generation Tool (TARGET) data system—Structured Ad Hoc
Reporting System
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Exhibit 2b. Age at Treatment Entry by Primary Drug, for King County, Washington, Admissions:
1999 and 2004
Age at
Treatment Entry

Cocaine

Alcohol

Marijuana

Heroin

Methamphetamine

1999

2004

1999

2004

1999

2004

1999

2004

1999

2004

2.7

2.5

7.7

7.3

62.8

44.9

0.5

0.5

7.4

6.8

18–29

15.6

12.4

20.5

22.6

23.8

33.2

16.6

16.8

41.5

39.6

30–44

69.9

60.4

51.9

44.5

11.5

18.6

53.0

42.3

48.2

48.4

45–54

10.4

22.6

15.9

20.6

1.8

2.8

27.2

34.0

2.8

5.0

17 and younger

55–64

1.1

2.1

3.6

4.6

0.1

0.5

2.5

5.8

0.0

0.3

65 and older

0.2

0.1

0.5

0.4

0.0

0.1

0.3

0.7

0.0

0.0

SOURCE: Washington State Treatment and Assessment Report Generation Tool (TARGET) data system—Structured Ad Hoc
Reporting System

1

Exhibit 2c. Racial Categories of Treatment Admissions in King County, Washington, by Primary Drug and
Percent: 2004
Alcohol
(n=3,912)

Cocaine
(n=1,592)

Heroin
(n=2,000)

Methamphetamine
(n=1,109)

Marijuana
(n=2,064)

Other
(n=572)

White

53

37

67

83

46

73

African-American

Racial Category

Percent of
Total
Admissions
by Race
56

18

47

17

2

31

9

22

Asian/Pacific Islander

5

2

2

2

4

4

3

Native American

7

2

4

2

3

3

4

Hispanic

10

6

7

5

8

5

8

Multiple Race

3

3

2

3

6

4

3

Other

5

3

2

3

2

3

3

1

N=11,249
SOURCE: Washington State Treatment and Assessment Report Generation Tool (TARGET) data system—Structured Ad Hoc
Reporting System
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Exhibit 3a. Drug Reports in Drug-Related ED Visits in King and Snohomish Counties, by Drug Category
2
(Unweighted ) and Percent: 2004

Number of Drug Reports
Type of Case
Suicide attempt
Seeking detox
Adverse reaction
Overmedication
Malicious poisoning
Accidental ingestion
"Drug Abuse"/Other
Gender
Male
Race/Ethnicity
White
Black
Hispanic
Race/ethnicity NTA
Not documented
Age Group
12–17
18–20
21–24
25–29
30–34
35–44
45–54
55–64
65 and older
Chief Complaint
Overdose
Intoxication
Seizures
Altered mental status
Psychiatric condition
Withdrawal
Seeking detox
Accident/injury/assault
Abscess/cellulitis/skin/tissue
Chest pain
Respiratory problems
Digestive problems
Other
Number of Complaints

Major
Substances
of Abuse3
10,002

Cocaine

Heroin

Meth

Marijuana

Rx Opiates

Anx/Sed/
Hyp

2,725

2,171

857

1,160

1,956

1,218

3.7
8.3
0.8
2.5
0.1
0.1
80.5

1.2
9.9
0.1
0.0
0.1
0.0
88.7

0.5
9.5
0.2
0.0
0.0
0.0
89.7

1.2
9.5
0.0
0.0
0.0
0.0
89.4

2.1
5.8
0.2
0.0
0.2
0.0
91.8

4.6
8.4
21.0
24.7
0.2
0.3
40.8

15.9
4.4
11.2
39.8
0.1
0.7
27.9

63.6

64.4

60.1

69.8

68.9

47.4

40.8

23.8
8.6
1.0
1.6
65.1

18.2
14.9
1.3
1.4
64.3

32.2
6.1
0.9
1.2
59.6

27.7
3.7
0.8
2.8
65.0

24.0
8.8
1.0
1.8
64.4

23.6
4.4
0.8
1.5
69.6

27.4
2.2
0.4
1.1
68.9

4.8
8.9
9.1
12.3
13.5
30.0
17.7
2.9
0.5

1.1
3.2
6.6
10.6
14.5
37.8
22.5
3.3
0.3

0.3
2.9
6.8
12.6
16.1
33.3
24.3
3.2
0.5

1.9
12.8
17.2
18.7
13.4
25.7
8.5
1.4
0.1

10.7
15.2
13.2
13.7
14.3
20.6
9.9
1.7
0.5

2.4
4.6
7.1
9.5
10.2
26.3
23.8
8.0
7.9

4.2
3.4
8.7
12.9
11.9
28.6
20.2
6.2
3.0

5.1
9.8
4.7
1.6
1.9
0.6
15.7
9.1
23.6
7.2
2.3
4.7
6.4
6.3
3.6
2.1
7.1
39.1
6.3
1.6
4.3
3.2
4.3
4.2
14.8
10.6
3,940
2,891
(Continued)

4.1
4.4
0.7
22.8
23.9
1.8
6.1
3.2
8.4
4.8
2.3
1.8
15.6
1,259

5.3
6.6
0.9
20.3
27.0
2.0
3.9
5.3
1.8
3.6
3.1
4.1
16.2
1,688

17.7
2.5
0.6
15.0
10.6
11.6
5.2
1.8
3.9
1.8
3.1
10.6
15.8
2,909

32.7
5.0
1.1
14.8
18.1
4.6
2.6
1.3
1.5
1.4
2.0
3.5
11.3
1,959

8.5
7.9
1.2
15.7
18.6
2.7
5.4
3.9
11.6
3.8
3.4
4.1
13.2
14,646

1

Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same visit). Therefore,
the number of drug reports will exceed the number of ED visits.
2
Unweighted data are from 10–13 Seattle EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on this
review, cases may be deleted and corrected and, therefore, are subject to change. Data are duplicated; a person may have used
multiple drugs. This can lead to odd data, such as suicide attempts that appear to involve marijuana. These data are not estimates
or rates.
3
Major Substances include all of the illegal drugs, as well as amphetamine and GHB.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 5/23/05
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Exhibit 3a. Drug Reports in Drug-Related ED Visits in King and Snohomish Counties, by Drug Category
2
(Unweighted ) and Percent: 2004 (Continued)

Patient Disposition
Discharged home
Released to police/jail
Referred to detox/treatment
Admitted to ICU/Critical care
Admitted to surgery
Admitted to chem. dependency/detox
Admitted to psychiatric unit
Admitted to other inpatient unit
Transferred
Left against medical advice
Died
Other
Not documented
Route of Administration
Oral
Injected
Inhaled, sniffed, snorted
Smoked
Other
Not documented

Major
Substances
of
Abuse3

Cocaine

Heroin

54.1
2.3
10.2
4.1
2.1
2.4
4.3
9.9
3.4
1.8
0.0
2.3
3.1

49.6
2.6
12.4
4.0
1.1
2.8
5.7
10.6
3.8
1.4
0.1
2.6
3.4

55.5
2.3
6.8
1.6
6.3
2.8
1.8
13.8
1.7
3.0
0.0
1.2
3.2

52.5
3.6
14.6
3.6
1.3
1.6
4.7
7.4
2.8
2.9
0.0
2.9
2.1

58.5
2.2
11.2
4.3
0.3
1.6
5.3
6.1
4.3
0.9
0.0
2.8
2.4

60.7
1.5
7.7
5.5
0.5
1.9
3.3
10.6
4.0
1.3
0.0
1.2
1.8

48.9
1.1
6.2
12.6
0.2
1.6
7.6
11.8
4.5
1.6
0.0
1.4
2.4

19.8
18.1
1.2
7.9
0.2
52.8

1.8
9.7
2.5
12.7
0.3
73.0

0.8
61.1
0.6
0.6
0.2
36.8

2.0
17.9
2.0
7.0
0.6
70.6

1.7
0.3
0.4
29.4
0.3
67.9

44.1
3.4
0.4
0.1
1.6
50.4

49.8
1.0
0.0
0.0
0.3
48.9

Meth

Marijuana

Rx Opiates

Anx/Sed/
Hyp

1

Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same visit). Therefore,
the number of drug reports will exceed the number of ED visits.
2
Unweighted data are from 10–13 Seattle EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on this
review, cases may be deleted and corrected and, therefore, are subject to change. Data are duplicated; a person may have used
multiple drugs. This can lead to odd data, such as suicide attempts that appear to involve marijuana. These data are not estimates
or rates.
3
Major Substances include all of the illegal drugs, as well as amphetamine and GHB.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 5/23/05
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Exhibit 3b.

Number of Drug Reports in Drug-Related ED Visits in King and Snohomish Counties, by Drug
2
Category (Unweighted ): 2004

Alcohol

2,575
2,172 Alcohol-in-combination
403 Alcohol only (age<21)

Cocaine

2,725

Heroin

2,171

Marijuana

1,159

Stimulants

1,068
213 Amphetamines
855 Methamphetamine

PCP

85

Ecstasy

91

Inhalants

18

1

Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same visit). Therefore,
the number of drug reports will exceed the number of ED visits.
2
Unweighted data are from 10–13 Seattle EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on this
review, cases may be deleted and corrected and, therefore, are subject to change. Data are duplicated; a person may have used
multiple drugs. This can lead to odd data, such as suicide attempts that appear to involve marijuana. These data are not estimates
or rates.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–4/14, 2005
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Exhibit 3c. Characteristics of Drug Abuse/Other Case Type Drug Reports for Prescription-Type Opiates and
2
Depressants (Unweighted ) in King and Snohomish Counties, by Percent: 2004
Characteristic

# of Drug Reports

Gender
Age

Male
12–17 years
18–20 years
21–24 years
25–29 years
30–34 years
35–44 years
45–54 years
55–64 years
65 years and older
Overdose
Intoxication
Seizures
Altered mental status
Psychiatric condition
Withdrawal
Seeking detox
Accident/injury/assault
Abscess/cellulitis/skin/tissue
Chest pain
Respiratory problems
Digestive problems
Other
Total Complaints (N)
Discharged home
Released to police/jail
Referred to detox/treatment
Admitted to ICU/Critical care
Admitted to surgery
Admitted to chemical dependency/detox
Admitted to psychiatric unit
Admitted to other inpatient unit
Transferred
Left against medical advice
Died
Other
Not documented
Oral
Injected
Inhaled, sniffed, snorted
Smoked
Other
Not documented

Chief Complaint

Patient Disposition

Route Of Administration

Rx Opiate
n=799
53
1
4
7
10
13
31
27
8
1
8
3
1
15
14
23
0
2
4
2
3
9
16
1,205
62
3
10
3
1
2
4
10
2
2
0
1
2
33
5
0
0
1
61

Anx/Sed/Hyp
n=340
55
2
3
8
12
14
31
22
6
1
15
6
3
15
21
13
0
2
1
3
1
4
15
539
53
3
13
4
1
1
4
9
4
3
0
1
4
32
1
0
0
0
67

1

Drug-related ED visits often involve multiple drugs (e.g., both cocaine and heroin may be reported for the same case). Therefore,
the number of drug reports will exceed the number of ED visits.
2
Unweighted data are from 10–13 Seattle-area EDs reporting to DAWN. All DAWN cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted and, therefore, are subject to change. These are not estimates or rates.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 5/23/05
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Exhibit 4.

Illicit Drug Help Line Calls for King County Residents, by Drug and Percent: 2001–2004
Helpline Calls, Adults
King County, WA

Helpline Calls, Youth
King County, WA

Methamphetamine

Methamphetamine

Ecstasy

Ecstasy

2001
2002
Cocaine

2003

Cocaine

2004

Heroin

Heroin

Marijuana

Marijuana

0%

20%

40%

0%

60%

20%

% of Illicit, Rx and OTC Calls

Drug

Percent of Adult Calls, by Drug
2001

2002

40%

60%

% of Illicit, Rx and OTC Calls

2003

Percent of Youth Calls, by Drug

2004

2001

2002

2003

2004

RX

9.5

11.0

5.4

4.4

4.1

3.1

3.0

2.4

Methadone

2.0

2.0

3.2

3.9

0.5

0.0

0.4

0.0

Other

1.2

1.3

2.2

1.6

0.9

2.0

2.5

1.6

LSD

0.5

0.1

0.1

0.1

0.0

0.0

0.0

0.5
50.6

Marijuana

21.0

20.3

18.2

20.5

42.3

49.6

52.9

Inhalant

0.2

0.3

0.1

0.1

1.0

1.0

0.7

0.2

Unknown

9.1

11.2

2.5

2.1

11.3

11.0

3.7

3.8

Heroin

11.2

12.3

16.0

14.8

1.9

1.7

2.5

3.8

Cocaine

23.5

23.6

32.6

31.6

7.8

9.7

9.8

11.7

Ecstasy

2.5

1.4

1.0

1.2

8.7

4.9

3.3

4.4

Hallucinogens

0.6

0.6

0.6

0.8

3.8

1.0

2.5

1.6

PCP
Methamphetamine

0.1

0.1

0.1

0.3

0.0

0.0

0.4

0.5

18.2

15.6

17.9

18.4

17.0

15.5

17.3

17.7

OTC

0.4

0.2

0.3

0.2

0.6

0.6

1.2

0.9

Total

100.0

100.0

100.0

100.0

100.0

100.0

100.0

100.0

Total Number of Calls

4,639

4,760

3,508

3,978

1,162

711

571

547

Newer Drug Categories
OxyContin

20

198

16

9

Rx Pain Pills

366

397

16

6

Amphetamine

31

18

2

0

Benzodiazepine

59

81

1

1

SOURCE: Washington State 24-Hour Alcohol and Drug Helpline
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Exhibit 5.

Drug Use in Prior 30 Days by 12th Graders in the Seattle Public Schools Communities That Care
Survey: 2002 and 2004
Prevalence

Substance
Alcohol
Cigarettes
Chewing Tobacco
Inhalants
Marijuana
Hallucinogens
Cocaine
MDMA (Ecstasy)
Stimulants (Amphetamines,
Methamphetamine)

Response Rate

2002

2004

47.9
22.8
3.9
2.1
27.0
3.6
1.7
3.4
1.1

2002

2004

51.1
16.1
3.2
1.4
25.4
2.5
2.5
2.8

%
51.3
52.0
51.8
50.0
50.7
50.4
50.4
50.3

N
1,287
1,305
1,301
1,256
1,273
1,265
1,266
1,263

%
61.0
61.3
61.3
60.0
60.6
60.5
60.3
60.4

N
1,475
1,481
1,481
1,451
1,464
1,462
1,457
1,461

2.0

49.8

1,250

59.8

1,445

SOURCE: Communities That Care Survey, http://www.seattleschools.org/area/ctc/survey/survey.xml
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Exhibit 6.

National Forensic Laboratory Information System Drug Test Results for Local Law Enforcement
Seizures in Seattle and the State of Washington: FYs 2003 and 2004

Seattle-Area Lab
Substance
Acetaminophen
Alprazolam**
Amphetamine
Caffeine
Cannabinol
Cannabis
Carisoprodol
Cathinone
Clonazepam**
Cocaine
Codeine*
Diazepam**
Heroin
Hydrocodone*
Hydromorphone*
Ibuprofen
Ketamine
Lorazepam**
MDA
MDMA
Methadone*
Methamphetamine
Methandrostenolone
(Methandienone)
Methylphenidate
Morphine*
Non-Controlled Non-Narcotic Drug
Oxycodone*
PCP
Propoxyphene*
Pseudoephedrine
Psilocin
Psilocybine
Sodium Bicarbonate
Total of Top 25 (#)
Subtotals:

*Other opiates
**Benzodiazepines

FY 2003
0.3
0.3
0.3
0.3

FY 2004
0.2
0.1
0.2
0.2

17.2
0.3
0.3
0.5
40.5
0.2
0.4
5.0
0.7

15.3

0.3
40.4
0.3
4.7
0.9
0.1

0.1
0.1
0.3
1.0
0.7
29.4

0.3
1.4
0.4
27.2
0.1

0.3
0.3
0.3
1.4
0.6
0.1
0.4
0.6
0.3

0.2
0.3
0.9
0.9
0.7
0.7

99.25
(3,188)
2.43
1.18

98.83
(3,454)
3.55
0.93

WA State Without Seattle-Area Lab
Substance
Acetaminophen
Alprazolam**
Amphetamine
Caffeine
Cannabinol
Cannabis
Carisoprodol
Cathinone
Clonazepam**
Cocaine
Codeine*
Diazepam**
Heroin
Hydrocodone*
Hydromorphone*
Ibuprofen
Ketamine
Lorazepam**
MDA
MDMA
Methadone*
Methamphetamine
Methandrostenolone
(Methandienone)
Methylphenidate
Morphine*
Non-Controlled Non-Narcotic Drug
Oxycodone*
PCP
Propoxyphene*
Pseudoephedrine
Psilocin
Psilocybine
Sodium Bicarbonate
Total of Top 25 (#)
Subtotals:

*Other opiates
**Benzodiazepines

FY 2003
0.2
0.2
0.3
0.2
0.2
15.5
0.2

FY 2004
0.1
0.2
0.4
0.2

0.3
20.6
0.2
0.4
6.5
1.1

0.3
18.2
0.1
0.3
4.8
1.3

15.6
0.1

0.1

0.1
0.5
0.4
47.8

0.5
0.6
51.7

0.1
0.3
0.5
1.2

0.1
0.4
0.7
1.1

0.8
0.5
0.3
0.2
98.62
(12,162)
3.25
0.85

0.1
0.7
0.7
0.2
0.2
98.63
(11,926)
3.51
0.81

Law Enforcement Seizure Drug Test Results

Seattle-Area Lab

Washington State (Without Seattle-Area) Lab

Cannabis

Cannabis

Clonazepam

Clonazepam

Cocaine

Cocaine

Diazepam

Diazepam

Heroin

FY 2003

Heroin

FY 2003

Hy drocodone

FY 2004

Hy drocodone

FY 2004

MDMA

MDMA

Methamphetamine

Methamphetamine

Methadone

Methadone

Ox y codone

Ox y codone

PCP

PCP

Pseudoephedrine

Pseudoephedrine

Illicit drugs are italicized.
Data for cannabinol/cannabis and psilocin/psilocybine may be duplicated.
SOURCE: National Forensic Laboratory Information Systems
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Exhibit 7a. Drug-Involved Deaths in King County, Washington, Related to Illicit and Prescription Drugs:
1997–2004
Number of Times Drug
Identified
160

140

120

Cocaine

100

Heroin/Op/Morphine
Rx Opiate
80

Depressant
Methamphetamine
Rx Stimulant

60

DXM/MDMA/PCP
Alcohol

40

20

0
1997

Drug
Cocaine

1998

1999

2000

2001

2002

2003

2004

1997

1998

1999

2000

2001

2002

2003

2004

66

69

76

89

49

79

52

92

Total of
Each
Drug
572

111

144

117

102

61

87

62

75

759

Rx Opiate

28

44

32

50

53

66

84

118

475

Depressant

45

51

28

33

40

54

71

82

404

Methamphetamine

3

3

13

10

5

13

18

18

83

Rx Stimulant

3

0

1

2

0

1

1

4

12

DXM/MDMA/PCP

2

0

1

2

3

9

11

9

37

82

103

67

76

50

61

58

71

568

178

220

196

213

146

195

186

253

1,587

Heroin/Opiates/Morphine

Alcohol
Total # of Deaths
1

Data are duplicated, most deaths involve multiple drugs.
SOURCE: Medical Examiners Office, Public Health Seattle & King County.
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Exhibit 7b. Numbers of Depressant and Prescription-Type Opiate-Involved Deaths in King County,
Washington: 1997–2004
Rx Opiates
Oxycodone
Methadone
Hydrocodone
Other Rx Opiates
Total # of
Rx Opiates
Total # Deaths
Involving
Rx Opiates

Depressants
Diazepam
Diphenhydramine
Promethazine
Meprobamate
Alprazolam
Cyclobenzaprine
Chlordiazepoxide
Phenobarbital
Zolpidem
Other Depressants
Total # of
Depressants
Total # of Deaths
Involving
Depressants

1998

1999

2000

2001

2002

2003

2004

2
14
0
18

5
20
3
21

4
19
1
12

12
25
1
17

18
24
4
13

20
37
4
18

14
47
12
20

32
67
14
33

Total # of Rx
Opiates
107
253
39
152

34

49

36

55

59

79

93

146

551

28

44

32

50

53

66

84

118

475

1998

1999

2000

2001

2002

2003

2004

22
10
3
5
5
3
4
5

10
7
3
1
1

9
6
3
4
3
1
2

23
16
5
2
4
3
3
3
13

27
25
9
5
5
8
4
4
3
13

23
29
11
7
9
6
4
3
4
17

Total # of
Depressants
142
111
39
32
31
22
20
20
16
103

1997

1997
17
11

10

1
3
1
9

1
10

11
7
5
6
3
1
2
1
3
12

55

67

36

39

51

72

103

113

536

45

51

28

33

40

54

71

82

404

2
1

4
1
19

SOURCE: Medical Examiners Office, Public Health Seattle & King County

Exhibit 7c. Combination Depressant and Prescription-Type Opiate-Involved Deaths in King County,
Washington: 1997–2004
140
120
100
80
60
40
20
0

1997

1998

1999

2000

2001

2002

2003

2004

Combo Rx Opiate/Depressant

10

17

9

16

23

26

41

51

Rx Opiate

28

44

32

50

53

66

84

118

Depressant

45

51

28

33

40

54

71

82

SOURCE: Medical Examiners Office, Public Health Seattle & King County
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Exhibit 7d. Demographics of Drug-Involved Deaths in King County, Washington: 1997–2004

Demographic

All
Drugs

Number of Times Identified

Cocaine

Depressant

Rx
Stim.

Metham.

DXM/
MDMA/
GHB/
PCP
37

Heroin/
Opiates/
Morphine

Rx
Opiate

Oxycodone1

Methadone1
253

1,584

572

404

12

83

759

475

107

Percent Male

71

78

57

75

80

57

81

58

60

61

Average Age

41.6

41.2

43.8

33.8

37.9

36.3

40.6

43

44.7

41.4

Race/Ethnicity
White
African-American
Asian/Pacific Islander
Native American
Hispanic
Other/Multiple

83
11
1
3
1
1

73
21
1
2
1
2

88
7
1
2
1
1

92
0
0
0
0
8

88
5
2
2
0
2

81
17
0
0
3
0

84
10
0
3
2
2

88
8
1
2
0
1

89
7
1
3
0
1

85
12
1
2
0
0

Manner of Death
Accident
Suicide
Homicide
Undetermined

81
11
0
9

94
1
0
5

63
24
0
14

92
0
0
8

94
1
0
5

68
11
0
22

92
2
0
6

79
11
0
11

70
22
0
8

90
1
0
9

Avg. Number of Drugs2

2.3

2.6

3.5

4.2

2.4

3.4

2.4

3.1

3.2

3.0

1

Oxycodone and Methadone are also included in the Rx Opiate category
Includes Alcohol, Cocaine, Heroin/Op/Mor, Rx Opiates, Depressants, Rx Stimulants, Meth., Hallucinogens. Excludes drugs such as
NSAIDS and anti-depressants.
SOURCE: Medical Examiner, Public Health & Seattle-King County.
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Exhibit 7e. Proportions of King County Deaths Involving at Least 2 Drugs: 2004
Depressant & Rx Opiate

20%

Cocaine & Heroin/Opiate

14%

Alcohol & Rx Opiate

11%

Cocaine & Rx Opiate

10%
9%

Cocaine & Depressant
Heroin/Opiate & Alcohol

8%

Alcohol & Depressant

8%

Alcohol & Cocaine

8%

Heroin/Opiate & Depressant

8%

Heroin/Opiate & Rx Opiate

6%
3%

Rx Opiate & Methamphetamine
Heroin/Opiate & Methamphetamine

1%

1

These data are duplicated. A person could have multiple 2-way drug combinations if, for example, they had used heroin, cocaine, a
prescription-type opiate, and a depressant.
SOURCE: Medical Examiner’s Office, Public Health-Seattle & King County

Exhibit 7f.

King County Prescription-Type Opiate- and Depressant-Involved Deaths and Proportion of
Single-Drug Deaths: 1997–2004

Depressants
%
N
26
6%
404
25%
1,587

1

No other drugs
All deaths involving substance
Total # of drug involved deaths

Prescription-type
Opiates
%
N
60
13%
475
30%
1,587

All Drugs
%
N
622
29%
1,587

1

Other drug=Illegal; prescription: muscle relaxants, opiates, depressants, and diphenhydramine.
SOURCE: Medical Examiner- Public Health- Seattle & King County

Exhibit 7g. Illegal Drug Presence in Prescription-Type Opiate- and Depressant-Involved Deaths in King
County: 1997–2004

Depressants
%
N
1

Illegal drugs present
All deaths involving substance
Total # of drug involved deaths

177
404
1,587

44%
25%

Prescription-type
Opiates
%
N
164
475
1,587

35%
30%

All Drugs
%
N
1056
67%
1,587

1

Illegal=Heroin, cocaine, and/or methamphetamine
SOURCE: Medical Examiner- Public Health- Seattle & King County
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Exhibit 8.

1

Opiate Substitution Treatment for King County Residents: 1999–2004

Admits
Discharges
Primary Drug at Admission (%)
Heroin
Prescription-type Opiates

1999

2000

2001

2002

2003

2004

Total

1,333
632

1,560
924

1,238
890

1,175
794

1,085
633

1,660
743

8,051
4,616

94.6
3.0

93.3
6.1

92.8
6.5

90.4
8.8

87.7
11.3

86.6
11.6

90.9
7.9

1
Note-Treatment Capacity Increased by 350 in 2000 and by approximately 200 in 2004.
SOURCE: Washington State Treatment and Assessment Report Generation Tool (TARGET) data system—Structured Ad Hoc
Reporting System Run Date: 05/23/2005

Exhibit 9.

Methadone Waiting List Managed by Syringe Exchange Program, King County: 1997–June 2005

Number on Wait List

1997

1998

1999

2000

2001

2002

2003

2004

198

307

548

624

495

663

638

487

1

June
2005
156

1

Note- Figures are for the close of each year.
SOURCE: Public Health- Seattle & King County, HIV/AIDS Program

Exhibit 10. Heroin Purity and Street-Level Purchases in the City of Seattle: 1997–June 2005
% Purity
50
45.8
45

44.9

40
35

Average

38.4

Median

37.0

30
25
20

18.9

17.3

12.9

15
10

16.8

13.7

8.5
11.8
7.4

5
0
1999

8.3

6.3
2000

2001

2002

2003

2004

2005

Fiscal year
Data differ from national reports due to exclusion of Tacoma data.
Each black dot=1 purchase. Purchases totaled 124 for 5 years.
SOURCE: Seattle Drug Enforcement Administration (2005), Domestic Monitor Program (used with permission)
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Exhibit 11. Percent Change in Amount of Prescription Opiates Sold to Hospitals and Pharmacies in the King
1
County Area : 1997–2003
600%

500%
Methadone
359%

400%
Oxycodone
312%
300%

200%

Fentanyl
174%

Hydrocodone
Hydromorphone 93%
80%

100%

Morphine
88%

TOTAL
68%

0%

-100%

Codeine
-27%

Meperidine
-30%

1
Data for ZIP Codes 980xx and 981xx, which approximate King County boundaries.
SOURCE: Automation of Reports and Consolidated Orders System and DEA,
http://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html

Exhibit 12. Percent Change in Amount of Prescription Stimulants Sold to Hospitals and Pharmacies in the
1
King County Area : 1997–2003
1200%

1,108%

1000%
800%
600%
400%
134%
200%

66%

0%
DL Amphetamine
e.g. Adderall

D Amphetamine
e.g. Dexedrine

Methylphenidate
e.g. Ritalin

1
Data for ZIP Codes 980xx and 981xx, which approximate King County boundaries.
SOURCE: Automation of Reports and Consolidated Orders System and DEA,
http://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html
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Exhibit 13. Number of Methamphetamine Labs and Dump Sites Reported in King and Neighboring Counties:
1990–2004
2000
1800
1600
1400
1200
#

1000
800
600
400
200
0

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

King

6

10

2

7

7

10

23

17

48

107

231

271

241

202

199

Kitsap

1

1

2

1

1

21

45

54

60

50

44

Pierce

10

18

18

12

129

318

545

589

438

466

541

40

42

Snohomish

2

2

WA State TOTAL

38

43

3
17

17

53
7

6

5

13

37

69

83

98

101

36

54

153

203

349

789

1454

1890

1693

1480

1337

2

42

SOURCE: Washington State Department of Ecology
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Exhibit 14. New HIV Infections in King County and Washington State, by Year of Diagnosis and
Demographic Characteristics: 1996–2004

TOTAL
HIV Exposure Category
MSM
IDU
MSM-IDU
Heterosexual contact
Blood product exposure
Perinatal exposure
3
Undetermined
Sex & Race/Ethnicity
Male
4
White Male
4
Black Male
Hispanic Male
4
Other Male
Female
4
White Female
4
Black Female
Hispanic Female
4
Other Female
Race/Ethnicity
4
White
4
Black
Hispanic
4
Asian & Pacific Islander
4
American Indian/ Alaska Native
4
Multi Race
Unknown
Age at Diagnosis of HIV
0–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65 and older

King County
1
2
2002–2004
Trend
No
(%)
1996–2004
1,006
(100)
651
67
71
109
3
0
105

(65)
(7)
(7)
(11)
(0)
(0)
(10)

889
571
155
103
60
117
33
62
8
14

(88)
(57)
(15)
(10)
(6)
(12)
(3)
(6)
(1)
(1)

604
217
111
33
21
16
4

(60)
(22)
(11)
(3)
(2)
(2)
(0)

10
72
141
191
244
173
90
47
24
8
6

(1)
(7)
(14)
(19)
(24)
(17)
(9)
(5)
(2)
(1)
(1)

up

down
up

up

down
up

up

down
down
up

up

WA State
1
2
2002–2004
Trend
No
(%)
1996–2004
1,576
(100)
901
153
102
218
6
2
194

(57)
(10)
(6)
(14)
(0)
(0)
(12)

1,319
877
207
149
86
257
103
95
25
34

(84)
(56)
(13)
(9)
(5)
(16)
(7)
(6)
(2)
(2)

980
302
174
56
40
16
8

(62)
(19)
(11)
(4)
(3)
(1)
(1)

down
up

19
129
218
277
343
266
159
84
47
18
16

(1)
(8)
(14)
(18)
(22)
(17)
(10)
(5)
(3)
(1)
(1)

down
up
down
down

up

down
up

up

up

up

1

Due to delays in reporting, data from recent years are incomplete
Statistical trends were identified from the chi-square test for trend, calculated for the periods 1996–98, 1999–2001, and 2002–04.
3
Includes persons for whom exposure information is incomplete (due to death, refusal to be interviewed, or loss to follow-up), patients still under investigation, patients whose only risk was heterosexual contact and where the risk of the sexual partner(s) was
(were) undetermined, persons exposed to HIV through their occupation, and patients whose mode of exposure remains undetermined.
4
And not Hispanic. The groups Asian, Native Hawaiian, and other Pacific Islanders were grouped due to small cell sizes. All categories are mutually exclusive.
SOURCES: Public Health—Seattle & King County, HIV/AIDS Epidemiology
2
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Exhibit 15. Syringes Exchanged and Number of Encounters for King County Syringe Exchanges:
2002–2004
2002
Syringes Exchanged
1
Encounters
Average Number of Syringes per Encounter

2003

2004

1,801,151
73,752

1,969,522
65,593

2,183,150
63,898

24

30

34

1
Encounters are duplicated
SOURCE: Public Health- Seattle & King County, HIV/AIDS Program

1

Exhibit 16. Trends in Primary Injection Drug in Seattle-Area IDUs Age 18–30 Participating in 4 Studies :
1994–2003

1997, 84.5

Percent
100.0
90.0

60.0

1994, 7.4

1997, 2.8

10.0

2003, 5.4

1994, 18.9

20.0

2003, 6.6

30.0

1994, 18.9

40.0

2000, 25.9

50.0

2003, 32.2

70.0

2001, 33.7

1994, 54.9

2003, 55.8

80.0

0.0
Speedballs2

Heroin

Cocaine

Amphetamines

Primary Injection Drug
1

The number of cases ranged from 27-333 per year, with an average of 164 in each year.
Speedballs refers specifically to the combination of heroin and cocaine.
SOURCE: Public Health-Seattle & King County, HIV/AIDS Epidemiology Unit

2
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Substance Abuse Trends in
Texas, June 2005

INTRODUCTION

Jane Carlisle Maxwell, Ph.D.1

The population of Texas in 2004 is 22,158,126, with
51 percent White, 12 percent Black, 34 percent Hispanic, and 3 percent “Other.” Illicit drugs continue to
enter from Mexico through cities such as El Paso,
Laredo, McAllen, and Brownsville, as well as through
smaller towns along the border. The drugs then move
northward for distribution through Dallas-Fort Worth
and Houston. In addition, drugs move eastward from
San Diego through Lubbock and from El Paso to
Amarillo and Dallas-Fort Worth.

ABSTRACT
Cocaine continues to be readily available, and it is
the primary illicit drug for which Texans enter
treatment. It remains a problem on the border with
Mexico, as documented in the school survey and
treatment data. Use of crack cocaine continues to
move beyond Black users to White and Hispanic
users. Alcohol is the primary drug of abuse in Texas
in terms of dependence, deaths, and treatment admissions; of minors treated in emergency departments for a problem with alcohol, some 37–38 percent were younger than 18. Heroin addicts entering
treatment are primarily injectors. In Texas, hydrocodone is a much larger problem than oxycodone or
methadone. Codeine cough syrup, ‘Lean,’ continues
to be abused. Treatment data show that marijuana
clients admitted with criminal justice problems are
less impaired than those who are referred from
other sources. Methamphetamine is a growing problem, particularly in north and east Texas, according
to the indicators, and smoking ice is increasing,
while the price of the drug continues to drop. Xanax
and Soma continue to be widely abused pharmaceutical drugs. Club drug users differ in their sociodemographic characteristics, just as the properties of
these drugs differ. Ecstasy use is moving out of the
White club scene, and indicators increased from
2003 to 2004. Ketamine continues as a problem.
GHB, GBL, and similar precursor drugs remain a
problem, particularly in the Dallas-Fort Worth
Metroplex area. Although indicators are down, Rohypnol remains a problem along the Texas-Mexico
border. PCP indicators are mixed; dextromethorphan is a problem with adolescents; and carisoprodol (Soma) is a growing problem and is often
abused in combination with other prescription
drugs. Inhalants remain a problem with different
types of users. The number of AIDS cases involving
females and persons of color is growing. The proportion of cases due to the heterosexual mode of
transmission now exceeds the proportion of cases
due to injecting drug use.

Area Description

There are multiple routes by which drugs enter
Texas. The international airports in Houston and
Dallas-Fort Worth are major ports for the distribution of drugs into and out of the State, and seaports
are used to import heroin and cocaine via commercial cargo vessels. Both private and express mail
companies are used to traffic narcotics and smuggle
money, and drugs are transported across the border
by private vehicles and couriers who walk the drugs
across on their bodies. Another problem is that U.S.
citizens can buy controlled substances in Mexican
pharmacies and then bring them into the States.
Data Sources
Substance Abuse Trends in Texas is an ongoing series which is published every 6 months as a report
for the Community Epidemiology Work Group
meetings sponsored by the National Institute on
Drug Abuse (NIDA). This report updates the January
2005 report. To compare the June 2005 report with
earlier periods, please access http://www.utexas.edu/
research/cswr/gcattc/drugtrends.html.
The information on each drug is discussed in the
following order of sources:
•

Student substance use data came from the
Texas School Survey of Substance Abuse:
Grades 7-12, 2004 and the Texas School Survey
of Substance Abuse: Grades 4-6, 2004, which
are published by the Texas Department of State
Health Services (DSHS), formerly the Texas
Commission on Alcohol and Drug Abuse.

•

Adult substance use data came from DSHS’s
2000 Texas Survey of Substance Use Among
Adults.

1

The author is affiliated with the University of Texas at Austin,
Center for Social Work Research, Austin, Texas.
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•

Data on use by Texans age 12 and older came
from the Substance Abuse and Mental Health
Services Administration’s (SAMHSA) State Estimates of Substance Use from the 2002-2003
National Survey on Drug Use and Health.

•

Poison control center data came from the
Texas Poison Center Network, DSHS, for 1998–
2004. Analysis was provided by Mathias Forrester, epidemiologist with the Texas Poison Center
Network, and by the author. In addition, findings
from four papers authored by Forrester, “Carisoprodol Abuse in Texas, 1998-2003,” “Flunitrazepam Abuse and Malicious Use in Texas,
1998-2003,” “Oxycodone Abuse in Texas, 19982003,” and “Methylphenidate Abuse in Texas,
1998-2004,” were used in this report.

•

Emergency department (ED) data were derived for calendar year 2004 from the Drug
Abuse Warning Network (DAWN) Live! restricted-access online query system administered
by the Office of Applied Studies (OAS),
SAMHSA. Eligible hospitals in the Dallas-Fort
Worth DAWN area totaled 49, with 48 in the
DAWN sample, and 49 EDs in the sample. During 2004, between 10 and 16 Dallas emergency
departments reported data each month. Eligible
hospitals in the Houston DAWN area totaled 44,
with 37 in the DAWN sample, and 39 EDs in the
sample. During 2004, between 14 and 15 Houston EDs reported data each month. The response
rates in both Dallas and Houston were relatively
low (exhibit 1). In Houston, this was because it
was new and, in Dallas, it was because few hospitals agreed to participate. Exhibits in this paper
reflect cases that were received by DAWN as of
April 13, 2005 and May 18, 2005. All DAWN
cases are reviewed for quality control. Based on
this review, cases may be corrected or deleted.
Therefore, the data presented in this paper are
subject to change. Data derived from DAWN
Live! represent drug reports in drug-related ED
visits. Drug reports exceed the number of drug
visits, since a patient may report use of multiple
drugs (up to six drugs plus alcohol). The DAWN
Live! data are unweighted and, thus, are not estimates for the reporting area. These data cannot
be compared to DAWN data from 2002 or before, nor can preliminary data be used for comparison with future data. Only weighted DAWN
data released by SAMHSA can be used for trend
analysis. A full description of the DAWN system
can be found at the DAWN Web site:
<http://dawninfo.samhsa.gov>.
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•

Treatment data were provided by DSHS’s client data system on clients at admission to treatment in DSHS-funded facilities from the first
quarter of 1987 through December 31, 2004. For
most drugs, the characteristics of clients entering
with a primary problem with the drug are discussed, but in the case of emerging club drugs,
information is provided on any client with a primary, secondary, or tertiary problem with that
drug. Analysis was by the author.

•

Overdose death data statewide on drug overdose deaths came from death certificates from
the Bureau of Vital Statistics, DSHS; analysis
was by the author. Findings are also presented
from Maxwell, J.C.; Pullum, T.W.; and Tannert,
K. “Deaths of Clients in Methadone Treatment in
Texas: 1994-2002,” Drug and Alcohol Dependence, 78(1); 73-82, 2005.

•

Drug and alcohol arrests data come from the
Uniform Crime Reports of the Texas Department
of Public Safety (DPS).

•

Information on drugs identified by laboratory
tests are from the Texas Department of Public
Safety, which submitted results from toxicological analyses of substances submitted in law enforcement operations for 1998 through December 31, 2004, to the National Forensic Laboratory Information System (NFLIS) of the Drug
Enforcement Administration (DEA). Analysis
was by the author.

•

Price, purity, trafficking, distribution, and
supply information was provided by first and
second quarter 2005 reports on trends in trafficking from the Dallas, El Paso, and Houston Field
Divisions of the DEA and from DEA’s 2003
Domestic Monitor Program.

•

Reports by users and street outreach workers
regarding drug trends for 2005 were reported to
DSHS by workers at local human immunodeficiency syndrome (HIV) counseling and testing
programs.

•

Acquired immunodeficiency syndrome (AIDS)
data were provided by DSHS for annual periods
through December 2004.

•

Hepatitis C (HCV) data were provided by
DSHS on HCV counseling and testing for the period January 1, 2003, to December 31, 2003.
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DRUG ABUSE PATTERNS AND TRENDS

than crack smokers and were most likely to be White
(exhibit 3).

Cocaine/Crack
The Texas School Survey of Substance Abuse:
Grades 7-12, 2004 reported that lifetime use of powder and crack cocaine had dropped from a high of 9
percent in 1998 to 8 percent in 2004, while pastmonth use dropped from 4 percent in 1998 to 3 percent in 2004. Some 7.0 percent of students in nonborder counties had ever used powder or crack cocaine, and 2.5 percent had used it in the past month.
In comparison, students in schools on the Texas border reported higher levels of cocaine use: 13 percent
lifetime and 6 percent past-month use (exhibit 2).
The 2000 Texas Survey of Substance Use Among
Adults reported 12 percent of Texas adults had ever
used powder cocaine. Some 2 percent had used it in
the past year. In 2002–2003, the National Survey on
Drug Use and Health estimated that 2 percent of
Texans age 12 and older had used cocaine in the past
year. Use by age group included 3 percent of those
age 12–17, 7 percent of those 18–25, and 2 percent
of those 26 and older.
Texas Poison Control Center calls involving the use
of cocaine increased from 503 in 1998 to 1,405 in
2004. Some 65 percent were male, and the average
age was 30.
Cocaine is the major illicit drug in terms of emergency
department reports. It represented 33 percent of the
unweighted DAWN ED reports for “major substances
of abuse” (including alcohol) in Dallas-Fort Worth
and 38 percent of the reports in Houston. In Dallas, 67
percent of the patients were male, 36 percent were
Anglo, 44 percent were Black, and 15 percent were
Hispanic; 35 percent were age 35–44 and 18 percent
were 45–54. In Houston, 64 percent of the patients
were male, 36 percent were Anglo, 42 percent were
Black, and 19 percent were Hispanic; 33 percent were
age 35–44 and 17 percent were 45–54.
Cocaine (crack and powder) together represented 26
percent of all admissions to DSHS-funded treatment
programs in 2004. With 18 percent of all admissions,
crack cocaine is the primary illicit drug problem of
clients admitted to publicly funded treatment programs in Texas (exhibit 30).
Abusers of powder cocaine represented 8 percent of
all admissions to treatment. Cocaine inhalers were
the youngest and most likely to be Hispanic and involved in the criminal justice or legal systems. Cocaine injectors were older than inhalers but younger
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The term “lag” refers to the period from first consistent or regular use of a drug to the date of admission
to treatment. Powder cocaine inhalers average 9
years between first regular use and entrance to treatment, while injectors average 15 years of use before
they enter treatment.
Between 1987 and 2004, the percentage of Hispanic
treatment admissions using powder cocaine increased from 23 percent to 51 percent, while for
Whites and Blacks, the proportions dropped from 48
percent to 36 percent, and from 28 percent to 11 percent, respectively. Exhibit 4 shows these changes by
route of administration. It also shows that the proportion of Black crack cocaine admissions fell from 75
percent in 1993 to 49 percent in 2004, while the proportion of Whites increased from 20 percent in 1993
to 33 percent in 2004. Hispanic admissions rose from
5 percent to 16 percent in the same time period.
Cocaine is also a problem on the border. Eighteen percent of treatment admissions on the Texas border in
2004 were for problems with powder cocaine (86 percent inhaled the drug and 13 percent injected it). Another 11 percent of admissions smoked crack cocaine.
The number of deaths statewide in which cocaine
was mentioned has increased over the years—from
223 in 1992 to 541 in 2002—but decreased to 477 in
2003 (exhibit 5). The average age of the decedents
was 39 in 2003, and 43 percent were White, 25 percent were Hispanic, and 31 percent were Black.
Eighty percent were male.
Exhibit 6 shows that the proportion of substances
identified as cocaine by the DPS labs is decreasing.
In 1998, cocaine accounted for 40 percent of all
items examined, compared with 31 percent in 2004.
In the second quarter of 2005, powder and crack cocaine were reported by the Dallas DEA Field Division
as being readily available in the Metroplex, in Lubbock, and in small towns and rural communities in
north Texas. In Dallas, crack was particularly popular
in the predominantly Black and Hispanic neighborhoods, and it was the most visible drug trafficked in
Tyler. In Fort Worth, crack and methamphetamine
were reported as the drugs of choice by young users;
in Lubbock, crack was used by all ethnic groups, although it was more prevalent in the Black community.
Both forms of cocaine were readily available in the El
Paso Field Division. Cocaine availability has remained constant in the Houston Field Division, with
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availability up in rural areas east of Austin (Elgin and
Bastrop). Crack availability and use is minimal in
Laredo. Cocaine is transshipped thorough the Lower
Rio Grande Valley to large metropolitan centers using
smaller private vehicles. Vehicle transport fees have
averaged $500–$700 per kilogram, with a fee of
$1,000–$1,500 for body carriers.
In addition to continuing to be readily available, the
price for a kilogram of powder cocaine remained
stable at $11,000–$22,500 in the first half of 2005
(exhibit 7). A gram of powder cocaine costs $50–$80
in Dallas, $50–$60 in El Paso, and $100 in Amarillo
and Lubbock. An ounce costs $400–$600 in
McAllen, $400–$650 in Houston, $500–$600 in
Austin, $800–$900 in Midland, $500–$600 in El
Paso, $400–$650 in Houston, $600–$950 in Dallas,
$600 in Alpine, $500–$700 in Waco, $650–$850 in
Amarillo, $500–$850 in Lubbock, $300–$750 in
Tyler, and $600–$750 in Fort Worth.
Across the State, a rock of crack costs $10–$50, with
$10–$20 being the most common price. An ounce of
crack cocaine costs $325–$450 in Houston, $500 in
Galveston, $400–$600 in San Antonio, $500–$600 in
Austin, $500–$700 in Waco, $700–$1,100 in Dallas,
$450–$550 in Tyler, $500–$800 in Beaumont, $450–
$1,000 in Amarillo and Lubbock, $400–$600 in San
Antonio, $830 in El Paso, $800–$900 in Midland,
$500 in McAllen, and $650–$750 in Fort Worth.
In Austin, street outreach workers report crack is
being sold for $200 per half-ounce or $150 for a
quarter piece. The quality is reported to be declining,
and the pieces of crack are becoming smaller and the
price increasing. A $10-size piece now costs $20.
Cocaine is being “cut” with baking soda and B-12
vitamins or a mixture of dishwashing liquid and
ammonia that is hardened and then combined with
cocaine to produce crack. BC powder for pain-relief
is also combined with powder cocaine to produce
crack. The baking soda and B-12 mixture is reported
to produce crack of a higher quality. Injecting crack
users use citric acid break down the crack. They report it is a “clean” shot and is less likely to cause
abscesses or swollen veins than crack that has been
dissolved in Kool Aid or lemon juice. Injecting crack
is also reported in Fort Worth.
In the Galveston-Brazoria area, powder cocaine use
is up, but crack is more commonly used, especially
in situations involving trading sex for drugs. Crack
cocaine continues to be the most visible drug on the
street.
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Alcohol
Alcohol is the primary drug of abuse in Texas. The
1998 secondary school survey found that 72 percent
of students had ever drunk alcohol and 38 percent
had drunk alcohol in the last month. In 2004, 68 percent had ever used alcohol and 33 percent had drunk
alcohol in the last month.
Of particular concern is heavy consumption of alcohol, or binge drinking, defined as drinking five or
more drinks at one time. In 2004, 15 percent of all
secondary students said that when they drank, they
usually drank five or more beers at one time, and 13
percent reported binge drinking of liquor. Binge
drinking increased with grade level. Among seniors,
27 percent binged on beer and 21 percent on liquor.
While the percentage binge drinking wine or wine
coolers has fallen from its peak in 1994, it is still
higher than in 1988 (exhibit 8). The percentage of
binge drinking of hard liquor has remained relatively
stable since 1994.
Among students in grades 4–6 in 2004, 26 percent
had ever drunk alcohol and 16 percent had drunk
alcohol in the past school year.
The 2000 Texas adult survey found that 50 percent
of Texas adults reported drinking alcohol in the past
month. Some 17 percent reported binge drinking, 6
percent reported heavy drinking in the past month,
and 5 percent of all adults met the criteria for being
dependent on alcohol. This estimate was based on
the Diagnostic and Statistical Manual of Mental Disorders, III-R (DSM III-R).
The 2002–2003 National Survey on Drug Use and
Health estimated that 47 percent of Texans age 12
and older had drunk alcohol in the past month (18
percent of those age 12–17, 58 percent of those 18–
25, and 50 percent of those 26 and older). Some 24
percent had drunk five or more drinks on at least 1
day (binge drinking) in the past month (10 percent of
those 12–17, 40 percent of those 18–24, and 23 percent of those age 26 and older). Some 8 percent met
the criteria for alcohol dependence based on the Diagnostic and Statistical Manual of Mental DisordersIV (DSM-IV). The level of alcohol dependence was
estimated at 6 percent of those age 12–17, 17 percent
for those 18–25, and 6 percent of those 26 and older.
Of all the unweighted DAWN emergency department reports for major substances of abuse in 2004,
26 percent in Dallas-Fort Worth and 27 percent in
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Houston involved alcohol. In Dallas-Fort Worth, 321
(4.5 percent) of the reports involved alcohol-only
among patients younger than 21. In Houston, 2.6
percent of the reports involved patients younger than
21. In Dallas-Fort Worth, 53 percent of the minors
were male, 53 percent were Anglo, 6 percent were
Black, and 30 percent were Hispanic; 63 percent of
these reports involved youths age 18–20, with 37
percent being 12–17. In Houston, 62 percent were
male, 38 percent were White, 8 percent were Black,
and 47 percent were Hispanic; 61 percent of these
reports involved youths age 18–20, and 38 percent
were 12–17.

lants remained level at 4 percent, and cocaine increased from 7 percent to 25 percent. Consuming
cocaine and alcohol at the same time produces cocaethylene, which intensifies cocaine's euphoric effects.

In 2004, 27 percent of all clients admitted to publicly
funded treatment programs had a primary problem
with alcohol (exhibit 30). They were among the oldest of the clients (average age of 37), and more likely
to be male. Of the 14,410 alcohol admissions, 901 (6
percent) were younger than age 21. Of these minors,
the average age was 17 and their average age of first
use was 13. Seventy percent of the minors were
male, 52 percent were Hispanic, 40 percent were
White, and 6 percent were Black. Seventy-three percent were referred to treatment by the criminal justice or legal system; average education was 9.7
years. In comparison, among adult alcohol clients, 68
percent were male, 24 percent were Hispanic, 59
percent were White, and 14 percent were Black.
Forty-four percent were referred by the criminal justice or legal system, and average education level was
12 years.

The proportion of Texas secondary students reporting
lifetime use of heroin dropped from 2.4 percent in
1998 to 1.6 percent in 2004. Past-month use dropped
from 0.7 percent in 1998 to 0.5 percent in 2004.

More Texans are arrested for public intoxication (PI)
than for any other substance abuse offense, although
the arrest rate for PI per 100,000 population is decreasing. The rates for the other substance abuse
offenses are fairly level (exhibit 9).
Heroin

The 2000 Texas adult survey found that 1.2 percent
of adults reported lifetime use of heroin and 0.1 percent reported past-month use.
Calls to Texas Poison Control Centers involving
confirmed exposures to heroin ranged from 181 in
1998 to a high of 296 in 2000 and dropped to 208 in
2003 and 184 in 2004. In 2004, the average age was
34, and 60 percent were male. Nine percent of heroin
exposures involved inhalation (snorting or smoking).

Minors entering treatment were more likely to report
problematic use of other substances: 71 percent reported a second drug of abuse, while among adults,
50 percent reported a second problem. Marijuana
was a problem for 48 percent of minors and 14 percent of adults, powder cocaine was a problem for 10
percent of minors and 12 percent of adults, and crack
cocaine was a problem for 2 percent of minors and
15 percent of adults.

Heroin represented 5 percent of the unweighted
DAWN ED reports for major substances of abuse in
Dallas-Fort Worth and 2 percent of the reports in
Houston in 2004. In Dallas-Fort Worth, 70 percent of
the patients were male, 53 percent were Anglo, 28
percent were Black, and 12 percent were Hispanic;
22 percent were age 35–44, 19 percent were 45–54,
and 18 percent were 25–29. In Houston, 68 percent
were male, 63 percent were Anglo, 10 percent were
Black, and 23 percent were Hispanic; 36 percent
were 35–44, 20 percent were 45–54, and 10 percent
were 25–29 or 30–34.

The characteristics of alcohol admissions have
changed over the years. In 1988, 82 percent of the
clients were male, compared with 68 percent in
2004. The proportion of White clients declined from
63 percent in 1988 to 58 percent in 2004; the proportion of Hispanic clients declined from 28 percent to
26 percent, while the proportion of Black clients
increased from 7 percent to 14 percent. The average
age increased from 35 to 37 years. The proportion of
alcohol clients reporting no secondary drug problem
dropped from 67 to 49 percent, while marijuana
dropped from 18 percent to 16 percent, but stimu-

Heroin is the primary drug of abuse for 10 percent of
clients admitted to treatment. The characteristics of
these addicts vary by route of administration, as exhibit 10 illustrates. Most heroin addicts entering
treatment inject heroin. While the number of individuals who inhale heroin is small, it is important to
note that the lag period from first use and seeking
treatment is 8 years rather than 16 years for injectors.
This shorter lag period means that contrary to street
rumors that “sniffing or inhaling is not addictive,”
inhalers can become addicted. They will either enter
treatment sooner while still inhaling or they will shift
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to injecting, increase their risk of hepatitis C and
HIV infection, become more impaired, and enter
treatment later.
Exhibit 11 shows that the proportion of treatment
clients who are Hispanic has increased since 1996,
but there has been little change since 2002.
There were 278 deaths statewide with a mention of
heroin or narcotics in 2003 (exhibit 12). Some 56
percent were White, 33 percent were Hispanic, and 9
percent were Black; 72 percent were male. The average age was 39.
Exhibit 6 shows that the proportion of items identified as heroin by DPS labs has remained constant at
1–2 percent over the years.
The predominant form of heroin in Texas is black
tar, which has a dark gummy, oily texture that can be
diluted with water and injected. Exhibit 13 shows the
decline in price over the years. Depending on the
location, black tar heroin sells on the street for $10–
$20 per capsule, $50–$350 per gram, $400–$4,500
per ounce, and $40,000–$80,000 per kilogram. An
ounce costs $1,000–$1,500 in Dallas, $1,200–$1,700
in Fort Worth, $1,000–$1,500 in El Paso, $2,100–
$2,200 in Alpine, $1,800–$4,000 in Midland,
$3,500–$4,500 in Lubbock, $1,200–$1,500 in Houston, $1,300 in Laredo, $400–$1,500 in McAllen,
$1,400–$1,600 in Austin, and $1,600–$2,400 in San
Antonio.

cost $0.98 per milligram pure, compared with 17.2
percent pure and $0.75 per milligram pure in 2002.
In El Paso in 2003, heroin was reported by DEA as
being available, although not plentiful. It could be
purchased for about $100 per gram. In 2003, 13
samples of Mexican heroin were purchased under the
DEA program, and of these, purity averaged 44.7
percent and cost was $0.40 per milligram pure. The
price rose from $0.13 and the purity rose from 40.3
percent in 2002. Colombian heroin is also being
mentioned in El Paso
The DEA Houston Field Division reported the supply of brown and black tar heroin was stable. There
were 44 DMP purchases of heroin, at a purity of 28.2
percent and cost of $0.45 per milligram pure in 2003,
compared with 28.2 percent pure and $0.64 per milligram pure in 2002. Mexican black tar and brown
are the primary types seen in the Houston Division,
although Colombian heroin is transported through
Houston to the Northeastern United States.
Street outreach workers in Austin report that heroin
supplies are plentiful and the drug is cut with lactose,
brown sugar, and instant coffee. A balloon, which is
equal to 0.3 gram, costs $15, with two balloons selling for $30, four selling for $40, and five selling for
$50. Amarillo street outreach workers report that
there is an increase in injecting heroin.
Other Opiates

Mexican brown heroin, which is black tar that has
been cut with lactose or another substance and then
turned into a powder to inject or snort, costs $10 per
cap and $70–$300 per gram. An ounce costs $500–
$800 in San Antonio, $1,100 in McAllen, $800–
$1,600 in Dallas, and $2,200–$3,000 in Lubbock.

This group excludes heroin but includes opiates such
as methadone, codeine, hydrocodone (Vicodin, Tussionex), oxycodone (OxyContin, Percodan, Percocet5, Tylox), d-propoxyphene (Darvon), hydromorphone (Dilaudid), morphine, meperidine (Demerol),
and opium.

Colombian heroin sells for $10 per cap, $2,000–
$4,000 per ounce, and $65,000–$80,000 per kilogram
in Dallas and $35,000–$80,000 in Houston. Asian
heroin costs $200–$350 per gram, $2,000–$4,000 per
ounce, and $70,000 per kilogram in Dallas.

The 2004 Texas secondary school survey found that
8 percent reported ever having drunk codeine cough
syrup to get high. Some 9 percent of Black and
White students reported lifetime use, as did 9 percent
of Native American students and 5 percent of Hispanic students. There was no difference by gender,
but lifetime use increased with grade level (from 3
percent of 7th graders to 11 percent of 12th graders).

In the Dallas area, black tar is readily available and
Colombian is available in multikilogram quantities.
Sources report white and beige-colored heroin is
now being produced in Mexico using Colombian
production methods, and Colombian heroin organizations are interested in developing a greater market
presence in the Dallas area. In 2003, 31 exhibits of
Mexican heroin purchased through the Domestic
Monitor Program (DMP) were 13.3 percent pure and
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The 2000 Texas adult survey found that lifetime use
of other opiates was 4 percent, and past-month use
was 0.5 percent in 2000. Some 2 percent of Texas
adults in 2000 reported ever having used codeine,
and 0.7 percent used in the past year. Lifetime use of
hydrocodone was 0.7 percent, and past-year use was
0.4 percent.
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Hydrocodone is a larger problem in Texas than is
oxycodone, but use of oxycodone is growing, as exhibit 14 shows. Among poison control center cases of
abuse and misuse, the average age of hydrocodone
callers was 33 and oxycodone callers was 32. A study
of oxycodone cases reported through the Texas Poison Center Network found that the proportion of calls
that involved abuse of the drug more than doubled
from 1998 to 2003. Oxycodone abuse involved
males, adolescents, exposures at other residences and
public areas, referral by the poison center to a health
care facility, and some sort of clinical effect; one-half
involved no other substance (Forrester, 2004).
Cases involving methadone are increasing. Methadone is not only used in liquid and 50-milligram
diskette forms in narcotic treatment programs, but 5and 10-milligram pills are used for pain management.
The poison control center, death certificate, and forensic laboratory data usually do not report the form
of methadone being abused. The form of the drug
could be an overdose by new patients in narcotic
treatment programs, liquid methadone which has
been diverted from treatment, pain pills diverted from
patients, or overdoses by pain patients who took too
many of the pills or took other drugs in combination
with the methadone pills. The number of poison control center cases involving misuse or abuse of methadone increased from 16 in 1998 to 106 in 2004. The
average age in 2004 was 33.
The unweighted 2004 DAWN ED reports showed
598 hydrocodone and hydrocodone combination reports in Dallas-Fort Worth and 664 in Houston. Of
the reports in Dallas-Fort Worth, 40 percent were
male, 67 percent were Anglo, 14 percent were Black,
and 8 percent were Hispanic; 22 percent of the patients were age 35–44 and 18 percent were 45–54. In
Houston, 48 percent were male, 67 percent were Anglo, 13 percent were Black, and 11 percent were Hispanic; 27 percent were age 35-44 and 20 percent
were 45-54. In comparison, there were 86 oxycodone
and oxycodone/combination reports in Dallas and 68
in Houston. Of the oxycodone patients in Dallas-Fort
Worth, 56 percent were male, 73 percent were Anglo,
28 percent were age 35–44 and 23 percent were 45–
54. In Houston, 53 percent were male, 74 percent
were Anglo, 26 percent were 45–54 and 19 percent
were 25–29. There were also 107 reports of methadone in Dallas-Fort Worth and 91 in Houston. Of the
methadone patients in Dallas-Fort Worth, 48 percent
were male, 77 percent were Anglo, 31 percent were
age 35–44, 21 percent were 45–54, and 19 percent
were 30–34. In Houston, 73 percent were male, 80
percent were Anglo, 33 percent were age 45–54, and
23 percent were 35–44.
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Some 5 percent of all clients who entered publicly
funded treatment during 2004 used opiates other than
heroin. Of these, 55 used illegal methadone and
2,759 used other opiates (exhibit 14). Those who
reported a primary problem with illicit methadone or
other opiates were different from those who reported
a problem with heroin. They were much more likely
to be female, to be White, to have recently visited an
emergency department, and to report more sickness
and health problems in the month prior to entering
treatment.
Of the hydrocodone deaths statewide, 49 percent
were male, 90 percent were White, and the average
age was 42. Of the oxycodone deaths, 67 percent
were male, 88 percent were White, and the average
age was 36—younger than the hydrocodone decedents. Of the methadone deaths, 66 percent were
male, 84 percent were White, and the average age
was 35. There were 10 deaths with a mention of fentanyl in 2003.
Narcotic treatment programs are required to report
deaths of their clients. Between 1994 and 2002, 776
deaths were reported. Twenty percent died of liver
disease, 18 percent of cardiovascular disease, and 14
percent of drug overdose. Compared with the standardized Texas population, narcotic treatment patients were 4.6 times more likely to die of a drug
overdose, 3.4 times more likely to die of liver disease, 1.7 times more likely to die of a respiratory
disease, 1.5 times more likely to die of a homicide,
and 1.4 times more likely to die of AIDS (Maxwell
et al., 2005).
In the Dallas DEA Field Division, there has been an
increase in seizures of codeine cough syrup and in
Tyler, OxyContin has surpassed hydrocodone as the
drug of choice among abusers of pharmaceuticals.
Dilaudid sells for $20–$80 per tablet, and hydrocodone (Vicodin) sells for $4–$6 per tablet. OxyContin sells for $1 per milligram. Methadone sells for
$10 per 10-milligram tablet. Codeine cough syrup is
mixed with Sprite or 7-Up and drunk in a soda bottle
to avoid police attention. Promethazine syrup with
codeine (“lean”) sells for $200–$300 per pint in Dallas and $20 per ounce in Fort Worth. In the Houston
Field Division, hydrocodone, promethazine with codeine, and other codeine cough syrups are the most
commonly abused pharmaceutical drugs. In Houston,
promethazine or phenergan cough syrup with codeine
sells for $75–$100 for 4 ounces, $125 for 8 ounces,
and $1,600 for a gallon. In San Antonio, hydrocodone sells for $3 per pill and OxyContin costs $1
per milligram; one OxyContin pill costs $25 in
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McAllen. Dilaudid sells for $10–$15 per dose in
McAllen.

the Houston patients were age 35–44, and another 17
percent were 21–24.

DPS labs report increases in the number of exhibits
of hydrocodone, oxycodone, and methadone each
year from 1998 through 2004 (exhibit 14). There
were 2 fentanyl exhibits in 2003 and 13 in 2004.

Marijuana was the primary problem for 19 percent of
admissions to treatment programs in 2004 (exhibit
30). The average age was 22. Some 43 percent were
Hispanic, 33 percent were White, and 22 percent were
Black; 53 percent had legal problems or had been referred from the criminal justice system, and these clients were less frequent users of marijuana than those
who came to treatment for other reasons. The criminal
justice-referred clients reported using marijuana on
6.6 days in the month prior to admission, compared
with 11 days for the non-criminal justice referrals. The
same differences were reported for number of days in
the past month that a second problem drug was used
(2.9 vs. 5.5 days) and the number of days a third problem drug was used (2.5 vs. 4.7 days). All these differences were significant at p<.0001. Criminal justice
referrals were more likely to report no second problem
drug (42 vs. 35 percent for non-criminal justice referrals); 31 percent of the criminal justice and 29 percent
of the non-criminal justice referrals reported a second
problem with alcohol; 1.3 percent of criminal justice
and 6 percent of non-criminal justice referrals had a
second problem with crack cocaine; and 10 percent of
criminal justice and 11 percent of non-criminal justice
referrals had a second problem with powder cocaine.

Outreach workers in Fort Worth and Galveston report codeine cough syrup remains a popular drug.
Marijuana
The proportion of Texas students in grades 4–6 who
have ever used marijuana dropped from 2.8 percent
in 2000 to 2.5 percent in 2004, and use in the past
school year dropped from 2.1 percent to 1.7 percent.
Among Texas secondary students (grades 7–12), 30
percent had ever tried marijuana and 13 percent had
used in the past month, levels lower than in 2000
(exhibit 15).
In comparison, the 2000 Texas adult survey found
that 37 percent of adults reported lifetime and 4 percent past-month marijuana use, compared with 34
percent lifetime and 3 percent past-month use in
1996. The prevalence was much higher among
younger adults. Thirteen percent of those age 18–24
reported past-month use, compared with 6 percent of
those 25–34 and 2 percent of those 35 and older. The
increase in past-year use between 1996 and 2000 (6
percent to 7 percent) is statistically significant.
The 2002–2003 National Survey on Drug Use and
Health estimated that 4.8 percent of Texans age 12
and older had used marijuana in the past month, with
6.4 percent of those 12–17, 12.9 percent of those 18–
25, and 3.0 percent of those 26 and older reporting
past-month use.
The Texas Poison Control Centers reported there
were 135 calls confirming exposure to marijuana in
1998, compared with 5,060 in 2004. The average age
was 24.
Marijuana represented 18 percent of all unweighted
DAWN ED reports for major substances of abuse in
Dallas-Fort Worth and 24 percent of the reports in
Houston. Of the Dallas-Fort Worth patients, 67 percent were male, 45 percent were Anglo, 36 percent
were Black, and 13 percent were Hispanic; 19 percent were age 35–44, 14 percent were 12–17, and 16
percent were 21–24. In Houston, 66 percent were
male, 43 percent were Anglo, 34 percent were Black,
and 18 percent were Hispanic. Some 17 percent of
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The Addiction Severity Index (ASI) scores were
lower for justice referrals: 30 percent of the criminal
justice referrals reported employment problems versus 45 percent non-criminal justice referred clients;
for sickness or health problems, 14 percent versus 20
percent; for family problems, 26 percent versus 45
percent; for social problems with peers, 20 percent
versus 32 percent; for emotional problems, 18 percent versus 36 percent; and for substance abuse problems, 37 percent versus 56 percent. These differences, all of which were significant at p<.0001, indicate that marijuana users who are referred to treatment by the criminal justice system may be more
appropriate for short-term intervention, with the
more impaired marijuana users in need of more intensive treatment services.
Cannabis was identified in 35 percent of all the exhibits analyzed by DPS laboratories in 2000, but its representation dropped to 27 percent in 2004 (exhibit 6).
The Houston DEA Field Division reports hydroponic
marijuana is especially available in Asian communities and that multi-kilogram amounts are available in
the Austin area. In the Dallas-Fort Worth area,
Mexican marijuana is readily available, but there are
continuing seizures of domestically grown marijuana
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(both indoor and outdoor grown). Mexican “sinsemilla” is also plentiful. Marijuana is reported as
stable in the El Paso Division. In the Dallas Division,
Mexican marijuana is readily available, along with
domestically grown marijuana. Prices are reported to
be dropping to below the cost to dealers because of
increased availability, and indoor grown marijuana is
producing THC content as high as 15 percent.
High quality sinsemilla sells for $900–$1,200 per
pound in the Dallas-Fort Worth area, $800 per pound
in Lubbock, and $600 per pound in Houston. Canadian BC Bud sells for $3,300 in Houston. Hydroponic
sells for $3,500 per pound in Houston, $4,600 in
McAllen, $3,000 in Austin, and $3,800 in Dallas. The
average price for a pound of commercial grade marijuana is $140–$160 in Laredo, $100–$200 in
McAllen, $350–$450 in San Antonio, $350–$375 in
Austin, $350–$425 in Houston, $500 in El Paso,
$500–$700 in Alpine, $375–$600 in Midland, $350–
$800 in the Dallas-Fort Worth area, $500–$600 in
Lubbock, and $340–$500 in Tyler. Locally grown
indoor marijuana sells for $3,800 per pound in Dallas.
Exhibit 16 shows the decline in prices since 1992.
Stimulants

and past-month use was 1 percent in 1996. The difference in past-year use from 1996 to 2000 (1.1 to
1.9 percent) was statistically significant.
There were 144 calls to Texas poison control centers
involving exposure to methamphetamines in 1998,
183 in 1999, 264 in 2000, 321 in 2001, 382 in 2002,
389 in 2003 and 423 in 2004. Of these 2004 calls,
there were 104 mentions of “ice” or “Crystal.” There
were also 187 calls involving abuse or misuse of amphetamine pills, phentermine, or Adderall, and another 21 calls involving abuse or misuse of Ritalin.
Forrester’s study of all calls involving Ritalin to poison control centers in Texas between 1998 and 2004
found that 8.5 percent involved misuse and abuse. Of
these abuse/misuse calls, 62 percent involved males,
20 percent were younger than 13, 55 percent were
age 13–19, and 25 percent were older than 19.
Ninety-three percent had swallowed the drug, 7 percent had inhaled it, and 67 percent of these
abuse/misuse calls also had used other substances. As
compared to non-abuse calls, abusers were significantly more likely to be older and to have misused
the drug while at school and to suffer minor, moderate, or major effects from using the drug.

The secondary school survey reported that lifetime
use of uppers was 8.1 percent in 1998 and 6.0 percent in 2004. Past-month use was 3.1 percent in 1998
and 2.5 percent in 2004.

DAWN ED reports test specifically for amphetamine
as compared to methamphetamine. In Dallas-Fort
Worth, methamphetamine represented 8 percent of
the reports for major substances of abuse, and amphetamine accounted for 6 percent of the reports. In
Houston, methamphetamine represented 1 percent of
all reports, with amphetamine representing 4 percent.
Of the methamphetamine patients in Dallas-Fort
Worth, 66 percent were male, 74 percent were Anglo, 3 percent were Black, and 13 percent were Hispanic; 22 percent were age 35–44 and 20 percent
were 25–29. In Houston, 63 percent were male, 75
percent were Anglo, 7 percent were Black, and 10
percent were Hispanic; 23 percent were age 21–24
and 22 percent were 25–29. Patients reporting amphetamines were less likely than methamphetamine
patients to be male: in Dallas-Fort Worth, 58 percent
were male and in Houston, 57 percent were male. In
Dallas-Fort Worth, 74 percent were Anglo, 8 percent
were Black, and 12 percent were Hispanic, but in
Houston, 60 percent were Anglo, 23 percent were
Black, and 12 percent were Hispanic. In Dallas-Fort
Worth, the most common age group was 35–44, (24
percent of admissions). In Houston, the population
was younger; 18 percent were 21–24 and 17 percent
were 25–29.

Among Texas adults, 12 percent reported lifetime
use of uppers and 1 percent reported past-month use
in 2000. In comparison, lifetime use was 10 percent

Methamphetamine/amphetamine admissions to treatment programs increased from 5 percent of all admissions in 2000 to 10 percent in 2004, and the aver-

Amphetamine-type substances come in different
forms and with different names. “Speed” (“meth,”
“crank”) is a powdered methamphetamine of relatively low purity and is sold in grams or ounces. It
can be snorted or injected. “Pills” can be pharmaceutical grade stimulants, such as dextroamphetamine,
Dexedrine, Adderall, or Ritalin (methylphenidate), or
they can be methamphetamine powder that has been
pressed into tablets and sold as amphetamines or ecstasy. Pills can be taken orally, crushed for inhalation, or dissolved in water for injection. There is also
a damp, sticky powder of higher purity than “Speed”
that is known as “Base” in Australia and “Peanut
Butter” in parts of the United States. “Ice,” also
known as “Crystal” or “Tina,” is methamphetamine
that has been “washed” in a solvent to remove impurities; it has longer-lasting physical effects and purity
levels above 80 percent. Ice can be smoked in a glass
pipe, “chased” on aluminum foil, mixed with marijuana and smoked through a bong, or injected.
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age age of clients admitted for a primary problem
with stimulants increased. In 1985, the average age
was 26; in 2004, it was 30. The proportion of White
clients rose from 80 percent in 1985 to 89 percent in
2004, while the proportion of Hispanics dropped
from 11 percent to 8 percent and the proportion of
Blacks dropped from 9 percent to 1 percent. Unlike
the other drug categories, more than one-half of
these clients entering treatment were women (53
percent) (exhibit 30). The proportion smoking ice
also increased from less than 1 percent in 1988 to 37
percent in 2004. The percentage of clients injecting
methamphetamine dropped from 84 percent in 1988
to 45 percent in 2004 (exhibit 17).
Users of amphetamines or methamphetamine tend to
differ depending on their route of administration, as
exhibit 18 shows. Those who took the substance
orally tended to be users of pills. Methamphetamine
injectors were more likely to have been in treatment
before (60 percent readmissions) compared with
amphetamine pill takers (48 percent), ice smokers
(40 percent), or inhalers (37 percent).
Statewide, there were 17 deaths in which amphetamines or methamphetamines were mentioned in
1997, 20 in 1998, 21 in 1999, 39 in 2000, 51 in 2001,
69 in 2002, and 80 in 2003. Of the decedents in
2003, 70 percent were male, 84 percent were White,
and the average age was 35.
To make methamphetamine, local labs are using the
“Nazi method,” which includes ephedrine or pseudoephedrine, lithium, and anhydrous ammonia, and
the “cold method,” which uses ephedrine, red phosphorus, and iodine crystals. The “Nazi method” is
the most common method used in North Texas. Before these methods became common, most illicit labs
used the “P2P method,” which is based on 1-phenyl2-propanone. The most commonly diverted chemicals are 60-milligram pseudoephedrine tablets such
as Xtreme Relief, Mini-Thins, Zolzina, Two-Way,
and Ephedrine Release.
Methamphetamine and amphetamine together represented 16 percent of all items examined by DPS
laboratories in 2000, but the percentage increased to
24 percent in 2004 (exhibit 6). Twenty-three percent
of the exhibits were methamphetamine, and less than
1 percent was amphetamine.
Methamphetamine is more of a problem in the northern half of the State, as exhibit 19 shows. In Abilene,
54 percent of all of the drug items examined by the
DPS laboratory were methamphetamine, while in
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McAllen and Laredo, only 1 percent were. Labs in
the northern part of the State were also more likely to
report analyzing substances that turned out to be
ammonia or pseudoephedrine, chemicals used in the
manufacture of methamphetamine. The NFLIS report shows that methamphetamine is also more of a
problem in the West than in the rest of the country:
38 percent of all items examined in the western
United States were methamphetamine, compared
with 8 percent in the South and the Midwest and less
than 1 percent in the East.
The Houston Field Division reports that the availability of both Mexican and locally produced
methamphetamine is increasing. Ice comes from
California via Houston and Dallas. Ice also comes
from the State of Jalisco, and methamphetamine is
produced in the States of Aguascalientes, Zacatecas,
Michoacan, and Guadalajara. Methamphetamine is
also manufactured in Texas by motorcycle gangs and
independent producers using small mobile pseudoephedrine labs that produce small amounts for
distribution in the local area.
The Dallas Field Division reports that the availability
of methamphetamine, especially ice, is steady or
rising at the retail level and has emerged as the primary problem in the Lubbock and Amarillo areas.
There is continued reporting of use of ice in the club
and rave scene, with some reports that sales of ice
rival ecstasy sales. Mexican methamphetamine
dominates this market, and it is available for purchase in multipound quantities and at a lower price
than 6 months ago. Mexican ice has a larger profit
margin than locally produced methamphetamine, so
low quality methamphetamine may be sold as “ice”
by some dealers. High-purity methamphetamine is
primarily distributed by Mexican nationals, but
Asian gangs are also involved.
The purity for 1–10 grams has risen from 46 percent
pure in the Dallas area in 2000 to 65 percent pure in
2004, according to NFLIS data. At the same time,
the number of labs seized has risen from 1,707 to
3,908, yet prices are dropping. The price for a pound
of methamphetamine was $8,000 in Houston 6
months ago; now it is $7,000. A pound sells for
$4,500–$5,500 in Laredo, $6,000–$8,000 in San
Antonio, $8,000 in Midland, $4,000–$10,000 in Dallas and in Fort Worth, and $7,000–$8,000 in Lubbock. An ounce of domestic methamphetamine sells
for $600–$800 in Dallas (it was $700–$1,000 a year
ago), while an ounce of Mexican sells for $400. An
ounce of methamphetamine sells for $600 in Fort
Worth, $600–$1,200 in Tyler, $700 in Lubbock,
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$960 in El Paso, $600 in Alpine, $700 in Midland,
$500–$850 in Houston, $700–$1,000 in San Antonio, and $900–$1,250 in Waco.
The price of ice has dropped even more, from
$13,000–$17,000 to $8,000–$12,000 in a year in
Houston. It costs $8,500–$16,000 in Dallas, $9,000–
$10,000 in Fort Worth, and $10,000–$18,000 in Tyler. An ounce of ice sells for $1,000–$1,400 in Dallas, $800–$1,000 in Fort Worth, $1,200 in Tyler,
$700–$1,200 in Houston, and $1,000–$1,500 in San
Antonio.
In the Galveston area, outreach workers reported the
amount of crystal methamphetamine on the street is
increasing each month, and there is more abuse of
pseudoephedrine products. In Fort Worth, ice is used
more often than regular methamphetamine.
Depressants
This “downer” category includes three groups of
drugs: barbiturates, such as phenobarbital and secobarbital (Seconal); nonbarbiturate sedatives, such as
methaqualone, over-the-counter sleeping aids, chloral
hydrate, and tranquilizers; and benzodiazepines, such
as diazepam (Valium), alprazolam (Xanax), flunitrazepam (Rohypnol), clonazepam (Klonopin or
Rivotril), flurazepam (Dalmane), lorazepam (Ativan),
and chlordiazepoxide (Librium and Librax). Rohypnol
is discussed separately in the Club Drugs section of
this report.
The 2004 secondary school survey reported lifetime
use of downers decreased from 7.1 percent in 2002
to 5.9 percent in 2004. Past-year use decreased from
3.4 percent in 2002 to 2.6 percent in 2004.
The 2000 adult survey reported lifetime use of
downers at 6.9 percent and past-month use at 0.6
percent; in 1996, lifetime use was 6.2 percent and
past-month use was 0.3 percent. The difference in
past-year use between 1996 and 2000 (1 percent to
1.8 percent) was statistically significant.
About 1 percent of the clients entering treatment in
2004 had a primary problem with barbiturates, sedatives, or tranquilizers. These clients were the most
likely to be female and highly impaired, based on
their ASI scores (see exhibit 30).
Alprazolam, clonazepam, and diazepam are among
the 15 most commonly identified substances according to DPS lab reports, although none of them represent more than 3 percent of all items examined in a
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year. The proportion of cases that are alprazolam
(Xanax) continues to increase (exhibit 20).
Alprazolam sells for $2–$5 in Dallas, Fort Worth,
and Houston, and for $5–$10 in Tyler. Depending on
the dosage unit, diazepam sells for $1–$10 in Dallas,
Fort Worth, and Tyler.
Street outreach workers in the Galveston area report
Xanax is becoming more popular with young adults
Club Drugs and Hallucinogens
Exhibit 21 shows the demographic characteristics of
clients entering DSHS-funded treatment programs
statewide with a problem with a club drug. The row
“Primary Drug” shows the percentage of clients citing a primary problem with the club drug shown at
the top of the column. The rows under the heading
“Other Primary Drug” show the percentage of clients
who had a primary problem with another drug, such
as marijuana, but who had a secondary or tertiary
problem with one of the club drugs shown at the top
of the table. Note that the treatment data uses a
broader category, “Hallucinogens,” that includes lysergic acid diethylamide (LSD), dimethyltryptamine
(DMT), STP, mescaline, psilocybin, and peyote.
Excluding ketamine (due to the small number of
cases), exhibit 21 shows that hallucinogen and Rohypnol admissions are the most likely to be male,
gamma hydroxybutyrate (GHB) clients are the most
likely to be White, phencyclidine (PCP) clients are
the most likely to be Black, Rohypnol clients are the
youngest, and GHB clients are the oldest. While users of PCP are the most likely to have a primary
problem with PCP, users of Rohypnol, ecstasy, and
hallucinogens are more likely to have primary problems with marijuana. Users of GHB tend to have a
primary problem with methamphetamine.
Exhibit 22 shows the percentage of exhibits identified
by DPS laboratories that contained various club drugs.
Only the proportion of PCP exhibits has not decreased
over time, although the increase in MDMA exhibits
between 2003 and 2004 is of concern.
Dextromethorphan
The most popular dextromethorphan (DXM) products are Robitussin-DM, Tussin, and Coricidin
Cough and Cold Tablets HBP, which can be purchased over the counter and can produce hallucinogenic effects if taken in large quantities. Coricidin
HBP pills are known as “Triple C’s” or “Skittles.”
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The 2004 Texas school survey reported that 4.3 percent of secondary students indicated they had used
DXM. Use increased from 2.5 percent in 7th grade to
5.8 percent in 12th grade. There was no difference
by gender, but Whites reported higher lifetime use
(6.1 percent) than Native Americans (5.8 percent),
Hispanics (3.6 percent), or Blacks (2.4 percent).
Poison control centers reported the number of abuse
and misuse cases involving dextromethorphan rose
from 99 in 1998 to a high of 432 in 2002, and
dropped to 232 in 2004. Average age was 21.6. The
number of cases involving abuse or misuse of Coricidin HBP was 7 in 1998 and rose to 268 in 2002 and
then decreased to 229 cases in 2004. Average age in
2004 was 16.5 years, which shows that youths can
easily access and misuse this substance.
DPS labs examined 2 substances in 1998 that were
dextromethorphan, 13 in 1999, 36 in 2000, 18 in
2001, 42 in 2002, 10 in 2003, and 15 in 2004.
Ecstasy (Methylenedioxymethamphetamine or
MDMA)
The 2004 Texas secondary school survey reported
that lifetime ecstasy use dropped from a high of 8.6
percent in 2002 to 5.5 percent in 2004, while pastyear use dropped from 3.1 percent to 1.8 percent.
The 2000 adult survey reported that 3.1 percent had
ever used ecstasy and 1.0 percent had used in the
past year.
Texas Poison Control Centers reported 23 calls involving misuse or abuse of ecstasy in 1998, 46 in 1999, 119
in 2000, 155 in 2001, 172 in 2002, 284 in 2003, and
302 in 2004. In 2004, the average age was 21.
There were 45 reports in Dallas-Fort Worth and 109
reports in Houston of ecstasy as one of the major
substances of abuse recorded in EDS reporting to
DAWN. In Dallas-Fort Worth, 62 percent of the unweighted ecstasy reports involved males, as did 58
percent of the Houston reports. Anglos accounted for
38 percent of the Dallas-Fort Worth patients and 44
percent of the Houston patients, while 27 percent in
Dallas-Fort Worth were Black, as were 35 percent in
Houston. Thirteen percent of the patients in DallasForth Worth and 14 percent of the patients in Houston were Hispanic. Fifty-eight percent of the patients
in Dallas-Fort Worth and 56 percent of the patients
in Houston were age 18–24, with another 13 percent
in Dallas-Fort Worth and 20 percent in Houston being 12–17.
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There were 63 admissions for a primary, secondary,
or tertiary problem with ecstasy in 1998, 114 in
1999, 199 in 2000, 349 in 2001, 521 in 2002, 502 in
2003, and 561 in 2004. Approximately 36 percent
reported marijuana as their primary problem drug,
compared with 14 percent who reported ecstasy as
their primary problem drug. Ecstasy has spread outside the White club scene and into the Hispanic and
Black communities, as evidenced by the declining
proportion of White treatment clients.
In 1999, there were two deaths that involved ecstasy
in Texas. There was one death in 2000, five in 2001,
five in 2002, and two in 2003.
Exhibit 22 shows the substances identified by DPS
labs. The labs identified MDMA in 107 exhibits in
1999, 387 in 2000, 814 in 2001, 503 in 2002, 484 in
2003, and 691 in 2004. Methylenedioxyamphetamine (MDA) was identified in 31 exhibits in 1999,
27 in 2000, 48 in 2001, 90 in 2002, 94 in 2003, and
60 in 2004.
According to the Houston DEA Field Division, ecstasy is more available at clubs, raves, and gyms, and
use is increasing in the Galveston, Beaumont, and
Fort Hood areas. Logos on the tablets include A&E,
Blue Dolphins, Bear, Music Notes, Crescent Moon,
Yellow Dolphins, Aladdin Lamp, Yellow Alligator,
Yellow Trumpets, Omega, X-5 (BMW), JJ, Spade,
and Footprints. While most tablets contain MDMA,
some have high concentrations of caffeine or
methamphetamine, with traces of ketamine in some
tablets. Ecstasy is stable in Austin, but use has increased in the Waco area among soldiers stationed at
Fort Hood.
The Dallas DEA Field Division reports that ecstasy
made in Europe is transshipped through other U.S.
ports into the Metroplex area. The club drug distribution in the Dallas and Houston Divisions is dominated by Asian traffickers who are also involved
with hydroponic marijuana and methamphetamine.
Combinations of drugs mentioned in Dallas include
“candy flipping” (LSD and MDMA), “hippie flipping” (mushrooms and MDMA), “love flipping”
(mescaline and MDMA), “robo flipping” (DXM and
MDMA), and “elephant flipping” (PCP and
MDMA).
Single dosage units of ecstasy sell for $6–$20 in Dallas, $5–$12.50 in Fort Worth, $12–$25 in Tyler,
$4.75–$25 in Houston, $20–$30 in McAllen, $20 in
Laredo, and $11–$20 in San Antonio. Multiple dosage units (1,000 tablets) sell for $5,000–$8,000 in
Houston.
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Gamma Hydroxybutyrate (GHB), Gamma Butyrate
Lactone (GBL), 1-4 Butanediol (1,4 BD)
The 2000 Texas adult survey reported that 0.4 percent had ever used GHB and 0.1 percent had used in
the past year.
The number of cases of misuse or abuse of GHB or
its precursors reported to Texas Poison Control Centers was 110 in 1998, 150 in 1999, 120 in 2000, 119
in 2001, 100 in 2002, 66 in 2003, and 84 in 2004.
The average age of the abusers in 2004 was 26, and
of the callers whose gender was known, 52 percent
were male.
The unweighted DAWN data show there were 41
GHB reports in Dallas-Fort Worth, and there were 4
in Houston. Of the patients in Dallas-Fort Worth, 49
percent were male, 78 percent were Anglo, 27 percent were age 18–24 years old, 39 percent were 25–
34, and 29 percent were 35–54.

In Dallas, the price of GHB had increased from
$100–$200 per gallon to $250–$500 per gallon. A
dose of GHB costs $20 in Dallas and $5–$10 in
Lubbock and San Antonio. A 16-ounce bottle costs
$100 in San Antonio and two 2-ounce bottles cost
$110 in Fort Worth. The DEA Field Division in Dallas reports that GHB is being manufactured in home
laboratories where GBL ordered over the Internet is
mixed with other chemicals and water to produce
GHB.
Ketamine
The 2000 adult survey reported that 0.3 percent had
ever used ketamine and 0.1 percent had used it in the
last year.
Eight cases of misuse or abuse of ketamine were
reported to Texas Poison Control Centers in 1998,
compared with 7 in 1999, 15 in 2000, 14 in 2001, 10
in 2002, 17 in 2003, and 7 in 2004.

Adult and adolescent clients with a primary, secondary, or tertiary problem with GHB, GBL, or 1,4
butanediol (1,4 BD) are seen in treatment. In 1998, 2
were admitted, compared with 17 in 1999, 12 in
2000, 19 in 2001, 35 in 2002, 31 in 2003, and 45 in
2004. Clients who used GHB tended to be the oldest
of all the club drug users (average age 29) and were
the most likely to be White (89 percent) and female
(67 percent). GHB users were more likely to have
used the so-called “hard-core” drugs; 47 percent had
a history of injecting drug use and 56 percent had a
primary problem with amphetamines or methamphetamine. Because of the sleep-inducing properties
of GHB, users will also use methamphetamine so
they can stay awake while they are “high” on GHB
or they use GHB to “come down” from their use of
methamphetamine (exhibit 21).

There was one report of ketamine in the unweighted
2004 Dallas-Fort Worth DAWN emergency department reports and zero in Houston.

In 1999, there were three deaths that involved GHB,
compared with five in 2000, three in 2001, two in
2002, and two in 2003.

Ketamine costs $2,200–$2,500 per liter in Fort
Worth and $65 per vial in Tyler, with a dose selling
for $20 per pill or gram. It costs $60 retail for a 10milliliter vial and $15–$20 for 0.2 grams of powder.

In 1998, there were 18 items identified by DPS labs
as being GHB; in 1999 112 were GHB, 4 were GBL,
and 4 were 1,4 BD (exhibit 22). In 2000, 45 were
GHB, 7 were GBL, and 4 were 1,4 BD. In 2001, 34
were GHB, 7 were GBL, and 19 were 1,4 BD. In
2002, 81 were GHB, 6 were GBL, and 4 were 1,4
BD. In 2003, 150 were GHB, 5 were GBL, and none
was 1,4 BD. In 2004, 95 were GHB, 1 was GBL, and
none was 1,4 BD. In 2004, 96 percent of the GHB
items were identified in the DPS lab in the Dallas
area, which shows use of GHB is centered in this
area of the State.
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Seven clients were admitted to DSHS-funded treatment programs in 2004 with a secondary or tertiary
problem with ketamine (exhibit 21). Forty-three percent had a history of injecting drug use, and all had
problems with the legal or criminal justice system.
There were two deaths in 1999 that involved use of
ketamine, none in 2000, one in 2001, and one in
2002.
In 1999, 25 substances were identified as ketamine
by DPS labs. There were 29 in 2000, 119 in 2001, 78
in 2002, 84 in 2003, and 73 in 2004 (exhibit 21).

LSD and Other Hallucinogens
The secondary school survey shows that use of hallucinogens (defined as LSD, PCP, mushrooms, etc.)
continues to decrease. Lifetime use peaked at 7.4
percent in 1996 and dropped to 4.8 percent by 2004.
Past-month use dropped from 2.5 percent in 1998 to
1.6 percent in 2004.
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The 2000 adult survey reported that 8.8 percent of
Texas adults had ever used LSD and 0.9 percent had
used in the past year.
Texas Poison Control Centers reported 82 mentions
of abuse or misuse of LSD in 1998, 113 in 1999, 97
in 2000, 70 in 2001, 129 in 2002, 20 in 2003, and 22
in 2004. There were also 98 cases of intentional misuse or abuse of hallucinogenic mushrooms reported
in 1998, 73 in 1999, 110 in 2000, 94 in 2001, 151 in
2002, 130 in 2003, and 172 in 2004. Average age in
2004 was 21 for the LSD cases and 19.6 for the
mushroom cases.
There were 29 unweighted reports in Dallas-Fort
Worth DAWN and 30 in Houston which involved
LSD or other hallucinogens. Of the Dallas-Fort
Worth patients, 76 percent were male, 59 percent
were Anglo, 7 percent were Black, and 14 percent
were Hispanic; 10 percent were younger than 18, 66
percent were 18–24, and 21 percent were 25–34. In
Houston, 75 percent were male, 43 percent were
Anglo, 10 percent were Black, and 33 percent were
Hispanic; 20 percent were younger than 18, 33 percent were 18–24, and 20 percent were 25–34.
The number of adults and youths with a primary,
secondary, or tertiary problem with hallucinogens
entering treatment is decreasing. There were 636
such admissions in 2000, 486 in 2001, 436 in 2002,
319 in 2003, and 266 in 2004. Of the admissions in
2004, the average age was 23, 75 percent were male,
61 percent were White, 25 percent were Hispanic,
and 12 percent were Black. Sixty-four percent were
referred from the criminal justice or legal system,
and 25 percent had a history of injecting drug use
(exhibit 21).

Texas Poison Control Centers reported cases of
“Fry,” “Amp,” “Water,” “Wack,” or “PCP.” Often,
marijuana joints are dipped in formaldehyde that
contains PCP or PCP is sprinkled on the joint. The
number of cases involving PCP increased from 102
in 1998 to a high of 237 in 2002 and decreased to
160 in 2004. There were also 18 cases involving
misuse or abuse of formaldehyde or formalin in 2003
and 55 in 2004. These formaldehyde or formalin
cases may be linked to the use of PCP, but the records were not clear.
There were 71 unweighted reports of PCP in DallasFort Worth DAWN emergency departments and 240
in Houston in 2004. Of these patients, 82 percent in
Dallas-Fort Worth and 69 percent in Houston were
male. Some 63 percent in Dallas-Fort Worth were
Black, as were 72 percent in Houston. Twenty-five
percent in Dallas-Fort Worth were Anglo, as were 13
percent in Houston, and 4 percent in Dallas-Fort
Worth and 10 percent in Houston were Hispanic.
PCP patients were not young; only 7 percent in each
area were younger than 18. Thirty-two percent in
Dallas-Fort Worth and 42 percent in Houston were
age 18–24; 39 percent in Dallas-Fort Worth and 40
percent in Houston were 25–34; and 20 percent in
Dallas-Fort Worth and 9 percent in Houston were
35–54.

Statewide, there were two deaths in 1999 with a
mention of LSD. No deaths with a mention of LSD
have been reported since.

Adolescent and adult admissions to treatment with a
primary, secondary, or tertiary problem with PCP
have varied over time, rising from 164 in 1998 to
417 in 2003 and then dropping to 295 in 2004 (exhibit 21). Of these clients in 2004, 81 percent were
Black, 57 percent were male, 56 percent were involved in the criminal justice system, 22 percent
were employed, and 14 percent were homeless.
While 43 percent reported a primary problem with
PCP, another 30 percent reported a primary problem
with marijuana, which demonstrates the link between
these two drugs and “Fry.”

DPS labs identified 69 substances as LSD in 1998,
compared with 406 in 1999, 234 in 2000, 122 in 2001,
10 in 2002, 10 in 2003, and 24 in 2004 (exhibit 22).

There were three deaths in 1999, three in 2000, five
in 2001, eight in 2002, and two in 2003 that involved
PCP.

A dosage unit of LSD is selling for $1–$10 in Dallas,
$5–$10 in Tyler, $6–$10 in Fort Worth, $7 in Lubbock, and $8–$12 in San Antonio. A dosage sheet of
100 sells for $800 in San Antonio.

DPS labs identified 10 substances as PCP in 1998,
84 in 1999, 104 in 2000, 163 in 2001, 95 in 2002,
143 in 2003, and 161 in 2004 (exhibit 22).

Phencyclidine (PCP)
The 2000 Texas adult survey reported that 0.9 percent of adults had ever used PCP or Angel Dust, and
0.1 percent had used it in the past year.
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PCP costs $700–$1,200 per ounce in San Antonio
and $30 per dosage unit in McAllen. In Dallas, it
costs $3,800 for a 16-ounce bottle, $375–$450 per
ounce, $25 per cigarette, and $10 for a piece of a
"sherm" stick. In Fort Worth, it costs $26,000–
$28,000 per gallon.
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Street outreach workers in the Galveston/Brazoria
area report “Water” is a problem.
Rohypnol
Rohypnol (flunitrazepam) is a benzodiazepine that
was never approved for use in the United States. The
drug is legal in Mexico, but since 1996, it has been
illegal to bring it into the United States. It continues
to be a problem along the Texas-Mexico border. As
shown in exhibit 23, the 2004 secondary school survey found that students from the border area were
about three times more likely to report Rohypnol use
than those living elsewhere in the State (9.1 percent
vs. 2.5 percent lifetime, and 3.5 percent vs. 2.5 percent current use). Use on both the border and nonborder has declined since its peak in 1998.
The 2000 Texas adult survey found that 0.8 percent
reported lifetime use and 0.1 percent reported pastyear use of Rohypnol.
The number of confirmed exposures to Rohypnol
reported to the Texas Poison Control Centers peaked
at 102 in 1998; 62 cases were reported in 2004. The
average age in 2004 was 17; 52 percent were male;
and 84 percent lived in counties on the border. A
study of all the exposure calls between 1998 and
2003 found a significantly higher proportion of flunitrazepam abuse and malicious use calls occurred in
border counties. The majority of the abuse calls involved males, while the majority of malicious use
calls involved females. Most abuse calls involved
adolescents, while the majority of the malicious calls
involved adults. Abuse cases occurred most frequently at the patient’s own residence or at school,
while malicious use occurred most often in public
areas, with the patient’s own residence ranking second (Forrester 2004). This analysis provides evidence of two patterns of Rohypnol use: (1) recreational use and abuse by adolescent males and (2) use
of the drug with criminal intent on adult women.
There were no reports of Rohypnol in the Dallas-Fort
Worth DAWN data in 2004, and there were four in
Houston.
The number of youths and adults admitted into
treatment with a primary, secondary, or tertiary problem with Rohypnol has varied: 247 in 1998, 364 in
1999, 324 in 2000, 397 in 2001, 368 in 2002, 331 in
2003, and 221 in 2004. In 2004, clients abusing Rohypnol were among the youngest of the club drug
patients (average age 19), and they were predominately Hispanic (97 percent), which reflects the
availability and use of this drug along the border
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(exhibit 21). Some 67 percent were involved with the
criminal justice or legal system. While 13 percent of
these clients said that Rohypnol was their primary
problem drug, 48 percent reported a primary problem
with marijuana.
DPS lab exhibits for Rohypnol numbered 43 in 1988,
56 in 1999, 32 in 2000, 35 in 2001, 22 in 2002, 17 in
2003, and 16 in 2004. The decline in the percentage
of Rohypnol seizures, as shown in exhibit 22, parallels the declines seen in other indicators.
Although Roche is reported to no longer be making
the 2-milligram Rohypnol tablet (a favorite with
abusers), generic versions are still produced. The
blue dye added to the Rohypnol tablet to warn potential victims is not in the generic version. Unfortunately, the dye is not proving effective, since people
intent on committing sexual assault may employ blue
tropical drinks and blue punches into which Rohypnol can be slipped.
Rohypnol sells for $2–$4 per pill in San Antonio.
Other Abused Substances
Inhalants
The 2004 elementary school survey found that 11
percent of students in grades 4 to 6 had ever used
inhalants, and 8 percent had used in the school year.
The 2004 secondary school survey found that 17
percent of students in grades 7–12 had ever used
inhalants and 7 percent had used in the past month.
Inhalant use exhibits a peculiar age pattern not observed with any other substance. The prevalence of
lifetime and past-month inhalant use was higher in
the lower grades and lower in the upper grades (exhibit 24). This decrease in inhalant use as students
age may be partially related to the fact that inhalant
users drop out of school early and hence are not in
school in later grades to respond to school-based
surveys.
The 2004 poison control center data show that automotive products such as carburetor cleaner and
transmission fluid were the inhalants abused or misused the most often, with 67 calls (exhibit 25). Average age was 29. There were 30 calls of abuse or misuse of paint (average age 29), 29 calls of misuse of
Freon or other propellants (average age 21), 22 calls
for misuse of air fresheners or dusting sprays (average age of 18), 21 calls of misuse of gasoline (average age 24), and 13 calls about abuse of toluene or
mineral spirits of thinning agents (average age 22).
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There were 42 unweighted reports of inhalants in
Dallas-Fort Worth and 52 in Houston in the 2004
DAWN emergency department reports. In DallasFort Worth, 71 percent were male, 48 percent were
Anglo, 21 percent were Black, and 31 percent were
Hispanic, while in Houston, 71 percent were male,
31 percent were Anglo, 17 percent were Black, and
52 percent were Hispanic. In Dallas-Fort Worth, 26
percent were age 30–34 and 24 percent were younger
than 21, whereas in Houston, 23 percent were 35–44,
21 percent were 25–29, and 21 percent were younger
than 21.

The NFLIS data for Texas reported testosterone was
the steroid most likely to be seized and submitted for
forensic testing.

Inhalant abusers represented 0.2 percent of the admissions to treatment programs in 2004. The clients
tended to be male (60 percent) and Hispanic (77 percent). The overrepresentation of Hispanics is related
to the fact that DSHS had developed and funded
treatment programs targeted specifically to this
group. The average age of the clients was 22. Sixtyfive percent were involved with the criminal justice
system; average education level was 8.7 years; 10
percent were homeless; and 17 percent had a history
of injection drug use.

Between 1998 and 2003, 51 percent of these poison
control center cases involved males and 83 percent
involved persons older than 19. Carisoprodol is a
substance that tends to be abused in combination
with other substances. Only 39 percent of the cases
involved that one drug; all the others involved combinations of drugs (Forrester, 2004).

In 2000, there were 12 deaths involving misuse of
inhalants, compared with 15 in 2001, 8 in 2002, and
13 in 2003. The categorization of inhalant deaths is
difficult and leads to underreporting. However, of
those reported in 2003, the average age was 34; 85
percent were male; 69 percent were White; and 31
percent were Hispanic.
A new trend in McAllen is the use of “Whip-It” nitrous oxide capsules by teenagers.
Steroids
The Texas school survey reported that 2 percent of all
secondary students surveyed in 2004 had ever used
steroids and that less than 1 percent had used steroids
during the month before the survey. Although steroids can be bought across the border, the school survey found lifetime usage lower among border students (1.4 percent) than among non-border students
(2.1 percent).
There were 17 persons admitted to DSHS-funded
treatment in 2004 with a primary, secondary, or tertiary problem with steroids. Sixty-five percent were
male, 59 percent were Anglo, and 35 percent were
Hispanic; the average age was 26. Some 65 percent
were involved with the criminal justice or legal system; 29 percent had a primary problem with alcohol,
24 percent had a primary problem with marijuana,
and 18 percent had a primary problem with steroids.
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Carisoprodol (Soma)
Poison control centers confirmed exposure cases of
intentional misuse or abuse of the muscle relaxant
carisoprodol (Soma) increased from 83 in 1998 to
298 in 2004. In addition to these abuse and misuse
cases, there were another 667 cases in which the
reason for the call was suspected suicide.

The unweighted DAWN emergency department reports showed that in 2004, there were 160 reports of
Soma in Dallas-Fort Worth and 429 in Houston. In
Dallas-Fort Worth, 38 percent were male, 78 percent
were Anglo, 30 percent were age 45–54 and 26 percent were 35–44. In Houston, 46 percent were male,
75 percent were White, 29 percent were age 35–44,
10 percent were 45–54, and 18 percent were 30–34.
In 2003, carisoprodol was mentioned on 51 death
certificates. Only one of the deaths involved only
carisoprodol. Hydrocodone, propoxyphene, alcohol,
and benzodiazepines were also substances that were
mentioned along with carisoprodol on the other
death certificates.
DPS lab exhibits of carisoprodol reported to NFLIS
increased from 13 in 1998 to 90 in 1999, 153 in
2000, 202 in 2001, 179 in 2002, 278 in 2003, and
249 in 2004.
According to the Dallas DEA Field Division, Soma
sells for $2–$5 per tablet.
INFECTIOUS DISEASES RELATED TO DRUG ABUSE
Hepatitis C
Exhibit 26 shows that 18 percent of the 8,798 tests
for HCV exposure given in 2003 were positive.
Some 41 percent of those with positive tests were
exposed through injection drug use. The rates were
higher for males, for American Indians and Blacks,
and for persons age 40 and older. The highest HCV
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positivity rates were reported by persons tested at
sexually transmitted disease clinics and drug treatment centers (22 percent each) and field outreach
centers and corrections and probation settings (20
percent each).
Forty-eight percent of the 200 clients in narcotic
treatment programs who were interviewed by the
author as part of NIDA Grant R21 DA014744 said
they were positive for hepatitis C, and 54 percent
said a doctor had told them they had liver problems.
However, only 5 percent reported they were HIV
positive.
HIV and AIDS Cases
In 2004, the percentage of AIDS cases involving
heterosexual exposures was greater than the percentage of cases related to injection drug use (exhibit
27). The proportion related to heterosexual contact
rose from 1 percent in 1987 to 26 percent in 2004,
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while the proportion attributed to injection drug use
was 15 percent in 2004.
In 1987, 3 percent of the AIDS cases were females
older than 12; in 2004, 23 percent were female. As
exhibit 28 shows, the proportion of Whites has
dropped, while the proportion of Blacks and Hispanics increased.
The proportion of adult needle users entering DSHSfunded treatment programs has decreased from 32
percent in 1988 to 19 percent in 2004. Heroin injectors are most likely to be older, and nearly two-thirds
are people of color, while injectors of stimulants and
cocaine are far more likely to be White (exhibit 29).
For inquiries concerning this report, please contact Jane C. Maxwell, Ph.D., Research Professor, Center for Social Work Research, The University of Texas at Austin, Suite 335, 1717 West
6th Street, Austin, TX 78703, Phone: 512-232-0610, Fax: 512232-0617, E-mail: jcmaxwell@sbcglobal.net.
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Exhibit 1. Dallas/Ft. Worth and Houston ED Data Summary: 2004

CEWG Area

No. of EDs Reporting per Month:
Completeness of Data ( percent)
90–100
50–89
<50
percent
percent
percent

Total Eligible
Hospitals1

No. of
Hospitals in
DAWN Sample

Total EDs in
DAWN
Sample2

49

48

49

8–13

0–4

0–2

33–39

44

37

39

9–14

0–4

0–1

24–25

Dallas/
Ft. Worth
Houston

No. of EDs
Not
Reporting

1

Short-term, general, non-Federal hospitals with 24-hour emergency departments based on the American Hospital Association
Annual Survey.
2
Some hospitals have more than one emergency department.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13-4/14, 2005

Exhibit 2. Percentage of Border and Nonborder Texas Secondary Students Who Had Ever Used Powder or
Crack Cocaine, by Grade: 2004
100%
90%
80%

Cocaine-Border

70%

Cocaine-Non-Border

60%
50%
40%
30%
20%
10%

5%

3%

8%

12%

4%

16%

6%

23%

20%

9%

11%

10%

0%
Grade 7

Grade 8

Grade 9

Grade 10

Grade 11

Grade 12

SOURCE: Texas Department of State Health Services

Exhibit 3. Characteristics of Clients Admitted to TDSHS-Funded Treatment with a Primary Problem with
Cocaine, by Route of Administration: 2004
Characteristics
# Admissions

Crack Cocaine
Smoke
9,131

Powder Cocaine
Inject
900

Powder Cocaine
Inhale
3,256

Cocaine All1
13,863

Percent of Cocaine Admissions

66

6

23

100

Lag-1st Use to Treatment (Years)

12

15

9

11

Average Age

37

35

29

35

Percent Male

54

62

54

55

Percent Black

50

5

13

37

Percent White

33

63

29

34

Percent Hispanic

16

29

57

27

Percent CJ-Involved

36

46

52

41

Percent Employed

12

13

33

18

Percent Homeless

18

11

5

14

1

Includes clients with “other” routes of administration.
SOURCE: Texas Department of State Health Services
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Exhibit 4. Routes of Administration of Cocaine by Race/Ethnicity from TDSHS Treatment Admissions:
1993–2004

100%
90%
80%
70%
60%
50%

Hispanic

40%

White

30%

Black

20%
10%
0%
Crack-93

Crack-04

IDU-93

IDU-04

Inhale-93

Inhale-04

SOURCE: Texas Department of State Health Services

Exhibit 5. Age and Race/Ethnicity of Persons Dying with a Mention of Cocaine in Texas: 1992–2003
40

600

39
38

400

37
36

300

35

200

34

Age (Years)

Number of Deaths

500

Black
Hispanic
White
Age

33

100

32

0

31
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003

SOURCE: Bureau of Vital Statistics, Texas Department of State Health Services
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Exhibit 6. Substances Identified by Texas DPS Labs: 1998–2004
45%

Cocaine

40%
35%

Marijuana

30%

Methamphetamine &
Amphetamine

25%
20%

Heroin

15%
10%
5%
0%
1998

1999

2000

2001

2002

2003

2004

SOURCE: NFLIS

Exhibit 7. Price of a Kilogram of Cocaine in Texas as Reported by the DEA: 1987–2004
$50,000
$45,000
$40,000
$35,000
$30,000
$25,000
$20,000
$15,000
$10,000
$5,000
$1987

1989

1991

1h93

1h94

1h95

1h96

1h97

1h98

1h99

1h00

1h01

1h02

1h03

1h04

1h05

1

Prices reported by half year since 1993.
SOURCE: DEA
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Exhibit 8. Percentage of Texas Secondary Students Who Reported They Normally Consumed Five or More
Drinks at One Time, by Specific Alcoholic Beverage: 1988–2004

25%
20%
15%
Beer
Wine Coolers

10%

Liquor
Wine

5%
0%
1988

1990

1992

1994

1996

1998
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SOURCE: Texas Department of State Health Services

Exhibit 9. Substance Abuse Arrests Per 100,000 Population in Texas: 1994–2004
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1,000
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DWI
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600
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400
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200
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SOURCE: Texas Department of Public Safety
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Exhibit 10.

Characteristics of Clients Admitted to TDSHS-Funded Treatment with a Primary Problem with
Heroin, by Route of Administration: 2004
Characteristic

Inject

Inhale

Smoke

All1

# Admissions

4,651

521

51

5,424

Percent of Heroin Admissions

86

10

1

100

Lag-1st Use to Treatment (Years)

16

8

9

15

Average Age

37

29

30

36

Percent Male

71

51

51

65

Percent Black

6

33

16

9

Percent White

37

16

35

36

Percent Hispanic

55

49

47

54

Percent CJ Involved

31

33

20

31

Percent Employed

12

14

10

13

Percent Homeless

12

8

8

11

1

Includes clients with “other” routes of administration.
SOURCE: Texas Department of State Health Services

Exhibit 11.

Heroin Admissions to TDSHS-Funded Treatment by Race/Ethnicity: 1986–2004
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SOURCE: Texas Department of State Health Services
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Age and Race/Ethnicity of Persons Dying with a Mention of Heroin in Texas: 1992–2003

400
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39.5

300

39
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38.5
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38
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37.5

100
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Exhibit 12.

Hispanic
White
Age

36.5

0

36
1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

SOURCE: Texas Department of State Health Services

Exhibit 13.

Price1 of an Ounce of Mexican Black Tar Heroin in Texas as Reported by the DEA: 1987–2004

$9,000
$8,000
$7,000
$6,000
$5,000
$4,000
$3,000
$2,000
$1,000
$1987

1989

1991

1h93
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1h05

1

Prices reported by half year since 1993
SOURCE: DEA

300

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Texas

Exhibit 14.

Hydrocodone, Oxycodone, and Methadone Indicators in Texas: 1998–2004

Indicator
1998
1999
Poison Control Center Cases of Abuse and Misuse
Hydrocodone
192
264
Oxycodone
12
26
Methadone
16
19
TDHSH Treatment Admissions
"Other Opiates"1
542
802
Methadone
53
68
Deaths with Mention of Substance (TDSHS)
Hydrocodone
25
Oxycodone
8
Methadone
30
36
Drug Exhibits Identified by DPS Laboratories
Hydrocodone
479
Oxycodone
36
Methadone
19

2000

2001

2002

2003

2004

286
22
21

339
34
26

429
68
50

414
64
41

516
77
106

879
44

1,336
50

1,752
63

2,227
66

2,759
55

52
20
62

107
40
93

168
56
131

140
60
122

629
72
22

771
115
42

747
106
49

1,212
174
63

1,534
241
116

1

”Other Opiates” refers to those other than heroin.
SOURCES: Texas Poison Center Network, Texas Department of State Health Services, and Texas Department of Public Safety

Exhibit 15.

Percentage of Texas Secondary Who Had Used Marijuana in the Past Month, by Grade:
1988–2004

20%

Grade 7

15%

Grade 8
Grade 9
10%

Grade 10
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Grade 12

5%
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1988
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SOURCE: Texas Department of State Health Services
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Exhibit 16.

Price of a Pound of Commercial Grade Marijuana in Texas, as Reported by the DEA: 1992–2004
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SOURCE: DEA

Exhibit 17.

Route of Administration of Methamphetamine by Clients Admitted to TDSHS-Funded Programs:
1988–2004
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Percent
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SOURCE: Texas Department of State Health Services
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Exhibit 18.

Characteristics of Clients Admitted to TDSHS-Funded Treatment with a Primary Problem of
Amphetamines or Methamphetamines, by Route of Administration: 2004

Characteristic

Smoke

Inject

Inhale

Oral

All1

# Admissions

1,951

2,363

601

248

5,262

37

45

11

5

100

Percent of Heroin Admissions
Lag-1st Use to Treatment (Years)

8

13

9

11

11

Average Age

28

31

30

31

30

Percent Male

47

47

45

43

47

Percent Black

1

0

2

2

1

Percent White

84

94

87

83

89

Percent Hispanic

13

4

9

13

8

Percent CJ Involved

50

52

52

57

52

Percent Employed

27

18

29

29

23

Percent Homeless

7

11

6

6

8

1

Includes clients with “other” routes of administration.
SOURCE: Texas Department of State Health Services

Exhibit 19.

Percent of Items Analyzed by Texas DPS Regional Laboratories Identified as Methamphetamine,
by Location of Laboratory (County and City): 2004

Location of Laboratory
County (City)
Hidalgo (McAllen)
Webb (Laredo)
El Paso (El Paso)
Nueces (Corpus Christi)
Harris (Houston)
Travis (Austin)
McLennan (Waco)
Smith (Tyler)
Dallas (Dallas)
Midland (Odessa)
Taylor (Abilene)
Lubbock (Lubbock)
Potter (Amarillo)

Percent of Items
0.5
1.1
3.8
11.4
11.7
24.1
29.3
29.0
35.7
16.4
54.3
26.5
41.3

SOURCE: NFLIS
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Exhibit 20.

Benzodiazepines Identified by DPS Labs in Texas: 1998–2004

5.0%

2004, 0.9%

2003

2002

2001

2000

1999

1998, 1.4%

2004, 0.7%

2003

2002

1.0%

2001

1998, 1.7%

2001
2000

1.5%

1999

2.0%

1998, 1.1%

2.5%

2002

3.0%

2003

3.5%

2000

4.0%

1999

2004, 3.4%

4.5%

0.5%
0.0%
Alprazolam

Diazepam

Clonazepam

SOURCE: NFLIS

Exhibit 21.

Characteristics of Clients Admitted to TDSHS-Funded Treatment with a Primary, Secondary, or
Tertiary Problem with Club Drugs: 2004

Characteristic

GHB

Hallucinogens

Ecstasy

PCP

Ketamine

Rohypnol

# Admissions

45

266

561

295

7

221

Percent Male

33

75

54

57

100

75

Percent White

89

61

55

9

57

1

4
0

25
12

21
20

10
81

43
0

97
0

Percent Hispanic
Percent Black
Average Age (Years)

29

23

23

25

18

19

Percent Criminal Justice Involved

44

64

63

56

100

67

Percent History Needle Use

47

25

23

4

43

15

Percent Primary Drug=Club Drug

24

20

14

43

14

13

Other Primary Drug
Percent Marijuana
Percent Alcohol
Percent Methamphet/Amphetamines
Percent Powder Cocaine
Percent Crack Cocaine
Percent Heroin

2
11
56
0
2
0

42
12
8
7
3
2

36
8
16
12
6
1

30
8
1
6
10
1

43
0
0
14
0
8

48
9
1
11
7
9

SOURCE: Texas Department of State Health Services

304

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Texas

Club Drugs Identified by DPS Labs in Texas: 1998–2004

2001
2002

1.8%

0.2%
0.0%

LSD

Ecstasy

PCP

Ketamine

GHB, GBL, 1-4BD

1998, 0.6%
1999
2000
2001
2002
2003
2004, 0.0%

2002
2003
2004, 0.0%

1999

2001

0.4%

1998, 0.2%
1999
2000
2001
2002
2003
2004, 0.2%

0.6%

2001
2002
2003
2004, 0.1%

2000

0.8%

1998, 0.1%
1999
2000
2001
2002
2003
2004, 0.3%

1.0%

2003

1.2%

2000

1.4%

1998, 1.0%
1999

1.6%

2004, 1.2%

Exhibit 22.

Rohypnol

SOURCE: NFLIS

Exhibit 23.

Percentage of Border and Nonborder Texas Secondary Students Who Had Ever Used Rohypnol,
by Grade: 2004

14%
12%
10%

Nonborder
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8%
6%
4%
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0%
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SOURCE: Texas Department of State Health Services
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Exhibit 24.

Percentage of Texas Secondary Students Who Had Used Inhalants Ever or in the Past Month, by
Grade: 2004
25%
20%

Lifetime Use

21%

20%

18%

Past-Month Use
16%

15%

14%

13%

Grade 11

Grade 12

10%
5%
0%
Grade 7

Grade 8

Grade 9

Grade 10

SOURCE: Texas Department of State Health Services

Exhibit 25: Exposures Involving Misuse or Abuse of Inhalants: 1998–2004

Product
Aerosol
Amyl/Butyl Nitrite
Carburetor Cleaner, Auto Fluids
Freon/Other Propellants
Gasoline
Lighter Fluid/Propane
Nitrous Oxide
Paint
Toluene/Mineral Spirits
Correction Fluid

1998
4
1
11
23
24
19
4
46
13
2

1999
3
2
12
24
19
15
4
35
25
4

2000
9
1
19
21
16
12
2
33
19
3

2001
3
1
30
20
18
5
5
26
16
1

2002
10
34
23
18
11
4
31
14
3

2003
4
8
46
15
6
7
2
15
6
2

2004
22
2
67
29
21
8
7
31
13
3

Total
55
15
219
155
122
77
28
217
106
18

SOURCE: Texas Poison Center Network
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Exhibit 26.

Texas HCV Exposures and Their Demographics: 2004

Demographic
Overall
By Mode of Exposure
Injection Drug Exposure
Medical exposure
Tattoo or piercing
Occupational
Other blood/needle
Sexual risk
Shared snorting equipment
No disclosed risk
Gender (%)
Male
Female
Race/Ethnicity (%)
Hispanic
Non-Hispanic
White
Black
Age Group (%)
13–19
20–24
25–29
30–39
40 and older

Percent
17.8
40.7
13.3
5.3
2.8
3.4
7.6
3.3
5.1
19.3
15.3
12.1
20.8
16.8
20.4
2.3
6.3
11.5
23.8
35.3

SOURCE: Texas Department of State Health Services

Exhibit 27.

AIDS Cases1 in Texas by Mode of Exposure: 1987–2004

100%

MSM-BiSexual

90%

MSM&IDU

80%

IDU

70%

Heterosexual

60%
50%
40%
30%
20%
10%
0%
1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
SOURCE: Texas Department of State Health Services
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Exhibit 28.

Texas Male and Female AIDS Cases by Race/Ethnicity: 1987–2004

100%

80%
Hispanic Male

60%

Black Male
White Male
Hispanic Female

40%

Black Female
White Female

20%

0%
1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
SOURCE: Texas Department of State Health Services

Exhibit 29.

Characteristics of Clients Admitted to TDSHS-Funded Treatment Who Used Needles: 2004
Characteristics
# Admissions

Heroin

Cocaine

4,651

900

Stimulants
2,363

Percent of Needle Admits\Drug

86

6

45

Lag-1st Use to Treatment (Years)-Yrs.

16

15

13

Average Age

37

35

31

Percent Male

71

62

47

Percent Black

6

5

0

Percent White

37

63

94

Percent Hispanic

55

29

4

Percent CJ Involved

31

46

52

Percent Employed

12

13

18

Percent Homeless

12

11

11

SOURCE: Texas Department of State Health Services
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Exhibit 30.

Adult and Youth Admissions to TDSHS-Funded Programs: 2004

Primary Substance
Total
Opiates
Alcohol
Depressants
Amphetamines
Cocaine
Marijuana
Hallucinogens
Other Drugs
Crack Cocaine

Primary Substance
Total
Opiates
Alcohol
Depressants
Amphetamines
Cocaine
Marijuana
Hallucinogens
Other Drugs
Crack Cocaine

Primary Substance
Total
Opiates
Alcohol
Depressants
Amphetamines
Cocaine
Marijuana
Hallucinogens
Other Drugs
Crack Cocaine

Total
Admissions
53,204
8,238
14,410
706
5,268
4,339
10,254
180
285
9,524

% of All
Admissions

Average Age

Average Age
1st Use

100.0
15.5
27.1
1.3
9.9
8.2
19.3
0.3
0.5
17.9

32.5
35.7
37.2
28.8
29.7
30.5
21.6
25.1
23.7
37.2

19.2
22.6
15.6
21.8
19.7
20.7
13.9
18.9
18.5
26.0

Avg. Lag-1st
Use to
Admission
14.0
14.0
23.0
8.0
11.0
10.0
8.0
7.0
6.0
12.0

% First
Treatment

Percent
Married

43.8
25.9
41.4
42.8
50.8
50.3
66.9
38.9
53.0
31.0

20.4
19.9
19.0
22.0
20.3
23.3
25.5
8.3
24.2
16.4

Percent
Male

% Use
Needles

% History of
IV Drug Use

Percent
Black

Percent
White

Percent
Hispanic

61.0
57.2
67.7
37.4
46.5
55.9
72.3
56.7
55.8
54.2

19.0
62.8
5.9
6.5
45.5
21.8
1.8
6.1
9.1
5.1

32.7
73.1
23.1
21.2
57.6
29.9
6.7
7.8
15.8
29.3

19.4
8.6
13.8
5.4
0.9
11.2
21.9
70.0
15.4
49.0

48.9
51.6
57.9
76.2
88.9
36.0
32.5
19.4
35.8
33.3

29.7
38.2
26.1
17.0
8.2
50.8
43.1
10.6
43.5
16.3

% Employed
Over Last 12
Months
48.5
30.1
45.8
44.2
51.6
50.7
75.7
58.9
62.8
36.4

Average
Education
(Years)
11.3
11.6
11.9
11.5
11.6
11.2
10.0
11.0
10.3
11.7

Average
Income at
Admission
$5,716
$4,394
$7,250
$4,823
$5,570
$5,986
$5,834
$3,312
$8,495
$4,539

# of Women
Pregnant at
Admission
1,081
115
99
14
185
152
242
8
9
257

Percent
Employed
3.8
2.9
4.6
3.3
3.8
4.3
4.8
3.1
2.8
2.9

Percent
Homeless
11.1
9.5
12.7
6.4
8.4
7.0
7.4
9.4
7.7
17.8

% Involved
With CJ or
Legal
System
26.9
12.7
26.9
22.5
23.1
28.9
53.1
27.2
32.6
12.2
% On
Medication
21.5
34.0
22.5
32.2
17.4
17.0
12.5
17.8
24.2
22.5

(Continued)
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Exhibit 30.

Adult and Youth Admissions to TDSHS-Funded Programs: 2004 (Continued)

Primary Substance
Total
Opiates
Alcohol
Depressants
Amphetamines
Cocaine
Marijuana
Hallucinogens
Other Drugs
Crack Cocaine

%
Emergency
Room Visit
33.8
40.0
38.2
46.5
40.3
32.6
14.9
37.8
22.8
38.8

% Sickness
or Health
Problems
24.8
29.5
26.3
31.0
27.3
21.9
15.0
18.9
20.4
28.8

%
Employment
Problems
51.2
63.7
52.0
53.3
56.5
46.5
33.7
46.1
35.1
57.7

% Family or
Marital
Problems
48.9
60.4
48.4
55.1
56.1
46.4
30.4
45.0
35.8
57.0

% Social/
Peer
Problems
39.9
51.9
40.5
40.5
43.6
34.7
23.1
33.3
28.4
47.2

% Psych/
Emotional
Problems
41.6
45.8
45.9
52.5
52.8
37.5
22.2
33.9
30.9
47.7

% Drug/
Alcohol
Problems
67.6
84.5
69.7
71.2
73.4
61.5
42.0
56.1
48.1
77.2

SOURCE: Texas Department of State Health Services
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Patterns and Trends of Drug
Abuse in Washington, DC
Erin Artigiani, M.A., Margaret Hsu, M.H.S.,
and Eric Wish, Ph.D.1
ABSTRACT
Cocaine/crack, marijuana, and heroin continued to
be the main illicit drug problems in Washington, DC,
in 2004, while the use and availability of PCP has
declined. Although cocaine/crack treatment admissions declined, cocaine remained one of the most serious drugs of abuse in the District as evidenced by
the fact that more adult arrestees tested positive for
cocaine than for any other drug in 2004. Pretrial Services test results indicate that PCP positives dropped
sharply during this time. Juvenile arrestees were more
likely to test positive for marijuana than for any other
drug, but the percentage testing positive decreased
slightly. Heroin treatment admissions increased
slightly. While other parts of the country have seen
shifts in the use of methamphetamine, use remains
low and confined to isolated populations in DC.
INTRODUCTION
Area Description
The Nation’s capital is home to approximately
570,898 people residing in 8 wards that remain
largely distinguishable by race and economic status
(U.S. Bureau of the Census, 2001 update). The
northwest part of the city tends to be home to residents who are wealthy and White, while the northeast
and southeast tend to be home to residents who are
poor and African-American. Slightly more females
than males live in DC, and the majority of the District’s population continues to be African-American
(60 percent). Nearly one-third of the population is
White (31 percent), and the remainder is primarily
Hispanic and/or Asian (U.S. Bureau of the Census,
2000 Census). The population of the District is
slightly older than the general U.S. population. One
in five residents are younger than 18, and slightly
more than 12 percent are age 65 and older. More than
one-third (39.1 percent) of adults age 25 or older
have at least a bachelor’s degree. (Pach et al. 2002).

1

The authors are affiliated with the Center for Substance Abuse
Research, College Park, Maryland. Some background material
was taken from prior CEWG reports.
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Data from the 2000 census reveal several key demographic changes since 1990. The total population
decreased by 5.7 percent during the 1990s, from
606,900 in 1990 to 572,059 in 2000. The number of
African-Americans decreased by 14.1 percent, the
number of Asians grew by 38.6 percent, and the
number of Hispanic residents grew by 37.4 percent.
The White population also grew by a much more
modest 2 percent during this time period (Pach et al.
2002).
Despite a nationwide economic recession, wealth
distributions in the District became more polarized
during 2002. Buoyed by the draw of potential income
from service employment, government spending, and
an established technology industry, measures of
wealth such as median household income ($40,127 in
the District in 1999) increased in the DC metropolitan region. The percentage of persons living in poverty also increased in many areas in and around
Washington (Pach et al. 2002). One in five residents
was living in poverty in 1999 (U.S. Census Bureau).
Alcohol abuse costs the District approximately $700
million per year, and illicit drug use costs about $500
million per year. In fiscal year (FY) 2005, the city
spent approximately $360 million to address the
problem. Nearly 1 in 10 residents (approximately
60,000) are addicted to illegal drugs and/or alcohol.
At least one-half (26,000–42,000) of these individuals have co-occurring substance abuse and mental
health disorders. The DC Household Survey indicates
that first-time drug use occurs at a younger age in the
District than in the rest of the Nation (Citywide
Comprehensive Substance Abuse Strategy for the
District of Columbia, 2003).
Homicides in the District decreased sharply from 248
in 2003 to 198 in 2004. Drugs are still listed as one of
the four most common motives behind these homicides, along with arguments, retaliation, and robberies.
Narcotic drug law violations account for 32 percent of
crime in 14 crime HotSpots identified by the Metropolitan Police Department (MPD 2/1/04–12/29/04).
The major drug problems in the District continue to be
cocaine/crack, marijuana, and heroin. The use and
availability of phencyclidine (PCP) increased from
2000 to 2002 but decreased in 2004. The use of club
drugs like methylenedioxymethamphetamine (MDMA)
also appears to be decreasing.
Information from the Department of Justice’s National Drug Intelligence Center (NDIC) suggests that
the District has a wide variety of drug transportation
options, including an extensive highway system,
three major airports, and rail and bus systems. While
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both NDIC and ethnographic information suggest
that traffickers extensively use all of these options,
Washington appears to be a secondary drug distribution center; most drugs intended for distribution in
DC are distributed first to larger cities, such as New
York and Miami (Pach et al. 2002). The street-level
dealing in DC was described as less organized and
more free-flowing than the organized networks in
these larger cities. Information from the NDIC suggests that Colombian drug trafficking organizations
continue to play a major role in supplying opiates and
cocaine to DC criminal groups of Colombian and Dominican descent.

•

Drug-related death data were derived from
DAWN, OAS, SAMHSA, and annual medical examiner (ME) data for 1997 to 2003. Because of
changes in methodology, DAWN mortality data
from 2003 cannot be compared to DAWN mortality data prior to that year.

•

Drug treatment data for 2000 to 2003 were obtained from the Treatment Episode Data Set
(TEDS), OAS, SAMHSA.

•

Arrest, crime, and law enforcement action data
were derived from the Metropolitan Police Department (MPD) crime statistics and press releases
pertaining to law enforcement action through December 2004, available at www.mpdc.dc.gov.

•

Arrestee urinalysis data were derived from the
District of Columbia Pretrial Services Agency for
adult and juvenile arrestees for 2000 to 2004.

•

Drug prices and trafficking trends were obtained from the NDIC Narcotics Digest Weekly
Special Issue: Illicit Drug Prices January 2004June 2004 and the Washington-Baltimore High
Intensity Drug Trafficking Area (HIDTA) “Washington/Baltimore Threat Assessment” reports released in 2003 and 2004.
General information on drug use was derived
from the University of Maryland’s Center for
Substance Abuse Research Drug Early Warning
System County indicators, DEWS Investigates reports, and CESAR Briefings available at
www.dewsonline.org and www.cesar.umd.edu.

Data Sources
A number of sources were used to obtain comprehensive information regarding the drug use trends
and patterns in Washington, DC. Data for this report
were obtained from the sources shown below. In addition, interviews were conducted with a sample of
substance abuse professionals in the fields of criminal
justice, public health, and recovery.
•

312

Emergency department (ED) data were derived for 2004 from the Drug Abuse Warning
Network (DAWN) Live! restricted-access online
query system administered by the Office of Applied Studies (OAS), Substance Abuse and Mental Health Services Administration (SAMHSA).
Eligible hospitals in the Washington, DC, area
totaled 34; hospitals in the DAWN sample numbered 29, with the number of EDs in the sample
totaling 30. (Some hospitals have more than one
emergency department.) During this 12-month
period, between 11 and 15 EDs reported data
each month. The completeness of data reported
by participating EDs varied by month (see exhibit 1a). Exhibits in this paper reflect cases that
were received by DAWN as of April 13–14,
2005. All DAWN cases are reviewed for quality
control. Based on this review, cases may be corrected or deleted. Therefore, the data presented
in this paper are subject to change. Data derived
from DAWN Live! represent drug reports in
drug-related ED visits. Drug reports exceed the
number of ED visits, since a patient may report
use of multiple drugs (up to six drugs and alcohol). The DAWN Live! data are unweighted
and, thus, are not estimates for the reporting area.
These data cannot be compared to DAWN data
from 2002 and before, nor can preliminary data
be used for comparison with future data. Only
weighted DAWN data released by SAMHSA can
be used for trend analysis. A full description of
the DAWN system can be found at the DAWN
Web site: http://dawninfo.samhsa.gov.

•

•

Census data for the District of Columbia were
derived from the “Council of the District of Columbia; Subcommittee on Labor, Voting Rights,
and Redistricting; Testimony of the Office of
Planning/State Data Center on Bill 14-137, The
Ward Redistricting Amendment Act of 2002.”

•

Test results on drug items analyzed by local
crime lab(s) were obtained from the National Forensic Laboratory Information System (NFLIS).

•

Regional counts on methamphetamine labs
seized were obtained from the El Paso Intelligence Center’s (EPIC) National Clandestine
Laboratory Seizure Database.

•

Additional information was provided by the
human immunodeficiency virus (HIV)/acquired
immunodeficiency syndrome (AIDS) Administration and members of the DC Epidemiology
Workgroup.
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DRUG ABUSE PATTERNS AND TRENDS
Cocaine/Crack
Cocaine, particularly in the form of crack, remains
the most serious drug of abuse in the District, accounting for more ED reports, adult arrestee positive
drug tests, and drug-related deaths than any other
drug. Only heroin has a higher percentage of treatment admissions. Cocaine is most often sold at openair markets in the poorer parts of the city and is decreasing in price. The NDIC reported that powder
cocaine sold for $27,500 to $28,000 per kilogram and
$60 to $100 per gram during the first 6 months of
2004. Crack sells for slightly more: $28,000 to
$34,000 per kilogram and $80 to $100 per gram.
NFLIS data for 2004 show that analyzed drug items
were more likely to test positive for cocaine than for
any other drug; cocaine-positive items represented 44
percent of all items analyzed by NFLIS. Cocaine is
smuggled into the District from New York, Miami,
Los Angeles, or Philadelphia.
Unweighted DAWN Live! data show that cocaine
was the most frequently involved substance in ED
reports. Of the 2,849 ED reports for cocaine in 2004,
61 percent were male, 74 percent were Black, and 20
percent were White (exhibits 1b and 1c). Nearly
three-quarters (74 percent) were age 35 or older, 19
percent were age 25–34, and 7 percent were between
the ages of 18 and 25.
Cocaine-involved deaths totaled 58 in 2002, 27 of
which were single-drug deaths (exhibit 2a). These 58
deaths represented an increase from 2001, when the
total was 42, and from 2000, when the total was 54.
In 2003, 87 cocaine-related deaths occurred (exhibit
2b). Due to changes in methodology, however, this
number cannot be compared to prior years. Nearly
one-half (43 percent) of these deaths in 2003 were
single-drug deaths.
In 2003, cocaine was the primary substance of abuse
among approximately 29 percent of treatment admissions reported to TEDS, with 19 percent reporting
smoked cocaine (referred to as “crack” here) (exhibit
3a). The percentage of primary admissions for nonsmoked cocaine (referred to as “powder” here) increased 51 percent from 474 admissions in 2001 to
717 in 2002, while those for crack decreased 19 percent from 1,450 to 1,172 during this time. In 2003,
the number of admissions for crack (912) continued
to decrease. Admissions for powder cocaine decreased for the first time since 2000. Treatment admissions in 2003 with powder cocaine and crack cocaine as the primary drugs of abuse were more likely
to be male (65.7 and 64.7 percent, respectively) than
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female (exhibit 3b). More than 94 percent of both
cocaine admissions groups were Black, and more
than one-half were age 36 to 45.
Reports from the DC Pretrial Services Agency indicate that the percentage of adult arrestees testing
positive for cocaine has remained about the same
since 2000 (exhibits 4a and 5). In 2004, 37 percent of
adult arrestees in DC tested positive for cocaine; in
2004, 3.3 percent of juveniles tested positive. The
percentage of juveniles testing positive for cocaine
appears to have decreased slightly from 2003 to 2004
(exhibits 4b and 6).
Heroin
Heroin is one of the three leading drug problems in
the District, along with cocaine and marijuana. The
MPD describes crack as a weekend drug, but heroin
as having a more steady ongoing market. The NDIC
reported that heroin sold for $74,000–$110,000 per
kilogram and $100–$110 per gram during the first 6
months of 2004. NFLIS data for 2004 show that approximately 10 percent of analyzed drug items tested
positive for heroin.
The number of heroin abusers in the District continued to increase in 2003, with estimates of 14,000 to
18,000 abusers according to the Washington/Baltimore HIDTA. Most heroin is from South
America, although Southeast Asian and Southwest
African heroin are still distributed by various groups.
Purity ranged from 20.8 percent (South American) to
22.7 percent pure (Southeast Asian). Northwest
Washington is frequented by White suburban users
purchasing high-purity heroin, while eastern Washington is frequented by more well-established sellers
and long-term addicts. Eastern Washington experiences higher levels of trafficking and associated violence.
Unweighted DAWN Live! data show that there were
1,486 heroin ED reports in 2004 (exhibit 1b). Nearly
two-thirds (65 percent) of these patients were male;
71 percent were Black and 24 percent were White
(exhibit 1c). More than three-quarters (78 percent)
were age 35 or older.
Of the 20 heroin-involved deaths in 2002, 4 were
single-drug deaths (exhibit 2a). The number of deaths
in 2002 was substantially lower than in 1997–2000,
but it was an increase from 2001; deaths peaked at 53
in 1998. Eighty-one opiate-related deaths occurred in
2003 (exhibit 2b); five were specified as heroin. Because of changes in methodology, however, these
numbers can not be compared to prior years. All of
the heroin deaths in 2003 involved multiple drugs.
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In 2003, heroin was the primary substance of abuse for
41.9 percent of treatment admissions, a steady increase
from 2000 (exhibit 3a). Of the 2,023 primary heroin
admissions in 2003, approximately 72 percent were
male and 96 percent were Black (exhibit 3b). More
than three-quarters (84 percent) were age 36–55.
As with cocaine, reports from the DC Pretrial Services Agency indicate that the percentage of adult
arrestees testing positive for opiates has remained
about the same since 2001 (exhibits 4a and 5). In
2004, 10 percent of adult arrestees tested positive for
opiates. Juvenile arrestees were not tested for opiates
during this time.
Other Opiates/Narcotics
Unweighted DAWN Live! data show 836 ED reports
for opiates/opioids in 2004. Of these 836 reports,
oxycodone/combinations accounted for 296 (35 percent) and hydrocodone/combinations accounted for
78 (9 percent). More than one-quarter (28 percent) of
opiates/opioids reports were for overmedication, and
20 percent involved individuals seeking detox. More
than one-half (53 percent) were designated “other.”
Twenty-six deaths involving narcotic analgesics were
reported in 2002. This is a substantial increase from
the 6 in 2001 and the 15–22 reported in the prior 3
years (exhibit 2a). The number of deaths involving
methadone in the DC Metropolitan Area increased
from 15 in 2001 to 18 in 2002. Two of the 2002
deaths occurred in DC. Eighty-one opiate-related
deaths occurred in 2003; 20 were specified as methadone and 63 were listed as other opiates (exhibit 2b).
Because of changes in methodology, however, these
numbers cannot be compared to prior years. Five of
the methadone deaths in 2003 were single-drug
deaths.

in blunts or joints, which can be combined with rocks
of cocaine or dipped in liquid PCP. Popular types of
marijuana in the District and Maryland suburbs include “chronic,” “kind bud,” “purple haze,” “blueberry,” and “orange tulip.” All of these types are reputed to have high levels of tetrahydrocannabinol
(THC). The NDIC reported that commercial grade
marijuana sold for $1,800 per pound and Hydro sold
for $5,000 per pound during the first 6 months of
2004. Joints sold for $5 to $10 during this time.
NFLIS data for 2004 show that approximately 35
percent of analyzed drug items tested positive for
marijuana, which makes marijuana the second most
frequently found drug.
Unweighted DAWN Live! data show 1,255 ED marijuana reports in 2004 (exhibit 1b). More than twothirds of these patients were male (68 percent), 58
percent were Black, and 34 percent were White (exhibit 1c). Twenty-nine percent were patients age 18–
24, 23 percent were patients age 25–34, and 31 percent were those age 35 and older. Seventeen percent
of the marijuana ED patients were age 12–17.
Marijuana in combination with other drug(s) was
involved in one death in the District in 2001 and one
in 2000 (exhibit 2a). No marijuana-involved deaths
were reported in 2002 or in 2003.
Marijuana was the primary substance of abuse for 7.0
percent of the 2003 treatment admissions, compared
with 6.4 percent in 2001 and 8.0 percent in 2000 (exhibit 3a). More than three-quarters of the 336 primary
marijuana admissions in 2003 were male, and nearly
87.8 percent were Black (exhibit 3b). Approximately
one-third (32.7 percent) of these admissions were age
12–17, and more than one-quarter (28.6 percent)
were age 18–25.

Other opiates were the primary substance of abuse
among 0.3 percent of the 4,832 treatment admissions
in 2003. This percentage has remained about the
same since 2000 (exhibit 3a). Oxycodone and methadone combined accounted for less than 1 percent of
analyzed drug items reported to NFLIS.

The DC Pretrial Services Agency does not test adult
arrestees for marijuana, but more than one-half of
juveniles tested positive for marijuana each year between 2000 and 2003. During 2004, 49 percent of
juveniles tested positive for marijuana (exhibits 4b
and 6). The proportion of juveniles testing positive
for marijuana has been decreasing slowly since 1999.

Marijuana

Phencyclidine

Marijuana is widely used in the District as it is in
many other jurisdictions. Commercial-grade and
high-grade marijuana are available for wide ranging,
but relatively stable, prices. Most of the marijuana is
transported into the District via package delivery services by Mexican and Jamaican trafficking organizations, according to the most recent NDIC and HIDTA
threat assessments. Marijuana is most often smoked

According to the MPD, the number of adult arrests
related to PCP increased 65 percent between 2001 and
2002 (from 142 to 234). According to the Washington/Baltimore HIDTA 2003 Threat Assessment, PCP
was rapidly becoming the drug of choice at raves and
nightclubs, sometimes used in combination with marijuana and/or MDMA (ecstasy). In 2004, however, PCP
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use began to decline, and PCP use is still well behind
that of crack and marijuana.
While most PCP is transported to the District from
southern California, the seizure of precursor chemicals and PCP at a clandestine laboratory in Baltimore
in 2004 indicates the drug has been produced in the
region. No clandestine labs have been identified to
date in the District. NFLIS data for 2004 show that
approximately 2 percent of analyzed drug items
tested positive for PCP, making it the fifth most frequently found drug after cocaine, marijuana, heroin,
and methamphetamine.
According to unweighted DAWN Live! data, there
were 289 ED PCP reports in 2004 (exhibit 1b).
There were 27 PCP deaths in the metropolitan area in
2002, including 8 in the District and 14 in Prince
George’s County, Maryland. The number of deaths in
the District increased from three in 2001 (data not
shown). In 2003, the DAWN methodology was
changed. PCP-related deaths are now only included
in the hallucinogens category. There were five hallucinogens-related deaths in 2003. (DAWN Metro Area
Profiles and Area Spotlights, 2001, 2002, 2003.)
In 2003, PCP was the primary substance of abuse
among 3.9 percent of treatment admissions, an increase from 2001 (1.8 percent) and 2000 (0.7 percent) (exhibit 3a). Of the 189 primary PCP admissions in 2003, nearly two-thirds were male, and
nearly all were Black (exhibit 3b). More than onehalf (55 percent) were age 18–25, and one-third (33
percent) were 26–35.
Data from the DC Pretrial Services Agency show a
rise in PCP use, from the low single digits in the late
1990s to the mid-teens (exhibits 5 and 6) in 2002 and
2003. But PCP use among adult arrestees declined in
2004 to 6 percent (a steady decrease from 10.6 percent in January to 3 percent in May; for the remainder of the year, positives ranged between 4 and 7
percent). Trend data from 1987 to the present indicate
that PCP use in the juvenile arrestee population has
mirrored that of the adult arrestee population (exhibits 4a and 4b), with spikes in the late 1980s, mid1990s, and again in the current decade. The proportion of juveniles testing positive for PCP decreased
from 13.4 percent in 2002 to 1.9 percent in 2004 (exhibits 4b and 6).
Amphetamine/Methamphetamine
Abuse of amphetamines and methamphetamine does
not appear to be a major problem in the District. Five
deaths involving amphetamines (2) or methampheta-
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mine (3) were reported from 1997 to 2002. One
methamphetamine-involved death and one amphetamine-involved death were reported in 2002 (exhibit
2a). Methamphetamine and amphetamine were not
included in the DAWN 2003 Area Profile.
From 2000 through 2003, amphetamines accounted
for less than 1 percent of all treatment admissions in
the District (exhibit 3a). Admissions involving
methamphetamine as a substance of abuse increased
steadily from 1 in 1998 to 47 in 2001 (exhibit 3c). In
2002, only 29 methamphetamine mentions occurred
among treatment admissions, a decrease of 38 percent from 2001 (exhibit 3c).
Unweighted DAWN Live! data show amphetamine
ED reports totaled 79 in 2004 and methamphetamine
ED reports totaled 31 (exhibit 1b). Nearly two-thirds
(61 percent) of the methamphetamine patients were
White and 87 percent were male. Nearly one-third
(32 percent) of the methamphetamine ED patients
were age 18–24, 48 percent were 25–34, and 16 percent were 35 and older. Three percent were age 12–
17.
The Washington/Baltimore HIDTA and other members of the DC Epidemiological Workgroup report
that methamphetamine use is established in the homosexual community. The Whitman Walker Addiction Services Clinic, which specializes in treating the
gay/lesbian/bisexual/transsexual community, currently reports that 75 percent of outpatient admissions
report crystal methamphetamine use. This is an increase from 50–60 percent in 2001 and 35 percent in
2000. Detectives from the Metropolitan Police Department report that both tablet and powder methamphetamine is visible in the Washington, DC, club
scenes.
NFLIS data for 2004 show that approximately 3 percent of analyzed drug items tested positive for
methamphetamine, making it the fourth most frequently found drug. The NDIC reported that
methamphetamine sold for $4,800 per one-half
pound, and 8-balls sold for $400 during the first 6
months of 2004. The DC Pre-trial Services Agency
does not regularly test for methamphetamine, but a
special study testing for methamphetamine and amphetamine found a positive rate of less than 1 percent
among all specimens tested.
As in the District, the demand for and availability of
methamphetamine in Maryland is extremely low
compared to other drugs. Methamphetamine users in
Maryland tend to be Caucasian males, particularly
youth, those involved with the rave and club scenes,
and middle- to lower-class blue collar workers.

315

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Washington, DC

Methamphetamine use is more prevalent in the rural
western, eastern, and southern parts of the State.
From January 2003 to May 2004, law enforcement
officials report that there were eight methamphetamine labs seized in Maryland: two in Garrett, one in
Washington, three in Charles, one in Prince George's,
and one in Cecil Counties. Additional information on
methamphetamine trends in Maryland is available in
the CESAR Briefing: Methamphetamine in Maryland
at www.cesar.umd.edu.

derall® were easy or very easy to get around campus.
Another prescription stimulant, Ritalin®, was rated
as easy or very easy to get by more than one-half of
the respondents. Non-medical use of prescription
stimulants was perceived to be widespread. Prescription stimulants were used most often to study for and
focus on exams. Student reporters rated the use of
prescription stimulants for studying to be much less
harmful than using them to party or mix with alcohol
or other drugs.

Although there is little indication that methamphetamine is an emerging problem in the District, there
have been increases in the number of methamphetamine labs seized in several of the States surrounding
the District. For example, 8 methamphetamine labs
were seized in Virginia in 1999, compared to 23 in
2003. In West Virginia and Pennsylvania, the number
of labs seized has increased even more dramatically
during this period, from 3 to 52 and 1 to 49, respectively.

The SDR findings are obtained from a panel of students oversampled to include students likely to be
familiar with drug use. They are not representative of
the general student population. In the coming year,
DEWS staff plan to expand the sample of SRs to include “lower risk” students who may have little
knowledge or experience with drug use. The larger
sample will enable staff to put the responses from the
higher risk group into the context of the general student population. Monthly reports are available on the
CESAR Web site at www.cesar.umd.edu. A DEWS
Investigates report on these results will also be released.

The Washington Post reported that nearly all of the
methamphetamine seized in Virginia in 2004 was
found in the Shenandoah Valley, and methamphetamine is the primary drug seized along the north-south
corridor between Winchester and Harrisonburg. A
special report on methamphetamine from the Washington/Baltimore HIDTA explains this trend further.
The cities of Harrisonburg and Strasburg, Virginia, in
particular, are highlighted by law enforcement as
having a substantial methamphetamine presence.
According to law enforcement, the primary users in
these areas are rural, White, working-class adults,
while the sellers are primarily Latino. Rival Hispanic
criminal groups such as MS-13 and South Side Locos
in Strasburg have collaborated in the sale of methamphetamine since early 2004, increasing the chance
that methamphetamine may increase in the area because of the presence of MS-13 in Maryland.
Prescription Stimulants
Drug Early Warning System (DEWS) staff at
CESAR recently launched the Student Drug Research
(SDR) survey, a new tool for monitoring drug trends
among college students. The SDR survey provides a
unique opportunity to collect useful and timely information about emerging drugs and patterns of use
among college students. A panel of 26 undergraduate
student reporters (SRs) at the University of Maryland
College Park has participated in 2 surveys of their
perceptions of drug availability and use by their
peers.
In the March and April 2005 surveys, nearly all respondents reported that alcohol, marijuana, and Ad-
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Other Drugs
Abuse of club drugs, such as MDMA, gamma
hydroxybutyrate (GHB), and ketamine, is also
relatively low in the District. MDMA is the most
readily available and frequently abused “club drug,”
selling for $18 to $25 per tablet in the fourth quarter
of 2002, according to the DEA Washington Division.
The Washington/Baltimore HIDTA estimated a
slightly lower range for the cost per dosage unit: $10
to $20. MDMA is most frequently used and
distributed by teens and young adults at raves and
nightclubs. MDMA is typically driven to the District
from New York, Philadelphia, Orlando, and Miami
by Dominican and Asian trafficking organizations.
According to unweighted DAWN Live! data, there
were 83 ED reports for MDMA, 9 for GHB, and 8 for
lysergic acid diethylamide (LSD) in 2004 (exhibit
1b). Only one ED report was for ketamine. MDMA
and methylenedioxyamphetamine (MDA) each accounted for approximately 1 percent of analyzed drug
items tested through NFLIS in 2004. GHB and ketamine were each found in less than 1 percent of analyzed drug items tested through NFLIS in 2004. No
drug items tested positive for LSD. No deaths involving club drugs were reported in the DAWN mortality
data for 1997–2002 (exhibit 2a). No deaths involving
club drugs were reported in 2003, but five hallucinogen-related deaths were reported. All of these deaths
involved multiple drugs. Because of changes in
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methodology, however, these numbers can not be
compared to prior years.
Benzodiazepines are reported in the DAWN ED and
mortality reports. In 2004, unweighted DAWN Live!
data show 549 ED benzodiazepines reports. One death
in 2001 was attributed solely to benzodiazepines (exhibit 2a); however, in the 1997 to 2000 time period,
mentions of benzodiazepines in the mortality data
ranged between 10 and 13. In 2002, four deaths were
attributed to multiple drugs including benzodiazepines.
In 2003, five deaths involving benzodiazepines and
multiple drugs were reported (exhibit 2b).
Unweighted 2004 DAWN Live! data show 2,518 ED
alcohol reports (exhibit 1b). DAWN mortality data
show a decrease in mentions of deaths involving alcohol in combination with other drugs—from 29 in 1997
to 17 in 2001, with a peak of 44 in 1998. Alcoholinvolved deaths more than doubled in 2002 to 37 (exhibit 2a). Fifty-one deaths in 2003 involved alcohol
(exhibit 2b). In 2003, primary alcohol admissions accounted for approximately 18 percent of all treatment
admissions, a slight decline from 2000 and 2001.
INFECTIOUS DISEASES RELATED TO SUBSTANCE
ABUSE
The diagnosis of AIDS cases increased rapidly from
1982 to 1993, when they peaked at 1,342 cases. The
number of cases decreased 49 percent from 1993 to
2001, but increased 37.5 percent between 2001 and
2002. There were 943 diagnosed cases in 2002, the
last year for which data are available. The number of
male cases decreased steadily from 1998 to 2001, but
increased in 2002. Males accounted for 70 percent of
cases diagnosed in 2002. Almost three-quarters of the
diagnoses in 2002 occurred among 30–49-year-olds
(exhibit 7). Almost two-thirds (62 percent) of people
in DC diagnosed with AIDS in 2002 were Black, and
about 21 percent had a history of injection drug use.
The rate of AIDS deaths decreased from 47 per
100,000 in 1998 to 25 per 100,000 in 2003, according
to the HIV/AIDS Epidemiologic Profile for the District of Columbia 2004. Of the new AIDS diagnoses
in 2004, 150 were related to intravenous drug use.
DC EPIDEMIOLOGY WORKGROUP
In 2003, the Mayor’s Interagency Task Force on Substance Abuse Prevention, Treatment, and Control was
established and charged with four goals: educate and
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empower DC residents to live healthy and drug-free
lifestyles; develop and maintain a continuum of care
that is efficient, effective, and accessible to individuals
needing treatment; increase the public’s safety and
improve treatment access for offenders to ensure fair
and effective administration of justice in the District;
and encourage a coordinated and focused regional
response to the problem of substance abuse. The task
force is chaired by the District’s Addiction Prevention
and Recovery Administration (APRA) and co-chaired
by the Metropolitan Police Department.
The first Citywide Comprehensive Substance Abuse
Strategy was released in 2004 and was updated earlier this year. To assess progress on implementing
the strategy and reaching the goals, APRA convened
the DC Epidemiology workgroup. The Workgroup
has assessed national and local data sources and identified more than 40 indicators of the consumption of
alcohol, tobacco, and other drugs and the health and
social consequences of drug use. Topics covered include current use, lifetime use, age of initial use,
cigarette and ethanol consumption per capita, treatment admissions, drug intoxication deaths, drug law
violations, AIDS diagnoses related to injection drug
use, poison center calls, motor vehicle crashes, and
substance abuse issues in child neglect and abuse
investigations. The indicators are based on indicators
developed by the Center for Substance Abuse Prevention (CSAP) as a part of the SPF SIG program
and indicators monitored by CESAR in Maryland as
a part of the Drug Early Warning System. Future
issues of this report will begin to highlight the data
collected and analyzed by the Workgroup.
REFERENCES
Citywide Comprehensive Substance Abuse Strategy
for the District of Columbia, 2003
Pach, A.; Brown, J.; Hendrickson, J.; Odom, T.; and
Nemes, S. “Patterns and Trends of Drug Abuse
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Exhibit 1a.

Data Completeness for Washington, DC, Metropolitan Area DAWN Live! Emergency Departments (n=30),1 by Month: 2004

Data
Completeness

Number of EDs, by Month and Year
MayJunJulAug04
04
04
04

Jan04

Feb04

Mar04

Apr04

9

11

11

12

10

11

13

4

2

2

1

3

2

2

Basically
Complete2
Partially
Complete3
Incomplete4
No Data Reported
Total EDs in
Sample5

Sep04

Oct04

Nov04

Dec04

8

8

9

10

9

5

3

3

3

4

0

0

2

0

0

1

0

2

0

2

0

1

17

17

15

17

17

16

15

15

19

16

17

16

30

30

30

30

30

30

30

30

30

30

30

30

1
Total eligible hospitals in area = 34; Hospitals in DAWN sample = 29; Hospitals not in DAWN Sample = 5. Tables reflect cases that
have been received by DAWN as of 4/14/05.
2
90%+ Complete; 350% to 89% Complete; 4Less than 50% Complete; 5Some hospitals in the DAWN sample have more than one
emergency department. All DAWN cases are reviewed for quality control. Based on this review, cases may be corrected or deleted. Therefore, these data are subject to change.
SOURCE: DAWN Live!, OAS, SAMHSA, update 4/13–4/14/2005

Exhibit 1b. Number of Selected Drug Reports in Washington, DC, Metropolitan Area DAWN EDs
(Unweighted1): 2004
Cocaine

2,849

Alcohol

2,518

Heroin

1,486

Marijuana

1,255

PCP

289

MDMA

83

Amphetamines

79

Inhalants

60

Methamphetamines

31

Misc. Hallucinogens

18

Combinations NTA

15

GHB

9

LSD

8

Ketamine

1

1

The unweighted data are from Washington, DC, metropolitan area hospitals reporting to DAWN. During calendar year 2004, between 11 and 15 EDs reported data each month. All DAWN cases are reviewed for quality control. Based on this review, cases
may be corrected or deleted. Therefore, these data are subject to change.
2
NTA=Not tabulated above.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–4/14/2005
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Exhibit 1c.

Demographic Characteristics of Patients Reporting Cocaine, Heroin, and Marijuana Abuse in
Washington, DC, Metropolitan Area DAWN EDs, by Percent (Unweighted1): 2004

Characteristic

Cocaine Reports
(n=2,849)

Heroin Reports
(n=1,486)

Marijuana Reports
(n=1,255)

61.3
38.6

65.0
35.0

68.0
32.0

19.5
73.6
1.6
0.4
4.8

23.6
71.0
1.1
0.7
3.6

34.2
58.2
2.5
1.4
3.7

0.7
7.1
18.5
42.8
26.3
4.4
0.2

0.2
7.2
14.4
32.0
39.0
7.1
0.1

17.4
28.7
23.3
19.3
9.6
1.9
0.0

Gender
Male
Female
Race/Ethnicity
White
Black
Hispanic
Race/ethnicity NTA2
Not documented
Age
17 and younger
18–24
25–34
35–44
45–54
55 and older
Not documented
1

The unweighted data are from Washington, DC, metropolitan area hospitals reporting to DAWN. During calendar year
2004, between 11 and 15 EDs reported data each month. All DAWN cases are reviewed for quality control. Based on this
review, cases may be corrected or deleted. Therefore, these data are subject to change.
2
NTA=Not tabulated above.
SOURCE: DAWN Live!, OAS, SAMHSA, updated 4/13–4/14/2005

Exhibit 2a.

Drug-Related Deaths in Washington, DC: 1997–2002

Drug
Alcohol-in-Combination
Cocaine
Heroin/Morphine
Marijuana
Amphetamines
Methamphetamine
Club Drugs1
Hallucinogens2
Inhalants
Narcotic Analgesics3
Other Analgesics
Benzodiazepines
Antidepressants
All Other3
Total Drug Deaths
Total Drug Mentions
Total Deaths Certified

1997
29
33
41
–
–
–
–
1
–
6
2
13
4
7
79
136
1,414

1998
44
63
53
–
–
1
–
–
–
22
3
13
14
30
145
243
1,607

1999
37
64
41
–
–
–
–
2
–
15
3
11
11
18
121
202
1,763

2000
26
54
36
1
1
1
–
1
–
20
2
10
4
10
100
166
1,751

2001
17
42
15
1
–
–
–
3
–
6
1
1
1
1
53
88
1,582

2002
37
58
20
_
1
1
_
8
_
26
1
4
_
5
91
161
1,754

SingleDrug
Deaths,
2002
N/A
27
4
_
_
_
_
2
_
6
1
_
_
1
41
41
N/A

1

Includes ecstasy (MDMA), ketamine, GHB-GBL, and Rohypnol®.
Includes PCP, LSD, and miscellaneous hallucinogens.
3
Not tabulated above.
SOURCES: DAWN, OAS, SAMHSA, updated September 2003
2
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Exhibit 2b. Multidrug vs. Single-Drug Deaths in Washington, DC: 2003
Number
100
90

Multidrug deaths

80

Single drug deaths

70
60
50
40
30
20
10
0
Cocaine

Opiates/opioids

Alcohol

Antidepressants

Benzodiazepines

SOURCE: DAWN, 2003: Area Profiles of Drug-Related Mortality

Exhibit 3a.

Percentages of Treatment Admissions in Washington, DC, with Abuse of Selected Substances
(Primary Substance of Abuse), by Year: 2000–2003

Drug
Total Admissions (N)
Cocaine (Smoked)
Cocaine (Other Form)
Heroin

2000

2001

2002

2003

(6,025)

(5,755)

(5,659)

(4,832)

27.0

25.2

20.7

18.9

7.4

8.2

12.7

9.6

35.2

37.9

39.2

41.9

Other Opiates

0.2

0.4

0.3

0.3

Marijuana

8.0

6.4

4.8

7.0

PCP
Alcohol
Amphetamines1

0.7

1.8

3.6

3.9

21.1

19.3

18.4

18.2

0.2

0.6

0.3

0.2

1

Amphetamines includes methamphetamines, Benzedrine, Dexedrine, Preludin, Ritalin, and any other amines and related drugs.
SOURCE: TEDS, SAMHSA
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Exhibit 3b. Demographic Characteristics of Treatment Admissions in Washington, DC, by Selected Primary
Drugs of Abuse and Percent: 20031
Drug
(N=)
Gender
Male
Female
Race/Ethnicity
Black
White
Other2
Age Group
17 and younger
18–25
26–35
36–45
46–55
56 and older

Cocaine
(Smoked)
(912)

Cocaine
(Other Form)
(466)

64.7
35.3

Ampheta3
mines
(10)

Heroin

Marijuana

PCP

(2,023)

(336)

(189)

65.7
34.3

72.0
28.0

75.9
24.1

63.0
37.0

90.0
10.0

94.8
1.2
4.0

94.4
0.9
4.8

95.8
1.8
2.3

87.8
0.9
11.3

98.4
0
1.6

10.0
90.0
0

0.2
2.7
18.3
58.2
18
2.4

0
4.5
15.8
54.5
21.9
3.2

0
1.7
9.9
45.6
38.4
4.4

32.7
28.6
20.8
12.2
5.1
0.6

2.1
55
32.8
6.3
2.7
1.1

0
10.0
30.0
60.0
0
0

1

May not add up to 100 percent due to rounding.
Primarily Hispanic or Latino.
3
Amphetamines includes methamphetamines, Benzedrine®, Dexedrine®, Preludin®, Ritalin®, and any other amines
and related drugs.
SOURCE: TEDS, SAMHSA
2

Exhibit 3c.

Numbers of Treatment Admissions in Washington, DC, Who Mentioned Methamphetamine as a
Substance of Abuse: 1994–2002

70
60

47

50
40

29

30

19

20
10

10
0

0

2

1994

1995

1996

2

1

1997

1998

0
1999

2000

2001

2002

SOURCE: TEDS, SAMHSA
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Exhibit 4a.

Percentages of Adult Arrestees in Washington, DC, Testing Positive for Selected Drugs:
2000–2004

Drug

2000

(N=)

2001

2002

2003

2004

(15,630)

(17,350)

(17,952)

(17,742)

(19,531)

Cocaine

33.6

34.2

35.2

34.8

36.6

PCP

9.3

12.7

14.2

13.5

6.2

Opiates

9.5

10.5

10.5

10.0

9.8

Any Drug

43.2

46.1

48.0

47.3

43.5

SOURCE: District of Columbia Pretrial Services Agency

Exhibit 4b. Percentages of Juvenile Arrestees in Washington, DC, Testing Positive for Selected Drugs:
2000–2004
Drug

2000

2001

2002

2003

2004

(N=)

(2,162)

(2,165)

(1,896)

(1,899)

(2,001)

Marijuana

60.7

56.9

54.2

50.8

49

Cocaine

5.7

4.8

5.5

3.7

3.3

PCP

9.8

13.5

13.4

11.1

1.9

Any Drug

62.0

59.1

56.4

53.1

49.6

SOURCE: District of Columbia Pretrial Services Agency
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Exhibit 5.

Percentages of Washington, DC, Adult Arrestees Testing Positive for Any Drug, Cocaine, PCP,
and Opiates: 1984–2004

80%
Any Positive

70%

Cocaine
Opiates

60%

PCP

50%
40%
30%
20%
10%

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1989

1988

1987

1986

1985

1984

0%

SOURCE: Adapted by the Center for Substance Abuse Research (CESAR) from data from the District of Columbia Pretrial Services
Agency

Exhibit 6.

Percentages of Washington, DC, Juvenile Arrestees Testing Positive for Any Drug,1 Cocaine,
PCP, and Marijuana: 1987–2004

80%
70%
60%
50%

Any Positive
Cocaine

40%

Marijuana
PCP

30%
20%
10%

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1989

1988

1987

0%

1

Any Positive includes opiates from 1987 through mid-1994 (<1%)
SOURCE: Adapted by the Center for Substance Abuse Research (CESAR) from data from the District of Columbia Pretrial Services
Agency
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Exhibit 7.

District of Columbia Diagnosed AIDS Cases by Gender, Race/Ethnicity, Age, and Exposure:
1981–2002
1998

Characteristic
Gender
Male
Female
Total Cases
Race/Ethnicity
White
Black
Hispanic
Asian/Pacific Islander
Undisclosed/Unknown
Age Group
0–12
13–19
20–29
30–39
40–49
50-59
60 and older
Mode of Exposure
MSM
IDU/MSM
IDU
Heterosexual contact
Mother with HIV
Hemophilia
Transfusion/transplant
Unknown/other
Deaths During Period

1999

2000

2001

2002

Cumulative
1981-2002
#
%

#

%

#

%

#

%

#

%

#

%

719
278
997

72
28

526
188
715

74
26

471
210
681

69
31

468
218
686

68
32

658
285
943

70
30

12,098
3,034
15,132

80
20

112
837
42
<5
<5

11
84
4
<1
<1

88
591
27
5
<5

12
83
4
<1
<1

68
562
32
<5
15

10
83
5
<1
2

59
567
28
<5
29

9
83
4
<1
4

46
584
22
<5
289

5
62
2
<1
31

2,962
11,286
485
48
351

20
75
3
<1
2

8
8
120
395
330
107
29

<1
<1
12
40
33
11
3

<5
<5
89
265
249
83
20

<1
<1
12
37
35
12
3

0
7
89
253
231
78
23

0
1
13
97
34
11
3

<5
<5
75
235
251
94
26

<1
<1
11
34
37
14
4

<5
8
85
319
347
149
32

<1
<1
9
34
37
16
3

179
71
2,248
6,327
4,575
1,363
369

1
<1
15
42
30
9
2

353
22
312
191
8
0
<5
108

35
2
31
19
<1
0
<1
11

268
14
165
169
<5
0
<5
90

38
2
23
24
<1
0
<1
13

200
14
163
176
0
0
<5
126

29
2
24
26
0
0
<1
19

195
20
146
149
<5
0
<5
172

28
3
21
22
<1
0
<1
25

271
16
179
253
<5
<5
<5
219

28
2
19
27
<1
<1
<1
23

7,204
673
3,939
2,095
172
22
104
923

48
4
26
14
<1
<1
<1
6

156

130

89

48

41

6,932

SOURCE: District of Columbia Department of Health, Division of Epidemiology, Administration for HIV/AIDS
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Stimulant Abuse in Ohio and
the Rural South
Robert G. Carlson, Ph.D.
INTRODUCTION
This paper summarizes the methods and findings
from two NIDA-supported studies of methamphetamine (MA) abuse in rural Ohio, Kentucky, and
Arkansas, conducted by researchers at the Wright
State University Boonshoft School of Medicine, the
University of Arkansas for Medical Sciences, and the
University of Kentucky. In addition, patterns of MA
abuse among young adult MDMA/ecstasy users in
urban central Ohio are described. Finally, preliminary
findings from the Ohio Substance Abuse Monitoring
Network on trends in methamphetamine abuse in
Dayton, Ohio, are presented.
SAMPLES AND METHODS
One natural history study focused on “MDMA/Club
Drug Use and STD/HIV Sex Risk Behavior in Ohio”
[NIDA grant RO1DA14488; R. Carlson, Principal
Investigator]. As part of this study, respondents were
asked about methamphetamine use. The other natural
history study, “Rural Stimulant Use and Mental
Health: Services and Outcomes” [RO1DA15363;
Brenda Booth, PI, Carl Leukefeld, Co-PI;
R01DA14340; Harvey Siegal/Carlson, PI], focused
on rural stimulant users and health services needs in
Ohio, Arkansas, and Kentucky. Finally, funded by
the Ohio Department of Alcohol and Drug Addiction
Services, the Ohio Substance Abuse Monitoring
Network (OSAM), was a targeted study of methamphetamine abuse in the first half of 2005; the preliminary findings are based on research conducted in
Dayton, Ohio.
For the urban MDMA study, 402 active ecstasy users
were recruited using respondent-driven sampling
(RDS) from May 2002 through June 2003. Participants completed an extensive baseline structured interview, including drug use patterns, mental health,
adverse consequences, and sex risk behaviors. Ethnographic interviews were conducted with a smaller
sample. For this study, the correlates of MA use were
examined using logistic regression.
The study on rural methamphetamine abuse was
based on a sample of 711 active (prior 30-day) stimulant (powder cocaine, crack, methamphetamine) users
recruited using RDS in rural Ohio, Arkansas, and
Kentucky. Data were collected from October 2002–
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March 2004 (Ohio), June 2003–June 2004 (Arkansas), and July 2003–September 2004 (Kentucky).
Participants completed an extensive baseline structured interview focusing on drug use, mental health,
and health services needs and use. Preliminary analyses were conducted using bivariate statistics.
For the OSAM study, qualitative interviews were
conducted with a convenience sample of 17 people
recruited in Dayton, Ohio, who had used methamphetamine in the previous 12 months. Interviews focused on trends in methamphetamine use during the
first half of 2005, initiation patterns, reasons for use,
and characteristics of users.
SELECTED FINDINGS
The MDMA Study
Among 402 young adult MDMA users recruited in an
urban setting in central Ohio, 91 had used methamphetamine (MA) in the 6 months prior to the baseline
interview. Logistic regression revealed that MA users
were significantly more likely than non-MA users to
not be enrolled in college and to have used cocaine,
hallucinogens, and inhalants in the previous 6
months. Participants who had used MDMA on 50 or
more lifetime occasions were also more likely to
have used MA than participants who had used
MDMA 1–10 times.
The Rural Stimulant Abuse Study
Among the 711 rural stimulant users in Ohio, Arkansas, and Kentucky, 342 (48.1 percent) had used MA
in the 30 days prior to interview. Compared with cocaine-only (n=367) and users of both MA and cocaine (249), MA-only users (93) were more likely to
be employed and on probation or parole. Cocaineonly users were more likely to be older, of non-White
ethnicity, and to have used alcohol in the past 30
days. Users of both MA and cocaine were more
likely than the other two groups to have less than a
high school diploma, to have engaged in illegal acts
for profit in the past 30 days, and to have used marijuana, OxyContin, other non-prescribed analgesics,
and non-prescribed tranquilizers.
The Ohio Substance Abuse Monitoring
Network
Ethnographic interviews with 17 recent (past-12
months) MA users in Dayton revealed that the availability of MA is increasing. Respondents ranged in
age from 21 to 57; 10 were men. Five participants
inhaled MA, seven smoked it, three inhaled and
smoked, and two injected. Seven were “old gen-
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eration” users who were first introduced to MA about
15 years ago; 10 were “new generation” users who
had initiated use 2–5 years ago. Five, sometimes
overlapping, pathways to MA use were identified
(powder cocaine to MA, crack to MA, MDMA to
MA, non-prescribed amphetamines to MA, and marijuana to MA).

Thirty-four persons whose primary stimulant of use
was methamphetamine (MA) participated in qualitative interviews: 12 men and 9 women from Kentucky
and 8 women and 5 men from Arkansas. Thirty-two
participants were White and 2 were AfricanAmerican. The average age for men and women was
32.2 and 29.3, respectively. Most participants earned
$10,000 per year or less.

CONCLUSIONS
Preliminary findings from these diverse studies indicate that there is a wide range of people who abuse
methamphetamine. MA user groups identified included gay men, young Whites, primarily in the
“party/rave” scene, and young/middle-aged Whites in
urban and rural settings. Findings from the OSAM
study suggest that after years of low levels of abuse,
MA use appears to be increasing in the Dayton area
among diverse populations. However, these reported
increases are not yet being observed by treatment
providers. In summary, the field is confronted with
multiple methamphetamine epidemics, each with its
own dynamic trajectory; different kinds of MA users
have different reasons for use, associated risks, and
prevention and treatment needs. At the same time,
barriers to intervention and treatment include paranoia associated with prolonged MA abuse and fear of
legal sanctions.

Rural Methamphetamine
Abuse: An Ethnographic
Perspective

The average age of first MA use for men and women
was 21.4 and 21.8, respectively. Men had used MA
for 10.6 years and women 7.6 years. The average
days of MA use per month was 7.8 for men and 7.9
for women. Thirty-three participants used other
drugs, including marijuana, cocaine, and diverted
prescription-type drugs, and 26 reported regular use
of alcohol and tobacco. The sample included six
White MA producers (“cookers”).
SUMMARY OF SOME KEY FINDINGS
Small-scale production (“cooking”) of MA using the
Birch/Nazi method has increased over the last decade. Primary ingredients like pseudoephedrine pills
and lithium batteries are obtained through purchases
or theft by drug users who trade them for MA. The
volatile chemical fertilizer anhydrous ammonia is
another key ingredient and is often stolen from farms
or distribution centers. MA is distributed within relatively small networks through sales, gift-giving, and
barter for cooking ingredients or other items. Smoking the drug on aluminum foil is the most common
route of use, followed by injecting, inhaling, and oral
use.
The participants identified a variety of reasons for
using MA, including the following:

Rocky L. Sexton, Ph.D., and Robert G.
Carlson, Ph.D.

•

Peer pressure and regular interactions with
methamphetamine-using acquaintances

INTRODUCTION

•

Boredom with rural life

This paper summarizes preliminary ethnographic
findings from a NIDA-supported study of stimulant
abuse and health service needs in rural areas
[RO1DA15363; Brenda Booth, Principal Investigator].

•

Availability and flexible distribution mechanisms

•

MA is more cost-effective than other stimulants
(e.g., cocaine) since its psychoactive effects last
exponentially longer

•

The psychoactive and physiological effects (e.g.,
enhanced energy, weight loss, enhanced sex) of
methamphetamine

SAMPLE AND METHODS
All interviewees were part of the larger natural history study that used respondent-driven sampling to
select participants in Kentucky and Arkansas. They
were selected to provide a diversified sample in terms
of gender, age, ethnicity, primary stimulant used, and
mode of use.
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Although the sample of African-Americans in this
study was small, the preliminary findings suggest
potential barriers to African-American use of MA…
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•

Fear of MA’s ingredients

•

Dislike of MA’s prolonged effects

•

Isolation/avoidance in regard to Whitedominated production and distribution networks

•

Well-established preference for cocaine

Pathways to limited use of MA by AfricanAmericans include…
•

Using MA while believing that it is powder cocaine

•

Situationally substituting MA for cocaine

•

Introduction to MA by a White friend or significant other

•

Involvement in a largely White social network
where MA use is common

Largely self-reported adverse consequences of MA
production and use include…

Stimulant Use Among New
York City Area Club-Going
Young Adults
Brian C. Kelly
INTRODUCTION
This paper presents preliminary findings from two
NIDA-supported studies [R03-DA016171-01; B.
Kelly, P.I.] and [R01-DA014925-02; J. Parsons, P.I.]
•

The Club Drugs and Health Project (CDHP),
which focuses on club drug use among young
adults in the New York City club scene

•

The Bridge and Tunnel Project (BTP), which
focused on club drug use among suburban youth
who attend clubs in New York City

Brief descriptions and findings from each project are
presented below.
THE CLUB DRUGS AND HEALTH PROJECT

•

Chemical spills from attempts to steal anhydrous
ammonia, accidents in MA “labs,” and toxic lab
waste

•

Dependence (e.g. uncontrollable cravings)

•

Paranoia, hallucinations, and violence associated
with binge use of MA

•

Tremors, feelings of paralysis, and back pain
caused by improperly prepared MA

•

Risky sexual behaviors

•

Dramatic and unhealthy weight loss

•

Dental problems, respiratory problems, and feelings of poor health in general
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CDHP was designed to study the patterns and contexts of club drug use and its associated risks among
young adults in the club scene with the intent of gaining data to guide prevention and educational efforts.
Three randomized elements (location, time, and individual) were used to select study participants. Intercept survey data from the first 1,828 adults who
agreed to participate in the screening interview reveal
that 70.8 percent had ever used (lifetime) any drug not counting alcohol or tobacco. Of the 1,828 participants, 46.4 percent had used ecstasy, 44.8 percent
cocaine, 22.0 percent ketamine, 16.6 percent crystal
methamphetamine (CM), and 11.5 percent gamma
hydroxybutyrate (GHB). One out of six were active
club drug users.
Gender differences for CM use were identified
(males 19.5 percent vs. females 13.7 percent) as were
sexual orientation differences for CM use
(gay/bisexual 21.4 percent vs. heterosexual 12.3 percent). The use of CM use among heterosexuals indicates that this phenomenon is not limited to the
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gay/bisexual community. Racial and ethnic differences were also identified. White young adults were
most likely to have used CM (18.9 percent). Differences in CM use among other racial and ethnic
groups were 9.3 percent among Black participants,
13.5 percent among Asian/Pacific Islanders (APIs),
15.8 percent among participants of "Mixed" racial/ethnic origin, and 16.5 percent among Latinos.
Cocaine remains more prevalent in New York than
CM. Unlike CM, cocaine use showed no significant
gender differences (43.2 vs. 45.7 for females and
males, respectively). Gay men and women reported
higher rates of cocaine use, albeit with less statistical
significance than the CM difference (gay/bisexual
47.1 percent vs. heterosexual 41.7 percent). Much
like CM, Whites were significantly more likely to
have used cocaine (50 percent). Differences among
other racial and ethnic groups were Blacks 31.5 percent, Latinos 38.8 percent; APIs 27.8 percent and
Mixed 42.6 percent.
THE BRIDGE AND TUNNEL PROJECT
BTP was an ethnographic research project focused on
club drug-using suburban youth who attended clubs
in New York City. All 40 youth participants had used
ecstasy and 33 reported using some sort of stimulant
drug, not including ecstasy. The main stimulant drug
was cocaine. About one-half reported cocaine use,
almost one-quarter CM use, and approximately onethird had used prescription (Rx) stimulants nonmedically.
Other than ecstasy, Rx drugs were the most prevalent
substances among these youth. More than one-third
of these youth abused Rx stimulants. More than onehalf had used any type of Rx drug; the most popular
non-stimulants were Vicodin, codeine, Xanax, and
other benzodiazepines. There were also some youth
who preloaded or postloaded with SSRIs (Selective
Serotonin Re-uptake Inhibitors) to reduce or eliminate the post-ecstasy crash, though this use pattern
appeared to be less frequent than abuse of the other
Rx drugs. Some youth who would not "use drugs"
relied on over-the-counter stimulants for the same
purposes.
Rx stimulants have proliferated because of a "tripleengine" of availability, reliability, and utility. Rx
stimulants are widely available to youth. Youth indicate they can more regularly predict the achievement
of the high they desire with Rx drugs and that Rx
drugs feel familiar to them. Rx stimulants were
viewed as very functional drugs by youth in the BTP;
they perceived Rx stimulants as useful outside the
partying milieu.
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Increased interest in and use of Rx drugs may be tied
to shifting ecstasy markets in the Nation. As adulteration of ecstasy increases, youth shift to Rx stimulants.
The shifts in ecstasy markets relate to other trends
including those that have allowed some youth to
"graduate up" to use of other stimulants, such as cocaine and methamphetamine. The shifting ecstasy
markets have also enabled the rise of new club drugs
such as tryptamines, especially 5-methoxy-N,Ndiisopropyltryptamine (5-MeO-DIPT, "foxy," or
"foxy methoxy") and alpha-methyltryptamine (IT290 or "AMT"), both tryptamines with hallucinogenic and stimulant qualities.

Stimulant Use Among Young
People in Hartford,
Connecticut
Jean J. Schensul
INTRODUCTION
This paper on stimulant use among urban youth in
Hartford is based on methods and findings from
NIDA-supported studies [1R01DA11421 and
DA01010].
SAMPLES AND METHODS
One study involved polydrug users (n=410); the other
involved a general population of urban youth
(n=548). The study methods included participant
observation, indepth interviews, contextual monitoring, and surveys. The first survey was conducted at 2
points in time, 15 months apart, and involved 400
young people age 16–24. The second survey was also
conducted at 2 points in time, 12 months apart, and
involved 500 young people age 16–30.
In the study of polydrug users, 70 percent were male,
38 percent were African-American, and 45 percent
were Puerto Rican; 62 percent had less than a high
school education and 57 percent were unemployed.
This study focused on polydrug and hard drug use; a
supplemental study focused on the sale and use of
ecstasy in clubs and other party settings. In the study
of the general population, 59 percent were male, 37
percent were African-American, and 47 percent were
Puerto Rican; 60 percent had less than a high school
education and 51 percent were unemployed. This
study focused on club drugs and stimulant use.
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SUMMARY OF SOME KEY FINDINGS
Ecstasy and cocaine are the primary stimulants used
among youth in Harford. The media and club-rave
marketing expanded the market for MDMA, which
diffused from suburban to urban youth networks
through urban clubs serving mixed clientele, the first
of which catered to Latinos. Club closings sent the
social scene “underground,” but it remained part of
the youth party drug repertoire. MDMA continues to
be firmly embedded in urban youth networks and is
readily available and affordable.
In the polydrug use study, 33 percent of the respondents reported ever using ecstasy, compared with
nearly 14 percent of 18–25-year-old respondents in
the 2002 National Survey on Drug Use and Health
maintained by the Substance Abuse and Mental
Health Services Administration. These Hartford
MDMA-using polydrug users were significantly
more likely than other respondent groups to be Latino, have less income and education, to be less optimistic about the future, to take more risks, and to
bear more legal consequences. In the second study,
differences between ecstasy users (“ever used”) and
nonusers showed that one-half of Whites, 25 percent
of the Latinos, and only 14 percent of AfricanAmericans reported ever using MDMA (p=.008).
Ecstasy users tended to be party goers and were significantly more likely than non-ecstasy users to fre-
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quent clubs, rave-like events, and no-pay parties.
Users expected ecstasy use to make them feel good,
enhance their mood, feel less stressed, and feel like
having sex and also expecting sex; fewer reported
expecting verbal and physical aggression to be part of
the ecstasy experience. Ecstasy users were more
likely than nonusers to be involved in risky sex, to
deal drugs, and to report negative consequences from
their drug use.
Other data from the studies show that phencyclidine
(PCP), alcohol, and marijuana use continue to be
stable parts of the drug repertories of young people in
Hartford. In a 1–year followup, alcohol use had increased by 4 percent and marijuana by 3 percent.
Ecstasy use, on the other hand, had increased by 8.5
percent; 18.5 percent reported using the drug in the
30 days prior to interview. Cocaine use decreased.
Continuing at relatively high levels were initiation
and past 30-day use of “dust” (a PCP derivative or
substitute of embalming fluid or formaldehyde).
One finding in both studies is that methamphetamine
use was not reported by these young people. The
question is: If methamphetamine abuse occurs in
Hartford, will it follow the same route as MDMA
(methylenedioxymethamphetamine, commonly referred to as ecstasy)?
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Monitoring Drug Abuse
Trends in Australia
Louisa Degenhardt, Ph.D.
OVERVIEW OF THE DRUG MONITORING SYSTEM
IN AUSTRALIA
The Illicit Drug Reporting System (IDRS), Australia’s national drug monitoring system, was established in 1996. IRDS is funded by the Australian
Government Department of Health and Aging and
the National Drug Law Enforcement Research
Fund. This paper provides an overview of the system used to monitor drug abuse patterns and trends
in Australia and past and current drug abuse trends.
The IDRS is conducted every year in every State
and territory by participating research institutions
and is coordinated by the National Drug and Alcohol Research Center. The IRDS monitors the price,
purity, availability, and patterns of use of illicit
drugs, and serves as an early warning system for
identifying and assessing emerging trends in illicit
drug markets through the triangulation of three data
sources…
•

•
•

A qualitative annual survey of approximately
950 injection drug users (IDUs) who serve as a
sentinel group for the detection of emerging illicit drug use trends
A qualitative survey of key experts (KEs) who
work in the illicit drug field
A synthesis of extant indicator data sources
such as Customs data, drug seizure purity data,
and arrest data

One information source, the Party Drugs Initiative
(PDI) survey targeted to ecstasy users and related
drug markets, provides data/information on emerging drug trends in Australia’s illicit drug markets.
The PDI, like the IDRS, consists of three components: interviews with individuals (about 850 ecstasy users) in sentinel groups of drug users in
every capital city; interviews with KEs; and drug
use indicator data such as numbers of treatment
admissions, arrests, overdoses, and seizures.
In addition, valuable data are provided through the
National Drug Strategy Household Survey. In 2004,
the stratified sample for the household survey involved nearly 30,000 persons age 14 and older.
DRUG ABUSE PATTERNS AND TRENDS

•

More than 2 million had recently used cannabis, 18,000 fewer that in 2004; 1 in 5 teenagers
had used cannabis in the 12 months prior to the
2004 survey

•

17,000 persons reported using cocaine in the
12 months prior to the 2004 survey

•

25,800 persons (14,800 males and 11,000 females) reported use of heroin in the 12 months
prior to the 2004 survey, approximately 12,000
fewer than in 2001

•

Nearly 560,000 persons reporting using ecstasy at least once in the 12 months prior to the
2004 survey, roughly 100,000 more than in
2001

Past and recent drug abuse trends in Australia show
that the heroin market increased in scale in the
1990s. There were approximately 1,000 opioid
deaths in 1999. A number of steps were taken to
address the heroin problem including seizures of
large shipments of heroin destined to Australia,
arrests of facilitators, and the disruption of heroin
networks. By 2001, the supply of heroin was cut
off and there was a growing shortage of the drug.
The purity of heroin at the street level was halved
and the price doubled.
Other drug trends identified by IDUs in different
parts of Australia show…
•

Illicit morphine use in the Northern Territory

•

Illicit methadone use in Tasmania

•

Injection of benzodiazepines, particularly in
Tasmania and Victoria

•

Injection of cocaine in New South Wales
(2001)

The most recent trends identified include the following:
•

A stable cannabis market

•

Increased use of psychostimulants including
ecstasy and crystal methamphetamine, with
some reports of regular users developing psychotic symptoms

•

Nonmedical use of pharmaceuticals among
regular IDUs

•

Decreases in heroin overdose and other harmful consequences

Some major findings from the 2004 Household
Survey on Australians age 14 and older show
that…
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Data are synthesized into an Annual Report covering developments across the EU. The system covers the 25 member States of the European Union
and Norway, which participates by special agreement. Bulgaria, Romania, and Turkey also now
provide some data.

OVERVIEW OF THE EMCDDA

SUMMARY OF FINDINGS

Established in 1993, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA),
based in Lisbon, Portugal, serves as the central
reference point for drug information in the European Union (EU).
The EMCDDA collects data/information on the
drug situation, responses to drug use, and policy
developments through its Reitox reporting network.
This report is restricted to the first of these tasks;
reporting on the drug situation. This network consists of “government nominated” focal points in
each member State, which are linked to expert
technical groups. Data are collected on the drug
situation, responses to drug use, and policy development. An additional specific task of the
EMCDDA is also to coordinate the EU mechanism
for monitoring the emergence of new synthetic
drugs that are not currently controlled under international or European agreements.

Cannabis indicators continue trending upward in
Europe with some signs of convergence and possibly stabilization among some countries where there
is a high prevalence of cannabis abuse. Historically, the United Kingdom (UK) reported the highest rates of cannabis use. Currently, cannabis use in
the UK appears stable and a number of other countries, notably France, the Czech Republic and
Spain, report cannabis use similar to that reported
in the UK, and on some measures, high rates of
use. Three waves (1996, 1999, and 2003) of the
school survey data for 15–year-olds from the
ESPAD are now available for comparison of time
trends in most European countries. The surveys
show increases in cannabis prevalence in almost all
countries between 1996 and 2003, with the greatest
changes occurring in the 1996 to 1999 period. Cannabis issues of concern include the need to better
assess trends in intensive and regular use, and the
factors behind reports of rising treatment demands.

Reporting on the drug situation is based on five key
indicators for epidemiological monitoring. These
indicators provide a common reporting standard for
EU member States and methodological guidelines.
The indicators cover the following topics:

Ecstasy indicators also continue to trend upwards
in most countries. A notably exception is the UK
where rates are high but stable. Overall, ecstasy has
replaced amphetamine as Europe’s second most
commonly used drug.

•

Prevalence and patterns of drug use in the general population, as measured by population
surveys

•

Problem drug use estimates (statistical estimates of number of long-term and chronic users of drugs like heroin and cocaine)

•

Drug-related infectious diseases (HIV, HCV,
HBV)

•

Drug-related mortality of drug users (registry
data and cohort studies)

Currently, significant methamphetamine use is only
reported from the Czech Republic. The use of
powder cocaine is increasing in many European
countries, and in some countries cocaine prevalence rates are already high. Estimates of recent use
(past-year prevalence) of powder cocaine in Spain
and the UK, for example, are similar to estimates
reported in the United States, although lifetime
prevalence estimates remain considerably lower in
European countries than in the United States. Crack
cocaine use remains rare with significant use limited to a few major cities.

EMCDDA Report on
Europe

•

Demand for treatment (first treatment demands
and all demands)

In addition to these data, other important sources of
information for monitoring the drug situation include statistics on drug law offenses and market
information, studies of young people and school
survey data (ESPAD), and reports from the Early
Warning System on new synthetic drugs.
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In most countries, heroin and injecting indicators
were stable or decreasing. Opiate-related deaths are
now declining but are still at historically high levels. The age of heroin-related deaths is also rising
and the proportion of those younger than 25 has
decreased substantially, suggesting an aging population. This observation does not apply to some of
the new EU member States where the more limited
data available suggest that opiate-related deaths are
representing younger users and the overall trend
may still be upwards.
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Surveys of at-risk populations show far higher
prevalence rates of drug use; however, making
generalizations from these data is difficult. However, they do give some indication of the current
relative popularity of different types of drug. For
example, a 2004 survey of “clubbers” who were
regular recreational drug users in the UK found that
the most commonly used drugs were cannabis, ecstasy, and powder cocaine, followed by amphetamine, amyl nitrates, magic mushrooms, and ketamine. Much more limited use was reported of other
substances. (e.g. salvia, GHB [gamma hydroxybutyrate], crack, heroin, methamphetamine, and new
synthetics).

Update of the Epidemiologic Surveillance System
of Addictions (SISVEA) in
Mexico: 2004
Roberto Tapia-Conyer, Patricia Cravioto,
Pablo Kuri, Mario Cortés, Santiago
Zaragoza, and Fernando Galván1
ABSTRACT
Alcohol was the most common drug of onset
among treatment clients at GTCs and NGCs in
2004, followed by marijuana. Alcohol was also the
most commonly detected substance among drugrelated decedents in 2004. For the current primary
drug of abuse, cocaine ranked first at GTCs, while
crystal (methamphetamine) surpassed heroin as the
most common current drug of abuse at NGCs in
2004. Among infractors at Juvenile Detention Centers in 2004, marijuana was the most common drug
of abuse, representing 35 percent.
INTRODUCTION
The Epidemiological Surveillance System of Addictions (SISVEA) is a permanent monitoring system of the use and abuse of tobacco, alcohol, and
medical or illegal drugs, as well as their effects on
morbidity and mortality and their association with
juvenile infractors. SISVEA was created in 1990
by the General Directorate of Epidemiology to investigate and document drug consumption in Mexico. Originally, SIVEA included eight cities located
at Mexico’s northern border; currently, SISVEA
provides information from 31 States of Mexico.

1
The authors are affiliated with the Ministry of Health of Mexico, Tlanepantla Edo. De Mexico.

Initially, SISVEA was based conceptually and operationally on three strategies, which have evolved
and been reinforced to form the present system.
The five main indicators of the present system give
continuity to the original model. The indicators and
data sources are shown below:
•

Information on consumption of tobacco, alcohol, and medical and illegal drugs is obtained
from treatment centers.

•

Data on diseases and accidental mortality are
provided by emergency rooms.

•

Information on mortality among drug users is
provided by coroners’ offices.

•

Statistics on crimes against health are obtained
from law enforcement agencies.

•

General information on consumption of tobacco, alcohol, and medical and illegal drugs in
the general population and risk groups is obtained from surveys and qualitative studies.

Data Sources
This report includes information on recent activities
of SISVEA during 2004. The sources of data used
for this are described below:
•

Treatment data are obtained from the government treatment centers (the Centers of Juvenile
Integration) and from the nongovernment treatment centers that participate in SISVEA cities.
Treatment data cover the characteristics and
consumption patterns related to the first drug of
use and primary drug of use for clients for 2004.

•

Drug consumption data are reported for the
general population and for targeted population
groups. Juvenile arrest data were provided by
Juvenile Detention Centers for 2004.

•

Medical examiner (ME) data are provided
for 2004 for drug-related deaths, including accidental or violent deaths (homicides or suicides) in cases in which drug abuse may be the
direct cause of death or a contributing factor.

DRUG ABUSE PATTERNS AND TRENDS
Marijuana
GTC Data
Marijuana was the second most common drug of
first choice (11.6 percent) among clients at government treatment centers (GTCs) in 2004. As a
primary drug, marijuana also ranked second among
2004 GTC patients (17.7 percent) (exhibit 1).
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According to GTCs, marijuana users during 2004
were mostly male (92.1 percent); 27.1 percent were
age 15–19 (exhibit 2). Forty-six percent had only a
middle school education; 61.4 percent were single;
and 49.0 percent came from a middle-low socioeconomic level. The age of onset for 49.1 percent
of marijuana users occurred between ages 10 and
14; 43.4 percent began to use between ages 15 and
19. Two-thirds reported daily use.

dent group was primarily male; 21.3 percent were
age 40 and older and 40.0 percent were age 25–34
(exhibit 7). The main cause of death in these cases
was asphyxia (20.8 percent), followed by run over
(12.5 percent). These deaths most commonly occurred on the street (36.1 percent) or at home (25.0
percent).

Based on natural history data for 2004, 10.4 percent of these marijuana GTC patients were
monodrug users upon treatment entry, and 89.6
percent had already begun to use a second drug,
usually alcohol (32.9 percent) or tobacco (21.4
percent) (exhibit 3a). Of multiple drug users, 84.8
percent had advanced to a third drug, usually alcohol (24.1 percent), tobacco (21.2 percent), or cocaine (20.4 percent).

GTC Data

NGC Data
Among patients at nongovernment treatment centers (NGCs) in 2004, marijuana was the second
most common drug of first choice (26.6 percent)
and the fourth most common primary drug of abuse
(9.9 percent) (exhibit 4).
The overwhelming majority of the marijuana clients
at NGCs were male (95.6 percent); 24.6 percent
were age 35 and older (exhibit 5). Forty-one percent
had a middle school education, and 59.4 percent
were single. The age of onset for marijuana use
among these patients was between 10 and 14 for
48.3 percent, and 82.6 percent reported daily use.
According to the natural history data of marijuana
consumption for these clients, 12.5 percent were
still monodrug users upon treatment entry, while
the remaining 87.5 percent had progressed to a
second drug, usually cocaine (26.1 percent) or alcohol (17.0 percent) (exhibit 3a). Of this group,
73.6 percent were already using a third drug,
mainly cocaine (21.9 percent) heroin (18.4 percent), and crystal (15.5 percent).
Juvenile Detention Center Data
Information from the Juvenile Detention Centers
showed that 34.8 percent of the 10,555 juveniles
arrested during 2004 had used marijuana (exhibit 6).
Most of this population were male (95.2 percent);
52.6 percent had an elementary school education;
41.6 percent were subemployed; 36.5 percent had a
tattoo; and 30.2 percent were gang members. Nearly
one-third (31.6 percent) of the offenses were committed while the offender was intoxicated, and 44.0
percent of the offenses were robberies.
ME Data
ME data indicated that 3.63 percent of deaths reported were associated with marijuana. This dece-
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Inhalants

During 2004, inhalants ranked as the third most
commonly reported drug of onset among GTC clients (7.4 percent) and fourth as a current primary
drug of abuse (10.6 percent) (exhibit 1).
Inhalant users attending GTCs were mostly male
(85.1 percent); nearly one-third (31.3 percent) were
age 15–19 (exhibit 2). Most patients had a middle
school education (55.3 percent); 76.4 percent were
single; and 55.1 percent were from a middle-low
socioeconomic level. Most began to use inhalants
between ages 10 and 14 (65.9 percent); 42.2 percent used them daily and 41.3 percent used them
once per week.
GTC data on the natural history of inhalant use
show that 25.7 percent of these clients were
monodrug users when they entered treatment; 74.3
percent were already using a second drug, mainly
marijuana (33.8 percent), alcohol (22.4 percent),
and tobacco (20.9 percent). Of the multiple drug
users, 81.0 percent used a third drug, mainly alcohol (27.9 percent), marijuana (20.0 percent), tobacco (17.9 percent), or cocaine (13.3 percent) (exhibit 3b).
NGC Data
Inhalants ranked third (11.8 percent) as drug of
onset and sixth (8.7 percent) as a primary drug
among clients in NGCs in 2004 (exhibit 4).
NGCs report that of the patients who used inhalants, most of them were male (93.2 percent), and
33.3 percent were age 15–19. Sixty percent had an
elementary school education, and 72.3 percent
were single (exhibit 4). More than one-half began
to use inhalants between ages 10 and 14 (58.5 percent), and 87.0 percent reported daily use.
Regarding the natural history of inhalants users,
55.0 percent of the patients had progressed to a
second drug upon treatment entry, which in order
of importance were marijuana (53.1 percent), alcohol (15.5 percent), and other inhalants (7.2 percent)
(exhibit 3b). Of these patients, 72.2 percent had
also begun to use a third drug, usually cocaine
(25.1 percent), marijuana (17.2 percent), or alcohol
(13.7 percent).
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Juvenile Detention Center Data
Of the juveniles arrested during 2004, 13.5 percent
used inhalants (exhibit 6). Most of these juveniles
were male (95.0 percent), had an elementary school
education (63.6 percent), and were subemployed
(46.0 percent). Thirty-nine percent had tattoos, and
38.8 percent belonged to a gang. More than onethird (37.6 percent) of these juveniles committed
their offense while intoxicated, and robbery was
the most common offense (44.7 percent).
Alcohol
GTC Data
Alcohol was the most commonly reported drug of
onset (33.3 percent), but it ranked third (17.4 percent) as a primary drug of abuse among GTC patients in 2004 (exhibit 1).
Of the 3,582 primary alcohol patients attending
GTCs in 2004, 82.6 percent were male, 24.0 percent were age 15–19, and 20.9 percent were age 35
or older (exhibit 2). Most had a middle school education (41.8 percent); 54.9 percent were single; and
more than one-half (54.5 percent) were from a
middle-low socioeconomic level. Nearly one-half
(47.0 percent) began to use alcohol between ages
15 and 19; 48.2 percent reported weekly use; and
31.3 percent reported using alcohol 1–3 times per
month.
According to the natural history data for alcohol,
91.4 percent had progressed to a second drug upon
treatment entry, usually tobacco (57.8 percent),
marijuana (17.3 percent), and cocaine (13.2 percent) (exhibit 3c). Of the multiple drug user group,
74.6 percent reported using a third drug, usually
marijuana (33.1 percent), cocaine (26.6 percent),
and inhalants (10.5 percent).
NGC Data
Among NGC clients in 2004, alcohol ranked first
as the drug of onset (30.0 percent) and second as a
current primary drug (19.5 percent) (exhibit 4).
Most of the 12,360 patients who were alcohol clients in 2004 were male (92.1 percent); 42.5 percent
were age 35 or older; and 32.2 percent had only an
elementary school education (exhibit 5). Fortythree percent were single, and most (46.5 percent)
started to use alcohol between ages 15 and 19.
One-half reported daily use, and 37.2 percent used
alcohol once per week.
The natural history of alcohol abuse provided by
NGCs during 2004 shows that 28.7 percent of these
clients were monodrug users upon treatment entry,
while the remaining 71.3 percent had progressed to
a second drug, typically marijuana (36.2 percent),

cocaine (22.0 percent), and tobacco (14.8 percent)
(exhibit 3c). Sixty-five percent of these clients had
progressed to a third drug, usually cocaine (31.5
percent), marijuana (17.1 percent), and crystal
(15.1 percent).
Juvenile Detention Center Data
Among juvenile infractors, 14 percent reported
alcohol abuse (exhibit 6). They were mostly male
(92.5 percent), and 44.8 percent had an elementary
school education. Forty percent were subemployed;
30.2 percent had tattoos; and 24.1 percent were
gang members. More than one-third of the juveniles (44.8 percent) committed the offense while
intoxicated, and robbery (42.2 percent) was the
most common offense.
ME Data
According to MEs, the abuse of alcohol is associated with 83.8 percent of drug-related deaths. Most
decedents were male (93.8 percent), and 39.4 percent were age 40 or older (exhibit 7). The main
cause of death was asphyxia (18.2 percent), followed by traffic accidents (18.1 percent). Deaths
typically occurred on the street (39.5 percent) or at
home (30.4 percent).
Cocaine
Among patients at GTCs in 2004, cocaine ranked
fourth as the first drug of choice (3.8 percent) and
first as primary drug of abuse (25.8 percent) (exhibit 1).
GTCs report that cocaine users during 2004 were
mostly male (78.6 percent); 26.3 percent each were
age 15–19 and 20–24 (exhibit 2). Nearly one-half
(45.6 percent) had a middle school education; 51.8
percent were single; and 26.7 percent were married.
More than one-half (56.9 percent) were members
of a middle-low socioeconomic level; 49.3 percent
initiated cocaine use between ages 15 and 19.
Forty-two percent reported weekly cocaine use, and
35.8 percent reported daily use.
The natural history data for GTC cocaine patients
in 2004 show that 25.7 percent were monodrug
users upon entering treatment, while the rest were
already using a second drug, usually alcohol (31.3
percent), marijuana (20.0 percent), and tobacco
(18.3 percent) (exhibit 3d). Of the multiple drug
users, 69.3 percent had started to use a third drug:
alcohol (28.4 percent), tobacco (26.9 percent), and
marijuana (19.7 percent).
NGC Data
In 2004, cocaine ranked fourth as the drug of onset
(5.9 percent) and fourth as current primary drug
(17.9 percent) among NGC patients (exhibit 4).
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Ninety-two percent of the cocaine users who attended NGCs in 2004 were male; 24.8 percent were
age 20–24; 38.6 percent had a middle school education; and 30.0 percent had an elementary school
education (exhibit 5). One-half of these cocaine
patients were single. Forty-four percent began to
use cocaine between ages 15 and 19; 60.4 percent
reported daily use and 29.6 percent reported
weekly use of the drug.
The natural history of cocaine abuse reported by
NGCs during 2004 shows that 34.2 percent were
still monodrug users upon treatment entry, and 65.8
percent had progressed to a second drug—usually
marijuana (25.3 percent), crystal (21.0 percent),
and alcohol (15.4 percent) (exhibit 3d). Of the multiple drug users, 47.7 percent had started to use a
third drug, generally crystal (21.7 percent), marijuana (17.4 percent), or alcohol (13.3 percent).
Juvenile Detention Center Data
Juvenile Detention Centers reported cocaine use
among 14.3 percent of these younger arrestees in
2004 (exhibit 6). They were mostly male (94.3 percent); more than one-half had an elementary school
education (55.8 percent); and 42.1 percent were
subemployed. Thirty-six percent had tattoos, and
30.6 percent were gang members. More than onequarter of the juvenile infractors (28.9 percent)
committed the offense while intoxicated; robbery
was the most common offense (49.1 percent).
Heroin
GTC Data
Of the patients attending GTCs during 2004, only
0.1 percent reported heroin as their drug of onset,
but as primary drug it ranked in fifth place (2.4
percent) (exhibit 1).
All of the heroin users at GTCs in 2004 were male;
27.3 percent were age 20–24; and 18.2 percent
were age 15–19 (exhibit 2). Thirty percent each of
these patients had an elementary, middle, or high
school education. Similar proportions (27.3 percent
each) were single, married, or divorced. Sixty percent were from a middle-low and 30.0 were from a
low socioeconomic level. The age of onset for 45.5
percent of heroin users occurred between ages 10
and 14; 100.0 percent reported daily use.
NGC Data
Among patients at NGCs, heroin as a drug of onset
has been increasing since 1994; 1.9 percent of pa-
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tients in 2004 reported heroin as their first drug of
use (exhibit 4). Heroin ranked third as a primary
drug of abuse among NGC patients in 2004 (38.4
percent).
The overwhelming majority of heroin patients at
NGCs in 2004 were male (91.8 percent), and 43.5
percent were age 35 and older (exhibit 5). More
than one-third (37.7 percent) of these patients had
only a middle school education, and 53.2 percent
were single. The age of first use of heroin among
these patients was between 15 and 19 (38.4 percent); 91.7 percent reported daily use.
Juvenile Detention Center Data
Information from the Juvenile Detention Centers
showed that 0.4 percent of the juveniles arrested
during 2004 used heroin (exhibit 6). Most of this
population were male (87.8 percent); 47.5 percent
had an elementary school education; and 36.6 percent were unemployed. Approximately one-third
(30.6 percent) had tattoos or were gang members
(34.1 percent). One-half of the offenses were committed under intoxication, and robbery was the
most common offense (58.5 percent).
CONCLUSIONS
Alcohol abuse remains a problem in Mexico. It is
still the most common drug of onset, although this
frequency varies in the different regions of the country. Alcohol is also the most frequently detected drug
in emergency rooms and by medical examiners.
Crystal surpassed heroin as the most common primary drug at NGCs in 2004, while cocaine remained
the most common primary drug among NGC patients. The proportion of cocaine patients at NGCs
has declined, however, since the peak of 40.3 percent in 1998 to 25.8 percent in 2004.
Among offenders at the Juvenile Detention Centers,
marijuana remains the most frequently abused substance; it represented 35 percent of the offenders in
2004. Offenders who abused cocaine, alcohol, and
inhalants remained at about 14 percent each.
Although SISVEA currently includes 31 States and
53 cities, the system has to be strengthened and
expanded to include to the rest of Mexico.
For inquiries concerning this report, please contact Santiago
Zaragoza, Especialista en Epidemiologia, Direccion General de
Epidemiologia, Llanura #48 Col. Plazas de la Colina, Tlanepantla Edo. De Mexico 54080, Phone: 55-55-93-1011, Fax: 5556-51-8338, E-mail: szaragoza@dgepi.salud.gob.mex.
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Exhibit 1. Comparison Between First Drug of Use and Current Drug of Use Among Patients at
Government Treatment Centers, by Percentage: 1991–2004
First Drug

Current Drug

40

40

35

35

30

30

25

25

20

20

15

15

10

10

5

5

0

0
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04

45

19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04

45

Marijuana
Inhalants
Alcohol
Cocaine
Heroin

SOURCE: SISVEA—Government treatment centers
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Exhibit 2. Demographic Characteristics of Government Treatment Center Patients, by First Drug of Use
and Percent: 2004
Demographic
Characteristic
Gender
Male
Female
Age
5–14 Years
15–19
20–24
25–29
30–34
35 and older
Schooling
Elementary school
Middle school
High school
College studies
No formal education
Other
Marital Status
Single
Married
Divorced
Widowed
Living together
Other
Socioeconomic Level
High, middle-high
Middle-low
Middle
Low
Age Of Onset
9 and younger
10–14
15–19
20–24
25–29
30–34
35 and older
Frequency
Daily
Once a Week
1–3 times per month
1–11 times per year

Global
N=10,761

Marijuana
n=1,250

Inhalants
n=799

Alcohol
n=3,582

Cocaine1
n=404

Heroin
n=11

Tobacco
n=4,460

82.4
17.6

92.1
7.9

85.1
14.9

82.6
17.4

78.6
21.4

100.0
0.0

79.3
20.7

8.7
26.8
18.5
15.1
11.1
19.8

6.6
27.1
19.7
18.0
12.9
15.8

28.6
31.3
15.3
11.0
6.5
7.3

7.0
24.0
18.9
16.5
12.7
20.9

6.5
26.3
26.3
22.1
11.7
7.1

0.0
18.2
27.3
9.1
0.0
45.4

7.2
28.3
17.7
13.3
10.2
23.2

19.4
43.9
22.1
9
0.4
5.1

22.9
46.0
21.3
6.5
0.5
2.7

33.2
55.3
8.1
0.5
0.9
2.0

16.8
41.8
24.8
10.3
0.6
5.8

15.9
45.6
25.9
6.5
0.3
5.8

30.0
30.0
30.0
10.0
0.0
0.0

18.2
43.0
22.4
10.4
0.2
5.8

57.9
23.4
2.1
0.6
10.4
5.6

61.4
18.4
1.8
0.2
11.9
6.3

76.4
10.2
0.6
0.0
8.9
3.9

54.9
26.2
2.3
0.4
10.4
5.8

51.8
26.7
1.6
0.0
13.7
6.2

27.3
27.3
27.3
0.0
18.2
0.0

56.6
24.8
2.3
1.0
10.0
5.4

15.3
54.2
7.4
23.2

14.0
49.0
9.5
27.5

8.4
55.1
4.5
32.0

15.4
54.5
7.6
22.5

12.2
56.9
5.1
25.9

10.0
60.0
0.0
30.0

16.9
54.9
7.4
20.7

5.2
48.4
40.2
4.3
1.1
0.4
0.4

2.1
49.1
43.4
4.5
0.6
0.2
0.1

6.5
65.9
26.6
0.8
0.1
0.0
0.0

5.2
39.5
47.0
6.1
1.3
0.5
0.5

1.7
29.1
49.3
8.6
7.6
2.3
1.3

0.0
45.5
27.3
18.2
0.0
9.1
0.0

6.1
53.5
35.7
3.2
0.9
0.3
0.3

53.9
27.6
16.8
1.7

66.1
21.1
11.2
1.6

42.2
41.3
14.6
1.9

16.7
48.2
31.3
3.8

35.8
42.3
20.9
1.0

100.0
0.0
0.0
0.0

79.2
12.4
8.0
0.4

1

Cocaine, basuco, crack
SOURCE: SISVEA—Centers for Juvenile Attention (government treatment centers)
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Exhibit 3a.

Natural History of Marijuana Use: 2004

Governmental Centers
89.6%
Marijuana

84.8%
Use a 2nd drug
Alcohol
Tobacco
Cocaine
Inhalants
Others

10.4%
Monodrug users

Use a 3rd drug
32.9%
21.4%
14.6%
11.7%
19.4%

15.2%

Alcohol
Tobacco
Cocaine
Crack
Others

24.1%
21.2%
20.4%
5.7%
28.6%

Nongovernmental Centers
87.5%
Marijuana

73.6%
Use a 2nd drug
Cocaine
Alcohol
Inhalants
Crystal
Tranquilizers
Others

12.5%
Monodrug users

Use a 3rd drug
26.1%
17.0%
14.7%
11.9%
8.1%
23.7%

26.4%

Cocaine
Heroin
Crystal
Alcohol
Tranquilizers
Others

21.9%
18.4%
15.5%
9.5%
7.6%
25.3%

SOURCE: SISVEA—Government and nongovernment treatment centers

Exhibit 3b. Natural History of Inhalants Use: 2004
Governmental Centers
74.3%
Inhalants

81.0%
Use a 2nd drug
Marijuana
Alcohol
Tobacco
Inhalants
Others

25.7%
Monodrug users

Use a 3rd drug
33.8%
22.4%
20.9%
11.4%
11.5%

19.0%

Alcohol
Marijuana
Tobacco
Cocaine
Others

27.9%
20.0%
17.9%
13.3%
20.9%

Nongovernmental Centers
55.0%
Inhalants

45.0%
Monodrug users

72.2%
Use a 2nd drug
Marijuana
Alcohol
Inhalants
Cocaine
Tranquilizers
Others

Use a 3rd drug
53.1%
15.5%
7.2%
6.3%
5.8%
11.1%

27.8%

Cocaine
Marijuana
Tranquilizers
Alcohol
Heroin
Others

25.1%
17.2%
11.3%
13.7%
9.4%
26.3%

SOURCE: SISVEA—Government and nongovernment treatment centers
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Exhibit 3c.

Natural History of Alcohol Use: 2004

Governmental Centers
91.4%
Alcohol

74.6%
Use a 2nd drug
Tobacco
Marijuana
Cocaine
Inhalants
Others

8.6%
Monodrug users

Use a 3rd drug
57.8%
17.3%
13.2%
5.2%
6.5%

25.4%

Marijuana
Cocaine
Inhalants
Tobacco
Others

33.1%
26.6%
10.5%
9.6%
20.2%

Nongovernmental Centers
71.3%
Alcohol

65.0%
Use a 2nd drug
Marijuana
Cocaine
Tobacco
Crystal
Inhalants
Others

28.7%
Monodrug users

Use a 3rd drug
36.2%
22.0%
14.8%
5.8%
4.5%
14.6%

35.0%

Cocaine
Marijuana
Crystal
Inhalants
Heroin
Others

31.5%
17.1%
15.1%
6.4%
4.4%
24.4%

SOURCE: SISVEA—Government and nongovernment treatment centers

Exhibit 3d. Natural History of Cocaine Use: 2004
Governmental Centers
74.3%
Cocaine

69.3%
Use a 2nd drug
Alcohol
Marijuana
Tobacco
Crystal
Others

25.7%
Monodrug users

Use a 3rd drug
31.3%
20.0%
18.3%
6.0%
24.4%

30.7%

Alcohol
Tobacco
Marijuana
Inhalants
Others

28.4%
26.9%
19.7%
7.2%
17.8%

Nongovernmental Centers
65.8%
Cocaine

34.2%
Monodrug users

47.7%
Use a 2nd drug
Marijuana
Crystal
Alcohol
Heroin
Crack
Others

Use a 3rd drug
25.3%
21.0%
15.4%
12.1%
9.3%
17.7%

52.3%

Crystal
Marijuana
Alcohol
Heroin
Inhalants
Others

21.7%
17.4%
13.3%
9.2%
8.2%
29.9%

SOURCE: SISVEA—Government and nongovernment treatment centers
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Exhibit 4. Comparison Between First Drug of Use and Current Drug of Use Among Patients at Nongovernment Treatment Centers, by Percent: 1994–2004
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SOURCE: SISVEA—Nongovernment treatment centers
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Exhibit 5. Demographic Characteristics of Nongovernment Treatment Center Patients, by First Drug of
Use and Percent: 2004
Demographic
Characteristic
Gender
Male
Female
Age
5–14 Years
15–19
20–24
25–29
30–34
35 and older
Schooling
Elementary school
Middle school
High school
College studies
No formal education
Other
Marital Status
Single
Married
Divorced
Widowed
Living together
Other
Age Of Onset
9 and younger
10–14
15–19
20–24
25–29
30–34
35 and older
Frequency
Daily
Once a Week
1–3 times per month
1–11 times per year

Global
N=41,135

Marijuana
n=10,927

Inhalants
n=4,857

Alcohol
n=12,360

Cocaine1
n=2,447

Heroin
n=800

Tobacco
n=7,663

93.1
6.9

95.6
4.4

93.2
6.8

92.1
7.9

91.7
8.3

91.8
8.3

91.5
8.5

2.0
15.7
19.2
18.0
15.7
29.4

1.6
16.5
21.7
19.3
16.3
24.6

6.5
33.3
22.9
16.3
9.8
11.2

0.9
9.2
14.5
16.5
16.4
42.5

1.3
17.7
24.8
20.8
18.3
17.2

0.1
3.6
14.9
20.4
17.5
43.5

1.7
14.4
19.8
18.6
16.2
29.3

36.6
41.0
16.4
2.6
3.2
0.2

36.6
41.0
16.4
2.6
3.2
0.2

60.3
27.1
4.6
0.5
7.5

32.2
31.7
20.4
9.4
5.5
0.7

30.0
38.6
23.4
5.8
1.9
0.3

37.4
37.7
16.7
3.8
4.3
0.1

34.6
40.2
18.7
3.7
2.7
0.2

54.1
22.7
4.1
6.5
0.9
11.7

59.4
18.4
4.0
5.9
0.6
11.8

72.3
11.7
1.6
4.5
0.3
9.6

42.6
31.0
5.2
7.9
1.6
11.6

50.0
28.1
3.2
5.6
0.6
12.6

53.2
19.7
4.9
7.8
1.1
13.2

54.9
20.9
4.3
6.6
0.9
12.4

5.6
43.4
40.1
6.7
2.3
1
0.8

4.8
48.3
39.8
4.7
1.5
0.6
0.4

8.5
58.5
30.2
2.1
0.5
0.1
0.2

4.4
34.8
46.5
9.3
2.8
1.2
0.9

1.2
20.6
44.0
17.0
9.8
4.3
3.2

0.9
16.2
38.4
20.8
11.2
6.4
6.1

8.8
50.9
35.4
3.7
0.7
0.3
0.2

73.2
19.5
5.3
2.0

82.6
11.9
3.4
2.0

87.0
9.0
2.5
1.5

49.8
37.2
10.2
2.7

60.4
29.6
6.9
3.1

91.7
5.3
2.9
0.1

90.9
6.7
1.6
0.9

1

Cocaine, basuco, crack
SOURCE: Nongovernment treatment centers
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Exhibit 6. Social Characteristics and Type of Offense Committed by Juvenile Drug-Using Arrestees, by
Percent: 2004
Total

Marijuana

Inhalants

Alcohol

Cocaine

Heroin

N=10,555

n=3,671

n=1,429

n=1,473

n=1,505

n=41

Male
91.4

Male
95.2

Male
95.0

Male
92.5

Male
94.3

Male
87.8

Elementary school
47.3

Elementary school
52.6

Elementary school
63.6

Elementary school
44.8

Elementary school
55.8

Elementary school
47.5

Subemployed
32.6

Subemployed
41.6

Subemployed
46.0

Subemployed
40.2

Subemployed
42.1

Unemployed
36.6

Tattoo
22.7

Tattoo
36.5

Tattoo
39.0

Tattoo
30.2

Tattoo
36.0

Tattoo
30.6

Belong to a gang
19.8

Belong to a gang
30.2

Belong to a gang
38.8

Belong to a gang
24.1

Belong to a gang
30.6

Belong to a gang
34.1

Offense under
intoxication
17.8

Offense under
intoxication
31.6

Offense under
intoxication
37.6

Offense under
intoxication
44.8

Offense under
intoxication
28.9

Offense under
intoxication
50.0

Frequent Offenses
Robbery
Against health
Injuries
Damages
Other

45.2
14.9
8.5
6.3
25.1

Robbery
Against health
Drug
Consumption
Injuries
Other

44.0 Robbery
27.8 Against health
Drug
8.8 Consumption
3.6 Arms bearing
15.8 Other

44.7 Robbery
21.8 Injuries
Against health
12.5 Damages
2.7 Other
18.3

42.2
11.1
10.9
6.9
28.9

Robbery
49.1 Robbery
Against health 30.0 Against health
Drug
Drug
Consumption
5.5 Consumption
Injuries
3.6 Other
Other
11.8

58.5
24.4
2.4
4.9
9.8

SOURCE: SISVEA—Juvenile detention centers
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Exhibit 7. Type of Death Under Intoxication of Selected Drugs1 in Mexico by Percent: 2004
Type of Death
Gender
Male
Female
Age Group
10–14
15–19
20–24
25–29
30–34
35–39
40 and older
Cause of Death
Run over
Traffic accident
Fall
Electrocuted
Burned
Beaten
Asphyxia
Crushed
Fire arm
Steel knife
Violation
Intoxicated
Poisoned
Other
Place of Death
Traffic
Home
Street
Public baths
Recreational areas
At work
Service areas
Other

Total
N=2,061

Alcohol
n=1,727

Marijuana
n=75

Opioids
n=82

92.2
7.8

93.8
6.2

93.3
6.7

92.7
7.3

0.6
8.0
13.0
13.2
13.4
12.6
39.2

0.5
7.6
13.4
13.5
12.9
12.7
39.4

0.0
12.0
17.3
20.0
20.0
9.3
21.3

0.0
9.8
12.2
20.7
23.2
13.4
20.7

12.3
16.2
4.8
0.6
1.2
2.9
17.2
0.2
8.8
4.2
0.1
9.7
0.5
21.1

13.6
18.1
5.1
0.5
0.8
3.2
18.2
0.2
9.4
4.8
0.1
6.1
0.4
19.0

12.5
11.1
4.2
1.4
0.0
2.8
20.8
1.4
9.7
8.3
0.0
5.6
0.0
22.2

0.0
1.2
0.0
0.0
0.0
0.0
1.2
0.0
1.2
0.0
0.0
93.9
1.2
1.2

15.4
30.0
38.0
0.1
3.5
0.8
8.4
3.7

16.8
30.4
39.5
0.1
3.8
0.9
5.7
2.7

8.3
25.0
36.1
1.4
6.9
2.8
8.3
11.1

0.0
23.2
51.2
1.2
0.0
0.0
20.7
3.7

2

1

Deaths fro all causes totaled 10,304.
Indicates opium, morphine, and heroin.
SOURCE: SISVEA—Medical examiner
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Southern African Development
Community Epidemiology
Network on Drug Use
(SENDU): Findings July
2001–June 2004
Charles D.H. Parry, Ph.D., and Andreas
Plüddemann, M.A2
ABSTRACT
The Southern African Development Community
(SADC) Regional Drug Control Program provides
for the establishment of a regional drug surveillance network (SADC Epidemiology Network on
Drug Use—SENDU) in the 13 SADC member
states. At the end of June 2004, data were available
from 11 countries: Botswana, Lesotho, Malawi,
Mozambique, Mauritius, Namibia, South Africa,
Swaziland, Tanzania, Zambia, and Zimbabwe. During this period, data on treatment demand were collected from 98 specialist drug treatment centres and
psychiatric hospitals in 9 countries and law enforcement agencies in 11 countries. Overall, the
region saw an increase in the demand for treatment
for substances other than alcohol and cannabis in
the first half of 2004 compared with the second half
of 2003 and an increase in police seizures of heroin.
Seizures of methaqualone (Mandrax), cocaine, and
amphetamine-type stimulants), however, showed a
decline. The most alarming findings reported were
the very high level of HIV/AIDS cases associated
with intravenous drug use in Mauritius and the
dramatic increase in treatment demand related to
methamphetamine use in one of the South Africa
sites, Cape Town. Among the policy recommendations requiring urgent attention at national and
regional levels are the need to (i) increase access to
substance abuse treatment outside of the psychiatric
hospital system, (ii) improve the training of personnel involved in treatment and prevention, (iii) increase interventions targeting high-risk populations,
(iv) ensure that law enforcement agencies are adequately equipped to enforce anti-drug legislation,
and (v) review and, if necessary, update relevant
legislation.
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INTRODUCTION
Background Information on SENDU
The South African Community Epidemiology Network on Drug Use (SACENDU) is an alcohol and
other drug (AOD) sentinel surveillance system comprising a network of researchers, practitioners, and
policymakers from five sites in South Africa. The
network, managed by the Medical Research Council
(MRC) of South Africa, has been operational since
July 1996. In 2000, with funding from the South
African Development Community (SADC) via the
European Commission, the MRC was contracted to
establish sentinel or country surveillance systems in
the other SADC member states.
The project forms part of the 5-year SADC Drug
Control Program. The broader (regional) network has
been named the SADC Epidemiology Network on
Drug Use (SENDU). This initiative has been driven
by the following: (1) the view that the burden of
harm from AOD use in Southern Africa is likely to
increase with development; (2) the realization that
various global, regional, and local factors have highlighted the need for monitoring substance use in
Southern Africa at this time; and (3) the SADC Drug
Protocol, signed in 1996, which highlights the importance of information and research to inform interdiction and demand reduction activities.
The overall goal of SENDU is to improve the information base for policymakers in SADC member
states in order to address the health and socioeconomic burden caused by misuse of AODs. SENDU’s
immediate purpose is to develop, establish, and
evaluate a substance abuse sentinel surveillance system in each of the SADC member states, building on
the SACENDU model operational in three cities and
two provinces in South Africa.
The SENDU initiative has the following core components:
•

Ongoing training and technical support

•

site- or country-specific network, and, if possible, the in (The “basic” system comprises treatment demand data from specialist substance
abuse treatment facilities [if available] and psychiatric hospitals, as well as information from
the police on arrests, seizures, and drug prices.
Additional components might include school
studies, mortuary or trauma unit studies, etc.)

•

Validation and collation of data during 6-month
country and regional report-back meetings
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•

Dissemination of findings via reports, newsletters, press briefings, and a Web site

Between 2001 and 2004, technical support visits
were undertaken to all SADC member states. The
focus of these visits was to learn more about patterns
of AOD use in the countries, inform government officials about the SENDU initiative, assist countries in
developing instruments to collect and collate secondary data on AOD use/associated consequences, provide technical support in other areas related to establishing and maintaining an AOD surveillance system,
support country coordinators in running an initial
meeting of potential members of an AOD surveillance network, conduct visits to agencies where data
are to be collected, and identify other areas requiring
technical or other forms of support.
Area Description
SADC was established in 1992 and comprises 13
member states (exhibit 1). These countries differ
greatly in land area, population, income levels, and
official languages (exhibit 2). The surveillance systems in Botswana, Lesotho, Malawi, Mauritius, Namibia, Swaziland, Zambia, and Zimbabwe are country-level systems. In Mozambique, the surveillance
system has been established in Maputo, and in Tanzania, systems are established in Dar es Salaam and
Zanzibar. SACENDU comprises six sentinel sites,
four of which are large port cities (Cape Town, Durban, Port Elizabeth, and East London); the other two
are provinces: Gauteng (a largely urban province
which includes the cities of Pretoria and Johannesburg) and Mpumalanga (a largely rural province bordered by Swaziland and Mozambique). The South
African sites cover just over one-third of country’s
population.
Data Sources
A summary of the data sources accessed in the above
countries during the first half of 2004 is indicated in
exhibit 3. The major sources of data are specialist
treatment centres, psychiatric hospitals, and the police. With regard to detailed information on treatment
demand, in the first half of 2004 data were obtained
from 98 treatment centres/hospitals in 9 countries (on
8,675 patients), up from 92 treatment centres (and
7,569 patients) in the second half of 2003. The focus
of this report is on the findings of Phase 16 of the
SACENDU Project, Phase 1 of the AOD abuse
surveillance system established in Zimbabwe, Phase
2 of the surveillance systems established in Swaziland and Zambia, Phase 3 of the surveillance system
established in Tanzania, Phase 4 of the surveillance
systems established in Malawi and Mozambique,
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tems established in Malawi and Mozambique, Phase
5 of the surveillance systems established in Botswana
and Namibia, and Phase 6 of the AOD abuse surveillance systems established in Lesotho and Mauritius.
This report covers the period January to June 2004
and preceding 6-month periods (if applicable).
DRUG ABUSE PATTERNS AND TRENDS
Treatment Demand Data
Information on primary drug of abuse reported at
specialist AOD treatment centres3 is provided in exhibits 4 and 5. To facilitate country comparisons, data
for South Africa are averaged over the six sentinel
sites in the country, and treatment data for Tanzania
are averaged over Dar es Salaam and Zanzibar.
In summary, in Mauritius, Mozambique (Maputo),
Namibia, South Africa, Swaziland, Tanzania, and
Zambia, there appears to be demand for (and supply
of) treatment for a greater range of substances of
abuse than in the other countries (i.e., Botswana, Lesotho, and Malawi), where alcohol and cannabis are
the primary drugs of abuse reported. Specifically,
based on treatment demand data, South Africa has a
greater range of substances available than other
SADC countries. South Africa also has the largest
number of treatment centres (in general, and included
in the SENDU project) and the largest number of
patients entering substance abuse treatment facilities.
Alcohol is the primary substance of abuse most likely
to be reported by patients at specialist substance
abuse treatment centres in six SADC countries;
among all SADC countries, the proportion of primary
alcohol admissions ranges from 18 percent in Tanzania to 62 percent in Swaziland. Averaging across the
nine countries for which data are available, just over
one-third (38 percent) of patients listed alcohol as a
primary drug of abuse. This is a decrease of 7 percentage points compared with the second half of
2003. Decreases were noted in six of the nine countries for which comparative data were available. The
implication of this is that there is an increase in the
demand for treatment for substances other than alcohol in these countries.
The proportion of patients entering treatment centres
with cannabis as their primary drug of abuse varied
greatly in the first half of 2004, ranging from 7 percent in Mauritius and Namibia to 79 percent in Malawi. In the nine countries, just over one-third (37
percent) of patients had cannabis as a primary drug of
abuse. This is similar to the previous reporting pe3

For Botswana, Malawi, Tanzania and Zambia information comes
from psychiatric hospitals/units only
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riod. The increase over time reported previously for
Malawi has not continued; the proportion of cannabis
admissions there declined from 85 percent in the second half of 2003 to 79 percent in the first half of
2004. An increase in treatment demand for problems
related to cannabis use was noted in Tanzania during
the same period (from 39 to 50 percent), while conversely a decrease was noted in Swaziland (from 60
to 36 percent).
Treatment demand for problems related to the use of
Mandrax (methaqualone) is confined to Namibia and
South Africa. In the previous reporting period, treatment demand for problems related to Mandrax use
was noted in Swaziland and Zambia, but this was no
longer the case in the first half of 2004. Over the past
three reporting periods, an increase in treatment demand related to this drug was noted in Namibia,
whereas in South Africa there appears to be no discernable trend.
Treatment demand for problems related to the use of
cocaine is mainly confined to Mozambique, Namibia,
and South Africa, and to a lesser extent in Swaziland
and Zambia, with increases being noted in all five
countries between the second half of 2003 and the
first half of 2004.
Treatment demand for problems related to the use of
heroin is confined to Mauritius, Mozambique, South
Africa, Tanzania, Zambia, and to a much lesser extent Swaziland, where it appeared in the treatment
demand data set for the first time since data were
collected in Swaziland as part of the SENDU project.
Mauritius has by far the greatest proportion of patients in treatment whose primary drug of abuse is
heroin (58.9 percent). Increases in treatment demand
related to heroin use were noted in all six countries,
especially in Mauritius, Mozambique, Tanzania, and
Zambia (by at least five percentage points since the
second half of 2003).
Injection use of heroin is extremely high in Mauritius
(more than 90 percent), but it is also high in the
South African sites (28 percent in Cape Town, 55
percent in Gauteng, and 32 percent in Mpumalanga),
in Maputo, Mozambique (23 percent), and in Tanzania (29 percent).
During the first half of 2004, ecstasy (methylenedioxymethamphetamine) was only reported as a primary substance of abuse in treatment centres in South
Africa (0.8 percent). Over-the-counter and prescription medicines (primarily benzodiazepines and analgesics) were only reported as primary drugs of abuse
in Mauritius, South Africa, and Swaziland, ranging
between 0.5 and 4 percent of admissions.
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Other drugs reflected in treatment demand data included khat, methcathinone (CAT), lysergic acid diethylamide (LSD), methamphetamine, and inhalants
(e.g., glue, petrol). A dramatic increase in treatment
demand for methamphetamine was noted in Cape
Town (South Africa), especially in the first half of
2004 and particularly among patients younger than
20. Almost 4 out of every 10 patients younger than
20 who attended drug treatment in Cape Town reported methamphetamine as a primary or secondary
drug of abuse.
Age and Mode of Drug Use
Across countries and sites, the proportion of patients
in treatment who are younger than 20 averages 12
percent and ranges from 0.5 percent (Mauritius) to 27
percent (Zambia). This has declined substantially
since the last reporting period. With the exception of
Mauritius, across sites the predominant mode of ingesting substances is by swallowing or smoking. In
Mauritius, however, more than one-half of persons in
treatment injected their primary drug of abuse. Overall, only 3 percent of patients in treatment centres in
the South African sites reported injection as their
primary mode of ingesting their primary substance.
The only other countries where intravenous drug use
was reported were Mozambique, Tanzania, and Zambia. Increases in intravenous drug use were noted in
Mauritius, South Africa, Tanzania, and Zambia.
Law Enforcement Data
Arrests
In Botswana and Swaziland, no arrests for drug dealing/trafficking were recorded in the first half of 2004
(exhibit 6). In Lesotho, Malawi, and Mozambique
(Maputo) in the first half of 2004, all arrests for drug
dealing (trafficking) involved cannabis. For South
Africa, information on cannabis arrests is not available, but information on police cases (by drug) for
drugs other than cannabis is available from the police
forensic science laboratories. The highest number of
arrests for dealing in cannabis in the first half of 2004
was noted in Tanzania (2,219), followed by Zambia
(1,423). Increases in the number of persons arrested
for dealing in cannabis were noted for five of the nine
countries for which comparative data were available:
Lesotho, Malawi, Mauritius, Mozambique, and Zambia, but in all cases except Maputo, there was no increase in the proportion of arrests for dealing in cannabis in the first half of 2004. Over the eight countries where arrests were made for dealing in cannabis
(excluding South Africa), on average 85 percent of
all arrests for dealing in drugs involved cannabis.
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Arrests for dealing in Mandrax (methaqualone) were
only made in Namibia (n=63, including arrests for
drug possession), South Africa (4,829), and Tanzania
(1) during this period. The proportion of arrests for
dealing in this drug stayed much the same in both
Namibia and South Africa in the last two reporting
periods. Arrests for dealing in cocaine were made in
Namibia, South Africa, Tanzania, Zambia, and Zimbabwe, though in the latter three countries the proportion of arrests for dealing in cocaine represented less
than 1 percent of all arrests. The largest increase in
the proportion of cocaine arrests was noted in Namibia, from 2.9 percent of all arrests in the second
half of 2003 to 12.4 percent in the first half of 2004.
In Mauritius, more than 6 out of every 10 arrests for
drug trafficking involved heroin. This is substantially
greater than for Namibia, South Africa, Tanzania,
and Zambia, the only other countries where arrests
for dealing in heroin were recorded. In these countries, the corresponding proportions were 0.3 percent,
3.3 percent, 9.9 percent, and 0.5 percent, respectively. Increases in the proportion of heroin arrests
across these five countries ranged from 0.3 percentage points in Namibia to 6.3 percentage points in
Tanzania.
With regard to ecstasy and other amphetamine-type
stimulants, a substantial number of cases relating to
dealing in ecstasy and methamphetamine have been
reported in South Africa over the past five reporting
periods. They accounted for 21.5 percent of all cases
(n=1,789) in the first half of 2004. A large increase in
arrests related to ecstasy dealing/possession was also
noted in Namibia. Of the 11 countries for which data
on drug-related arrests were recorded as part of the
SENDU project in 2004, only in South Africa were
persons arrested for dealing in LSD (fewer than 1
percent in the first half of 2004). Arrests for dealing
in prescription medicines were noted in Zambia and
South Africa, and arrests for dealing in khat were
reported in Tanzania (4 percent of all arrests) and in
Zambia.
Seizures
The largest amount of cannabis seized during the first
half of 2004 occurred in Tanzania: 234,045 kilograms. No seizure information regarding cannabis is
available for South Africa. Increased cannabis seizures were noted in three countries, while decreases
occurred in four. Heroin seizures were noted in Mauritius, Namibia, South Africa, Swaziland, Tanzania,
and Zambia. The quantity seized, however, was very
low in most countries, except for Mauritius, South
Africa, and Zambia. The amount of heroin seized
over the 11 countries was 17.5 kilograms, with in-
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creases being noted in Mauritius, South Africa, and
Zambia (off a fairly low base). Seizures of Mandrax
(methaqualone) were noted in Botswana, Namibia,
South Africa, and Tanzania, with the equivalent of
592,968 Mandrax tablets being recorded by the four
police forensic science laboratories in South Africa.
Mandrax seizures were down in Namibia and South
Africa, but they substantially increased in Botswana
and Tanzania. Cocaine seizures in the region overall
(67 kilograms) were less than in the previous reporting period and totalled more than 10 kilograms in
only Namibia and South Africa. Seizures of amphetamine-type stimulants (mainly ecstasy) were
noted in four countries (147,809 units in total), with
the largest seizures being noted in South Africa and
Zambia. A small quantity of LSD was seized in
South Africa, and 251 kilograms of khat were seized
in Tanzania, substantially less than was seized in the
second half of 2003.
DISCUSSION
Cannabis and alcohol continue to dominate treatment
demand and community concern in most SADC
countries. They both represent more than one-third of
the demand for drug treatment in the region. Across
the region, there continues to be strong evidence of
the burden placed by alcohol and cannabis on health
and law enforcement sectors, and the number of persons arrested for dealing/trafficking in cannabis increased in more than one-half of the countries. There
is also evidence of substantial use of other drugs such
as Mandrax (methaqualone), heroin, cocaine, and
amphetamine-type stimulants in certain countries and
trafficking of these drugs in many countries (not just
those where use has been reported).
Heroin use is particularly high in countries in the
south and east of the region, including South Africa,
Mozambique, Tanzania, and Mauritius. In addition,
use of heroin and dealing/trafficking in this drug was
increasing in the landlocked country of Zambia in the
first half of 2004. Increases in treatment demand,
seizures,4 and in the proportion of arrests for dealing/trafficking in this drug were noted in most countries where heroin use was reported.
Treatment demand and/or law enforcement indicators
for cocaine are highest in Mozambique, Namibia, and
South Africa (i.e., in the coastal countries in the south
and east of the SADC region). There was an increase
in problems associated with cocaine in all countries
where there was a demand for treatment for the drug.
Regionally, however, there was a decline in seizures
for cocaine in the first half of 2004. One of the biggest changes noted was the increase in the proportion
4

Except Tanzania. In addition it should be noted that the increase
in heroin seizures in Swaziland was negligible.

Proceedings of the Community Epidemiology Work Group, Vol. II, June 2005

EPIDEMIOLOGIC TRENDS IN DRUG ABUSE—Panel on International Drug Abuse: Emerging/Current Trends

of arrests related to cocaine relative to other drugs in
Namibia.

•

Treatment demand and law enforcement indicators
related to Mandrax (methaqualone) continue to be
high in Namibia and South Africa. However, as compared to the previous 6-month period, there appears
to have been a shift in countries where there is lesser
evidence of use of Mandrax and/or in dealing in this
drug, with such evidence no longer being noted in
Mozambique, Swaziland, and Zambia. Evidence of
use in Botswana and Tanzania is now apparent.
Treatment demand and law enforcement indicators
indicate use of and trafficking in amphetamine-type
stimulants, especially ecstasy and methamphetamine
in South Africa. Trafficking of these substances was
also noted in Botswana, Namibia and Zambia.
Across sites, just over 1 in 10 patients receiving
treatment for alcohol or drug related problems is
younger than 20, but this proportion has decreased
over time. Drug price information is provided in exhibit 8, and a rough comparison of levels of substance use and associated consequences to society
based on treatment demand and law enforcement
indicators is provided in exhibit 8.
Various policy implications were raised in the country reports for January–June 2004 and at the sixth
SENDU Regional Report-Back Meeting. These are
indicated below, with reference to specific target
groups and intervention approaches:
•

Primary Prevention
-

Target children at a young age, focusing on
gateway drugs such as alcohol, tobacco and
cannabis.

-

Intensify AOD education.

-

Intervene to address the abuse of drugs by
sex workers.

-

Reduce alcohol-related violence in and
around liquor outlets, and educate the public
that abuse of alcohol can put them at risk for
being a victim of a violent assault.
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•

Treatment/Rehabilitation
-

Increase the availability of affordable treatment centres, especially outside of the psychiatric system.

-

Provide special facilities for female drug addicts.

-

Create special interventions that cater to the
needs of unemployed persons.

-

Increase training in management of substance abuse and in mental health problems
to workers in the health and social services.

-

Provide training to emergency/trauma personnel to ensure that they are equipped to
deal with cases involving heroin and
methamphetamine (selected countries).

-

Increase treatment and prevention programs
aimed at workers.

-

Pilot test harm reduction strategies to reduce
infections and other problems, such as overdoses.

Other
-

Review and increase the enforcement of
drug trafficking and related legislation.

-

Ensure that police have adequate resources
to enforce anti-drug legislation.

Across countries, various issues requiring further
monitoring or more indepth research were also
raised, including…
•

Reasons for use of AODs by youth (Malawi)

•

Impact of AOD use on mental health (Malawi,
Namibia), violence (Mauritius), overdose deaths
(Mauritius), and crime (Botswana)

•

Poly-drug use (Mauritius)

•

Strategies to combat inhalant use among children
(Mauritius)

•

Incidence of human immunodeficiency virus
(HIV), hepatitis B (HBV), and hepatitis C
(HCV) among injection drug users (IDUs) and
non-injection drug users (non-IDUs) (Mauritius)

•

The relationship between drug abuse and
HIV/AIDS (Swaziland, Zambia)

•

Barriers to treatment for women and other sectors of the population (Mauritius, Namibia,
South Africa)
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•

Female drug traffickers (Botswana, Mauritius)

•

Relationship between drug use, tuberculosis
(TB), and HIV/AIDS (DRC, Swaziland, Zambia)

•

The relationship between patterns of drug abuse
and expulsions from school (Zimbabwe)

•

Treatment models for resource-poor countries

The first phase of the SENDU project is scheduled to
be completed at the end of June 2005. By the completion of this phase, at least one 6-month data collection period should have been should have been completed at each site, including the DRC and Angola.

Persuading all available treatment centres in the
sentinel sites to contribute treatment demand
data and to continue participation in the network

•

Adding additional sources of data to complement
existing sources (mainly treatment demand and
law enforcement)

•

Ensuring that data on the links between substance use and infectious diseases and crime are
also collected

Improving the quality of written and oral reports,
particularly moving from more descriptive reporting to more analytical reporting

•

Getting the SENDU findings to have a greater
impact on local, national, and regional alcohol/drug policy and practice

•

Ensuring the long-term sustainability and maturation of the national networks, as well as
SENDU as a whole
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Exhibit 1. Member States of SADC1

Seychelles

DR Congo
Tanzania

Angola

Malawi
Zambia

Mozambique

Zimbabwe
Namibia

Mauritius

Botswana

South Africa

Swaziland
Lesotho

1

The Seychelles left SADC in 2003.
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Exhibit 2. Description of SADC Member States, by Selected Indicators
SADC Member
State
Angola
Botswana
Congo (DRC) 2
Lesotho
Malawi
Mauritius
Mozambique
Namibia
South Africa
Swaziland
Tanzania
Zambia
Zimbabwe
Total

Land Area
(sq kms)

Population
(2003 est.)

1,246,700
600,370
2,345,410
30,355
118,480
1,860
801,590
825,418
1,219,919
17,363
945,087
752,614
390,580
9,296,201

10,978,552
1,561,973
55,225,478
1,865,040
11,906,855
1,220,481
18,811,731
1,954,033
42,718,530
1,169,241
36,588,225
10,462,436
12,671,860
207,134,435

GDP per
capita1

Population Age
14 and Younger
(%)
43.5
39.2
37.3
46.8
24.8
43.6
42.4
29.5
41.0
44.2
46.1
39.4

Official Language

$1,900
$8,800
$590
$3,000
$600
$11,400
$1,200
$7,100
$10,700
$4,900
$600
$800
$1,900

Portuguese
English
French
English
English, Chichewa
English
Portuguese
English
11 official languages3
English, Swati
English, Swahili
English
English

1

Purchasing power parity (2003 estimate)
2002 estimate
3
English predominates
SOURCE: U.S. Central Intelligence Agency. The World Fact Book 2001. Washington, DC: Author, 2002.
2

Mauritius

Mozambique

Namibia

S. Africa

Swaziland

Tanzania

Zambia

7
(556)
Y

8
(596)
Y

5
(151)
Y

3
(54)
Y

58
(6,680)
Y

2
(223)
Y

3
(169)
Y

3
(183)
Y

N/A

ITC3

ITC

Y

ITC

N/A

Y

ITC

ITC

ITC

N/A

–

–

–

Y

–

–

–

–

–

–

-

Treatment Centres
(patients in period Jan–Jun 2004)
Police Drug Data/Forensic

N/A2

Psychiatric Hospitals
Prisons

Zimbabwe

Malawi

Y

9
(63)
Y

Botswana1

Source

Lesotho

Exhibit 3. Data Sources, by Sites: January–June 2004

N/A
Y

Mortuaries

–

–

–

–

–

–

Y

–

–

–

-

Orthopedic Unit

–

–

–

–

–

–

–

–

Y

–

-

Surveys, Studies

–

–

–

–

–

–

Y

–

–

–

Other Health Statistics

–

–

–

Y

–

–

–

–

–

–

-

Education Ministry

–

–

–

–

–

–

–

–

–

–

Y

1

No data were available as data collection system was being revamped.
N/A=Not applicable
3
ITC=Included with treatment centre data
2
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Exhibit 4. Treatment Demand Data, by Primary Drug of Abuse1: January 2002–June 2004
Country

Period

Botswana

Jan–Jun ‘02
Jul–Dec ‘02
Jan–Jun ‘03
Jul–Dec ‘03
Jan–Jun ‘04

70.3
69.6
83.6
73.7
N/A

23.8
29.0
16.4
26.3
N/A

Methaqualone
(Mtq)
0.5
0.0
0.0
0.0
N/A

Lesotho

Jul–Dec ‘01
Jan–Jun ‘02
Jul–Dec ‘02
Jan–Jun ‘03
Jul–Dec ‘03
Jan–Jun ‘04

54.3
85.0
97.8
70.2
51.0
52.4

45.7
15.0
2.2
29.8
49.0
47.6

Malawi

Jul–Dec ‘02
Jan–Jun ‘03
Jul–Dec ‘03
Jan–Jun ‘04

32.7
19.6
14.9
20.7

Jul–Dec ‘01
Jan–Jun ‘02
Jul–Dec ‘02
Jan–Jun ‘03
Jul–Dec ‘03
Jan–Jun ‘04
Oct–Dec ‘02
Jan–Jun ‘03
Jul–Dec ‘03
Jan–Jun ‘04

Alcohol

Cannabis

Heroin

0.5
0.0
0.0
0.0
N/A

0.0
0.0
0.0
0.0
N/A

0.0
0.0
0.0
0.0
N/A

0.0
0.0
0.0
0.0
N/A

4.9
1.5
0.0
0.0
N/A

188
72
73
19
N/A

9
5
4
4
N/A

0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0

45
20
46
67
49
63

6
5
3
7
6
9

67.3
79.8
85.1
79.3

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.6
0.0
0.0

445
361
417
556

3
5
7
7

21.8
32.7
33.0
36.5
36.7
28.4
63.7
68.3
54.3
39.1

14.1
6.6
10.3
8.2
6.1
7.4
20.5
20.2
16.5
19.2

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0
0.9
0.0
3.2
8.6

70.7
59.3
52.9
51.7
53.5
58.9
15.0
10.6
25.2
33.1

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0

1.3
1.1
2.8
3.2
3.2
4.2
0.0
0.0
0.0
0.0

1.5
0.2
0.5
0.4
0.5
1.2
0.0
1.0
0.8
0.0

467
452
427
561
591
596
234
104
127
151

8
8
8
8
8
8
7
4
6
5

Jan–Jun ‘02
Jul–Dec ‘02
Jan–Jun ‘03
Jul–Dec ‘03
Jan–Jun ‘04
Jul–Dec ‘01
Jan–Jun ‘02
Jul–Dec ‘02
Jan–Jun ‘03
Jul–Dec ‘03
Jan–Jun ‘04

74.0
78.0
82.9
66.7
53.7
52.2
54.0
54.1
51.7
48.7
47.9

8.0
8.7
0.0
3.7
7.4
21.4
19.3
21.0
18.2
18.9
16.6

12.0
8.7
14.3
22.2
26.0
10.1
10.3
9.5
12.6
14.1
11.9

6.0
2.2
2.9
7.4
13.0
5.1
5.7
5.3
5.8
6.2
8.2

0.0
0.0
0.0
0.0
0.0
5.1
5.3
4.6
5.5
5.2
6.2

0.0
2.2
0.0
0.0
0.0
1.1
1.0
1.1
0.9
0.8
0.8

0.0
0.0
0.0
0.0
0.0
3.1
3.1
2.7
3.1
2.8
2.9

0.0
0.0
0.0
0.0
0.0
1.6
1.2
1.7
2.1
2.3
5.0

50
46
35
54
54
5,667
6,108
5,830
5,886
5,726
6,680

2
3
2
2
3
48
50
50
52
50
58

Swaziland

Jul–Dec ‘03
Jan–Jun ‘04

30.6
61.9

59.7
36.3

9.7
0.0

0.0
0.5

0.0
0.5

0.0
0.0

0.0
0.5

0.0
0.5

62
223

2
2

Tanzania

Jul–Dec ‘03
Jan–Jun ‘04

39.1
17.8

38.8
50.3

0.0
0.0

0.0
0.0

18.2
30.2

0.0
0.0

0.0
0.0

3.9
1.8

330
169

3
3

Zambia

Aug–Dec ‘03
Jan–Jun ‘04

34.6
24.0

61.8
64.5

0.5
0.0

0.5
1.1

0.5
8.2

0.0
0.0

1.6
0.0

0.5
2.2

191
183

4
3

Mauritius

Mozamb.

Namibia

South
Africa

1
2

Ecstasy

OTC/
Rx2

# Tx.
Ctrs

Cocaine

Other

N

Row percentages add to 100 percent. Information on drug treatment demand is not yet available for Zimbabwe.
Includes psychotropic medicines.
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Exhibit 5. Treatment Demand Data, by Primary or Secondary Drugs of Abuse for Selected Substances and
Selected Sites: January–June 2004

71
59.5

Mauritius

Alcohol

0

0

0

0

0

Lesotho

0

0

0

Mozambique

Cannabis
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Methaq

South Africa

Cocaine

Zambia

Heroin
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8.2

10

2.7

8.8

20.9

20

17.5

29.3

39.1

41.1
26.5

30

68.9

67.5

40

26.5

31.9

50

19.2

60

60.3

70

68.3

Percent
80
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Exhibit 6. Police Arrests for Drug Dealing, by Drug1: January 2002–June 2004

Botswana2

Jan-Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan-Jun ‘04

100.0
100.0
96.5
0.0
0.0

0.0
0.0
1.2
0.0
0.0

Cocaine/
Crack
0.0
0.0
1.2
0.0
0.0

Lesotho

Jul-Dec ‘01
Jan-Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan-Jun ‘04

100.0
100.0
100.0
100.0
100.0
100.0

0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0

Malawi

Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan-Jun ‘04

100.0
100.0
100.0
100.0

0.0
0.0
0.0
0.0

Country

Period

Cannabis/
Hashish

Methaqualone

Ecstasy/
ATS
0.0
0.0
1.2
0.0
0.0

Heroin

Rx

LSD

Khat

N

0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0

0.0

226
183
170
0
0

0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0
0.0

0.0

108
87
93
103
56
146

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0

0.0
0.0

431
348
182
355

Jul-Dec ‘01

47.0

0.0

0.0

0.0

53.0

0.0

0.0

-

156

Jan-Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan-Jun ‘04

37.0
59.1
46.0
41.0
37.2

0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0

63.0
40.9
54.0
59.0
62.8

0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0

0.0
0.0

125
149
153
122
199

Mozambique
(Maputo) 2

Oct-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan-Jun ‘04

N/A
100.0
0.0
100.0

N/A
0.0
0.0
0.0

N/A
0.0
100.0
0.0

N/A
0.0
0.0
0.0

N/A
0.0
0.0
0.0

N/A
0.0
0.0
0.0

N/A
0.0
0.0
0.0

0.0
0.0

N/A
4
0
44

Namibia2

Jan-Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan-Jun ‘04

84.4
84.9
88.9
79.8
64.2

14.1
9.3
9.6
16.5
17.7

1.0
3.5
1.0
2.9
12.4

0.5
2.2
0.5
0.8
5.4

0.0
0.0
0.0
0.0
0.3

0.0
0.0
0.0
0.0
0.0

0.0
0.0
0.0
0.0
0.0

0.0
0.0

397
226
208
491
355

Mauritius

Jul-Dec ‘01

-

65.7

16.2

13.8

3.0

0.0

1.3

-

4,756

Jan-Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan-Jun ‘04

-

60.5
61.3
66.2
59.9
58.0

19.1
16.5
13.5
12.0
16.8

15.2
16.8
16.6
24.5
21.5

4.8
4.6
2.9
3.0
3.3

0.0
0.0
0.0
0.0
0.0

0.4
0.8
0.8
0.6
0.4

0.0
0.0

4,818
5,131
5,910
7,373
8,321

Swaziland

Jul-Dec ‘03
Jan-Jun ‘04

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0.0
0.0

0
0

Tanzania

Jan-Jun ‘032
Jul-Dec ‘03
Jan-Jun ‘04

85.8
90.4
85.7

0.2
0.0
0.04

0.7
0.0
0.1

0.0
0.0
0.0

5.7
3.6
9.9

0.0
0.0
0.0

0.0
0.0
0.0

7.5
6.1
4.2

2,701
3,418
2,590

Aug-Dec ‘03

98.0

0.1

0.1

0.0

0.2

1.0

0.0

0.6

1,247

Jan-Jun ‘04

95.7

0.0

0.5

0.0

0.5

2.0

0.0

1.4

1,487

Jan-Jun ‘04

99.8

0.0

0.2

0.0

0.0

0.0

0.0

0.0

568

South
Africa3

Zambia
Zimbabwe2
1

Row percentages add to 100 percent.
Including possession.
South African data refer to national cases seen by the Forensic Science Laboratory rather than arrests per se. These laboratories
do not routinely analyse all cases involving seizures of cannabis.
2
3
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Exhibit 7. Police Seizures, by Drug: January 2002–June 2004
Country

Period

Botswana

Jan-Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan–Jun ‘04

1,471
1,471
1,189
1,359
581

Methaqualone
(tablets)1
0
0
5
0
2 784

Lesotho

Jul-Dec ‘01
Jan-Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan–Jun ‘04

19,671
4,154
4,417
5,380
2,020
7,349

Malawi

Jul-Dec ‘02
Jan-Jun –03
Jul-Dec ‘03
Jan–Jun ‘04

4,659
6,242
4,527
7,808

Cannabis
(kg)

0
0
1.77
0
0

Amphetamine
(tablets) 1
0
0
31
0
29

0
0
0
0
0
0

0
0
0
0
0
0

10 045
0
0
0
0
0

0
0
0
0
0
0

0
0
0
0
0
0

0
0

0
0
0
0

0
0
0
0

0
0
0
0

0
0
0
0

0
0
0
0

0
0

Cocaine
(g)

Heroin
(g)

LSD
(units)

Khat
(kg)

0
0
0
0
0

0
0
0
0
0

0
0

Jul-Dec ‘01

30

0

0

0

22 441

0

-

Jan–Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan–Jun ‘04

23
44
9
34
39

0
0
0
0
0

0
0
0
0
0

0
0
0
0
0

4995
6 973
15 432
517
2 357

0
0
0
0
0

0
0

Oct-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan–Jun ‘04

N/A
10
23
22

N/A
0
1 000
0

N/A
5 100
9 200
0

N/A
0
0
0

N/A
0
15
0

N/A
0
0
0

0
0

Jan-Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03

775
147
532
96

9179
679
2 714
6 426

10
36
14
162

0
0
0
0

0
0
0
0

0

Jan–Jun ‘04

434

1 185

169

2

0

0

Jul-Dec ‘01
Jan-Jun ‘02
Jul-Dec ‘02
Jan-Jun ‘03
Jul-Dec ‘03
Jan-Jun ‘04

N/A
N/A
N/A
N/A
N/A
N/A

12 872 000
2 668 595
750 099
630 844
10 935 182
592 968

78 rocks
189 rocks
96 rocks
55
15 350 + 141
rocks
191 143
375 535
67 148
237 728
188 298
46 305

121 562
150 324
275 362
256 927
257 406
76 407

1 856
6 273
77 041
16 340
2 190
13 655

6 632
322
1 303
532
756
235

0

Jul-Dec ‘03

8,463

473

3 832

0

0.02

0

0

Jan–Jun ‘04

3,919

0

0

0

0.05

0

0

Tanzania

Jan-Jun ‘03
Jul-Dec ‘03
Jan–Jun ‘04

413,361
599,613
234,043

212
0
1000

1.335
1 392
620

0
0
0

2 531
2 000
10.65

0
0
0

1 454
10 548
251

Zambia

Aug-Dec ‘03
Jan–Jun ‘04

1,322
2,510

8
0

0.1
0.7

69 152
71 204

55.5
1 446

0
0

0
0

Zimbabwe

Jan–Jun ‘04

555

0

0.7

0

0

0

0

Mauritius

Mozambique
(Maputo)

Namibia

South Africa

Swaziland

1

Or equivalent (calculated from powder seized): 1g = 2 tablets.
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Exhibit 8. Drug Prices in Local Currencies, by Drug: January–June 2004

Country

Currency

Mandrax
(tablet)

Cocaine
(g)

Crack
(rock)2

Ecstasy
(tablet)

2
6–83
5
300
3,000
5
0.8

80
N/A
N/A
N/A
N/A
50
50

100
N/a
N/a
N/a
N/A
150
–
50–
150
–
N/a
–

80
N/a
N/a
N/a
N/A
120
–

–

Botswana
Lesotho
Malawi
Mauritius
Mozambique
Namibia
Swaziland
South
Africa
Swaziland
Tanzania
Zambia

Rands

1–2

28–35

Emlangeni
Shilling
Kwacha

0.5
15
500

–
1,000/gm
7,000

350
N/A
N/A
N/A
700,000
450
212
250–
350
–
20,000
170,000

Zimbabwe

Dollar

2,000

50,000

300,000

1
2
3

Pula
Maloti
Kwacha
Rupees
Metical
Dollar
Lilangeni

Cannabis
(g)1

50–80
–
N/a
–
80–
100K

Heroin
(g)

N/A
N/a
N/a
10,000
600,000
450
180
180–
200
455
18,000
140,000
250,000

Khat
(g)

Speed
(unit)

Approx.
Local
Currency
to 1 US$

N/A
N/A
N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A
N/A

4.66
6.28
106.33
26.40
23,300.00
6.28
6.28

N/A

3–60

6.28

–
N/A
3,500

–
N/A
–

6.28
1,082.30
4,675.00

N/a

N/A

4,277.10

0.5 g=1 joint.
Depends on size.
Per small plastic bank bag.

Exhibit 9. Composite Assessment of the Use of Various Substances per SADC Country and Negative Effect
on Health and Social Systems, Based on Treatment Demand (Tx-D) and Law Enforcement (Law-E)
Indicators: January–June 2004
Cannabis
Country
Botswana
DRC#
Lesotho
Malawi
Mauritius
Mozambique
Namibia
South Africa
Swaziland
Tanzania
Zambia
Zimbabwe

Tx-D
N/A
++
+++
+++
+
++
+
++
++
+++
+++
N/A

Law-E
+
+
+++
+++
+
++
++
N/A
+
+++
+++
++

Mandrax
(methaqualone)
Tx-D
Law-E
N/A
+
++
++
++
+++
+
N/A
-

Cocaine
Tx-D
N/A
++
++
++
+
+
N/A

Law-E
+
++
++
+
+
+

Heroin
Tx-D
N/A
+++
+++
++
+
+++
++
N/A

Law-E
+
++
+
++
+
++
++
-

ATS
Tx-D
N/A
+
+
N/A

Law-E
+
+
++
++
-

- Substance either not used or not showing up substantially on indicators.
+ Some evidence of use of drug and/or dealing in the country.
++ Law enforcement and/or treatment demand indicators suggest moderate use of and/or dealing in substance.
+++ Substantial use and/or negative consequences indicated (e.g., arrests for dealing).
#From presentation by Mr. Justin Ntambwa on Kinshasa (DRC).
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Patterns and Trends of Drug
Abuse in Taiwan: A Brief
History and Report from
2000 through 2004
Jih-Heng Li, Ph.D., Shu-Fen Liu, M.S., and
Wen-Jing Yu, B.S.5

tively small, it is densely populated, with a population of 22,604,550 (2003 census). Such a high population density (625 people per square kilometer of
land area or 3,750 people per square kilometer of
arable land) has made life on this tiny island very
crowded and competitive. Nevertheless, the economy
of Taiwan has been rapidly improved. The per capita
national income in 2003 was New Taiwan (NT)
$452,820 (US$13,156), which was a fivefold increase
over the income of US$2,669 in 1981.6
Brief History of Drug Abuse in Taiwan

ABSTRACT
Taiwan encountered the first wave of drug abuse in
the late nineteenth century, when 6.3 percent of the
total population consumed opium. The Japanese
colonial government adopted the ‘gradual prohibition’ policy to grant an opium quota for addicts.
The measure is similar to today’s methadone maintenance program, and the opium problem was alleviated eventually. The second wave of drug abuse in
Taiwan began in the early 1990s, when methamphetamine abuse became prevalent among youngsters. Methamphetamine and heroin remained the
two predominant illicit drugs of abuse from 2000
through 2004. The abuse of club drugs such as
MDMA and ketamine has been increasing rapidly.
Cannabis seizures exceeded 100 kilograms per year
in 2001 and 2003, but cannabis abuse was still a
minor problem as evidenced by urine testing. A high
proportion of drug administration through injection
was observed: 34.7 percent of the drug addicts consumed drugs by injection in 2000, and the percentage surged to 63.9 percent in 2004. In addition, the
percentage of needle sharing among addiction
treatment admissions increased from 4.0 percent in
2000 to 15 percent in 2004. In order to prevent the
spread of infectious diseases such as AIDS and
hepatitis B and hepatitis C through drug abuse, the
Department of Health has been implementing harm
reduction measures, including substitution treatment, education programs for jail inmates, and possibly needle exchange programs.
INTRODUCTION
Area Description
Located in the West Pacific, Taiwan is separated
from Mainland China by the Taiwan Strait. Taiwan
consists of the Taiwan Island proper and some 85
islets, with a total land area of 36,000 square kilometers (14,400 square miles). Although Taiwan is rela5

The authors are affiliated with the National Bureau of Controlled
Drugs, Department of Health, Taiwan.
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In the late nineteenth century, opium smoking was a
common practice in the Ching Dynasty of China.
Taiwan, under the reign of Ching Dynasty at that
time, also suffered from the same problem. After the
Sino-Japan War, Taiwan was ceded to Japan for 50
years (1895–1945). Realizing the severe problem of
opium smoking, the Japanese colonial government
adopted the “gradual prohibition” policy. Based upon
the opinion of public physicians, opium addicts were
issued opium licenses to obtain an opium quota. According to license issuance records, it was estimated
that there were some 169,000 opium addicts, or approximately 6.3 percent of the total 2,500,000 inhabitants, in 1900. The opium license system, which is
similar to today's methadone maintenance program
except that the opium quota system was distributed
by the government monopoly, brought a fortune for
the colonial government and alleviated the problem
of opium smoking to a manageable situation.7
When the Republic of China reclaimed Taiwan after
World War II, only 2,000 addicts remained. Chiang
Kai-Shek, after being defeated by the Chinese Communists, soon retreated with his army and implemented martial law in Taiwan. In the subsequent two
decades (1940s–1950s), Taiwan was practically a
drug-free society. However, inhalant abuse (glue
sniffing) began to emerge among young people in the
early 1960s. It was not until the 1970s that pentazocine replaced glue as the drug of choice. The abuse of
pentazocine was eliminated after it was enlisted and
controlled as a narcotic by the Department of Health.
In the early 1980s, the trend of abuse switched to
psychotropic agents. Two barbiturates (secobarbital
and amobarbital) and methaqualone, all of which
were legal medicines, became the predominant drugs
of abuse. This was soon brought under control after
6

Accessed June 3, 2005, from “My E-Government” at http://www.
gov.tw/EBOOKS/TWANNUAL.
7
Li, Jih-Heng (1998). Drug Abuse Situation and Anti-Drug Programmes in Taiwan, R.O.C., in International Monograph Series 11,
Report of the Asian Multicity Epidemiology Work Group 1997,
edited by V. Navaratnam and A.A. Baker, pp151–156. Center for
Drug Research, Universiti Sains Malaysia, Minden, Pulau Pinang,
Malaysia.
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methaqualone was banned and the two barbiturates
were enlisted as controlled drugs. Although these
substances were abused during 1960s, 1970s, and
1980s, drug abuse was not regarded as a serious
problem in these three decades.8
In 1987, the martial law that had been implemented
in Taiwan since 1949 was lifted. Being a young
democratic country with flourishing economy,
Taiwan has witnessed a deluge of methamphetamine
and heroin abuse since early 1990s. In the past
several years, abuse of club drugs such as
methylenedioxymethamphetamine (MDMA), flunitrazepam (FM2, Rohypnol), and ketamine has been
reported in pubs and karaoke parlors. Facing the
worsening drug abuse situation, the obsolete “Act for
Eradication of Illicit Narcotics” was revised into
“Drugs Hazard Control Act” in 1998. The new act
states that the “illicit use” of Schedule I and II drugs
is a criminal offence. A positive result of urine
testing for Schedule I or II drugs serves as evidence
of drug use. Once convicted, the penalty for using
illicit drugs is relatively harsh. The maximum
penalties for use of Schedule I and II drugs can be
imprisonment for 5 and 3 years, respectively. Although the first-time offender who is not addicted
may be released without being indicted, a drug user is
generally reluctant to reveal his/her drug use
behaviors to strangers. As a result, the epidemiologic
data of drug abuse may be underestimated, and this
should be taken into account.
Data Sources
For this report, data were collected from the National
Bureau of Controlled Drugs (NBCD), Department of
Health. In cooperation with all the incumbent agencies, the NBCD has established a systematic surveillance system to monitor the drug abuse trends and
situations since 1999. Information from the following
sources was compiled for the Monthly Drug Abuse
Report collected and prepared by the NCBD, February 2005:
•

8

Data for court referrals on arrests, seizures,
and laboratory reports on urine samples of
drug abusers from 2000 to 2004 were obtained
from the Investigation Bureau, Ministry of Justice; the National Police Administration, Ministry of Interior; the Military Police Command,
Ministry of National Defense; the Coastal Guard,
Executive Yuan; the National Bureau of Controlled Drugs, Department of Health; and all local health departments.

•

Information from the Surveillance System of
Drug Abuse and Addiction Treatment from
2000 to 2004 was provided by NCBD, Department of Health. The Bureau has, in collaboration
with the designated medical care institutions and
private institutions for addiction treatment, set up
the surveillance system. Cases of drug abuse and
addiction have been reported online since 2002.

•

Data on acquired immunodeficiency syndrome
(AIDS), human immunodeficiency virus (HIV)
infection, and routes of drug administration
from December 1984 to December 2004 were obtained from the Center for Disease Control, Department of Health, Taiwan.

DRUG ABUSE PATTERNS AND TRENDS
From 2000 through 2004, methamphetamine and
heroin were the two most prevalent illicit drugs used
in Taiwan, while the abuse of club drugs such as
MDMA and ketamine has been increasing rapidly.
The drug abuse situation from 2000 through 2004 is
described in the following sections.
Methamphetamine
An average of 37,500 methamphetamine abusers
were identified each year during the past 5 years,
according to the results of urine tests for court referrals, performed by all local health departments, certified laboratories, National Police Administration, and
the Investigation Bureau of the Ministry of Justice.
Methamphetamine was identified in 62.7 percent of
the total positive cases of urine testing in 2004 (exhibit 1). Methamphetamine seizures have increased
nearly fourfold since 2000. Methamphetamine remained the most commonly seized drug in 2004 (at
3,165.5 kilograms), and the quantity has been increasing (exhibit 2). Both the methamphetaminepositive urines and methamphetamine seizures demonstrate the efforts exerted by the judicial systems to
identify and combat methamphetamine abuse.
Among the total treatment admissions from 2000 to
2004, methamphetamine remained the second most
commonly reported substance, following only heroin
(exhibit 3). The wholesale price of methamphetamine
has increased nearly twofold from NT$310,000
(US$10,000) per kilogram in 2000 to NT$520,000
(US$16,774) per kilogram in 2004 (exhibit 4).
Heroin
Among the 51,429 urine tests in 2004, 32,295 (or
62.8 percent) were positive for morphine (heroin)
(exhibit 1). The quantity of heroin seized in Taiwan
increased by 132 percent between 2000 (277 kilo-

Ibid.
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grams) and 2004 (644 kilograms) (exhibit 2). Heroin
remained the most frequently mentioned drug among
treatment admissions during the past 5 years. In
2004, 94 percent of all treatment admissions mentioned heroin as a drug of abuse (exhibit 3). The
wholesale price of heroin has sharply increased, from
NT$1,270,000 (US$40,968) per kilogram in 2000 to
NT$2,710,000 (US$87,419) per kilogram in 2004
(exhibit 4). It is worth noting that most heroin users
administered the drug by injection, a practice that has
posed a threat of spreading infectious diseases, such
as AIDS.

grams, representing 90.4 percent of total benzodiazepines seized. The amount of benzodiazepines
seized has dramatically increased, from 3.4 kilograms
in 2000 to 141.3 kilograms in 2004 (exhibit 2); nimetazepam replaced FM2 as the most commonly
seized benzodiazepine in 2004 and represented 97.4
percent of these seizures. Among addiction treatment
admissions, the abuse of benzodiazepines has consistently ranked third (exhibit 3), with FM2 being the
most abused benzodiazepine.

MDMA

According to the United Nations Office on Drugs and
Crime (UNODC) 2004 World Drug Report, cannabis
is the most prevalent drug of abuse in the world. The
amounts of cannabis seized exceeded 100 kilograms
each year in 2001 and 2003 (exhibit 2), but cannabis
does not seem to be a main concern in Taiwan.
Among the 51,429 drug-positive urine tests in 2004,
only 119 were positive for cannabis (exhibit 1), and
only 43 treatment admissions reported cannabis
abuse in 2004 (exhibit 3).

The amount of seized MDMA totaled about 5 kilograms in 2000, compared with 303 kilograms in
2004, thus demonstrating the expanding supply of the
drug (exhibit 2). MDMA-positive urine cases increased from 266 in 2000 to 2,245 in 2004 (exhibit
1). Polydrug use is very common among MDMA
users; since 2001, MDMA-positive urine cases have
frequently been positive for other substances.
MDMA abuse cases among treatment admissions
peaked at 251 in 2002, before declining to 152 in
2003 and 103 in 2004 (exhibit 3).
Ketamine
The amount of seized ketamine totaled 9.5 kilograms
in 2001; this increased to 613 kilograms in 2004 (exhibit 2). Ketamine now ranks as the third most commonly seized drug in Taiwan. Meanwhile, the combined use of ketamine with methamphetamine,
MDMA, and FM2 (Rohypnol) has been detected
among urine tests since 2003. Although the first case
of ketamine abuse among treatment admissions was
identified in 2002, ketamine abuse cases increased to
49 in 2004—thus demonstrating the increasing abuse
of the drug.
Benzodiazepines
Abuse of depressants is a relatively new concern in
Taiwan. Triazolam was the predominant drug among
seized benzodiazepines in 2000, accounting for 92.4
percent. However, flunitrazepam (Rohypnol, also
nicknamed as FM2) replaced triazolam as the most
frequently seized benzodiazepine in 2001, and the
amounts of seized FM2 have continued to increase.
In 2003, the amount of seized FM2 totaled 12 kilo-
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Cannabis

INFECTIOUS DISEASES RELATED TO SUBSTANCE
ABUSE
Positive cases of HIV and AIDS increased rapidly in
Taiwan from December 1984 through December
2004 (exhibit 5). Between 1984 and 2004, 646
HIV/AIDS cases in Taiwan (approximately 10 percent) were among injection drug users (IDUs) (exhibit 6). According to reports by addiction treatment
admissions, 34.7 percent administered drugs by injection in 2000; this percentage increased to 63.9 percent in 2004 (exhibit 7). In addition, the percentage
of users sharing needles increased from 4.0 percent in
2000 to 15 percent in 2004. In response to the new
drug abuse situation, the Department of Health has
been implementing harm reduction measures, including pilot studies on buprenorphine substitution treatments, education programs for jail inmates, and possibly needle exchange program through outreach
groups, to avoid the spread of HIV.
For inquiries concerning this report, please contact Jih-Heng Li,
Ph.D., Director General, National Bureau of Controlled Drugs,
Department of Health, No. 6. Linsen South Road, Taipei City 100,
Taiwan, R.O.C., Phone: 886-2-2-351-7109, Fax: 886-2-2-3411635, E-mail: jhli@nbcd.gov.tw.
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Exhibit 1. Results of Laboratory Urine Testing in Taiwan: 2000–2004
Drug

2000
Case

All morphine positives

16,655

19.8

21,816

42.8

23,385

52.4

27,741

62.8

32,295

62.8

All methamphetamine
positives

71,891

85.5

36,575

71.7

22,567

50.6

24,632

55.7

32,240

62.7

Morphine-only
Methamphetamine-only
Methamphetamine and
Morphine
Methamphetamine, Morphine, and other drugs
MDMA
Ketamine
Cannabis
Total

%

2001
Case

%

2002
Case

%

2003
Case

%

2004
Case

%

2,838

3.4

8,838

17.3

13,341

29.9

13,916

31.5

9,140

17.8

45,187

53.8

23,597

46.3

12,523

28.1

10,807

34.5

16,109

31.3

12,885

15.3

11,706

22.9

8,260

18.5

9,947

22.5

8,849

17.2

932

1.1

1,272

2.5

1,784

4.0

3,878

8.8

7,006

13.6

266

0.3

1,388

2.8

4,878

10.9

2,159

4.9

2,245

4.4

0

0.0

0

0.0

98

0.2

208

0.5

476

0.9

0

0.0

3

0.0

42

0.1

81

0.2

119

0.2

84,044

51,017

44,634

44,200

51,429

SOURCES: Certified laboratories for Urine Testing; National Bureau of Controlled Drugs, Department of Health; all local health departments; Investigation Bureau, Ministry of Justice; National Police Administration, Ministry of Interior and Military Police Command, Ministry of National Defense

Exhibit 2. Drug Seizures in Taiwan: 2000–2004
Seizures in Kilograms
Year

Methamphetamine

Heroin

MDMA (Ecstasy)

Benzodiazepines

Cannabis

Ketamine

2000

277.33

836.24

4.93

73.98

3.44

－

2001

362.50

1,421.01

44.65

106.99

6.51

9.54

2002

599.09

1,298.06

132.65

11.06

2.54

63.16

2003

532.64

3,980.51

405.63

121.17

13.40

600.48

2004

644.50

3,165.51

303.28

38.65

141.28

613.41

SOURCES: Investigation Bureau, Ministry of Justice; Police Administration, Ministry of Interior; Military Police Command, Ministry of
National Defense; Directorate General of Customs, Ministry of Finance; Coastal Guard, Executive Yuan

Exhibit 3. Reported Cases of Drug Addicts Admitted for Treatment in Psychiatric Hospitals/Clinics in
Taiwan: 2000–2004

2000

Total No. of
Cases
2,871

1,513

Methamphetamine
1,452

23

Benzodiazepines
315

2001

3,545

2,265

1,490

164

145

344

0

2002

7,654

6,233

2,152

251

62

386

18

2003

8,283

7,353

1,551

152

47

441

42

2004

12,232

11,479

2,663

103

43

431

49

Year

Heroin

MDMA (Ecstasy)
9

Cannabis

Ketamine
0

SOURCE: National Bureau of Controlled Drugs, Department of Health
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Exhibit 4.

Wholesale Prices of Heroin and Methamphetamine in Taiwan: 2000–2004
NT$ (in Thousands)
per Kilogram
3,000
2,500
2,000
1,500
1,000
500
0
Heroin
Methamphetamine

2H 2000

1H 2001

2H 2001

1H 2002

2H 2002

1H 2003

2H 2003

1H 2004

1,270

1,360

1,460

1,510

1,430

1,630

1,970

2,710

310

320

370

360

380

380

430

520

SOURCE: Investigation Bureau, Ministry of Justice

Exhibit 5. Reported Cases of HIV/AIDS in Taiwan, by Year of Diagnosis: 1984–2004
Number of Cases
1,800
1,521

1,600
HIV (+)
AIDS

1,400
1,200

774

861

1,000

654

800

257

229

180

161

180

179

153

136

98

160

277

228

174
65

35

23

16

6

36

43
9

29
4

12
1

11
1

15
0

19
84
19
85
19
86
19
87
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04

0

9
0

91

136

200

137

350

400

401

479

535

600

SOURCE: Center for Disease Control, Department of Health
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Exhibit 6. Reported Cases of HIV/AIDS in Taiwan, by Exposure Category: 1984–2004
Exposure Category
Heterosexuals
Homosexuals
Bisexuals
Hemophiliacs
Injection Drug Users
Blood recipients
Vertical transmission
Unknown
Total

HIV Infection1
Total
%
2,396
35.4
2,334
34.5
687
10.2
53
0.8
603
8.9
14
0.2
11
0.2
664
9.8
6,762
100.0

AIDS
Total
927
532
291
20
43
4
2
61
1,880

Death
%
49.3
28.3
15.5
1.1
2.3
0.2
0.1
3.2
100.0

Total
516
234
169
34
25
7
1
39
1,025

%
50.3
22.8
16.5
3.3
2.4
0.7
0.1
3.8
100.0

1

AIDS cases are included; foreigners are not included.
SOURCE: Center for Disease Control, Department of Health

Exhibit 7. Routes of Drug Administration1 Among Patients Admitted for Addiction Treatment in Psychiatric
Hospitals/Clinics in Taiwan: 2000–2004
Percent
60
50
40
30
20
10
0

2000

2001

2002

2003

2004

Oral

10.3

9.5

6.7

6.8

4.7

Injection w ith Needle-Sharing

4.0

4.6

6.0

15.3

15.0

Injection w ithout NeedleSharing

30.7

29.8

50.7

47.9

48.9

Smoking

14.8

18.8

14.2

13.9

16.1

Inhalation

33.3

27.4

18.4

12.7

12.6

Snorting

0.7

4.0

1.9

0.4

0.6

Sniffing

0.0

0.0

1.0

1.9

0.7

Other

6.3

5.2

2.2

1.0

0.6

1

A drug user may administer drugs through more than one route.
SOURCE: National Bureau of Controlled Drugs, Department of Health
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